2021-01-18 18:30:59 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_multi_underscore/checkpoint_best.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out_fp32_best/multi_underscore_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_underscore', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_multi_underscore/checkpoint_best.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out_fp32_best/multi_underscore_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-18 18:31:00 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-18 18:31:00 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-18 18:31:00 | INFO | fairseq_cli.generate | loading model(s) from /global/lv71502/clang/fairseq/mBART_termeval/checkpoint_multi_underscore/checkpoint_best.pt
2021-01-18 18:31:38 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.src
2021-01-18 18:31:38 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.label
2021-01-18 18:31:38 | INFO | fairseq.tasks.translation | ./postprocessed/en_underscore test src-label 2024 examples
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-0.7518896460533142	
D-1685	-0.7518896460533142	
P-1685	-1.2602 -0.2436
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.3864240348339081	
D-664	-0.3864240348339081	
P-664	-0.5800 -0.1929
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.568248450756073	▁EH
D-1528	-0.568248450756073	EH
P-1528	-1.1035 -0.3251 -0.2761
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.7345783114433289	
D-1451	-0.7345783114433289	
P-1451	-1.2160 -0.2532
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.25529107451438904	
D-133	-0.25529107451438904	
P-133	-0.3212 -0.1894
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.37684375047683716	
D-228	-0.37684375047683716	
P-228	-0.5399 -0.2138
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.7783730030059814	▁d XA
D-1496	-0.7783730030059814	dXA
P-1496	-0.6554 -0.3787 -1.8409 -0.2385
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.37564587593078613	▁FM
D-18	-0.37564587593078613	FM
P-18	-0.5497 -0.4079 -0.1693
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf pna
H-1699	-0.8995129466056824	▁h z ▁p na
D-1699	-0.8995129466056824	hz pna
P-1699	-1.3044 -1.7963 -0.7967 -0.9554 -0.3731 -0.1712
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.9371384382247925	▁molecular _ ▁mechanism
D-1607	-0.9371384382247925	molecular_ mechanism
P-1607	-0.2056 -0.1893 -3.7583 -0.3175 -0.2151
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.3720296323299408	
D-307	-0.3720296323299408	
P-307	-0.5266 -0.2174
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal_artery_stenosis
H-1592	-0.4677402675151825	▁Ren al _ ▁arter y _ ▁sten osis
D-1592	-0.4677402675151825	Renal_ artery_ stenosis
P-1592	-0.5487 -0.1023 -0.4027 -0.1727 -0.7173 -0.3649 -1.6355 -0.0532 -0.4734 -0.2068
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise cardiovascular health
H-1897	-0.46968814730644226	▁exercise ▁cardiovascular _ ▁health
D-1897	-0.46968814730644226	exercise cardiovascular_ health
P-1897	-0.4716 -0.0374 -0.8014 -1.0090 -0.2529 -0.2459
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.62890625	▁tertia ry _ re fér ral _ centre
D-1497	-0.62890625	tertiary_reférral_centre
P-1497	-0.2108 -0.0795 -0.9857 -0.5650 -1.5063 -0.1034 -0.8901 -1.2679 -0.3799 -0.3004
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart_failure
H-1066	-0.8775219321250916	▁devices ▁heart _ fail ure
D-1066	-0.8775219321250916	devices heart_failure
P-1066	-1.6932 -0.7110 -0.3309 -1.1822 -1.6497 -0.3228 -0.2530
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse_events
H-1916	-0.5805076956748962	
D-1916	-0.5805076956748962	
P-1916	-0.8903 -0.2708
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver_disease
H-233	-1.0577974319458008	▁disease
D-233	-1.0577974319458008	disease
P-233	-2.6639 -0.2976 -0.2118
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary_end_point inhospital mortality
H-190	-0.4337064325809479	▁in hospital _ ▁mortal ity
D-190	-0.4337064325809479	inhospital_ mortality
P-190	-1.2383 -0.0486 -0.6677 -0.3093 -0.1431 -0.3420 -0.2870
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective_cohort_study
H-1712	-0.41132470965385437	
D-1712	-0.41132470965385437	
P-1712	-0.5662 -0.2565
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute_care_surgery heart_transplant
H-1279	-0.7156739234924316	▁surgery ▁heart _ ▁transplant
D-1279	-0.7156739234924316	surgery heart_ transplant
P-1279	-1.4630 -0.4882 -0.5477 -0.4752 -1.0530 -0.2670
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.46918097138404846	
D-256	-0.46918097138404846	
P-256	-0.7334 -0.2049
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic_breathing heart_beat
H-1345	-0.6136627793312073	▁breath ing ▁heart _ ▁beat
D-1345	-0.6136627793312073	breathing heart_ beat
P-1345	-1.4867 -0.1604 -0.5519 -0.8399 -0.5281 -0.4596 -0.2691
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational_cohort_study
H-811	-0.47515255212783813	
D-811	-0.47515255212783813	
P-811	-0.7074 -0.2429
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective_cohort
H-211	-0.5655168890953064	
D-211	-0.5655168890953064	
P-211	-0.8519 -0.2792
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart_failure latin_america
H-1788	-0.5933452248573303	▁heart _ ▁failure ▁Latin _ america
D-1788	-0.5933452248573303	heart_ failure Latin_america
P-1788	-0.4552 -0.3351 -1.4771 -0.6151 -0.4334 -0.9212 -0.3206 -0.1890
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.4410128593444824	
D-1982	-0.4410128593444824	
P-1982	-0.6329 -0.2491
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.7483640909194946	HF
D-346	-0.7483640909194946	HF
P-346	-1.0391 -0.9862 -0.2197
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.3991953730583191	
D-589	-0.3991953730583191	
P-589	-0.5734 -0.2250
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.708570122718811	▁environment
D-796	-0.708570122718811	environment
P-796	-1.5020 -0.3692 -0.2545
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.2779535949230194	
D-1944	-0.2779535949230194	
P-1944	-0.3707 -0.1852
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate_models
H-241	-0.45655587315559387	
D-241	-0.45655587315559387	
P-241	-0.5904 -0.3227
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.3620910346508026	▁doctor s
D-1686	-0.3620910346508026	doctors
P-1686	-0.6513 -0.2371 -0.3747 -0.1852
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.4992583990097046	
D-44	-0.4992583990097046	
P-44	-0.7476 -0.2509
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.34079915285110474	
D-1846	-0.34079915285110474	
P-1846	-0.4826 -0.1990
S-422	Heart rate was minimally altered.<unk>
T-422	heart_rate
H-422	-0.4996219277381897	▁Heart _ rate
D-422	-0.4996219277381897	Heart_rate
P-422	-0.3804 -0.3614 -1.0405 -0.4994 -0.2165
S-1620	SETTING: Northwest United States.<unk>
T-1620	united_states
H-1620	-0.23045524954795837	▁north west _ uni ted _ state s
D-1620	-0.23045524954795837	northwest_united_states
P-1620	-0.5860 -0.0197 -0.1633 -0.5791 -0.0531 -0.1865 -0.0545 -0.0339 -0.4355 -0.1930
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart_failure
H-1356	-0.4463343024253845	▁Nutrition ▁heart _ fail ure
D-1356	-0.4463343024253845	Nutrition heart_failure
P-1356	-0.5557 -0.2551 -0.4412 -0.8555 -0.5283 -0.3066 -0.1820
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.4918535351753235	▁Cross - sec tional
D-795	-0.4918535351753235	Cross-sectional
P-795	-2.1515 -0.1054 -0.0076 -0.0602 -0.3476 -0.2787
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.4018101990222931	
D-1595	-0.4018101990222931	
P-1595	-0.5839 -0.2197
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.5569429993629456	▁surgery
D-363	-0.5569429993629456	surgery
P-363	-1.1207 -0.3200 -0.2302
S-1683	She is going into heart failure.<unk>
T-1683	heart_failure
H-1683	-1.0863176584243774	▁heart
D-1683	-1.0863176584243774	heart
P-1683	-0.6881 -2.3386 -0.2322
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.5114738941192627	
D-798	-0.5114738941192627	
P-798	-0.8518 -0.1711
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.24721835553646088	
D-1249	-0.24721835553646088	
P-1249	-0.2790 -0.2154
S-979	Heart failure in the young.<unk>
T-979	heart_failure
H-979	-0.7024253010749817	▁Heart
D-979	-0.7024253010749817	Heart
P-979	-0.2671 -1.6117 -0.2285
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.23494094610214233	
D-1687	-0.23494094610214233	
P-1687	-0.3238 -0.1461
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.27758288383483887	▁c lin
D-1246	-0.27758288383483887	clin
P-1246	-0.5622 -0.0904 -0.2805 -0.1773
S-1248	Sci.<unk>
T-1248	
H-1248	-0.7881040573120117	
D-1248	-0.7881040573120117	
P-1248	-1.3795 -0.1967
S-1247	Trans.<unk>
T-1247	
H-1247	-1.2609210014343262	▁trans
D-1247	-1.2609210014343262	trans
P-1247	-0.2712 -3.3043 -0.2073
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end_point
H-1763	-0.33316513895988464	
D-1763	-0.33316513895988464	
P-1763	-0.4330 -0.2333
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.40036940574645996	
D-392	-0.40036940574645996	
P-392	-0.5412 -0.2595
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.5022655725479126	▁inter media te _ fra il ty
D-1005	-0.5022655725479126	intermediate_frailty
P-1005	-1.2706 -0.4594 -0.1188 -0.1841 -1.3840 -0.1242 -0.4269 -0.3561 -0.1963
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.3842436373233795	
D-1963	-0.3842436373233795	
P-1963	-0.3983 -0.3702
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.48770830035209656	▁CHF
D-222	-0.48770830035209656	CHF
P-222	-0.2329 -1.0068 -0.2234
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.19183418154716492	▁do d son
D-205	-0.19183418154716492	dodson
P-205	-0.2499 -0.0904 -0.0111 -0.4452 -0.1627
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.5531144142150879	▁exercise
D-575	-0.5531144142150879	exercise
P-575	-1.0258 -0.3474 -0.2862
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.4360591173171997	
D-126	-0.4360591173171997	
P-126	-0.6636 -0.2086
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air heart_failure
H-1805	-0.814271092414856	▁air ▁pollution ▁heart _ fail ure
D-1805	-0.814271092414856	air pollution heart_failure
P-1805	-0.0582 -3.9534 -0.0996 -0.6598 -0.4678 -0.6414 -0.3816 -0.2524
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients cardiovascular_disease
H-247	-0.840516209602356	▁cardiovascular _ ▁disease
D-247	-0.840516209602356	cardiovascular_ disease
P-247	-0.5332 -1.0444 -2.0046 -0.3811 -0.2392
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients followed_up
H-825	-0.41319555044174194	
D-825	-0.41319555044174194	
P-825	-0.6309 -0.1955
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective_matched_cohort_study
H-1619	-0.5175456404685974	
D-1619	-0.5175456404685974	
P-1619	-0.7653 -0.2698
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal_support
H-1296	-0.487641841173172	▁extra corp o real
D-1296	-0.487641841173172	extracorporeal
P-1296	-1.7088 -0.0884 -0.3750 -0.1315 -0.4682 -0.1539
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf mi
H-1101	-1.067272424697876	▁h f ▁MI
D-1101	-1.067272424697876	hf MI
P-1101	-1.1882 -1.3998 -1.8752 -0.6360 -0.2371
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart_failure disease therapeutics
H-1073	-0.65608149766922	▁Heart _ fail ure ▁disease
D-1073	-0.65608149766922	Heart_failure disease
P-1073	-0.3707 -0.5580 -1.2240 -1.3213 -0.4131 -0.4888 -0.2167
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary_outcomes hemostasis
H-1116	-0.43432682752609253	▁hemos tas is
D-1116	-0.43432682752609253	hemostasis
P-1116	-0.9688 -0.2649 -0.2820 -0.4154 -0.2406
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote_ischemic_conditioning patients heart_failure
H-53	-0.5410396456718445	▁remote _ ische mic _ condition ing ▁heart _ fail ure
D-53	-0.5410396456718445	remote_ischemic_conditioning heart_failure
P-53	-0.4684 -0.4529 -0.0560 -0.4185 -0.3904 -0.3672 -0.1357 -1.2048 -0.3466 -1.4733 -1.1186 -0.3966 -0.2046
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart_rate_variability risk_stratification cardiac patients
H-1584	-0.8817504644393921	▁Heart _ ▁rate ▁cardiac _ ▁pacientes
D-1584	-0.8817504644393921	Heart_ rate cardiac_ pacientes
P-1584	-0.3881 -0.3558 -1.6245 -0.8568 -1.0387 -2.0495 -0.4369 -0.3037
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart_failure
H-1886	-0.9434317946434021	▁Heart _ fail ure ▁uk
D-1886	-0.9434317946434021	Heart_failure uk
P-1886	-1.0136 -0.2984 -1.6782 -1.7372 -1.2983 -0.3476 -0.2307
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.3775523006916046	
D-1754	-0.3775523006916046	
P-1754	-0.5134 -0.2417
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.39309364557266235	▁CHF
D-673	-0.39309364557266235	CHF
P-673	-0.6162 -0.3588 -0.2043
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-0.4513733685016632	▁compliance ▁treatment
D-749	-0.4513733685016632	compliance treatment
P-749	-0.4786 -0.7823 -0.3442 -0.2003
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.7107139229774475	▁Sham - opera ted _ ▁animals
D-1339	-0.7107139229774475	Sham-operated_ animals
P-1339	-0.3713 -0.2127 -0.0109 -0.1859 -0.4271 -3.7940 -0.3718 -0.3120
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.37684449553489685	▁policy
D-312	-0.37684449553489685	policy
P-312	-0.0846 -0.8570 -0.1890
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.2781209945678711	
D-311	-0.2781209945678711	
P-311	-0.3531 -0.2032
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.37404295802116394	
D-885	-0.37404295802116394	
P-885	-0.5050 -0.2431
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.40046435594558716	
D-1399	-0.40046435594558716	
P-1399	-0.4766 -0.3243
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-0.6534103751182556	▁tax ono my
D-1125	-0.6534103751182556	taxonomy
P-1125	-0.2980 -0.1253 -2.1203 -0.4616 -0.2618
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse_events
H-1988	-0.28672870993614197	
D-1988	-0.28672870993614197	
P-1988	-0.3803 -0.1931
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin injected
H-957	-0.18392404913902283	▁do xor ubi cin
D-957	-0.18392404913902283	doxorubicin
P-957	-0.1150 -0.0285 -0.0114 -0.0589 -0.6755 -0.2143
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting cell anand
H-1037	-0.34909120202064514	▁report ing ▁cell ▁Anand
D-1037	-0.34909120202064514	reporting cell Anand
P-1037	-0.0175 -0.0311 -1.6230 -0.0130 -0.2348 -0.1752
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox_proportional_hazards_models
H-712	-0.6529833078384399	▁co x _ ▁proportion al _ ▁hazard s
D-712	-0.6529833078384399	cox_ proportional_ hazards
P-712	-0.6182 -0.2881 -1.1188 -0.9847 -0.1780 -0.2428 -1.8874 -0.4463 -0.5077 -0.2578
S-949	No major complications occurred during follow-up.<unk>
T-949	complications follow-up
H-949	-0.17829401791095734	▁follow - up
D-949	-0.17829401791095734	follow-up
P-949	-0.0942 -0.2834 -0.0149 -0.3047 -0.1943
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient hf
H-364	-0.7134894132614136	▁h f
D-364	-0.7134894132614136	hf
P-364	-1.5764 -0.7031 -0.3216 -0.2529
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors blood_transfusions
H-1684	-0.488164484500885	▁doctor s ▁blood _ trans fusion s
D-1684	-0.488164484500885	doctors blood_transfusions
P-1684	-1.9942 -0.4452 -0.4909 -0.2406 -0.1098 -0.0272 -0.3583 -0.4324 -0.2949
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart_failure patients bisphosphonates
H-1534	-0.4937022030353546	▁Heart _ ▁failure ▁bis phos phon ates
D-1534	-0.4937022030353546	Heart_ failure bisphosphonates
P-1534	-0.3317 -0.6189 -1.2021 -0.1286 -0.0286 -0.2658 -1.0562 -0.5587 -0.2528
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic heart_failure outcomes
H-1198	-0.5226128101348877	▁di ure tic ▁heart _ fail ure
D-1198	-0.5226128101348877	diuretic heart_failure
P-1198	-0.6653 -0.1187 -0.1700 -0.8336 -1.0925 -0.7584 -0.4747 -0.3794 -0.2109
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 gene_expression heart_failure
H-169	-0.6510463953018188	▁Cas pas e -3 _ ▁gene _ expression ▁heart _ fail ure
D-169	-0.6510463953018188	Caspase-3_ gene_expression heart_failure
P-169	-0.5850 -0.0212 -0.2490 -1.9801 -1.9447 -0.3879 -0.2516 -0.1582 -0.2664 -0.3970 -1.1643 -1.0902 -0.3731 -0.2459
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute_right_heart_failure pulmonary_hypertension
H-1090	-0.5165554881095886	▁right _ ▁heart ▁pulmonar y _ ▁hyper tension
D-1090	-0.5165554881095886	right_ heart pulmonary_ hypertension
P-1090	-0.3032 -0.2591 -1.8617 -0.1055 -0.1606 -0.5028 -1.4278 -0.0016 -0.3479 -0.1953
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise cardiovascular
H-1900	-0.5031262040138245	▁benefits ▁exercise ▁cardiovascular _ system
D-1900	-0.5031262040138245	benefits exercise cardiovascular_system
P-1900	-1.0221 -1.0487 -0.0753 -0.7276 -0.0606 -0.3681 -0.2194
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american hf
H-1843	-0.9127909541130066	▁ HF
D-1843	-0.9127909541130066	HF
P-1843	-2.7479 -0.2864 -0.4187 -0.1982
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.5691495537757874	▁internal _ re li ability ▁cro n bach
D-786	-0.5691495537757874	internal_reliability cronbach
P-786	-0.2507 -0.4112 -0.8985 -3.1092 -0.0550 -0.0438 -0.1399 -0.0511 -0.5017 -0.2305
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients hypertension
H-1889	-0.40118083357810974	▁hyper tension
D-1889	-0.40118083357810974	hypertension
P-1889	-0.9441 -0.0018 -0.3794 -0.2793
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.6007803082466125	
D-1616	-0.6007803082466125	
P-1616	-0.9671 -0.2344
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.38080018758773804	
D-32	-0.38080018758773804	
P-32	-0.5184 -0.2432
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.37970349192619324	
D-804	-0.37970349192619324	
P-804	-0.5307 -0.2287
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths strokes
H-778	-0.6039037704467773	▁stroke s
D-778	-0.6039037704467773	strokes
P-778	-1.8284 -0.1529 -0.2788 -0.1555
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty heart_failure
H-1000	-0.6741538047790527	▁fra il ty ▁heart _ fail ure
D-1000	-0.6741538047790527	frailty heart_failure
P-1000	-0.7552 -0.2661 -0.4119 -1.5953 -0.4118 -0.9689 -0.9511 -0.4210 -0.2861
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea afterload
H-518	-0.5813511610031128	▁HR ▁Ea ▁after load _ ▁burde n
D-518	-0.5813511610031128	HR Ea afterload_ burden
P-518	-1.8098 -1.0504 -0.2192 -0.0029 -0.6490 -0.6718 -0.1010 -0.5018 -0.2263
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.6586095690727234	
D-1469	-0.6586095690727234	
P-1469	-1.0986 -0.2186
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard_ratios cox_regression_analysis
H-1770	-0.3501661419868469	▁Hazard _ rati os ▁co x _ re gression
D-1770	-0.3501661419868469	Hazard_ratios cox_regression
P-1770	-0.1065 -0.2916 -0.0896 -0.3194 -0.1660 -0.1923 -0.5345 -0.1133 -0.1583 -1.5899 -0.2905
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras atherosclerosis
H-1594	-0.6354014873504639	RAS ▁at hero sc ler osis
D-1594	-0.6354014873504639	RAS atherosclerosis
P-1594	-0.3140 -1.0213 -0.0848 -0.0738 -2.8124 -0.1086 -0.4399 -0.2283
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient conditions
H-0	-0.4451354742050171	▁conditions
D-0	-0.4451354742050171	conditions
P-0	-0.6388 -0.4104 -0.2862
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss exercise training outcomes
H-1932	-0.5989118814468384	▁ps s ▁exercise
D-1932	-0.5989118814468384	pss exercise
P-1932	-1.0241 -0.2288 -0.2849 -1.2234 -0.2334
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas heart_failure disease
H-1479	-0.5302873253822327	▁micro RNA s ▁heart _ fail ure ▁disease _ management
D-1479	-0.5302873253822327	microRNAs heart_failure disease_management
P-1479	-0.2793 -0.0529 -0.1513 -0.4365 -0.5044 -1.3913 -0.8146 -0.2073 -1.7292 -0.1694 -0.4371 -0.1902
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise quality_of_life heart_failure
H-612	-0.8083454370498657	▁exercise ▁heart _ fail ure
D-612	-0.8083454370498657	exercise heart_failure
P-612	-1.0176 -0.9470 -0.5456 -0.9958 -1.4430 -0.4415 -0.2679
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology bromodomain halts heart_failure
H-1033	-0.5991127490997314	▁Card i ology ▁bro modo main _ ▁inhibi tion ▁heart _ ▁failure
D-1033	-0.5991127490997314	Cardiology bromodomain_ inhibition heart_ failure
P-1033	-0.5482 -1.7000 -0.0170 -0.5625 -0.0210 -0.0452 -1.1069 -0.3923 -0.1028 -0.9980 -0.3623 -1.9258 -0.4180 -0.1877
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart_failure_with_preserved_ejection_fraction
H-1885	-0.4501776099205017	▁heart _ ▁failure ▁e je ction _ fraction
D-1885	-0.4501776099205017	heart_ failure ejection_fraction
P-1885	-0.7710 -0.3348 -1.7617 -0.3392 -0.2319 -0.0783 -0.2422 -0.0153 -0.4679 -0.2595
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.6211925148963928	▁implant ed _ monitor ing _ ▁Device s
D-156	-0.6211925148963928	implanted_monitoring_ Devices
P-156	-0.0226 -0.2386 -0.3473 -0.0856 -0.2616 -0.3761 -4.1609 -0.1230 -0.3714 -0.2248
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.37887752056121826	
D-677	-0.37887752056121826	
P-677	-0.5137 -0.2440
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.302960604429245	
D-1759	-0.302960604429245	
P-1759	-0.3970 -0.2090
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart_failure mortality
H-204	-0.36810487508773804	▁Heart _ ▁failure ▁cognitive _ ▁im pair ment ▁mortal ity
D-204	-0.36810487508773804	Heart_ failure cognitive_ impairment mortality
P-204	-0.2899 -0.5444 -0.8797 -0.2651 -0.5759 -0.8872 -0.0152 -0.1794 -0.1175 -0.0669 -0.3775 -0.2186
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv_fibrosis
H-280	-0.6686562299728394	▁LV _ ▁fibro sis
D-280	-0.6686562299728394	LV_ fibrosis
P-280	-0.0752 -1.0885 -0.0651 -0.6641 -1.9322 -0.1869
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology hospital
H-812	-0.9160199761390686	▁card i ology ▁hospital
D-812	-0.9160199761390686	cardiology hospital
P-812	-2.0358 -0.8599 -0.0430 -1.9714 -0.3654 -0.2206
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.6671082973480225	HF p EF
D-1078	-0.6671082973480225	HFpEF
P-1078	-2.1621 -0.0607 -0.3518 -0.5759 -0.1850
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf hf
H-1309	-1.1685906648635864	current HF HF HF
D-1309	-1.1685906648635864	currentHFHFHF
P-1309	-1.9656 -1.9590 -0.9509 -0.7709 -1.1292 -0.2360
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic_balance
H-1375	-0.42502760887145996	▁autonomi c _ ▁balance
D-1375	-0.42502760887145996	autonomic_ balance
P-1375	-0.0687 -0.7745 -0.2702 -0.8050 -0.4070 -0.2248
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty hf
H-624	-0.37211549282073975	▁fra il ty HF
D-624	-0.37211549282073975	frailtyHF
P-624	-0.8356 -0.1194 -0.2157 -0.4591 -0.4010 -0.2018
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient hospital heart_failure
H-1960	-0.9659465551376343	▁heart _ fail ure
D-1960	-0.9659465551376343	heart_failure
P-1960	-2.1439 -0.4506 -0.5777 -2.0718 -0.3252 -0.2265
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 functional_capacity
H-702	-0.38558435440063477	▁ST 2 ▁functional _ capaci ty
D-702	-0.38558435440063477	ST2 functional_capacity
P-702	-1.0325 -0.0571 -0.8321 -0.4526 -0.0994 -0.0545 -0.3350 -0.2215
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient medical conditions
H-1688	-0.6860196590423584	▁medical ▁conditions
D-1688	-0.6860196590423584	medical conditions
P-1688	-0.6771 -1.5223 -0.2986 -0.2461
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral_stenosis medical_treatment heart_failure
H-332	-0.7518786191940308	▁mit ral _ ▁sten osis ▁medical ▁heart _ fail ure
D-332	-0.7518786191940308	mitral_ stenosis medical heart_failure
P-332	-1.7819 -0.0264 -0.3241 -2.2156 -0.1054 -0.2128 -0.5516 -0.3587 -1.3214 -1.4003 -0.4597 -0.2647
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up_duration
H-495	-0.39330992102622986	▁follow - up _ du ration
D-495	-0.39330992102622986	follow-up_duration
P-495	-0.0885 -0.3851 -0.0493 -1.4130 -0.1279 -0.3446 -0.5040 -0.2341
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral_growth
H-511	-0.3803216516971588	▁competitive
D-511	-0.3803216516971588	competitive
P-511	-0.5567 -0.3289 -0.2554
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated mixed_linear_models
H-325	-0.5392608642578125	▁co
D-325	-0.5392608642578125	co
P-325	-0.4184 -0.9184 -0.2810
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart_failure hospitalization cardiovascular_death
H-410	-0.8361424207687378	▁heart _ fail ure ▁cardiovascular _ ▁death
D-410	-0.8361424207687378	heart_failure cardiovascular_ death
P-410	-0.7123 -0.4315 -1.3861 -2.2742 -0.4189 -0.8846 -0.7829 -0.3971 -0.2377
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary_outcomes quality_of_life
H-1654	-0.4679657816886902	▁cognitive _ function
D-1654	-0.4679657816886902	cognitive_function
P-1654	-0.6702 -0.7624 -0.2372 -0.3681 -0.3019
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin congestive_heart_failure
H-633	-0.47445395588874817	▁vaso press in ▁con ges tive _ heart _ fail ure
D-633	-0.47445395588874817	vasopressin congestive_heart_failure
P-633	-0.1034 -0.0625 -1.1805 -0.1216 -0.0659 -0.4481 -0.2438 -1.8396 -0.3151 -0.7998 -0.4625 -0.3227 -0.2024
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended_criteria_cardiac_transplantation
H-707	-0.3277311325073242	▁cardiac _ ▁transplant ation
D-707	-0.3277311325073242	cardiac_ transplantation
P-707	-0.1435 -0.2203 -0.9187 -0.0799 -0.3716 -0.2324
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness anemia
H-1679	-0.8264704346656799	▁Jehovah _ s _ ▁Wit ness ▁an emia
D-1679	-0.8264704346656799	Jehovah_s_ Witness anemia
P-1679	-0.0076 -0.6806 -2.1033 -0.2410 -1.1837 -1.1669 -1.9864 -0.1714 -0.4720 -0.2519
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 hf
H-1211	-0.5749174952507019	▁p de 2 HF
D-1211	-0.5749174952507019	pde2HF
P-1211	-0.3296 -0.0235 -0.0338 -2.5336 -0.3431 -0.1861
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.4107542932033539	▁residu al _ con found ing ▁follow - up
D-1839	-0.4107542932033539	residual_confounding follow-up
P-1839	-2.2632 -0.0465 -0.7033 -0.5279 -0.0628 -0.0746 -0.0340 -0.2384 -0.0231 -0.3607 -0.1838
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.48878923058509827	
D-1998	-0.48878923058509827	
P-1998	-0.7288 -0.2488
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-0.8727250695228577	▁black
D-1634	-0.8727250695228577	black
P-1634	-0.2197 -2.0631 -0.3354
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.4682706594467163	
D-1261	-0.4682706594467163	
P-1261	-0.6201 -0.3164
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.6440305113792419	▁ metric ▁read mission _ meter s
D-134	-0.6440305113792419	metric readmission_meters
P-134	-1.1489 -0.0892 -0.6550 -0.2682 -0.3772 -1.8498 -0.6611 -0.4402 -0.3067
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-0.9135937690734863	▁mechanism ▁et ▁CHF
D-261	-0.9135937690734863	mechanism et CHF
P-261	-0.9368 -2.5708 -0.5315 -0.3323 -0.1967
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.3221326470375061	▁read mission _ metric
D-145	-0.3221326470375061	readmission_metric
P-145	-0.2239 -0.2664 -0.4967 -0.0926 -0.5910 -0.2621
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-0.4339359998703003	
D-958	-0.4339359998703003	
P-958	-0.6441 -0.2237
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician hospital physician
H-1726	-0.7718237042427063	▁physician
D-1726	-0.7718237042427063	physician
P-1726	-0.4416 -1.5704 -0.3035
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.2045036405324936	▁follow - up
D-1758	-0.2045036405324936	follow-up
P-1758	-0.2269 -0.2758 -0.0199 -0.3124 -0.1875
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs expenditures
H-1238	-0.6343127489089966	▁ar rhythm ia - related _ ▁costs ▁ex pendi tures
D-1238	-0.6343127489089966	arrhythmia-related_ costs expenditures
P-1238	-1.8135 -0.2923 -1.1729 -0.1249 -0.0490 -0.6924 -2.3980 -0.0441 -0.0143 -0.2611 -0.5239 -0.2253
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication sst2
H-403	-0.515541136264801	▁Medica tion ▁s st 2
D-403	-0.515541136264801	Medication sst2
P-403	-0.6683 -0.1861 -0.0524 -1.5500 -0.0960 -0.8255 -0.2306
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable_hf
H-481	-0.8418123126029968	HF
D-481	-0.8418123126029968	HF
P-481	-1.8302 -0.4928 -0.2024
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality sts
H-159	-0.4992726743221283	▁mortal ity ▁s ts ▁h m
D-159	-0.4992726743221283	mortality sts hm
P-159	-0.4286 -0.1710 -0.5432 -0.2683 -1.8188 -0.1489 -0.4146 -0.2008
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-1.2817623615264893	
D-150	-1.2817623615264893	
P-150	-2.2970 -0.2665
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.28914675116539	▁pro pens ity
D-1837	-0.28914675116539	propensity
P-1837	-0.2527 -0.1434 -0.4354 -0.3534 -0.2609
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed mortality random-effects_models
H-64	-0.49069643020629883	▁mortal ity ▁random - effect s
D-64	-0.49069643020629883	mortality random-effects
P-64	-0.0371 -0.3479 -0.5302 -0.3888 -0.0097 -0.1958 -2.0749 -0.3411
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary_outcomes functional_capacity quality_of_life
H-616	-0.39125552773475647	▁functional _ capaci ty
D-616	-0.39125552773475647	functional_capacity
P-616	-0.8825 -0.7437 -0.1008 -0.0606 -0.3186 -0.2413
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end_point
H-266	-0.28112706542015076	
D-266	-0.28112706542015076	
P-266	-0.3814 -0.1809
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical hypothermic_circulatory_arrest
H-598	-0.8607764840126038	▁circula tory _ ▁arrest
D-598	-0.8607764840126038	circulatory_ arrest
P-598	-1.5366 -0.0505 -0.1890 -2.6389 -0.4858 -0.2638
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf patients intubated
H-219	-0.22055016458034515	▁CHF ▁in tuba ted
D-219	-0.22055016458034515	CHF intubated
P-219	-0.0975 -0.2499 -0.1396 -0.1727 -0.4543 -0.2092
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection_fraction bnp
H-194	-0.4465927183628082	▁e je ction _ fraction ▁b NP
D-194	-0.4465927183628082	ejection_fraction bNP
P-194	-0.4518 -0.2162 -0.0219 -0.1876 -0.0131 -1.3070 -1.0997 -0.5133 -0.2088
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic_hf death
H-1796	-0.33622220158576965	▁Chro nic _ HF
D-1796	-0.33622220158576965	Chronic_HF
P-1796	-0.1158 -0.0514 -0.1597 -0.5701 -0.9096 -0.2106
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology diagnosed
H-352	-0.35460177063941956	▁et i ology ▁MR ▁MS
D-352	-0.35460177063941956	etiology MR MS
P-352	-0.0931 -0.3681 -0.0104 -0.4546 -1.0281 -0.3508 -0.1771
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients hfpef
H-787	-0.5373185276985168	HF p EF
D-787	-0.5373185276985168	HFpEF
P-787	-1.6510 -0.0549 -0.3871 -0.3674 -0.2262
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac_amyloidosis
H-997	-0.3013256788253784	▁Card iac _ a my lo idos is
D-997	-0.3013256788253784	Cardiac_amyloidosis
P-997	-0.5113 -0.0229 -0.1581 -0.1328 -0.8030 -0.0715 -0.1595 -0.5298 -0.4558 -0.1685
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic medication death
H-507	-0.3976013958454132	▁Pig s ▁anti ar rhythm ic _ ▁medication
D-507	-0.3976013958454132	Pigs antiarrhythmic_ medication
P-507	-0.1957 -0.1645 -0.1009 -0.2181 -0.1005 -0.0993 -1.5158 -0.5248 -0.8119 -0.2446
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training heart_failure patients
H-1911	-0.8897150158882141	▁Robot - assist ed _ training ▁heart _ fail ure
D-1911	-0.8897150158882141	Robot-assisted_training heart_failure
P-1911	-2.2224 -0.3440 -0.0013 -0.2967 -0.5882 -1.1077 -1.0928 -0.3201 -1.5257 -1.8686 -0.9978 -0.3113
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients functional_capacity symptoms
H-550	-0.2976802587509155	▁functional _ capaci ty
D-550	-0.2976802587509155	functional_capacity
P-550	-0.5843 -0.4137 -0.1261 -0.0590 -0.3640 -0.2390
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up patients
H-1009	-0.29280251264572144	▁follow - up
D-1009	-0.29280251264572144	follow-up
P-1009	-0.2870 -0.2459 -0.0140 -0.7140 -0.2032
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic biomarkers chronic_heart_failure
H-1471	-0.49595576524734497	▁bio mark ers ▁chronic _ heart _ ▁failure
D-1471	-0.49595576524734497	biomarkers chronic_heart_ failure
P-1471	-0.1242 -0.0433 -0.2567 -0.4710 -0.2417 -1.3305 -0.2125 -1.7036 -0.3503 -0.2257
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart_rate arterial_pressure
H-424	-0.5896141529083252	▁Heart _ rate ▁arterial _ tension
D-424	-0.5896141529083252	Heart_rate arterial_tension
P-424	-0.4102 -0.3421 -1.0968 -0.2985 -0.3449 -1.6865 -0.3343 -0.2036
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients therapy beta_blockade
H-1736	-0.9483940005302429	▁beta _ block ade
D-1736	-0.9483940005302429	beta_blockade
P-1736	-3.3189 -0.2670 -1.0766 -0.4568 -0.3281 -0.2430
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb correlated baseline hrqol
H-840	-0.5269963145256042	▁h gb ▁base line ▁HR Qo l
D-840	-0.5269963145256042	hgb baseline HRQol
P-840	-0.0827 -0.2674 -0.0121 -0.0448 -1.7435 -0.0208 -1.9083 -0.4536 -0.2098
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients cardiac inflammatory biomarkers
H-1914	-0.35935044288635254	▁cardiac ▁infla mma tory _ ▁bio mark ers
D-1914	-0.35935044288635254	cardiac inflammatory_ biomarkers
P-1914	-0.0530 -0.2498 -0.4881 -0.0668 -0.3462 -1.0880 -0.0870 -0.2469 -0.5591 -0.4086
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected patients systolic_dysfunction
H-1069	-0.6288948059082031	▁sy sto lic _ ▁dys function
D-1069	-0.6288948059082031	systolic_ dysfunction
P-1069	-2.6927 -0.2208 -0.5054 -0.3189 -0.5999 -0.0518 -0.4243 -0.2174
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved_ejection_fraction outcomes
H-1464	-0.389782577753067	▁e je ction _ fraction
D-1464	-0.389782577753067	ejection_fraction
P-1464	-0.2142 -0.4587 -0.1057 -0.2461 -0.0339 -1.4136 -0.2564
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated_hf cardiovascular hospitalization
H-1797	-0.6368796229362488	▁h f ▁cardiovascular
D-1797	-0.6368796229362488	hf cardiovascular
P-1797	-1.2250 -0.5368 -0.1094 -1.0015 -0.3116
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes patients heart_failure emergency_department
H-461	-1.1892437934875488	▁heart _ fail ure
D-461	-1.1892437934875488	heart_failure
P-461	-1.3158 -0.3462 -1.3832 -2.3685 -1.5112 -0.2107
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-0.3865815997123718	▁health care
D-603	-0.3865815997123718	healthcare
P-603	-0.4998 -0.1155 -0.6030 -0.3280
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.6030699610710144	▁prognos tic _ factor s
D-591	-0.6030699610710144	prognostic_factors
P-591	-1.6005 -0.6898 -0.7150 -0.0978 -0.4032 -0.3863 -0.3290
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.4408475160598755	
D-1923	-0.4408475160598755	
P-1923	-0.6191 -0.2626
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.34680426120758057	
D-800	-0.34680426120758057	
P-800	-0.5065 -0.1871
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.8449526429176331	▁cardiac _ t 2
D-746	-0.8449526429176331	cardiac_t2
P-746	-0.7397 -2.0344 -0.5015 -0.0320 -1.5367 -0.2254
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug japan
H-1197	-0.8198068737983704	▁drug ▁japan
D-1197	-0.8198068737983704	drug japan
P-1197	-1.4686 -1.3274 -0.3013 -0.1819
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.6819747686386108	▁benefits
D-1028	-0.6819747686386108	benefits
P-1028	-1.4459 -0.3833 -0.2167
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.4240490198135376	
D-1206	-0.4240490198135376	
P-1206	-0.6190 -0.2291
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max significance
H-1255	-0.5421692132949829	▁VO 2 max
D-1255	-0.5421692132949829	VO2max
P-1255	-1.9163 -0.1392 -0.0764 -0.3519 -0.2271
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients esrd
H-394	-1.6425859928131104	▁ES RD
D-394	-1.6425859928131104	ESRD
P-394	-3.7282 -1.9387 -0.5771 -0.3263
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.26092207431793213	▁bio mark ers
D-70	-0.26092207431793213	biomarkers
P-70	-0.1925 -0.0638 -0.2175 -0.4923 -0.3384
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated hf
H-608	-0.7464468479156494	▁HR HF
D-608	-0.7464468479156494	HRHF
P-608	-1.5046 -0.9043 -0.3845 -0.1924
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome tug_test
H-799	-0.8979633450508118	AIN _ o UTC OME ▁tu g _ test
D-799	-0.8979633450508118	AIN_oUTCOME tug_test
P-799	-4.7410 -0.2282 -1.0243 -0.0378 -0.2663 -0.4105 -1.5435 -0.7790 -0.2097 -0.4493 -0.1880
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart_failure
H-1204	-0.9106818437576294	▁heart _ fail ure
D-1204	-0.9106818437576294	heart_failure
P-1204	-1.3255 -0.2759 -1.5272 -1.7001 -0.4188 -0.2165
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.28418678045272827	
D-1854	-0.28418678045272827	
P-1854	-0.3423 -0.2261
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality_of_life
H-1919	-0.8542099595069885	
D-1919	-0.8542099595069885	
P-1919	-1.5095 -0.1989
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart_failure_with_preserved_left_ventricular_ejection_fraction
H-1299	-0.4797515273094177	▁Heart _ ▁failure ▁left _ vent ri cular _ e je ction _ fraction
D-1299	-0.4797515273094177	Heart_ failure left_ventricular_ejection_fraction
P-1299	-0.2168 -0.8413 -0.9052 -0.5446 -0.4325 -0.6171 -0.6422 -0.3949 -0.6099 -0.3556 -0.7388 -0.2949 -0.2457 -0.0104 -0.5799 -0.2463
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet aortic_pressure
H-581	-0.5582054257392883	▁ VET ▁a or tic _ press ure _ cur ve
D-581	-0.5582054257392883	VET aortic_pressure_curve
P-581	-2.7299 -0.0971 -0.2673 -0.2523 -0.1608 -0.2457 -1.7319 -0.4004 -0.3619 -0.2784 -0.0975 -0.4161 -0.2173
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart_failure hf therapy
H-1067	-0.7322157025337219	▁Device s ▁corner stone _ of _ ▁heart _ fail ure HF ▁ therapy
D-1067	-0.7322157025337219	Devices cornerstone_of_ heart_failureHF therapy
P-1067	-2.9461 -0.0808 -0.3831 -0.0468 -0.7817 -0.0586 -0.3729 -2.1006 -0.2082 -1.0335 -1.3841 -0.6332 -1.1524 -0.0188 -0.3023 -0.2124
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician outcomes discharge
H-1414	-0.4020787179470062	▁physician _ continu ity ▁dis charge
D-1414	-0.4020787179470062	physician_continuity discharge
P-1414	-0.0423 -0.8137 -0.1789 -0.3920 -1.1918 -0.0105 -0.3576 -0.2299
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart_failure public health
H-1606	-0.6949114799499512	▁Heart _ fail ure ▁public _ ▁health
D-1606	-0.6949114799499512	Heart_failure public_ health
P-1606	-0.9759 -0.5060 -1.3758 -0.7762 -0.0196 -0.9385 -0.4565 -0.8533 -0.3524
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity patients breast_cancer
H-669	-0.3587372303009033	▁Tras tuz um ab - related _ ▁cardio toxic ity ▁breast _ cancer
D-669	-0.3587372303009033	Trastuzumab-related_ cardiotoxicity breast_cancer
P-669	-0.5959 -0.0351 -0.1026 -0.0993 -0.2396 -0.0821 -0.3865 -0.0653 -0.6862 -0.4848 -0.3777 -0.4042 -1.1087 -0.4329 -0.2801
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital coprimary_outcome
H-1651	-0.5554724335670471	▁hospital
D-1651	-0.5554724335670471	hospital
P-1651	-1.0536 -0.3214 -0.2914
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac symptoms congenital lesions
H-983	-0.825355052947998	▁Card iac
D-983	-0.825355052947998	Cardiac
P-983	-0.6841 -0.1592 -2.2033 -0.2549
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative albumin
H-539	-0.5990830063819885	▁album in
D-539	-0.5990830063819885	albumin
P-539	-1.1975 -0.5124 -0.4934 -0.1930
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan vasopressin_type_2_receptor_antagonist
H-1195	-0.3776005506515503	▁Tol va p tan ▁vaso press in ▁receptor _ ▁anta gon ist
D-1195	-0.3776005506515503	Tolvaptan vasopressin receptor_ antagonist
P-1195	-0.0857 -0.0165 -0.3059 -0.0743 -0.1171 -0.0225 -1.4711 -0.0190 -1.4785 -0.3416 -0.0046 -0.5094 -0.6211 -0.2191
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular_scaffolds heart pathology
H-989	-0.7330259680747986	▁e RK ▁molecular _ sc af fold s ▁heart _ path ology
D-989	-0.7330259680747986	eRK molecular_scaffolds heart_pathology
P-989	-2.8889 -0.0572 -0.3895 -0.2973 -2.1648 -2.2832 -0.2555 -0.3570 -0.2795 -0.3896 -0.0661 -0.0876 -0.4437 -0.3023
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional_ms reported patients degenerative_mr
H-339	-0.7644287347793579	▁Fun ction al _ ▁MS ▁de genera tive _ ▁MR
D-339	-0.7644287347793579	Functional_ MS degenerative_ MR
P-339	-2.6293 -0.0526 -0.0778 -0.9087 -1.2272 -0.7039 -0.0194 -0.0584 -1.2588 -1.4752 -0.5240 -0.2379
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart_failure hf leading mortality society
H-1034	-0.6751291751861572	▁Heart _ fail ure HF ▁society
D-1034	-0.6751291751861572	Heart_failureHF society
P-1034	-0.6145 -0.2264 -0.7899 -2.4732 -0.6728 -0.0864 -0.3320 -0.2059
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone systolic_heart_failure
H-437	-0.413688600063324	▁spi rono lac tone ▁sy sto lic _ heart _ fail ure
D-437	-0.413688600063324	spironolactone systolic_heart_failure
P-437	-0.0827 -0.0166 -0.3788 -0.1166 -0.2825 -0.2291 -0.4059 -0.1910 -1.8132 -0.3540 -0.8352 -0.5456 -0.3263 -0.2141
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology chronic_heart_failure bisoprolol
H-645	-0.5793414115905762	▁chronic _ heart _ fail ure ▁bis o pro lol
D-645	-0.5793414115905762	chronic_heart_failure bisoprolol
P-645	-1.3912 -0.2501 -1.5204 -0.1984 -1.2792 -0.8091 -0.1445 -0.2532 -0.0637 -0.3318 -0.4860 -0.2245
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate_adjustment cox_proportional_hazards_models
H-785	-0.5187469720840454	▁co x
D-785	-0.5187469720840454	cox
P-785	-0.3253 -0.7995 -0.6731 -0.2771
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic hf
H-1072	-1.0024969577789307	▁stand - a lone _ dia meter s HF
D-1072	-1.0024969577789307	stand-alone_diametersHF
P-1072	-1.4966 -0.2537 -0.1890 -0.0518 -0.0744 -5.0201 -0.2155 -0.8736 -2.3581 -0.2906 -0.2040
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician hf
H-1732	-0.9537402391433716	▁h f
D-1732	-0.9537402391433716	hf
P-1732	-2.0169 -0.9923 -0.5900 -0.2157
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.4580961763858795	
D-1576	-0.4580961763858795	
P-1576	-0.5131 -0.4031
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.6447467803955078	▁ therapy
D-1965	-0.6447467803955078	therapy
P-1965	-1.8608 -0.1031 -0.3374 -0.2777
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient circulation
H-1824	-0.20958198606967926	▁circulation
D-1824	-0.20958198606967926	circulation
P-1824	-0.0377 -0.3576 -0.2334
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north_america
H-75	-0.6928948163986206	▁north _ america
D-75	-0.6928948163986206	north_america
P-75	-1.2135 -0.7963 -0.8804 -0.4046 -0.1696
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.3266030251979828	▁c PG s
D-1848	-0.3266030251979828	cPGs
P-1848	-0.1458 -0.6526 -0.0953 -0.4914 -0.2479
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.36749279499053955	▁ms ▁surgery
D-372	-0.36749279499053955	ms surgery
P-372	-0.7493 -0.0586 -0.4653 -0.1967
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis pathophysiological
H-1276	-0.7881901860237122	
D-1276	-0.7881901860237122	
P-1276	-1.3306 -0.2458
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity outcomes
H-709	-0.37591442465782166	
D-709	-0.37591442465782166	
P-709	-0.4980 -0.2538
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha esc
H-1908	-1.0702636241912842	AHA ▁ESC
D-1908	-1.0702636241912842	AHA ESC
P-1908	-1.0733 -2.3863 -0.5168 -0.3047
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income expenditure health
H-1792	-0.43983832001686096	▁income ▁ex pendi ture ▁health
D-1792	-0.43983832001686096	income expenditure health
P-1792	-1.1722 -0.1779 -0.0290 -0.1426 -0.1158 -1.1996 -0.2417
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients heart_failure
H-1821	-1.067034125328064	▁heart _ fail ure
D-1821	-1.067034125328064	heart_failure
P-1821	-2.5897 -0.3706 -1.0300 -1.7758 -0.3659 -0.2703
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients lvad implantation
H-545	-0.42944470047950745	▁l VAD ▁implant ation
D-545	-0.42944470047950745	lVAD implantation
P-545	-1.1074 -0.0973 -0.5338 -0.0873 -0.4829 -0.2679
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.4637340009212494	
D-1881	-0.4637340009212494	
P-1881	-0.6492 -0.2783
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis patients implantation
H-913	-0.4133928120136261	▁di al ysis ▁device _ ▁implant ation
D-913	-0.4133928120136261	dialysis device_ implantation
P-913	-0.0713 -0.0899 -0.1348 -1.3276 -1.1651 -0.0630 -0.0771 -0.5227 -0.2691
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive_statistics cox_proportional_hazards_models
H-675	-0.6331480741500854	▁co x _ ▁proportion al _ ▁hazard s
D-675	-0.6331480741500854	cox_ proportional_ hazards
P-675	-0.1349 -0.1317 -1.0671 -0.8763 -0.1125 -0.2289 -1.9861 -0.5355 -0.9594 -0.2990
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle_heart_failure_model
H-2011	-0.27891215682029724	▁Seattle _ ▁Heart _ fail ure _ model
D-2011	-0.27891215682029724	Seattle_ Heart_failure_model
P-2011	-0.1325 -0.3773 -0.3368 -0.2319 -0.5165 -0.0341 -0.3964 -0.1672 -0.3722 -0.2243
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping baseline heart_failure
H-1059	-0.4727407991886139	▁base line ▁heart _ fail ure
D-1059	-0.4727407991886139	baseline heart_failure
P-1059	-0.0416 -0.0784 -0.3723 -0.3047 -1.2648 -0.6495 -0.8029 -0.2678
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise life_expectancy
H-1902	-0.6837809681892395	▁exercise
D-1902	-0.6837809681892395	exercise
P-1902	-1.4008 -0.3065 -0.3440
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate_analyses
H-826	-0.5837463140487671	
D-826	-0.5837463140487671	
P-826	-0.9142 -0.2533
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary_angiography lesions
H-349	-0.5467209219932556	▁Corona ry _ ang i ography
D-349	-0.5467209219932556	Coronary_angiography
P-349	-0.0442 -0.3296 -0.2517 -0.6652 -1.7971 -0.4609 -0.5727 -0.2523
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient surgery echocardiography
H-358	-0.3954392671585083	▁ms ▁surgery ▁e cho card i ography
D-358	-0.3954392671585083	ms surgery echocardiography
P-358	-1.0042 -0.2263 -0.2273 -0.3078 -0.3735 -0.5623 -0.2710 -0.4134 -0.1731
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic_phenotype fontan
H-223	-0.618040144443512	▁Hem o dynamic _ ▁ph eno type ▁Font
D-223	-0.618040144443512	Hemodynamic_ phenotype Font
P-223	-0.3473 -0.3290 -0.0209 -1.0063 -2.3245 -0.0571 -0.0131 -0.1246 -1.7620 -0.1957
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal heartmate_ii
H-772	-0.4324190318584442	▁off - pump ▁spar ing ▁Heart Mate _ ▁II _ ▁exchange
D-772	-0.4324190318584442	off-pump sparing HeartMate_ II_ exchange
P-772	-0.0322 -0.2876 -0.3659 -1.2231 -0.1013 -0.4569 -0.1492 -0.3522 -0.3830 -0.3588 -1.2657 -0.4200 -0.2256
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart_failure cox_proportional_hazard_analyses
H-1537	-0.5607015490531921	▁heart _ fail ure ▁co x
D-1537	-0.5607015490531921	heart_failure cox
P-1537	-0.4158 -0.2347 -1.0060 -1.9101 -0.0862 -0.1250 -0.5171 -0.1907
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized walking patients severe_heart_failure
H-567	-0.950713038444519	▁Nordic _ ▁walking ▁heart _ fail ure
D-567	-0.950713038444519	Nordic_ walking heart_failure
P-567	-1.2151 -0.5010 -2.3137 -0.6023 -0.4875 -1.2869 -1.3647 -0.4446 -0.3407
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient postoperatively multiorgan_failure sepsis
H-551	-0.5682359337806702	▁multi organ _ fail ure ▁se psis
D-551	-0.5682359337806702	multiorgan_failure sepsis
P-551	-1.5697 -0.0287 -0.3213 -0.8727 -1.7389 -0.0503 -0.0120 -0.3128 -0.2077
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological acute_heart_failure
H-1465	-0.8980506658554077	▁Pharma c ological ▁a cute _ heart _ fail ure
D-1465	-0.8980506658554077	Pharmacological acute_heart_failure
P-1465	-3.0869 -0.3356 -0.1848 -1.9151 -0.0349 -0.1415 -1.8219 -0.2721 -1.1053 -0.5673 -1.0579 -0.2533
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients acute_kidney_injury postoperatively
H-975	-0.7085797190666199	▁ki dne y _ indu stry
D-975	-0.7085797190666199	kidney_industry
P-975	-1.4946 -0.5182 -0.2494 -0.6144 -1.9938 -0.1646 -0.3637 -0.2697
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial_function flow-mediated_dilatation
H-253	-0.5032446384429932	▁en dot heli al _ function ▁flow - media ted _ di la tation
D-253	-0.5032446384429932	endothelial_function flow-mediated_dilatation
P-253	-0.7578 -2.8055 -0.5041 -0.0543 -0.5430 -0.2789 -0.0330 -0.0825 -0.1473 -0.2445 -0.2245 -1.5130 -0.1100 -0.0245 -0.5361 -0.1928
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric self-care_of_heart_failure_index_version_6.2
H-1503	-0.4517754018306732	▁Psycho metric ▁self - Car e _ of _ ▁Heart _ fail ure _ index
D-1503	-0.4517754018306732	Psychometric self-Care_of_ Heart_failure_index
P-1503	-0.3991 -0.0157 -0.9074 -0.1271 -2.6400 -0.3311 -0.1937 -0.0828 -0.2412 -0.6332 -0.2228 -0.6522 -0.0575 -0.2627 -0.2757 -0.3729 -0.2650
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse_events
H-1263	-0.3967048227787018	
D-1263	-0.3967048227787018	
P-1263	-0.6266 -0.1668
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients surgical
H-547	-0.9378103017807007	▁AI ▁sur g ical
D-547	-0.9378103017807007	AI surgical
P-547	-1.6890 -2.5635 -0.0930 -0.0327 -0.9860 -0.2627
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-1.2947120666503906	▁gr s ▁cv
D-810	-1.2947120666503906	grs cv
P-810	-1.3396 -1.7021 -1.1931 -2.0225 -0.2163
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-0.23677478730678558	▁mortal ity
D-1696	-0.23677478730678558	mortality
P-1696	-0.1801 -0.1640 -0.3482 -0.2547
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit_index
H-1006	-0.42089834809303284	▁deficit _ index
D-1006	-0.42089834809303284	deficit_index
P-1006	-0.7170 -0.1719 -0.3782 -0.6364 -0.2010
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.31680741906166077	
D-1855	-0.31680741906166077	
P-1855	-0.4024 -0.2312
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.21398915350437164	▁follow - up
D-1165	-0.21398915350437164	follow-up
P-1165	-0.1324 -0.2955 -0.0235 -0.4099 -0.2085
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients hospitals
H-3	-0.5010676383972168	
D-3	-0.5010676383972168	
P-3	-0.7889 -0.2133
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing nursing
H-1397	-0.779764711856842	▁nur sing _ ▁terminologi es
D-1397	-0.779764711856842	nursing_ terminologies
P-1397	-1.4732 -0.0630 -1.2317 -0.3608 -0.2447 -1.7486 -0.3363
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise training outcomes
H-1640	-0.8294654488563538	▁exercise
D-1640	-0.8294654488563538	exercise
P-1640	-1.6991 -0.5376 -0.2517
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs_duration
H-888	-0.8015832901000977	▁QR s
D-888	-0.8015832901000977	QRs
P-888	-0.7276 -1.2475 -0.9893 -0.2421
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.47666576504707336	▁guide line ▁ms ▁surgery
D-370	-0.47666576504707336	guideline ms surgery
P-370	-0.9752 -0.0314 -1.2072 -0.0628 -0.3721 -0.2112
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal_muscle exercise_capacity fontan_circulation
H-1491	-0.8135603666305542	kelet al _ ▁muscle ▁exercise _ capaci ty ▁Font an _ circ ulation
D-1491	-0.8135603666305542	keletal_ muscle exercise_capacity Fontan_circulation
P-1491	-3.2208 -0.1932 -0.3567 -3.4624 -0.5840 -0.4335 -0.0534 -0.0679 -0.5601 -0.2804 -0.1866 -1.8901 -0.1969 -0.5064 -0.2110
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone_system_inhibitors heart_failure
H-1486	-0.39559778571128845	▁re nin - angi oten sin - al do ster one _ system _ ▁inhibi tors ▁heart _ fail ure
D-1486	-0.39559778571128845	renin-angiotensin-aldosterone_system_ inhibitors heart_failure
P-1486	-0.4692 -0.4972 -0.1569 -0.0540 -0.0255 -1.1830 -0.5596 -0.0725 -0.9167 -0.3056 -0.5411 -0.3237 -0.1073 -0.3182 -0.0784 -0.0315 -0.1155 -0.2720 -1.3800 -0.6379 -0.3867 -0.2704
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf unilateral_renal_dnx cardiac autonomic_balance
H-1372	-0.3871411681175232	▁CHF ▁unilateral _ ▁renal _ ▁DN x ▁cardiac _ ▁autonomi c _ ▁balance
D-1372	-0.3871411681175232	CHF unilateral_ renal_ DNx cardiac_ autonomic_ balance
P-1372	-0.0420 -0.0372 -0.4296 -0.1106 -1.2462 -1.0106 -0.0310 -0.0236 -0.3808 -0.3013 -0.4299 -0.3065 -0.9229 -0.3557 -0.1791
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute_heart_failure
H-1014	-0.5827793478965759	▁a cute _ heart _ fail ure
D-1014	-0.5827793478965759	acute_heart_failure
P-1014	-0.5312 -0.0582 -0.1314 -1.8108 -0.1427 -0.8170 -0.7599 -0.7527 -0.2412
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic anaerobic_threshold heart_failure
H-1752	-0.6599624156951904	▁ana ero bic _ ▁thre s hold ▁heart _ ▁failure
D-1752	-0.6599624156951904	anaerobic_ threshold heart_ failure
P-1752	-0.5233 -0.3877 -0.7233 -0.9394 -0.9054 -0.1326 -0.3477 -0.2200 -0.4967 -2.5206 -0.4798 -0.2431
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr_variability cardiac_death
H-1589	-0.6052230596542358	▁ab normal _ HR _ ▁variabil ity ▁cardiac _ ▁death
D-1589	-0.6052230596542358	abnormal_HR_ variability cardiac_ death
P-1589	-1.9279 -0.0369 -0.4218 -1.7479 -0.3854 -1.0398 -0.1294 -0.0786 -0.1940 -0.7137 -0.3534 -0.2339
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome all-cause_readmissions
H-1580	-0.923617422580719	AIN _ o UTC OME ▁read missions
D-1580	-0.923617422580719	AIN_oUTCOME readmissions
P-1580	-5.2725 -0.2292 -1.0180 -0.0599 -0.4067 -0.5227 -0.1084 -0.4497 -0.2453
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac cardiac_hypertrophy
H-1782	-0.6286273002624512	▁a ac ▁cardiac _ ▁hyper trop hy
D-1782	-0.6286273002624512	aac cardiac_ hypertrophy
P-1782	-1.5723 -0.6580 -0.1198 -0.2978 -1.9840 -0.1628 -0.1130 -0.4784 -0.2717
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation postsystolic_function
H-331	-0.4312130808830261	▁posts y sto lic _ function
D-331	-0.4312130808830261	postsystolic_function
P-331	-0.9868 -0.3386 -0.2528 -0.2488 -0.7288 -0.2733 -0.3971 -0.2236
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician outcomes patients heart_failure
H-1720	-0.9510087370872498	▁physical ▁heart _ fail ure
D-1720	-0.9510087370872498	physical heart_failure
P-1720	-1.0582 -1.1800 -0.4460 -1.4885 -1.6964 -0.4727 -0.3153
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication resting_hemodynamics
H-828	-0.6743163466453552	▁medication ▁rest ing _ hem o dynamic s
D-828	-0.6743163466453552	medication resting_hemodynamics
P-828	-0.6751 -0.4723 -0.0646 -0.2783 -3.0340 -1.3187 -0.0210 -0.1468 -0.5160 -0.2162
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic_blood_pressure
H-1048	-0.8090474009513855	▁ toxic ity ▁system ic _ ▁blood _ tension
D-1048	-0.8090474009513855	toxicity systemic_ blood_tension
P-1048	-0.6048 -0.5625 -0.2311 -1.1073 -0.2319 -0.2177 -2.4134 -0.2283 -2.6860 -0.3899 -0.2266
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary_outcome patient post
H-617	-0.48179271817207336	
D-617	-0.48179271817207336	
P-617	-0.7026 -0.2610
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral_regurgitation hf symptoms surgery
H-362	-0.647213876247406	▁mit ral _ re gur gi tation HF ▁surgery
D-362	-0.647213876247406	mitral_regurgitationHF surgery
P-362	-2.9856 -0.0261 -0.1722 -0.1486 -0.0454 -0.3756 -0.0935 -1.4856 -1.2576 -0.3340 -0.1954
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations hospital longitudinal change
H-143	-0.7977614402770996	▁change
D-143	-0.7977614402770996	change
P-143	-1.7677 -0.3394 -0.2863
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence systolic_hf
H-1798	-0.4864039421081543	▁sy sto lic _ HF
D-1798	-0.4864039421081543	systolic_HF
P-1798	-0.8656 -0.1887 -0.0854 -0.7530 -1.0083 -0.3153 -0.1886
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission hospital heart_failure discharge
H-147	-0.5487294793128967	▁Read mission ▁hospital ▁heart _ fail ure ▁dis charge
D-147	-0.5487294793128967	Readmission hospital heart_failure discharge
P-147	-1.8865 -0.0325 -0.4554 -0.9875 -0.2106 -0.6016 -0.9394 -0.2919 -0.0110 -0.3457 -0.2738
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end_stage_heart_failure
H-1669	-0.9692811369895935	▁heart _ fail ure
D-1669	-0.9692811369895935	heart_failure
P-1669	-2.1394 -0.2548 -1.6280 -1.2894 -0.3340 -0.1701
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease lead hypertension kidney_failure
H-1598	-0.44333434104919434	▁lead ▁hyper tension ▁ki dne y _ fail ure
D-1598	-0.44333434104919434	lead hypertension kidney_failure
P-1598	-1.6915 -0.1355 -0.0012 -0.1259 -0.2132 -0.1441 -0.7872 -0.6324 -0.5947 -0.3622 -0.1886
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients chronic_kidney_disease ckd
H-898	-0.8036198616027832	▁chronic _ ▁ki dne y _ ▁disease CK d
D-898	-0.8036198616027832	chronic_ kidney_ diseaseCKd
P-898	-0.1896 -0.2479 -2.4790 -0.3327 -0.2925 -0.2029 -1.7074 -2.4477 -0.2469 -0.4731 -0.2202
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.7610062956809998	▁h f
D-556	-0.7610062956809998	hf
P-556	-1.0704 -1.3616 -0.3879 -0.2242
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu mortality
H-582	-0.5043911933898926	ICU ▁mortal ity
D-582	-0.5043911933898926	ICU mortality
P-582	-0.1374 -1.5352 -0.1155 -0.4647 -0.2692
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses patients disease
H-2020	-1.3002227544784546	▁nurse s ▁disease
D-2020	-1.3002227544784546	nurses disease
P-2020	-4.6567 -0.1816 -1.0623 -0.3459 -0.2547
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt patients
H-905	-0.7953840494155884	▁c t ▁di al ysis - dependent
D-905	-0.7953840494155884	ct dialysis-dependent
P-905	-0.5395 -2.9243 -0.6272 -0.1979 -0.0761 -0.2389 -0.0582 -2.2414 -0.2550
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf patients
H-217	-0.3524961471557617	▁CHF
D-217	-0.3524961471557617	CHF
P-217	-0.4061 -0.4805 -0.1708
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-0.36291125416755676	▁RM
D-163	-0.36291125416755676	RM
P-163	-0.4306 -0.4481 -0.2100
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic accounting cost
H-1582	-0.358887642621994	▁economic ▁cost
D-1582	-0.358887642621994	economic cost
P-1582	-0.7345 -0.1634 -0.3205 -0.2173
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western_blot immunohistochemistry electron_microscopy
H-1252	-0.5133803486824036	▁western _ ▁blot ▁immun oh isto che mist ry ▁electro n _ micro s copy
D-1252	-0.5133803486824036	western_ blot immunohistochemistry electron_microscopy
P-1252	-0.9380 -0.1793 -1.0895 -0.2506 -0.1152 -0.4556 -0.7152 -1.0632 -0.2834 -0.0055 -0.0425 -0.1515 -1.1651 -0.8158 -0.7508 -0.4728 -0.2334
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic_cardiomyopathy mortality
H-67	-0.49478650093078613	▁cardio my o pathy ▁mortal ity
D-67	-0.49478650093078613	cardiomyopathy mortality
P-67	-0.9967 -0.6780 -0.3859 -0.0130 -0.9059 -0.1993 -0.5175 -0.2620
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence idiopathic_dilated_cardiomyopathy
H-1741	-0.4537985324859619	▁evidence ▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1741	-0.4537985324859619	evidence idiopathic dilated_ cardiomyopathy
P-1741	-0.3798 -1.7138 -0.0074 -0.0153 -0.2520 -1.6168 -0.0122 -0.1957 -0.0979 -1.0193 -0.3181 -0.0118 -0.4759 -0.2372
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf chromatin_hyperacetylation
H-1036	-0.9554477334022522	▁ha w t ▁chr omat in _ ▁hyper ace ty lation
D-1036	-0.9554477334022522	hawt chromatin_ hyperacetylation
P-1036	-2.4522 -0.7542 -0.5221 -0.2142 -0.0842 -1.7801 -0.1959 -2.5335 -2.3052 -0.9693 -0.1004 -0.3498 -0.1598
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic_dysfunction patients peripheral_artery_disease
H-1566	-0.4954233765602112	▁dia sto lic _ ▁dys function ▁per i pher al _ ▁arter y _ ▁disease
D-1566	-0.4954233765602112	diastolic_ dysfunction peripheral_ artery_ disease
P-1566	-0.0259 -0.2978 -0.4625 -0.4256 -0.4637 -0.0296 -0.2606 -0.4702 -0.0442 -0.5146 -0.4008 -0.6026 -0.6680 -1.2487 -1.6509 -0.6100 -0.2465
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded_protein_response cardiac_sodium systolic heart_failure
H-1079	-0.81288081407547	▁un fold ed _ ▁Protein ▁cardiac _ so dium _ current ▁sy sto lic ▁heart _ fail ure
D-1079	-0.81288081407547	unfolded_ Protein cardiac_sodium_current systolic heart_failure
P-1079	-0.6129 -0.0027 -0.0718 -0.3476 -2.1686 -3.5662 -0.2930 -1.1868 -0.0311 -0.0713 -2.1475 -0.4112 -0.2346 -0.1987 -2.0580 -0.6563 -1.0697 -0.5419 -0.3307 -0.2571
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin_receptor_neprilysin_inhibitor heart_failure
H-1461	-0.6070703268051147	▁ang io ten sin _ ▁receptor ▁nepri ly sin _ ▁inhibi tor ▁heart _ fail ure
D-1461	-0.6070703268051147	angiotensin_ receptor neprilysin_ inhibitor heart_failure
P-1461	-0.0663 -4.5912 -0.2383 -0.9509 -0.3901 -0.2241 -0.0166 -0.0400 -0.1906 -0.1967 -0.4506 -0.1017 -0.1271 -0.3647 -1.4920 -0.8346 -0.4134 -0.2384
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient diagnosed hypertensive_lv_dysfunction
H-350	-0.5048436522483826	▁hyper tensi ve _ ▁LV ▁ms
D-350	-0.5048436522483826	hypertensive_ LV ms
P-350	-1.0466 -0.2441 -0.0470 -0.8642 -0.5735 -0.7692 -0.3341 -0.1601
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians patients hf
H-1724	-1.0736773014068604	▁physician s HF
D-1724	-1.0736773014068604	physiciansHF
P-1724	-2.9443 -0.1282 -1.7749 -0.3322 -0.1888
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia prognostic patients heart_failure
H-529	-0.5210753679275513	▁hypo album in emia ▁heart _ fail ure
D-529	-0.5210753679275513	hypoalbuminemia heart_failure
P-529	-0.4679 -0.1827 -0.2457 -0.1576 -0.9764 -0.3984 -1.0337 -1.0800 -0.4462 -0.2220
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute_heart_failure
H-468	-0.6335430145263672	▁a cute _ heart _ fail ure
D-468	-0.6335430145263672	acute_heart_failure
P-468	-0.6690 -0.0555 -0.1565 -2.2596 -0.1610 -1.0406 -0.6999 -0.3645 -0.2953
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia patients heart_disease
H-39	-0.8543313145637512	▁benefits ▁an emia ▁heart _ ▁disease
D-39	-0.8543313145637512	benefits anemia heart_ disease
P-39	-0.6843 -1.0999 -0.2725 -1.7625 -0.4136 -2.0034 -0.3706 -0.2279
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort_study
H-1829	-0.4112808406352997	
D-1829	-0.4112808406352997	
P-1829	-0.5310 -0.2916
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad_ai
H-543	-1.1322193145751953	▁treatment ▁post - L VAD _ ai
D-543	-1.1322193145751953	treatment post-LVAD_ai
P-543	-2.5954 -0.5422 -0.0552 -4.4334 -0.0461 -0.7098 -1.2546 -0.3139 -0.2394
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative operative outcomes
H-299	-0.3846357464790344	
D-299	-0.3846357464790344	
P-299	-0.5165 -0.2528
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth longitudinal medicare
H-1617	-1.0841962099075317	▁tele health ▁medica re
D-1617	-1.0841962099075317	telehealth medicare
P-1617	-5.4745 -0.1733 -0.0134 -0.0417 -0.5187 -0.2836
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public_reporting patients hospitals
H-1689	-0.5617154240608215	▁public _ report ing
D-1689	-0.5617154240608215	public_reporting
P-1689	-0.3642 -0.9638 -0.1917 -0.2219 -1.3401 -0.2886
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control outcomes
H-1232	-0.6700839400291443	▁ Rhythm - _ and _ ▁rate - control
D-1232	-0.6700839400291443	Rhythm-_and_ rate-control
P-1232	-0.6580 -0.1381 -0.2403 -2.8458 -0.2730 -0.4966 -1.1897 -0.3855 -0.0139 -0.8907 -0.2394
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus_rhythm adverse_outcomes
H-1644	-0.4175172448158264	▁sinus _ rhythm ▁AF
D-1644	-0.4175172448158264	sinus_rhythm AF
P-1644	-0.4343 -0.2523 -0.4142 -0.8628 -0.3404 -0.2011
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal diagnostic filling_pressures
H-490	-0.997269332408905	▁diagnostic ▁fill ing _ press ures
D-490	-0.997269332408905	diagnostic filling_pressures
P-490	-3.6563 -0.6311 -0.1269 -0.3991 -1.7732 -0.6544 -0.5009 -0.2362
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial_infarction
H-1137	-0.5370050668716431	▁My o card ial _ in far ction ▁Wi star _ ▁rat s
D-1137	-0.5370050668716431	Myocardial_infarction Wistar_ rats
P-1137	-1.1159 -0.3223 -0.4706 -0.2572 -0.2680 -0.2940 -0.0481 -0.1554 -0.9442 -0.4425 -0.4246 -2.4020 -0.0805 -0.5781 -0.2517
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis hf etiologies
H-1795	-0.776293158531189	▁et i ologie s
D-1795	-0.776293158531189	etiologies
P-1795	-3.4428 -0.4870 -0.0543 -0.1304 -0.3724 -0.1709
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients heart_failure cardiac_rehabilitation
H-568	-0.8671556711196899	▁heart _ fail ure ▁cardiac _ rehabilit ation
D-568	-0.8671556711196899	heart_failure cardiac_rehabilitation
P-568	-1.6385 -0.4335 -1.3735 -1.6725 -0.0656 -0.7450 -1.3330 -0.5465 -0.5756 -0.2879
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity_pathway_analysis
H-875	-0.4001919627189636	▁ingen u ity _ path way
D-875	-0.4001919627189636	ingenuity_pathway
P-875	-0.9726 -0.3093 -0.1184 -0.2776 -0.1567 -0.1905 -0.8266 -0.3499
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone severe_heart_failure
H-1701	-0.3293784260749817	▁Race ▁spi rono lac tone ▁heart _ fail ure
D-1701	-0.3293784260749817	Race spironolactone heart_failure
P-1701	-0.1788 -0.0959 -0.0142 -0.5070 -0.2002 -0.1977 -0.2783 -0.9085 -0.7417 -0.2918 -0.2091
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins tac
H-872	-0.5894127488136292	▁protein s TAC
D-872	-0.5894127488136292	proteinsTAC
P-872	-1.2746 -0.2902 -0.8408 -0.3103 -0.2312
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery mva
H-361	-0.4716377258300781	▁ms ▁m va
D-361	-0.4716377258300781	ms mva
P-361	-1.0675 -0.5631 -0.1641 -0.3708 -0.1927
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.5814476609230042	▁c RF
D-1769	-0.5814476609230042	cRF
P-1769	-0.4716 -1.2295 -0.4269 -0.1978
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.6698654294013977	▁DAS h
D-688	-0.6698654294013977	DASh
P-688	-0.7533 -0.1678 -1.4805 -0.2779
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise exercise
H-1931	-0.9485147595405579	▁exercise
D-1931	-0.9485147595405579	exercise
P-1931	-1.3232 -1.2344 -0.2879
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.4019249677658081	▁re hospital ization
D-1711	-0.4019249677658081	rehospitalization
P-1711	-1.1926 -0.0543 -0.1653 -0.3175 -0.2799
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate_models odds_ratios accounting hospital
H-191	-0.49691256880760193	▁odds _ rati os ▁hospital _ ▁cluster ing
D-191	-0.49691256880760193	odds_ratios hospital_ clustering
P-191	-0.0771 -0.3737 -0.0946 -0.2101 -0.8580 -0.4409 -2.0166 -0.0707 -0.5354 -0.2920
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk_stratification death all-cause_hospitalization heart_failure clinic outpatients
H-377	-1.19292414188385	▁heart _ fail ure
D-377	-1.19292414188385	heart_failure
P-377	-1.8873 -0.3156 -1.3158 -1.3560 -1.9664 -0.3165
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl hno acute heart_failure
H-412	-0.49314209818840027	▁ni tro x yl ▁h no ▁heart _ fail ure
D-412	-0.49314209818840027	nitroxyl hno heart_failure
P-412	-0.9459 -0.0494 -0.0389 -0.2670 -0.5049 -0.2881 -1.1692 -0.3072 -1.0002 -0.8178 -0.3429 -0.1861
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref hfpef patients regression_line
H-497	-0.7917439937591553	▁h f ▁ HF p EF ▁re gression _ line
D-497	-0.7917439937591553	hf HFpEF regression_line
P-497	-0.5648 -1.3771 -2.6916 -0.8942 -0.2073 -0.6605 -1.7691 -0.0177 -0.3011 -0.2553 -0.4775 -0.2846
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart_block pulmonary_artery bivp
H-322	-0.5102384090423584	▁Heart _ block ▁pulmonar y _ ▁arter y ▁Bi VP
D-322	-0.5102384090423584	Heart_block pulmonary_ artery BiVP
P-322	-0.7375 -0.4210 -1.4382 -0.2034 -0.3767 -0.3670 -0.1129 -0.5421 -1.1426 -0.2350 -0.3462 -0.2002
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute_walk_distance peak_vo2 baseline
H-1636	-0.38430511951446533	▁black s ▁VO 2 ▁base line
D-1636	-0.38430511951446533	blacks VO2 baseline
P-1636	-0.5591 -0.1827 -1.5130 -0.1091 -0.0107 -0.0548 -0.3924 -0.2527
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home hospital readmission congestive_heart_failure
H-1573	-0.6074197888374329	▁hospital - to - Home ▁hospital _ ▁read mission _ re duction _ programm e ▁con ges tive _ heart _ fail ure
D-1573	-0.6074197888374329	hospital-to-Home hospital_ readmission_reduction_programme congestive_heart_failure
P-1573	-0.4804 -0.3399 -0.1035 -0.2886 -0.5205 -1.2992 -0.8238 -2.8518 -0.1293 -0.2691 -0.1150 -0.0179 -0.7154 -0.6937 -0.7720 -0.8269 -0.0845 -0.5936 -0.2823 -1.5721 -0.2348 -0.9053 -0.5637 -0.4301 -0.2724
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization_therapy heart_failure narrow_qrs_complex
H-844	-0.45183122158050537	▁Card iac - re syn chron ization _ therapy ▁heart _ fail ure ▁QR s
D-844	-0.45183122158050537	Cardiac-resynchronization_therapy heart_failure QRs
P-844	-0.7763 -0.0785 -0.1173 -0.1130 -0.1128 -0.0126 -0.8216 -0.7946 -0.6577 -0.6377 -0.2380 -1.0725 -0.7434 -0.2441 -0.7361 -0.2992 -0.2256
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician death readmission discharge patients heart_failure
H-1412	-1.0860258340835571	▁physician _ continu ity ▁death ▁urgent _ dis charge ▁heart _ fail ure
D-1412	-1.0860258340835571	physician_continuity death urgent_discharge heart_failure
P-1412	-0.2574 -2.2553 -0.1518 -0.1428 -2.3283 -0.4071 -0.4117 -5.2254 -0.1204 -1.0590 -0.3195 -1.2864 -1.6903 -0.3854 -0.2496
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance attrition
H-1319	-0.33469530940055847	▁compliance ▁att ri tion
D-1319	-0.33469530940055847	compliance attrition
P-1319	-0.0077 -0.8411 -0.0285 -0.3417 -0.5755 -0.2137
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients diabetes eo-cfus functional_capacity
H-132	-0.7131552696228027	▁diabetes ▁e EO - c FU s
D-132	-0.7131552696228027	diabetes eEO-cFUs
P-132	-0.1231 -0.7862 -3.0716 -0.0735 -0.4054 -0.6461 -0.2047 -0.8934 -0.2143
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life patients
H-161	-0.7332615852355957	
D-161	-0.7332615852355957	
P-161	-1.2176 -0.2490
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients patients echocardiographic
H-813	-0.844174325466156	▁af ▁e cho car dio graphic
D-813	-0.844174325466156	af echocardiographic
P-813	-0.4873 -0.7315 -0.5554 -0.1713 -1.9446 -1.3916 -1.2168 -0.2549
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf surgical
H-353	-0.63103187084198	▁ms HF ▁ms
D-353	-0.63103187084198	msHF ms
P-353	-0.7573 -1.2557 -0.4870 -0.4723 -0.1828
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac_function catheter
H-1143	-0.3248191177845001	▁Card iac _ function ▁pressure - volu me _ con duct ance ▁cat heter _ system
D-1143	-0.3248191177845001	Cardiac_function pressure-volume_conductance catheter_system
P-1143	-0.3018 -0.2582 -0.3848 -0.2966 -0.0487 -0.1153 -0.0551 -0.1478 -0.8123 -0.6577 -0.0937 -0.1451 -0.9124 -0.0450 -0.8247 -0.0884 -0.4669 -0.1925
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 therapy
H-401	-0.4342763423919678	▁s st 2 ▁BB _ therapy
D-401	-0.4342763423919678	sst2 BB_therapy
P-401	-0.0139 -1.2609 -0.0784 -0.7901 -0.6539 -0.0716 -0.3760 -0.2293
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf pb
H-1349	-0.2703620195388794	▁PV f ▁recovery ▁p b ▁amplitud e
D-1349	-0.2703620195388794	PVf recovery pb amplitude
P-1349	-0.6083 -0.2950 -0.0429 -0.1023 -0.2849 -0.3278 -0.2377 -0.3906 -0.1437
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital heart lesions
H-985	-0.8904677629470825	▁con geni tal _ heart _ ▁les ions
D-985	-0.8904677629470825	congenital_heart_ lesions
P-985	-1.8347 -0.0272 -0.0877 -0.2153 -1.9808 -0.2307 -3.4897 -0.3871 -0.4152 -0.2362
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.31613942980766296	▁beta - block ers
D-865	-0.31613942980766296	beta-blockers
P-865	-0.5487 -0.1094 -0.3914 -0.2755 -0.3694 -0.2025
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up cardiovascular_events deaths
H-974	-0.797580897808075	▁follow - up ▁cardiovascular
D-974	-0.797580897808075	follow-up cardiovascular
P-974	-0.7457 -0.2330 -0.0198 -0.1520 -3.3954 -0.2395
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical patients functional_ms
H-373	-0.8242816925048828	▁MS
D-373	-0.8242816925048828	MS
P-373	-1.8138 -0.4116 -0.2474
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic outcomes hf
H-1202	-0.3686330318450928	▁di ure tic HF
D-1202	-0.3686330318450928	diureticHF
P-1202	-0.2154 -0.0610 -0.1512 -1.2333 -0.3730 -0.1779
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad systolic_hf prognostic
H-1183	-0.3423311114311218	▁CAD ▁sy sto lic HF
D-1183	-0.3423311114311218	CAD systolicHF
P-1183	-0.1643 -0.3092 -0.1325 -0.0855 -0.8573 -0.6808 -0.1668
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray genes heart_failure
H-1605	-0.9665607213973999	▁bio informati c ▁heart _ fail ure
D-1605	-0.9665607213973999	bioinformatic heart_failure
P-1605	-0.3087 -0.2516 -0.7124 -4.3826 -0.2419 -1.0472 -1.0518 -0.4553 -0.2476
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change lvet admission follow-up outcome
H-588	-0.43657606840133667	▁change ▁l VET ▁follow - up
D-588	-0.43657606840133667	change lVET follow-up
P-588	-0.2516 -0.9635 -0.1138 -0.0224 -0.2359 -0.0264 -1.6673 -0.2118
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin inflammation metabolism heart_disease
H-940	-0.6813103556632996	▁ inflammation ▁metabolism ▁heart _ ▁disease
D-940	-0.6813103556632996	inflammation metabolism heart_ disease
P-940	-1.2762 -0.3142 -0.0615 -0.2600 -0.4518 -2.4679 -0.3170 -0.3017
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary_disease leading heart_failure
H-981	-0.7230123281478882	▁corona ry _ ▁disease ▁heart _ fail ure
D-981	-0.7230123281478882	coronary_ disease heart_failure
P-981	-0.1745 -0.4153 -0.2582 -2.8090 -0.6372 -0.2549 -0.6645 -1.3375 -0.4626 -0.2165
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative hypoalbuminemia prognosis lvad surgery
H-538	-0.34206563234329224	▁hypo album in emia ▁l VAD ▁surgery
D-538	-0.34206563234329224	hypoalbuminemia lVAD surgery
P-538	-0.0770 -0.2676 -0.2409 -0.2589 -0.2813 -0.0245 -1.3573 -0.3686 -0.2025
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling_pathways cardiac_remodelling
H-992	-0.5220405459403992	▁cardiac _ ▁remodel ling
D-992	-0.5220405459403992	cardiac_ remodelling
P-992	-0.6435 -0.3495 -1.4162 -0.0896 -0.3994 -0.2340
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia right_ventricle heart_failure
H-1457	-0.5299735069274902	▁Fat ▁cache xia ▁right _ vent ric le ▁heart _ fail ure ▁complici ty
D-1457	-0.5299735069274902	Fat cachexia right_ventricle heart_failure complicity
P-1457	-0.3782 -0.4790 -0.0692 -0.1104 -0.3830 -0.5557 -2.4190 -1.0591 -0.3298 -0.5441 -0.4681 -0.4252 -0.5435 -0.1025 -0.4099 -0.2028
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial_fibrillation patients heart_failure
H-1231	-0.6124721169471741	▁at rial _ fi bril lation AF ▁heart _ fail ure
D-1231	-0.6124721169471741	atrial_fibrillationAF heart_failure
P-1231	-1.2991 -0.1756 -0.3401 -0.7535 -0.1903 -0.1495 -1.7006 -0.2608 -0.4883 -0.8749 -0.9939 -0.4937 -0.2419
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit_index biological_phenotype mortality
H-1012	-0.9237367510795593	▁deficit _ index ▁bi ological ▁mortal ity
D-1012	-0.9237367510795593	deficit_index biological mortality
P-1012	-3.5637 -0.1050 -0.2810 -0.2818 -0.0969 -3.1906 -0.1890 -0.3183 -0.2873
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical connected elevated resistin heart_failure
H-929	-0.6722896695137024	▁connected ▁heart _ fail ure
D-929	-0.6722896695137024	connected heart_failure
P-929	-0.0841 -1.4572 -0.2841 -1.1532 -1.2188 -0.3230 -0.1857
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd vvd free_wall_rs
H-328	-0.5447267889976501	▁av d ▁VVD ▁free _ wall ▁RS
D-328	-0.5447267889976501	avd VVD free_wall RS
P-328	-0.1427 -0.1712 -1.0103 -0.0038 -0.2229 -1.5333 -1.2446 -0.3688 -0.2051
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence esrd outpatients hf
H-388	-0.7856484055519104	▁incide nce ▁ec d ▁out patient s ▁h f
D-388	-0.7856484055519104	incidence ecd outpatients hf
P-388	-0.3145 -0.0498 -2.6261 -1.0991 -0.5470 -0.0585 -0.1375 -0.5180 -2.6319 -0.4020 -0.2578
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise_intolerance chronic_heart_failure prognosis
H-1273	-0.6903250813484192	▁exercise _ in tolerance ▁chronic _ heart _ fail ure
D-1273	-0.6903250813484192	exercise_intolerance chronic_heart_failure
P-1273	-0.7024 -0.7693 -0.3268 -0.1990 -0.7684 -0.4080 -1.7591 -0.2349 -1.2282 -1.1548 -0.4551 -0.2778
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical atherosclerosis linear_models
H-1557	-0.6144779920578003	▁sub clin ical _ at hero sc ler osis ▁general _ ▁linear
D-1557	-0.6144779920578003	subclinical_atherosclerosis general_ linear
P-1557	-0.3328 -0.4910 -0.0882 -0.2863 -0.4364 -0.3073 -0.0819 -2.3723 -0.1264 -0.4134 -0.2641 -0.5699 -2.5248 -0.3080
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling hf haemodynamic neuronal_stressors
H-1039	-0.4339018166065216	▁h f ▁ha emo dynamic ▁neuron al _ stress ors
D-1039	-0.4339018166065216	hf haemodynamic neuronal_stressors
P-1039	-0.8892 -0.5437 -0.0455 -0.0782 -0.0180 -0.2418 -0.2455 -0.4572 -2.0022 -0.0414 -0.4523 -0.1919
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right_ventricular_function prognosis heart_failure
H-1157	-0.713495671749115	▁right _ vent ri cular _ function ▁body _ ▁composición ▁heart _ fail ure
D-1157	-0.713495671749115	right_ventricular_function body_ composición heart_failure
P-1157	-0.1219 -0.3973 -1.2866 -0.8526 -0.5311 -0.4720 -0.3590 -0.8130 -0.6265 -1.7053 -1.3100 -0.3784 -0.9298 -1.0405 -0.3340 -0.2580
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart_transplantation left_ventricular_assist_device
H-306	-0.8958894610404968	▁heart _ ▁transplant ation ▁left _ vent ri cular _ assist _ ▁device
D-306	-0.8958894610404968	heart_ transplantation left_ventricular_assist_ device
P-306	-1.3853 -0.4824 -1.5634 -0.1132 -0.6029 -0.5701 -0.6552 -1.4680 -0.4314 -0.2551 -0.0155 -1.3253 -3.8160 -0.5338 -0.2207
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ecgs electrocardiographers
H-884	-0.460886150598526	▁base line _ e CG s ▁electro car dio graph ers
D-884	-0.460886150598526	baseline_eCGs electrocardiographers
P-884	-0.0118 -0.1087 -1.3879 -0.9406 -0.7734 -0.1478 -0.0386 -0.1053 -0.8535 -0.3040 -0.3528 -0.6960 -0.2712
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart_rate
H-1446	-1.012091875076294	▁heart _ rate _ vari ance
D-1446	-1.012091875076294	heart_rate_variance
P-1446	-1.5831 -0.6074 -1.3714 -1.8966 -0.0791 -1.9054 -0.3917 -0.2621
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end_point neurological cardiovascular_events
H-1872	-0.46359148621559143	▁neurologi cal ▁cardiovascular
D-1872	-0.46359148621559143	neurological cardiovascular
P-1872	-0.4088 -0.2125 -0.0394 -1.3946 -0.2627
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications dialysis patients
H-908	-0.3498772084712982	▁di al ysis
D-908	-0.3498772084712982	dialysis
P-908	-0.2642 -0.0853 -0.0867 -1.0537 -0.2594
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ffm stable
H-20	-0.9872595071792603	▁f f f f ▁FM ▁body _ weight ▁CC
D-20	-0.9872595071792603	ffff FM body_weight CC
P-20	-0.9941 -0.5765 -0.5902 -1.3070 -3.0979 -1.7969 -0.2899 -0.4090 -1.3182 -0.2723 -0.2079
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty hf
H-632	-0.9474549889564514	▁Fra il ty HF
D-632	-0.9474549889564514	FrailtyHF
P-632	-3.0586 -0.3475 -0.3163 -0.7997 -0.9406 -0.2221
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac_cachexia
H-9	-0.9379720687866211	▁Card iac _ ▁cache xia ▁body _ ▁composición
D-9	-0.9379720687866211	Cardiac_ cachexia body_ composición
P-9	-0.9052 -0.0600 -0.1167 -1.8681 -0.1101 -2.2538 -0.5111 -2.9887 -0.3314 -0.2346
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota hf
H-1003	-0.3434641361236572	▁south e a stern _ ▁Minnesota ▁h f
D-1003	-0.3434641361236572	southeastern_ Minnesota hf
P-1003	-0.2157 -0.0486 -0.0112 -0.0120 -0.1763 -1.1124 -0.2480 -0.8118 -0.6078 -0.1909
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart_failure nurse
H-84	-0.9153324365615845	▁heart _ fail ure ▁nurse
D-84	-0.9153324365615845	heart_failure nurse
P-84	-2.1610 -0.3223 -1.0640 -0.9560 -0.7964 -0.8494 -0.2583
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical hfpef
H-943	-0.3121691346168518	▁af ▁precipit ating _ factor ▁h f f
D-943	-0.3121691346168518	af precipitating_factor hff
P-943	-0.7413 -0.0286 -0.0535 -0.2350 -0.0173 -0.1050 -1.0000 -0.3193 -0.4129 -0.2089
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome hdl
H-254	-0.8563169240951538	▁prote ome ▁HD l _ parti cles ▁shot gun
D-254	-0.8563169240951538	proteome HDl_particles shotgun
P-254	-0.2893 -0.8998 -1.2607 -1.9018 -1.4719 -0.1206 -0.2054 -0.1616 -0.3279 -2.5842 -0.1965
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left_bundle_branch_block
H-1153	-0.6473760604858398	▁bund le ▁bran ch _ block ▁electric al _ activa tion _ se que nce
D-1153	-0.6473760604858398	bundle branch_block electrical_activation_sequence
P-1153	-0.1755 -1.5860 -2.5816 -0.1296 -0.2757 -2.4502 -0.7786 -0.2640 -0.3182 -0.2953 -0.1305 -0.2278 -0.6212 -0.4381 -0.0367 -0.4825 -0.2141
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients heart_transplant ecct
H-714	-0.8693678379058838	▁heart _ ▁transplant ▁ec t
D-714	-0.8693678379058838	heart_ transplant ect
P-714	-2.0653 -0.2581 -1.5609 -0.2535 -1.3995 -0.3332 -0.2151
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise training endothelial_function
H-248	-0.6563172340393066	▁exercise _ training ET ▁en dot heli al _ function
D-248	-0.6563172340393066	exercise_trainingET endothelial_function
P-248	-0.4680 -2.0256 -0.4413 -2.2013 -0.3699 -1.1295 -0.1647 -0.0632 -0.3102 -0.1883 -0.3131 -0.2008
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death stroke hospitalisation heart_failure
H-815	-0.745481550693512	▁cv ▁death ▁non - fa tal _ stro ke ▁heart _ fail ure
D-815	-0.745481550693512	cv death non-fatal_stroke heart_failure
P-815	-1.2882 -2.7353 -0.1451 -0.0541 -0.0464 -0.1638 -0.2278 -0.3145 -2.5204 -0.5475 -0.4099 -0.5158 -1.5219 -0.3909 -0.3007
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct heart_failure therapy patients
H-718	-0.8597396016120911	▁ec t ▁advanced _ heart _ fail ure _ therapy
D-718	-0.8597396016120911	ect advanced_heart_failure_therapy
P-718	-0.3803 -1.6477 -1.5674 -0.2840 -2.0514 -0.2059 -1.3612 -0.9542 -0.6905 -0.3276 -0.5713 -0.2754
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4_inhibitors drugs
H-1834	-0.4846559166908264	▁h HF ▁d p -4 _ ▁inhibi tors ▁drugs
D-1834	-0.4846559166908264	hHF dp-4_ inhibitors drugs
P-1834	-0.0034 -1.7261 -0.0903 -1.5769 -0.1475 -0.6197 -0.4745 -0.0513 -0.1167 -0.3282 -0.1965
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade holosystolic_murmur third_heart_sound apex
H-342	-0.47337087988853455	▁holo sy sto lic _ mur mur ▁heart
D-342	-0.47337087988853455	holosystolic_murmur heart
P-342	-0.0077 -0.2498 -0.2490 -0.2302 -0.5502 -0.6400 -0.4157 -0.9049 -1.2707 -0.2156
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain_proteins
H-1042	-0.48708486557006836	bro modo main _ ▁protein s
D-1042	-0.48708486557006836	bromodomain_ proteins
P-1042	-1.1218 -0.2406 -0.0327 -0.3119 -1.2682 -0.2149 -0.4569 -0.2495
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart_failure readmission outcome
H-1030	-0.7137213349342346	▁heart _ fail ure _ care
D-1030	-0.7137213349342346	heart_failure_care
P-1030	-0.4978 -0.2531 -1.3250 -0.8697 -1.9527 -0.1061 -0.4795 -0.2258
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up hf
H-288	-0.4268239140510559	▁follow - up ▁h f
D-288	-0.4268239140510559	follow-up hf
P-288	-0.1899 -0.2501 -0.0194 -0.6361 -1.4346 -0.2706 -0.1871
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.4204622209072113	▁ pharma ce ut ically
D-948	-0.4204622209072113	pharmaceutically
P-948	-1.5086 -0.0646 -0.1466 -0.0887 -0.0442 -0.9040 -0.1866
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse_event hypotension
H-1970	-0.54412442445755	▁hypo tension ▁interrupt
D-1970	-0.54412442445755	hypotension interrupt
P-1970	-0.3964 -0.0033 -0.8342 -1.2751 -0.2116
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt dt implantation
H-315	-0.4061434268951416	▁b t ▁d t ▁implant ation
D-315	-0.4061434268951416	bt dt implantation
P-315	-0.3770 -0.3761 -1.4757 -0.0437 -0.0456 -0.1292 -0.5941 -0.2078
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient mortality therapeutic
H-1667	-0.4627477824687958	▁mortal ity _ rate
D-1667	-0.4627477824687958	mortality_rate
P-1667	-0.0669 -0.0966 -0.9620 -0.8571 -0.5614 -0.2325
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak_vo2
H-1498	-0.251751184463501	▁Peak _ vo 2
D-1498	-0.251751184463501	Peak_vo2
P-1498	-0.0736 -0.3165 -0.1185 -0.3375 -0.4046 -0.2599
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 patients plasma
H-699	-0.596081554889679	▁ST 2 ▁plasma _ ▁sample s
D-699	-0.596081554889679	ST2 plasma_ samples
P-699	-0.6909 -0.0579 -0.6734 -1.4253 -1.1042 -0.1040 -0.4869 -0.2262
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients discharge follow-up medication
H-730	-0.6136612296104431	▁dis charge ▁follow - up ▁medication
D-730	-0.6136612296104431	discharge follow-up medication
P-730	-1.2928 -0.0224 -0.0154 -0.2378 -0.0191 -1.8092 -1.2396 -0.2731
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions septal surgical
H-984	-0.9110628366470337	▁sept al _ ▁defect s
D-984	-0.9110628366470337	septal_ defects
P-984	-0.6245 -0.1814 -0.6823 -2.7514 -0.2350 -1.6559 -0.2470
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients extubated blood transfusion
H-777	-0.3974561095237732	▁ex tuba ted ▁blood _ ▁loss ▁trans fusion
D-777	-0.3974561095237732	extubated blood_ loss transfusion
P-777	-0.3120 -0.0324 -0.1532 -0.6495 -0.3212 -1.2864 -0.0103 -0.0248 -0.9651 -0.2196
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis mortality patients
H-61	-0.4301678240299225	▁mortal ity ▁i CD - HF
D-61	-0.4301678240299225	mortality iCD-HF
P-61	-0.2781 -0.1612 -0.3000 -0.9677 -0.0946 -0.3882 -0.9463 -0.3053
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas cardiac pathogenesis
H-1484	-0.4460381269454956	▁mi RNA s ▁cardiac _ path ogen es is
D-1484	-0.4460381269454956	miRNAs cardiac_pathogenesis
P-1484	-2.2099 -0.0602 -0.2028 -0.0810 -0.4250 -0.0778 -0.2723 -0.6124 -0.2967 -0.4495 -0.2188
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers hf
H-1475	-0.2692311704158783	▁bio mark ers HF
D-1475	-0.2692311704158783	biomarkersHF
P-1475	-0.0363 -0.0477 -0.2410 -0.6655 -0.3876 -0.2373
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative clinical mortality
H-532	-0.3503316640853882	▁mortal ity
D-532	-0.3503316640853882	mortality
P-532	-0.4366 -0.3072 -0.3889 -0.2685
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes hospitalization
H-566	-0.44673657417297363	
D-566	-0.44673657417297363	
P-566	-0.6411 -0.2523
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.0090014934539795	▁financial s ▁en roll ed
D-1955	-1.0090014934539795	financials enrolled
P-1955	-3.0452 -0.4610 -1.8459 -0.1508 -0.2001 -1.1294 -0.2306
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals outcome
H-1690	-0.8801056146621704	
D-1690	-0.8801056146621704	
P-1690	-1.4910 -0.2692
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf patients
H-671	-0.43671804666519165	▁tras tuz um ab - related _ ▁CHF
D-671	-0.43671804666519165	trastuzumab-related_ CHF
P-671	-1.2971 -0.0411 -0.2218 -0.1507 -0.3262 -0.1974 -0.9710 -0.4775 -0.3971 -0.2872
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients transplants
H-2000	-0.44813114404678345	▁transplant s
D-2000	-0.44813114404678345	transplants
P-2000	-0.4080 -0.3903 -0.7754 -0.2188
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy engage exercise
H-1903	-0.9562051296234131	▁aero bic _ ▁exercise
D-1903	-0.9562051296234131	aerobic_ exercise
P-1903	-1.9691 -0.3413 -1.3753 -1.2555 -0.4171 -0.3790
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.5892008543014526	▁hospital s
D-1694	-0.5892008543014526	hospitals
P-1694	-1.5668 -0.3627 -0.2116 -0.2156
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients condition economic
H-1575	-0.5888471603393555	▁condition ▁economic
D-1575	-0.5888471603393555	condition economic
P-1575	-1.1533 -0.4093 -0.4945 -0.2983
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-0.9040532112121582	
D-1	-0.9040532112121582	
P-1	-1.5802 -0.2279
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon_matched-pairs_signed-rank_tests
H-923	-0.5253323912620544	▁Wil co xon ▁match ed - pair s ▁signed - rank
D-923	-0.5253323912620544	Wilcoxon matched-pairs signed-rank
P-923	-0.6468 -0.0120 -0.4207 -1.3374 -0.1122 -0.2378 -0.0842 -0.0866 -0.3355 -0.1190 -0.1577 -3.0104 -0.2690
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left_ventricular_assist_device right_ventricular_support
H-293	-0.7386851906776428	▁left _ vent ri cular _ assist ance ▁right _ vent ri cular _ support
D-293	-0.7386851906776428	left_ventricular_assistance right_ventricular_support
P-293	-1.0717 -0.4158 -0.8080 -0.8758 -0.3413 -0.2566 -0.0166 -2.2809 -1.1288 -0.3955 -0.6374 -0.9020 -0.3099 -0.8271 -1.6133 -0.4354 -0.2414
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis atherosclerosis cardiovascular_events rotterdam_study
H-1554	-0.5654270052909851	▁psoriasis ▁at hero sc ler osis ▁cardiovascular ▁Rotterdam
D-1554	-0.5654270052909851	psoriasis atherosclerosis cardiovascular Rotterdam
P-1554	-0.1961 -0.2085 -0.0546 -0.0625 -2.5054 -0.0587 -0.0565 -1.7490 -0.5591 -0.2038
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal_artery_stenosis ras peripheral_arterial_disease
H-1593	-0.5240635275840759	▁Ren al _ ▁arter y _ ▁sten osis RAS ▁per i pher al _ ▁arterial _ ▁disease
D-1593	-0.5240635275840759	Renal_ artery_ stenosisRAS peripheral_ arterial_ disease
P-1593	-0.6557 -0.1024 -0.3748 -0.2607 -0.7233 -0.1940 -1.6794 -0.0703 -0.1114 -0.2503 -0.2071 -0.0418 -0.1803 -0.2343 -1.2905 -0.7258 -2.2616 -0.3889 -0.2047
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart_failure patients rheumatoid_arthritis tnf_antagonist
H-600	-0.6450338959693909	▁Heart _ ▁failure ▁rhe um ato id _ ar thri tis ▁t NF _ ▁anta gon ist
D-600	-0.6450338959693909	Heart_ failure rheumatoid_arthritis tNF_ antagonist
P-600	-0.4233 -0.5860 -1.3868 -0.2234 -0.1561 -0.5839 -1.3020 -0.1612 -0.8499 -0.8485 -0.9491 -0.0949 -0.6180 -1.9761 -0.2618 -0.0206 -0.8429 -0.7111 -0.2602
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary_artery_disease cad systolic_heart_failure hf
H-1182	-0.5852279663085938	▁Corona ry _ ▁arter y _ ▁disease CAD ▁sy sto lic _ heart _ fail ure HF
D-1182	-0.5852279663085938	Coronary_ artery_ diseaseCAD systolic_heart_failureHF
P-1182	-0.0533 -0.1870 -0.3142 -0.3351 -0.2682 -0.3558 -2.3502 -0.9380 -0.4912 -0.0946 -0.6504 -0.1902 -1.8393 -0.1874 -0.8607 -0.4912 -1.0522 -0.2946 -0.1657
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality hf hospital admissions transplant ventricular_assist_device
H-125	-0.7384482622146606	▁mortal ity HF ▁hospital ▁ad missions ▁transplant ▁vent ri cular _ assist ance _ ▁device
D-125	-0.7384482622146606	mortalityHF hospital admissions transplant ventricular_assistance_ device
P-125	-0.5215 -0.1350 -1.0954 -2.2127 -1.5619 -0.0157 -0.0527 -0.0344 -0.5239 -0.3364 -0.3033 -0.0061 -1.6780 -0.6218 -2.8913 -0.3619 -0.2016
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.36587968468666077	
D-154	-0.36587968468666077	
P-154	-0.4603 -0.2715
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.7431074380874634	
D-1713	-0.7431074380874634	
P-1713	-1.2201 -0.2661
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient heart_failure_with_reduced_ejection_fraction
H-1203	-0.588483452796936	▁heart _ fail ure ▁e je ction _ fraction
D-1203	-0.588483452796936	heart_failure ejection_fraction
P-1203	-1.2482 -0.3483 -1.0479 -1.7777 -0.4396 -0.1695 -0.0912 -0.3104 -0.0106 -0.8039 -0.2261
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral_renal_denervation autonomic_balance chronic_heart_failure
H-1369	-0.6272174119949341	▁renal _ ▁den er va tion ▁autonomi c _ ▁balance ▁rabbi ts ▁chronic _ heart _ fail ure
D-1369	-0.6272174119949341	renal_ denervation autonomic_ balance rabbits chronic_heart_failure
P-1369	-0.4056 -0.4525 -2.5269 -0.2574 -0.1331 -0.1578 -0.0091 -0.5756 -0.3500 -0.8928 -0.0540 -0.0318 -2.1350 -0.3153 -1.3483 -0.2863 -1.4307 -0.5642 -0.3683 -0.2497
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression type_i_regulatory_subunit ri hf
H-1429	-0.7143543362617493	▁expression ▁regulator y _ sub un it RI ▁h f
D-1429	-0.7143543362617493	expression regulatory_subunitRI hf
P-1429	-0.0621 -0.3107 -0.3398 -1.5629 -0.3174 -0.4205 -0.0587 -2.1144 -0.6385 -2.2145 -0.3191 -0.2137
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat mir-25 transcription_factor hand2 heart_failure
H-638	-0.5399594902992249	▁na fat ▁mi r -25 ▁tran scription _ factor ▁hand 2 ▁heart _ fail ure
D-638	-0.5399594902992249	nafat mir-25 transcription_factor hand2 heart_failure
P-638	-2.0323 -1.0470 -1.1799 -0.5611 -0.0856 -0.1347 -0.0713 -0.4508 -0.0315 -0.9003 -0.1249 -0.1259 -0.4424 -0.7870 -0.6296 -0.2988 -0.2760
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf_inhibition cardiac_function remodeling
H-458	-0.7238812446594238	▁VE GF ▁cardiac _ function ▁remodel ing
D-458	-0.7238812446594238	VEGF cardiac_function remodeling
P-458	-1.6794 -0.4837 -2.1736 -0.3499 -0.3850 -0.7873 -0.0820 -0.3938 -0.1801
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas right_atrium embolize pulmonary_arterial_vasculature
H-594	-0.5255050659179688	▁My xo mas ▁right _ at rium ▁pulmonar y _ ▁arterial
D-594	-0.5255050659179688	Myxomas right_atrium pulmonary_ arterial
P-594	-1.1222 -0.0688 -0.3009 -0.0751 -0.2632 -1.0024 -0.1182 -0.0081 -0.3396 -0.3649 -0.9311 -1.9128 -0.3243
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right_atrial_myxoma pulmonary_embolism right_heart_failure
H-592	-0.6857780814170837	▁right _ at rial _ My xo ma ▁pulmonar y _ e mbol ism ▁right _ ▁heart _ fail ure
D-592	-0.6857780814170837	right_atrial_Myxoma pulmonary_embolism right_ heart_failure
P-592	-0.1582 -0.2626 -1.2078 -0.3046 -0.2985 -3.8680 -0.3344 -1.1561 -0.0067 -0.3813 -0.7844 -0.2586 -0.0096 -0.0596 -0.0633 -0.2537 -2.7116 -0.6352 -0.6436 -1.0608 -0.4275 -0.2009
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic_heart_transplantation oht end-stage_heart_failure
H-1280	-0.8992356061935425	▁Ort ho topic _ heart _ ▁transplant ation ▁o w t ▁heart _ fail ure
D-1280	-0.8992356061935425	Orthotopic_heart_ transplantation owt heart_failure
P-1280	-0.3798 -0.1376 -0.1158 -0.2534 -2.5040 -0.2348 -1.0188 -0.0574 -0.4210 -4.7350 -0.2133 -2.0186 -0.3762 -1.1866 -1.1025 -0.3457 -0.1864
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary_heart_disease stroke heart_failure
H-1564	-0.7871029376983643	▁corona ry _ ▁heart _ ▁Disease ▁stroke ▁heart _ fail ure
D-1564	-0.7871029376983643	coronary_ heart_ Disease stroke heart_failure
P-1564	-0.0653 -0.3128 -0.3244 -3.2638 -0.3984 -2.2957 -0.1717 -0.2833 -0.2556 -0.8008 -1.4224 -0.3748 -0.2634
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing β-blocker sst2
H-400	-0.6121031045913696	▁β - block er BB ▁s st 2
D-400	-0.6121031045913696	β-blockerBB sst2
P-400	-0.1041 -0.1088 -0.7148 -0.6387 -2.1635 -0.0426 -1.3264 -0.0804 -0.7276 -0.2142
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone primary_composite_endpoint
H-1227	-0.28954556584358215	▁e pler en one
D-1227	-0.28954556584358215	eplerenone
P-1227	-0.3639 -0.0244 -0.1571 -0.1302 -0.8489 -0.2128
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet exercise_rehabilitation patients chf
H-1884	-0.9544711112976074	▁c PET _ ▁gu iding _ ▁exercise ▁CHF
D-1884	-0.9544711112976074	cPET_ guiding_ exercise CHF
P-1884	-0.7918 -2.2756 -3.9120 -0.8314 -0.0048 -0.2680 -0.5940 -0.3226 -0.3257 -0.2188
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline outcomes ecct cardiac_transplant
H-711	-0.5135467052459717	▁base line ▁ec t ▁cardiac _ ▁transplant
D-711	-0.5135467052459717	baseline ect cardiac_ transplant
P-711	-0.1893 -0.0520 -0.1400 -1.3845 -0.0477 -0.1851 -0.6985 -1.6675 -0.2573
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate_ii lvads patients
H-776	-0.6443178653717041	▁technique ▁exchange _ mal function ing ▁Heart Mate _ ▁II _ l VAD s
D-776	-0.6443178653717041	technique exchange_malfunctioning HeartMate_ II_lVADs
P-776	-0.1445 -0.6414 -1.2905 -0.6163 -0.0463 -0.1207 -0.7473 -0.1690 -0.4338 -0.5314 -0.4901 -3.7667 -0.0480 -0.3348 -0.5894 -0.3390
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart_failure hf cardiovascular hospitalization
H-1074	-0.7234437465667725	▁Heart _ fail ure HF ▁cardiovascular
D-1074	-0.7234437465667725	Heart_failureHF cardiovascular
P-1074	-0.6627 -0.2268 -0.9388 -2.2350 -0.4635 -0.1359 -0.8485 -0.2763
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing medications heart_failure
H-1121	-1.0258550643920898	▁medication s ▁heart _ fail ure
D-1121	-1.0258550643920898	medications heart_failure
P-1121	-2.4001 -0.1440 -1.5598 -0.3998 -1.3589 -1.5388 -0.5285 -0.2770
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient asymptomatic follow-up
H-599	-0.3962060511112213	▁recovery ▁follow - up
D-599	-0.3962060511112213	recovery follow-up
P-599	-0.5093 -1.0607 -0.2147 -0.0222 -0.3800 -0.1903
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality_of_life mlhf_questionnaire
H-1991	-1.2395132780075073	▁ml f
D-1991	-1.2395132780075073	mlf
P-1991	-1.3595 -2.1741 -1.1639 -0.2606
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients heart_failure diagnostic medication follow-up
H-732	-1.2643166780471802	▁heart _ fail ure ▁medication
D-732	-1.2643166780471802	heart_failure medication
P-732	-1.3401 -0.3779 -1.5213 -1.6344 -1.3855 -2.3536 -0.2375
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation resistin correlated ejection_fraction
H-938	-0.3672640919685364	▁resist in ▁e je ction _ fraction
D-938	-0.3672640919685364	resistin ejection_fraction
P-938	-0.2329 -0.6417 -0.3134 -0.1606 -0.0851 -0.3280 -0.0121 -1.2549 -0.2767
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart_failure hf morbidity mortality
H-199	-0.6715933680534363	▁Pediatri c _ heart _ fail ure HF ▁morbi d ity ▁mortal ity
D-199	-0.6715933680534363	Pediatric_heart_failureHF morbidity mortality
P-199	-0.1627 -0.1289 -0.7491 -2.2422 -0.1626 -0.6062 -1.8467 -0.7178 -2.4955 -0.0394 -0.1172 -0.0293 -0.0611 -0.4585 -0.2565
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change readmissions follow-up heart_failure readmission
H-720	-0.6299839019775391	▁read missions ▁follow - up ▁heart _ fail ure ▁read mission
D-720	-0.6299839019775391	readmissions follow-up heart_failure readmission
P-720	-1.2377 -0.0951 -0.0084 -0.2474 -0.0100 -1.1041 -0.2427 -1.1867 -0.5794 -1.0319 -0.1066 -2.0727 -0.2669
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic inflammatory abdominal
H-1285	-0.9974246621131897	▁ ische mic ▁abdominal _ problem s ▁MT
D-1285	-0.9974246621131897	ischemic abdominal_problems MT
P-1285	-1.6129 -0.1860 -0.7529 -3.8320 -0.9640 -0.3829 -0.3038 -1.1760 -0.5273 -0.2365
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase myocardium
H-171	-0.5456060767173767	▁band _ of _ activa ted _ ca pas e ▁pace d _ My o car dium
D-171	-0.5456060767173767	band_of_activated_capase paced_Myocardium
P-171	-0.3567 -0.3322 -0.1280 -0.2563 -0.2342 -0.1982 -0.7061 -0.7936 -0.9646 -0.4381 -0.2049 -0.2159 -0.2297 -4.0951 -0.2899 -0.0478 -0.2495 -0.4280 -0.1976
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations acr cms
H-140	-0.4821533262729645	▁a cr ▁CMS
D-140	-0.4821533262729645	acr CMS
P-140	-0.7578 -0.5619 -0.3148 -0.5147 -0.2616
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline embase cinahl
H-62	-0.8397422432899475	▁med line EMBA se ▁c INA HL
D-62	-0.8397422432899475	medlineEMBAse cINAHL
P-62	-0.5185 -0.8069 -0.3257 -0.9204 -2.2369 -1.4827 -0.6841 -0.4177 -0.1648
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal_dysfunction morbidity
H-719	-0.29060283303260803	▁renal _ ▁dys function ▁post - trans plant ▁morbi d ity
D-719	-0.29060283303260803	renal_ dysfunction post-transplant morbidity
P-719	-0.4387 -0.2363 -0.9471 -0.0416 -0.0205 -0.0836 -0.0595 -0.0707 -0.7214 -0.1089 -0.3016 -0.4868 -0.2612
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia heart_disease
H-40	-0.9242132306098938	▁benefits ▁an emia ▁heart _ ▁Disease
D-40	-0.9242132306098938	benefits anemia heart_ Disease
P-40	-1.7529 -0.7629 -0.3379 -1.1377 -0.3212 -2.5184 -0.3279 -0.2348
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart_failure disease medical
H-2008	-1.0260168313980103	▁Heart _ fail ure ▁disease ▁medical
D-2008	-1.0260168313980103	Heart_failure disease medical
P-2008	-0.7020 -0.3968 -2.3606 -1.1588 -1.2345 -1.8688 -0.2226 -0.2640
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin sitagliptin
H-1828	-0.7099981904029846	▁h f ▁sax ag lip tin ▁si tag lip tin
D-1828	-0.7099981904029846	hf saxagliptin sitagliptin
P-1828	-0.0029 -2.3182 -0.1692 -0.0272 -0.8168 -2.0452 -0.3937 -0.0021 -0.2455 -1.8274 -0.4631 -0.2087
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based therapies patients fes
H-1333	-0.6251071691513062	▁evidence - based _ therapie s ▁f es
D-1333	-0.6251071691513062	evidence-based_therapies fes
P-1333	-0.0481 -0.0810 -0.0048 -0.6288 -0.2648 -0.1277 -3.3644 -0.9195 -0.5692 -0.2428
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction pump driveline pump curative
H-774	-0.8597636222839355	▁dys function ▁pump ▁drive line _ ▁injury ▁isola ted _ pump _ ▁replace ment
D-774	-0.8597636222839355	dysfunction pump driveline_ injury isolated_pump_ replacement
P-774	-2.9038 -0.0142 -0.8112 -0.8223 -0.1695 -1.9098 -0.6925 -1.9762 -0.0214 -0.9680 -1.0751 -0.3547 -1.3577 -0.1770 -0.2821 -0.2207
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up hf deaths
H-1771	-0.7004420757293701	▁follow - up ▁h f
D-1771	-0.7004420757293701	follow-up hf
P-1771	-1.0572 -0.1767 -0.0163 -0.9614 -1.4789 -0.9949 -0.2178
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital discharge
H-302	-1.0547864437103271	▁sur vi val ▁hospital _ dis charge
D-302	-1.0547864437103271	survival hospital_discharge
P-302	-6.6367 -0.0416 -0.1239 -1.6125 -0.3362 -0.1131 -0.0157 -0.3666 -0.2467
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal_dnx plasma
H-1381	-0.44982582330703735	▁Ren al _ d x ▁circula ting _ ▁plasma ▁CHF - in v _ ▁rabbi ts
D-1381	-0.44982582330703735	Renal_dx circulating_ plasma CHF-inv_ rabbits
P-1381	-1.2292 -0.0264 -0.3964 -1.0613 -0.4847 -0.0380 -0.2810 -0.4331 -0.6970 -0.7159 -0.1226 -0.0623 -0.2797 -1.1703 -0.4476 -0.0340 -0.3865 -0.2310
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna genotyped
H-1454	-0.8814309239387512	▁h ct ▁germ line _ DNA
D-1454	-0.8814309239387512	hct germline_DNA
P-1454	-1.4505 -1.9932 -0.8446 -0.1086 -0.1734 -1.1202 -1.0695 -0.2914
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients lvad implantation
H-531	-0.29358264803886414	▁l VAD ▁implant ation
D-531	-0.29358264803886414	lVAD implantation
P-531	-0.5586 -0.1247 -0.3247 -0.0928 -0.4253 -0.2354
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients cad cad
H-1189	-1.2619452476501465	▁deriva tion ▁CAD ▁CAD
D-1189	-1.2619452476501465	derivation CAD CAD
P-1189	-2.2181 -0.1319 -3.1627 -1.4897 -0.3257 -0.2436
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients randomized
H-1874	-0.7214759588241577	
D-1874	-0.7214759588241577	
P-1874	-1.1518 -0.2911
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient clinical symptoms
H-1468	-0.9616053700447083	
D-1468	-0.9616053700447083	
P-1468	-1.6752 -0.2480
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients blood medication
H-729	-0.5061428546905518	▁blood _ work ▁medication
D-729	-0.5061428546905518	blood_work medication
P-729	-0.9309 -0.3676 -0.3674 -0.1839 -0.9288 -0.2583
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.6436254978179932	▁HD L - bound _ ▁malo ndi alde hy de ▁HD l - indu ced
D-252	-0.6436254978179932	HDL-bound_ malondialdehyde HDl-induced
P-252	-0.4554 -3.7985 -0.0644 -0.0470 -0.5107 -0.4614 -0.1780 -0.0415 -0.2637 -0.1247 -0.8252 -2.6968 -0.0389 -0.0005 -0.0117 -1.2361 -0.1871
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients trastuzumab
H-676	-0.1663924604654312	▁tras tuz um ab
D-676	-0.1663924604654312	trastuzumab
P-676	-0.2895 -0.0291 -0.0775 -0.0283 -0.3695 -0.2045
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses patients
H-1021	-1.1688693761825562	NP ▁ED
D-1021	-1.1688693761825562	NP ED
P-1021	-1.7460 -1.8194 -0.8311 -0.2790
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow_up hf
H-627	-0.4991271495819092	▁follow _ up ▁h f
D-627	-0.4991271495819092	follow_up hf
P-627	-0.1004 -0.3650 -0.3351 -0.7873 -1.4757 -0.2548 -0.1757
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical outcomes hfpef
H-1525	-0.7549211978912354	▁EH HF p EF
D-1525	-0.7549211978912354	EHHFpEF
P-1525	-1.0336 -2.5198 -0.0573 -0.2981 -0.4093 -0.2115
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ambulatory patients heart_failure functional_capacity outcomes
H-695	-0.823743462562561	▁Solu ble _ s 2 ▁ambula tory _ ▁pacientes ▁heart _ fail ure
D-695	-0.823743462562561	Soluble_s2 ambulatory_ pacientes heart_failure
P-695	-0.6711 -0.1205 -0.3928 -1.4098 -0.5045 -0.4774 -0.0509 -1.1237 -1.6919 -1.9806 -0.2580 -1.4496 -1.2543 -0.7016 -0.2694
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote_monitoring hospital discharge patients heart_failure meta-analysis
H-146	-0.5721650123596191	▁remote _ monitor ing ▁hospital _ dis charge ▁heart _ fail ure
D-146	-0.5721650123596191	remote_monitoring hospital_discharge heart_failure
P-146	-0.2200 -0.5537 -0.0734 -0.0370 -1.0858 -0.7608 -0.2310 -0.0161 -1.7119 -0.2240 -1.3501 -0.8893 -0.5671 -0.2900
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline echocardiograms evidence reverse_remodeling
H-907	-0.361105740070343	▁base line ▁e cho card i ogram s ▁rever se _ re cover ing
D-907	-0.361105740070343	baseline echocardiograms reverse_recovering
P-907	-0.1262 -0.1398 -0.1211 -0.3018 -0.2710 -0.6622 -0.0158 -0.3424 -0.0540 -0.0669 -0.2314 -0.9307 -1.3755 -0.4397 -0.4666 -0.2326
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin_hypophosphorylation myocardial_dd
H-771	-0.5992721915245056	▁Tit in _ hy phos phor y lation ▁my o card ial
D-771	-0.5992721915245056	Titin_hyphosphorylation myocardial
P-771	-0.0762 -0.9031 -0.3783 -0.4671 -0.4649 -0.4767 -0.8605 -0.1031 -0.7973 -0.2338 -0.4593 -0.3119 -2.6665 -0.1910
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac_overexpression mammalian_enabled mena heart_failure
H-1809	-0.6221356391906738	▁Card iac _ over expression ▁Mamma lian _ ▁enabled ▁men a ▁heart _ fail ure
D-1809	-0.6221356391906738	Cardiac_overexpression Mammalian_ enabled mena heart_failure
P-1809	-0.4091 -0.0737 -0.2682 -0.3194 -0.0992 -0.1106 -0.3971 -1.7607 -0.1119 -2.6193 -0.0453 -0.3431 -0.3420 -1.1862 -0.8366 -1.3787 -0.2751
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis chronic_heart_failure tachycardia
H-164	-0.7864606380462646	▁apo pto sis ▁can ine _ model ▁chronic _ heart _ fail ure ▁ta chy car dia
D-164	-0.7864606380462646	apoptosis canine_model chronic_heart_failure tachycardia
P-164	-2.5384 -0.2142 -2.6031 -0.1138 -0.0872 -0.7590 -0.1432 -1.6719 -0.2547 -1.9582 -0.2170 -1.4709 -0.8871 -1.0863 -0.1938 -0.0469 -0.0572 -0.4163 -0.2236
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker uptitration hfpef
H-183	-0.5250609517097473	▁benefit RAS - ▁β - block er _ up tit ration HF p EF
D-183	-0.5250609517097473	benefitRAS- β-blocker_uptitrationHFpEF
P-183	-0.1831 -1.8204 -0.1009 -0.1026 -0.0578 -0.4451 -0.7242 -0.2119 -0.4323 -0.7404 -0.4010 -2.0860 -0.0759 -0.6164 -0.2597 -0.1433
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise adverse_events coronary_artery_disease cad
H-1899	-0.5137286186218262	▁corona ry _ ▁arter y _ ▁disease CAD
D-1899	-0.5137286186218262	coronary_ artery_ diseaseCAD
P-1899	-0.3451 -0.3016 -0.3343 -0.2430 -0.3543 -0.1936 -2.1887 -0.6384 -0.3320 -0.2062
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv_filling_pressure stable severe_systolic_hf
H-489	-0.7294448614120483	▁LV ▁fill ing _ press ure ▁sy sto lic HF
D-489	-0.7294448614120483	LV filling_pressure systolicHF
P-489	-0.0876 -0.2142 -0.0821 -0.2062 -1.9390 -0.6374 -2.1937 -0.3089 -0.0898 -2.5297 -0.2871 -0.1776
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal_bleeding patients ventricular_assist_devices cardiac nurse
H-1656	-0.6597058176994324	▁Gastro inte stin al _ blad ed ing ▁vent ri cular _ assist _ ▁devices ▁cardiac _ ▁nurse
D-1656	-0.6597058176994324	Gastrointestinal_bladeding ventricular_assist_ devices cardiac_ nurse
P-1656	-0.5367 -0.0603 -1.0231 -0.1603 -0.4507 -2.5279 -0.2308 -0.2436 -0.0438 -0.4701 -0.3383 -0.2853 -0.0141 -1.7790 -3.5099 -0.0232 -0.4005 -0.4026 -0.4649 -0.2287
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas bridge_to_transplantation destination_therapy
H-1999	-0.5258913636207581	▁l VAS ▁ bridge _ to _ ▁transplant ation ▁destination _ therapy
D-1999	-0.5258913636207581	lVAS bridge_to_ transplantation destination_therapy
P-1999	-0.4691 -0.7805 -0.5370 -0.0555 -0.5582 -1.0100 -0.3215 -1.6611 -0.0465 -0.6794 -0.4067 -0.1677 -0.4664 -0.2027
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 prognosis heart_failure
H-399	-1.129143476486206	▁heart _ fail ure
D-399	-1.129143476486206	heart_failure
P-399	-3.0552 -0.4360 -1.1304 -1.5824 -0.3456 -0.2253
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs functional_capacity peak_vo2
H-123	-0.7208331823348999	▁c PC s ▁functional _ capaci ty ▁VO 2
D-123	-0.7208331823348999	cPCs functional_capacity VO2
P-123	-0.0797 -2.5497 -0.0900 -0.2937 -0.3580 -0.0360 -0.0336 -3.4197 -0.2857 -0.5132 -0.2698
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac_hypertrophy energy_metabolism
H-1778	-0.48688310384750366	▁Card iac _ ▁hyper trop hy ▁energy _ ▁metabolism
D-1778	-0.48688310384750366	Cardiac_ hypertrophy energy_ metabolism
P-1778	-1.0355 -0.2564 -0.1284 -2.0647 -0.2517 -0.1301 -0.1591 -0.2527 -0.3307 -0.4904 -0.2561
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east rhythm_control_therapy cardiovascular complications
H-1648	-0.4195632040500641	▁e ast ▁ rhythm _ control _ therapy ▁cardiovascular ▁AF
D-1648	-0.4195632040500641	east rhythm_control_therapy cardiovascular AF
P-1648	-0.7478 -0.2880 -0.2278 -0.4213 -0.3497 -0.0197 -0.5375 -0.1474 -0.0373 -1.6248 -0.3314 -0.3021
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty heart_failure health
H-621	-1.427024006843567	▁heart _ ▁failure ▁health ▁body _ ▁composición
D-621	-1.427024006843567	heart_ failure health body_ composición
P-621	-2.3288 -0.3220 -2.9430 -2.4330 -1.5272 -0.3835 -2.3046 -0.3872 -0.2138
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil orally doxorubicin
H-959	-0.16702131927013397	▁Nico rand il ▁do xor ubi cin
D-959	-0.16702131927013397	Nicorandil doxorubicin
P-959	-0.0070 -0.0113 -0.0467 -0.0860 -0.0334 -0.0114 -0.0691 -1.1085 -0.1298
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients clinical radiological hf hospitalization
H-560	-0.4870699644088745	▁radi ological HF
D-560	-0.4870699644088745	radiologicalHF
P-560	-0.2105 -0.3078 -1.2373 -0.3853 -0.2945
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart heart_failure arrhythmias
H-747	-0.7381718754768372	▁Heart _ t 2 ▁heart _ fail ure ▁ar rhythm ias
D-747	-0.7381718754768372	Heart_t2 heart_failure arrhythmias
P-747	-1.0163 -0.9031 -0.4940 -0.0155 -1.4567 -0.8346 -0.6169 -1.9370 -0.0982 -0.2365 -1.3811 -0.3996 -0.2068
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham_heart_study hf ef
H-1103	-0.6285460591316223	▁Fram ing ham _ ▁Heart _ ▁Study ▁h f
D-1103	-0.6285460591316223	Framingham_ Heart_ Study hf
P-1103	-0.2569 -0.1175 -0.2020 -0.3365 -0.3432 -0.5560 -1.7536 -1.1130 -0.7947 -1.2276 -0.2131
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations congestive_heart_failure
H-208	-0.46411946415901184	▁ed ▁in tuba tions ▁con ges tive _ heart _ fail ure
D-208	-0.46411946415901184	ed intubations congestive_heart_failure
P-208	-0.8347 -0.0315 -0.1172 -0.1408 -0.3871 -0.0341 -0.3269 -0.1925 -1.9683 -0.1951 -0.6774 -0.9647 -0.4171 -0.2102
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics symptoms patients heart_failure hf
H-1199	-0.7447938919067383	▁di ure tics ▁heart _ fail ure HF
D-1199	-0.7447938919067383	diuretics heart_failureHF
P-1199	-0.3193 -0.1058 -0.9993 -2.1936 -0.2445 -1.2938 -0.8204 -0.8343 -0.3972 -0.2397
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence acp clinical_practice_guidelines
H-35	-0.7761852741241455	▁evidence ▁a CP ▁clinic al _ prac tice
D-35	-0.7761852741241455	evidence aCP clinical_practice
P-35	-0.5563 -1.1570 -1.8558 -0.9077 -0.1902 -0.4214 -0.1538 -0.0334 -2.2516 -0.2347
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck_stent chronic_myocardial_ischemia heart_failure
H-502	-0.6168718934059143	▁bottle ne ck _ ▁sten t ▁chronic _ My o card ial _ ische mia ▁heart _ ▁failure ▁pig s
D-502	-0.6168718934059143	bottleneck_ stent chronic_Myocardial_ischemia heart_ failure pigs
P-502	-0.2600 -0.1482 -0.0456 -0.4191 -2.7764 -0.0985 -0.2636 -0.3743 -3.4154 -0.6654 -0.4915 -0.3216 -0.3003 -0.0975 -0.9638 -0.1463 -0.5552 -1.4461 -0.1009 -0.1215 -0.3575 -0.2024
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis mortality patients
H-68	-0.6374990344047546	▁mortal ity _ pred ors ▁i CD - HF
D-68	-0.6374990344047546	mortality_predors iCD-HF
P-68	-0.0421 -0.3350 -1.2146 -0.0675 -2.2340 -0.2309 -1.1601 -0.0669 -0.5019 -0.8637 -0.2958
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient patients discharged hf
H-1400	-0.8734360933303833	▁in patient _ ▁records HF
D-1400	-0.8734360933303833	inpatient_ recordsHF
P-1400	-0.6260 -0.1451 -1.0514 -2.1504 -1.4197 -0.4662 -0.2553
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report aric hf
H-290	-0.7168231010437012	▁report ▁a RIC _ HF
D-290	-0.7168231010437012	report aRIC_HF
P-290	-0.0145 -0.8006 -0.8077 -0.2840 -2.1959 -0.6463 -0.2687
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients therapy hospitalized cardiovascular
H-1223	-0.6450337767601013	▁cardiovascular
D-1223	-0.6450337767601013	cardiovascular
P-1223	-1.2271 -0.3933 -0.3148
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients pneumonia surgical conditions
H-5	-0.5227195024490356	▁pneu monia ▁conditions
D-5	-0.5227195024490356	pneumonia conditions
P-5	-0.0565 -1.6129 -0.2606 -0.4249 -0.2587
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis therapy
H-1467	-0.6891398429870605	▁ therapy
D-1467	-0.6891398429870605	therapy
P-1467	-2.0118 -0.1004 -0.3446 -0.2997
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.3392333388328552	
D-1852	-0.3392333388328552	
P-1852	-0.4440 -0.2345
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease accounting cardiac_transplants
H-982	-0.6732441782951355	▁pa e dia tric _ ▁cardiac _ ▁transplant s
D-982	-0.6732441782951355	paediatric_ cardiac_ transplants
P-982	-2.1028 -0.3185 -0.0944 -0.9860 -0.2371 -0.1153 -0.2042 -1.1816 -0.4147 -1.4449 -0.3062
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter_ablation sinus_rhythm
H-945	-0.4458986818790436	▁AF - free _ ▁probabil ity ▁cat heter _ ab lation ▁sinus _ rhythm
D-945	-0.4458986818790436	AF-free_ probability catheter_ablation sinus_rhythm
P-945	-0.5245 -0.0715 -0.0344 -0.5718 -2.8505 -0.0694 -0.0301 -0.1184 -0.3168 -0.5437 -0.0817 -0.4655 -0.2537 -0.4599 -0.4683 -0.2743
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc outcomes outcome admission discharge
H-1401	-0.5985815525054932	▁no c ▁ad mission _ to _ dis charge
D-1401	-0.5985815525054932	noc admission_to_discharge
P-1401	-0.8166 -1.1851 -0.6398 -0.0308 -1.6961 -0.8924 -0.4012 -0.2661 -0.0180 -0.3595 -0.2789
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients implantation crt
H-848	-0.864413321018219	▁device _ ▁implant ation ▁c RT
D-848	-0.864413321018219	device_ implantation cRT
P-848	-1.4978 -0.5278 -0.1358 -0.1692 -0.3716 -3.0674 -0.9120 -0.2336
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol exercise training baseline hgb
H-843	-0.5843574404716492	▁HR Qo l ▁exercise ▁base line ▁h gb
D-843	-0.5843574404716492	HRQol exercise baseline hgb
P-843	-1.5757 -0.0567 -2.1214 -0.1701 -0.1312 -0.0550 -0.7037 -0.3961 -0.3985 -0.2352
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs osprey
H-1611	-0.4311389625072479	▁de g s ▁o spre y ▁network s
D-1611	-0.4311389625072479	degs osprey networks
P-1611	-0.3733 -2.1160 -0.3755 -0.0734 -0.0331 -0.0827 -0.4164 -0.1953 -0.4550 -0.1907
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.3533006012439728	▁ir on
D-49	-0.3533006012439728	iron
P-49	-0.0617 -0.3470 -0.7631 -0.2414
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-0.4005647301673889	▁ed ▁CHF
D-216	-0.4005647301673889	ed CHF
P-216	-0.8598 -0.2233 -0.3012 -0.2178
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit_index
H-1008	-0.3872449994087219	▁deficit _ index SD
D-1008	-0.3872449994087219	deficit_indexSD
P-1008	-0.2209 -0.1423 -0.2212 -1.3851 -0.1673 -0.1867
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare policy
H-1716	-0.2509571611881256	▁Medica re ▁post - a cute _ care _ transfer ▁policy
D-1716	-0.2509571611881256	Medicare post-acute_care_transfer policy
P-1716	-0.2512 -0.0308 -0.0829 -0.0760 -0.0326 -0.0288 -0.1583 -0.5127 -0.2188 -0.5074 -0.5656 -0.5449 -0.2526
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-0.8984974026679993	▁benefit ▁QR s
D-892	-0.8984974026679993	benefit QRs
P-892	-1.0255 -1.1464 -1.1043 -1.0455 -0.1709
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical change
H-792	-0.3454285264015198	▁change
D-792	-0.3454285264015198	change
P-792	-0.5190 -0.3000 -0.2173
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-0.8224085569381714	▁Diet ▁nu ts ▁whole _ ▁grain _ in take ▁mortal ity
D-692	-0.8224085569381714	Diet nuts whole_ grain_intake mortality
P-692	-2.4741 -2.5755 -0.0274 -1.1456 -0.3855 -2.5304 -0.2794 -0.2291 -0.3399 -0.0389 -0.0972 -0.3387 -0.2296
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-1.0178794860839844	▁benefit
D-619	-1.0178794860839844	benefit
P-619	-2.4560 -0.3706 -0.2270
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.6842065453529358	
D-1508	-0.6842065453529358	
P-1508	-1.0599 -0.3085
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt_intervals sd_of_all_qt_intervals sdqt
H-1439	-0.7184556722640991	▁ QT _ ▁interval s ▁SD ▁ QT _ ▁interval s SD QT
D-1439	-0.7184556722640991	QT_ intervals SD QT_ intervalsSDQT
P-1439	-0.8039 -0.8804 -0.1864 -0.4753 -0.2306 -0.9649 -0.7669 -1.0619 -0.2815 -0.3971 -0.2569 -2.0480 -1.9548 -0.2371 -0.2312
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic right_ventricular_contractile_reserve patients pulmonary_hypertension
H-821	-0.5907544493675232	▁right _ vent ri cular _ contract ile ▁pulmonar y _ hy tension
D-821	-0.5907544493675232	right_ventricular_contractile pulmonary_hytension
P-821	-0.1472 -0.4671 -0.9054 -0.8946 -0.3099 -0.2051 -0.2524 -0.9522 -1.5595 -0.3134 -0.4895 -1.8114 -0.0172 -0.3251 -0.2113
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart_rate aortic blood_flow doxorubicin
H-960	-0.38806405663490295	▁Heart _ rate ▁a or tic _ ▁blood _ flow ▁do xor ubi cin
D-960	-0.38806405663490295	Heart_rate aortic_ blood_flow doxorubicin
P-960	-0.5986 -0.3620 -1.3349 -0.2008 -0.0887 -0.0726 -0.1560 -1.8840 -0.2141 -0.5116 -0.0457 -0.0763 -0.0378 -0.1109 -0.3614 -0.1534
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute autonomic_nervous_system qtv hf patients
H-1447	-0.8955037593841553	▁a cute _ ▁autonomi c _ ▁ner vous _ system _ modul ation ▁Q TV HF
D-1447	-0.8955037593841553	acute_ autonomic_ nervous_system_modulation QTVHF
P-1447	-0.9424 -0.0212 -0.1697 -1.1819 -0.3168 -0.1848 -4.1409 -0.7437 -0.1560 -0.1047 -0.7767 -0.9023 -0.0491 -1.8442 -1.6669 -2.2628 -0.5021 -0.1528
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular_death hf hospitalization exercise training patients btes
H-1933	-0.562881350517273	▁cardiovascular ▁h f ▁exercise _ training ▁b tes
D-1933	-0.562881350517273	cardiovascular hf exercise_training btes
P-1933	-0.2570 -0.9350 -1.1727 -0.1269 -1.2315 -0.3268 -0.5468 -0.4453 -0.3478 -0.2388
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac_resynchronization_therapy patients heart_failure
H-903	-0.445577472448349	▁cardiac _ re syn chron ization _ therapy ▁di al ysis - dependent ▁heart _ fail ure
D-903	-0.445577472448349	cardiac_resynchronization_therapy dialysis-dependent heart_failure
P-903	-0.0861 -0.3104 -0.0948 -0.0721 -0.0198 -0.6796 -1.0816 -0.4994 -0.3596 -0.1517 -0.1435 -0.2291 -0.0555 -1.3277 -0.3878 -1.4126 -0.7561 -0.4688 -0.3298
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo bivp correlated rs_synchrony
H-327	-0.8021813631057739	rv po ▁Bi VP ▁RS _ syn chron y
D-327	-0.8021813631057739	rvpo BiVP RS_synchrony
P-327	-2.1770 -0.9720 -0.7050 -0.4053 -1.8057 -0.6654 -0.0485 -0.0053 -0.8386 -0.9415 -0.2596
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ventricular-arterial_coupling
H-526	-0.4155888557434082	▁e es ▁vent ri cular - arte rial _ ▁coup ling ▁SV
D-526	-0.4155888557434082	ees ventricular-arterial_ coupling SV
P-526	-0.7561 -0.2450 -0.1637 -0.4819 -0.1851 -0.4259 -0.1970 -0.2018 -0.5034 -1.1310 -0.3503 -0.4656 -0.4683 -0.2431
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial pde2 expression activity hf
H-1213	-0.5686061382293701	▁my o card ial _ p de 2 ▁activity ▁h z
D-1213	-0.5686061382293701	myocardial_pde2 activity hz
P-1213	-1.8125 -0.3797 -0.2841 -0.3492 -0.5618 -0.8314 -0.0684 -0.0685 -0.1515 -0.1683 -2.0553 -0.4151 -0.2461
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1_mapping clinically myocardial_fibrosis
H-1065	-0.5745458006858826	▁technique ▁my o card ial _ ▁fibro sis
D-1065	-0.5745458006858826	technique myocardial_ fibrosis
P-1065	-0.4885 -1.0602 -0.4273 -0.8608 -0.4633 -0.2155 -0.1656 -1.4506 -0.3767 -0.2370
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat sympathetic_outflow parasympathetic_activity
H-1869	-0.5356698632240295	▁BAT ▁sympa the tic _ out flow ▁para sy mpa the tic ▁activity
D-1869	-0.5356698632240295	BAT sympathetic_outflow parasympathetic activity
P-1869	-0.0476 -0.1188 -0.4951 -0.2271 -0.2070 -0.1076 -0.0880 -0.1735 -0.3043 -0.8849 -1.2556 -0.5171 -2.8142 -0.5244 -0.2699
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin acute anthracycline-induced_cardiotoxicity
H-931	-0.47040027379989624	▁resist in ▁an thra cycli ne - indu ced _ ▁cardio toxic ity
D-931	-0.47040027379989624	resistin anthracycline-induced_ cardiotoxicity
P-931	-0.5047 -0.3919 -0.5376 -0.1343 -0.1689 -1.9994 -0.5559 -0.0001 -0.0122 -0.4481 -0.1624 -0.7701 -0.4879 -0.5722 -0.3104
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal_muscle correlated vo2_max
H-1500	-0.8854367733001709	▁skelet al _ ▁muscle _ ▁mass ▁VO 2
D-1500	-0.8854367733001709	skeletal_ muscle_ mass VO2
P-1500	-0.6612 -0.1843 -0.3960 -3.9124 -0.2732 -1.4641 -1.2712 -0.0982 -0.4118 -0.1819
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized double-blind active placebo
H-77	-0.952449381351471	▁active
D-77	-0.952449381351471	active
P-77	-0.5630 -2.0378 -0.2566
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac_catheterization patient extubated transferred
H-1297	-0.3542323708534241	▁emergency _ ▁cardiac _ ▁cat heter ization ▁ex tuba ted ▁intermedi ate _ care
D-1297	-0.3542323708534241	emergency_ cardiac_ catheterization extubated intermediate_care
P-1297	-0.3550 -0.1924 -0.1407 -0.2085 -2.4336 -0.0375 -0.3004 -0.1383 -0.0262 -0.0634 -0.0836 -0.6416 -0.3088 -0.2011 -0.3086 -0.2277
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients atrial_fibrillation pacemaker
H-883	-0.30079352855682373	▁at rial _ fi bril lation ▁pace maker
D-883	-0.30079352855682373	atrial_fibrillation pacemaker
P-883	-0.5607 -0.2753 -0.3919 -0.5227 -0.1086 -0.1389 -0.1025 -0.1269 -0.5706 -0.2098
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump pump pump_thrombosis hemolysis
H-2004	-0.641546368598938	▁pump _ ex change s ▁pump _ mal function s ▁pump _ thro mbo sis ▁hem ol ysis _ event s
D-2004	-0.641546368598938	pump_exchanges pump_malfunctions pump_thrombosis hemolysis_events
P-2004	-0.5405 -0.5606 -2.6475 -0.0142 -0.1457 -0.6278 -0.9854 -1.8889 -0.0329 -0.2044 -0.5302 -0.9196 -0.1675 -0.2858 -1.5455 -0.2056 -0.1479 -0.1377 -0.5486 -1.9712 -0.0976 -0.3291 -0.2212
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world_health_organization hf
H-1791	-1.0888854265213013	▁world _ ▁health _ organisation ▁h f ▁la
D-1791	-1.0888854265213013	world_ health_organisation hf la
P-1791	-0.4460 -0.1772 -1.6809 -0.0949 -1.8406 -0.6915 -1.1016 -1.3352 -3.3541 -0.1669
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial_tissue pka
H-1426	-0.8051665425300598	▁my o card ial _ ▁tissu e ▁p ka
D-1426	-0.8051665425300598	myocardial_ tissue pka
P-1426	-2.9666 -0.3469 -0.2553 -0.2283 -0.2052 -2.2536 -0.2968 -0.5525 -1.0324 -0.5055 -0.2138
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body_mass_index crf exercise
H-1768	-0.4824984073638916	▁body _ ▁mass _ index ▁c RF ▁tre ad m ill _ ▁exercise
D-1768	-0.4824984073638916	body_ mass_index cRF treadmill_ exercise
P-1768	-0.2504 -0.4028 -1.2493 -0.1837 -0.3490 -0.1557 -0.9324 -1.3725 -0.0299 -0.2649 -0.0540 -0.3705 -0.5494 -0.8241 -0.2490
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition compliance exercise injections patients
H-1321	-0.37519460916519165	▁compliance ▁exercise ▁inject ions
D-1321	-0.37519460916519165	compliance exercise injections
P-1321	-0.0171 -1.2101 -0.0976 -0.1567 -0.5117 -0.2580
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic_failure cardiomyopathic
H-986	-0.3979487717151642	▁dia sto lic _ fail ure ▁cardio my o pathi c ▁flow
D-986	-0.3979487717151642	diastolic_failure cardiomyopathic flow
P-986	-0.0887 -0.2545 -0.3082 -0.6439 -0.4582 -0.5240 -0.1034 -1.4278 -0.5886 -0.0240 -0.3281 -0.1347 -0.4430 -0.2440
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic_nervous_system activity qtv
H-1436	-0.9037970304489136	▁autonomi c _ ▁ner vous _ system _ activ ity ▁Q TV
D-1436	-0.9037970304489136	autonomic_ nervous_system_activity QTV
P-1436	-0.0210 -0.8144 -0.2280 -4.8221 -0.7607 -0.1317 -0.1527 -0.6172 -0.2172 -0.0986 -2.3260 -1.9650 -0.3118 -0.1867
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial exercise training heart_failure hf patients
H-1925	-0.6898387670516968	▁Psycho social _ factor s ▁exercise ▁heart _ fail ure HF
D-1925	-0.6898387670516968	Psychosocial_factors exercise heart_failureHF
P-1925	-1.4204 -0.0913 -1.0159 -0.0826 -0.2079 -0.0682 -1.1848 -0.2275 -1.5750 -1.5021 -0.7448 -0.5881 -0.2592
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical outcomes hospitalisations readmissions mortality
H-1850	-0.4717245399951935	
D-1850	-0.4717245399951935	
P-1850	-0.6789 -0.2646
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise training patients chronic_heart_failure high-density_lipoprotein
H-245	-1.1130632162094116	▁exercise _ training ▁chronic _ heart _ fail ure ▁lipo prote in
D-245	-1.1130632162094116	exercise_training chronic_heart_failure lipoprotein
P-245	-3.8059 -2.4314 -0.3836 -0.7940 -0.3331 -2.0080 -0.1665 -1.4257 -1.1816 -1.2705 -0.2386 -0.7047 -0.5740 -0.2653
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf intubation
H-221	-0.4298516809940338	▁ed ▁CHF ▁in tub ation _ rate s
D-221	-0.4298516809940338	ed CHF intubation_rates
P-221	-0.6548 -0.2586 -0.0330 -0.1025 -0.0637 -0.7912 -1.5407 -0.0455 -0.5748 -0.2338
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty health outcomes
H-623	-0.8106400370597839	▁Fra il ty ▁health _ ▁outcome s
D-623	-0.8106400370597839	Frailty health_ outcomes
P-623	-2.5182 -0.1587 -0.2633 -0.5727 -1.3602 -1.7657 -0.0610 -0.3602 -0.2357
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical therapeutic
H-1368	-0.44207727909088135	
D-1368	-0.44207727909088135	
P-1368	-0.6239 -0.2603
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare hospitalizations
H-1714	-0.40985357761383057	▁Medica re ▁fee - for - service
D-1714	-0.40985357761383057	Medicare fee-for-service
P-1714	-0.1536 -0.0237 -1.5436 -0.1266 -0.0395 -0.3421 -0.0085 -1.1691 -0.2819
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician conditions hospital discharge
H-1422	-0.3258609175682068	▁physician _ continu ity ▁conditions ▁hospital _ dis charge
D-1422	-0.3258609175682068	physician_continuity conditions hospital_discharge
P-1422	-0.1925 -0.8488 -0.2164 -0.2747 -0.0383 -0.6578 -0.5936 -0.1589 -0.0185 -0.3247 -0.2601
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-0.9603885412216187	▁die t SD
D-1983	-0.9603885412216187	dietSD
P-1983	-1.9289 -0.1563 -2.0794 -0.3913 -0.2460
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.5190276503562927	
D-1862	-0.5190276503562927	
P-1862	-0.8212 -0.2169
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol mortality
H-650	-0.2938939929008484	▁bis o pro lol ▁mortal ity
D-650	-0.2938939929008484	bisoprolol mortality
P-650	-0.2537 -0.3216 -0.0538 -0.6713 -0.2052 -0.1624 -0.4833 -0.1998
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss btes exercise
H-1928	-0.9600706100463867	▁ps s ▁social ▁b tes ▁exercise
D-1928	-0.9600706100463867	pss social btes exercise
P-1928	-1.4061 -0.1471 -2.6443 -1.6965 -0.3689 -0.8005 -0.3900 -0.2271
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics_rounds
H-1681	-0.6731257438659668	thi cs _ ▁Round s
D-1681	-0.6731257438659668	thics_ Rounds
P-1681	-1.9732 -0.6675 -0.4342 -0.4398 -0.2030 -0.7795 -0.2148
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients prognosis
H-1315	-0.46688559651374817	
D-1315	-0.46688559651374817	
P-1315	-0.6964 -0.2374
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac_stress β-ar drive
H-1219	-0.3492547571659088	▁defense _ me chan ism ▁cardiac _ stress ▁β - ar _ drive
D-1219	-0.3492547571659088	defense_mechanism cardiac_stress β-ar_drive
P-1219	-0.1396 -0.1927 -0.3706 -0.1066 -0.0103 -0.1031 -0.2150 -2.1785 -0.3559 -0.0414 -0.7155 -0.1761 -0.1048 -0.3148 -0.2139
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.2868932783603668	▁white
D-626	-0.2868932783603668	white
P-626	-0.2969 -0.3329 -0.2308
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.41939783096313477	
D-2013	-0.41939783096313477	
P-2013	-0.5828 -0.2560
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart_rate_reduction ivabradine left_ventricle heart_failure patients
H-515	-0.7087414264678955	▁heart _ rate _ re duction ▁i va bra dine _ un load s ▁left _ vent ric le ▁heart _ ▁failure
D-515	-0.7087414264678955	heart_rate_reduction ivabradine_unloads left_ventricle heart_ failure
P-515	-2.3242 -0.7187 -1.3877 -1.1160 -0.1119 -0.0126 -0.0783 -0.0132 -0.0724 -0.3106 -0.3721 -0.6847 -0.0128 -0.1570 -0.2134 -0.4024 -0.4214 -2.7001 -1.6080 -0.5139 -0.4364 -2.2156 -0.7809 -0.3456
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic reverse_remodeling cardiac_resynchronization_therapy
H-426	-0.38990318775177	▁e cho car dio graphic ▁rever se _ ▁remodel ing ▁cardiac _ re syn chron ization _ therapy
D-426	-0.38990318775177	echocardiographic reverse_ remodeling cardiac_resynchronization_therapy
P-426	-0.7688 -0.4798 -0.2996 -0.9400 -0.9140 -0.0228 -0.0620 -0.1273 -1.1119 -0.1446 -0.0293 -0.2249 -0.1475 -0.0309 -0.0126 -0.6734 -0.7263 -0.2124 -0.6064 -0.2634
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers neurohormonal_stimulation inflammation endothelial_dysfunction
H-13	-0.28442901372909546	▁bio mark ers ▁neuro hormon al _ stimul ation ▁ inflammation ▁en dot heli al _ ▁dys function
D-13	-0.28442901372909546	biomarkers neurohormonal_stimulation inflammation endothelial_ dysfunction
P-13	-0.1724 -0.0560 -0.1669 -0.1375 -0.1626 -0.1694 -1.4299 -0.1277 -0.0477 -0.1976 -0.1966 -0.1188 -1.1429 -0.1870 -0.0440 -0.3415 -0.3842 -0.0362 -0.3279 -0.2419
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis medical heart_failure canadian_cardiovascular_society
H-198	-0.8327435851097107	▁medical ▁heart _ ▁failure ▁Canadian _ ▁Card io vas cular _ soci ety
D-198	-0.8327435851097107	medical heart_ failure Canadian_ Cardiovascular_society
P-198	-0.1206 -0.7843 -0.1837 -1.9809 -1.3066 -0.4345 -1.0212 -3.3464 -0.5564 -0.5182 -0.2062 -0.9857 -0.0141 -0.8226 -0.2096
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal pathophysiology congestive_heart_failure chf
H-634	-0.5514399409294128	▁Neuro hormon al _ ab normal ities ▁pat ho phy si ology ▁con ges tive _ heart _ fail ure ▁gh f
D-634	-0.5514399409294128	Neurohormonal_abnormalities pathophysiology congestive_heart_failure ghf
P-634	-1.0190 -0.3082 -0.0568 -0.5409 -0.2691 -0.2701 -0.1144 -0.3694 -0.0987 -0.0137 -1.1177 -0.0261 -0.2485 -0.0686 -0.5333 -0.2414 -2.1398 -0.1707 -0.9783 -0.4656 -3.4899 -0.1721 -0.3133 -0.2092
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart_failure pathophysiology diagnosis medical_treatment nursing
H-2018	-0.5849788188934326	▁Heart _ fail ure ▁Path o phy si ology ▁medical
D-2018	-0.5849788188934326	Heart_failure Pathophysiology medical
P-2018	-0.4199 -0.4450 -0.4969 -0.0288 -0.2334 -1.1544 -0.0037 -0.6668 -0.0172 -0.3986 -2.9203 -0.2348
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic_neurotransmission acetylcholinesterase_inhibition
H-1135	-0.38733941316604614	▁para sy mpa the tic _ ▁neuro trans mission ▁a ce tyl cho line ster ase _ ▁inhibi tion
D-1135	-0.38733941316604614	parasympathetic_ neurotransmission acetylcholinesterase_ inhibition
P-1135	-0.0314 -0.2156 -0.4141 -0.4245 -0.1071 -0.1503 -0.4296 -0.0191 -0.0367 -0.0863 -0.1545 -0.4058 -1.4542 -0.2167 -1.0635 -0.9255 -0.8107 -0.3090 -0.1184 -0.5436 -0.2175
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence end-stage_renal_disease outpatients systolic_heart_failure
H-386	-0.5515455007553101	▁end - s tage _ ▁renal _ ▁disease ▁out patient s ▁sy sto lic _ heart _ fail ure
D-386	-0.5515455007553101	end-stage_ renal_ disease outpatients systolic_heart_failure
P-386	-1.0766 -0.0994 -0.0513 -0.0150 -0.3066 -0.1843 -0.2170 -1.7554 -0.5702 -0.0313 -0.0474 -0.8885 -0.2059 -0.9195 -0.2314 -2.1420 -0.1868 -1.3504 -0.7140 -0.3428 -0.2467
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia patients heart_disease clinical_practice_guideline american_college_of_physicians
H-29	-0.810255765914917	▁an emia ▁heart _ ▁disease ▁american _ col lege _ of _ phy s iques
D-29	-0.810255765914917	anemia heart_ disease american_college_of_physiques
P-29	-1.1714 -0.1528 -0.7210 -0.2445 -1.8605 -2.0047 -0.4315 -1.1700 -2.6084 -0.2084 -0.0919 -0.3408 -0.6160 -0.4689 -0.9808 -0.4499 -0.2528
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal_dnx cardiac autonomic_balance chf sympathetic_tone
H-1382	-0.44139957427978516	▁renal _ ▁DN x ▁cardiac _ ▁autonomi c _ ▁balance ▁CHF ▁sympa the tic _ tone
D-1382	-0.44139957427978516	renal_ DNx cardiac_ autonomic_ balance CHF sympathetic_tone
P-1382	-0.0461 -1.1952 -1.3956 -0.0567 -0.0242 -0.2638 -0.4837 -0.3938 -0.3055 -0.7490 -0.0715 -0.0822 -0.4107 -0.3548 -0.4048 -1.0981 -0.3800 -0.2295
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right_ventricle rv cardiac_function medical
H-1091	-0.6021050810813904	▁right _ vent ric le RV ▁cardiac _ function ▁medical
D-1091	-0.6021050810813904	right_ventricleRV cardiac_function medical
P-1091	-0.0187 -0.2809 -0.4036 -2.1520 -1.0430 -1.5317 -0.0613 -0.7552 -0.1824 -0.0365 -0.5447 -0.2153
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical radiological hf quality_of_life
H-565	-0.3628993034362793	▁radi ological HF
D-565	-0.3628993034362793	radiologicalHF
P-565	-0.0719 -0.3090 -0.8997 -0.2708 -0.2631
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive_heart_failure chf
H-209	-0.9709596633911133	▁con ges tive _ heart _ fail ure ▁ch f
D-209	-0.9709596633911133	congestive_heart_failure chf
P-209	-1.2946 -0.0637 -0.2933 -0.2352 -2.1886 -0.1845 -0.9337 -1.0749 -3.5672 -1.1855 -0.4041 -0.2262
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri_scanner baseline heart_failure
H-1057	-0.5645692944526672	▁m ri ▁base line ▁heart _ fail ure
D-1057	-0.5645692944526672	mri baseline heart_failure
P-1057	-0.6032 -1.9303 -0.1984 -0.0420 -0.4439 -0.7604 -0.3581 -0.6807 -0.3737 -0.2548
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness sickle_cell_disease anemia
H-1682	-0.6313213109970093	▁Jehovah _ s _ ▁Wit ness ▁sick le _ cell _ ▁disease ▁an emia
D-1682	-0.6313213109970093	Jehovah_s_ Witness sickle_cell_ disease anemia
P-1682	-0.0074 -0.9658 -2.0677 -0.3714 -1.4964 -0.6935 -0.1892 -0.4443 -0.2700 -0.4153 -0.3793 -1.2173 -0.7597 -0.0746 -0.4319 -0.3173
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin_subproteome diseased heart
H-99	-1.1790211200714111	▁mouse _ ▁heart
D-99	-1.1790211200714111	mouse_ heart
P-99	-3.4357 -0.2426 -1.6495 -0.3345 -0.2329
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash mortality heart_failure health
H-684	-0.8243615031242371	▁DAS h ▁mortal ity ▁women ▁heart _ fail ure ▁women _ s _ ▁health _ initiative
D-684	-0.8243615031242371	DASh mortality women heart_failure women_s_ health_initiative
P-684	-0.6281 -0.1660 -2.1610 -0.0561 -1.9839 -0.6048 -0.1469 -1.1087 -0.7312 -1.0856 -0.9539 -1.1761 -0.5364 -1.9725 -0.4464 -0.4696 -0.3724 -0.2389
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad_variant congestive_heart_failure
H-1670	-0.8643113374710083	▁l - type _ ca 2 _ current s ▁Rad ▁con ges tive _ ▁Heart _ fail ure
D-1670	-0.8643113374710083	l-type_ca2_currents Rad congestive_ Heart_failure
P-1670	-5.1251 -0.1594 -0.0412 -0.2146 -0.0534 -0.1459 -1.1497 -2.2736 -0.3782 -1.1223 -0.6421 -0.0774 -0.5312 -0.2644 -2.2854 -0.3050 -1.0585 -0.7851 -0.4172 -0.2563
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary exercise prognostically heart_failure
H-1274	-0.8251013159751892	▁cardio pul mon ary _ ▁exercise ▁heart _ fail ure
D-1274	-0.8251013159751892	cardiopulmonary_ exercise heart_failure
P-1274	-0.4978 -0.8037 -2.7122 -0.0943 -0.9660 -1.0629 -0.6830 -0.3046 -1.0351 -1.1458 -0.3815 -0.2144
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity mortality quality_of_life patients hf
H-2023	-0.3109636902809143	▁morbi d ity ▁mortal ity HF
D-2023	-0.3109636902809143	morbidity mortalityHF
P-2023	-0.2761 -0.0773 -0.2296 -0.0325 -0.1168 -1.2036 -0.3005 -0.2514
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes costs patients heart_failure hf
H-1721	-0.5815255045890808	▁costs ▁heart _ fail ure HF
D-1721	-0.5815255045890808	costs heart_failureHF
P-1721	-0.1989 -0.4111 -0.2335 -0.9123 -1.5020 -0.8475 -0.3431 -0.2038
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome heart_failure fontan
H-1493	-0.47120463848114014	▁muscle - was ting _ ▁syndrome ▁acquire d _ heart _ fail ure ▁Font an
D-1493	-0.47120463848114014	muscle-wasting_ syndrome acquired_heart_failure Fontan
P-1493	-0.8700 -0.1582 -0.0350 -0.0246 -0.2392 -1.3256 -0.2456 -0.0628 -0.2195 -1.9758 -0.0846 -0.5341 -1.5921 -0.1915 -0.1161 -0.1602 -0.1756
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas therapeutic heart_failure
H-1485	-0.6779194474220276	▁mi RNA s ▁heart _ fail ure
D-1485	-0.6779194474220276	miRNAs heart_failure
P-1485	-2.2524 -0.0502 -0.2685 -0.6687 -0.2845 -1.0448 -0.8981 -0.3904 -0.2436
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health_buddy_program telehealth
H-1622	-0.7451972961425781	▁health _ ▁Budd y _ program ▁tele health
D-1622	-0.7451972961425781	health_ Buddy_program telehealth
P-1622	-0.1718 -0.4042 -1.8675 -0.1140 -0.4674 -1.3318 -0.7135 -0.1549 -1.9409 -0.2860
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin breast_cancer patients cardiotoxicity
H-936	-0.5823002457618713	▁resist in ▁an thra cycli ne - tre ated ▁breast _ ▁cancer ▁cardio toxic ity
D-936	-0.5823002457618713	resistin anthracycline-treated breast_ cancer cardiotoxicity
P-936	-0.9711 -0.8508 -0.5548 -0.0900 -0.3022 -1.5743 -0.2871 -0.0345 -0.2471 -1.8140 -0.2067 -1.2961 -0.1566 -0.3461 -0.4339 -0.5030 -0.2309
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine furosemide outcome
H-586	-0.31902334094047546	▁do bu tamine ▁fur os em ide _ ▁dose ▁oxygen _ flow
D-586	-0.31902334094047546	dobutamine furosemide_ dose oxygen_flow
P-586	-0.2625 -0.0906 -0.0729 -0.1710 -0.1035 -0.1658 -0.0646 -1.2106 -0.9463 -0.3159 -0.2038 -0.2080 -0.4876 -0.1632
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic patients heart_failure
H-1740	-0.9651595950126648	▁heart _ fail ure
D-1740	-0.9651595950126648	heart_failure
P-1740	-2.5015 -0.4370 -1.1223 -1.0330 -0.4393 -0.2578
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality deaths acs consultation operation
H-1287	-1.2134654521942139	▁Mor t ality ▁a CS ▁operation
D-1287	-1.2134654521942139	Mortality aCS operation
P-1287	-4.5176 -0.4668 -0.0272 -1.6812 -2.2438 -0.0650 -0.4658 -0.2403
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs outcomes patients diabetes
H-130	-0.6270681023597717	▁c PC s ▁diabetes
D-130	-0.6270681023597717	cPCs diabetes
P-130	-0.1856 -2.5250 -0.0950 -0.2434 -0.4152 -0.2982
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential_effect lvef mortality
H-118	-0.49909287691116333	▁LV EF ▁long - term _ ▁mortal ity
D-118	-0.49909287691116333	LVEF long-term_ mortality
P-118	-0.7300 -1.1533 -0.5636 -0.1633 -0.5946 -0.2106 -0.6545 -0.1610 -0.4832 -0.2768
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health_buddy_program hospital hospitalized
H-1626	-0.7788187861442566	▁health _ ▁Budd y _ programm e ▁ed
D-1626	-0.7788187861442566	health_ Buddy_programme ed
P-1626	-0.1144 -0.4313 -1.1982 -0.1443 -0.9381 -1.5070 -0.3093 -1.0931 -1.7963 -0.2563
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital mortality patients bnp mortality
H-195	-0.5767483115196228	hospital _ ▁mortal ity ▁b NP ▁mortal ity
D-195	-0.5767483115196228	hospital_ mortality bNP mortality
P-195	-2.4806 -0.6200 -0.2746 -0.1240 -0.1279 -1.0136 -0.4047 -0.1798 -0.3453 -0.1971
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt nt-probnp hf
H-291	-0.49514591693878174	▁c t n t ▁NT - pro b NP HF
D-291	-0.49514591693878174	ctnt NT-probNPHF
P-291	-0.0164 -0.1393 -0.0613 -0.1205 -0.1341 -0.0590 -0.0421 -1.0144 -0.3072 -2.5381 -1.2941 -0.2152
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv_dysfunction correlated lean_body_mass
H-1164	-0.5546286106109619	RV _ ▁dys function ▁weight _ los s ▁fat lean _ ▁Body _ ▁mass _ rati o
D-1164	-0.5546286106109619	RV_ dysfunction weight_loss fatlean_ Body_ mass_ratio
P-1164	-1.0966 -0.9951 -0.3944 -0.0313 -0.3358 -0.4138 -0.9766 -0.1944 -0.8988 -1.1241 -0.4479 -1.4617 -0.2068 -0.8845 -0.2932 -0.0830 -0.0513 -0.3993 -0.2493
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-0.573776364326477	▁fut ility ▁safety ▁monitoring _ board
D-850	-0.573776364326477	futility safety monitoring_board
P-850	-0.5383 -0.2071 -0.9325 -1.9483 -0.3080 -0.0338 -0.3749 -0.2473
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients consultation abdominal
H-1284	-0.6662405729293823	▁MT ▁abdominal _ problem s
D-1284	-0.6662405729293823	MT abdominal_problems
P-1284	-1.0103 -0.6261 -1.1538 -0.5382 -0.5063 -0.5600 -0.2690
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic complication
H-1661	-0.9438989162445068	
D-1661	-0.9438989162445068	
P-1661	-1.6751 -0.2127
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.39179179072380066	▁mortal ity
D-2001	-0.39179179072380066	mortality
P-2001	-0.8611 -0.1997 -0.2928 -0.2136
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.46806710958480835	▁follow - up
D-727	-0.46806710958480835	follow-up
P-727	-0.1560 -0.2430 -0.0411 -1.6922 -0.2081
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection_fraction clinical cardiac_resynchronization_therapy mild_heart_failure
H-750	-0.3404383957386017	▁e je ction _ fraction ▁cardiac _ re syn chron ization _ therapy ▁heart _ fail ure
D-750	-0.3404383957386017	ejection_fraction cardiac_resynchronization_therapy heart_failure
P-750	-0.1622 -0.1940 -0.0634 -0.1916 -0.0161 -0.0384 -0.2222 -0.1454 -0.0734 -0.0199 -0.4601 -0.8239 -0.5088 -0.5850 -0.3087 -1.2012 -0.9246 -0.3038 -0.2257
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular_pacing left_heart_twist strain right_heart_failure
H-318	-0.830599844455719	▁bi ven tri cular _ pa cing ▁left _ ▁heart ▁twist ▁strain ▁por cine ▁right _ ▁Heart _ fail ure
D-318	-0.830599844455719	biventricular_pacing left_ heart twist strain porcine right_ Heart_failure
P-318	-0.5461 -0.3938 -0.8490 -1.1268 -0.3064 -1.0870 -0.1771 -0.8966 -0.2775 -2.9845 -0.6451 -1.7975 -0.9650 -0.6256 -0.1435 -0.3624 -2.4489 -1.0169 -0.6774 -0.3461 -0.3187 -0.2815
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress_doppler_echocardiography prognostic pulmonary_hypertension patients
H-832	-0.5948952436447144	▁do pp ler _ e cho card i ography ▁pulmonar y _ hy tension
D-832	-0.5948952436447144	doppler_echocardiography pulmonary_hytension
P-832	-1.8331 -0.0777 -1.4309 -0.2021 -0.2639 -0.8049 -0.7516 -0.8391 -0.5865 -0.0291 -0.2838 -0.3517 -0.9396 -0.1232 -0.7537 -0.2474
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical aortic_valve_insufficiency left_ventricular_assist_device implantation
H-541	-0.7483040690422058	▁a or tic _ val ve _ insu ffi cie ncy ▁left _ vent ri cular _ assist _ ▁device ▁implant ation
D-541	-0.7483040690422058	aortic_valve_insufficiency left_ventricular_assist_ device implantation
P-541	-0.9924 -0.2391 -0.1117 -0.4326 -2.2086 -0.3749 -1.1171 -0.9951 -0.0320 -1.5869 -0.2060 -0.4532 -0.7226 -0.7431 -0.8581 -0.2369 -0.3482 -0.0105 -1.2932 -3.9427 -0.1141 -0.0779 -0.5479 -0.3148
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left_ventricular_ejection_time acute_heart_failure precapillary_pulmonary_hypertension
H-576	-0.5276821851730347	▁vent ri cular _ e je ction _ ▁time ▁a cute _ heart _ fail ure ▁pre cap illa ry _ ▁pulmonar y _ ▁hyper tension
D-576	-0.5276821851730347	ventricular_ejection_ time acute_heart_failure precapillary_ pulmonary_ hypertension
P-576	-0.4774 -0.8087 -0.2580 -0.5243 -0.1695 -0.2192 -0.0905 -0.3975 -2.6665 -0.8345 -0.0272 -0.2831 -1.9629 -0.2113 -1.2614 -0.5632 -0.0149 -0.2497 -0.0591 -0.1599 -0.5483 -0.1333 -0.3100 -0.5238 -1.2794 -0.0016 -0.4589 -0.2813
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial_diastolic_dysfunction dd collagen_deposition titin
H-761	-0.41596338152885437	▁my o card ial _ dia sto lic _ ▁dys function ▁d dd ▁collage n _ de position ▁titi n
D-761	-0.41596338152885437	myocardial_diastolic_ dysfunction ddd collagen_deposition titin
P-761	-0.5457 -0.3724 -0.4109 -0.3366 -0.2280 -0.2522 -0.4479 -0.5973 -0.4643 -0.2648 -0.0283 -1.2418 -1.3184 -0.4209 -0.1684 -0.4909 -0.1179 -0.1168 -0.2044 -0.2123 -0.7446 -0.1664
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated septal wall avd free_wall_cs vvd
H-329	-0.6445949077606201	▁co ▁sept al _ wall ▁av d ▁free _ wall ▁VVD
D-329	-0.6445949077606201	co septal_wall avd free_wall VVD
P-329	-0.2425 -0.5075 -0.3066 -0.2467 -1.8992 -0.1575 -0.2028 -0.0024 -0.4570 -1.6811 -2.0655 -0.3522 -0.2588
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic acute_rv_failure left_ventricular_dysfunction
H-1092	-0.6188309192657471	▁et i ologic ▁ rv _ fail ure ▁left _ vent ri cular _ ▁dys function
D-1092	-0.6188309192657471	etiologic rv_failure left_ventricular_ dysfunction
P-1092	-0.1281 -0.3231 -0.1590 -2.4007 -1.1653 -1.8359 -0.5960 -0.2302 -0.3043 -0.3695 -0.7548 -0.6923 -0.2987 -0.5284 -0.6129 -0.0449 -0.4340 -0.2609
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left_pulmonary_artery right_pulmonary_artery
H-597	-0.44478341937065125	▁left _ ▁pulmonar y _ ▁arter y ▁right _ ▁pulmonar y _ ▁arter y
D-597	-0.44478341937065125	left_ pulmonary_ artery right_ pulmonary_ artery
P-597	-0.5759 -0.3814 -0.1985 -0.2881 -0.2237 -0.4965 -0.6113 -1.4272 -0.3412 -0.1745 -0.3806 -0.2066 -0.5338 -0.4979 -0.5533 -0.2259
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student_t_test confidence_intervals cis regression_analyses
H-215	-0.54815274477005	▁t _ test ▁confidence _ ▁interval s ▁ci s
D-215	-0.54815274477005	t_test confidence_ intervals cis
P-215	-0.1272 -0.1753 -1.0076 -0.4567 -0.2609 -0.3236 -0.2477 -2.3261 -0.1579 -0.7179 -0.2287
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv_strain strain echocardiography baseline ablation
H-946	-0.3370054066181183	▁LV ▁strain ▁strain _ rate ▁e cho card i ography ▁base line ▁ab lation
D-946	-0.3370054066181183	LV strain strain_rate echocardiography baseline ablation
P-946	-0.1306 -0.2536 -0.3040 -0.3641 -1.1465 -0.1400 -0.2228 -0.5127 -0.8288 -0.4556 -0.0210 -0.1062 -0.2722 -0.0516 -0.3802 -0.2024
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr_reduction beta_blockers exercise_capacity hfref
H-1937	-0.6653621196746826	▁HR _ re duction ▁beta _ block ers ▁exercise _ capaci ty ▁h f
D-1937	-0.6653621196746826	HR_reduction beta_blockers exercise_capacity hf
P-1937	-1.2702 -2.1976 -0.0502 -0.0109 -0.2934 -0.2873 -0.8833 -0.2242 -0.0145 -0.3561 -0.0808 -0.1272 -0.1897 -2.4785 -1.9519 -0.2300
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle_cohort_study canada
H-1951	-1.056631088256836	▁Canada
D-1951	-1.056631088256836	Canada
P-1951	-2.6668 -0.2911 -0.2121
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs functional_capacity outcomes heart_failure hf
H-121	-0.6366615295410156	▁c PC s ▁functional _ capaci ty ▁heart _ fail ure HF
D-121	-0.6366615295410156	cPCs functional_capacity heart_failureHF
P-121	-0.0326 -2.4812 -0.1185 -0.8975 -0.5787 -0.0578 -0.0351 -0.2906 -0.2594 -1.2182 -1.2348 -1.1774 -0.2932 -0.2382
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed_up adverse_events death transplantation circulatory_assist_device
H-1162	-0.9315428733825684	▁transplant ation ▁circula tory _ assist _ ▁device
D-1162	-0.9315428733825684	transplantation circulatory_assist_ device
P-1162	-2.1884 -0.0440 -0.1534 -0.0386 -0.3324 -0.0069 -1.5689 -4.3237 -0.4591 -0.2000
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary_outcome sympathetic_activity myocardial_washout
H-1115	-0.6051905155181885	▁sympa the tic ▁activity ▁i - mi BG ▁my o card ial _ was hout
D-1115	-0.6051905155181885	sympathetic activity i-miBG myocardial_washout
P-1115	-1.2581 -0.1532 -0.0385 -0.0816 -0.1209 -0.1594 -0.9981 -1.8832 -1.1026 -0.3764 -0.5837 -0.1693 -0.3017 -2.4163 -0.1056 -0.3113 -0.2282
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating_progenitor_cells outcome heart_failure patients longitudinal
H-119	-0.586844801902771	▁circula ting _ pro gen itor _ cell s ▁heart _ ▁failure
D-119	-0.586844801902771	circulating_progenitor_cells heart_ failure
P-119	-0.3797 -0.1105 -0.9292 -0.3129 -0.1577 -0.6749 -0.2754 -0.3324 -0.3706 -0.6794 -0.2525 -2.8424 -0.6212 -0.2770
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic diastolic_mitral_leaflet_motions organic lesion
H-351	-0.6251004934310913	▁sy sto lic ▁dia sto lic _ met ral _ le a flet ▁organic
D-351	-0.6251004934310913	systolic diastolic_metral_leaflet organic
P-351	-0.6864 -0.2923 -0.2599 -0.0472 -0.2440 -0.2206 -1.2261 -0.8674 -0.0539 -0.2754 -2.4027 -0.2657 -0.0189 -0.3273 -2.5155 -0.2985
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein_kinase_a guanylate_cyclase contractile_response
H-418	-0.8229193687438965	▁inhibi tion _ of _ ▁protein _ ▁kina se ▁gua ny late _ ▁cy cla se ▁contract ile
D-418	-0.8229193687438965	inhibition_of_ protein_ kinase guanylate_ cyclase contractile
P-418	-1.5128 -0.0964 -1.9248 -0.0971 -0.4870 -1.2780 -0.2391 -0.1327 -0.2625 -0.4358 -0.3790 -1.9835 -0.2172 -1.7305 -0.1106 -1.4065 -0.1398 -0.7177 -2.9911 -0.3163
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta_blockers mortality patients heart_failure
H-649	-0.828087329864502	▁beta _ block ers ▁heart _ fail ure
D-649	-0.828087329864502	beta_blockers heart_failure
P-649	-0.5524 -0.3411 -1.4361 -0.3370 -2.2855 -0.3510 -1.1884 -1.2409 -0.3238 -0.2246
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd congestive_heart_failure chf
H-902	-0.6655245423316956	▁p d ▁re frac tory ▁end - s tage _ con ges tive _ heart _ fail ure ▁gh f
D-902	-0.6655245423316956	pd refractory end-stage_congestive_heart_failure ghf
P-902	-0.3594 -1.7696 -0.3136 -0.2202 -0.0566 -1.6711 -0.1327 -0.1095 -0.0205 -0.3067 -0.4633 -0.2589 -0.2949 -0.2512 -2.1919 -0.1992 -0.6897 -0.4460 -4.0903 -0.2734 -0.3284 -0.1947
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype perioperative deaths
H-279	-0.33149805665016174	
D-279	-0.33149805665016174	
P-279	-0.4290 -0.2340
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients trastuzumab cardiac comorbidities
H-682	-0.5442795157432556	▁tras tuz um ab ▁cardiac
D-682	-0.5442795157432556	trastuzumab cardiac
P-682	-0.9373 -0.0399 -0.0741 -0.0392 -0.0418 -2.3689 -0.3087
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic patients heart_failure québec canada
H-1233	-0.7963508367538452	▁economic ▁af ▁heart _ fail ure ▁Québec ▁Canada
D-1233	-0.7963508367538452	economic af heart_failure Québec Canada
P-1233	-0.1050 -0.7992 -0.1006 -0.2941 -1.4467 -1.6521 -0.3465 -2.8104 -0.2375 -0.1713
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression_models comorbidities
H-662	-0.7126862406730652	▁insurance ▁como rbi di ties
D-662	-0.7126862406730652	insurance comorbidities
P-662	-2.2656 -1.6404 -0.0094 -0.2952 -0.0307 -0.4421 -0.3055
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline st2 interquartile_range
H-701	-0.4727700650691986	▁base line ▁inter quart ile _ range
D-701	-0.4727700650691986	baseline interquartile_range
P-701	-0.2286 -0.0525 -2.4469 -0.0492 -0.0667 -0.7325 -0.0609 -0.4007 -0.2169
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac mena_deletion cardiac_dysfunction hypertrophy
H-1811	-0.551129937171936	▁cardiac _ ▁Men a _ ▁dele tion ▁cardiac _ ▁dys function ▁hyper trop hy
D-1811	-0.551129937171936	cardiac_ Mena_ deletion cardiac_ dysfunction hypertrophy
P-1811	-0.1330 -0.7226 -3.4409 -0.0600 -0.3312 -1.7920 -0.0637 -0.0438 -0.4258 -0.3637 -0.0237 -0.4567 -0.2377 -0.1725 -0.3089 -0.2418
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left_bundle-branch_block lbbb
H-886	-0.9516586661338806	▁bund le - bran ch _ block LB b ▁non - LB b
D-886	-0.9516586661338806	bundle-branch_blockLBb non-LBb
P-886	-0.0114 -1.0225 -0.2590 -0.2623 -0.1648 -0.2117 -2.2050 -1.1916 -1.4116 -2.1709 -0.0916 -2.5140 -2.2760 -0.2739 -0.2086
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf atrial_explants cells explants
H-1341	-0.37199899554252625	▁CHF _ at rial _ ex plant s ▁sham _ ex plant s
D-1341	-0.37199899554252625	CHF_atrial_explants sham_explants
P-1341	-0.0975 -1.4115 -0.7264 -0.1599 -0.2337 -0.3114 -0.0309 -0.2933 -0.3417 -0.2246 -0.7481 -0.0319 -0.3664 -0.3941 -0.2086
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf valve_plasty mva
H-369	-0.516635000705719	▁h f ▁ms ▁m va
D-369	-0.516635000705719	hf ms mva
P-369	-0.9610 -0.3917 -1.2802 -0.2922 -0.1490 -0.3606 -0.1819
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms patients nyha
H-1893	-0.8643033504486084	▁NY ha
D-1893	-0.8643033504486084	NYha
P-1893	-1.2935 -0.7382 -1.2089 -0.2167
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure_ulcers surgical patients
H-6	-0.4104250371456146	▁pressure _ ▁ul cer s ▁sur g ical
D-6	-0.4104250371456146	pressure_ ulcers surgical
P-6	-0.1200 -0.2389 -0.1943 -0.0145 -0.2782 -0.7272 -0.0462 -0.0283 -2.1541 -0.3024
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients chronic_organ_failure
H-793	-0.7987238168716431	▁time _ up _ and _ go _ test ▁chronic _ organ _ fail ure
D-793	-0.7987238168716431	time_up_and_go_test chronic_organ_failure
P-793	-1.9677 -1.5051 -0.6351 -0.5916 -1.1498 -0.4727 -0.6946 -1.3011 -0.6486 -1.2490 -0.2892 -0.0469 -0.5058 -0.8580 -0.9843 -0.3672 -0.3116
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome change hospitalized heart_failure
H-1395	-1.099114179611206	▁Nur sing - sensitiv e _ ▁outcome _ change _ ▁score s ▁heart _ fail ure
D-1395	-1.099114179611206	Nursing-sensitive_ outcome_change_ scores heart_failure
P-1395	-3.5643 -0.0549 -0.0823 -0.0015 -0.6257 -0.4471 -2.2589 -0.4637 -0.3069 -1.3387 -3.6401 -0.0480 -3.6698 -0.2557 -1.3223 -0.9559 -0.4498 -0.2984
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation heart_iron
H-748	-0.5854618549346924	▁che lation ▁heart _ ▁ir on
D-748	-0.5854618549346924	chelation heart_ iron
P-748	-0.5164 -0.0562 -2.8808 -0.2141 -0.3084 -0.1757 -0.3250 -0.2071
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter invasive surgery
H-553	-0.2528735399246216	▁trans cat heter ▁surgery
D-553	-0.2528735399246216	transcatheter surgery
P-553	-0.0821 -0.4575 -0.1215 -0.1957 -0.3935 -0.2669
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up outcomes mortality
H-1637	-0.2856345474720001	▁black _ race ▁mortal ity
D-1637	-0.2856345474720001	black_race mortality
P-1637	-0.0690 -0.1644 -1.0160 -0.0397 -0.0807 -0.3781 -0.2515
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise clinical outcomes
H-1926	-0.5305116176605225	▁exercise
D-1926	-0.5305116176605225	exercise
P-1926	-0.9509 -0.3538 -0.2869
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin heart_failure breast_cancer
H-927	-0.6801979541778564	▁resist in ▁che mo therapy - indu ced _ heart _ ▁failure ▁breast _ cancer
D-927	-0.6801979541778564	resistin chemotherapy-induced_heart_ failure breast_cancer
P-927	-3.3125 -0.3325 -0.2887 -0.1657 -0.0376 -0.2497 -0.0004 -0.0203 -0.4950 -1.5818 -0.1861 -1.4152 -1.7507 -0.3309 -0.7351 -0.3807 -0.2805
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic diagnostic fluid_overload
H-1071	-0.807428777217865	▁fluid _ over load
D-1071	-0.807428777217865	fluid_overload
P-1071	-3.4923 -0.1762 -0.4708 -0.0263 -0.4026 -0.2763
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing outcomes hospitalized hf
H-1402	-1.562513828277588	▁nur sing HF
D-1402	-1.562513828277588	nursingHF
P-1402	-4.8168 -0.0928 -2.2069 -0.4574 -0.2386
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome death hospitalization heart_failure
H-849	-1.0772403478622437	▁death ▁heart _ fail ure
D-849	-1.0772403478622437	death heart_failure
P-849	-2.8931 -0.9765 -0.2967 -0.9558 -1.8034 -0.3497 -0.2654
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical echocardiographic invasive hemodynamic outcome
H-1527	-0.5400161743164062	▁e cho car dio graphic ▁invasi ve _ hem o dynamic
D-1527	-0.5400161743164062	echocardiographic invasive_hemodynamic
P-1527	-0.1555 -0.3269 -0.0827 -0.6967 -1.0479 -0.0510 -0.1273 -0.4672 -2.7229 -0.5216 -0.0135 -0.5603 -0.2468
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right_atrium prolapse tricuspid_valve stenotic_physiology
H-596	-0.4322585165500641	▁right _ at rium _ ▁mass ▁pro lapse ▁tri cus pid _ val ve ▁ste no tic _ ▁physio log y
D-596	-0.4322585165500641	right_atrium_ mass prolapse tricuspid_valve stenotic_ physiology
P-596	-0.0074 -0.2334 -0.9610 -0.1119 -0.2428 -1.2975 -0.0909 -0.3324 -0.0937 -0.7509 -0.1903 -0.2600 -1.7364 -0.3999 -0.1187 -0.0869 -0.0739 -0.9271 -0.6690 -0.5396 -0.1858 -0.4440 -0.1885
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis pacing-induced_dilated_cardiomyopathy
H-165	-0.6875620484352112	▁apo pto sis ▁pa cing - indu ced _ ▁dil ated _ ▁cardio my o pathy
D-165	-0.6875620484352112	apoptosis pacing-induced_ dilated_ cardiomyopathy
P-165	-1.3125 -0.4883 -2.9717 -1.1866 -0.4335 -0.1408 -0.0005 -0.0161 -0.7579 -1.8865 -0.0165 -0.2130 -0.1822 -1.4099 -0.5243 -0.0186 -0.5024 -0.3148
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative serum_albumin patients left_ventricular_assist_device implantation
H-528	-0.7411468625068665	▁pre operativ e _ se rum _ album in ▁left _ vent ri cular _ assist _ de part ment ▁implant ation
D-528	-0.7411468625068665	preoperative_serum_albumin left_ventricular_assist_department implantation
P-528	-2.2913 -0.1495 -0.2046 -0.5492 -0.4066 -0.6266 -0.1198 -0.2714 -0.4156 -0.8422 -0.4759 -1.1743 -1.5232 -0.2840 -0.2948 -0.0119 -1.7789 -4.0147 -1.0260 -0.1291 -0.4108 -0.0741 -0.4743 -0.2387
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac_catheterization thrombotic_obstruction right_coronary_artery
H-1292	-0.4122847616672516	▁cardiac _ ▁cat heter ization ▁ thro mbo tic _ ob struct ion ▁right _ ▁corona ry _ ▁arter y
D-1292	-0.4122847616672516	cardiac_ catheterization thrombotic_obstruction right_ coronary_ artery
P-1292	-0.8660 -0.3728 -1.6044 -0.0259 -0.3259 -0.4796 -0.0613 -0.3201 -0.5162 -0.6386 -0.3705 -0.0709 -0.0706 -0.1986 -0.2158 -0.7642 -0.3719 -0.2571 -0.1123 -0.6569 -0.4939 -0.2770
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western_blots monoclonal_antibodies ser83 phosphorylation hf
H-1431	-0.6173915863037109	▁western _ ▁blot s ▁mono clo nal _ anti bo dies ▁ser 83 ▁ phos phor y lation ▁h z
D-1431	-0.6173915863037109	western_ blots monoclonal_antibodies ser83 phosphorylation hz
P-1431	-0.9947 -0.2033 -0.6022 -0.3324 -0.0026 -0.9474 -0.5099 -0.1676 -0.1697 -0.2002 -0.3173 -0.3969 -0.5018 -1.8024 -0.2013 -1.4574 -1.3306 -0.2074 -0.6270 -2.0029 -0.3619 -0.2455
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan_failure systolic_ventricular_function liver_disease
H-224	-0.6372816562652588	▁Font _ fail ure ▁sy sto lic _ vent ri cular ▁ liver _ ▁Disease
D-224	-0.6372816562652588	Font_failure systolic_ventricular liver_ Disease
P-224	-0.3190 -0.9612 -0.7361 -1.5296 -0.6248 -0.1553 -0.5836 -0.1815 -0.4798 -0.3809 -0.2491 -0.8490 -0.3020 -0.3899 -2.4711 -0.3891 -0.2319
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary_outcome functional_capacity 6-minute_walk_test 6mwt
H-571	-0.3745972514152527	▁functional _ capaci ty ▁mw t
D-571	-0.3745972514152527	functional_capacity mwt
P-571	-0.7591 -0.3464 -0.0588 -0.0866 -0.9828 -0.1840 -0.3405 -0.2386
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine dilated_cardiomyopathy patients heart_failure
H-1257	-0.5567517876625061	▁Chinese _ ▁herbal _ ▁medicine ▁dil ated _ ▁cardio my o pathy ▁heart _ fail ure
D-1257	-0.5567517876625061	Chinese_ herbal_ medicine dilated_ cardiomyopathy heart_failure
P-1257	-0.7496 -0.4317 -0.1463 -0.1998 -0.6107 -1.6565 -0.0311 -0.2714 -0.1922 -1.6001 -0.3813 -0.0239 -0.3088 -0.3657 -1.6032 -0.7636 -0.3949 -0.2907
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic_heart_failure chf sympathetic_tone autonomic_imbalance
H-1370	-0.6885181665420532	▁chronic _ heart _ fail ure ▁gh f ▁sympa the tic _ ▁tone ▁autonomi c _ ▁im balance
D-1370	-0.6885181665420532	chronic_heart_failure ghf sympathetic_ tone autonomic_ imbalance
P-1370	-0.1336 -0.2710 -2.2372 -0.1595 -0.7584 -1.3109 -3.1739 -0.0914 -0.1277 -0.2146 -0.1037 -0.4716 -0.9859 -0.0084 -0.7322 -0.6433 -1.6323 -0.0541 -0.4152 -0.2458
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient implantable_cardioverter-defibrillator
H-1856	-0.44552725553512573	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1856	-0.44552725553512573	implantable cardioverter-defibrillator_deactivation
P-1856	-0.0127 -0.1215 -1.6501 -0.1505 -0.1300 -0.3933 -0.0856 -1.3744 -1.4424 -0.1057 -0.5003 -0.2849 -0.1146 -0.2653 -0.3260 -0.3228 -0.2938
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical_delay dyssynchronous_heart_failure
H-1146	-0.6567674875259399	▁mechanic ▁electro me chan ical _ de lay ▁dys syn chron ous _ heart _ fail ure
D-1146	-0.6567674875259399	mechanic electromechanical_delay dyssynchronous_heart_failure
P-1146	-1.6313 -2.1860 -0.2214 -0.0662 -0.1187 -1.2748 -0.1617 -0.1904 -0.0188 -0.0782 -0.0202 -0.2402 -0.4053 -2.3451 -0.2930 -1.0963 -0.4287 -1.3548 -0.3475
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated cardiac_filling_pressures adverse_outcomes
H-1532	-0.5922790169715881	▁EH ▁cardiac _ ▁fill ing _ tension s
D-1532	-0.5922790169715881	EH cardiac_ filling_tensions
P-1532	-1.2979 -0.0590 -0.5068 -1.4038 -0.1065 -0.3942 -1.1302 -0.2664 -0.5165 -0.2415
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef sodium ventricular vascular_stiffness
H-917	-0.4527736008167267	▁h f f ▁so dium ▁vent ri cular ▁vas cular
D-917	-0.4527736008167267	hff sodium ventricular vascular
P-917	-0.2640 -0.9809 -0.3483 -0.2158 -0.0172 -0.1312 -0.2873 -0.3147 -0.7450 -0.4543 -1.4453 -0.2294
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart_failure leading mortality western society cardiovascular_diseases
H-1480	-0.752651035785675	▁Heart _ ▁failure ▁society ▁cardiovascular _ ▁disease s
D-1480	-0.752651035785675	Heart_ failure society cardiovascular_ diseases
P-1480	-0.8451 -0.3311 -2.3821 -0.1476 -0.1629 -0.4338 -2.5003 -0.0928 -0.3964 -0.2345
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein genes western_blot dna_fragmentation tunel
H-167	-0.5250185132026672	▁protein ▁western _ ▁blot ▁DNA _ ▁fragment ation ▁tu nel ▁auto psy
D-167	-0.5250185132026672	protein western_ blot DNA_ fragmentation tunel autopsy
P-167	-0.5497 -1.2982 -0.1554 -1.2433 -0.3232 -0.2692 -0.5992 -0.0608 -0.1671 -0.3079 -1.4201 -0.1048 -0.5952 -0.2562
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully_magnetically_levitated_left_ventricular_assist_system hf
H-1992	-0.6102559566497803	▁magnet ically _ ▁Lev itate d _ le ft _ vent ri cular _ assist _ system _ for _ tre ating _ ▁Advanced _ h f
D-1992	-0.6102559566497803	magnetically_ Levitated_left_ventricular_assist_system_for_treating_ Advanced_hf
P-1992	-0.0706 -0.0780 -0.6381 -1.3281 -0.9030 -0.0804 -0.7863 -3.0848 -0.1234 -0.2124 -0.6221 -1.1984 -0.2993 -0.1308 -0.0264 -0.2231 -0.0783 -1.8599 -0.1077 -0.2938 -0.2644 -0.0100 -0.5942 -0.3150 -0.4458 -1.9131 -1.1078 -0.6532 -0.2490
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological cardiovascular bound
H-1875	-0.5033214688301086	▁neurologi cal ▁cardiovascular ▁event - free _ rate ▁confidence
D-1875	-0.5033214688301086	neurological cardiovascular event-free_rate confidence
P-1875	-0.0739 -0.1238 -0.0997 -1.3368 -0.2703 -0.0454 -0.4439 -1.0890 -1.1540 -0.7014 -0.1983
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart_failure
H-1539	-0.7605268955230713	▁heart _ fail ure
D-1539	-0.7605268955230713	heart_failure
P-1539	-0.8200 -0.3106 -1.0936 -1.8472 -0.2845 -0.2072
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up patients hf
H-1106	-0.7358970642089844	HF
D-1106	-0.7358970642089844	HF
P-1106	-1.3166 -0.6680 -0.2231
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients madit-crt
H-858	-1.4562166929244995	▁MAD - c RT
D-858	-1.4562166929244995	MAD-cRT
P-858	-0.0835 -2.7039 -0.5633 -3.6962 -1.4539 -0.2364
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical nitrite vascular
H-414	-0.6956486105918884	▁chemical ▁nit rite
D-414	-0.6956486105918884	chemical nitrite
P-414	-1.1723 -1.1394 -0.5146 -0.3723 -0.2796
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech_republic
H-1972	-0.5043548941612244	▁Czech _ re public
D-1972	-0.5043548941612244	Czech_republic
P-1972	-0.8754 -0.4695 -0.7202 -0.4184 -0.3039 -0.2387
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets tac hf
H-1050	-0.9025729298591614	BET s ▁mouse ▁ TAC ▁h f
D-1050	-0.9025729298591614	BETs mouse TAC hf
P-1050	-0.4352 -0.3889 -0.9678 -2.8922 -0.1438 -0.5393 -2.2173 -0.2905 -0.2481
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized dopamine nesiritide
H-76	-0.46279481053352356	▁dop amine ▁nesi riti de _ strate gy
D-76	-0.46279481053352356	dopamine nesiritide_strategy
P-76	-1.2927 -0.1775 -0.0046 -0.0860 -0.1179 -1.4676 -0.5848 -0.3503 -0.3122 -0.2344
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c_statistics
H-383	-1.0516372919082642	▁UM / va ▁va - RT
D-383	-1.0516372919082642	UM/va va-RT
P-383	-0.5062 -2.3848 -0.4446 -2.1439 -0.4862 -1.8455 -0.3439 -0.2581
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion mortality
H-50	-0.4467853307723999	▁trans fusion ▁mortal ity _ rate s
D-50	-0.4467853307723999	transfusion mortality_rates
P-50	-0.0977 -0.1517 -0.9810 -0.1811 -0.7531 -0.9120 -0.0817 -0.5405 -0.3222
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations patients patients
H-1282	-0.4332920014858246	▁consultation s
D-1282	-0.4332920014858246	consultations
P-1282	-0.7119 -0.2676 -0.5116 -0.2420
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac nurses
H-1662	-0.2953784465789795	▁cardiac _ ▁nurse s
D-1662	-0.2953784465789795	cardiac_ nurses
P-1662	-0.0264 -0.2594 -0.7199 -0.1847 -0.2825 -0.2995
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients randomization
H-851	-0.5093443393707275	
D-851	-0.5093443393707275	
P-851	-0.7978 -0.2209
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-0.6873313188552856	▁health ▁benefits
D-614	-0.6873313188552856	health benefits
P-614	-1.2095 -0.9526 -0.3342 -0.2530
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california_office_of_statewide_health_planning_and_development_patient_discharge_data_nonpublic_file
H-136	-0.6702509522438049	▁California ▁office _ of _ state wide _ ▁health _ plan ning ▁Patient _ dis charge
D-136	-0.6702509522438049	California office_of_statewide_ health_planning Patient_discharge
P-136	-1.8724 -1.0386 -0.4011 -0.0455 -0.4439 -0.0314 -1.4461 -0.2507 -1.7026 -0.4205 -0.0308 -0.1118 -1.6241 -0.7294 -0.1154 -0.0283 -1.4986 -0.2731
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal_membrane_oxygenation refractory_right_heart_failure
H-1290	-0.5036315321922302	▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁ bridge _ to _ re cover y ▁in far ction - related _ re frac tory _ right _ heart _ ▁failure
D-1290	-0.5036315321922302	extracorporeal_ membrane_ oxygenation bridge_to_recovery infarction-related_refractory_right_heart_ failure
P-1290	-0.3947 -0.1004 -0.6485 -0.5739 -0.1837 -1.4716 -0.1097 -0.2867 -0.9541 -0.0655 -0.4792 -0.0075 -0.3341 -0.8619 -0.2922 -0.8119 -0.5570 -0.3236 -0.6137 -0.0259 -0.0956 -0.2394 -0.0234 -1.1393 -0.0792 -0.0814 -0.0783 -1.3219 -0.5763 -0.3273 -2.4534 -0.4277 -1.0119 -0.4541 -0.2218
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation therapy heart_disease rate_control
H-1652	-0.6483376622200012	▁antico ag ulation ▁heart _ ▁disease ▁rate _ control
D-1652	-0.6483376622200012	anticoagulation heart_ disease rate_control
P-1652	-1.4016 -0.1878 -0.0270 -1.3556 -0.2381 -2.3409 -0.1775 -0.5665 -0.0169 -0.5562 -0.2636
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality_of_life seattle_heart_failure_model
H-2012	-0.28739258646965027	▁Seattle _ ▁Heart _ fail ure
D-2012	-0.28739258646965027	Seattle_ Heart_failure
P-2012	-0.0288 -0.2544 -0.3616 -0.1941 -0.2615 -0.0861 -0.8698 -0.2428
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change paco2 cerebral blood_flow perfusion carotid
H-1350	-0.40584397315979004	▁Paco 2 ▁cerebral _ ▁blood _ flow ▁per fusion ▁caro tid _ bo dies
D-1350	-0.40584397315979004	Paco2 cerebral_ blood_flow perfusion carotid_bodies
P-1350	-0.3730 -0.0700 -0.1513 -0.3540 -1.1741 -0.1921 -0.3491 -0.3514 -0.0294 -0.3999 -0.3881 -1.5216 -0.2629 -0.1272 -0.4744 -0.2748
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology hf diagnosis medical nursing
H-2021	-0.5342963933944702	▁pat ho phy si ology HF ▁medical
D-2021	-0.5342963933944702	pathophysiologyHF medical
P-2021	-1.0858 -0.2932 -0.0128 -0.9298 -0.0326 -1.5639 -0.0971 -0.5626 -0.2308
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients physicians hospitals new_jersey new_york
H-212	-1.023594856262207	▁ed _ ▁physician s ▁New _ ▁Jersey ▁New _ York
D-212	-1.023594856262207	ed_ physicians New_ Jersey New_York
P-212	-0.3764 -2.8502 -0.8941 -0.0892 -1.4420 -1.0459 -0.8495 -0.9936 -0.7281 -2.3428 -0.4456 -0.2256
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart_failure protein_kinase_a expression
H-1423	-0.5347866415977478	▁heart _ fail ure ▁protein _ ▁kina se ▁expression ▁post - trans la tional _ state
D-1423	-0.5347866415977478	heart_failure protein_ kinase expression post-translational_state
P-1423	-1.9644 -0.6585 -0.8345 -1.8579 -1.0937 -0.3077 -0.0463 -0.1963 -0.3696 -0.2696 -0.0686 -0.0403 -0.3715 -0.0334 -0.7178 -0.0242 -0.4340 -0.3379
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox_regression cardiovascular_events psoriasis
H-1558	-0.32370874285697937	▁co x _ re gression ▁cardiovascular ▁psoriasis
D-1558	-0.32370874285697937	cox_regression cardiovascular psoriasis
P-1558	-0.1331 -0.1771 -0.2530 -0.0970 -0.1509 -0.1588 -1.4259 -0.2488 -0.2688
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy_metabolism heart_failure hypertrophied heart
H-1779	-0.49444422125816345	▁energy _ ▁metabolism ▁heart ▁hyper trop hi ed _ heart
D-1779	-0.49444422125816345	energy_ metabolism heart hypertrophied_heart
P-1779	-0.5836 -0.2419 -0.4434 -0.2763 -0.9526 -0.2194 -0.0477 -0.1400 -0.3876 -2.1623 -0.2786 -0.2000
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients clinical echocardiography baseline shunt implantation
H-1954	-0.2924707531929016	▁e cho card i ography ▁base line ▁shu nt _ ▁implant ation
D-1954	-0.2924707531929016	echocardiography baseline shunt_ implantation
P-1954	-0.1400 -0.2806 -0.5752 -0.5398 -0.5014 -0.0632 -0.0629 -0.4770 -0.1276 -0.3875 -0.1494 -0.0736 -0.4602 -0.2563
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic_effect beta_blockers heart_failure
H-648	-0.55610591173172	▁in o tropi c _ effect ▁beta _ block ers ▁heart _ fail ure
D-648	-0.55610591173172	inotropic_effect beta_blockers heart_failure
P-648	-0.3519 -0.9282 -0.0665 -0.2674 -0.8857 -0.2059 -0.3714 -0.3592 -1.4549 -0.2509 -0.5861 -0.3719 -1.2224 -0.9544 -0.3679 -0.2530
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline mechanical_cardiac_support renal_function
H-1388	-0.38771286606788635	▁base line ▁mechanic al _ ▁cardiac _ support ▁renal _ function
D-1388	-0.38771286606788635	baseline mechanical_ cardiac_support renal_function
P-1388	-0.2352 -0.1370 -0.0124 -0.1366 -0.3595 -0.2109 -0.9306 -1.3673 -0.0221 -0.4085 -0.5468 -0.3971 -0.2763
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ecmo patients vad ecmo vad
H-1390	-1.7599326372146606	▁ec mo ▁ VAD ▁ec mo - VAD
D-1390	-1.7599326372146606	ecmo VAD ecmo-VAD
P-1390	-1.7859 -2.0302 -1.7726 -0.2568 -1.3739 -2.4329 -6.1638 -0.6779 -0.8093 -0.2961
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional_ms lv_dilatation functional_ms
H-368	-1.053846001625061	▁ms ▁dynamic ▁LV _ di la tation ▁ms
D-368	-1.053846001625061	ms dynamic LV_dilatation ms
P-368	-2.5010 -0.0437 -0.3593 -2.2978 -1.5412 -0.1511 -0.0416 -2.9376 -0.4090 -0.2562
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp circulation hf patients
H-1513	-0.591896116733551	▁NT - pro b NP ▁circulation ▁h f
D-1513	-0.591896116733551	NT-probNP circulation hf
P-1513	-0.2708 -0.1224 -0.0405 -0.9576 -0.4848 -0.0222 -0.9957 -1.7794 -0.9671 -0.2783
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality morbidity health-care budget
H-1075	-0.24833829700946808	▁mortal ity ▁morbi d ity ▁cancer s ▁budget
D-1075	-0.24833829700946808	mortality morbidity cancers budget
P-1075	-0.4126 -0.1833 -0.0589 -0.0586 -0.3706 -0.2372 -0.1847 -0.3124 -0.3959 -0.2690
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp sensitivity
H-271	-0.4714656174182892	▁cut off ▁NT - pro b NP
D-271	-0.4714656174182892	cutoff NT-probNP
P-271	-0.0860 -0.0738 -1.8393 -0.0716 -0.0761 -0.7701 -0.4131 -0.6795 -0.2338
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation flow-mediated_dilatation
H-259	-0.7420936822891235	▁HD l - indu ced ▁flow - media ted _ di la tation ▁ET
D-259	-0.7420936822891235	HDl-induced flow-mediated_dilatation ET
P-259	-2.8164 -2.5125 -0.0546 -0.0004 -0.0098 -0.1360 -0.1120 -0.6389 -0.4600 -0.1305 -1.3776 -0.1574 -0.0791 -2.6861 -0.4752 -0.2270
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients systolic_function therapeutic
H-1070	-0.5169367790222168	▁sy sto lic _ function
D-1070	-0.5169367790222168	systolic_function
P-1070	-1.6147 -0.2559 -0.2742 -0.3604 -0.1623 -0.6921 -0.2588
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ahf risk_stratification
H-58	-0.8923510909080505	▁a HF
D-58	-0.8923510909080505	aHF
P-58	-1.8872 -0.7173 -0.6382 -0.3267
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients pad ankle-brachial_index
H-1568	-0.316270649433136	PAD ▁an kle - bra chi al _ index
D-1568	-0.316270649433136	PAD ankle-brachial_index
P-1568	-0.2439 -0.4200 -0.6442 -0.2977 -0.0430 -0.2337 -0.1319 -0.2600 -0.2309 -0.7357 -0.2380
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective_studies cpg hf
H-1845	-0.9137004613876343	▁c p ▁h z
D-1845	-0.9137004613876343	cp hz
P-1845	-0.8898 -1.0910 -0.6719 -2.1846 -0.4367 -0.2081
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr_reduction ivabradine tac ea
H-525	-0.6610704064369202	▁HR ▁i va bra dine TAC ▁ea
D-525	-0.6610704064369202	HR ivabradineTAC ea
P-525	-1.6909 -0.2290 -0.0169 -0.0325 -0.2231 -1.1453 -1.9586 -0.3899 -0.2636
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause_hospitalisations sts
H-160	-0.44192346930503845	▁TM ▁s ts
D-160	-0.44192346930503845	TM sts
P-160	-0.5502 -0.3623 -0.4751 -0.5791 -0.2429
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol linear_mixed_models intention-to-treat
H-838	-0.867696225643158	▁treatment _ group _ effect s ▁HR Qo l
D-838	-0.867696225643158	treatment_group_effects HRQol
P-838	-1.8103 -0.9114 -0.1518 -0.4873 -0.4587 -0.1148 -2.7353 -0.0260 -2.0608 -0.5928 -0.1953
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic clinicians patients
H-1124	-0.7335368394851685	▁Reason s _ for _ non tre at ment
D-1124	-0.7335368394851685	Reasons_for_nontreatment
P-1124	-1.4630 -0.2016 -1.9923 -0.2683 -0.2906 -0.5022 -0.0362 -0.0848 -0.0855 -2.9327 -0.2118
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions hospital
H-144	-0.5283240675926208	▁computing _ ▁read missions ▁hospital ▁pay - for - per form ance
D-144	-0.5283240675926208	computing_ readmissions hospital pay-for-performance
P-144	-0.1738 -0.2842 -3.3226 -0.0672 -0.9792 -1.1513 -0.1725 -0.0866 -0.2589 -0.0196 -0.0151 -0.0055 -0.5163 -0.3437
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd patients
H-65	-0.8882842063903809	▁i CD
D-65	-0.8882842063903809	iCD
P-65	-0.2441 -2.3453 -0.6669 -0.2969
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.9436937570571899	HF
D-1002	-0.9436937570571899	HF
P-1002	-1.6003 -0.9702 -0.2605
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients patients
H-267	-0.5776271820068359	
D-267	-0.5776271820068359	
P-267	-0.9310 -0.2243
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular_assist_device extracorporeal_membrane_oxygenation renal_function heart_failure
H-1383	-0.6897439956665039	▁vent ri cular _ assist _ ▁device ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁renal _ function ▁pediatr ic _ heart _ fail ure
D-1383	-0.6897439956665039	ventricular_assist_ device extracorporeal_ membrane_ oxygenation renal_function pediatric_heart_failure
P-1383	-0.0381 -0.4973 -0.2689 -0.3776 -0.0137 -1.7824 -3.8321 -0.2024 -0.1759 -0.4920 -0.3158 -0.2912 -1.5197 -0.0986 -0.9575 -0.5001 -0.0941 -0.0239 -1.1656 -0.1914 -1.1464 -0.0226 -0.8004 -1.9942 -0.2264 -1.4825 -0.9414 -0.2967 -0.2538
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory_fitness body_mass_index heart_failure mortality cooper_center_longitudinal_study
H-1765	-0.6412429213523865	▁Card i ore spira tory _ ▁fitness ▁body _ ▁mass _ index ▁heart _ ▁failure ▁Cooper _ ▁Center _ long itud in al _ studie s
D-1765	-0.6412429213523865	Cardiorespiratory_ fitness body_ mass_index heart_ failure Cooper_ Center_longitudinal_studies
P-1765	-2.0538 -0.4154 -0.4136 -0.1203 -0.0572 -0.8058 -1.0803 -0.0990 -0.2991 -1.1838 -0.1886 -0.3755 -0.2687 -0.2799 -2.5695 -1.3630 -0.2820 -2.2966 -0.4842 -0.0668 -0.3880 -0.4326 -0.1411 -0.4136 -0.8336 -0.4351 -0.3910 -0.2168
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations cox_models st2 functional_capacity outcomes
H-700	-0.4235568940639496	▁co x _ model s ▁ST 2 ▁functional _ capaci ty
D-700	-0.4235568940639496	cox_models ST2 functional_capacity
P-700	-0.2089 -0.1414 -0.9996 -1.1320 -0.3006 -1.2124 -0.0521 -0.2928 -0.3411 -0.1379 -0.0724 -0.3507 -0.2644
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new_york_heart_association_classification 6-min_walk_test quality-of-life
H-2005	-0.8489779233932495	▁New _ York _ ▁Heart _ association
D-2005	-0.8489779233932495	New_York_ Heart_association
P-2005	-0.5838 -0.5507 -2.8272 -0.1960 -0.6460 -0.1560 -0.3372 -2.1244 -0.2195
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise_intolerance heart_failure exercise diagnosis prognosis therapeutic
H-1272	-0.6778259873390198	▁exercise _ in tolerance ▁heart _ fail ure ▁exercise
D-1272	-0.6778259873390198	exercise_intolerance heart_failure exercise
P-1272	-0.5056 -0.9542 -0.1878 -0.0908 -1.3238 -0.3269 -1.1481 -1.9874 -0.3051 -0.4195 -0.2069
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse_correlation pro-adrenomedullin mr-proadm ffm
H-15	-0.41834813356399536	▁pro - ad re nom edu llin MR - pro ad m ▁f m
D-15	-0.41834813356399536	pro-adrenomedullinMR-proadm fm
P-15	-0.0834 -0.0807 -0.0738 -0.0600 -0.2008 -0.8948 -1.1854 -0.7182 -0.0216 -0.0529 -0.4553 -0.1120 -0.4905 -1.5063 -0.5519 -0.2061
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin_receptor_antagonist tolvaptan heart_failure patients
H-1194	-0.6059339642524719	▁vaso press in _ ▁receptor ▁to lv ap tan ▁Japanese _ heart _ fail ure
D-1194	-0.6059339642524719	vasopressin_ receptor tolvaptan Japanese_heart_failure
P-1194	-0.0987 -0.0449 -1.2846 -0.2352 -0.3246 -0.3292 -0.2410 -0.3194 -0.0868 -1.0818 -0.6326 -1.9615 -0.2501 -1.5037 -0.7524 -0.9091 -0.2452
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional_ms ring_annuloplasty ischemic_mr lv_dilatation
H-366	-0.7177202105522156	▁ms ▁ring _ ▁ann ulo plast y ▁ ische mic ▁MR ▁LV _ di la tation
D-366	-0.7177202105522156	ms ring_ annuloplasty ischemic MR LV_dilatation
P-366	-1.2121 -0.0764 -0.2266 -3.0648 -0.1819 -0.0237 -0.3451 -0.9699 -0.0555 -0.3445 -2.2618 -0.0488 -1.0489 -2.2534 -0.0828 -0.0244 -0.4969 -0.2014
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp nt-probnp diagnostic prognostic biomarkers patients heart_failure
H-1365	-0.4291746914386749	▁b NP ▁NT - pro b NP ▁bio mark ers ▁heart _ fail ure
D-1365	-0.4291746914386749	bNP NT-probNP biomarkers heart_failure
P-1365	-0.1802 -0.9341 -0.3037 -0.1218 -0.0129 -0.7701 -0.4509 -0.1552 -0.0947 -0.2719 -0.5579 -0.3833 -1.2270 -0.8292 -0.3495 -0.2246
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis patients diastolic_blood_pressure body_mass_index
H-1560	-0.7031621336936951	▁psoriasis ▁dia sto lic _ ▁blood _ tension ▁body _ ▁mass _ index
D-1560	-0.7031621336936951	psoriasis diastolic_ blood_tension body_ mass_index
P-1560	-0.3304 -1.9576 -0.3480 -0.3388 -0.3940 -1.2849 -0.3849 -2.3187 -0.2009 -0.5227 -0.9556 -0.2728 -0.3187 -0.6465 -0.2730
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin_receptor st2 beta-blocker therapy chronic_heart_failure
H-398	-0.670665442943573	▁inter le u kin _ ▁receptor ▁ST 2 ▁beta - block er _ therapy ▁chronic _ heart _ fail ure
D-398	-0.670665442943573	interleukin_ receptor ST2 beta-blocker_therapy chronic_heart_failure
P-398	-0.0784 -1.2175 -0.0883 -3.4167 -0.1497 -0.3689 -1.2247 -0.0164 -0.3987 -0.0829 -0.4488 -0.5013 -0.8847 -0.1465 -0.5803 -0.3000 -2.0613 -0.2023 -1.3701 -0.6903 -0.3075 -0.2194
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf symptom cardiac_murmurs blood_pressure
H-356	-0.4953017234802246	▁h f ▁cardiac _ mur mur s ▁blood _ tension ▁h g
D-356	-0.4953017234802246	hf cardiac_murmurs blood_tension hg
P-356	-1.0534 -1.2899 -0.1192 -0.2254 -0.6010 -0.2637 -0.2680 -0.7167 -0.1689 -1.4301 -0.2034 -0.0353 -0.2813 -0.2777
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular_dysfunction outcome patients heartmate_ii
H-305	-0.6000522375106812	▁bi ven tri cular _ ▁dys function ▁isola ted _ ▁Heart Mate _ ▁II
D-305	-0.6000522375106812	biventricular_ dysfunction isolated_ HeartMate_ II
P-305	-1.1922 -0.4656 -1.2335 -0.7909 -0.2197 -0.8399 -0.0837 -0.9121 -0.0297 -0.6871 -0.8358 -0.2679 -0.9805 -0.4260 -0.3671 -0.2691
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal_dysfunction mechanical_cardiac_support
H-1394	-0.34318721294403076	▁renal _ ▁dys function ▁mechanic al _ ▁cardiac
D-1394	-0.34318721294403076	renal_ dysfunction mechanical_ cardiac
P-1394	-0.3881 -0.3167 -0.8314 -0.0197 -0.0146 -0.0841 -0.1994 -0.4005 -0.9464 -0.2309
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular_assist_devices therapies
H-203	-0.6218224167823792	▁vent ri cular _ assist ances ▁device _ therapie s
D-203	-0.6218224167823792	ventricular_assistances device_therapies
P-203	-0.0656 -0.5208 -0.1974 -0.2358 -0.0085 -4.1479 -0.7284 -0.6440 -0.1458 -0.1138 -0.3868 -0.2671
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional_ms medical_treatment surgical
H-376	-1.0885878801345825	▁Fun ction al _ ▁MS ▁medical
D-376	-1.0885878801345825	Functional_ MS medical
P-376	-3.2860 -0.0398 -0.0934 -0.7552 -1.6078 -0.1397 -2.5318 -0.2549
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients left_ventricular_dilatation dysfunction
H-1746	-0.745887279510498	▁vent ri cular _ di la tation ▁dys function
D-1746	-0.745887279510498	ventricular_dilatation dysfunction
P-1746	-2.0661 -0.5265 -0.3457 -0.3431 -1.6945 -0.2390 -0.1723 -1.9453 -0.0813 -0.5109 -0.2800
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade evidence anemia patients heart_disease
H-38	-0.9054678082466125	▁an emia ▁heart _ ▁disease
D-38	-0.9054678082466125	anemia heart_ disease
P-38	-2.2039 -0.1938 -0.5833 -0.3182 -2.3269 -0.4224 -0.2898
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients heart_failure systolic_heart_failure
H-725	-0.9192832112312317	▁heart _ fail ure ▁sy sto lic _ heart _ fail ure
D-725	-0.9192832112312317	heart_failure systolic_heart_failure
P-725	-1.9068 -0.3385 -1.3059 -1.7111 -0.5194 -0.2929 -0.8382 -0.3282 -2.5218 -0.2683 -0.6950 -1.5796 -0.3269 -0.2373
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients hf spontaneous_vt qt_intervals
H-1445	-0.5411479473114014	▁h f ▁v t ▁beat - to - beat _ QT _ ▁interval s
D-1445	-0.5411479473114014	hf vt beat-to-beat_QT_ intervals
P-1445	-1.1098 -0.8034 -0.2187 -0.3451 -0.0454 -0.3460 -0.1827 -0.4747 -0.2888 -1.8282 -0.4259 -0.7270 -0.6526 -0.2689 -0.6645 -0.2766
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol cxl-1020 myocytes hearts
H-419	-0.38352733850479126	▁iso prot eren ol ▁c XL -10 20 ▁my o cy tes ▁heart s
D-419	-0.38352733850479126	isoproterenol cXL-1020 myocytes hearts
P-419	-0.0086 -0.0691 -0.2927 -0.3539 -0.3945 -0.8314 -0.1808 -0.0690 -1.4353 -0.1747 -0.0664 -0.4624 -0.9205 -0.2229 -0.4206 -0.2337
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted patients adverse_events follow-up
H-1956	-0.19937628507614136	▁implant ed ▁follow - up
D-1956	-0.19937628507614136	implanted follow-up
P-1956	-0.0412 -0.2100 -0.2862 -0.2673 -0.0152 -0.3483 -0.2275
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb patients hf
H-1351	-0.5623468160629272	▁p b ▁h f ▁primary _ os cilla tions ▁central _ pat tern _ genera tor
D-1351	-0.5623468160629272	pb hf primary_oscillations central_pattern_generator
P-1351	-0.0995 -0.4651 -0.9942 -0.9475 -0.6276 -0.4572 -0.3024 -0.0187 -0.2468 -0.2246 -0.1839 -1.9735 -1.2813 -0.3292 -0.6303 -0.6790 -0.4317 -0.2297
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug_test patients copd chf crf
H-806	-0.7175766825675964	▁tu g _ test ▁COP d ▁CHF ▁c RF
D-806	-0.7175766825675964	tug_test COPd CHF cRF
P-806	-0.8037 -1.3671 -0.6168 -0.4303 -0.9426 -0.4918 -0.0982 -0.7848 -1.7034 -0.4131 -0.2416
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart_failure hf chronic disease
H-2019	-0.9992968440055847	▁Heart _ ▁failure HF ▁chronic _ ▁disease
D-2019	-0.9992968440055847	Heart_ failureHF chronic_ disease
P-2019	-0.5840 -0.2310 -2.9195 -0.7550 -0.8175 -0.7201 -2.3850 -0.3308 -0.2507
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline rhythm-control rate-control
H-1237	-0.2870227098464966	▁base line ▁ rhythm - control ▁rate - control
D-1237	-0.2870227098464966	baseline rhythm-control rate-control
P-1237	-0.1997 -0.1204 -0.2274 -0.5717 -0.3788 -0.0157 -0.5038 -0.2869 -0.0222 -0.5935 -0.2371
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf epidemiology health hf
H-1790	-1.0493509769439697	▁h f ▁health _ service ▁h f ▁LA
D-1790	-1.0493509769439697	hf health_service hf LA
P-1790	-2.2752 -0.7144 -0.0901 -0.4043 -0.0479 -2.0428 -0.8606 -3.2645 -0.5220 -0.2716
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin health outcomes
H-43	-0.7700309753417969	▁hem o glob in ▁health
D-43	-0.7700309753417969	hemoglobin health
P-43	-0.5724 -0.4328 -0.1894 -1.6886 -0.7339 -1.5136 -0.2595
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes heart_failure hf
H-555	-0.9099826216697693	▁heart _ fail ure HF
D-555	-0.9099826216697693	heart_failureHF
P-555	-2.1400 -0.2328 -0.9770 -1.5798 -0.8348 -0.3579 -0.2475
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates coagulability
H-1113	-0.29337412118911743	▁se rum _ factor s ▁coa gul ability
D-1113	-0.29337412118911743	serum_factors coagulability
P-1113	-0.4531 -0.3942 -0.1769 -0.0538 -0.2113 -0.4616 -0.2069 -0.3092 -0.4250 -0.2418
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up lvad patients heart_failure
H-548	-1.0792179107666016	▁CF _ l VAD ▁AI ▁heart _ fail ure
D-548	-1.0792179107666016	CF_lVAD AI heart_failure
P-548	-1.5178 -1.0001 -3.4305 -0.0766 -1.6935 -0.2960 -0.4975 -0.7918 -1.9267 -0.3921 -0.2488
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory_factor_analysis cfa
H-1506	-0.46718665957450867	▁explora tory _ factor _ analyse ▁c fa
D-1506	-0.46718665957450867	exploratory_factor_analyse cfa
P-1506	-0.0758 -0.0073 -0.2307 -0.0381 -1.2181 -0.5955 -0.6338 -1.1400 -0.4699 -0.2628
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical patient hemodynamically cpr
H-1294	-0.97812420129776	▁hem o dynamic ally _ ▁uns table ▁c PR
D-1294	-0.97812420129776	hemodynamically_ unstable cPR
P-1294	-3.8154 -0.2915 -0.0233 -0.1634 -1.8585 -1.6136 -0.0326 -0.5646 -1.7104 -0.4858 -0.2002
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing mandate accountable outcomes nursing
H-1396	-0.6593299508094788	▁social ▁mandat e ▁account able ▁nur sing _ care
D-1396	-0.6593299508094788	social mandate accountable nursing_care
P-1396	-1.7269 -1.5127 -0.2671 -0.0135 -0.0473 -2.2393 -0.0771 -0.4499 -0.2566 -0.3396 -0.3227
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical activity cardiovascular obesity diabetes_mellitus hypertension hyperlipidaemia
H-1898	-0.23300108313560486	▁physical _ activ ity ▁cardiovascular ▁diabetes _ ▁mell itus ▁hyper tension ▁hyper li pida emia
D-1898	-0.23300108313560486	physical_activity cardiovascular diabetes_ mellitus hypertension hyperlipidaemia
P-1898	-0.1516 -0.8715 -0.1956 -0.4446 -0.0587 -0.3892 -0.3172 -0.2767 -0.0403 -0.0110 -0.0051 -0.0424 -0.3650 -0.0973 -0.1867 -0.2948 -0.2133
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-0.9605269432067871	
D-1979	-0.9605269432067871	
P-1979	-1.6717 -0.2493
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.5944349765777588	
D-272	-0.5944349765777588	
P-272	-0.8758 -0.3131
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac_death
H-1905	-0.5701078772544861	▁sud den _ ▁cardiac _ ▁death
D-1905	-0.5701078772544861	sudden_ cardiac_ death
P-1905	-1.5857 -0.0247 -0.1290 -0.2833 -0.2818 -1.4631 -0.5688 -0.2246
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital mortality
H-1692	-0.3890564441680908	▁hospital _ ▁mortal ity
D-1692	-0.3890564441680908	hospital_ mortality
P-1692	-0.3781 -0.4024 -0.5654 -0.2121 -0.4412 -0.3352
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration chf
H-683	-0.4028855264186859	▁administration ▁tras tuz um ab - related _ ▁CHF
D-683	-0.4028855264186859	administration trastuzumab-related_ CHF
P-683	-0.0246 -0.5893 -0.0634 -0.2537 -0.1094 -0.7767 -0.0853 -1.1695 -0.6845 -0.4099 -0.2655
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital rehospitalization
H-1719	-0.7240239977836609	▁hospital _ leng th ▁re hospital ization
D-1719	-0.7240239977836609	hospital_length rehospitalization
P-1719	-2.4403 -0.8697 -0.0454 -0.0054 -2.4092 -0.0529 -0.1494 -0.3026 -0.2412
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.6246858239173889	▁hospital s
D-142	-0.6246858239173889	hospitals
P-142	-0.8575 -0.3878 -0.9436 -0.3098
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.7178943753242493	▁bio mark er - guide d
D-1476	-0.7178943753242493	biomarker-guided
P-1476	-1.2893 -0.1371 -0.3144 -0.2532 -0.0172 -0.1295 -3.2384 -0.3640
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.983449399471283	▁medical _ report s
D-1131	-0.983449399471283	medical_reports
P-1131	-0.0452 -0.7476 -4.1292 -0.3440 -0.3629 -0.2717
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal_pro-b-type_natriuretic_peptides plasma heart_failure patients
H-1510	-0.5399887561798096	▁Circula ting ▁na tri ure tic _ pe pti des ▁plasma ▁heart _ ▁failure
D-1510	-0.5399887561798096	Circulating natriuretic_peptides plasma heart_ failure
P-1510	-0.7884 -0.0770 -0.4774 -0.2234 -0.0628 -0.6283 -0.2475 -0.9981 -0.5225 -1.3926 -0.1277 -0.2411 -0.2837 -1.5656 -0.6908 -0.3130
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients heart_failure hf preserved_left_ventricular_ejection_fraction hfpef
H-1300	-0.5623939037322998	▁heart _ fail ure HF ▁left _ vent ri cular _ e je ction _ fraction ▁h p EF
D-1300	-0.5623939037322998	heart_failureHF left_ventricular_ejection_fraction hpEF
P-1300	-0.6443 -0.2834 -1.2599 -1.9026 -0.6848 -0.9009 -0.3555 -0.5914 -0.6538 -0.3509 -0.4232 -0.2162 -0.4556 -0.2267 -0.1820 -0.0131 -1.0471 -0.2454 -0.7986 -0.3560 -0.2190
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine myocyte collagen left_ventricle
H-1141	-0.391743928194046	▁Pyr ido stig mine ▁my o cy te _ dia meter ▁collage n _ dens ity ▁left _ vent ric le
D-1141	-0.391743928194046	Pyridostigmine myocyte_diameter collagen_density left_ventricle
P-1141	-0.0494 -0.0519 -0.0024 -0.0556 -0.4821 -0.2390 -0.0658 -0.2357 -0.4128 -0.0431 -0.0034 -0.0742 -0.2139 -0.2438 -1.1189 -0.0763 -0.6030 -0.2812 -0.3784 -2.2592 -1.4914 -0.4117 -0.2169
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac_angiogenesis in_vivo_coronary_perfusion cardiac_fibrosis
H-454	-0.7259505391120911	▁cardiac _ ▁ang io gene sis ▁corona ry _ per fusion ▁cardiac _ ▁fibro sis
D-454	-0.7259505391120911	cardiac_ angiogenesis coronary_perfusion cardiac_ fibrosis
P-454	-0.6318 -0.2778 -1.6443 -2.6239 -0.8165 -2.7679 -0.6834 -0.3236 -0.2996 -0.1261 -0.0273 -0.1382 -0.3454 -0.1442 -0.8896 -0.3959 -0.2056
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality patients implantable_cardiac_defibrillator meta-analysis
H-59	-0.2891634404659271	▁implant able _ ▁cardiac _ de fi br illa tor
D-59	-0.2891634404659271	implantable_ cardiac_defibrillator
P-59	-0.1759 -0.1287 -0.5473 -0.1750 -0.2641 -0.1691 -0.2585 -0.5501 -0.1013 -0.3616 -0.4200 -0.3183
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors adenylyl_cyclase g-protein_coupling
H-1406	-0.3857109844684601	▁receptor s ▁a den yl yl _ ▁cy cla se ▁differenti al _ g - prote in _ ▁coup ling
D-1406	-0.3857109844684601	receptors adenylyl_ cyclase differential_g-protein_ coupling
P-1406	-0.0734 -0.2116 -0.0426 -0.0719 -0.9262 -0.3909 -0.3959 -0.8164 -0.0158 -0.9558 -0.2999 -0.0183 -0.9322 -0.3814 -0.1631 -0.2285 -0.6725 -0.1758 -0.7259 -0.2675 -0.4753 -0.2446
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization patients heart_failure ventricular_tachycardia
H-1434	-0.9124587774276733	▁heart _ fail ure ▁vent ri cular _ ta chy car dia
D-1434	-0.9124587774276733	heart_failure ventricular_tachycardia
P-1434	-4.7663 -0.4857 -1.7580 -1.1559 -0.0509 -0.7311 -0.4171 -1.0786 -0.9857 -0.2815 -0.0637 -0.0588 -0.6134 -0.3276
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling_pathways pressure-overload-induced_heart_failure
H-877	-0.6748489737510681	▁pressure - over load - indu ced _ heart _ fail ure
D-877	-0.6748489737510681	pressure-overload-induced_heart_failure
P-877	-3.1165 -0.2384 -0.0873 -0.0258 -0.5379 -0.0003 -0.0288 -0.7044 -1.7605 -0.2678 -1.1126 -0.8323 -0.3976 -0.3375
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise_intolerance symptom chronic_hfpef quality_of_life qol
H-1975	-0.8975334763526917	▁exercise _ in tolerance ▁h f f
D-1975	-0.8975334763526917	exercise_intolerance hff
P-1975	-0.3714 -0.5449 -0.2553 -0.1272 -0.8689 -0.9913 -0.5794 -4.1140 -0.2255
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients systolic_hf etiology coronary_angiography
H-1184	-0.5715204477310181	▁sy sto lic _ HF ▁et i ology ▁corona ry _ ang i ography
D-1184	-0.5715204477310181	systolic_HF etiology coronary_angiography
P-1184	-0.8398 -0.1516 -0.1269 -1.3293 -0.6303 -1.6989 -0.3782 -0.0138 -0.1337 -0.4128 -0.3612 -0.5163 -1.4506 -0.3319 -0.5248 -0.2443
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart_failure hf elevated sympathetic_activity parasympathetic_control heart
H-1133	-0.6429229378700256	▁Heart _ ▁failure HF ▁sympa the tic _ activ ity ▁para sy mpa the tic _ control ▁heart
D-1133	-0.6429229378700256	Heart_ failureHF sympathetic_activity parasympathetic_control heart
P-1133	-0.5938 -0.2709 -2.5978 -0.9650 -0.6004 -0.4191 -0.2447 -0.7216 -0.2542 -0.0659 -0.3673 -0.1868 -0.4640 -1.0656 -0.4809 -1.0353 -0.0083 -1.8781 -0.3773 -0.2613
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp xo-mediated_ros mitochondrial_respiration contractile_function
H-471	-0.577301561832428	▁ATP ▁ XO - media ted _ ros ▁mito cho ndri al _ re spira tion ▁contract ile _ function
D-471	-0.577301561832428	ATP XO-mediated_ros mitochondrial_respiration contractile_function
P-471	-0.5225 -2.2199 -0.6282 -0.0226 -0.1207 -0.0267 -0.3453 -0.9835 -0.0777 -1.3369 -0.7047 -0.1998 -0.3658 -1.1586 -1.5463 -0.0721 -0.0459 -0.3935 -1.1315 -0.2091 -0.3595 -0.2300
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients end-stage_heart_failure implantation ventricular_assist_device
H-1657	-0.8661755323410034	▁end - s tage _ heart _ fail ure ▁implant ation ▁long - term _ vent ri cular _ assist _ ▁device
D-1657	-0.8661755323410034	end-stage_heart_failure implantation long-term_ventricular_assist_ device
P-1657	-1.5193 -0.1688 -0.1389 -0.0278 -0.2353 -2.8894 -0.2800 -1.3930 -1.7949 -0.0223 -0.0869 -1.0946 -0.2031 -0.8505 -0.8779 -1.3803 -1.4561 -0.3836 -0.2393 -0.0082 -1.1874 -3.6417 -0.5828 -0.3261
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial_fibrillation congestive_heart_failure cost rhythm-control rate-control
H-1230	-0.49529051780700684	rial _ fi bril lation ▁con ges tive _ heart _ fail ure ▁cost ▁ rhythm - control ▁rate - control
D-1230	-0.49529051780700684	rial_fibrillation congestive_heart_failure cost rhythm-control rate-control
P-1230	-1.9273 -0.5693 -0.8084 -0.1071 -0.1050 -0.0893 -0.0655 -0.2874 -0.2620 -1.4380 -0.3170 -0.9925 -0.6630 -0.0286 -0.5368 -0.6091 -0.2339 -0.0089 -0.8437 -0.3718 -0.0100 -0.8485 -0.2688
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection_fraction ef infarct collateral_growth myocardial_perfusion
H-506	-0.6679981350898743	▁e je ction _ fraction EF ▁in far ct _ size ▁col lateral _ ▁growth ▁my o card ial _ per fusion
D-506	-0.6679981350898743	ejection_fractionEF infarct_size collateral_ growth myocardial_perfusion
P-506	-0.4435 -0.3584 -0.0430 -0.2883 -0.0087 -2.2535 -1.3983 -0.0603 -0.4853 -1.8976 -2.4255 -1.1406 -0.0096 -0.2559 -1.4923 -0.8920 -0.5004 -0.4688 -0.4672 -0.2854 -0.1029 -0.0484 -0.4489 -0.2572
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf_antagonists nbdmard
H-607	-0.7336141467094421	▁HR ▁t NF ▁n b DM ARD
D-607	-0.7336141467094421	HR tNF nbDMARD
P-607	-1.5827 -0.1524 -0.8638 -0.7827 -0.0652 -2.0009 -0.5398 -0.4202 -0.1948
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical revascularization revascularization
H-1603	-0.5422490239143372	▁medical _ re vas cular ization ▁cat heter - based _ re vas cular ization
D-1603	-0.5422490239143372	medical_revascularization catheter-based_revascularization
P-1603	-4.3119 -0.9005 -0.0616 -0.2838 -0.2622 -0.3106 -0.2855 -0.0076 -0.1314 -0.0086 -0.6684 -0.1241 -0.3874 -0.2482 -0.3903 -0.5412 -0.2950
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based nucleolin protein_expression
H-96	-0.6525630354881287	▁Mor pho lino - based _ ▁knock down ▁nucleo lin ▁protein _ expression
D-96	-0.6525630354881287	Morpholino-based_ knockdown nucleolin protein_expression
P-96	-1.6923 -0.3057 -0.4443 -0.1435 -0.0074 -0.7395 -0.5388 -0.2422 -0.5821 -3.7529 -0.1939 -0.1378 -0.0895 -0.6596 -0.2591
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence bnp patients pad bnp hf
H-1572	-0.7113246917724609	▁b NP PAD ▁b NP ▁h z
D-1572	-0.7113246917724609	bNPPAD bNP hz
P-1572	-0.5953 -0.5979 -0.3519 -1.0218 -0.6117 -0.5674 -2.0554 -0.3801 -0.2203
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd psoriasis hazard_ratio confidence_interval
H-1563	-0.4899347424507141	▁cv d ▁psoriasis
D-1563	-0.4899347424507141	cvd psoriasis
P-1563	-0.7954 -0.0970 -0.0248 -1.3401 -0.1923
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam_study psoriasis cardiovascular outcomes
H-1556	-0.5949123501777649	▁Rotterdam ▁psoriasis ▁cardiovascular
D-1556	-0.5949123501777649	Rotterdam psoriasis cardiovascular
P-1556	-1.2817 -0.3772 -0.0367 -1.0750 -0.2038
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes exercise training patients ambulatory hf
H-1631	-0.8867397904396057	▁exercise ▁ambula tory _ HF
D-1631	-0.8867397904396057	exercise ambulatory_HF
P-1631	-0.8871 -1.4868 -0.0340 -0.9159 -2.3428 -0.2702 -0.2705
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients hfpef adverse_outcomes
H-237	-0.4056389331817627	HF p EF
D-237	-0.4056389331817627	HFpEF
P-237	-0.9152 -0.0806 -0.2529 -0.5345 -0.2451
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence parasympathetic therapeutic hf
H-1134	-0.5663759112358093	▁para sy mpa the tic _ function HF
D-1134	-0.5663759112358093	parasympathetic_functionHF
P-1134	-0.4155 -0.3609 -0.4051 -0.4287 -0.1864 -0.2761 -0.1733 -2.7857 -0.4287 -0.2033
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes_mellitus cardiovascular_disease baseline
H-630	-0.5571761727333069	▁diabetes _ ▁mell itus ▁cardiovascular _ ▁disease ▁base line
D-630	-0.5571761727333069	diabetes_ mellitus cardiovascular_ disease baseline
P-630	-0.3699 -0.3399 -0.9546 -0.0743 -0.0342 -0.5852 -2.9140 -0.2139 -0.0724 -0.2965 -0.2741
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical rule cad systolic_hf
H-1185	-0.46844547986984253	▁der ive ▁rule ▁CAD ▁sy sto lic HF
D-1185	-0.46844547986984253	derive rule CAD systolicHF
P-1185	-0.0782 -0.0513 -1.7581 -0.4803 -0.1769 -0.1678 -0.1486 -1.3201 -0.3090 -0.1943
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality readmission
H-207	-0.5964305400848389	▁cognitive _ ▁im pair ment ▁mortal ity
D-207	-0.5964305400848389	cognitive_ impairment mortality
P-207	-0.4309 -0.3742 -1.1757 -0.0605 -0.1613 -1.0221 -0.2393 -1.6346 -0.2694
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence schfi_v.6.2 clinical
H-1509	-0.7825778126716614	▁evidence ▁sch fi
D-1509	-0.7825778126716614	evidence schfi
P-1509	-0.2165 -1.1146 -2.0385 -0.3358 -0.2075
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo egfr egfr
H-1392	-0.762395977973938	▁ec mo ▁e g FR ▁e g FR
D-1392	-0.762395977973938	ecmo egFR egFR
P-1392	-0.2982 -1.6133 -0.4698 -0.4394 -1.7476 -0.3168 -0.5283 -1.6258 -0.3943 -0.1903
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise haemodynamic pulmonary
H-1277	-0.47315195202827454	▁ha emo dynamic ▁pulmonar y
D-1277	-0.47315195202827454	haemodynamic pulmonary
P-1277	-1.2835 -0.0900 -0.0201 -0.0093 -0.2766 -1.3521 -0.2804
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic rule prospectively
H-1188	-0.8550689220428467	▁predict ion _ ▁rule
D-1188	-0.8550689220428467	prediction_ rule
P-1188	-2.0687 -0.1813 -0.2827 -1.9943 -0.3847 -0.2187
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule patients cad patients cad
H-1191	-1.043627381324768	▁predict ion _ ▁rule ▁CAD ▁CAD
D-1191	-1.043627381324768	prediction_ rule CAD CAD
P-1191	-1.7135 -0.1596 -0.4708 -1.4430 -1.1061 -2.8767 -0.3796 -0.1997
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia rv_function
H-1159	-0.9183416962623596	▁cache xia ▁ RV _ function ▁body _ ▁composición
D-1159	-0.9183416962623596	cachexia RV_function body_ composición
P-1159	-1.7450 -0.2907 -1.2829 -0.8206 -1.5795 -0.3701 -0.5222 -0.5061 -2.4138 -0.3669 -0.2040
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute_hf
H-1018	-0.7033483386039734	▁h f ▁out line
D-1018	-0.7033483386039734	hf outline
P-1018	-1.1796 -1.3292 -0.8366 -0.0350 -0.5634 -0.2764
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline hgb exercise training kccq
H-841	-0.623294472694397	▁base line _ h gb ▁exercise ▁k cc q
D-841	-0.623294472694397	baseline_hgb exercise kccq
P-841	-0.1273 -0.0637 -1.6184 -0.7165 -0.0797 -0.0620 -2.1925 -0.0712 -1.2570 -0.4473 -0.2206
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital cardiac hospital south_dakota
H-1577	-0.41617217659950256	▁general _ hospital ▁cardiac _ special ty _ hospital ▁south _ da kota
D-1577	-0.41617217659950256	general_hospital cardiac_specialty_hospital south_dakota
P-1577	-0.2255 -0.2715 -0.2681 -0.0143 -1.0357 -0.3310 -0.0626 -0.2473 -0.3043 -0.7342 -1.2045 -0.9489 -0.0479 -0.3228 -0.2238
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications acs patients patients vad
H-1286	-1.1049067974090576	▁a CS ▁MT ▁ VAD
D-1286	-1.1049067974090576	aCS MT VAD
P-1286	-0.8502 -1.9266 -2.3480 -1.8178 -0.0698 -0.4378 -0.2842
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic histological gastrointestinal
H-1359	-0.9496573805809021	▁sono graphic ▁his t ological ▁functional ▁gastro inte stin al
D-1359	-0.9496573805809021	sonographic histological functional gastrointestinal
P-1359	-3.9880 -1.3013 -1.0181 -0.1549 -0.1246 -1.0641 -1.3399 -0.0316 -1.0156 -0.3734 -0.7278 -0.2565
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy_substrate_metabolism hearts aac
H-1781	-0.3734753131866455	▁energy _ ▁substrat e _ ▁metabolism ▁working _ heart s ▁a ac
D-1781	-0.3734753131866455	energy_ substrate_ metabolism working_hearts aac
P-1781	-0.4302 -0.1737 -0.3477 -0.2555 -0.1924 -0.3353 -0.1098 -0.2111 -1.4173 -0.2566 -0.3658 -0.6847 -0.2635 -0.1850
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular_venous_pressure peripheral_oedema patient
H-1895	-0.5688668489456177	▁jugu lar _ ve nous _ tension ▁per i pher al _ ▁oed ema ▁volume
D-1895	-0.5688668489456177	jugular_venous_tension peripheral_ oedema volume
P-1895	-0.0091 -0.6553 -0.2461 -1.1534 -0.7818 -0.1552 -1.3659 -0.1656 -0.1807 -0.0235 -0.2970 -0.2607 -1.8154 -0.1608 -1.2091 -0.9773 -0.2137
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone hyperkalemia acute_kidney_injury
H-445	-0.33929455280303955	▁Spir ono lac tone ▁hyper kal emia ▁ki dne y _ ▁injury
D-445	-0.33929455280303955	Spironolactone hyperkalemia kidney_ injury
P-445	-0.2982 -0.0419 -0.1076 -0.0548 -0.0509 -0.4703 -0.2135 -0.2465 -0.4526 -0.2480 -0.8691 -1.1263 -0.3764 -0.1940
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up deaths heart_transplantations lv_assist_device_implantations heart_failure admissions
H-434	-0.9117070436477661	▁follow - up ▁heart _ ▁transplant ations LV _ assist ance _ ▁Device _ ▁implant ations ▁heart _ fail ure
D-434	-0.9117070436477661	follow-up heart_ transplantationsLV_assistance_ Device_ implantations heart_failure
P-434	-3.0118 -0.1937 -0.0108 -1.5991 -0.3828 -1.3739 -0.2582 -0.4353 -1.0261 -0.0081 -2.1472 -0.1695 -2.9495 -0.3102 -0.1667 -0.2433 -1.0024 -0.3566 -1.7078 -0.9913 -1.4342 -0.2792
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-333	-0.5915907025337219	▁functional _ met ral _ ▁sten osis ▁ring _ ▁ann ulo plast y ▁ ische mic _ mit ral _ re gur gi tation
D-333	-0.5915907025337219	functional_metral_ stenosis ring_ annuloplasty ischemic_mitral_regurgitation
P-333	-0.1838 -0.6272 -2.3219 -0.1020 -0.1707 -1.9087 -0.0961 -0.0760 -0.3009 -2.6981 -0.1501 -0.0199 -0.2412 -1.4558 -0.0292 -0.2933 -0.4160 -2.5033 -0.3141 -0.2739 -0.0577 -0.0214 -0.3633 -0.0272 -0.4870 -0.2425
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants antiplatelet_drugs heart_failure atrial_fibrillation
H-1352	-0.47503527998924255	▁antico a gul ants ▁anti plate let _ drug s ▁heart _ fail ure ▁at rial _ fi bril lation
D-1352	-0.47503527998924255	anticoagulants antiplatelet_drugs heart_failure atrial_fibrillation
P-1352	-1.0883 -0.3016 -0.1382 -0.1427 -0.0461 -0.2793 -0.8321 -0.5551 -1.5030 -0.0733 -0.4628 -0.2332 -1.0941 -1.0526 -0.2751 -0.6333 -0.3156 -0.7236 -0.0858 -0.1382 -0.3117 -0.1649
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical_cardiac_support renal_function end-stage_heart_failure
H-1384	-0.5902964472770691	▁mechanic al _ ▁cardiac ▁renal _ function ▁end - s tage _ heart _ fail ure
D-1384	-0.5902964472770691	mechanical_ cardiac renal_function end-stage_heart_failure
P-1384	-0.0100 -0.1556 -0.2760 -0.3761 -0.3325 -0.3919 -0.2116 -3.0515 -0.0847 -0.0512 -0.0183 -0.2007 -2.2033 -0.2095 -0.9864 -1.2942 -0.4800 -0.2918
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic_peptide biomarkers point_of_care poc
H-1023	-0.410692036151886	▁na tri ure tic _ pe pti de ▁bio mark ers ▁point _ of _ care
D-1023	-0.410692036151886	natriuretic_peptide biomarkers point_of_care
P-1023	-0.6729 -0.2181 -0.0758 -0.1579 -0.2483 -1.1471 -0.1707 -0.5586 -0.4706 -0.0472 -0.1811 -0.0256 -0.2435 -0.0929 -0.2366 -0.2134 -2.4294 -0.2025
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart_failure hf condition morbidity mortality
H-1487	-0.5076700448989868	▁Heart _ ▁failure HF ▁condition ▁morbi d ity ▁mortal ity
D-1487	-0.5076700448989868	Heart_ failureHF condition morbidity mortality
P-1487	-0.7413 -0.2340 -2.6578 -0.4386 -0.1038 -0.9916 -0.0632 -0.1475 -0.0593 -0.0883 -0.3369 -0.2298
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients systolic_blood_pressure renal_impairment hypertension
H-1529	-0.5822250247001648	▁eh ▁sy sto lic _ ▁blood _ tension ▁renal _ im pair ment ▁hyper tension
D-1529	-0.5822250247001648	eh systolic_ blood_tension renal_impairment hypertension
P-1529	-1.1073 -1.0289 -0.1825 -0.4872 -0.2202 -1.9746 -0.3590 -1.6790 -0.0444 -0.5534 -1.1289 -0.0469 -0.1107 -0.3529 -0.0069 -0.3569 -0.2585
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo_sternotomy cardiopulmonary_bypass
H-775	-0.8311612010002136	▁pump - ex change ▁technique ▁redo _ ster no to my ▁cardio pul mon ary _ ▁by pass
D-775	-0.8311612010002136	pump-exchange technique redo_sternotomy cardiopulmonary_ bypass
P-775	-1.8682 -0.2238 -0.0415 -0.0071 -1.4047 -1.1222 -0.7117 -1.1274 -0.0608 -0.2929 -1.9773 -0.0877 -1.1607 -2.6623 -0.0759 -0.3896 -2.7150 -0.0041 -0.4202 -0.2699
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic_myocardial_ischemia heart_failure therapeutic
H-503	-0.7601281404495239	▁chronic _ My o card ial _ ische mia ▁heart _ fail ure
D-503	-0.7601281404495239	chronic_Myocardial_ischemia heart_failure
P-503	-0.7477 -0.3135 -3.9015 -0.6870 -0.6035 -0.5782 -0.2634 -0.1054 -0.8487 -0.3405 -0.2496 -0.7250 -1.3565 -0.4373 -0.2442
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf transition compensated_lv_hypertrophy hf hhd
H-283	-0.8375808000564575	▁mouse ▁ HF ▁transition ▁compensa ted _ ▁LV _ ▁hyper trop hy ▁h h
D-283	-0.8375808000564575	mouse HF transition compensated_ LV_ hypertrophy hh
P-283	-0.3929 -2.7516 -0.3945 -0.1218 -1.0107 -0.0715 -1.0518 -1.0034 -0.2585 -1.6534 -0.2767 -0.2834 -0.5312 -2.8270 -0.5593 -0.2136
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical_treatment hf functional_ms medical_treatment
H-354	-0.9318613409996033	▁ms ▁medical HF ▁ms ▁dynamic ▁medical
D-354	-0.9318613409996033	ms medicalHF ms dynamic medical
P-354	-1.2328 -0.2103 -2.2779 -1.3383 -1.0662 -0.0520 -1.1163 -0.1610
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic parasympathetic_activity hf symptoms disease
H-1868	-0.5125126838684082	▁sympa the tic ▁para sy mpa the tic _ activ ity ▁h f
D-1868	-0.5125126838684082	sympathetic parasympathetic_activity hf
P-1868	-0.3821 -0.2958 -0.1329 -0.1640 -0.2437 -0.4642 -0.9269 -0.3734 -1.3960 -0.2103 -0.0892 -0.5562 -1.0394 -1.2175 -0.1960
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical_treatment hf hf symptom mva
H-371	-0.7787498235702515	▁medical ▁h f ▁h f ▁ms ▁m va
D-371	-0.7787498235702515	medical hf hf ms mva
P-371	-0.6669 -1.1355 -1.1533 -1.3507 -1.5980 -0.6207 -0.6355 -0.1433 -0.3166 -0.1671
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis heart_failure_with_preserved_ejection_fraction clinical doppler_echocardiography
H-21	-0.628159761428833	▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁do pp ler _ e cho card i ography
D-21	-0.628159761428833	heart_ failure preserved_ejection_fraction doppler_echocardiography
P-21	-1.7754 -0.3121 -2.5898 -0.6058 -0.3510 -0.2097 -0.3854 -0.2412 -0.4234 -0.0647 -0.1968 -0.0081 -0.1742 -0.2570 -2.4299 -0.2982 -0.1895 -1.1423 -0.6918 -0.9518 -0.3986 -0.5056 -0.2450
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based patient outcomes
H-85	-0.32077690958976746	▁evidence - based _ prac tice s
D-85	-0.32077690958976746	evidence-based_practices
P-85	-0.4625 -0.0973 -0.0056 -0.8178 -0.1137 -0.0091 -0.1515 -0.9128 -0.3165
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular conditions patients hf
H-694	-0.6517395973205566	▁cardiovascular _ condition s ▁h f
D-694	-0.6517395973205566	cardiovascular_conditions hf
P-694	-0.7018 -0.6411 -0.7254 -0.1370 -0.7762 -1.6225 -0.3380 -0.2718
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health health u.s. drug administration
H-1830	-0.4777410924434662	▁health _ ▁insurance ▁health _ system ▁u . s . _ ▁Food _ and _ drug _ administration
D-1830	-0.4777410924434662	health_ insurance health_system u.s._ Food_and_drug_administration
P-1830	-0.0807 -0.5903 -2.1277 -0.0260 -0.2708 -0.0989 -0.1970 -0.1132 -0.3380 -0.1037 -1.1370 -1.5906 -0.4551 -0.3256 -0.4739 -0.5856 -0.1895 -0.1460 -0.3998 -0.3054
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary congenital heart death
H-1906	-0.5560628771781921	▁her edit ary ▁con geni tal _ ab normal ities ▁heart ▁non trau matic _ ▁death
D-1906	-0.5560628771781921	hereditary congenital_abnormalities heart nontraumatic_ death
P-1906	-3.8310 -0.1635 -0.0950 -0.3946 -0.0322 -0.0691 -0.4283 -0.5203 -0.6329 -0.1734 -0.9949 -0.2520 -0.0786 -0.2883 -0.2322 -0.9444 -0.4945 -0.3839
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling_pathway remodelling
H-994	-0.485061377286911	▁Raf - MEK 1/2 - er k 1/2
D-994	-0.485061377286911	Raf-MEK1/2-erk1/2
P-994	-0.0839 -0.1243 -0.0318 -0.1383 -0.1507 -0.5716 -0.5266 -0.3477 -2.6231 -0.2528
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin lvad postoperative
H-536	-0.6990756988525391	▁album in ▁l VAD ▁post operativ e _ ▁survival
D-536	-0.6990756988525391	albumin lVAD postoperative_ survival
P-536	-0.3874 -0.8973 -1.7028 -0.0882 -0.6560 -0.2343 -0.3152 -0.9864 -1.7110 -0.4377 -0.2735
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients heartmate_ii lvad
H-303	-0.932207465171814	▁isola ted _ ▁Heart Mate _ ▁II _ VAD
D-303	-0.932207465171814	isolated_ HeartMate_ II_VAD
P-303	-1.8003 -0.0291 -1.3704 -1.2693 -0.3361 -0.2237 -0.7133 -0.2878 -3.4805 -0.4346 -0.3091
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate heart_failure
H-1544	-0.8074806928634644	▁bis phos phon ate ▁heart _ fail ure
D-1544	-0.8074806928634644	bisphosphonate heart_failure
P-1544	-1.6536 -0.0446 -0.1604 -2.2410 -0.5519 -0.2563 -0.9582 -1.5359 -0.4281 -0.2448
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary_outcomes
H-620	-0.372283011674881	▁sustain ability ▁commission ing
D-620	-0.372283011674881	sustainability commissioning
P-620	-0.3501 -0.0502 -1.0178 -0.1468 -0.4098 -0.2590
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling emd
H-1151	-1.0481610298156738	▁em d
D-1151	-1.0481610298156738	emd
P-1151	-2.9002 -0.1513 -0.9455 -0.1957
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi mi hf
H-1104	-0.8411543369293213	▁MI ▁late - ons et ▁MI ▁h f
D-1104	-0.8411543369293213	MI late-onset MI hf
P-1104	-1.5172 -1.3788 -0.1296 -0.3149 -0.3160 -1.3603 -0.6344 -2.1141 -0.4031 -0.2433
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs outcomes
H-2009	-0.22685782611370087	▁costs
D-2009	-0.22685782611370087	costs
P-2009	-0.0763 -0.3471 -0.2572
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-1.1296435594558716	
D-1473	-1.1296435594558716	
P-1473	-2.0251 -0.2342
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-0.8226752281188965	▁patient _ safe ty
D-7	-0.8226752281188965	patient_safety
P-7	-0.7369 -1.1333 -2.1651 -0.0838 -0.5924 -0.2245
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine_oxidase_inhibition left_ventricular systolic diastolic_function cardiac_volume_overload
H-469	-0.645454466342926	▁Xan thi ne _ oxid ase _ ▁inhibi tion ▁vent ri cular _ sy sto lic ▁dia sto lic ▁cardiac _ ▁volume _ over load
D-469	-0.645454466342926	Xanthine_oxidase_ inhibition ventricular_systolic diastolic cardiac_ volume_overload
P-469	-0.0054 -0.0609 -0.6974 -0.2331 -0.8243 -3.4504 -0.2567 -0.6905 -0.0739 -0.0352 -0.6268 -0.3391 -0.4485 -1.6031 -1.0372 -0.8238 -0.0296 -0.3908 -0.4429 -0.9205 -0.6500 -1.9073 -0.7283 -0.3112 -0.0057 -0.5973 -0.2373
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global_left_ventricular_longitudinal_systolic_strain cardiovascular_events patients atrial_fibrillation
H-808	-0.6490985155105591	▁left _ vent ri cular _ ▁longitud in al _ sy sto lic ▁cardiovascular _ event s ▁at rial _ fi bril lation
D-808	-0.6490985155105591	left_ventricular_ longitudinal_systolic cardiovascular_events atrial_fibrillation
P-808	-1.3213 -0.3992 -1.0219 -1.0208 -0.2867 -0.2345 -0.8877 -0.3652 -0.0790 -0.3696 -1.9808 -1.0434 -0.3955 -0.4780 -0.6734 -2.3594 -0.1188 -0.3215 -0.3649 -0.3733 -1.2510 -0.0603 -0.1447 -0.4332 -0.2433
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart_failure clinical medicine prevalence coronary_disease
H-980	-0.5808908939361572	▁Heart _ ▁failure ▁medicine ▁a ther omat ous _ ▁corona ry _ ▁Disease
D-980	-0.5808908939361572	Heart_ failure medicine atheromatous_ coronary_ Disease
P-980	-0.8737 -0.5008 -1.9874 -0.1461 -0.0727 -0.0610 -0.0605 -0.2551 -0.3026 -0.8434 -0.3219 -0.4257 -2.2174 -0.3946 -0.2504
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications outpatients heart_failure ncdr_pinnacle
H-658	-0.6814862489700317	▁medication s ▁out patient s ▁heart _ fail ure ▁NC DR _ ▁PIN na CLE
D-658	-0.6814862489700317	medications outpatients heart_failure NCDR_ PINnaCLE
P-658	-0.8720 -0.1512 -0.6506 -0.0234 -0.1802 -0.6653 -0.3055 -1.4960 -0.7420 -0.5675 -1.9329 -0.9004 -0.5167 -0.7086 -1.1258 -0.4795 -0.2676
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart hr_reduction patients systolic_heart_failure
H-527	-0.7281851172447205	▁un load ing _ of _ the _ heart ▁isola ted _ ▁HR _ re duction ▁sy sto lic _ heart _ fail ure
D-527	-0.7281851172447205	unloading_of_the_heart isolated_ HR_reduction systolic_heart_failure
P-527	-0.6880 -0.0093 -0.1131 -1.8702 -0.0928 -0.5393 -0.2045 -0.5034 -2.9576 -1.2119 -0.0225 -0.4588 -1.2088 -1.7177 -0.0462 -0.0051 -0.9254 -0.3582 -0.9281 -0.2507 -2.2243 -0.1990 -0.8794 -0.9212 -0.3485 -0.2490
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic hfpef medical_history physical_examination
H-1892	-0.7735751867294312	▁diagnostic _ test HF p EF ▁medical ▁physical
D-1892	-0.7735751867294312	diagnostic_testHFpEF medical physical
P-1892	-2.0673 -0.5840 -0.5903 -2.5748 -0.1725 -0.3666 -0.2036 -0.4249 -0.4914 -0.2602
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical symptoms hfpef symptoms breathlessness fluid_retention
H-1891	-0.6519067883491516	▁h f p EF ▁breath less ness ▁fatigue ▁fluid _ re tention
D-1891	-0.6519067883491516	hfpEF breathlessness fatigue fluid_retention
P-1891	-0.8927 -2.2610 -0.0927 -0.7265 -1.8551 -0.0381 -2.1001 -0.0299 -0.1172 -0.2474 -0.0354 -0.1086 -0.3471 -0.2750
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin insulin_resistance monocytes inflammatory
H-928	-0.473111629486084	▁circula ting _ media tor _ of _ ▁insulin _ ▁resist ance ▁mono cy tes ▁infla mma tory _ stimul i
D-928	-0.473111629486084	circulating_mediator_of_ insulin_ resistance monocytes inflammatory_stimuli
P-928	-0.0183 -0.1289 -0.3353 -1.0172 -0.3477 -1.0032 -0.0892 -0.3852 -0.2094 -0.3228 -3.5942 -0.0343 -0.0119 -0.0677 -0.4676 -0.2519 -0.3789 -0.0472 -1.0805 -0.1067 -0.3929 -0.3066 -0.2840
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp patients acute_heart_failure
H-262	-0.5802586674690247	▁cut off _ valu e ▁NT - pro b NP ▁ED ▁a cute _ heart _ fail ure
D-262	-0.5802586674690247	cutoff_value NT-probNP ED acute_heart_failure
P-262	-0.2085 -0.0927 -0.5973 -0.5544 -0.2797 -0.1833 -0.0490 -0.0351 -0.9676 -0.2449 -1.6254 -1.4505 -0.1113 -0.1842 -2.3203 -0.2112 -1.1810 -0.7581 -0.3125 -0.2381
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report patients aortic_valve surgery post-lvad_ai
H-544	-0.7711241245269775	▁report ▁a or tic _ val ve _ ▁surgery ▁new - ons et _ post - L VAD _ ai
D-544	-0.7711241245269775	report aortic_valve_ surgery new-onset_post-LVAD_ai
P-544	-0.0023 -0.1796 -0.1415 -0.0831 -0.2559 -1.9271 -0.1215 -0.8314 -1.0977 -1.2053 -0.2062 -0.2261 -0.2818 -0.2594 -2.1992 -0.0954 -4.2004 -0.0772 -1.7188 -1.1552 -0.4682 -0.2313
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking cardiac_rehabilitation functional_capacity outcomes patients heart_failure
H-574	-0.9042093753814697	▁Nordic _ ▁walking ▁cardiac _ rehabilit ation ▁functional _ capaci ty ▁heart _ fail ure
D-574	-0.9042093753814697	Nordic_ walking cardiac_rehabilitation functional_capacity heart_failure
P-574	-0.4096 -0.3599 -2.4724 -0.0552 -0.5368 -0.9236 -1.1589 -3.3368 -0.8106 -0.0702 -0.0351 -1.1155 -0.4721 -1.4523 -1.4644 -0.4028 -0.2953
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone diagnosed systolic_heart_failure clinical
H-439	-0.5041640996932983	▁spi rono lac tone ▁sy sto lic _ heart _ fail ure
D-439	-0.5041640996932983	spironolactone systolic_heart_failure
P-439	-0.1250 -0.0214 -0.4167 -0.1498 -0.5971 -0.3353 -0.5003 -0.2240 -2.0890 -0.2570 -0.8655 -0.9358 -0.3457 -0.1958
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape functional_enrichment_analysis david
H-1612	-0.7662734389305115	▁Cy to scape ▁DA VID
D-1612	-0.7662734389305115	Cytoscape DAVID
P-1612	-1.8665 -0.0757 -0.1252 -2.3652 -0.0928 -0.5711 -0.2674
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension diabetes ischemic etiology
H-1635	-0.25387290120124817	▁black s ▁hyper tension ▁diabetes ▁ ische mic _ eth i ology ▁socio economic ▁white s
D-1635	-0.25387290120124817	blacks hypertension diabetes ischemic_ethiology socioeconomic whites
P-1635	-0.5362 -0.2308 -0.0453 -0.0014 -0.0610 -0.5426 -0.0194 -0.3622 -0.4573 -0.5241 -0.7124 -0.0150 -0.0769 -0.0520 -0.0881 -0.2232 -0.3481 -0.2735
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection nt-probnp antibodies terminal
H-1521	-0.2665688991546631	▁immun o det ection ▁NT - pro b NP ▁anti bo dies
D-1521	-0.2665688991546631	immunodetection NT-probNP antibodies
P-1521	-0.1225 -0.2009 -0.4160 -0.0809 -0.3419 -0.1312 -0.0430 -0.9364 -0.4093 -0.1113 -0.0344 -0.2802 -0.4178 -0.2061
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients fontan_circulation svr cardiac_index
H-232	-0.6163741946220398	▁Font an _ circ ulation ▁s VR _ index ▁cardiac _ index
D-232	-0.6163741946220398	Fontan_circulation sVR_index cardiac_index
P-232	-0.2743 -0.5368 -0.1905 -1.7736 -0.1200 -0.5080 -0.6085 -2.1648 -0.2127 -0.0491 -0.5454 -0.3272 -1.0729 -0.2456
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid_receptor_antagonists
H-1709	-0.9537971019744873	▁mineral o cor tico id _ ▁receptor ▁race
D-1709	-0.9537971019744873	mineralocorticoid_ receptor race
P-1709	-0.2954 -0.3565 -0.7320 -1.8034 -1.1243 -0.1029 -0.3537 -4.1281 -0.3848 -0.2570
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization medicare discharged nursing
H-1710	-0.450707346200943	▁re hospital ization ▁medica re ▁fee - for - service
D-1710	-0.450707346200943	rehospitalization medicare fee-for-service
P-1710	-0.4382 -0.0341 -0.1238 -0.0285 -0.0467 -0.6011 -0.0802 -0.0279 -0.2596 -0.0028 -3.5077 -0.2580
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative_care patients terminal disease therapeutic
H-1820	-0.7924684286117554	▁palli ative _ care ▁disease
D-1820	-0.7924684286117554	palliative_care disease
P-1820	-0.3341 -0.5959 -0.8070 -0.3932 -2.7088 -0.4581 -0.2501
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death hf hospitalization crt hazard_ratio
H-755	-0.6312218308448792	▁h f ▁c t haz ard _ rati o
D-755	-0.6312218308448792	hf cthazard_ratio
P-755	-0.9581 -1.5395 -0.7575 -2.5379 -0.0370 -0.1155 -0.2072 -0.0189 -0.0235 -0.4848 -0.2634
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients lvad patients biventricular_support
H-297	-0.8943456411361694	▁isola ted _ VAD ▁bi ven tri cular
D-297	-0.8943456411361694	isolated_VAD biventricular
P-297	-0.2188 -0.0377 -0.4241 -3.5058 -1.4868 -0.3797 -0.6890 -0.4967 -1.4091 -0.2958
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative_stress gtpase rac1 activity hearts
H-281	-0.5278334617614746	▁o xi da tive _ stress ▁GT Pas e _ ▁Rac 1 ▁activity ▁heart s ANS _ mi ce
D-281	-0.5278334617614746	oxidative_stress GTPase_ Rac1 activity heartsANS_mice
P-281	-0.6033 -0.0517 -0.1092 -0.1966 -0.2676 -1.9028 -0.4215 -1.1724 -0.0399 -0.2941 -0.5425 -0.7006 -0.0546 -0.3309 -0.1902 -2.0643 -0.4553 -0.6764 -0.3750 -0.4353 -0.2004
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan_circulation skeletal_muscle metabolic
H-1494	-0.6865498423576355	▁Font an _ circ ulation ▁skelet al _ ▁muscle _ ▁mass ▁metabol ic _ ab normal ities
D-1494	-0.6865498423576355	Fontan_circulation skeletal_ muscle_ mass metabolic_abnormalities
P-1494	-0.2937 -0.4009 -0.1467 -1.4644 -0.2178 -0.3844 -0.3466 -0.4240 -4.7765 -0.3728 -1.2913 -0.1192 -0.1122 -1.0916 -0.3996 -0.5100 -0.0920 -0.4111 -0.1896
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right_heart_circulation right_heart_failure
H-1459	-0.9211189150810242	▁right _ ▁Heart _ circ ulation ▁right _ ▁Heart _ fail ure
D-1459	-0.9211189150810242	right_ Heart_circulation right_ Heart_failure
P-1459	-0.2295 -0.4000 -3.0814 -0.2404 -2.6605 -0.0869 -0.3327 -0.3588 -2.8727 -0.3213 -0.9087 -0.8431 -0.3300 -0.2296
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart_failure hf latin_america health hf
H-1789	-1.1728297472000122	▁Heart _ ▁failure HF ▁Latin _ america ▁la d ▁health _ service _ plan ning ▁h f
D-1789	-1.1728297472000122	Heart_ failureHF Latin_america lad health_service_planning hf
P-1789	-0.8678 -0.2991 -2.4996 -0.9449 -0.9642 -0.4922 -0.9952 -1.5551 -5.3919 -0.3142 -0.7197 -0.0215 -1.5249 -0.2452 -1.7510 -1.2738 -1.8588 -0.3537 -0.2112
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd clinical hospitalizations complications therapy end-stage_hf
H-895	-0.7364581823348999	▁p d ▁complica tions ▁ therapy ▁h f
D-895	-0.7364581823348999	pd complications therapy hf
P-895	-0.4969 -1.1385 -0.9123 -0.2755 -1.5726 -0.0463 -0.6351 -1.7407 -0.2965 -0.2502
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.3296191692352295	▁transform ed
D-86	-0.3296191692352295	transformed
P-86	-0.3648 -0.2467 -0.4161 -0.2910
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.31308647990226746	
D-158	-0.31308647990226746	
P-158	-0.3576 -0.2686
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients heart_failure hf heart_failure_adherence_and_retention_trial hart
H-238	-0.5706929564476013	▁heart _ fail ure HF ▁Heart _ fail ure _ ad her ence _ and _ re tention _ tri al HAR t
D-238	-0.5706929564476013	heart_failureHF Heart_failure_adherence_and_retention_trialHARt
P-238	-1.2357 -0.2890 -1.1037 -1.0313 -0.8627 -0.8563 -0.3996 -0.7112 -0.1539 -1.5089 -0.0716 -0.3511 -0.0513 -0.6291 -0.1620 -0.3992 -0.0349 -0.1364 -0.1361 -1.1469 -0.6226 -0.7913 -1.0259 -0.3193 -0.2371
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic_receptor_blockade mortality all-cause_hospitalizations patients heart_failure hf
H-1424	-0.7327951192855835	▁β - ad r energi c _ ▁receptor _ block ade ▁heart _ fail ure HF
D-1424	-0.7327951192855835	β-adrenergic_ receptor_blockade heart_failureHF
P-1424	-0.0785 -0.0420 -1.7922 -1.4201 -0.0888 -0.1168 -0.1862 -0.3946 -0.3151 -1.7722 -0.6211 -1.8366 -0.3080 -1.2919 -1.0987 -1.2320 -0.3659 -0.2298
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial_infarction left_anterior_descending_coronary_artery_occlusion
H-1338	-0.6786419153213501	▁my o card ial _ in far ction ▁left _ ▁anterior _ ▁descend ing _ ▁corona ry _ ▁arter y ▁oc clusi on
D-1338	-0.6786419153213501	myocardial_infarction left_ anterior_ descending_ coronary_ artery occlusion
P-1338	-2.7464 -0.7740 -0.5187 -0.4148 -0.4324 -0.6195 -0.0703 -0.2164 -1.8338 -0.4923 -1.1976 -0.6035 -0.2447 -0.0666 -1.1954 -0.6282 -0.4606 -0.3404 -0.1759 -1.0835 -1.7977 -0.0514 -0.1953 -0.5561 -0.2505
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right_ventricle leads stroke_volume shortens left_ventricular_ejection_time lvet
H-578	-0.6570736765861511	▁right _ vent ric le _ over load _ ▁lead s ▁stroke ▁vent ri cular _ e je ction _ ▁time ▁l VET
D-578	-0.6570736765861511	right_ventricle_overload_ leads stroke ventricular_ejection_ time lVET
P-578	-0.1642 -0.4670 -1.0430 -2.5639 -1.5063 -0.5139 -0.1274 -0.0055 -1.0723 -0.4530 -0.0944 -0.3938 -0.3031 -0.6420 -0.2208 -0.6150 -0.2879 -0.4510 -0.1640 -0.2963 -1.9917 -2.1337 -0.2095 -0.4821 -0.2250
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective_beta-blockers cardiac_sympathetic_activity hemostasis patients heart_failure
H-1110	-0.5547531843185425	▁non sel ective ▁beta - block ers ▁cardiac _ ▁sympa the tic _ activ ity ▁hemos tas is ▁heart _ ▁failure
D-1110	-0.5547531843185425	nonselective beta-blockers cardiac_ sympathetic_activity hemostasis heart_ failure
P-1110	-1.8556 -0.0994 -0.1058 -0.8427 -0.1503 -0.4065 -0.3433 -0.0592 -0.4601 -1.6593 -0.2494 -0.6515 -0.5747 -0.2102 -0.0971 -0.1332 -0.2619 -0.6944 -0.5134 -0.4182 -2.3253 -0.3829 -0.2649
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end_point cardiovascular_death cardiac_transplant secondary_end_point death
H-1757	-0.6663503646850586	▁cardiovascular _ ▁death ▁urgent _ ▁cardiac _ ▁transplant ▁death
D-1757	-0.6663503646850586	cardiovascular_ death urgent_ cardiac_ transplant death
P-1757	-0.6215 -1.3378 -1.2023 -0.1178 -0.3744 -0.1561 -0.1176 -0.9656 -1.8556 -0.2901 -0.2909
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated_proteins chromatin_structure changing dna gene_expression_profile
H-90	-0.8348585367202759	▁Chro mat in - as soci ated _ ▁Protein s ▁chr omat in ▁DNA ▁gene _ expression _ profil e
D-90	-0.8348585367202759	Chromatin-associated_ Proteins chromatin DNA gene_expression_profile
P-90	-1.5752 -0.1561 -3.5272 -0.2809 -0.0486 -0.0070 -0.0662 -0.2127 -2.3465 -0.3197 -0.2155 -0.1947 -2.1736 -3.9518 -0.9717 -0.3419 -0.1764 -0.9264 -0.0861 -0.1448 -0.3700 -0.2739
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis clinical prognostic diastolic_dysfunction leading hfpef
H-26	-0.42968109250068665	▁dia sto lic _ ▁dys function ▁h f f
D-26	-0.42968109250068665	diastolic_ dysfunction hff
P-26	-0.1332 -0.3401 -0.3681 -0.4888 -0.5370 -0.0271 -0.1334 -1.4213 -0.5297 -0.5153 -0.2323
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade cardiac_angiogenesis heart_failure vegf_signaling_pathway
H-459	-0.8953151106834412	▁β - Block ade ▁cardiac _ ▁ang io gene sis ▁heart _ fail ure ▁ve GF
D-459	-0.8953151106834412	β-Blockade cardiac_ angiogenesis heart_failure veGF
P-459	-0.1164 -0.0729 -0.3498 -1.5832 -0.0885 -0.3880 -1.0657 -2.5011 -0.9481 -2.5691 -0.1391 -0.2666 -1.6550 -1.1942 -0.9064 -0.8339 -1.1350 -0.3025
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp hf patient plasma immunoprecipitation mass_spectrometric_analysis
H-1515	-0.5562667846679688	▁NT - pro b NP ▁h bf ▁immun o preci pit ation ▁mass _ spec tro metric _ analyse
D-1515	-0.5562667846679688	NT-probNP hbf immunoprecipitation mass_spectrometric_analyse
P-1515	-0.0451 -0.0830 -0.0274 -1.0528 -0.4828 -0.8741 -2.4412 -0.3423 -0.1884 -0.1984 -0.0793 -0.1295 -0.0526 -0.4154 -1.7334 -0.7628 -0.0766 -1.5010 -0.3467 -0.6256 -0.2232
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic_tone pyridostigmine ventricular_dysfunction heart_failure
H-1132	-0.35284391045570374	▁para sy mpa the tic _ tone ▁py rido stig mine ▁vent ri cular _ ▁dys function ▁heart _ fail ure
D-1132	-0.35284391045570374	parasympathetic_tone pyridostigmine ventricular_ dysfunction heart_failure
P-1132	-0.1220 -0.3280 -0.1744 -0.2818 -0.1162 -0.3188 -0.3975 -0.0073 -0.0115 -0.0019 -0.0440 -0.0251 -0.5584 -0.5263 -1.0897 -0.4607 -0.0293 -0.5469 -0.3304 -1.5834 -0.5844 -0.3522 -0.2251
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes myocardial_ischemic_events patients cardiac_resynchronization_therapy
H-101	-0.5342493653297424	▁my o card ial _ ische mic _ event s ▁cardiac _ re syn chron ization _ therapy
D-101	-0.5342493653297424	myocardial_ischemic_events cardiac_resynchronization_therapy
P-101	-2.5926 -0.3918 -0.4360 -0.4428 -0.2791 -0.0599 -0.6798 -0.4973 -2.6214 -0.0563 -0.1154 -0.2232 -0.1095 -0.0242 -0.0120 -0.5218 -0.7544 -0.2247 -0.3881 -0.2547
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf_with_preserved_ejection_fraction hfpef hypertension
H-1076	-0.4484851360321045	HF ▁pres er ved _ e je ction _ fraction HF p EF ▁hyper tension
D-1076	-0.4484851360321045	HF preserved_ejection_fractionHFpEF hypertension
P-1076	-0.9293 -1.5296 -0.4375 -0.5801 -0.2005 -0.3255 -0.5430 -0.1099 -0.1663 -0.0127 -1.4087 -0.1188 -0.5232 -0.1924 -0.0027 -0.3293 -0.2145
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end_points nyha_functional_class quality-of-life 6-minute_hall_walk
H-1873	-0.864798903465271	▁NY ha ▁quality - of - life
D-1873	-0.864798903465271	NYha quality-of-life
P-1873	-1.0822 -0.6490 -1.6225 -0.1113 -0.0127 -0.4391 -0.0634 -3.5448 -0.2582
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ischemic_heart_failure
H-1613	-0.7530189156532288	▁non - ische mic ▁ ische mic _ and _ ische mic _ heart _ fail ure
D-1613	-0.7530189156532288	non-ischemic ischemic_and_ischemic_heart_failure
P-1613	-1.5754 -0.0784 -0.2334 -0.4975 -0.9687 -0.0631 -0.6592 -2.1069 -1.3942 -0.7727 -0.1491 -0.6889 -0.3753 -1.7559 -0.1598 -0.7030 -1.4831 -0.3819 -0.2608
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv_dysfunction prognosis hf
H-1160	-0.7340995669364929	RV _ ▁dys function ▁weight _ los s ▁body _ ▁composición ▁h f
D-1160	-0.7340995669364929	RV_ dysfunction weight_loss body_ composición hf
P-1160	-0.7123 -1.2257 -0.3447 -0.0288 -0.4335 -0.4451 -1.0656 -0.1622 -0.4694 -0.2733 -2.5822 -0.6248 -2.1210 -0.2498 -0.2730
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart_failure emergency_department patient outcomes
H-462	-0.7538430094718933	▁he art _ fail ure ▁Emer gen cy _ de part ment ▁ed ▁ed
D-462	-0.7538430094718933	heart_failure Emergency_department ed ed
P-462	-3.1542 -0.0877 -0.2530 -0.7434 -2.1344 -0.3861 -0.1505 -0.0869 -0.1959 -1.2672 -0.1120 -0.1284 -1.2030 -0.6563 -1.2666 -0.2360
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut inflammation heart_failure patients heart_failure
H-1363	-0.9403629302978516	▁gut ▁ inflammation ▁heart _ fail ure ▁heart _ fail ure
D-1363	-0.9403629302978516	gut inflammation heart_failure heart_failure
P-1363	-0.4833 -0.3283 -0.1789 -1.0475 -0.3725 -1.6770 -2.1554 -1.3661 -0.3192 -1.3963 -2.0340 -0.6036 -0.2627
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf patients emergency_department intubated
H-210	-0.6203423142433167	▁CHF ▁emergency _ ▁department ▁ed ▁in tuba ted
D-210	-0.6203423142433167	CHF emergency_ department ed intubated
P-210	-0.1256 -0.6509 -0.5239 -2.5359 -1.1989 -0.2789 -0.1098 -0.1259 -0.4261 -0.2274
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait therapy lokomat heart_failure patients
H-1912	-0.7357528805732727	▁robot - assist ed _ ga it _ therapy ▁Lok omat _ system ▁heart _ fail ure
D-1912	-0.7357528805732727	robot-assisted_gait_therapy Lokomat_system heart_failure
P-1912	-2.5283 -0.2493 -0.0038 -0.1969 -0.2650 -1.3274 -0.2612 -0.2504 -0.2338 -0.3229 -0.2316 -1.7802 -1.5546 -0.5607 -0.3632 -1.5541 -1.2266 -0.8149 -0.2546
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient symptomatic therapeutic exercise hemodynamic
H-1179	-0.6937849521636963	▁exercise ▁hem o dynamic
D-1179	-0.6937849521636963	exercise hemodynamic
P-1179	-1.4500 -1.0687 -0.5834 -0.0323 -0.7621 -0.2662
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-0.3591727912425995	
D-609	-0.3591727912425995	
P-609	-0.5093 -0.2090
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet sensitivity specificity death icu
H-584	-0.5921407341957092	▁l VET ▁death ICU
D-584	-0.5921407341957092	lVET deathICU
P-584	-1.5751 -0.1841 -0.9691 -0.3247 -0.3069 -0.1929
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission patients
H-1581	-0.530929446220398	▁read mission _ rate
D-1581	-0.530929446220398	readmission_rate
P-1581	-1.0711 -0.1055 -0.4218 -0.7470 -0.5390 -0.3012
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous symptoms patients heart_failure
H-51	-0.6470896601676941	▁Intra ven ous _ ▁ir on ▁heart _ fail ure ▁ir on _ de fici en cy
D-51	-0.6470896601676941	Intravenous_ iron heart_failure iron_deficiency
P-51	-1.1451 -0.0518 -0.9835 -0.3115 -1.7278 -0.5296 -1.2256 -0.2901 -0.8845 -1.4619 -0.0595 -0.6598 -0.7958 -0.2109 -0.1738 -0.8784 -0.1178 -0.5129 -0.2745
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr acr cms correlated
H-141	-0.720714807510376	▁p p ▁a cr ▁CMS
D-141	-0.720714807510376	pp acr CMS
P-141	-0.4201 -2.0773 -0.6243 -0.4987 -0.5761 -0.5525 -0.2961
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality lcx lad disease
H-513	-0.6044942736625671	▁mortal ity LC x ▁ LAD ▁two - ves sel _ ▁Disease
D-513	-0.6044942736625671	mortalityLCx LAD two-vessel_ Disease
P-513	-0.7199 -0.1073 -0.5069 -0.4593 -0.9660 -0.4259 -0.1155 -0.1398 -0.3408 -0.0546 -0.2488 -3.1389 -1.0026 -0.2366
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions remodelling leading heart_failure
H-991	-0.9611108303070068	▁stress ▁conditions ▁heart _ fail ure
D-991	-0.9611108303070068	stress conditions heart_failure
P-991	-0.9668 -0.3243 -3.1861 -0.5763 -0.8412 -1.0834 -0.4097 -0.3011
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis systemic followed_up
H-1559	-1.0320852994918823	▁psoriasis UV
D-1559	-1.0320852994918823	psoriasisUV
P-1559	-0.0174 -1.4415 -2.4367 -0.2327
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients diagnosis congestive_heart_failure
H-1578	-0.7459377646446228	▁con ges tive _ heart _ fail ure
D-1578	-0.7459377646446228	congestive_heart_failure
P-1578	-1.0272 -0.0583 -0.5262 -0.2550 -2.4167 -0.2549 -0.7109 -1.5248 -0.4272 -0.2582
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker patients resting_hr bpm p_value
H-1941	-0.9288966059684753	▁Beta - block er _ ▁dose ▁HR ▁bp m
D-1941	-0.9288966059684753	Beta-blocker_ dose HR bpm
P-1941	-0.3723 -0.0745 -0.2131 -0.8397 -0.9854 -1.2472 -4.5811 -1.2333 -0.1564 -0.3596 -0.1552
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive patients pulmonary_hypertension heart_failure
H-577	-0.6102530360221863	▁pulmonar y _ hy tension ▁heart _ fail ure
D-577	-0.6102530360221863	pulmonary_hytension heart_failure
P-577	-0.2400 -0.4179 -0.3468 -1.0464 -0.0995 -1.6656 -0.3644 -1.0658 -0.7670 -0.4179 -0.2815
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new_zealand renal_dnx pacing-induced_chf
H-1373	-0.6159859895706177	▁New _ ▁Zealand ▁white _ ▁rabbi ts ▁renal _ ▁DN x ▁CHF
D-1373	-0.6159859895706177	New_ Zealand white_ rabbits renal_ DNx CHF
P-1373	-2.0355 -1.3537 -0.5438 -0.6785 -0.2185 -0.5525 -0.0369 -0.0246 -0.8588 -1.0590 -0.0576 -0.4909 -0.4525 -0.2609
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 healthy heart_muscle cells phenotype pathological hypertrophy
H-641	-0.7780578136444092	▁line ▁mu tant _ mi ce ▁over express ing ▁hand 2 ▁heart _ ▁muscle _ cell s ▁path ological _ ▁hyper trop hy
D-641	-0.7780578136444092	line mutant_mice overexpressing hand2 heart_ muscle_cells pathological_ hypertrophy
P-641	-2.0398 -0.6207 -0.1358 -0.2241 -0.3432 -0.3317 -1.9576 -0.3336 -0.0529 -1.7564 -0.7413 -0.4610 -0.4529 -4.0114 -0.4968 -0.1535 -0.4704 -0.1763 -0.4493 -0.6463 -2.7266 -0.1105 -0.1250 -0.3269 -0.3073
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis patients adverse_events echocardiographic outcomes
H-914	-0.5415077209472656	▁di al ysis ▁e cho car dio graphic
D-914	-0.5415077209472656	dialysis echocardiographic
P-914	-0.1040 -0.2442 -0.1575 -0.2720 -0.7781 -0.1366 -1.0532 -1.4277 -0.9398 -0.3020
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients heart_failure_and_reduced_ejection_fraction
H-668	-0.5381112098693848	▁heart _ fail ure ▁e je ction _ fraction
D-668	-0.5381112098693848	heart_failure ejection_fraction
P-668	-1.4415 -0.3310 -0.8016 -1.5265 -0.4970 -0.2753 -0.1202 -0.2480 -0.0263 -0.3903 -0.2615
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt_variability qtv repolarization qtv cardiac_death
H-1435	-1.3306050300598145	▁ QT _ ▁variabil ity ▁q t ▁Q t ▁cardiac _ ▁death
D-1435	-1.3306050300598145	QT_ variability qt Qt cardiac_ death
P-1435	-1.4654 -0.6559 -1.1872 -1.8671 -0.2927 -1.7445 -1.1869 -4.3464 -2.3783 -1.6889 -0.3446 -0.8876 -0.3342 -0.2487
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial_structure sarcomeric_microstructure
H-1250	-0.9647661447525024	▁mito cho ndri al ▁sar come ric _ micro structure
D-1250	-0.9647661447525024	mitochondrial sarcomeric_microstructure
P-1250	-0.1162 -1.2987 -0.2514 -0.1896 -1.7823 -0.9066 -2.7128 -1.2165 -0.7666 -1.6759 -0.4132 -0.2475
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory hf patients left_ventricular_ejection_fraction
H-122	-0.5636354684829712	▁ambula tory _ HF ▁vent ri cular _ e je ction _ fraction
D-122	-0.5636354684829712	ambulatory_HF ventricular_ejection_fraction
P-122	-0.4267 -0.0226 -1.1339 -1.3226 -1.5980 -0.6315 -0.4083 -0.7904 -0.2528 -0.5165 -0.2980 -0.2630 -0.0283 -0.5227 -0.2392
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy hdl chf-nyha-iiib hdl
H-258	-1.1628522872924805	▁ET ▁HD l _ function ▁et h ▁CHF - NY ha - III b ▁HD l _ function
D-258	-1.1628522872924805	ET HDl_function eth CHF-NYha-IIIb HDl_function
P-258	-4.5739 -1.9486 -2.6051 -0.2053 -0.3588 -2.7103 -2.0293 -0.7837 -0.1571 -0.5235 -0.7591 -0.2186 -0.2316 -0.1465 -1.6963 -2.9305 -0.2459 -0.6755 -0.2719 -0.1854
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient implantable_cardioverter-defibrillator
H-1859	-0.5557698607444763	▁a im ▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1859	-0.5557698607444763	aim implantable cardioverter-defibrillator_deactivation
P-1859	-2.4933 -0.5702 -0.0124 -0.0835 -1.0182 -0.1866 -0.1774 -0.4196 -0.1544 -1.8395 -1.5128 -0.1547 -0.2918 -0.4277 -0.1280 -0.1483 -0.2414 -0.4427 -0.2571
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence micrornas mirnas pathogenesis heart_failure
H-1481	-0.6184269189834595	▁micro RNA s mi RNA s ▁heart _ fail ure
D-1481	-0.6184269189834595	microRNAsmiRNAs heart_failure
P-1481	-0.5637 -0.2034 -0.1914 -2.1581 -0.1298 -0.1856 -0.8980 -0.2914 -1.2888 -0.9190 -0.3715 -0.2205
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients uptitration heart_rate renal_function spironolactone
H-180	-0.6175028681755066	▁heart _ rate ▁renal _ function ▁spi rono lac tone
D-180	-0.6175028681755066	heart_rate renal_function spironolactone
P-180	-3.4057 -0.6541 -0.8495 -0.0500 -0.8182 -0.2375 -0.2796 -0.0175 -0.2859 -0.1027 -0.3982 -0.3110
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis patients chf therapeutic neurohormonal_systems
H-635	-0.6239714026451111	▁CHF ▁activa ted _ ▁neuro hormon al _ system s
D-635	-0.6239714026451111	CHF activated_ neurohormonal_systems
P-635	-0.5278 -2.0786 -0.1412 -0.4242 -1.5457 -0.6388 -0.2022 -0.6602 -0.4184 -0.1553 -0.4567 -0.2387
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician follow-up discharge death readmission patients heart_failure
H-1413	-0.857796847820282	▁physician ▁follow - up _ ▁after _ dis charge ▁read mission ▁heart _ fail ure
D-1413	-0.857796847820282	physician follow-up_ after_discharge readmission heart_failure
P-1413	-1.3555 -0.3811 -0.2116 -0.0323 -0.5920 -3.9415 -0.2566 -0.1028 -0.0232 -2.4100 -0.0583 -0.8663 -0.3229 -1.7121 -1.5952 -0.4615 -0.2596
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter_ablation antiarrhythmic_drugs rhythm_control_therapy
H-1647	-0.3746128976345062	▁cat heter _ ab lation ▁anti ar rhythm ic _ drug s ▁ rhythm _ control _ therapy
D-1647	-0.3746128976345062	catheter_ablation antiarrhythmic_drugs rhythm_control_therapy
P-1647	-0.0359 -0.1218 -0.3574 -0.4995 -0.1043 -0.0586 -0.5302 -0.7927 -0.1438 -0.6166 -1.0906 -0.0784 -0.2910 -0.6032 -0.4663 -0.0161 -0.6421 -0.3242 -0.4371 -0.2824
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage poc
H-1029	-1.4516088962554932	▁po c ▁technology
D-1029	-1.4516088962554932	poc technology
P-1029	-3.1800 -2.1464 -1.1771 -0.4483 -0.3062
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac_dysfunction subcellular metoprolol heart_failure myocardial_infarction
H-1546	-0.38314127922058105	▁cardiac _ ▁dys function ▁sub cel lular ▁met o pro lol ▁heart _ ▁failure ▁my o card ial _ in far ction
D-1546	-0.38314127922058105	cardiac_ dysfunction subcellular metoprolol heart_ failure myocardial_infarction
P-1546	-0.3072 -0.5167 -0.4892 -0.0311 -0.1911 -0.1069 -0.2297 -0.3122 -0.1702 -0.0427 -0.4895 -0.2505 -0.2782 -1.5320 -0.5843 -0.4471 -1.2199 -0.3355 -0.4747 -0.2827 -0.0259 -0.1987 -0.4201 -0.2592
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac_magnetic_resonance_postcontrast_t1_time outcome patients heart_failure preserved_ejection_fraction
H-733	-0.6190375089645386	▁Card iac _ ▁magnetic _ re on ance _ ▁post contra st ▁heart _ fail ure ▁e je ction _ fraction
D-733	-0.6190375089645386	Cardiac_ magnetic_reonance_ postcontrast heart_failure ejection_fraction
P-733	-0.5209 -0.1435 -0.1633 -1.2595 -0.1761 -1.0449 -2.6304 -0.1137 -0.7961 -1.3831 -0.1689 -0.4326 -0.9594 -0.2830 -1.4315 -1.3048 -0.2338 -0.1692 -0.1113 -0.2853 -0.0129 -0.4101 -0.2037
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv_diastolic_dysfunction filling_pressures non-invasively doppler_echocardiography
H-28	-0.5214326977729797	▁LV ▁dia sto lic _ ▁dys function ▁fill ing _ tension s ▁do pp ler _ e cho card i ography
D-28	-0.5214326977729797	LV diastolic_ dysfunction filling_tensions doppler_echocardiography
P-28	-0.1072 -0.7591 -0.5377 -0.3012 -0.4673 -0.4146 -0.0320 -0.0920 -0.0610 -0.3672 -1.7965 -0.2538 -0.2768 -0.2049 -2.0244 -0.2499 -0.1906 -0.8088 -0.9224 -0.8354 -0.4984 -0.5152 -0.2765
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart_magnetic_resonance_imaging chelation compliance heart_disease patients thalassaemia_major
H-744	-0.7999176383018494	▁heart _ ▁magnetic _ re on ance _ ▁imagin g ▁che lation ▁compliance ▁heart _ ▁disease ▁tha lassa emia
D-744	-0.7999176383018494	heart_ magnetic_reonance_ imaging chelation compliance heart_ disease thalassaemia
P-744	-1.5266 -0.5560 -1.4846 -0.3257 -1.7369 -2.5935 -0.2598 -0.2159 -1.9595 -0.1570 -0.3449 -0.0338 -0.7589 -1.0338 -0.9339 -1.7946 -0.0193 -0.1688 -0.2572 -0.4045 -0.2331
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial_collagen collagen_cross-linking titin isoforms phosphorylation
H-764	-0.4798631966114044	▁My o card ial _ ▁collage n ▁collage n _ ▁cross - link ing ▁titi n _ iso form s ▁ phos phor y lation
D-764	-0.4798631966114044	Myocardial_ collagen collagen_ cross-linking titin_isoforms phosphorylation
P-764	-2.0303 -0.2036 -0.5214 -0.4029 -0.2618 -0.2075 -0.2652 -0.5457 -0.3260 -0.8297 -2.4389 -0.1129 -0.0492 -0.1021 -0.1409 -0.1699 -0.3588 -1.0185 -0.2757 -0.2818 -0.3209 -0.1039 -0.5332 -0.6940 -0.0783 -0.4656 -0.2177
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping mri tidal_respiration myocardial_t1 heart_failure
H-1054	-0.6479729413986206	▁m ri ▁tid al _ ▁respira tion ▁my o card ial _ t 1 ▁s win e ▁heart _ fail ure
D-1054	-0.6479729413986206	mri tidal_ respiration myocardial_t1 swine heart_failure
P-1054	-1.5694 -2.0428 -0.5075 -0.0485 -0.2646 -2.6651 -0.0725 -0.2085 -0.3552 -0.3918 -0.1484 -1.0654 -0.5344 -0.1663 -0.1734 -0.0593 -0.6104 -1.0576 -0.5410 -0.9100 -0.7756 -0.4569 -0.2788
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker uptitration clinical outcome patients hfref hfpef
H-185	-0.66619473695755	RAS - block er _ up tit ration ▁h f f ▁h f p EF
D-185	-0.66619473695755	RAS-blocker_uptitration hff hfpEF
P-185	-0.2665 -0.0870 -0.4494 -1.3563 -0.4563 -0.4554 -1.0162 -0.4584 -0.2009 -2.1705 -0.2294 -0.7812 -1.6435 -0.1135 -0.9817 -0.4425 -0.2165
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems_proteomics cardiac_chromatin nucleolin cellular_plasticity cardiomyocytes
H-88	-0.8532396554946899	▁systems _ prote o mics ▁cardiac _ ch omat in ▁nucleo lin ▁regulator _ of _ ▁growth ▁cardio my o cy tes
D-88	-0.8532396554946899	systems_proteomics cardiac_chomatin nucleolin regulator_of_ growth cardiomyocytes
P-88	-0.5245 -0.2370 -3.1193 -1.3063 -0.0345 -0.1060 -0.2040 -1.4349 -0.1464 -1.5962 -0.0394 -3.2580 -0.1873 -1.0760 -0.0972 -0.3179 -1.6752 -1.1705 -1.5834 -0.7435 -0.0663 -0.9246 -0.4102 -0.2191
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac_failure death patients type_2_diabetes diabetes heart_failure
H-652	-0.6487693786621094	▁Card iac _ fail ure ▁diabetes ▁molecular _ me chan ism ▁diabetes ▁heart _ fail ure
D-652	-0.6487693786621094	Cardiac_failure diabetes molecular_mechanism diabetes heart_failure
P-652	-1.8628 -0.3945 -0.1903 -1.2419 -2.7759 -0.2292 -0.0570 -0.2632 -0.3550 -0.0691 -0.0138 -0.4113 -0.3455 -0.3510 -0.8329 -1.7169 -0.3610 -0.2065
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese zsf1 heart_failure_with_preserved_ejection_fraction
H-770	-0.5108999609947205	▁z SF 1 ▁heart _ fail ure ▁e je ction _ fraction
D-770	-0.5108999609947205	zSF1 heart_failure ejection_fraction
P-770	-0.3002 -0.9103 -0.1766 -1.0855 -0.2714 -1.0578 -1.6926 -0.2176 -0.2403 -0.1265 -0.2773 -0.0353 -0.4726 -0.2886
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin exercise training health patients chronic_heart_failure hf-action randomized
H-833	-0.9592382907867432	▁Hem o glob in ▁exercise ▁health _ status ▁chronic _ heart _ fail ure HF - ac tion
D-833	-0.9592382907867432	Hemoglobin exercise health_status chronic_heart_failureHF-action
P-833	-0.8150 -0.2368 -0.0720 -1.2178 -0.5785 -2.1241 -2.4785 -0.0812 -1.1932 -0.2726 -1.6269 -0.2126 -1.3862 -1.2671 -0.9640 -0.0492 -1.6417 -2.0764 -0.6110 -0.2800
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf shift chronic_heart_failure chronic_heart_failure cardiology
H-1964	-0.6888285875320435	▁para DIG m - HF ▁chronic _ heart _ fail ure ▁Chro nic _ heart _ fail ure ▁card i ology
D-1964	-0.6888285875320435	paraDIGm-HF chronic_heart_failure Chronic_heart_failure cardiology
P-1964	-1.0654 -1.3088 -0.6847 -0.0501 -0.4373 -1.5775 -0.1927 -2.0202 -0.2351 -1.2326 -0.8003 -0.3468 -0.1769 -0.1638 -2.3028 -0.2110 -0.4850 -1.0651 -0.5893 -0.3084 -0.0196 -0.3366 -0.2331
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial_tonometry lvet prognostic patients precapillary_ph heart_failure
H-579	-0.7464683055877686	▁arterial _ ton ometr y ▁ VET ▁pre cap illa ry _ ▁PH ▁heart _ fail ure
D-579	-0.7464683055877686	arterial_tonometry VET precapillary_ PH heart_failure
P-579	-0.2019 -0.3842 -4.5628 -0.0815 -0.2555 -1.6862 -0.1807 -0.2142 -0.1882 -0.1078 -0.4170 -0.8504 -1.3506 -0.3078 -0.3977 -1.1600 -1.2130 -0.3970 -0.2263
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal_echocardiography shunts thrombosis
H-1957	-0.5391472578048706	▁trans o es op hage al _ e cho card i ography ▁patent ▁ thro mbo sis ▁migration
D-1957	-0.5391472578048706	transoesophageal_echocardiography patent thrombosis migration
P-1957	-0.0832 -0.4326 -0.5784 -0.3082 -0.0413 -0.2514 -0.2748 -0.2735 -0.2518 -0.5642 -0.5942 -0.5029 -2.8350 -0.3923 -0.1653 -0.1779 -2.0768 -0.3290 -0.4350 -0.2151
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk heart adipose_tissue cachectic_heart_failure patients prospective_study
H-8	-0.9332931041717529	▁Cross - talk ▁heart ▁adi pose _ ▁tissu e ▁cache ctic _ heart _ fail ure ▁body _ ▁composición
D-8	-0.9332931041717529	Cross-talk heart adipose_ tissue cachectic_heart_failure body_ composición
P-8	-1.2085 -0.2019 -0.0673 -3.0728 -0.1451 -0.0255 -0.2712 -2.3933 -0.4269 -0.0507 -1.3039 -0.4745 -1.7040 -0.1940 -1.0860 -1.5033 -1.1624 -0.5364 -2.9954 -0.4916 -0.2841
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause_readmissions
H-726	-0.33440619707107544	▁read missions
D-726	-0.33440619707107544	readmissions
P-726	-0.5582 -0.1709 -0.3878 -0.2206
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular_disease baseline
H-1767	-0.6525294184684753	▁cardiovascular _ ▁disease ▁base line
D-1767	-0.6525294184684753	cardiovascular_ disease baseline
P-1767	-0.7204 -0.3780 -2.4182 -0.0553 -0.0732 -0.6521 -0.2706
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal hospital hf patients cms conditions
H-139	-1.4002937078475952	▁financial _ financi ers HF ▁CMS ▁conditions
D-139	-1.4002937078475952	financial_financiersHF CMS conditions
P-139	-2.6756 -1.3148 -3.0940 -0.3511 -2.0505 -2.4410 -0.0704 -0.3510 -0.2543
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal likelihood_ratio
H-487	-1.0567843914031982	▁cut off sept al
D-487	-1.0567843914031982	cutoffseptal
P-487	-0.5006 -0.0804 -0.0765 -0.0709 -5.3901 -0.2223
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis cardiovascular_disease cvd
H-1555	-0.7131832242012024	▁psoriasis ▁cardiovascular _ ▁disease ▁cv d
D-1555	-0.7131832242012024	psoriasis cardiovascular_ disease cvd
P-1555	-0.2023 -0.0615 -0.5569 -2.4101 -1.7010 -0.0350 -0.5151 -0.2234
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs patients oht transplant vad
H-1288	-1.2695555686950684	▁a CS ▁o HT _ bridge d _ to _ trans plant ▁MT VAD
D-1288	-1.2695555686950684	aCS oHT_bridged_to_transplant MTVAD
P-1288	-0.6304 -2.9569 -0.5648 -4.0713 -2.7949 -0.0149 -0.2387 -1.3285 -0.5371 -0.3211 -2.0416 -0.6823 -2.4663 -1.1092 -0.3269 -0.2279
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients beta-blocker therapy
H-1939	-0.652802050113678	▁beta - block er _ therapy
D-1939	-0.652802050113678	beta-blocker_therapy
P-1939	-2.8693 -0.0910 -0.4572 -0.4120 -0.4848 -0.2193 -0.3928 -0.2959
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs clinical
H-2015	-0.3268794119358063	▁costs
D-2015	-0.3268794119358063	costs
P-2015	-0.2561 -0.4468 -0.2778
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital_compare ami mortality
H-1697	-0.7497742772102356	▁hospital AMI ▁mortal ity _ rate s
D-1697	-0.7497742772102356	hospitalAMI mortality_rates
P-1697	-2.1242 -1.2173 -0.6508 -0.1343 -0.8924 -0.7919 -0.0401 -0.5641 -0.3328
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins subproteome
H-94	-1.1223018169403076	▁protein s ▁acid
D-94	-1.1223018169403076	proteins acid
P-94	-2.9092 -0.5451 -1.6504 -0.3090 -0.1979
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma collected hf patients
H-1514	-0.7899263501167297	▁Plas ma _ ▁sample s ▁h f
D-1514	-0.7899263501167297	Plasma_ samples hf
P-1514	-0.4648 -0.6473 -1.3995 -1.0993 -0.0962 -0.7925 -1.8287 -0.5931 -0.1880
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician patient admission admission
H-1417	-0.2777888774871826	▁index _ ad mission ▁index _ ad mission
D-1417	-0.2777888774871826	index_admission index_admission
P-1417	-0.0802 -0.2263 -0.6971 -0.0573 -0.0885 -0.2059 -0.6166 -0.0950 -0.3756 -0.3354
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis medical hf
H-200	-0.6110320091247559	▁medical HF
D-200	-0.6110320091247559	medicalHF
P-200	-0.1716 -1.7129 -0.2859 -0.2737
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm_control_therapy
H-1645	-0.27186429500579834	▁ Rhythm _ control _ therapy
D-1645	-0.27186429500579834	Rhythm_control_therapy
P-1645	-0.2150 -0.1526 -0.2510 -0.0184 -0.2947 -0.2643 -0.8028 -0.1760
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy patients follow-up
H-861	-0.731543242931366	▁ therapy ▁follow - up
D-861	-0.731543242931366	therapy follow-up
P-861	-2.7488 -0.1130 -0.1023 -0.2131 -0.0291 -1.6742 -0.2403
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients cardiovascular_disease drs
H-1838	-0.7343566417694092	▁cardiovascular _ ▁disease ▁d RS _ de ci les
D-1838	-0.7343566417694092	cardiovascular_ disease dRS_deciles
P-1838	-0.1700 -0.8532 -1.9769 -0.0925 -1.1413 -1.4390 -0.7669 -0.2650 -0.6939 -0.4256 -0.2535
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported heart_failure clcnka snp
H-1804	-1.030596375465393	▁heart _ fail ure ▁c cn ka _ s NP
D-1804	-1.030596375465393	heart_failure ccnka_sNP
P-1804	-1.3860 -0.2928 -1.3004 -1.6135 -2.6900 -0.8652 -1.5840 -1.0161 -0.1510 -0.7372 -0.4748 -0.2563
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas cardiac_remodeling heart_failure
H-1483	-0.5215489268302917	▁mi RNA s ▁cardiac _ ▁remodel ing ▁heart _ fail ure
D-1483	-0.5215489268302917	miRNAs cardiac_ remodeling heart_failure
P-1483	-1.8075 -0.0211 -0.1517 -0.0354 -0.5635 -0.5448 -0.0725 -0.3531 -0.3252 -0.8969 -1.4543 -0.3509 -0.2032
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa immunoassays nt-probnp
H-1516	-0.5385087132453918	▁sandwich ▁Alpha lis a ▁immun o assa ys ▁NT - pro b NP
D-1516	-0.5385087132453918	sandwich Alphalisa immunoassays NT-probNP
P-1516	-0.8827 -1.3466 -1.0158 -0.3540 -0.1171 -0.3183 -0.4246 -1.5488 -0.3148 -0.0694 -0.0496 -0.6773 -0.3856 -0.3937 -0.1793
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf patients rheumatoid_arthritis ra
H-602	-0.9330170750617981	▁h f ▁rhe um ato id _ ar thri tis RA
D-602	-0.9330170750617981	hf rheumatoid_arthritisRA
P-602	-1.2072 -0.1900 -0.9208 -0.1719 -0.8271 -1.6783 -0.1442 -0.5063 -1.3670 -1.2661 -3.1991 -0.3994 -0.2518
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction_pathways engage signalling_proteins
H-993	-0.5103192925453186	▁trans duction _ path ways ▁protein s
D-993	-0.5103192925453186	transduction_pathways proteins
P-993	-0.1969 -0.1107 -0.3427 -0.0698 -0.2588 -2.5571 -0.3907 -0.4067 -0.2595
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical diastolic_dysfunction mortality
H-25	-0.29640841484069824	▁dia sto lic _ ▁dys function ▁mortal ity
D-25	-0.29640841484069824	diastolic_ dysfunction mortality
P-25	-0.0525 -0.1775 -0.4289 -0.2634 -1.0135 -0.0326 -0.2049 -0.1644 -0.3853 -0.2413
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation anti-inflammatory chf
H-1362	-0.3649754822254181	▁regula tion _ of _ ▁feed ing ▁nutrition al ▁anti - in flam ma tory _ effect s ▁CHF
D-1362	-0.3649754822254181	regulation_of_ feeding nutritional anti-inflammatory_effects CHF
P-1362	-0.1120 -0.0964 -0.3393 -0.0546 -0.1534 -0.6139 -0.1069 -0.6209 -0.1848 -0.3279 -0.0974 -0.5219 -0.1376 -1.4894 -0.0694 -0.8016 -0.3305 -0.1043 -0.8925 -0.3964 -0.2134
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes hypertrophic
H-1217	-0.598809540271759	▁p de 2- over express ing _ ▁cardio my o cy tes ▁no re pine ph rine - indu ced _ ▁hyper trop hic
D-1217	-0.598809540271759	pde2-overexpressing_ cardiomyocytes norepinephrine-induced_ hypertrophic
P-1217	-1.0387 -0.0245 -0.2346 -0.0494 -0.3481 -0.0445 -1.3393 -0.2882 -1.8073 -0.4224 -0.1444 -1.1341 -0.1707 -0.1470 -0.1283 -2.8258 -0.5139 -0.4191 -0.0006 -0.0275 -0.6402 -1.7374 -0.0630 -0.1427 -1.5470 -0.3300
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate alendronate heart_failure
H-1545	-0.8612962365150452	▁ale ndr onate ▁ale ndr onate ▁heart _ fail ure
D-1545	-0.8612962365150452	alendronate alendronate heart_failure
P-1545	-2.1036 -0.2646 -0.2912 -3.1646 -0.3300 -0.3722 -0.7170 -0.2807 -1.3908 -0.8123 -0.4029 -0.2057
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty heart_failure hf
H-622	-0.7601199746131897	▁fra il ty ▁heart _ fail ure HF
D-622	-0.7601199746131897	frailty heart_failureHF
P-622	-1.1712 -0.2502 -0.3783 -0.7062 -0.2537 -0.7984 -1.9554 -1.1275 -0.7043 -0.2560
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression bax bcl-2 proteins pacing
H-170	-0.3953459858894348	▁expression ▁Bax ▁b cl -2 _ ▁protein s ▁ratio ▁dog s
D-170	-0.3953459858894348	expression Bax bcl-2_ proteins ratio dogs
P-170	-0.0188 -0.0547 -0.1124 -0.0689 -0.1033 -0.4424 -0.9957 -0.3170 -0.9304 -1.3433 -0.1208 -0.3595 -0.2721
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients β-blocker patients uptitration
H-179	-0.8336011171340942	RAS - ▁β - block er _ ▁dose
D-179	-0.8336011171340942	RAS- β-blocker_ dose
P-179	-1.9031 -0.2106 -0.3812 -0.0811 -0.5330 -0.8522 -1.1043 -1.1536 -1.8348 -0.2821
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt gdmt bat
H-1871	-1.1090166568756104	▁GD m ▁gh t ▁BAT
D-1871	-1.1090166568756104	GDm ght BAT
P-1871	-0.5173 -2.8538 -3.1786 -0.5961 -0.1523 -0.2602 -0.2049
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart_failure patients bisphosphonates
H-1535	-0.6810079216957092	▁heart _ fail ure ▁bis phos phon ates
D-1535	-0.6810079216957092	heart_failure bisphosphonates
P-1535	-1.4228 -0.3507 -0.9763 -1.2040 -0.5269 -0.0982 -0.4095 -0.9845 -0.5463 -0.2908
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline patients resting_hr bpm
H-1940	-0.6914832592010498	▁base line ▁HR
D-1940	-0.6914832592010498	baseline HR
P-1940	-0.0924 -0.0692 -2.4149 -0.6940 -0.1870
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac_angiogenesis therapy cardiac_function remodeling
H-460	-0.5996455550193787	▁β - Block er - indu ced ▁cardiac _ ▁ang io gene sis ▁ therapy ▁cardiac _ function ▁remodel ing
D-460	-0.5996455550193787	β-Blocker-induced cardiac_ angiogenesis therapy cardiac_function remodeling
P-460	-0.4229 -0.0333 -0.5323 -0.2486 -0.0618 -0.0003 -0.0246 -1.2369 -0.1709 -1.1251 -2.0132 -0.5793 -1.9822 -1.5026 -0.0365 -0.1864 -0.3044 -0.3930 -1.6856 -0.0558 -0.3873 -0.2093
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
H-966	-0.22382426261901855	▁nic oran dil ▁cy to toxic ▁do xor ubi cin ▁eh r lich _ car cino ma
D-966	-0.22382426261901855	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
P-966	-0.0509 -0.1214 -0.2907 -0.0745 -0.1008 -0.2409 -0.4039 -0.1039 -0.0197 -0.1622 -0.4400 -0.0545 -0.0101 -0.1826 -0.2212 -0.1337 -1.0503 -0.3883 -0.2030
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death c-statistics biological_phenotype deficit_index
H-1011	-0.38011324405670166	▁death ▁bi ological _ ▁ph eno type ▁deficit _ index
D-1011	-0.38011324405670166	death biological_ phenotype deficit_index
P-1011	-0.2886 -0.4309 -0.1411 -0.7502 -1.6000 -0.0584 -0.0147 -0.2766 -0.1548 -0.2628 -0.3125 -0.2708
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas cardiac benign_tumors left_atrium right_atrium
H-593	-0.3701971173286438	▁My xo mas ▁cardiac _ ▁benign _ ▁tumor s ▁left _ at rium ▁right _ at rium
D-593	-0.3701971173286438	Myxomas cardiac_ benign_ tumors left_atrium right_atrium
P-593	-1.6901 -0.0591 -0.1577 -0.0909 -0.7469 -0.0664 -0.2160 -0.3258 -0.1666 -0.7438 -0.1704 -0.6860 -0.0709 -0.3169 -0.2192 -0.7441 -0.0796 -0.2457 -0.2376
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic_peptides point_of_care ambulatory
H-1019	-0.46772560477256775	▁na tri ure tic _ pe pti des
D-1019	-0.46772560477256775	natriuretic_peptides
P-1019	-0.0599 -0.1375 -0.0559 -0.2807 -0.3517 -0.9099 -0.1728 -1.1371 -1.3487 -0.2230
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv_diastolic_dysfunction combination figure hfpef
H-24	-0.3697350025177002	▁LV _ ▁dia sto lic _ ▁dys function ▁figure ▁mechanism ▁h f f
D-24	-0.3697350025177002	LV_ diastolic_ dysfunction figure mechanism hff
P-24	-0.1410 -0.8328 -0.8095 -0.1699 -0.1935 -0.1812 -0.5457 -0.0208 -0.0776 -0.1219 -0.2382 -1.1235 -0.5234 -0.3752 -0.1919
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal_denervation dnx chf patients symptomatic
H-1371	-0.7224240303039551	▁Ren al _ den er va tion ▁d n x ▁CHF
D-1371	-0.7224240303039551	Renal_denervation dnx CHF
P-1371	-1.8309 -0.1434 -0.2399 -3.0253 -0.7677 -0.1013 -0.1798 -0.2897 -0.7456 -0.0945 -0.3113 -1.4667 -0.1955
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported patient implantable_cardioverter-defibrillator
H-1858	-0.4146423935890198	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1858	-0.4146423935890198	implantable cardioverter-defibrillator_deactivation
P-1858	-0.0747 -0.0916 -1.3692 -0.1922 -0.1441 -0.3229 -0.0968 -1.4350 -1.3707 -0.1068 -0.3316 -0.3111 -0.1212 -0.1821 -0.3003 -0.3645 -0.2340
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic_adult_fontan saf patients catheterization
H-226	-0.3426629602909088	▁Font an SAF ▁cat heter ization
D-226	-0.3426629602909088	FontanSAF catheterization
P-226	-0.7967 -0.1753 -0.2386 -0.2053 -0.0371 -0.4274 -0.5758 -0.2851
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients heart_failure left_ventricular ejection_fraction
H-22	-0.5901411175727844	▁heart _ fail ure ▁left _ vent ri cular LV ▁e je ction _ fraction
D-22	-0.5901411175727844	heart_failure left_ventricularLV ejection_fraction
P-22	-1.1434 -0.3423 -1.2999 -1.5486 -1.5067 -0.3066 -0.8811 -0.9127 -0.4261 -0.2975 -0.2201 -0.1811 -0.1024 -0.2238 -0.0127 -0.3930 -0.2343
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory icd patients mortality multivariable_regression
H-63	-0.42277389764785767	▁ambula tory _ i CD ▁mortal ity ▁multi vari able _ re gression
D-63	-0.42277389764785767	ambulatory_iCD mortality multivariable_regression
P-63	-0.1651 -0.0548 -0.5619 -1.9067 -1.0472 -0.4149 -0.2069 -0.6353 -0.0096 -0.1639 -0.2975 -0.0827 -0.0900 -0.3847 -0.3205
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients sinus_rhythm antiplatelet_agents anticoagulants
H-1354	-0.3497726023197174	▁sinus _ rhythm ▁anti plate let _ agent s ▁antico a gul ants
D-1354	-0.3497726023197174	sinus_rhythm antiplatelet_agents anticoagulants
P-1354	-0.4473 -0.2825 -0.5039 -0.1187 -0.1810 -1.0328 -0.3122 -0.2355 -0.4720 -0.2959 -0.4342 -0.1813 -0.0714 -0.4492 -0.2288
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician follow-up discharge physician outcomes patients heart_failure
H-1421	-0.8283445239067078	▁physician ▁follow - up _ ▁after _ dis charge ▁physician _ continu ity ▁heart _ fail ure
D-1421	-0.8283445239067078	physician follow-up_ after_discharge physician_continuity heart_failure
P-1421	-1.3029 -0.3070 -0.2246 -0.0390 -0.7090 -4.1812 -0.3131 -0.1081 -0.0157 -0.0197 -1.5242 -0.0770 -0.2775 -1.9288 -0.3333 -1.8142 -1.8314 -0.4704 -0.2615
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence vad acs consultations operations mortality morbidity
H-1289	-0.9288657307624817	▁MT ▁ VAD ▁a CS
D-1289	-0.9288657307624817	MT VAD aCS
P-1289	-0.4649 -0.6301 -0.0930 -1.3125 -2.3894 -1.3558 -0.2563
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity doxorubicin anti-neoplastic_agent
H-955	-0.2093638926744461	▁cardio toxic ity ▁do xor ubi cin ▁anti - neo plast ic _ agent ▁cancer s
D-955	-0.2093638926744461	cardiotoxicity doxorubicin anti-neoplastic_agent cancers
P-955	-0.1181 -0.6637 -0.3496 -0.0378 -0.0728 -0.0297 -0.1262 -0.0401 -0.1002 -0.1945 -0.0601 -0.0299 -0.5927 -0.0748 -0.4647 -0.2856 -0.3145 -0.2138
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes patients preserved_ejection_fraction hfpef
H-1328	-0.7231876254081726	▁f es ▁pres er ved _ e je ction _ fraction ▁h p f
D-1328	-0.7231876254081726	fes preserved_ejection_fraction hpf
P-1328	-3.2382 -0.7524 -1.8590 -0.2996 -0.3076 -0.2444 -0.4563 -0.6689 -0.1920 -0.1976 -0.0335 -0.8668 -0.4076 -1.4354 -0.3846 -0.2272
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs hf_with_reduced_ejection_fraction hfref
H-1077	-0.5554280877113342	▁drugs HF ▁e je ction _ fraction HF r EF
D-1077	-0.5554280877113342	drugsHF ejection_fractionHFrEF
P-1077	-0.6100 -1.5397 -0.6322 -0.2200 -0.0661 -0.2254 -0.0173 -2.1623 -0.1114 -0.5867 -0.3270 -0.1671
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations refractory_congestive_heart_failure peritoneal_dialysis
H-893	-0.4922226071357727	▁re frac tory _ con ges tive _ heart _ ▁failure ▁per ito ne al _ di al ysis
D-893	-0.4922226071357727	refractory_congestive_heart_ failure peritoneal_dialysis
P-893	-0.0514 -0.1056 -0.1751 -0.4318 -0.1535 -0.2088 -0.2642 -0.2455 -1.4557 -0.1786 -1.7644 -0.1152 -0.9205 -0.8488 -0.2136 -0.3005 -2.1326 -0.0902 -0.0649 -0.3537 -0.2621
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened lvet icu admission prognostic patients precapillary_ph heart_failure
H-590	-0.7804531455039978	▁l VET ICU _ ad mission ▁pre cap illa ry _ ▁PH ▁heart _ fail ure
D-590	-0.7804531455039978	lVETICU_admission precapillary_ PH heart_failure
P-590	-3.8889 -0.2814 -0.2070 -2.0623 -0.5514 -0.0213 -0.4249 -0.2531 -0.1447 -0.5953 -0.7951 -1.6576 -0.3918 -0.4169 -1.0414 -0.6626 -0.3872 -0.2654
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial irs1 irs2 heart_failure p38alpha mapk insulin_resistance
H-651	-0.5715053081512451	▁my o card ial _ los s ▁i RS 1 ▁i RS 2 ▁heart _ fail ure ▁p 38 al pha _ ▁MA PK ▁insulin _ ▁resist ance
D-651	-0.5715053081512451	myocardial_loss iRS1 iRS2 heart_failure p38alpha_ MAPK insulin_ resistance
P-651	-1.3934 -0.3356 -0.4063 -0.2103 -0.2907 -1.8532 -0.1262 -0.4047 -1.0140 -0.1359 -0.6119 -1.1771 -0.0169 -0.2144 -0.3288 -1.2058 -0.4832 -0.0227 -0.1855 -0.1291 -0.0244 -0.2030 -1.7103 -0.2650 -0.0608 -0.6068 -3.0701 -0.0124 -0.4101 -0.2368
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni_inhibitors angiotensin-receptor_neprilysin_inhibitors
H-1966	-0.526379406452179	▁ar ni _ ▁inhibi tors angi oten sin - recept or ▁nepri ly sin _ ▁inhibi tors
D-1966	-0.526379406452179	arni_ inhibitorsangiotensin-receptor neprilysin_ inhibitors
P-1966	-1.1178 -0.8963 -1.3355 -0.9181 -0.0650 -0.0231 -0.0449 -1.1616 -0.7379 -0.1990 -0.1973 -0.9750 -0.1315 -0.1293 -0.3169 -0.9786 -0.0955 -0.4241 -0.2538
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-337	-0.6352647542953491	▁function al _ met ral _ ▁sten osis ▁m s ▁ring _ ▁ann ulo plast y ▁ ische mic _ met ral _ re gur gi tation MR
D-337	-0.6352647542953491	functional_metral_ stenosis ms ring_ annuloplasty ischemic_metral_regurgitationMR
P-337	-1.4132 -0.3851 -0.4263 -2.3713 -0.0733 -0.2414 -1.7206 -0.1307 -0.9552 -1.5576 -0.3571 -0.3937 -2.0180 -0.1486 -0.0119 -0.2027 -0.7586 -0.0639 -0.2833 -0.3901 -2.2644 -0.2065 -0.3060 -0.0645 -0.0347 -0.6246 -0.0327 -0.9306 -0.4645 -0.2267
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence heart_failure_with_preserved_ejection_fraction hfpef prognosis
H-23	-0.47585105895996094	▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁h f f
D-23	-0.47585105895996094	heart_ failure preserved_ejection_fraction hff
P-23	-0.7090 -0.2577 -2.7258 -0.5923 -0.2732 -0.4485 -0.1754 -0.2506 -0.3354 -0.0698 -0.1787 -0.0106 -0.1247 -1.0002 -0.3418 -0.3746 -0.2210
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_reserve
H-916	-0.5675879120826721	▁Heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁h f f ▁cardiovascular _ re serve
D-916	-0.5675879120826721	Heart_ failure preserved_ejection_fraction hff cardiovascular_reserve
P-916	-1.0890 -0.4288 -2.6381 -0.6024 -0.4189 -0.2487 -0.2199 -0.2664 -0.5188 -0.0643 -0.1937 -0.0146 -0.1210 -1.0621 -0.3464 -0.1137 -0.4342 -0.8764 -1.6402 -0.3890 -0.2325
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 hypertensive obese zsf1 hypertensive diabetic
H-766	-0.8560969233512878	▁lean _ z SF 1 ▁obes e ▁z SF 1 ▁diabet ic
D-766	-0.8560969233512878	lean_zSF1 obese zSF1 diabetic
P-766	-0.1570 -1.5812 -1.5465 -0.8394 -0.3440 -1.6251 -0.3703 -2.2037 -1.3018 -0.3238 -1.0920 -0.0883 -0.3213 -0.1910
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian_enabled mena cytoskeletal_actin_dynamics heart_failure hf
H-1810	-0.5398609042167664	▁Mamma lian _ ▁enabled ▁men a ▁regulator ▁cy tos kelet al _ act in _ dynamic s ▁heart _ fail ure HF
D-1810	-0.5398609042167664	Mammalian_ enabled mena regulator cytoskeletal_actin_dynamics heart_failureHF
P-1810	-0.2840 -0.3706 -0.3709 -0.3433 -1.4368 -0.0441 -0.6446 -0.2305 -0.8412 -0.1537 -0.1370 -0.4644 -0.1561 -1.6035 -0.8870 -0.8846 -0.0971 -0.2520 -0.2710 -1.1785 -0.5982 -1.2761 -0.2699 -0.1615
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal_bleeding reported patients ventricular_assist_devices
H-1659	-0.6948816180229187	▁Gastro inte stin al _ blad ed ing ▁vent ri cular _ assist _ ▁devices
D-1659	-0.6948816180229187	Gastrointestinal_bladeding ventricular_assist_ devices
P-1659	-0.7895 -0.0811 -1.1500 -0.1230 -0.5056 -2.1581 -0.1822 -0.2533 -0.0794 -0.5929 -0.3621 -0.2801 -0.0070 -0.6652 -3.8751 -0.4958 -0.2126
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart hospitalization death patients preserved_left_ventricular_ejection_fraction
H-235	-0.7690205574035645	▁heart _ ▁failure - related _ hospital ization ▁death ▁left _ vent ri cular _ e je ction _ fraction
D-235	-0.7690205574035645	heart_ failure-related_hospitalization death left_ventricular_ejection_fraction
P-235	-1.8976 -0.7280 -3.1362 -0.5747 -0.0054 -1.5697 -0.0764 -0.1341 -1.7994 -0.9380 -0.4693 -0.8854 -1.3196 -0.5019 -0.4253 -0.3940 -0.6129 -0.2754 -0.2879 -0.0184 -0.4563 -0.4126
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial pde2 intracellular antiadrenergic therapeutic hf
H-1220	-0.5759409666061401	▁my o card ial _ p de 2 ▁intra cel lular _ anti ad r energi c HF
D-1220	-0.5759409666061401	myocardial_pde2 intracellular_antiadrenergicHF
P-1220	-1.9530 -0.2405 -0.3462 -0.3241 -0.7783 -0.9013 -0.0502 -0.0393 -0.9396 -0.2536 -0.1858 -0.5723 -0.0954 -0.4511 -0.6356 -0.1491 -0.3242 -2.6823 -0.3518 -0.2452
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic bnp nt-probnp patients coronary_artery_disease cad
H-1366	-0.5591772198677063	▁b NP ▁NT - pro b NP ▁corona ry _ ▁arter y _ ▁disease CAD
D-1366	-0.5591772198677063	bNP NT-probNP coronary_ artery_ diseaseCAD
P-1366	-0.3436 -1.7230 -0.1880 -0.1241 -0.0205 -0.9119 -0.6800 -0.0707 -0.4669 -0.3158 -0.4230 -0.6171 -0.2777 -2.2332 -0.5008 -0.3796 -0.2303
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients heart_failure elevated left_atrial_pressure symptoms hospital admission
H-1949	-0.8457884788513184	▁heart _ fail ure ▁left _ at rial _ tension ▁hospital _ ad mission
D-1949	-0.8457884788513184	heart_failure left_atrial_tension hospital_admission
P-1949	-0.9752 -0.3232 -0.9510 -1.9898 -1.9157 -0.2500 -1.2417 -0.8544 -0.1829 -1.8231 -1.2147 -0.8178 -0.2689 -0.0303 -0.4230 -0.2708
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia acute_kidney_injury spironolactone clinical
H-444	-0.4282623827457428	▁hyper kal emia ▁ki dne y _ ▁injury ▁spi rono lac tone
D-444	-0.4282623827457428	hyperkalemia kidney_ injury spironolactone
P-444	-0.8428 -0.6862 -0.1091 -0.1718 -0.3716 -0.2686 -1.2721 -1.2142 -0.0620 -0.0191 -0.2827 -0.0636 -0.4339 -0.1981
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_morbidity mortality
H-236	-0.4897831380367279	▁Heart _ ▁failure ▁pres er ved _ e je ction _ fraction HF p EF ▁cardiovascular
D-236	-0.4897831380367279	Heart_ failure preserved_ejection_fractionHFpEF cardiovascular
P-236	-0.6278 -0.2788 -1.8561 -0.4206 -0.4991 -0.3374 -0.1762 -0.2555 -0.4951 -0.0541 -0.1520 -0.0119 -1.6239 -0.0660 -0.5157 -0.0642 -1.1588 -0.2226
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg crt clinical
H-881	-0.881798267364502	▁ec g ▁c t
D-881	-0.881798267364502	ecg ct
P-881	-0.6661 -0.5922 -0.5902 -2.5815 -0.6253 -0.2355
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.44116637110710144	▁NT - pro b NP
D-1512	-0.44116637110710144	NT-probNP
P-1512	-0.9796 -0.1626 -0.0495 -0.9366 -0.3319 -0.3992 -0.2289
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions patients heart_disease
H-48	-0.5430935621261597	▁trans fusion s ▁heart _ ▁Disease
D-48	-0.5430935621261597	transfusions heart_ Disease
P-48	-0.1433 -0.0527 -0.2960 -0.7587 -0.3447 -2.0178 -0.4422 -0.2893
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone clinical medications
H-447	-0.6519564390182495	▁benefits ▁spi rono lac tone
D-447	-0.6519564390182495	benefits spironolactone
P-447	-0.5066 -0.5452 -0.0228 -0.4010 -0.1583 -2.7251 -0.2048
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination exercise peak_vo2 joint
H-1985	-0.509488582611084	▁exercise ▁pe ak _ vo 2 jo int _ effect
D-1985	-0.509488582611084	exercise peak_vo2joint_effect
P-1985	-0.6931 -1.8127 -0.0395 -0.2538 -0.0995 -0.3296 -1.2870 -0.2977 -0.2060 -0.0515 -0.7605 -0.2831
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up hf hospitalization
H-690	-0.5761498808860779	▁follow - up HF
D-690	-0.5761498808860779	follow-upHF
P-690	-0.0956 -0.2483 -0.0203 -1.1316 -1.7438 -0.2173
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients sst2 cardiovascular_event
H-407	-0.7111776471138	▁s st 2 ▁low - dos e _ bb ▁cardiovascular _ event _ rate
D-407	-0.7111776471138	sst2 low-dose_bb cardiovascular_event_rate
P-407	-0.0135 -1.2952 -0.0893 -1.6609 -0.0383 -0.7121 -0.3525 -1.3625 -0.8991 -0.1353 -0.6180 -1.8605 -0.2430 -0.9371 -0.9098 -0.2517
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast_cancer patients chf reported clinical
H-681	-0.5058534145355225	▁breast _ cancer ▁tras tuz um b - related _ ▁CHF
D-681	-0.5058534145355225	breast_cancer trastuzumb-related_ CHF
P-681	-0.4004 -0.3770 -1.2765 -1.1549 -0.0648 -0.1973 -0.5564 -0.4302 -0.0927 -0.8010 -0.4439 -0.5340 -0.2468
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf pb bp
H-1348	-0.610136091709137	▁PV f ▁p b ▁BP
D-1348	-0.610136091709137	PVf pb BP
P-1348	-0.5297 -0.3040 -0.1364 -0.2378 -2.4665 -0.3790 -0.2176
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant exercise
H-1883	-0.4767872095108032	▁exercise
D-1883	-0.4767872095108032	exercise
P-1883	-0.3969 -0.7631 -0.2704
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ecct
H-713	-0.5101354122161865	▁ec t
D-713	-0.5101354122161865	ect
P-713	-0.5420 -0.8522 -0.4120 -0.2344
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.4226597547531128	▁aero bic _ capaci ty ▁left - hand _ grip _ ▁strength ▁body _ weight ▁wa ist _ ▁circum ferenc e ▁anxiety
D-573	-0.4226597547531128	aerobic_capacity left-hand_grip_ strength body_weight waist_ circumference anxiety
P-573	-1.6864 -0.4804 -0.4084 -0.1370 -0.0569 -0.7727 -0.2474 -0.0475 -0.1255 -0.9003 -0.5859 -1.9047 -0.1781 -0.2773 -0.3738 -0.0587 -0.0723 -0.2445 -0.6492 -0.0579 -0.0972 -0.2674 -0.2908 -0.2235
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.4651225209236145	▁Process _ re design
D-1851	-0.4651225209236145	Process_redesign
P-1851	-0.9038 -0.4724 -0.0641 -0.1482 -0.9564 -0.2459
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue_doppler left_ventricular_filling_pressure patients stable severe_systolic_heart_failure
H-479	-0.8175407648086548	▁tissu e ▁do pp ler _ ▁imagin g ▁left _ vent ri cular _ ▁fill ing _ tension ▁sy sto lic _ heart _ fail ure
D-479	-0.8175407648086548	tissue doppler_ imaging left_ventricular_ filling_tension systolic_heart_failure
P-479	-0.5215 -0.3091 -0.6742 -0.0557 -1.5647 -0.4083 -2.1616 -0.0931 -0.1785 -0.5395 -0.9034 -1.5194 -0.3044 -1.8713 -0.9381 -0.0882 -0.3844 -2.3456 -0.5608 -0.3579 -0.9284 -0.3258 -2.4801 -0.3620 -1.4092 -0.9159 -0.4034 -0.2867
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart_failure hypertensive_heart_disease angiotensin_ii infusion nephrectomy salt_loading
H-273	-0.5468797087669373	▁heart _ ▁failure ▁hyper tensi ve _ heart _ ▁disease ▁ang io ten sin _ ▁II _ in fusion ▁nep hr ecto my ▁salt _ load ing
D-273	-0.5468797087669373	heart_ failure hypertensive_heart_ disease angiotensin_ II_infusion nephrectomy salt_loading
P-273	-0.5936 -0.3516 -1.7302 -0.1561 -0.1435 -0.0516 -0.3443 -2.2419 -0.2592 -1.9330 -0.0150 -3.0447 -0.1965 -0.5833 -0.2274 -0.4498 -0.4359 -0.2280 -0.0472 -0.0569 -0.2739 -0.0399 -1.1931 -0.0680 -0.3306 -0.1436 -0.0509 -0.4440 -0.2259
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas_city_cardiomyopathy_questionnaire patients heart_failure reduced_ejection_fraction
H-779	-0.5109504461288452	▁Kansas _ city ▁Card i om yo pathy _ ▁Question naire ▁heart _ fail ure ▁e je ction _ fraction
D-779	-0.5109504461288452	Kansas_city Cardiomyopathy_ Questionnaire heart_failure ejection_fraction
P-779	-0.0135 -0.3874 -0.3085 -2.6059 -0.0629 -0.0715 -0.8087 -0.0892 -2.2279 -0.1280 -0.0110 -0.3716 -0.2848 -0.9081 -1.6116 -0.1795 -0.1162 -0.0943 -0.2917 -0.0090 -0.3757 -0.2840
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians patient anemic patients heart_disease
H-34	-0.9005677700042725	▁guide line ▁a ne mic ▁ir on - d eficient ▁heart _ ▁disease
D-34	-0.9005677700042725	guideline anemic iron-deficient heart_ disease
P-34	-2.5103 -0.1179 -1.8579 -0.4838 -0.4187 -0.2667 -0.1765 -0.2132 -0.1502 -0.4367 -3.3389 -0.3247 -2.5768 -0.3933 -0.2430
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence prevalence heart_failure leading death hospitalisation
H-1664	-1.0264780521392822	▁heart _ fail ure
D-1664	-1.0264780521392822	heart_failure
P-1664	-0.5727 -0.2387 -1.1152 -2.3711 -1.5326 -0.3286
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab chf nontrastuzumab_users
H-678	-0.29590755701065063	▁tras tuz um ab ▁CHF ▁non tras tuz um ab
D-678	-0.29590755701065063	trastuzumab CHF nontrastuzumab
P-678	-0.4728 -0.0643 -0.1953 -0.0649 -0.2642 -0.1655 -0.5627 -0.0461 -0.4939 -0.1182 -0.9326 -0.1705
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration patients hr_reduction beta-blocker therapy
H-1947	-0.7016481161117554	▁HR ▁beta - block er _ therapy
D-1947	-0.7016481161117554	HR beta-blocker_therapy
P-1947	-3.0834 -0.7697 -0.1077 -0.4243 -0.4977 -0.6838 -0.1739 -0.3491 -0.2254
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary_occlusion collateral_growth stent
H-510	-0.39128822088241577	▁corona ry _ ▁oc clusi on ▁col lateral _ ▁growth ▁sten t _ ▁oc clusi on
D-510	-0.39128822088241577	coronary_ occlusion collateral_ growth stent_ occlusion
P-510	-0.1516 -0.4438 -0.4071 -0.1071 -0.2188 -0.4196 -0.3190 -0.0230 -0.3623 -2.0443 -0.4039 -0.2856 -0.3985 -0.0833 -0.3166 -0.4258 -0.4044 -0.2287
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis patients disease atherosclerosis cardiovascular_events psoriasis
H-1565	-0.4450201988220215	▁psoriasis ▁at hero sc ler osis ▁cardiovascular ▁psoriasis
D-1565	-0.4450201988220215	psoriasis atherosclerosis cardiovascular psoriasis
P-1565	-0.1656 -1.2349 -0.0760 -0.0503 -1.5198 -0.0739 -0.0536 -0.5339 -0.4315 -0.3107
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid_intima-media_thickness psoriasis
H-1561	-0.6278766393661499	▁caro tid ▁intim a - media _ thi ck ness ▁psoriasis
D-1561	-0.6278766393661499	carotid intima-media_thickness psoriasis
P-1561	-1.4528 -0.2491 -2.5785 -0.1036 -0.2067 -0.4292 -0.5176 -0.8566 -0.2483 -1.0255 -0.0235 -0.2875 -0.1833
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 hearts acute β-ar
H-1218	-0.49029815196990967	▁p de 2 ▁heart s ▁β - ar _ stimul ation
D-1218	-0.49029815196990967	pde2 hearts β-ar_stimulation
P-1218	-0.3416 -0.0183 -0.0406 -0.9635 -0.2324 -1.7122 -0.0363 -1.0140 -0.9814 -0.1256 -0.0767 -0.4795 -0.3518
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients narrow_qrs_complex crt patients
H-846	-0.6289636492729187	▁mechanic al _ ▁dys syn chron y ▁QR s ▁c RT
D-846	-0.6289636492729187	mechanical_ dyssynchrony QRs cRT
P-846	-0.0350 -0.1100 -0.2161 -1.3743 -0.0209 -0.0065 -0.6665 -0.1963 -1.0954 -0.8860 -2.8072 -0.5194 -0.2430
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote_monitoring rm heart_failure
H-148	-0.6057652235031128	▁remote _ monitor ing RM ▁heart _ fail ure
D-148	-0.6057652235031128	remote_monitoringRM heart_failure
P-148	-0.2935 -0.3033 -0.0626 -0.0289 -0.7174 -1.6299 -0.3598 -1.3589 -1.1005 -0.5957 -0.2128
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart_failure hf death crt-d
H-105	-0.8276413679122925	▁i e ▁heart _ fail ure HF ▁death ▁c RT - d
D-105	-0.8276413679122925	ie heart_failureHF death cRT-d
P-105	-0.3568 -0.9530 -0.6495 -0.2294 -0.8582 -1.6740 -1.7401 -1.7219 -0.5071 -1.9544 -0.0603 -0.2601 -0.4023 -0.2199
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv_dysfunction cardiac_cachexia
H-1168	-0.6885195374488831	RV _ ▁dys function ▁cardiac _ ▁cache xia ▁mechan ist ically
D-1168	-0.6885195374488831	RV_ dysfunction cardiac_ cachexia mechanistically
P-1168	-1.4061 -2.6466 -0.1487 -0.0234 -0.0241 -0.2671 -1.8468 -0.1952 -0.3991 -0.8054 -0.3573 -0.5484 -0.2826
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr diuretics hypertension patients esrd
H-397	-0.6362332701683044	▁e g FR ▁di ure tics ▁hyper tension ▁ES RD
D-397	-0.6362332701683044	egFR diuretics hypertension ESRD
P-397	-0.1933 -0.5069 -1.0235 -0.0583 -0.0345 -0.9817 -0.0580 -0.0039 -2.3361 -1.7108 -0.5195 -0.2083
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence chronic_heart_failure hungary
H-646	-0.9272168278694153	▁chronic _ heart _ ▁failure ▁Hungary
D-646	-0.9272168278694153	chronic_heart_ failure Hungary
P-646	-0.4873 -0.2023 -2.0263 -0.1898 -3.3395 -0.4816 -0.4709 -0.2200
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic clinical pharmacologic
H-1470	-0.6547188758850098	▁ pharma c ologic ▁ pharma c ologic
D-1470	-0.6547188758850098	pharmacologic pharmacologic
P-1470	-0.6032 -0.1856 -0.1745 -0.1842 -3.2299 -0.1584 -0.1880 -0.2286 -1.2845 -0.3102
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care outpatient acute_heart_failure
H-1026	-0.6239408254623413	▁point - of - care _ system s NP ▁ed ▁out patient _ setting s ▁a cute _ heart _ fail ure
D-1026	-0.6239408254623413	point-of-care_systemsNP ed outpatient_settings acute_heart_failure
P-1026	-0.9398 -0.1950 -0.0068 -0.2982 -0.1228 -0.6807 -0.2302 -0.0624 -2.0412 -1.4663 -0.7190 -0.0886 -1.6381 -0.0479 -0.1598 -0.2504 -0.1024 -0.1901 -2.1395 -0.2593 -1.2226 -1.3668 -0.4224 -0.3242
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal_dysfunction all-cause_mortality cardiovascular_events postoperative cabg
H-978	-0.6842042207717896	▁Ren al _ ▁dys function ▁all - ca use _ ▁mortal ity ▁cardiovascular _ event s ▁ca BG
D-978	-0.6842042207717896	Renal_ dysfunction all-cause_ mortality cardiovascular_events caBG
P-978	-2.2300 -0.1258 -0.2443 -0.6077 -0.0388 -2.5205 -0.0899 -0.0240 -0.3088 -0.1893 -0.4243 -0.1995 -0.0223 -0.4729 -2.3788 -0.1327 -1.4855 -1.5728 -0.3766 -0.2393
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea total_arterial_compliance tac end-systolic_elastance ees baseline
H-520	-0.35931965708732605	▁ea ▁arterial _ ▁compliance TAC ▁end - sy sto lic _ ▁elastan ce ▁e es ▁base line
D-520	-0.35931965708732605	ea arterial_ complianceTAC end-systolic_ elastance ees baseline
P-520	-0.8389 -0.3831 -0.4325 -0.9735 -0.2646 -0.6840 -0.1173 -0.2492 -0.1881 -0.2387 -0.3328 -0.0466 -0.4086 -0.5642 -0.0336 -0.1307 -0.0611 -0.6921 -0.1875
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal_dysfunction mortality myocardial_infarction coronary_artery_bypass_grafting cabg
H-969	-0.5942994356155396	▁Ren al _ ▁dys function ▁long - term _ ▁mortal ity ▁my o card ial _ in far ction ▁corona ry _ ▁arter y _ ▁by pass _ ▁graf ting ▁ca BG
D-969	-0.5942994356155396	Renal_ dysfunction long-term_ mortality myocardial_infarction coronary_ artery_ bypass_ grafting caBG
P-969	-1.5957 -0.1667 -0.3763 -0.2880 -0.0263 -2.7029 -0.1300 -0.1624 -0.3578 -0.4496 -0.0831 -0.7470 -0.3533 -0.5808 -0.4859 -0.3839 -0.4050 -0.0586 -0.1623 -0.0520 -0.2750 -0.4463 -0.2142 -1.2928 -0.5518 -3.0298 -0.0176 -0.3772 -0.1929 -0.8395 -0.6359 -2.1003 -0.4117 -0.2533
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular diabetes_mellitus atrial_fibrillation coronary_artery_disease hfpef
H-1890	-0.4150112569332123	▁cardiovascular _ risk _ factor s ▁diabetes _ ▁mell itus ▁at rial _ fi bril lation ▁corona ry _ ▁arter y HF p EF
D-1890	-0.4150112569332123	cardiovascular_risk_factors diabetes_ mellitus atrial_fibrillation coronary_ arteryHFpEF
P-1890	-0.0920 -1.1504 -0.3682 -0.6028 -0.0383 -0.1639 -0.1092 -0.2854 -0.3847 -0.0892 -0.1103 -0.0835 -0.3493 -0.7032 -0.0623 -0.0835 -0.0198 -0.2900 -0.2856 -0.2567 -0.6528 -3.7308 -0.0936 -0.2880 -0.2946 -0.2023
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical coronary_artery_disease patients systolic_heart_failure etiology
H-1181	-0.6316666007041931	▁corona ry _ ▁arter y ▁sy sto lic _ heart _ fail ure ▁et i ology
D-1181	-0.6316666007041931	coronary_ artery systolic_heart_failure etiology
P-1181	-0.0895 -0.8235 -0.3820 -0.4409 -0.6947 -1.3201 -0.3615 -0.9426 -0.2201 -2.2848 -0.3582 -0.8071 -0.7698 -0.6352 -0.6074 -0.0239 -0.3608 -0.2480
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic congestive_heart_failure haematopoietic_cell_transplantation
H-1448	-0.5871140360832214	▁Gene tic _ ▁sus cept i bility ▁an thra cycli ne - related _ con ges tive _ heart _ ▁failure ▁ha e mato po ie tic _ cell _ ▁transplant ation
D-1448	-0.5871140360832214	Genetic_ susceptibility anthracycline-related_congestive_heart_ failure haematopoietic_cell_ transplantation
P-1448	-0.7539 -0.0412 -2.0849 -0.9977 -0.0010 -0.1663 -0.0039 -0.0657 -0.1645 -0.5318 -2.0540 -0.6834 -0.0338 -0.8956 -1.5516 -0.2457 -0.7503 -0.3209 -1.6848 -0.2460 -1.6301 -0.0191 -0.2247 -0.0975 -0.3657 -1.4711 -0.5649 -0.2264 -0.4884 -0.3592 -0.3887 -0.0393 -0.5154 -0.2943
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular_support heartmate_ii lvad centrimag rvad mortality hospital discharge
H-304	-0.8479440808296204	▁bi ven tri cular _ support ▁Heart Mate _ ▁II _ l VAD ▁centri Mag _ r VAD ▁mortal ity ▁hospital _ dis charge
D-304	-0.8479440808296204	biventricular_support HeartMate_ II_lVAD centriMag_rVAD mortality hospital_discharge
P-304	-3.5439 -0.3810 -0.9031 -0.9000 -1.6188 -0.8427 -1.3617 -0.1227 -0.3510 -0.5266 -0.3198 -3.9136 -0.0576 -0.5990 -1.4036 -0.4731 -2.0820 -0.1612 -0.2109 -0.0972 -0.6548 -0.5640 -0.2230 -0.0276 -0.3587 -0.3489
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus mortality hazard_ratio confidence_interval
H-129	-0.582770586013794	EO - c FU s ▁mortal ity haz ard _ rati o ▁confidence _ ▁interval
D-129	-0.582770586013794	EO-cFUs mortalityhazard_ratio confidence_ interval
P-129	-4.0912 -0.0681 -0.5885 -1.1990 -0.2321 -0.4045 -0.1441 -0.0235 -0.0768 -0.1834 -0.0548 -0.0334 -0.9032 -0.5378 -0.5925 -0.5266 -0.2478
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart_failure preserved_ejection_fraction myocardial_infarction
H-1098	-0.5285806059837341	▁heart _ ▁failure ▁e je ction _ fraction ▁my o card ial _ in far ction
D-1098	-0.5285806059837341	heart_ failure ejection_fraction myocardial_infarction
P-1098	-0.6942 -0.3137 -2.5611 -0.1815 -0.1766 -0.0761 -0.2168 -0.0156 -1.0834 -0.5899 -1.0724 -0.8399 -0.3294 -0.3176 -0.0396 -0.3708 -0.3891 -0.2467
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline isoprenaline infusion sdqt hf patients
H-1443	-0.7217466831207275	▁base line ▁iso pren a line _ in fusion ▁SD QT ▁h n ▁ HF
D-1443	-0.7217466831207275	baseline isoprenaline_infusion SDQT hn HF
P-1443	-0.0525 -0.1140 -0.0327 -0.1835 -0.3149 -0.1482 -0.3138 -0.2876 -0.0623 -0.1427 -2.2201 -0.0806 -3.5446 -3.4085 -0.7312 -0.4324 -0.2001
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis post-myocardial_infarction heart heart_failure
H-449	-1.060459852218628	▁ang io gene sis ▁post - my o card ial _ in far ction ▁heart ▁heart _ fail ure
D-449	-1.060459852218628	angiogenesis post-myocardial_infarction heart heart_failure
P-449	-0.2326 -4.6103 -1.2392 -2.8951 -0.0257 -0.1025 -3.4810 -0.8475 -1.4903 -0.6164 -0.3930 -0.3374 -0.0636 -0.2727 -1.9493 -0.5698 -0.5787 -1.0662 -0.8549 -0.3991 -0.2442
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical clinical outcomes aldosterone_antagonist heart_failure
H-1734	-0.6727205514907837	▁al do ster one _ ▁anta gon ist ▁heart _ fail ure
D-1734	-0.6727205514907837	aldosterone_ antagonist heart_failure
P-1734	-0.6508 -0.2671 -0.5296 -0.3484 -0.3575 -0.6282 -0.0620 -1.5370 -1.2107 -0.3561 -1.6662 -1.0330 -0.5169 -0.2545
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute_heart_failure ahf symptoms heart_failure hf
H-1466	-1.1308338642120361	▁a cute _ heart _ fail ure ▁a HF ▁heart _ fail ure HF
D-1466	-1.1308338642120361	acute_heart_failure aHF heart_failureHF
P-1466	-1.2001 -0.0146 -0.1160 -2.8160 -0.1309 -1.1582 -1.8947 -2.6400 -1.1266 -1.3785 -0.2369 -1.1857 -1.5357 -2.1392 -0.3092 -0.2111
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery medical_treatment hf hypertension vasodilators diuretics
H-355	-0.39070406556129456	▁medical HF ▁hyper tension ▁vaso dila tors ▁di ure tics
D-355	-0.39070406556129456	medicalHF hypertension vasodilators diuretics
P-355	-1.4773 -1.1441 -0.0483 -0.0033 -0.0348 -0.0269 -0.0373 -0.2056 -0.0398 -0.9790 -0.5002 -0.1920
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf remodeling emd dyssynchronous_failing_heart
H-1150	-0.6675790548324585	▁h f ▁em d ▁dys syn chron ous _ fail ing _ heart
D-1150	-0.6675790548324585	hf emd dyssynchronous_failing_heart
P-1150	-1.5061 -1.3453 -1.8315 -0.1320 -0.0329 -0.0751 -0.0280 -0.3550 -0.6236 -0.3890 -0.2600 -0.2213 -2.5266 -0.4361 -0.2511
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt implants transseptal_catheterisation transoesophageal_echocardiographic general_anaesthesia
H-1953	-0.5975214838981628	▁Shu nt _ ▁implant s ▁trans sept al _ ▁cat heter isation ▁trans o es op hage al _ e cho car dio graphic ▁general _ ▁ana es the sia
D-1953	-0.5975214838981628	Shunt_ implants transseptal_ catheterisation transoesophageal_echocardiographic general_ anaesthesia
P-1953	-1.9346 -0.1420 -0.4404 -0.2180 -0.2498 -0.0779 -0.0615 -0.5564 -0.6481 -1.3403 -0.0211 -0.1759 -0.0316 -1.3008 -0.8728 -0.3838 -0.0666 -0.4047 -0.5466 -0.2976 -0.9985 -0.6164 -1.2772 -2.1414 -0.0936 -0.2117 -2.3843 -0.1792 -0.0785 -0.4156 -0.6460 -0.3077
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine nesiritide placebo
H-78	-0.28306806087493896	▁dop amine ▁nesi riti de
D-78	-0.28306806087493896	dopamine nesiritide
P-78	-0.0358 -0.0842 -0.0327 -0.0896 -0.1210 -1.4598 -0.1583
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients hfpef prospective
H-736	-0.5260159373283386	▁h f f
D-736	-0.5260159373283386	hff
P-736	-0.3717 -0.9094 -0.5337 -0.5865 -0.2288
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline embase cochrane clinical
H-41	-0.7622914910316467	▁med line EMBA se ▁co ch rane
D-41	-0.7622914910316467	medlineEMBAse cochrane
P-41	-0.7853 -0.3575 -1.8093 -0.5090 -0.1798 -0.2908 -0.0690 -2.5991 -0.2608
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr vad ecmo vad ecmo
H-1393	-1.496559977531433	▁e g FR ▁ VAD ▁ec mo _ group ▁ec mo _ group
D-1393	-1.496559977531433	egFR VAD ecmo_group ecmo_group
P-1393	-0.2382 -0.3651 -2.0543 -1.1087 -0.3244 -1.5495 -2.0373 -3.1714 -4.7166 -1.6221 -2.1606 -1.4962 -1.0054 -0.4049 -0.1937
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf hospitalization cardiovascular_mortality
H-1639	-0.4277140498161316	▁black _ race HF ▁cardiovascular _ ▁mortal ity
D-1639	-0.4277140498161316	black_raceHF cardiovascular_ mortality
P-1639	-0.0352 -0.1487 -0.8722 -1.6115 -0.1225 -0.4664 -0.2542 -0.1191 -0.3976 -0.2497
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical nonprescribing patients
H-1128	-0.43321236968040466	▁bio medic al ▁non pre scribi ng
D-1128	-0.43321236968040466	biomedical nonprescribing
P-1128	-0.0203 -0.1259 -0.0372 -2.4750 -0.0124 -0.0981 -0.3267 -0.5392 -0.2641
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician nonprescribing patient
H-1127	-0.885661780834198	
D-1127	-0.885661780834198	
P-1127	-1.5064 -0.2649
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients severe_hf prognostic hf
H-1764	-1.008955955505371	HF HF HF HF HF
D-1764	-1.008955955505371	HFHFHFHFHF
P-1764	-1.4898 -0.7299 -0.9034 -1.0044 -1.7991 -0.8148 -0.3213
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth health outcomes medicare
H-1628	-0.7120265364646912	▁Care _ management ▁tele health _ tech n ology ▁health _ ▁outcome s ▁Medica re
D-1628	-0.7120265364646912	Care_management telehealth_technology health_ outcomes Medicare
P-1628	-3.2312 -0.6247 -0.1908 -1.9010 -0.1769 -1.8166 -0.2305 -0.0077 -0.0421 -0.0897 -1.6815 -0.8895 -0.0800 -0.5060 -0.0269 -0.3337 -0.2756
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective lvas
H-1995	-0.6197617053985596	▁single - arm ▁multi center ▁l VAS
D-1995	-0.6197617053985596	single-arm multicenter lVAS
P-1995	-0.5957 -0.2182 -0.1453 -0.3994 -0.1132 -2.7104 -0.7470 -0.4127 -0.2360
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant erc epicatechin muscle
H-1256	-0.7731263041496277	ERC ▁epi cate chin ▁muscle _ function
D-1256	-0.7731263041496277	ERC epicatechin muscle_function
P-1256	-1.1999 -2.1178 -0.0081 -0.2779 -1.6017 -0.6598 -0.3497 -0.4359 -0.3075
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ea tac ees patients
H-522	-0.7845613956451416	▁base line ▁ea ▁ TAC ▁HR ▁e es ▁i va bra dine
D-522	-0.7845613956451416	baseline ea TAC HR ees ivabradine
P-522	-0.1885 -0.1049 -1.0055 -1.0630 -0.6084 -2.5028 -1.0769 -0.0477 -2.0408 -0.0283 -0.0457 -0.3033 -1.6696 -0.2986
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician hf cpgs
H-1853	-0.7402689456939697	▁physician HF _ c PG s
D-1853	-0.7402689456939697	physicianHF_cPGs
P-1853	-1.7055 -1.5169 -0.7147 -0.3992 -0.7547 -0.0942 -0.4627 -0.2744
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf hf mortality
H-1774	-0.854411780834198	▁h f ▁ HF _ risk _ factor s ▁ HF _ ▁mortal ity
D-1774	-0.854411780834198	hf HF_risk_factors HF_ mortality
P-1774	-1.8443 -0.6102 -2.5043 -0.2378 -1.7852 -0.2248 -0.4042 -0.0610 -0.2458 -2.7975 -0.4696 -0.9612 -0.3134 -0.1348 -0.7933 -0.2831
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl chf vascular
H-260	-1.1337597370147705	▁HD l _ function ▁CHF ▁et h
D-260	-1.1337597370147705	HDl_function CHF eth
P-260	-1.1237 -3.0008 -0.5728 -0.2271 -0.1234 -0.6865 -1.4777 -2.7886 -0.2033
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine vascular_endothelial_growth_factor protein left_ventricle myocardial_angiogenesis
H-1142	-0.7611460089683533	▁Pyr ido stig mine ▁vas cular _ en dot heli al _ ▁Growth _ factor _ ▁protein ▁left _ vent ric le ▁my o card ial _ ang io gene sis
D-1142	-0.7611460089683533	Pyridostigmine vascular_endothelial_ Growth_factor_ protein left_ventricle myocardial_angiogenesis
P-1142	-0.0595 -0.0429 -0.0023 -0.0656 -0.1296 -0.5211 -0.6053 -0.5019 -2.2733 -0.3295 -0.0546 -0.3114 -2.0508 -0.3950 -0.0198 -1.5985 -1.1552 -0.1668 -0.3415 -0.3053 -2.5216 -1.3408 -0.8066 -0.3872 -0.9105 -0.4388 -0.3315 -0.3610 -4.4683 -0.5438 -1.3728 -0.4671 -0.2376
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis idiopathic_dilated_cardiomyopathy
H-1742	-0.6213181018829346	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy _ co hor t
D-1742	-0.6213181018829346	idiopathic dilated_ cardiomyopathy_cohort
P-1742	-2.1024 -0.0810 -0.0396 -0.4021 -2.5952 -0.0107 -0.2486 -0.1221 -1.7191 -0.4901 -0.0267 -1.3162 -0.0868 -0.2439 -0.4080 -0.3850 -0.2851
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics chromatin-associated_proteins disease
H-93	-1.1875500679016113	▁prote o mics
D-93	-1.1875500679016113	proteomics
P-93	-0.3219 -1.0272 -0.0539 -4.3441 -0.1906
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf_antagonists hf hospital admissions nbdmards ra
H-611	-0.6159652471542358	▁t NF _ ▁anta gon ists ▁h f ▁hospital ▁ad missions ▁n b DM ARD s ▁RA
D-611	-0.6159652471542358	tNF_ antagonists hf hospital admissions nbDMARDs RA
P-611	-0.0876 -0.7700 -2.2627 -0.1459 -0.0177 -1.1053 -0.8688 -1.1266 -0.4666 -1.1860 -0.0474 -0.2066 -0.0554 -1.2423 -0.8143 -0.1476 -0.5581 -0.3634 -0.2308
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic acute_hf adverse_event chronic_hf
H-1016	-0.9481396675109863	▁ pharma c ologic _ management ▁a cute _ HF ▁chronic _ HF
D-1016	-0.9481396675109863	pharmacologic_management acute_HF chronic_HF
P-1016	-1.0844 -0.0593 -0.0835 -0.1437 -2.2416 -0.0746 -3.0313 -0.0332 -0.3463 -1.3596 -2.9086 -0.6527 -1.6555 -0.3229 -0.2249
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients heartmate_ii biventricular_support heartmate_ii implantation
H-300	-0.8234958052635193	▁Heart Mate _ ▁II _ insertion ▁bi ven tri cular ▁Heart Mate _ ▁II _ ▁implant ation
D-300	-0.8234958052635193	HeartMate_ II_insertion biventricular HeartMate_ II_ implantation
P-300	-1.6444 -0.2603 -0.5352 -0.8701 -1.9516 -0.0664 -1.7651 -0.3513 -1.2061 -0.4740 -2.4191 -0.4770 -0.3714 -0.7468 -1.4423 -0.1853 -0.0839 -0.4514 -0.3448
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv_dysfunction body_mass_index fat_mass cachexia
H-1163	-0.5516635179519653	RV _ ▁dys function ▁body _ ▁mass _ index ▁fat _ ▁mass _ index ▁cache xia
D-1163	-0.5516635179519653	RV_ dysfunction body_ mass_index fat_ mass_index cachexia
P-1163	-1.2938 -1.3959 -0.4168 -0.0383 -0.4821 -0.4000 -1.4657 -0.2439 -0.3955 -0.6017 -0.3436 -0.6179 -0.1535 -0.5457 -0.5471 -0.2342 -0.4839 -0.2707
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy atrial_fibrillation patients carvedilol metoprolol
H-867	-0.3130892217159271	▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-867	-0.3130892217159271	atrial_fibrillation carvedilol metoprolol
P-867	-0.9373 -0.3242 -0.3568 -0.4892 -0.1328 -0.1075 -0.6404 -0.0385 -0.1482 -0.1380 -0.2750 -0.0244 -0.3485 -0.5391 -0.1964
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline crf hf mortality hf
H-1775	-0.7508420944213867	▁base line ▁c RF ▁ HF ▁mortal ity _ risk ▁ HF
D-1775	-0.7508420944213867	baseline cRF HF mortality_risk HF
P-1775	-0.0368 -0.0506 -1.1627 -1.6635 -1.6330 -0.3111 -0.8432 -0.0550 -1.0351 -0.2311 -1.2926 -0.6289 -1.3234 -0.2449
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients chf international_classification_of_diseases
H-213	-0.5391414165496826	▁CHF ▁international _ ▁Classifica tion _ of _ ▁Disease s ▁Nin th _ re vision
D-213	-0.5391414165496826	CHF international_ Classification_of_ Diseases Ninth_revision
P-213	-1.5017 -0.4234 -0.3912 -0.1909 -0.0641 -0.2748 -0.0600 -0.4584 -0.3532 -0.1475 -0.3879 -0.0541 -0.3609 -0.1805 -0.1567 -3.8671 -0.2931
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise health cardiac_disease heart_failure
H-1904	-0.8063594698905945	▁exercise ▁health _ bene fit s ▁cardiac _ ▁disease ▁heart _ fail ure
D-1904	-0.8063594698905945	exercise health_benefits cardiac_ disease heart_failure
P-1904	-0.9239 -0.3340 -1.1734 -2.0402 -0.1036 -0.1521 -0.1116 -0.4748 -2.4872 -0.8371 -0.3735 -1.6203 -0.7995 -0.3997 -0.2643
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 hno cxl-1051 t1
H-416	-0.5230333805084229	▁c XL -10 20 ▁convert s ▁h no ▁in active ▁c XL -10 51
D-416	-0.5230333805084229	cXL-1020 converts hno inactive cXL-1051
P-416	-0.7407 -1.0737 -0.3691 -0.2907 -1.1481 -0.6505 -0.4780 -0.1967 -0.1643 -0.0490 -0.6831 -1.1522 -0.4060 -0.1314 -0.5944 -0.2405
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium expression pka downstream_signaling
H-1433	-0.4733738899230957	▁my o car dium ▁expression ▁p ka ▁down stream _ signal ing
D-1433	-0.4733738899230957	myocardium expression pka downstream_signaling
P-1433	-0.6324 -0.1787 -0.0559 -0.2284 -0.8317 -1.3515 -1.2200 -0.0586 -0.0053 -0.6742 -0.2685 -0.2812 -0.5458 -0.2951
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests cardiac_growth disease chromatin remodeling
H-92	-1.0219265222549438	▁cardiac _ ▁growth ▁disease ▁chr omat in _ ▁remodel ing
D-92	-1.0219265222549438	cardiac_ growth disease chromatin_ remodeling
P-92	-0.0656 -0.7846 -1.9141 -1.0004 -2.1218 -0.1639 -2.0262 -0.7304 -1.6731 -0.0833 -1.4267 -0.2731
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 n2bus s12884 pevk
H-769	-0.7785605192184448	▁s 39 91 ▁elastic _ n 2 bu s ▁s 12 884 ▁PE v k
D-769	-0.7785605192184448	s3991 elastic_n2bus s12884 PEvk
P-769	-1.3533 -0.2069 -0.2006 -0.0499 -0.6555 -0.4281 -0.1128 -1.2670 -1.4279 -2.2887 -0.0270 -0.0510 -1.0122 -0.9342 -1.7424 -1.2832 -0.1948
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait therapy lokomat heart_failure patients
H-1921	-0.6210530996322632	▁Robot - assist ed _ ga it _ therapy ▁Lok omat _ system ▁heart _ fail ure
D-1921	-0.6210530996322632	Robot-assisted_gait_therapy Lokomat_system heart_failure
P-1921	-0.7003 -0.2622 -0.0028 -0.3379 -0.2163 -0.9873 -0.2634 -0.1997 -0.3028 -0.3416 -0.1667 -1.3178 -2.2338 -0.4483 -0.3702 -1.1541 -1.5367 -0.7411 -0.2172
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil mitochondrial_dysfunction heart_failure cardioprotection
H-954	-0.34324294328689575	▁Nico rand il ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin - indu ced _ heart _ ▁failure ▁rat s ▁mechanism _ of _ ▁cardio protec tion
D-954	-0.34324294328689575	Nicorandil mitochondrial_ dysfunction doxorubicin-induced_heart_ failure rats mechanism_of_ cardioprotection
P-954	-0.0040 -0.0151 -0.0387 -0.1476 -1.7829 -0.6562 -0.2413 -0.4863 -0.3506 -0.0276 -0.0417 -0.0723 -0.0127 -0.2893 -0.1728 -0.0011 -0.0651 -0.4141 -2.0979 -0.1983 -1.5724 -0.2387 -0.0589 -0.1012 -0.3655 -0.1221 -0.3108 -0.2308 -0.0659 -0.0606 -0.5453 -0.1961
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ras asymptomatic clinically hypertension nephropathy congestive_heart_failure
H-1597	-0.41299372911453247	RAS ▁hyper tension ▁nep hro pathy ▁con ges tive _ heart _ fail ure
D-1597	-0.41299372911453247	RAS hypertension nephropathy congestive_heart_failure
P-1597	-0.1242 -0.1735 -0.0028 -0.0305 -0.0307 -0.0227 -0.1072 -0.0599 -0.6914 -0.3842 -1.8897 -0.3011 -1.1969 -0.8882 -0.4391 -0.2657
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic admission brain_natriuretic_peptide bnp creatinine natremia
H-585	-0.7113236784934998	▁se rum _ level s ▁brain ▁na tri ure tic _ pe pti de ▁b NP ▁creati nine ▁na trem ia
D-585	-0.7113236784934998	serum_levels brain natriuretic_peptide bNP creatinine natremia
P-585	-3.7019 -0.4372 -1.4210 -1.0502 -0.2815 -1.4172 -1.3095 -0.0924 -0.0203 -0.2637 -0.2117 -0.5025 -0.4175 -0.6380 -0.3928 -1.2593 -0.1082 -1.2957 -0.1089 -0.0523 -0.7902 -0.3727 -0.2155
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart_failure cardiology-cardiovascular_surgery_consensus_report heart_failure disease
H-1818	-0.8953813910484314	▁heart _ fail ure ▁mechanic al ▁Card i ology - car dio vas cular _ sur ger y ▁report ▁Heart _ fail ure
D-1818	-0.8953813910484314	heart_failure mechanical Cardiology-cardiovascular_surgery report Heart_failure
P-1818	-1.8343 -0.4632 -1.5997 -2.3845 -0.0060 -0.0978 -2.7454 -0.2789 -0.0402 -0.1183 -1.0433 -1.9001 -1.3306 -0.4227 -0.6794 -0.2558 -0.7407 -0.0956 -0.7483 -1.4109 -0.3292 -1.2293 -0.8358 -1.5586 -0.2358
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart_rate_reduction exercise heart_failure_with_reduced_ejection_fraction beta-blocker
H-1935	-0.5017054677009583	▁Heart _ rate _ re duction ▁exercise ▁heart _ ▁failure ▁e je ction _ fraction ▁beta - block er ▁hypo - respons e
D-1935	-0.5017054677009583	Heart_rate_reduction exercise heart_ failure ejection_fraction beta-blocker hypo-response
P-1935	-1.0432 -0.4598 -1.6593 -0.6926 -0.0960 -0.0299 -0.0331 -1.9027 -0.2002 -2.2702 -0.2112 -0.0736 -0.0416 -0.2234 -0.0055 -0.7359 -0.0504 -0.3331 -0.2209 -1.1652 -0.0901 -0.0063 -0.4518 -0.3297 -0.2171
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt sd_of_rr_intervals sdrr qtv heart_rate_variability
H-1440	-1.4122117757797241	▁ratio ▁SD QT ▁ rd _ ▁interval s ▁s d r ▁q t ▁heart _ rate
D-1440	-1.4122117757797241	ratio SDQT rd_ intervals sdr qt heart_rate
P-1440	-1.8942 -0.5903 -1.6301 -1.9780 -2.7016 -0.2910 -0.3447 -0.1975 -2.1724 -0.8577 -3.5346 -3.2578 -1.8817 -1.2338 -0.4676 -1.0524 -1.0604 -0.2739
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care_of_heart_failure_index_version_6.2 schfi_v.6.2 psychometric
H-1504	-0.5487135052680969	▁self - Car e _ of _ ▁Heart _ fail ure _ index ▁sch fi ▁psycho metric _ profil e
D-1504	-0.5487135052680969	self-Care_of_ Heart_failure_index schfi psychometric_profile
P-1504	-0.7517 -0.1346 -2.6228 -0.5195 -0.2813 -0.0841 -0.2433 -0.8730 -0.2118 -0.3647 -0.0906 -0.1398 -0.2180 -1.0110 -2.7616 -0.1593 -0.0172 -0.8922 -0.0358 -0.0867 -0.3626 -0.2102
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric_focusing riα ser77 ser83 in_vivo phosphorylation
H-1430	-0.5679625868797302	▁iso electric ▁RI α ▁ser 77 ▁ser 83 ▁vivo _ phos phor y lation
D-1430	-0.5679625868797302	isoelectric RIα ser77 ser83 vivo_phosphorylation
P-1430	-0.2698 -0.4571 -2.0374 -0.4160 -0.2524 -0.1358 -0.1917 -0.6359 -0.1736 -0.5994 -0.2782 -0.9930 -1.1470 -0.1569 -1.1263 -0.2171
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient functional_ms patient valve_plasty degenerative_mr dilated disease
H-367	-0.5821288824081421	▁MS ▁val ve _ plast y ▁de genera tive _ ▁MR ▁LV ▁disease
D-367	-0.5821288824081421	MS valve_plasty degenerative_ MR LV disease
P-367	-1.6672 -0.9633 -0.0264 -0.3335 -0.0682 -0.6358 -0.6436 -0.0251 -0.0779 -0.7072 -2.5044 -0.2188 -0.3537 -0.3069 -0.2000
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end_stage_heart_failure heart_failure public health patient europe north_america
H-1663	-0.8758070468902588	▁end _ ▁stage _ heart _ fail ure ▁Heart _ fail ure ▁public _ ▁health ▁ europe ▁north _ america
D-1663	-0.8758070468902588	end_ stage_heart_failure Heart_failure public_ health europe north_america
P-1663	-1.9972 -0.4535 -1.2504 -0.2229 -2.3424 -0.3364 -1.7856 -1.9330 -0.9262 -0.3938 -1.1489 -1.6216 -0.0176 -0.9935 -0.3891 -0.1884 -0.0270 -0.6385 -1.5889 -0.4258 -0.3723 -0.2147
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient st-segment-elevation_mis killip_class comorbid conditions
H-1105	-0.7438502311706543	▁MI s ▁Kill ip ▁conditions
D-1105	-0.7438502311706543	MIs Killip conditions
P-1105	-3.9337 -0.1630 -0.3225 -0.0526 -0.0451 -0.3873 -0.3026
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology myocardial_infarction mi outcomes heart_failure hf
H-1099	-0.7870730757713318	▁epidemi ology ▁my o card ial _ in far ction ▁m ▁heart _ fail ure HF
D-1099	-0.7870730757713318	epidemiology myocardial_infarction m heart_failureHF
P-1099	-1.5151 -0.1805 -1.0097 -0.3457 -0.6853 -0.5960 -0.1870 -0.6367 -0.0758 -0.3487 -1.9128 -2.2664 -0.2192 -1.3071 -1.0761 -1.2229 -0.3468 -0.2354
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial_elastance ea pulsatile_afterload heart pressure_volume_relation
H-517	-0.6931727528572083	▁arterial _ ▁elastan ce ▁pulsa tile _ ▁after load ▁heart ▁pressure _ ▁volume
D-517	-0.6931727528572083	arterial_ elastance pulsatile_ afterload heart pressure_ volume
P-517	-0.2206 -0.5328 -0.1257 -0.4707 -0.0255 -0.2300 -0.4690 -3.9822 -0.0070 -0.5446 -0.0955 -0.7802 -1.4740 -1.1839 -0.2558
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated baseline nt-probnp mr-proanp mr-proadm
H-17	-0.42412081360816956	▁base line ▁NT - pro b NP ▁MR - pro an p ▁MR - pro ad m
D-17	-0.42412081360816956	baseline NT-probNP MR-proanp MR-proadm
P-17	-0.0250 -0.0629 -1.1683 -0.0917 -0.0883 -1.1024 -0.3902 -0.6135 -0.0951 -0.0479 -1.8450 -0.3709 -0.8420 -0.1333 -0.0658 -0.4765 -0.0588 -0.3540 -0.2269
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect heart_failure patients implantable_cardioverter-defibrillator
H-1860	-0.4769560396671295	▁ground ed _ the ory ▁heart _ ▁failure ▁implant able ▁cardio ver ter - de fi br illa tor
D-1860	-0.4769560396671295	grounded_theory heart_ failure implantable cardioverter-defibrillator
P-1860	-0.5778 -0.1144 -0.2176 -0.1084 -0.0584 -1.6690 -0.4698 -1.8788 -0.0079 -0.0743 -1.6027 -0.1342 -0.1493 -0.6269 -0.1030 -0.5612 -0.6706 -0.1043 -0.1696 -0.4815 -0.2364
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate left_ventricular_assist_system lvas patients heart_failure
H-1993	-0.7500605583190918	▁Heart Mate ▁left _ vent ri cular _ assist _ system ▁l VAS ▁heart _ fail ure
D-1993	-0.7500605583190918	HeartMate left_ventricular_assist_system lVAS heart_failure
P-1993	-1.1767 -0.2342 -0.5709 -0.4500 -0.7856 -1.1096 -0.3448 -0.2516 -0.0201 -1.3370 -0.1353 -0.6556 -0.6794 -2.3755 -0.6110 -1.5035 -1.3798 -0.3863 -0.2443
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed patients hf drug_treatment paf biosynthetic_enzymes lyso-paf-at
H-1271	-0.7202255725860596	▁h f ▁drug _ ▁Treatment ▁PA f ▁bio syn the tic _ ▁enzym es ▁lys o - pa f - at
D-1271	-0.7202255725860596	hf drug_ Treatment PAf biosynthetic_ enzymes lyso-paf-at
P-1271	-1.0882 -0.7018 -0.8538 -0.7197 -3.1611 -2.4723 -0.9950 -0.6243 -0.0309 -0.5532 -0.3382 -0.1141 -0.5709 -0.4368 -0.0925 -0.0830 -0.0601 -0.8601 -1.5360 -0.1441 -0.3518 -0.5096 -0.2677
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 sst2 outcomes
H-406	-0.9542117714881897	▁s st 2/ low - dos e _ ▁BB ▁s st 2 ▁high - dos e _ ▁BB
D-406	-0.9542117714881897	sst2/low-dose_ BB sst2 high-dose_ BB
P-406	-0.0705 -1.5067 -1.0871 -0.5914 -0.1304 -1.5754 -0.4865 -0.8373 -1.1741 -0.1063 -1.6166 -1.2961 -3.4974 -0.1621 -1.8582 -0.6118 -0.7425 -1.1590 -0.3450 -0.2297
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence hf ami mortality
H-1314	-0.7015541791915894	▁h f AMI ▁mortal ity
D-1314	-0.7015541791915894	hfAMI mortality
P-1314	-1.0371 -0.6752 -2.1863 -0.2114 -0.1402 -0.4163 -0.2443
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin genomic_reprogramming disease
H-100	-0.3372421860694885	▁zebra fish ▁nu cle olin ▁genom ic _ re programm ing ▁disease
D-100	-0.3372421860694885	zebrafish nucleolin genomic_reprogramming disease
P-100	-0.0403 -0.3359 -0.4658 -0.0085 -0.8269 -0.3676 -0.2045 -0.3673 -0.0403 -0.1881 -0.1283 -1.2374 -0.3042 -0.2065
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients t1_times cardiac_events
H-740	-0.8102530837059021	▁cardiac _ event s
D-740	-0.8102530837059021	cardiac_events
P-740	-0.4187 -0.3367 -3.2966 -0.0998 -0.4672 -0.2425
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv_ejection_fraction pcwp
H-483	-0.3898474872112274	▁LV ▁e je ction _ fraction ▁pc WP ▁h g
D-483	-0.3898474872112274	LV ejection_fraction pcWP hg
P-483	-0.0734 -0.4062 -0.2032 -0.1090 -0.1731 -0.0189 -0.1847 -2.3094 -0.5647 -0.0544 -0.3986 -0.1826
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf chf patients intubated
H-214	-0.711997389793396	▁CHF ▁ED ▁CHF ▁patients _ in tuba ted
D-214	-0.711997389793396	CHF ED CHF patients_intubated
P-214	-0.3648 -1.5010 -0.8158 -2.1053 -1.3603 -0.2414 -0.0743 -0.0667 -0.3953 -0.1951
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate_analysis gls
H-817	-1.4901670217514038	▁gr s ▁cv
D-817	-1.4901670217514038	grs cv
P-817	-0.8914 -1.1889 -3.7010 -1.3259 -0.3436
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr vad ecmo vad renal_function
H-1391	-0.9782090187072754	▁e g FR ▁ VAD ▁ec mo + VAD ▁renal _ function
D-1391	-0.9782090187072754	egFR VAD ecmo+VAD renal_function
P-1391	-0.2588 -0.2502 -1.8047 -1.6150 -0.1764 -0.8822 -1.4277 -5.0088 -0.3395 -0.2358 -0.5410 -0.6522 -0.2988 -0.2038
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician mortality hf physicians
H-1731	-0.6848509311676025	▁physical ▁mortal ity HF ▁non car dio logist
D-1731	-0.6848509311676025	physical mortalityHF noncardiologist
P-1731	-0.4339 -1.4377 -0.1561 -1.7383 -0.1761 -0.1723 -0.7314 -0.3215 -1.4499 -0.2312
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ejection_fraction
H-1236	-0.22705228626728058	▁e je ction _ fraction
D-1236	-0.22705228626728058	ejection_fraction
P-1236	-0.1695 -0.3198 -0.1454 -0.2386 -0.0507 -0.4107 -0.2547
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality hospitals
H-1695	-0.3930911123752594	▁mortal ity
D-1695	-0.3930911123752594	mortality
P-1695	-0.1263 -0.1742 -1.0173 -0.2546
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized exercise exercise
H-1981	-0.6736640930175781	▁exercise ▁die t ▁exercise
D-1981	-0.6736640930175781	exercise diet exercise
P-1981	-0.3526 -0.3834 -0.1916 -0.3772 -2.4450 -0.2921
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses magnet
H-87	-0.9530518054962158	▁nurse s ▁magnet
D-87	-0.9530518054962158	nurses magnet
P-87	-1.4736 -0.1632 -2.1765 -0.7128 -0.2392
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician evidence
H-1842	-1.1311986446380615	
D-1842	-1.1311986446380615	
P-1842	-2.0355 -0.2269
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-868	-0.6403965950012207	ADI t - c t ▁multi center _ automat ic _ de ib rilla tor _ ▁implant ation ▁Card iac _ re syn chron ization _ ▁Therapy
D-868	-0.6403965950012207	ADIt-ct multicenter_automatic_deibrillator_ implantation Cardiac_resynchronization_ Therapy
P-868	-2.3176 -0.2356 -0.0715 -0.4265 -3.0915 -0.4408 -0.0711 -0.3635 -0.5109 -0.1112 -0.4846 -0.9297 -1.6896 -0.6069 -0.1886 -0.7740 -0.5377 -0.0511 -0.6727 -0.2183 -0.3201 -0.0695 -0.0953 -0.0107 -0.6040 -0.4595 -0.5359 -2.4500 -0.2330
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic tests cardiac_magnetic_resonance_imaging t1_mapping invasive_hemodynamic_assessments baseline
H-737	-0.7493974566459656	▁cardiac _ magnet ic _ re on ance _ ▁imagin g ▁invasi ve _ ▁Hem o dynamic ▁base line
D-737	-0.7493974566459656	cardiac_magnetic_reonance_ imaging invasive_ Hemodynamic baseline
P-737	-0.0528 -0.2440 -0.6893 -2.0372 -0.1884 -0.7393 -1.9897 -0.1805 -0.1900 -1.6964 -0.1592 -1.4760 -0.1646 -0.4814 -3.7134 -0.6976 -0.0253 -0.2218 -0.0744 -0.4425 -0.2736
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity mortality hfpef patients hf reduced_ef
H-1301	-0.5705251693725586	▁Morbi d ity ▁mortal ity HF p EF HF ▁EF
D-1301	-0.5705251693725586	Morbidity mortalityHFpEFHF EF
P-1301	-0.9044 -0.0767 -0.1610 -0.0360 -0.1031 -0.8851 -0.1316 -0.2398 -1.1988 -1.5550 -1.3732 -0.1818
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic_regression primary_outcome secondary_outcome death
H-973	-0.6240456104278564	▁Log istic _ re gression _ model s ▁death
D-973	-0.6240456104278564	Logistic_regression_models death
P-973	-0.2633 -0.0620 -0.4654 -0.0530 -0.0477 -1.2692 -1.4018 -0.5096 -2.2382 -0.2810 -0.2734
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence intravenous exercise_tolerance quality_of_life patients heart_failure
H-46	-0.7892104983329773	▁intra ven ous _ ▁ir on ▁exercise ▁heart _ fail ure
D-46	-0.7892104983329773	intravenous_ iron exercise heart_failure
P-46	-2.6999 -0.0416 -0.9787 -0.2802 -1.1196 -0.3249 -0.0897 -1.0600 -0.3855 -1.5902 -0.9551 -0.4990 -0.2353
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency_department acute_heart_failure clinical patient collins
H-56	-0.7251240611076355	▁emergency _ ▁department ▁a cute _ heart _ fail ure ▁Collins
D-56	-0.7251240611076355	emergency_ department acute_heart_failure Collins
P-56	-1.0751 -0.2328 -2.0520 -0.1463 -0.0355 -0.1117 -1.9233 -0.1745 -1.0254 -1.5745 -0.4769 -0.3897 -0.2088
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence biomarkers pathophysiology chronic_hf therapeutic
H-1474	-0.6401249766349792	▁molecular _ ▁bio mark ers ▁pat ho phy si ology ▁chronic _ HF
D-1474	-0.6401249766349792	molecular_ biomarkers pathophysiology chronic_HF
P-1474	-0.8284 -0.1911 -1.8481 -0.1000 -0.2838 -1.1519 -0.1955 -0.0185 -0.9875 -0.0316 -0.2974 -0.5010 -2.2106 -0.6680 -0.2885
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet bromodomain-containing_protein_4 brd4 cardiac
H-1045	-0.6849773526191711	▁knock down BET ▁bro modo main - conta ining _ ▁protein ▁rob 4 ▁cardiac _ ▁tissu es
D-1045	-0.6849773526191711	knockdownBET bromodomain-containing_ protein rob4 cardiac_ tissues
P-1045	-1.1419 -0.1655 -1.2789 -1.0699 -0.1093 -0.1431 -0.4025 -0.0042 -0.5368 -0.1761 -1.1253 -2.4060 -0.6049 -0.0418 -0.4057 -2.0890 -0.6930 -0.3819 -0.2388
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission hospital congestive_heart_failure united_states
H-1574	-0.5068431496620178	▁read mission _ rate ▁hospital _ ▁stay ▁con ges tive _ heart _ fail ure ▁unit ed _ state s
D-1574	-0.5068431496620178	readmission_rate hospital_ stay congestive_heart_failure united_states
P-1574	-0.6843 -0.0787 -0.4572 -0.5151 -0.9405 -0.7570 -0.7493 -0.1530 -0.0608 -0.4348 -0.2083 -1.6478 -0.1492 -0.7487 -1.7632 -0.4769 -0.0079 -0.3966 -0.0814 -0.0783 -0.4866 -0.2750
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs septal qrs resynchronization
H-486	-0.6780189871788025	▁uc s sept al sept al ▁QR s _ width ▁re syn chron ization
D-486	-0.6780189871788025	ucsseptalseptal QRs_width resynchronization
P-486	-2.1357 -0.1815 -3.3011 -0.1689 -0.5328 -0.1258 -0.3330 -1.1002 -1.3952 -0.0715 -0.0745 -0.0387 -0.0122 -0.6251 -0.4936 -0.2585
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart_failure hf risk_stratification inpatient outpatient
H-378	-0.7220892906188965	▁heart _ fail ure HF ▁in patient ▁out patient
D-378	-0.7220892906188965	heart_failureHF inpatient outpatient
P-378	-0.4634 -0.2660 -1.3659 -1.3697 -0.8290 -1.9522 -0.1031 -0.2693 -0.1091 -0.9216 -0.2938
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective diuretics morbidity mortality
H-1200	-0.36768338084220886	▁di ure tics ▁morbi d ity ▁mortal ity
D-1200	-0.36768338084220886	diuretics morbidity mortality
P-1200	-0.0898 -0.0341 -1.0772 -1.0604 -0.1217 -0.3842 -0.0370 -0.1650 -0.4474 -0.2600
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc_occlusion correlated rs rs_synchrony
H-326	-0.39751046895980835	▁IV c ▁oc clusi on ▁co ▁twist ▁ap ical _ ro tation ▁RS ▁RS _ syn chron y
D-326	-0.39751046895980835	IVc occlusion co twist apical_rotation RS RS_synchrony
P-326	-0.5866 -0.3907 -0.1999 -0.0632 -0.3147 -0.4342 -0.5704 -1.1788 -0.0455 -0.3086 -0.1951 -0.0257 -0.3612 -0.5289 -1.1800 -0.1335 -0.0036 -0.6663 -0.5082 -0.2551
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol metoprolol therapy heart_failure patients
H-857	-0.6057957410812378	▁car vedi lol ▁met o pro lol ▁heart _ fail ure
D-857	-0.6057957410812378	carvedilol metoprolol heart_failure
P-857	-0.8160 -0.0360 -0.2410 -0.0438 -0.1686 -0.0297 -0.6514 -0.9327 -0.3693 -1.3169 -1.5595 -1.4592 -0.2512
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health_care clinically gastrointestinal_bleeding
H-1658	-0.7814972996711731	▁gastro inte stin al _ blad ed ing
D-1658	-0.7814972996711731	gastrointestinal_bladeding
P-1658	-2.4325 -0.0501 -0.8494 -0.1489 -0.3848 -2.7792 -0.2422 -0.2335 -0.4852 -0.2093
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital readmission patients heart_failure follow-up
H-731	-0.8176044225692749	▁read mission _ rate ▁heart _ fail ure ▁follow - up
D-731	-0.8176044225692749	readmission_rate heart_failure follow-up
P-731	-2.5966 -0.0720 -0.5229 -0.7209 -1.3246 -0.2291 -1.3140 -1.8534 -0.0339 -0.3734 -0.0218 -1.3068 -0.2593
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians public health air cardiovascular health lead hospitalisation death
H-1808	-0.6622851490974426	▁public _ ▁health ▁air _ ▁pollution ▁cardiovascular _ ▁health ▁lead
D-1808	-0.6622851490974426	public_ health air_ pollution cardiovascular_ health lead
P-1808	-0.1331 -0.4966 -0.9743 -0.0582 -0.6177 -2.0274 -0.3496 -0.9453 -0.8188 -0.0832 -1.1087 -0.3347
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare inpatient hf admissions acute hospitals united_states
H-1723	-0.32300519943237305	▁Medica re _ in patient ▁h f ▁ad missions ▁a cute _ care _ hospital s ▁unit ed _ state s
D-1723	-0.32300519943237305	Medicare_inpatient hf admissions acute_care_hospitals united_states
P-1723	-0.1165 -0.0211 -1.6723 -0.0363 -0.0486 -0.2678 -1.5530 -0.0275 -0.0415 -0.4392 -0.0717 -0.2051 -0.5223 -0.4113 -0.2336 -0.1494 -0.3200 -0.0093 -0.3673 -0.1284 -0.0683 -0.4755 -0.2431
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping tidal_respiration administration gadolinium-chelate_contrast_agent
H-1058	-0.7195467948913574	▁t 1- ma pping _ se que nce ▁tid al _ re spira tion ▁administration ▁ gado lini um - che late _ ▁contrast _ agent
D-1058	-0.7195467948913574	t1-mapping_sequence tidal_respiration administration gadolinium-chelate_ contrast_agent
P-1058	-2.8547 -0.1414 -0.6141 -0.1440 -0.0780 -0.3497 -0.6840 -0.0347 -0.3397 -0.0838 -0.2192 -1.3146 -2.0952 -0.1013 -0.0151 -0.6834 -0.2302 -0.9297 -0.2639 -0.2989 -0.4194 -2.7443 -0.1313 -4.1109 -0.2949 -0.1669 -0.5491 -0.2548
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf heart_failure t2d type_2_diabetes skm skeletal_muscle
H-1244	-0.7376869916915894	HF heart _ ▁failure ▁t 2 d ▁diabetes ▁Sk m ▁skelet al _ ▁muscle
D-1244	-0.7376869916915894	HFheart_ failure t2d diabetes Skm skeletal_ muscle
P-1244	-0.2880 -0.7688 -0.3723 -1.8327 -0.2248 -0.0219 -0.2175 -1.2961 -0.2694 -0.1203 -3.0444 -0.0903 -0.4376 -2.3334 -0.3107 -0.1748
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction
H-941	-0.3964744508266449	▁cat heter _ ab lation ▁at rial _ fi bril lation ▁heart _ ▁failure ▁e je ction _ fraction
D-941	-0.3964744508266449	catheter_ablation atrial_fibrillation heart_ failure ejection_fraction
P-941	-0.0196 -0.1718 -0.4456 -0.4700 -0.0731 -0.5024 -0.4365 -0.4453 -0.5396 -0.1559 -0.1014 -0.3159 -0.3546 -2.5400 -0.3305 -0.2359 -0.1484 -0.3277 -0.0121 -0.4438 -0.2558
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine nesiritide acute_heart_failure renal_dysfunction rose acute_heart_failure randomized
H-71	-0.5300105214118958	▁low - dos e _ ▁dop amine ▁low - dos e _ ▁nesi riti de ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁ro se ▁a cute _ heart _ ▁failure
D-71	-0.5300105214118958	low-dose_ dopamine low-dose_ nesiritide acute_heart_ failure renal_ dysfunction rose acute_heart_ failure
P-71	-0.2395 -0.0572 -1.5650 -0.5046 -0.3698 -0.0898 -0.0870 -0.0875 -0.0458 -0.7548 -0.4408 -0.1522 -0.0810 -0.2116 -0.2058 -0.2758 -0.0257 -0.1733 -2.3508 -0.1559 -1.6476 -0.0447 -0.2733 -0.2640 -0.0287 -1.0620 -0.6557 -0.2220 -0.0565 -0.1827 -3.0683 -0.2434 -2.3059 -0.3826 -0.2393
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary_exercise_test quality_of_life muscular peak_quadriceps_force
H-1915	-0.721472978591919	▁cardio pul mon ary _ ▁exercise ▁muscular _ streng th ▁pe ak _ ▁quadri cep s _ force
D-1915	-0.721472978591919	cardiopulmonary_ exercise muscular_strength peak_ quadriceps_force
P-1915	-0.2981 -0.9243 -2.8189 -0.1872 -0.4741 -1.4334 -2.4510 -0.4852 -0.7446 -0.3984 -0.0997 -0.0718 -0.1546 -2.5346 -0.1610 -0.2423 -0.2400 -0.0375 -0.4376 -0.2352
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report dapc dystrophin-associated_protein_complex sarcomeric_microstructure baseline
H-1253	-0.425476610660553	▁report ▁DAP c dys trop hin - as soci ated _ ▁protein _ ▁complex ▁sar come ric ▁base line
D-1253	-0.425476610660553	report DAPcdystrophin-associated_ protein_ complex sarcomeric baseline
P-1253	-0.0017 -0.0645 -0.4360 -0.2275 -0.2655 -1.0150 -0.2496 -0.0786 -0.0019 -0.0616 -0.1430 -1.3513 -0.1353 -1.6862 -0.2093 -0.3993 -1.7099 -0.2020 -0.1063 -0.3592 -0.2314
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf pyridostigmine basal_heart_rate sympathetic_control_of_heart_rate
H-1140	-0.597583532333374	▁h f ▁py rido stig mine ▁bas al _ ▁Heart _ rate ▁va gal ▁sympa the tic _ control ▁heart _ rate
D-1140	-0.597583532333374	hf pyridostigmine basal_ Heart_rate vagal sympathetic_control heart_rate
P-1140	-0.6861 -0.8958 -0.5805 -0.0174 -0.0014 -0.0691 -0.1135 -0.2601 -0.2516 -2.9688 -0.3206 -1.0433 -0.1049 -0.0169 -0.4430 -0.2946 -0.2108 -1.2717 -0.0079 -2.5356 -0.4463 -1.0866 -0.4460 -0.2697
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg congenital accessory ion_channelopathies cardiomyopathy
H-1909	-0.7047915458679199	▁ec g ▁accesso ry _ path ways ▁ion _ ▁channel o pathi es ▁cardio my o pathy
D-1909	-0.7047915458679199	ecg accessory_pathways ion_ channelopathies cardiomyopathy
P-1909	-0.9233 -0.6908 -3.9416 -0.0991 -0.3554 -0.1493 -0.3454 -0.4149 -0.2073 -2.1533 -0.9204 -0.0700 -0.6410 -0.4290 -1.0581 -0.1943 -0.0204 -0.5231 -0.2544
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras neprilysin_inhibition change stable chronic_heart_failure systolic_dysfunction
H-1971	-0.7064298391342163	▁Dual _ RAS ▁nepri ly sin _ ▁inhibi tion ▁chronic _ heart _ fail ure ▁sy sto lic _ ▁dys function
D-1971	-0.7064298391342163	Dual_RAS neprilysin_ inhibition chronic_heart_failure systolic_ dysfunction
P-1971	-2.6397 -0.3949 -0.7379 -0.0595 -0.0905 -0.0917 -0.3299 -1.6515 -0.0667 -2.1033 -0.3554 -1.7529 -0.3118 -1.1952 -0.8103 -0.1579 -0.2630 -0.6666 -0.3491 -0.8213 -0.0328 -1.1180 -0.2482
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf hhd salt_loading uninephrectomy ang_ii_infusion
H-275	-0.5503337979316711	▁mouse ▁h h ▁h d ▁salt _ load ing ▁un ine ph r ecto my ▁ANG _ ▁II _ in fusion
D-275	-0.5503337979316711	mouse hh hd salt_loading uninephrectomy ANG_ II_infusion
P-275	-0.0999 -0.2746 -1.9474 -0.1754 -1.7731 -0.4918 -0.2468 -0.1265 -0.0885 -0.1642 -0.3960 -2.3329 -0.2021 -0.0480 -1.9847 -0.1643 -0.2166 -0.3436 -0.6335 -0.2830 -0.0465 -0.3674 -0.2511
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf_with_preserved_ejection_fraction pef uptitration hospitalization
H-176	-0.6177083253860474	▁h f ▁e je ction _ fraction ▁p EF ▁up tit ration
D-176	-0.6177083253860474	hf ejection_fraction pEF uptitration
P-176	-2.9038 -1.1765 -0.8113 -0.3710 -0.1410 -0.2218 -0.0150 -0.4795 -1.0941 -0.3431 -0.1856 -0.0850 -0.5665 -0.2536
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs québec_health_insurance_board costs ontario_case_costing_initiative
H-1235	-0.6471613049507141	▁costs ▁Québec ▁health _ ▁Insurance _ board ▁costs ▁Ontario _ case _ ▁Cost ing _ initiative
D-1235	-0.6471613049507141	costs Québec health_ Insurance_board costs Ontario_case_ Costing_initiative
P-1235	-0.5586 -0.4747 -1.0804 -0.3009 -0.8195 -0.3985 -0.0433 -0.2597 -1.1955 -1.4915 -0.1759 -0.3592 -2.9930 -0.1961 -0.2527 -0.4355 -0.4103 -0.2036
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients idiopathic_dilated_cardiomyopathy tuscany evidence-based
H-1739	-0.35647791624069214	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁tu sca ny
D-1739	-0.35647791624069214	idiopathic_ dilated_ cardiomyopathy tuscany
P-1739	-1.2360 -0.0306 -0.0375 -0.2148 -0.3311 -0.6402 -0.0101 -0.1619 -0.0798 -1.2657 -0.2746 -0.0183 -0.1535 -0.0033 -0.0907 -1.2863 -0.2259
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating_agents patients anemia heart_disease
H-52	-0.5590338110923767	▁er y thro po ies is - stimul ating _ agent s ▁an emia ▁heart _ ▁Disease
D-52	-0.5590338110923767	erythropoiesis-stimulating_agents anemia heart_ Disease
P-52	-1.5270 -0.5146 -0.2168 -0.0866 -1.6664 -0.1331 -0.4915 -0.3171 -0.1814 -0.4111 -0.3417 -0.2282 -0.6379 -0.1083 -0.3268 -0.3331 -2.5004 -0.3335 -0.2662
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report mitral_valve_plasty degenerative_mitral_regurgitation
H-335	-0.4304955005645752	▁report ▁mit ral _ val ve _ plast y ▁mit ral _ re gur gi tation
D-335	-0.4304955005645752	report mitral_valve_plasty mitral_regurgitation
P-335	-0.0016 -0.2067 -0.1142 -0.2676 -1.2814 -0.1721 -0.3222 -0.1322 -0.9826 -2.3797 -0.3126 -0.2260 -0.0824 -0.0821 -0.4868 -0.0681 -0.4074 -0.2232
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial titin_hypophosphorylation heart_failure_with_preserved_ejection_fraction metabolic
H-759	-0.5400508642196655	▁my o card ial _ ▁titi n _ hy phos phor y lation ▁heart _ ▁failure ▁e je ction _ fraction ▁rat ▁metabol ic _ risk
D-759	-0.5400508642196655	myocardial_ titin_hyphosphorylation heart_ failure ejection_fraction rat metabolic_risk
P-759	-1.6816 -0.1649 -0.2404 -0.1609 -0.7952 -2.8496 -0.0831 -0.4315 -0.4758 -0.1563 -0.5320 -0.8498 -0.0722 -0.3113 -0.2459 -2.3094 -0.1314 -0.0855 -0.0573 -0.2853 -0.0159 -0.1104 -0.0367 -0.0285 -0.9630 -0.7576 -1.0365 -0.2535
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients hfpef kccq health prognostic
H-791	-0.8038355708122253	HF p EF ▁k cc q ▁health _ status
D-791	-0.8038355708122253	HFpEF kccq health_status
P-791	-1.1091 -0.0767 -0.3334 -2.1857 -0.0644 -1.5104 -1.1454 -1.4628 -0.1940 -0.5108 -0.2495
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf mi reduced_ejection_fraction ef
H-1100	-0.7859429717063904	▁h f ▁MI ▁e je ction _ fraction EF
D-1100	-0.7859429717063904	hf MI ejection_fractionEF
P-1100	-0.5596 -0.8556 -2.8798 -1.1835 -0.2347 -0.1372 -0.2633 -0.0298 -1.7931 -0.4598 -0.2490
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd diuretic peripheral_edema functional_class
H-899	-0.6412209272384644	▁p d ▁weight _ los s ▁di ure tic _ re duction ▁per i pher al _ ed ema ▁functional
D-899	-0.6412209272384644	pd weight_loss diuretic_reduction peripheral_edema functional
P-899	-0.5703 -0.5607 -1.0322 -0.2933 -0.9576 -0.1671 -0.1088 -0.0272 -0.0798 -0.7377 -1.2075 -2.7903 -0.3053 -0.2496 -0.0530 -0.2932 -0.2846 -2.2593 -0.0380 -1.3465 -0.5694 -0.1755
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients baseline serum_creatinine serum_potassium
H-441	-0.6351627707481384	▁base line _ se rum _ rati o ▁se rum _ po tas s ium
D-441	-0.6351627707481384	baseline_serum_ratio serum_potassium
P-441	-0.0383 -0.0685 -0.5306 -0.5024 -0.4312 -0.1525 -3.4688 -0.4731 -0.7078 -0.2413 -0.2521 -1.0051 -1.0870 -0.2794 -0.7520 -0.5848 -0.2229
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv_failure diagnostic left_ventricular_dysfunction
H-1093	-0.8551074266433716	▁ rv _ fail ure ▁intr in sic _ ▁left _ vent ri cular _ ▁dys function
D-1093	-0.8551074266433716	rv_failure intrinsic_ left_ventricular_ dysfunction
P-1093	-2.4261 -0.7402 -1.9528 -0.5306 -0.3522 -0.8354 -0.1561 -0.3595 -0.3533 -4.3365 -0.2680 -0.6257 -0.8408 -0.3307 -0.5488 -0.8232 -0.0467 -0.4598 -0.2605
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality inpatient admissions hospital emergency_department
H-1623	-0.5686693787574768	▁Mor t ality ▁in patient _ ad missions ▁emergency _ de part ment ▁ed
D-1623	-0.5686693787574768	Mortality inpatient_admissions emergency_department ed
P-1623	-2.3804 -0.3527 -0.1008 -0.1071 -0.1343 -0.2108 -0.3104 -0.0321 -0.3255 -0.1947 -2.5556 -0.2701 -0.0860 -1.3872 -0.3676 -0.2834
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic_heart_failure yield atrial cells
H-1334	-0.7834131121635437	▁Chro nic _ heart _ ▁failure ▁transform ing _ ▁growth _ factor
D-1334	-0.7834131121635437	Chronic_heart_ failure transforming_ growth_factor
P-1334	-0.1232 -0.0563 -0.1632 -2.1302 -0.2285 -2.0351 -0.0272 -0.0830 -0.5894 -2.0378 -0.3733 -0.0223 -2.8548 -0.2433
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia patients chronic_heart_failure hf prevalence outcomes
H-834	-0.7993081212043762	▁an emia ▁chronic _ heart _ fail ure HF
D-834	-0.7993081212043762	anemia chronic_heart_failureHF
P-834	-1.2146 -0.0605 -0.2906 -0.2037 -2.1689 -0.1478 -1.2061 -1.7607 -0.9811 -0.5066 -0.2518
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients heartmate_ii lvad centrimag rvad
H-298	-0.9317019581794739	▁Heart Mate _ ▁II _ l VAD ▁centri Mag _ r VAD
D-298	-0.9317019581794739	HeartMate_ II_lVAD centriMag_rVAD
P-298	-0.7062 -0.1419 -0.3053 -0.7536 -0.3378 -4.1689 -0.0613 -1.1382 -1.8329 -0.3723 -2.2553 -0.1331 -0.5900 -0.2470
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change readmission follow-up follow-up
H-724	-0.4635372757911682	▁read mission _ rate ▁follow - up ▁follow - up
D-724	-0.4635372757911682	readmission_rate follow-up follow-up
P-724	-0.7798 -0.1286 -0.5709 -0.8555 -0.0036 -0.3040 -0.0170 -0.2080 -0.3251 -0.0203 -2.1168 -0.2330
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic crt
H-428	-1.0505118370056152	▁multi para metric _ e cho car dio graphic _ sco ut ▁c t
D-428	-1.0505118370056152	multiparametric_echocardiographic_scout ct
P-428	-0.4759 -0.2732 -0.1044 -0.4810 -0.2359 -1.0551 -0.2829 -1.0677 -1.2059 -0.7988 -1.0268 -4.2478 -0.6038 -2.3342 -2.3829 -0.2318
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence economic lvad outcomes
H-317	-0.5326668620109558	▁economic ▁l VAD
D-317	-0.5326668620109558	economic lVAD
P-317	-0.1678 -1.8389 -0.0586 -0.4007 -0.1973
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection_fraction patients
H-909	-0.2668977975845337	▁e je ction _ fraction
D-909	-0.2668977975845337	ejection_fraction
P-909	-0.3692 -0.2946 -0.1118 -0.2636 -0.0143 -0.5808 -0.2341
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized af_ablation
H-953	-0.698929488658905	▁af _ ab lation
D-953	-0.698929488658905	af_ablation
P-953	-2.3660 -0.4864 -0.5832 -0.0482 -0.4446 -0.2653
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac insulin-resistance mitochondrial_energy_production systolic_heart_failure pressure-overload_hypertrophy
H-1777	-0.37925398349761963	▁Card iac ▁insulin - re si stance ▁mito cho ndri al _ ener gy _ product ion ▁sy sto lic _ heart _ fail ure ▁pressure - over load _ ▁hyper trop hy
D-1777	-0.37925398349761963	Cardiac insulin-resistance mitochondrial_energy_production systolic_heart_failure pressure-overload_ hypertrophy
P-1777	-1.3192 -0.2647 -0.7642 -0.1160 -0.0337 -0.2829 -0.0081 -0.0315 -1.0385 -0.3821 -0.1571 -0.2331 -0.2704 -0.0682 -0.2131 -0.2171 -0.0223 -0.1926 -0.2255 -0.4336 -0.2272 -2.0281 -0.3116 -0.8085 -0.3049 -0.0211 -0.3406 -0.0689 -0.0132 -0.6027 -1.5568 -0.0557 -0.0827 -0.3447 -0.2333
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel_inhibition hemodynamic exercise_tolerance heart_failure_with_preserved_ejection_fraction randomized
H-1170	-0.46546605229377747	▁if - chan nel _ ▁inhibi tion ▁hem o dynamic ▁exercise ▁heart _ fail ure ▁e je ction _ fraction
D-1170	-0.46546605229377747	if-channel_ inhibition hemodynamic exercise heart_failure ejection_fraction
P-1170	-2.6947 -0.1720 -0.0736 -0.2013 -0.4034 -1.0422 -0.1735 -0.2368 -0.3933 -0.0388 -0.1576 -0.6895 -0.3156 -1.1788 -0.9294 -0.2445 -0.1748 -0.1157 -0.2880 -0.0120 -0.4776 -0.2270
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients heart_failure heart_failure nurses follow-up cardiology mortality
H-1896	-0.9093748331069946	▁heart _ ▁failure ▁heart _ ▁failure ▁follow - up ▁card i ology ▁mortal ity
D-1896	-0.9093748331069946	heart_ failure heart_ failure follow-up cardiology mortality
P-1896	-1.8327 -0.4195 -3.6053 -1.3489 -0.2952 -3.2682 -0.4376 -0.2747 -0.0151 -0.8672 -0.2047 -0.0361 -1.1992 -0.0849 -0.4057 -0.2549
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline follow-up paf activity metabolic enzymes patients heart_failure healthy
H-1266	-0.5767748355865479	▁base line ▁PA f ▁activity ▁metabol ic _ ▁enzym es ▁heart _ fail ure
D-1266	-0.5767748355865479	baseline PAf activity metabolic_ enzymes heart_failure
P-1266	-0.2025 -0.1977 -2.4170 -0.6499 -0.3647 -0.0857 -0.0274 -0.2436 -0.7279 -0.3301 -0.4159 -0.4223 -1.4643 -0.8630 -0.5203 -0.2961
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 hearts beta-adrenergic_responses cardiomyocytes
H-1207	-0.5583580136299133	▁Pho s pho dies tera se -2 ▁heart s ▁beta - ad r energi c ▁cardio my o cy tes
D-1207	-0.5583580136299133	Phosphodiesterase-2 hearts beta-adrenergic cardiomyocytes
P-1207	-0.8232 -0.1814 -0.1695 -0.4057 -0.2124 -0.6051 -0.4315 -1.3980 -0.1742 -2.0715 -0.1001 -0.2104 -1.1923 -0.3602 -0.3628 -0.4620 -1.0040 -0.2417 -0.0356 -1.0004 -0.5457 -0.2962
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab adjuvant outcomes cardiotoxicity congestive_heart_failure chf
H-670	-0.5758019685745239	▁tras tuz um ab ▁cardio toxic ity ▁con ges tive _ heart _ fail ure ▁ch f
D-670	-0.5758019685745239	trastuzumab cardiotoxicity congestive_heart_failure chf
P-670	-0.1456 -0.0336 -0.0563 -0.0470 -0.1497 -0.5961 -0.4179 -0.0584 -0.0275 -0.6473 -0.2780 -2.2152 -0.1805 -0.7961 -0.5411 -3.1003 -1.0656 -0.3806 -0.2034
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin protein-c phosphorylation troponin_i phosphorylation hf
H-1427	-0.6864631772041321	▁my os in _ binding _ ▁protein - c _ phos phor y lation ▁ser 23 /24 ▁trop onin _ I _ phos phor y lation ▁h z
D-1427	-0.6864631772041321	myosin_binding_ protein-c_phosphorylation ser23/24 troponin_I_phosphorylation hz
P-1427	-1.1446 -0.0381 -1.0126 -0.3032 -0.0256 -0.4179 -0.6363 -0.1105 -0.5292 -0.3982 -0.3985 -2.1165 -1.5317 -0.1368 -0.5146 -0.2284 -0.0460 -0.3679 -0.4382 -0.2531 -2.0361 -0.4931 -0.3187 -2.5783 -1.7436 -0.1620 -0.6874 -1.3848 -0.3373 -0.2047
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative renal_dysfunction stroke myocardial_infarction heart_failure cabg
H-970	-0.5336864590644836	▁renal _ ▁dys function ▁stroke ▁my o card ial _ in far ction ▁heart _ fail ure ▁ca BG
D-970	-0.5336864590644836	renal_ dysfunction stroke myocardial_infarction heart_failure caBG
P-970	-0.1751 -0.4217 -0.6612 -0.0270 -0.2538 -1.0332 -0.4452 -0.9172 -0.4957 -0.3940 -0.6396 -0.0656 -0.3786 -0.4372 -0.2956 -1.0480 -1.0276 -0.3755 -1.5743 -0.2917 -0.2495
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine administration methylatropine propranolol cardiac sympathovagal_balance
H-1138	-0.4092041254043579	▁py rido stig mine ▁administration ▁met hy la tropi ne ▁propra no lol ▁cardiac _ ▁sympa t hova gal _ ▁balance
D-1138	-0.4092041254043579	pyridostigmine administration methylatropine propranolol cardiac_ sympathovagal_ balance
P-1138	-0.0128 -0.0502 -0.0024 -0.0509 -1.5503 -0.1007 -0.0301 -0.2718 -0.0201 -1.6927 -0.0040 -0.0065 -0.3489 -0.0659 -0.5255 -2.1792 -0.4607 -0.0352 -0.1678 -0.1924 -1.0837 -0.3571 -0.2028
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic cardiac_resynchronization_therapy crt
H-427	-0.596462607383728	▁e cho car dio graphic ▁cardiac _ re syn chron ization _ therapy ▁c t
D-427	-0.596462607383728	echocardiographic cardiac_resynchronization_therapy ct
P-427	-0.0996 -0.4593 -0.1728 -0.9729 -0.8078 -0.3341 -0.1963 -0.0848 -0.0872 -0.0163 -0.6307 -0.3144 -0.8412 -1.6207 -2.6794 -0.5349 -0.2875
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin_subproteomes heart_failure proteins chromatin_structure
H-91	-1.1259037256240845	▁chr omat in _ sub prote om es ▁heart _ fail ure ▁mechanism s ▁protein s ▁chr omat in
D-91	-1.1259037256240845	chromatin_subproteomes heart_failure mechanisms proteins chromatin
P-91	-2.6822 -0.3979 -1.8003 -0.4202 -0.5771 -0.5614 -1.2709 -0.7763 -0.2919 -0.2004 -1.0491 -1.7842 -0.7504 -0.1483 -3.9310 -0.2954 -1.3111 -0.4687 -1.9787 -2.7122 -0.2363
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp antibodies nonterminal_epitopes
H-1519	-0.5211028456687927	▁NT - pro b NP ▁anti bo dies ▁non gly cos yla ted ▁non termin al _ e pito pes
D-1519	-0.5211028456687927	NT-probNP antibodies nonglycosylated nonterminal_epitopes
P-1519	-0.8455 -0.1343 -0.0412 -0.9242 -0.4344 -0.1888 -0.0333 -0.3678 -0.0951 -1.6761 -0.3401 -0.5228 -0.0839 -0.4034 -3.0096 -0.0345 -0.3207 -0.2978 -0.1876 -0.7885 -0.4916 -0.2429
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac_mrna inflammatory cell_adhesion_genes retn
H-934	-0.36060696840286255	▁Hum - re t n _ mi ce ▁cardiac _ ▁m RNA ▁infla mma tory ▁cell _ a dhe sion ▁Ret n
D-934	-0.36060696840286255	Hum-retn_mice cardiac_ mRNA inflammatory cell_adhesion Retn
P-934	-0.4041 -0.1420 -0.7953 -0.7278 -0.0621 -0.2410 -0.4328 -0.2686 -0.0514 -0.6507 -0.8375 -0.0865 -0.7409 -0.1241 -0.0451 -0.1844 -0.1937 -0.2951 -0.0367 -0.0442 -0.3050 -0.0383 -1.6570 -0.2903
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard tnf_antagonist baseline covariates
H-606	-0.5414994359016418	▁n b DM ARD ▁t NF ▁base line _ co varia tes
D-606	-0.5414994359016418	nbDMARD tNF baseline_covariates
P-606	-0.1202 -0.0628 -1.1404 -0.3755 -0.1772 -1.5604 -0.0512 -0.1608 -1.4255 -0.2193 -1.1204 -0.3764 -0.5306 -0.2603
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage_heart_failure mechanical_cardiac_support
H-1386	-0.7084079384803772	▁end - s tage _ heart _ fail ure ▁mechanic al _ ▁cardiac
D-1386	-0.7084079384803772	end-stage_heart_failure mechanical_ cardiac
P-1386	-2.6790 -0.1477 -0.0716 -0.0263 -0.3264 -1.8585 -0.2591 -1.3046 -1.9989 -0.0357 -0.2814 -0.3295 -0.3244 -0.7455 -0.2375
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref exercise resting_hr bpm beta-blocker therapy
H-1946	-0.8639905452728271	▁h f ▁exercise ▁h w ▁beta - block er _ therapy
D-1946	-0.8639905452728271	hf exercise hw beta-blocker_therapy
P-1946	-0.6323 -2.1284 -1.0018 -0.5651 -2.9903 -1.8779 -0.1139 -0.3020 -0.3334 -0.4784 -0.1064 -0.4657 -0.2363
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods_study exercise patients heart_failure
H-615	-0.9971393942832947	▁exercise ▁heart _ fail ure
D-615	-0.9971393942832947	exercise heart_failure
P-615	-2.6509 -1.1605 -0.4470 -1.0330 -0.9696 -0.4726 -0.2464
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox_hazard_models esrd death composite_end_point esrd death esrd
H-391	-1.6525905132293701	▁co x _ ▁hazard _ model s ▁ES RD ▁eu RD ▁death ▁ES RD
D-391	-1.6525905132293701	cox_ hazard_models ESRD euRD death ESRD
P-391	-0.4984 -0.0463 -0.2688 -1.3252 -1.1449 -1.3187 -0.2041 -3.9880 -2.4683 -4.7517 -2.7446 -1.8394 -2.9452 -2.2263 -0.4477 -0.2238
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.5091983079910278	
D-557	-0.5091983079910278	
P-557	-0.7869 -0.2315
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery rheumatic surgery mva
H-359	-0.5798932909965515	▁rhe u matic ▁MS ▁m va
D-359	-0.5798932909965515	rheumatic MS mva
P-359	-2.0248 -0.0479 -0.0682 -1.3079 -0.4612 -0.1554 -0.3726 -0.2011
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior_vena_cava ivc
H-321	-0.4832428991794586	▁pig s ▁ve na _ ca va ▁i cc ▁snar ed ▁co
D-321	-0.4832428991794586	pigs vena_cava icc snared co
P-321	-1.7693 -0.1966 -0.6959 -0.4677 -0.3210 -0.1488 -0.2492 -0.8409 -0.7644 -0.4237 -0.0850 -0.2188 -0.3709 -0.2132
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin resistin
H-932	-0.582192063331604	▁do xor ubi cin ▁i p ▁in duction _ of _ se rum _ re duction s ▁Hum - re t n _ mi ce
D-932	-0.582192063331604	doxorubicin ip induction_of_serum_reductions Hum-retn_mice
P-932	-0.0079 -0.0472 -0.0089 -0.0548 -1.2028 -0.0852 -2.7891 -0.0089 -0.8255 -0.0443 -0.3519 -0.6759 -0.1392 -0.0926 -0.3785 -4.1242 -1.0736 -0.2985 -0.1820 -0.7999 -1.0825 -0.0360 -0.1376 -0.1806 -0.3359 -0.5207 -0.2349
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf proteins
H-1361	-0.7517750263214111	▁CHF ▁fat ▁car bo hydrat es ▁protein s ▁micro nutri ents
D-1361	-0.7517750263214111	CHF fat carbohydrates proteins micronutrients
P-1361	-2.2065 -2.1061 -0.7646 -0.0699 -0.2895 -0.4016 -0.9899 -0.3530 -1.8034 -0.1427 -0.0946 -0.3284 -0.2227
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs physicians hospital
H-1729	-0.5948323607444763	▁costs ▁physician s
D-1729	-0.5948323607444763	costs physicians
P-1729	-0.0755 -1.5596 -0.1465 -0.9835 -0.2090
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.6215776205062866	
D-1864	-0.6215776205062866	
P-1864	-1.0581 -0.1850
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university_of_connecticut_heart_failure_center heart_failure nurse_practitioner
H-728	-0.7174524068832397	▁university _ of _ connect i cut ▁Heart _ fail ure _ center ▁cardio logist ▁heart _ fail ure
D-728	-0.7174524068832397	university_of_connecticut Heart_failure_center cardiologist heart_failure
P-728	-1.1662 -0.3005 -0.0483 -0.4387 -2.7639 -0.4964 -1.0286 -1.4947 -0.2542 -0.4289 -0.1940 -0.3288 -1.9841 -0.0934 -0.3106 -0.5593 -0.3125 -1.0676 -0.6631 -0.8684 -0.2644
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone_receptor_antagonists randomized morbidity mortality symptomatic_systolic_heart_failure
H-438	-0.6915962100028992	▁al do ster one _ ▁receptor _ ▁anta gon ists ▁morbi d ity ▁mortal ity ▁sy sto lic _ heart _ fail ure
D-438	-0.6915962100028992	aldosterone_ receptor_ antagonists morbidity mortality systolic_heart_failure
P-438	-0.4247 -0.3786 -0.5432 -0.3416 -0.1268 -0.3414 -0.2747 -0.3799 -0.0480 -2.6451 -2.8554 -0.0467 -0.1883 -0.2523 -0.0630 -1.0162 -0.3044 -1.0645 -0.2718 -2.1001 -0.2115 -1.5097 -1.2544 -0.4262 -0.2215
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo_inhibition cardiomyocyte_bioenergetics lv_function chronic_acf
H-472	-0.6537355184555054	XO ▁cardio my o cy te _ ▁bio ener ge tics ▁LV ▁chronic _ a cf ▁rat
D-472	-0.6537355184555054	XO cardiomyocyte_ bioenergetics LV chronic_acf rat
P-472	-1.8010 -1.8332 -1.4219 -0.1965 -0.1870 -0.4693 -0.2269 -0.8167 -0.0725 -0.1748 -1.1642 -0.3051 -0.2952 -0.5429 -0.4727 -1.0782 -0.7035 -0.4279 -0.2313
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory
H-1324	-0.6589239835739136	▁electro car dio graphic ▁na tri ure tic _ pe pti de ▁infla mma tory _ ▁marker s
D-1324	-0.6589239835739136	electrocardiographic natriuretic_peptide inflammatory_ markers
P-1324	-3.4424 -0.8101 -0.7981 -0.9102 -1.4196 -0.1867 -0.0532 -0.2854 -0.5410 -0.7824 -0.3304 -0.6994 -0.2009 -0.4075 -0.1183 -0.4180 -0.8720 -0.1732 -0.4448 -0.2850
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf pyridostigmine stroke_volume ejection_fraction cardiac_output contractility left_ventricle
H-1144	-0.47625264525413513	▁h f ▁py rido stig mine ▁stroke ▁e je ction _ fraction ▁cardiac _ out put ▁contract ility ▁left _ vent ric le
D-1144	-0.47625264525413513	hf pyridostigmine stroke ejection_fraction cardiac_output contractility left_ventricle
P-1144	-1.0235 -0.9307 -1.1000 -0.0162 -0.0020 -0.0932 -0.5455 -0.7841 -0.0970 -0.0567 -0.3131 -0.0077 -0.0525 -0.2284 -0.2362 -0.0088 -0.0943 -0.5679 -0.2121 -0.2546 -0.3500 -2.5928 -1.7179 -0.3954 -0.2257
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol thromboembolic_events patients heart_failure β2-receptor_haplotype
H-1120	-0.5587937235832214	▁car vedi lol ▁ thro mbo e mbol ic _ event s ▁heart _ fail ure ▁β 2- recept or _ ha plo type
D-1120	-0.5587937235832214	carvedilol thromboembolic_events heart_failure β2-receptor_haplotype
P-1120	-0.3105 -0.0149 -0.4112 -0.5587 -0.0622 -0.5897 -0.8793 -0.1101 -0.2511 -1.3129 -2.7290 -0.1903 -0.4622 -0.3698 -1.0740 -1.2876 -0.1171 -0.1531 -0.2134 -0.1166 -0.3755 -1.0280 -0.4921 -0.0802 -1.0980 -0.2410
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr protein_kinase_r-like_er_kinase perk calreticulin chop hf
H-1084	-0.5219045877456665	▁u PR ▁protein _ ▁kina se ▁er _ ▁kina se per k ▁cal ret icul in ▁cho p ▁h z
D-1084	-0.5219045877456665	uPR protein_ kinase er_ kinaseperk calreticulin chop hz
P-1084	-0.0880 -1.4969 -0.8964 -0.3929 -0.1123 -0.2736 -0.1882 -0.2514 -0.0560 -0.1934 -0.3708 -0.8679 -0.0172 -0.6944 -0.0099 -0.6814 -0.3640 -1.2494 -0.4629 -1.8910 -0.7107 -0.2132
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients heart_failure hf cardiopulmonary_exercise_test anaerobic_threshold
H-1753	-0.714734673500061	▁heart _ fail ure HF ▁cardio pul mon ary _ ▁exercise ▁ana ero bic _ ▁thre s hold
D-1753	-0.714734673500061	heart_failureHF cardiopulmonary_ exercise anaerobic_ threshold
P-1753	-0.6527 -0.2509 -1.0232 -2.1454 -0.5277 -0.1948 -0.5498 -2.3657 -0.1349 -0.4576 -1.4902 -0.5920 -0.0919 -0.6898 -0.2981 -1.2328 -0.0920 -0.7932 -0.4918 -0.2201
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled_trials rcts observational_cohort_studies contemporaneous_control_group
H-152	-1.1524994373321533	▁r t s
D-152	-1.1524994373321533	rts
P-152	-2.5928 -2.2592 -0.2754 -0.3865 -0.2486
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic biomarkers molecular_dysfunction chronic_hf
H-1477	-0.4667447507381439	▁bio mark ers ▁molecular _ ▁dys function ▁chronic _ HF
D-1477	-0.4667447507381439	biomarkers molecular_ dysfunction chronic_HF
P-1477	-0.3942 -0.0865 -0.3355 -0.1735 -0.2932 -0.5862 -0.0394 -0.2963 -0.7650 -1.9760 -0.3897 -0.2655
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths stroke hospitalisations heart_failure follow-up
H-816	-0.7229422926902771	▁non - fa tal _ stro ke ▁heart _ fail ure ▁follow - up
D-816	-0.7229422926902771	non-fatal_stroke heart_failure follow-up
P-816	-2.5048 -0.0801 -0.0636 -0.2616 -0.1826 -0.3090 -3.6662 -0.9800 -0.2786 -0.7315 -1.4783 -0.0321 -0.2309 -0.0135 -0.5303 -0.2240
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective patients rule sensitivity specificity cad sensitivity cad
H-1192	-0.9221839308738708	▁rule ▁CAD ▁CAD
D-1192	-0.9221839308738708	rule CAD CAD
P-1192	-0.5847 -0.5938 -2.8247 -0.3601 -0.2476
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected clinical death medical hospitalization hf clinic outpatients
H-379	-0.9500495791435242	▁medical ▁h f
D-379	-0.9500495791435242	medical hf
P-379	-1.0258 -0.4915 -1.9119 -1.0439 -0.2771
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a upr downregulation cardiac genes hf
H-1089	-0.7278174757957458	▁s cn 5 a ▁u PR ▁down regul ation ▁cardiac _ ▁gene s ▁h z
D-1089	-0.7278174757957458	scn5a uPR downregulation cardiac_ genes hz
P-1089	-0.4869 -0.3203 -0.2354 -0.1514 -0.4156 -2.2049 -1.7829 -0.1725 -0.0418 -0.4754 -0.4964 -2.4994 -0.1875 -0.4928 -1.7537 -0.3834 -0.2726
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east rhythm_control_therapy diagnosis cardiovascular complications
H-1655	-0.539425790309906	▁e ast ▁ rhythm _ control _ therapy ▁af ▁cardiovascular ▁AF
D-1655	-0.539425790309906	east rhythm_control_therapy af cardiovascular AF
P-1655	-1.3016 -0.3761 -0.1837 -0.4620 -0.2707 -0.0202 -0.2822 -0.1566 -1.1680 -0.0689 -2.1119 -0.3094 -0.3013
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air cardiovascular health acute_myocardial_infarction
H-1806	-0.7240354418754578	▁Ambient _ air _ ▁pollution ▁cardiovascular _ ▁health ▁a cute _ My o card ial _ in far ction
D-1806	-0.7240354418754578	Ambient_air_ pollution cardiovascular_ health acute_Myocardial_infarction
P-1806	-0.0669 -0.3293 -0.2437 -0.5752 -1.8086 -0.0527 -0.8116 -0.3879 -2.4355 -0.0304 -0.2757 -4.6800 -0.8633 -0.5283 -0.3886 -0.2497 -0.2518 -0.0285 -0.5189 -0.4540 -0.2242
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic nhs chronic disease exercise acute hospital
H-613	-0.5999215245246887	▁economic ▁NH s ▁behaviour al - change ▁chronic _ ▁disease ▁exercise
D-613	-0.5999215245246887	economic NHs behavioural-change chronic_ disease exercise
P-613	-0.0492 -1.5221 -0.4367 -0.5419 -0.3425 -0.1742 -0.0045 -0.7308 -0.2821 -2.1426 -0.5285 -0.7394 -0.3045
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac_deaths atherosclerotic_cad
H-1907	-0.40469199419021606	▁cardiac _ ▁death s ▁a ther os cle ro tic ▁CAD
D-1907	-0.40469199419021606	cardiac_ deaths atherosclerotic CAD
P-1907	-0.4897 -0.5227 -0.5400 -0.1907 -0.1213 -0.0408 -0.1770 -0.2945 -0.0475 -0.0844 -2.1483 -0.3210 -0.2830
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients hf crt implantation complications
H-912	-0.609311580657959	▁di al ysis - dependent HF ▁c RT ▁implant ation
D-912	-0.609311580657959	dialysis-dependentHF cRT implantation
P-912	-0.2378 -0.1927 -0.0742 -0.1010 -0.0362 -1.3580 -1.8927 -1.9569 -0.4304 -0.1121 -0.7218 -0.1980
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak_oxygen_consumption pulse patients
H-1918	-0.7697692513465881	▁Peak _ ▁oxygen _ ▁consum p tion ▁oxygen _ ▁puls e
D-1918	-0.7697692513465881	Peak_ oxygen_ consumption oxygen_ pulse
P-1918	-0.0132 -0.1452 -2.4237 -0.1396 -2.9126 -0.1861 -0.2023 -0.6011 -0.0890 -2.3838 -0.3073 -0.3890 -0.2143
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv pathophysiologic rv_dysfunction
H-1094	-0.6027656197547913	▁ rv ▁pat ho phy si ologic _ me chan ism s ▁ RV
D-1094	-0.6027656197547913	rv pathophysiologic_mechanisms RV
P-1094	-1.9230 -0.9479 -1.0127 -0.3495 -0.0427 -1.1253 -0.3410 -0.5383 -0.1910 -0.0243 -0.0377 -0.1356 -0.9105 -0.5777 -1.1999 -0.2872
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf patients hct city_of_hope
H-1452	-0.7946406602859497	▁post - h ct _ ▁CHF ▁h ct ▁city _ of _ ▁Hope
D-1452	-0.7946406602859497	post-hct_ CHF hct city_of_ Hope
P-1452	-0.7295 -0.0375 -0.7786 -1.3543 -0.8422 -0.5218 -0.5888 -2.1445 -2.0674 -0.4674 -0.0686 -0.2955 -1.3817 -0.4501 -0.1916
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health followed_up hf hospitalization death contact
H-687	-0.7670193910598755	▁women _ s _ ▁health _ initiative ▁h f
D-687	-0.7670193910598755	women_s_ health_initiative hf
P-687	-1.3429 -0.6555 -0.6643 -0.4282 -1.8596 -0.2880 -0.5713 -0.6860 -1.1617 -0.5144 -0.2653
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients vad patients ecmo vad patients ecmo
H-1389	-1.8066812753677368	▁ VAD _ group ▁ec mo + VAD ▁ec mo _ group
D-1389	-1.8066812753677368	VAD_group ecmo+VAD ecmo_group
P-1389	-2.0405 -0.2467 -4.0079 -1.0354 -1.9121 -1.8504 -5.8670 -0.3385 -2.1545 -2.2135 -1.8076 -1.1529 -0.4079 -0.2587
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin inflammation hepatic prognosis patients lvad implantation
H-540	-0.4495944678783417	▁album in ▁nutrition ▁ inflammation ▁he pati c _ function ▁l VAD ▁implant ation
D-540	-0.4495944678783417	albumin nutrition inflammation hepatic_function lVAD implantation
P-540	-0.4315 -0.5487 -1.9709 -0.2470 -0.1564 -0.1137 -0.1994 -0.5328 -0.5196 -0.3223 -0.9569 -0.0604 -0.3711 -0.0816 -0.4248 -0.2564
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right_ventricular rv left_ventricular_assist_device lvad outcomes
H-294	-0.9584832191467285	▁right _ vent ri cular RV ▁left _ vent ri cular _ assist _ ▁device ▁l VAD
D-294	-0.9584832191467285	right_ventricularRV left_ventricular_assist_ device lVAD
P-294	-0.2512 -0.2839 -1.0705 -1.2766 -0.5863 -1.3751 -1.8549 -0.4191 -1.0536 -1.2537 -0.4935 -0.4507 -0.0143 -1.6279 -4.4562 -0.9427 -0.0558 -0.5127 -0.2325
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration neurohumoral_blockers hf hospitalization patients co-morbidity
H-184	-0.3866482377052307	▁neuro hu moral _ block ers HF ▁co - mor bid ity _ ▁burde n
D-184	-0.3866482377052307	neurohumoral_blockersHF co-morbidity_ burden
P-184	-0.2542 -0.1032 -0.0414 -0.4423 -0.6306 -0.2942 -1.0159 -0.4065 -0.2141 -0.5209 -0.5073 -0.2063 -0.4949 -0.7363 -0.0698 -0.3997 -0.2355
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 c_statistic net_reclassification_improvement integrated_discrimination_improvement
H-705	-0.5668979287147522	▁ST 2 ▁net _ re class ification ▁discrimina tion
D-705	-0.5668979287147522	ST2 net_reclassification discrimination
P-705	-0.7380 -0.0273 -2.0589 -0.3045 -0.1162 -0.2153 -0.0967 -1.4781 -0.3769 -0.5781 -0.2459
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ami complications heart_failure kidney_infection uti complications rehospitalization
H-1718	-0.7052319049835205	AMI ▁heart _ fail ure ▁ki dne y _ ▁infection UTI
D-1718	-0.7052319049835205	AMI heart_failure kidney_ infectionUTI
P-1718	-0.8993 -0.8839 -0.5973 -1.0986 -1.8489 -0.0973 -0.1944 -0.2949 -0.4038 -1.5874 -0.5938 -0.3951 -0.2734
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox_proportional_hazards_models health health hazard_ratios confidence_intervals
H-689	-0.830458402633667	▁co x ▁health _ be havi our s ▁health ▁hazard _ rati os
D-689	-0.830458402633667	cox health_behaviours health hazard_ratios
P-689	-0.3001 -0.0970 -2.6291 -1.0681 -1.0801 -0.0270 -0.1045 -0.1195 -0.1395 -3.3858 -0.3600 -0.1267 -0.1980 -2.5600 -0.2615
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone_therapy exercise_rehabilitation patients chronic_heart_failure testosterone double-blind randomized
H-1316	-0.8856784701347351	▁tests o ster one _ therapy ▁exercise ▁chronic _ heart _ fail ure ▁testosteron e
D-1316	-0.8856784701347351	testsosterone_therapy exercise chronic_heart_failure testosterone
P-1316	-2.6914 -0.9893 -0.3298 -0.2778 -0.6985 -0.2990 -0.4355 -3.1020 -0.2854 -1.6177 -0.2772 -1.3909 -1.3964 -0.2924 -0.1318 -0.5911 -0.2504
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence adjusted_odds_ratio hazard_ratio death hf ami admission discharge
H-1308	-0.5182027816772461	▁odds _ rati o haz ard _ rati o ▁h f AMI ▁ad mission ▁dis charge
D-1308	-0.5182027816772461	odds_ratiohazard_ratio hfAMI admission discharge
P-1308	-0.2398 -0.3421 -0.1091 -0.0674 -0.0299 -0.1659 -0.1252 -0.0550 -0.0613 -1.4906 -2.4299 -1.6267 -1.7145 -0.0330 -0.2506 -0.0264 -0.3102 -0.2500
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse pasp downward regression_line shift pasp tapse
H-496	-0.9887433052062988	▁pas p ▁down ward _ re gression _ line _ ▁shift ▁non sur viv ors ▁PAS p ▁t AP se
D-496	-0.9887433052062988	pasp downward_regression_line_ shift nonsurvivors PASp tAPse
P-496	-4.2993 -2.8448 -1.1994 -0.1474 -0.2584 -0.0741 -0.0189 -0.1573 -0.1522 -0.1634 -0.2889 -1.5362 -0.0106 -0.0115 -0.0691 -1.4600 -1.7584 -2.7026 -2.7583 -1.3585 -0.2702 -0.2130
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq kaplan-meier_curves death all-cause_hospitalization
H-784	-0.7867846488952637	▁k cc q ▁ka plan - me ier _ cur ves ▁death
D-784	-0.7867846488952637	kccq kaplan-meier_curves death
P-784	-2.1405 -0.1228 -1.0223 -1.2984 -0.0708 -0.0864 -1.3170 -1.0800 -0.1874 -0.3613 -1.1296 -1.3027 -0.5290 -0.3668
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome gls beat cox_proportional_hazards_analyses
H-814	-0.8084307312965393	▁g s ▁index _ ▁beat _ ▁method ▁cv ▁co x
D-814	-0.8084307312965393	gs index_ beat_ method cv cox
P-814	-2.7826 -1.7007 -0.0135 -0.1282 -0.4774 -0.9093 -1.9417 -0.4889 -0.3495 -0.1002 -0.6198 -0.1893
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis expenditure b_natriuretic_peptides nps
H-10	-0.3522360920906067	▁li poly sis ▁energy _ ex pendi ture ▁na tri ure tic _ pe pti des NP s cc
D-10	-0.3522360920906067	lipolysis energy_expenditure natriuretic_peptidesNPscc
P-10	-0.2520 -0.0254 -1.1921 -0.4697 -0.3195 -0.6654 -0.0307 -0.1502 -0.0345 -0.1411 -0.0454 -0.2823 -0.2736 -0.6918 -0.2880 -0.7195 -0.1722 -0.0349 -1.0688 -0.3209 -0.2189
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ischemic_heart_failure biomarkers heart_failure
H-1615	-0.8391271829605103	▁non - ische mic ▁ ische mic ▁heart _ fail ure ▁bio mark ers ▁heart _ fail ure
D-1615	-0.8391271829605103	non-ischemic ischemic heart_failure biomarkers heart_failure
P-1615	-2.6482 -0.0508 -0.1138 -0.7913 -1.4888 -0.0256 -0.5827 -2.9131 -0.1830 -1.5411 -1.5670 -0.0368 -0.0332 -0.4047 -0.8129 -0.2926 -0.8828 -1.8173 -0.3095 -0.2875
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted left_ventricle_end-diastolic_pressure
H-1340	-0.6829681396484375	▁CHF - develop ed _ in far cted _ animal s ▁left _ vent ric le ▁end - dia sto lic _ press ure ▁h g ▁scar
D-1340	-0.6829681396484375	CHF-developed_infarcted_animals left_ventricle end-diastolic_pressure hg scar
P-1340	-0.5519 -0.5726 -0.0157 -0.1330 -0.5604 -0.1760 -0.0168 -0.5933 -0.6955 -1.0749 -0.3159 -0.2786 -0.5063 -0.5783 -2.0948 -1.3258 -2.9183 -0.1843 -0.0515 -1.6463 -0.6389 -0.2320 -1.9493 -0.4920 -0.1565 -0.0247 -0.7848 -1.0228 -0.2149
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted_county minnesota mi diagnosed hf followed-up
H-1102	-0.9851754307746887	▁Ol m sted _ ▁County ▁Minnesota ▁MI ▁h f
D-1102	-0.9851754307746887	Olmsted_ County Minnesota MI hf
P-1102	-2.6597 -0.0589 -0.0709 -0.3763 -2.5437 -0.7786 -1.3083 -1.0307 -1.3559 -0.4741 -0.1798
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts mena cardiac_injury mena hf pathophysiology
H-1817	-0.7127435803413391	▁heart s ▁men a ▁cardiac _ indu stry ▁men a HF _ pat ho phy si ology
D-1817	-0.7127435803413391	hearts mena cardiac_industry menaHF_pathophysiology
P-1817	-0.7985 -0.1764 -1.8594 -0.2408 -0.1437 -0.4624 -0.9955 -0.6264 -2.3341 -0.2242 -2.1668 -0.7277 -0.2837 -0.4251 -0.0236 -1.3723 -0.0385 -0.4401 -0.2030
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ras doppler_ultrasonography tomographic_angiography magnetic_resonance_angiography
H-1599	-0.5582187175750732	RAS ▁do pp ler _ ▁ultra son ography ▁com put ed _ to mo graphic _ ang i ography ▁magnetic _ re on ance _ ang i ography
D-1599	-0.5582187175750732	RAS doppler_ ultrasonography computed_tomographic_angiography magnetic_reonance_angiography
P-1599	-0.2622 -0.6604 -0.1119 -1.9011 -0.2095 -0.6815 -0.1008 -0.6897 -1.6067 -0.0121 -0.0359 -0.6333 -0.0865 -0.2309 -0.6190 -0.2703 -0.3466 -0.9946 -0.4852 -0.1492 -0.2525 -0.7686 -2.2439 -0.2541 -0.2442 -0.2992 -1.3317 -0.4490 -0.5241 -0.2918
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence lvad transplantation patients budget
H-316	-0.5744713544845581	▁evidence ▁l VAD ▁transplant ation ▁budget
D-316	-0.5744713544845581	evidence lVAD transplantation budget
P-316	-1.3733 -0.7467 -0.1244 -1.3190 -0.0986 -0.2713 -0.4673 -0.1953
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients terminal diagnostic follow-up
H-1819	-0.8037891983985901	▁diagnose s ▁follow - up
D-1819	-0.8037891983985901	diagnoses follow-up
P-1819	-3.2169 -1.4844 -0.1061 -0.2454 -0.0150 -0.3233 -0.2355
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d therapy
H-107	-0.6019690632820129	▁c RT - d ▁IE ▁de fi br illa tor - on ly _ therapy
D-107	-0.6019690632820129	cRT-d IE defibrillator-only_therapy
P-107	-0.3817 -2.9275 -0.0911 -0.3665 -1.8467 -0.5312 -0.2245 -0.6338 -0.0608 -0.1495 -0.1854 -0.1804 -0.5383 -0.3183 -0.4056 -1.1640 -0.2282
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ic multicenter_automatic_defibrillator_implantation_trial-cardiac_resynchronization_therapy
H-103	-0.41031143069267273	▁i cc ▁multi center _ automat ic _ de ib rilla tor _ ▁implant ation ▁tri al - Card iac _ re syn chron ization _ ▁Therapy
D-103	-0.41031143069267273	icc multicenter_automatic_deibrillator_ implantation trial-Cardiac_resynchronization_ Therapy
P-103	-0.5429 -0.4518 -0.4249 -0.1400 -0.3176 -0.5778 -0.1086 -0.2732 -1.0563 -1.5380 -0.7405 -0.1908 -0.3606 -0.5043 -0.0673 -0.1253 -0.5754 -0.2793 -0.4296 -0.8499 -0.1887 -0.0920 -0.0688 -0.0112 -0.4466 -0.4645 -0.4474 -0.3754 -0.2504
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health_buddy_program admissions chronic_obstructive_pulmonary_disease mortality congestive_heart_failure
H-1627	-0.6695907711982727	▁health _ ▁Budd y _ programm e ▁chronic _ ob struct ive _ ▁pulmonar y _ ▁disease ▁mortal ity ▁con ges tive _ heart _ fail ure
D-1627	-0.6695907711982727	health_ Buddy_programme chronic_obstructive_ pulmonary_ disease mortality congestive_heart_failure
P-1627	-0.1185 -0.4205 -1.5078 -0.0730 -0.9798 -1.2358 -0.4179 -0.6802 -0.6108 -0.7277 -0.1237 -0.1266 -0.3813 -0.2086 -0.1756 -0.6877 -1.9729 -1.7503 -0.0898 -0.2468 -0.0520 -0.9021 -0.3256 -2.7558 -0.2187 -1.1793 -0.8110 -0.3933 -0.2451
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary_exercise_testing echocardiographic myocardial_function left_ventricular_filling exercise
H-1174	-0.7601122260093689	▁cardio pul mon ary _ ▁exercise ▁e cho car dio graphic ▁my o card ial _ function ▁left _ vent ri cular _ fill ing ▁exercise
D-1174	-0.7601122260093689	cardiopulmonary_ exercise echocardiographic myocardial_function left_ventricular_filling exercise
P-1174	-2.4315 -1.0420 -2.1756 -0.2117 -1.3429 -1.1975 -0.3284 -0.2503 -0.2320 -0.8452 -1.0807 -1.7940 -0.2633 -0.9851 -0.6356 -0.2780 -0.4841 -0.3595 -0.3296 -0.4799 -0.8338 -0.2636 -0.4398 -1.5265 -0.0995 -0.8415 -0.3251 -0.2061
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle_tracking_echocardiography ste bivp acute right_ventricular_pressure_overload rvpo
H-320	-0.6999427080154419	▁spec kle _ track ing _ e cho card i ography ▁ste ▁Bi VP ▁right _ vent ri cular _ press ure _ over load RV po
D-320	-0.6999427080154419	speckle_tracking_echocardiography ste BiVP right_ventricular_pressure_overloadRVpo
P-320	-0.1874 -3.1706 -0.3572 -0.1070 -0.0961 -1.1662 -0.2899 -0.1770 -0.2058 -0.5101 -0.3836 -1.6642 -1.6889 -1.0117 -0.3492 -0.4949 -0.7005 -1.0547 -0.3999 -0.4540 -1.4211 -0.4235 -0.6057 -0.2086 -0.0118 -0.7112 -1.7700 -0.4309 -0.2469
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia postoperative mortality patients left_ventricular_assist_device lvad implantation
H-530	-0.6258513331413269	▁hypo album in emia ▁post operativ e _ ▁mortal ity ▁left _ vent ri cular _ assist ance _ ▁device ▁l VAD ▁implant ation
D-530	-0.6258513331413269	hypoalbuminemia postoperative_ mortality left_ventricular_assistance_ device lVAD implantation
P-530	-0.0139 -0.2444 -0.2700 -0.3332 -0.1467 -0.2913 -0.3950 -0.4578 -0.1444 -0.0580 -0.5166 -0.4924 -1.3380 -2.0255 -0.4242 -0.2895 -0.0179 -1.4206 -0.5407 -5.0413 -0.9692 -0.0497 -0.0421 -0.1178 -0.3889 -0.2431
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular_endothelial_growth_factor vegf transition compensatory_hypertrophy cardiac_failure
H-450	-0.7503067851066589	▁inhibi tion ▁vas cular _ en dot heli al _ ▁Growth _ factor ve g f ▁transition ▁compensa tory _ ▁hyper trop hy ▁cardiac _ fail ure
D-450	-0.7503067851066589	inhibition vascular_endothelial_ Growth_factorvegf transition compensatory_ hypertrophy cardiac_failure
P-450	-2.8012 -0.0851 -1.4719 -0.7799 -0.3223 -0.5732 -2.7293 -0.3594 -0.0388 -0.2641 -2.0364 -0.3600 -0.0225 -2.1451 -1.5755 -0.2013 -0.0900 -0.0474 -0.0404 -0.3764 -2.7799 -0.0843 -0.2057 -0.0112 -0.2912 -0.5633 -1.0733 -0.2748 -0.1549
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left_ventricular_ejection_fraction mortality patients heart_failure heart_failure_survey israel
H-110	-0.7564387917518616	▁left _ vent ri cular _ e je ction _ fraction ▁mortal ity ▁heart _ fail ure ▁Heart _ fail ure _ ▁Survey ▁ir ra el
D-110	-0.7564387917518616	left_ventricular_ejection_fraction mortality heart_failure Heart_failure_ Survey irrael
P-110	-2.1940 -0.4794 -1.1011 -1.2448 -0.5631 -0.4569 -0.2796 -0.2884 -0.2505 -0.2207 -0.0213 -3.2431 -0.0556 -0.6649 -0.3269 -1.2598 -0.5744 -0.7055 -0.3322 -0.6808 -0.2450 -1.2681 -0.4205 -3.2282 -0.3209 -0.0258 -0.4537 -0.2752
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity diabetes_mellitus metabolic comorbidities heart_failure_with_preserved_ejection_fraction
H-760	-0.5586403608322144	▁obes ity ▁diabetes _ ▁mell itus ▁metabol ic _ risk _ factor s ▁heart _ fail ure ▁e je ction _ fraction
D-760	-0.5586403608322144	obesity diabetes_ mellitus metabolic_risk_factors heart_failure ejection_fraction
P-760	-2.8222 -0.4648 -0.1392 -0.2342 -0.4342 -0.1181 -0.2765 -0.0442 -1.5310 -0.3367 -0.8368 -0.1027 -0.2384 -1.6762 -0.2627 -1.2547 -0.8438 -0.3180 -0.1191 -0.1047 -0.3512 -0.0119 -0.5552 -0.3309
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil cardioprotection apoptotic_signaling_pathway dna_fragmentation mitochondrial
H-965	-0.4411931037902832	▁nic oran dil ▁cardio protec tion ▁apo pto tic _ signal ing _ path way ▁DNA _ ▁fragment ation ▁mito cho ndri al _ ▁ultra struct ural
D-965	-0.4411931037902832	nicorandil cardioprotection apoptotic_signaling_pathway DNA_ fragmentation mitochondrial_ ultrastructural
P-965	-0.0714 -0.0953 -0.5615 -0.2903 -0.0264 -0.0434 -0.1362 -0.1216 -0.2400 -0.1351 -0.2846 -0.4035 -0.1447 -0.2918 -0.2577 -0.1927 -0.4081 -1.0337 -0.0594 -0.0711 -1.5769 -0.7022 -0.1862 -0.4418 -2.5211 -0.4142 -0.0073 -1.8227 -0.2539
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous coronary_revascularization hemodynamically stable patient intensive_care_unit icu
H-1293	-0.41489851474761963	▁corona ry _ re vas cular ization ▁hem o dynamic ally
D-1293	-0.41489851474761963	coronary_revascularization hemodynamically
P-1293	-0.8109 -0.6301 -0.3720 -0.0852 -0.2737 -0.2927 -0.2844 -0.3310 -0.2268 -0.0170 -0.1438 -1.7535 -0.1728
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary_endpoints therapy atrial_fibrillation atrial_tachyarrhythmias atp shock_therapy
H-860	-0.6137803792953491	▁at rial _ fi bril lation ▁at rial _ ta chy ar rhythm ias ▁ATP ▁shock _ therapy
D-860	-0.6137803792953491	atrial_fibrillation atrial_tachyarrhythmias ATP shock_therapy
P-860	-1.0669 -0.9437 -0.3517 -0.5437 -0.0798 -0.0972 -0.0864 -1.4539 -0.4007 -1.1669 -1.1226 -0.0930 -0.2817 -3.0397 -0.2509 -0.0334 -0.4067 -0.1888 -0.4301 -0.2378
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic renal_underperfusion renin-_angiotensin-aldosterone_pathway
H-1596	-0.5705759525299072	▁pat ho phy si ologic _ me chan ism ▁renal _ under per fusion ▁re nin - ▁ang io ten sin - al do ster one _ path way
D-1596	-0.5705759525299072	pathophysiologic_mechanism renal_underperfusion renin- angiotensin-aldosterone_pathway
P-1596	-0.8698 -0.3629 -0.0376 -0.8528 -0.3889 -0.2241 -0.4876 -0.1017 -0.0075 -0.3133 -0.2285 -0.3827 -0.0943 -0.1071 -0.0307 -0.8422 -0.1854 -3.9653 -3.3190 -0.3211 -1.3734 -0.7977 -0.0822 -0.4342 -0.1744 -0.2167 -0.5310 -0.1321 -0.0934 -0.4351 -0.2952
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics pressure-overload-induced_heart_failure mitochondrial-targeted_peptides
H-869	-0.6217917799949646	▁global _ ▁prote o mics ▁path way ▁pressure - over load - indu ced _ heart _ fail ure ▁mito cho ndri al - tar get ed _ pe pti des
D-869	-0.6217917799949646	global_ proteomics pathway pressure-overload-induced_heart_failure mitochondrial-targeted_peptides
P-869	-1.0751 -0.3842 -1.7975 -0.8974 -0.0351 -1.5804 -0.1088 -1.5312 -0.1833 -0.0780 -0.0259 -0.5133 -0.0006 -0.0325 -0.5699 -1.7929 -0.2025 -1.0461 -1.1156 -0.1122 -1.5524 -1.4890 -0.3458 -0.4079 -0.0436 -0.1031 -0.0529 -0.3526 -1.0205 -0.2225 -1.0676 -0.5105 -0.2683
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration hr_reduction bpm p_value
H-1942	-0.5345025658607483	▁dose _ up tit ration ▁HR _ re duction ▁bp m
D-1942	-0.5345025658607483	dose_uptitration HR_reduction bpm
P-1942	-0.3904 -0.3365 -0.5989 -0.6848 -0.2312 -1.8807 -0.8016 -0.0763 -0.0269 -0.9265 -0.3616 -0.3844 -0.2487
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv_fractional_shortening lung incidence
H-278	-0.6516647338867188	ANS _ mi ce ▁LV ▁lung _ weight
D-278	-0.6516647338867188	ANS_mice LV lung_weight
P-278	-2.6940 -0.2629 -0.3799 -0.2174 -0.2172 -1.2222 -0.3576 -0.4429 -0.4819 -0.2406
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional_enrichment_analysis regulation cell_death degs
H-1614	-0.4445608854293823	▁functional _ en rich ment _ analyse ▁programme d _ cell _ ▁death ▁de g s
D-1614	-0.4445608854293823	functional_enrichment_analyse programmed_cell_ death degs
P-1614	-0.6580 -0.3879 -0.2965 -0.0075 -0.0509 -0.9922 -0.4537 -0.7819 -0.0842 -0.1083 -0.3585 -0.0767 -0.7311 -0.2656 -1.8959 -0.2686 -0.3364 -0.2481
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction rad_variant q66p congestive_heart_failure
H-1673	-0.8633676171302795	▁Rad _ variant ▁q 66 p ▁con ges tive _ heart _ fail ure ▁humans
D-1673	-0.8633676171302795	Rad_variant q66p congestive_heart_failure humans
P-1673	-0.9994 -0.5964 -0.7329 -3.7154 -0.3405 -0.3271 -0.1100 -0.0408 -0.5194 -0.2603 -2.5157 -0.1991 -1.3229 -0.8979 -1.5231 -0.3693 -0.2069
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk scn5a kv4.3 mrna mrna_splice
H-1087	-0.6143251657485962	▁per k _ ▁inhibi tion ▁full - leng th ▁s cn 5 a ▁kv 4.3 ▁m RNA ▁na + _ ▁channel ▁m RNA _ ▁sp lice
D-1087	-0.6143251657485962	perk_ inhibition full-length scn5a kv4.3 mRNA na+_ channel mRNA_ splice
P-1087	-1.4864 -1.3926 -0.3832 -1.4342 -0.0886 -0.0145 -0.0634 -0.0142 -0.0248 -0.5636 -0.5976 -0.7290 -0.1477 -0.0352 -0.0741 -0.0679 -0.1202 -0.2216 -4.4162 -0.2712 -1.5231 -0.3305 -0.3117 -0.2842 -1.8245 -0.0500 -0.5224 -0.2087
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic_heart_failure spironolactone hospitalization death
H-446	-0.4732465445995331	▁sy sto lic _ heart _ fail ure ▁spi rono lac tone
D-446	-0.4732465445995331	systolic_heart_failure spironolactone
P-446	-0.3856 -0.1713 -0.4628 -0.1624 -1.9396 -0.1907 -0.7685 -0.9816 -0.1485 -0.0138 -0.2281 -0.1239 -0.7964 -0.2523
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg atherosclerotic_cad cardiac_death
H-1910	-0.4778929650783539	▁ec g ▁a ther os cle ro tic _ ▁CAD ▁sud den _ ▁cardiac _ ▁death
D-1910	-0.4778929650783539	ecg atherosclerotic_ CAD sudden_ cardiac_ death
P-1910	-1.5323 -0.6266 -0.2528 -0.1091 -0.1490 -0.2562 -0.0663 -0.0730 -0.9257 -1.1571 -1.2278 -0.0338 -0.1782 -0.1304 -0.3051 -0.7667 -0.5360 -0.2762
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr_variability risk_stratification
H-1587	-1.1317355632781982	▁HR ▁dynamic s ▁HR _ ▁variabil ity
D-1587	-1.1317355632781982	HR dynamics HR_ variability
P-1587	-1.3458 -0.7285 -0.2460 -2.4473 -1.9487 -1.4361 -0.2912 -1.4173 -0.3246
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef bnp hf patients prognostic significance bnp ef
H-188	-1.4793975353240967	▁b NP ▁h f ▁b NP
D-188	-1.4793975353240967	bNP hf bNP
P-188	-2.1825 -2.6783 -0.6271 -1.6954 -1.0753 -1.7893 -1.5593 -0.2280
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ami hazard_ratio mortality
H-1313	-0.7863897085189819	▁h f ▁index AMI ▁hazard _ rati o ▁mortal ity
D-1313	-0.7863897085189819	hf indexAMI hazard_ratio mortality
P-1313	-1.0898 -0.7490 -1.2421 -2.6177 -1.8662 -0.3791 -0.0574 -0.0395 -0.1532 -0.6801 -0.2860 -0.2764
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets transcriptional_pause_release pathological
H-1052	-0.5823672413825989	BET s ▁tran scription al _ pause _ release ▁tran scription ▁path ological _ stress
D-1052	-0.5823672413825989	BETs transcriptional_pause_release transcription pathological_stress
P-1052	-0.1764 -0.4181 -0.7434 -0.0906 -0.6191 -0.4935 -1.6878 -0.2191 -0.8953 -1.2486 -0.0501 -0.1249 -0.4470 -0.6585 -1.3339 -0.3941 -0.2998
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis pathogenesis heart_failure
H-173	-0.7985167503356934	▁apo pto sis ▁path ogen es is ▁heart _ fail ure
D-173	-0.7985167503356934	apoptosis pathogenesis heart_failure
P-173	-0.6797 -0.1427 -2.3152 -0.3606 -0.2817 -0.2907 -0.2791 -2.2442 -0.2270 -0.7066 -2.1522 -0.4541 -0.2470
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic neurohormonal symptoms fluid_overload
H-1201	-0.3295453190803528	▁di ure tic ▁neuro hormon al _ activa tion ▁fluid _ over load
D-1201	-0.3295453190803528	diuretic neurohormonal_activation fluid_overload
P-1201	-0.2572 -0.1380 -0.2129 -1.7320 -0.2538 -0.0942 -0.3750 -0.3331 -0.0880 -0.3893 -0.1595 -0.3676 -0.0152 -0.3199 -0.2076
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr mrna_splice cardiac hf
H-1088	-1.1222646236419678	▁u PR ▁na + _ ▁channel _ m RNA _ ▁sp lice ▁cardiac ▁na + ▁h z
D-1088	-1.1222646236419678	uPR na+_ channel_mRNA_ splice cardiac na+ hz
P-1088	-0.1280 -3.2573 -0.1564 -4.5786 -0.5120 -1.5707 -1.2823 -0.7512 -0.0638 -0.1648 -0.9851 -0.0530 -0.0856 -0.4508 -4.0068 -1.3799 -1.3043 -0.3755 -0.2169
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients preserved_lvef lvef
H-114	-0.4793456196784973	▁LV EF ▁LV EF
D-114	-0.4793456196784973	LVEF LVEF
P-114	-0.2116 -1.0662 -0.2742 -0.6368 -0.4409 -0.2463
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated mena_expression correlates hf mena cardiac pathophysiology
H-1812	-0.8085297346115112	▁men a _ expression ▁h f ▁men a ▁cardiac _ pat ho phy si ology
D-1812	-0.8085297346115112	mena_expression hf mena cardiac_pathophysiology
P-1812	-3.4307 -0.4058 -0.4202 -0.1114 -0.4047 -1.5269 -3.3736 -0.1902 -0.1121 -0.2908 -0.5530 -0.5511 -0.0183 -1.6155 -0.0354 -0.4624 -0.2430
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc nps clinical
H-1024	-1.173331618309021	NP ▁PO c NP s ▁clinic al _ care
D-1024	-1.173331618309021	NP POcNPs clinical_care
P-1024	-0.9126 -4.2166 -1.8792 -0.9234 -0.1463 -1.8565 -0.1521 -0.5756 -0.3276 -1.6664 -0.2504
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence intestinal patients chf
H-1358	-0.5870588421821594	▁REC ENT _ financi ers ▁intestinal _ morph ology ▁per me ability ▁ab sor p tion _ function ▁CHF
D-1358	-0.5870588421821594	RECENT_financiers intestinal_morphology permeability absorption_function CHF
P-1358	-1.3389 -1.1610 -0.1657 -1.9300 -0.4492 -2.0768 -0.4855 -0.0596 -0.1671 -0.5292 -0.0993 -0.0496 -0.0367 -0.1350 -1.6604 -0.3293 -0.2869 -0.1917 -0.5629 -0.3636 -0.2498
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized follow-up
H-1751	-0.2247254103422165	▁benefits ▁follow - up
D-1751	-0.2247254103422165	benefits follow-up
P-1751	-0.1621 -0.1147 -0.2674 -0.0386 -0.5294 -0.2362
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis heart_failure myocardial_tissue left_ventricular trichrome_blue_histologic_analysis
H-1060	-0.6963809132575989	▁fibro sis ▁heart _ fail ure ▁my o card ial _ ▁tissu e ▁left _ vent ri cular _ ▁tissu e ▁tri ch rom e _ blue _ ▁his t ologic
D-1060	-0.6963809132575989	fibrosis heart_failure myocardial_ tissue left_ventricular_ tissue trichrome_blue_ histologic
P-1060	-0.0396 -1.7269 -0.9213 -0.2844 -1.3765 -1.1336 -1.1571 -0.5206 -0.5884 -0.5285 -0.3508 -2.6095 -0.3540 -0.2902 -0.3156 -1.1759 -0.9873 -0.2276 -0.2220 -2.1771 -0.2796 -0.0350 -0.0194 -0.0125 -0.1138 -0.1852 -1.3921 -0.4913 -1.8999 -0.3288 -0.1951 -0.7663 -0.2746
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid_annular_plane_systolic_excursion pulmonary_arterial_systolic_pressure heart_failure right_ventricular_contractile_function prognosis
H-491	-0.6885972023010254	▁tri cus pid _ ▁ann ular _ plan e _ sy sto lic _ excursion ▁pulmonar y _ ▁arterial _ sy sto lic _ tension ▁heart _ fail ure ▁index ▁right _ vent ri cular _ contract ile
D-491	-0.6885972023010254	tricuspid_ annular_plane_systolic_excursion pulmonary_ arterial_systolic_tension heart_failure index right_ventricular_contractile
P-491	-0.1616 -0.3745 -0.2730 -0.4285 -2.3071 -0.0101 -0.1990 -0.5560 -0.0837 -0.5719 -2.2010 -1.3990 -0.5286 -1.6160 -0.0312 -0.0035 -0.1899 -1.4187 -0.7998 -0.5585 -1.0430 -0.6023 -0.5505 -0.2435 -1.6989 -0.1713 -0.5233 -1.1351 -0.6369 -1.1420 -0.8585 -0.4383 -0.7372 -1.2866 -0.2400 -0.4268 -0.2658 -0.6133 -1.0068 -0.2124
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes patients atrial_fibrillation early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial
H-1642	-0.6219127178192139	▁at rial _ fi bril lation ▁at rial _ fi bril lation ▁Stro ke
D-1642	-0.6219127178192139	atrial_fibrillation atrial_fibrillation Stroke
P-1642	-1.2350 -0.5007 -0.4346 -0.9843 -0.3772 -0.3021 -1.1338 -0.3289 -0.3993 -0.9291 -0.2967 -0.3361 -0.7893 -0.2037 -1.4670 -0.2330
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas_city_cardiomyopathy_questionnaire kccq hf_with_reduced_ef patients hfpef
H-781	-0.571241021156311	▁Kansas _ city _ ▁Card i om yo pathy _ ▁Question naire ▁kv cc q ▁h f ▁h f p EF
D-781	-0.571241021156311	Kansas_city_ Cardiomyopathy_ Questionnaire kvccq hf hfpEF
P-781	-0.0114 -0.4851 -0.3025 -1.8834 -1.2292 -0.0655 -0.0714 -0.7171 -0.0713 -0.7416 -0.2063 -0.0267 -0.6756 -0.5882 -0.8144 -0.5800 -0.4265 -1.0040 -1.3489 -0.6726 -0.6640 -0.3331 -0.2198
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab chf nontrastuzumab_users hazard_ratio
H-679	-0.18250378966331482	▁Tras tuz um ab ▁CHF ▁non tras tuz um ab haz ard _ rati o
D-679	-0.18250378966331482	Trastuzumab CHF nontrastuzumabhazard_ratio
P-679	-0.4996 -0.0620 -0.1236 -0.0400 -0.1325 -0.0884 -0.2045 -0.0310 -0.4036 -0.1611 -0.0157 -0.0496 -0.2935 -0.0139 -0.0335 -0.7280 -0.2222
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood_pressure arm_cuff stroke_volume ejection_fraction end-diastolic_volume echocardiography
H-521	-0.605079174041748	▁Blood _ tension ▁arm _ cu ff ▁stroke _ ▁volume ▁e je ction _ fraction ▁end - dia sto lic ▁e cho card i ography
D-521	-0.605079174041748	Blood_tension arm_cuff stroke_ volume ejection_fraction end-diastolic echocardiography
P-521	-0.1959 -0.3090 -2.0903 -0.2459 -0.3700 -0.8290 -1.0306 -0.1824 -0.8463 -1.7273 -1.3137 -0.1175 -0.0413 -0.3069 -0.0152 -0.6545 -0.2010 -0.0512 -1.8886 -0.7168 -0.9003 -0.3725 -0.3068 -0.6381 -0.4213 -0.3704 -0.1943
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients atrial_fibrillation heart_failure hf stroke anticoagulation patients
H-1353	-0.6504708528518677	▁at rial _ fi bril lation AF ▁heart _ fail ure HF ▁stroke ▁antico ag ulation
D-1353	-0.6504708528518677	atrial_fibrillationAF heart_failureHF stroke anticoagulation
P-1353	-0.3525 -0.2081 -0.3715 -0.5369 -0.0751 -0.1634 -1.3996 -0.2783 -0.3657 -1.1603 -2.3422 -1.5794 -0.7046 -0.9422 -0.2819 -0.0629 -0.6695 -0.2144
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt_loading uninephrectomy ang_ii_infusion cardiac_function hf
H-282	-0.5274507403373718	▁salt _ load ing ▁un ine ph r ecto my ▁ANG _ ▁II _ in fusion ▁cardiac _ function ▁h z
D-282	-0.5274507403373718	salt_loading uninephrectomy ANG_ II_infusion cardiac_function hz
P-282	-0.1533 -0.3668 -0.1136 -0.0844 -0.0840 -0.1430 -0.8483 -0.0945 -0.0200 -2.0368 -0.6789 -0.3134 -0.3208 -0.3549 -0.2325 -0.0550 -1.7344 -0.2977 -0.5240 -2.1802 -1.0034 -0.2807 -0.2108
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck_stent myocardial_infarction antiplatelet_medication
H-508	-0.6537430286407471	▁oc clusi on _ time ▁bottle ne ck _ ▁sten t ▁my o card ial _ in far ction ▁anti plate let ▁medication
D-508	-0.6537430286407471	occlusion_time bottleneck_ stent myocardial_infarction antiplatelet medication
P-508	-0.7746 -0.0450 -0.0607 -0.5892 -2.8858 -0.0645 -0.2407 -0.0410 -0.3322 -2.4531 -0.1059 -1.1723 -0.5118 -0.9550 -0.5215 -0.3256 -0.3001 -0.0405 -0.1677 -0.0670 -0.2546 -1.5919 -2.1761 -0.4352 -0.2316
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential_effect lvef mortality hospitalization acute decompensated_hf
H-112	-0.6685230731964111	▁LV EF ▁mortal ity ▁hospital ization ▁a cute _ de com pensa ted _ HF
D-112	-0.6685230731964111	LVEF mortality hospitalization acute_decompensated_HF
P-112	-0.3542 -1.5714 -0.8637 -0.1638 -1.5115 -0.2048 -2.4613 -0.1178 -0.2907 -0.1437 -0.0599 -0.0327 -0.1803 -0.5681 -2.1749 -0.3271 -0.3392
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination echocardiographic lv_reverse_remodeling sensitivity specificity
H-433	-0.5358798503875732	▁e cho car dio graphic ▁LV ▁rever se _ ▁remodel ing
D-433	-0.5358798503875732	echocardiographic LV reverse_ remodeling
P-433	-0.1316 -0.4716 -0.1476 -0.6928 -1.2048 -0.6517 -0.0650 -0.1027 -0.1630 -1.9297 -0.0946 -1.0027 -0.3086
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan_failure circulatory hemodynamic portal_hypertension cardiac_output
H-234	-0.4885084629058838	▁Font an _ fail ure ▁circula tory _ de rang ement ▁hem o dynamic ▁portal _ ▁hyper tension ▁cardiac _ out put
D-234	-0.4885084629058838	Fontan_failure circulatory_derangement hemodynamic portal_ hypertension cardiac_output
P-234	-0.3295 -2.6156 -0.3205 -0.4236 -2.0700 -0.0849 -0.0729 -1.1815 -0.2218 -0.0446 -0.0919 -0.8903 -0.3409 -0.0316 -0.0912 -0.3183 -1.4164 -0.0032 -0.0927 -0.2490 -0.1741 -0.0341 -0.3888 -0.2364
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients biventricular_support heartmate_ii lvad centrimag right_ventricular_assist_device rvad
H-296	-0.7949799299240112	▁bi ven tri cular ▁hybrid _ system ▁Heart Mate _ ▁II _ l VAD ▁centri Mag ▁right _ vent ri cular _ assist _ ▁device ▁r VAD
D-296	-0.7949799299240112	biventricular hybrid_system HeartMate_ II_lVAD centriMag right_ventricular_assist_ device rVAD
P-296	-0.5531 -0.3089 -0.4942 -0.6729 -0.5866 -0.9890 -0.0875 -1.1776 -0.1150 -0.2974 -0.5267 -0.2749 -2.9708 -0.0807 -0.6970 -1.3242 -0.2908 -0.2093 -0.3272 -1.1327 -0.4330 -0.2352 -0.0152 -1.0421 -3.6564 -3.8337 -0.2041 -0.2945 -0.2235
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action correlation baseline hgb baseline hrqol kccq
H-842	-0.7628989219665527	HF - ac tion _ co hor t ▁base line ▁h gb ▁base line _ ▁HR Qo l ▁k cc q
D-842	-0.7628989219665527	HF-action_cohort baseline hgb baseline_ HRQol kccq
P-842	-2.6468 -0.0587 -1.0926 -1.4047 -1.9999 -0.0965 -0.1672 -0.4849 -0.0259 -0.1174 -0.4665 -0.3211 -0.0153 -0.1332 -1.7816 -0.9752 -0.0408 -2.3031 -1.3902 -0.1372 -1.2693 -0.4145 -0.2042
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional_ms patients valve_plasty degenerative_mr dilated disease
H-340	-0.4933411777019501	▁functional ▁MS ▁val ve _ plast y ▁ann ular _ size _ re duction ▁de genera tive _ ▁MR ▁LV ▁disease
D-340	-0.4933411777019501	functional MS valve_plasty annular_size_reduction degenerative_ MR LV disease
P-340	-0.4625 -1.3368 -1.0823 -0.0411 -0.2874 -0.0546 -0.4419 -0.0693 -0.0086 -0.1964 -2.0677 -0.2099 -0.0529 -0.0074 -0.9681 -0.0209 -0.0886 -0.6148 -2.4105 -0.1922 -0.2450 -0.2980 -0.1896
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined_training peak_work_rate peak_quadriceps_force
H-1917	-0.3753803074359894	▁pe ak _ work _ rate ▁pe ak _ ▁quadri cep s _ force
D-1917	-0.3753803074359894	peak_work_rate peak_ quadriceps_force
P-1917	-0.6136 -0.0869 -0.1730 -0.6789 -0.3214 -0.8221 -0.0418 -0.0735 -0.1557 -1.6678 -0.1094 -0.2060 -0.2134 -0.0967 -0.4871 -0.2588
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological remodelling heart cardiac_hypertrophy hf death fibrosis inflammation
H-1035	-0.7340425848960876	▁path ological _ ▁remodel ling ▁heart ▁cardiac _ ▁hyper trop hy ▁h f ▁death ▁fibro sis ▁ inflammation
D-1035	-0.7340425848960876	pathological_ remodelling heart cardiac_ hypertrophy hf death fibrosis inflammation
P-1035	-1.8548 -0.5742 -1.1445 -0.7690 -0.2803 -1.2180 -0.0837 -0.1807 -2.0240 -0.1191 -0.1426 -0.6245 -1.5700 -2.0977 -0.0459 -0.8625 -0.2864 -0.0940 -0.3893 -0.3197
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based prognosis idiopathic_dilated_cardiomyopathy
H-1750	-0.5181661248207092	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1750	-0.5181661248207092	idiopathic_ dilated_ cardiomyopathy
P-1750	-1.9541 -0.3726 -0.0511 -0.4205 -0.8500 -0.8712 -0.0124 -0.1747 -0.2596 -1.3219 -0.3172 -0.0254 -0.4141 -0.2093
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report functional_ms patient valve_plasty degenerative_mr dilated disease
H-375	-0.5414445996284485	▁case _ report ▁MS ▁val ve _ plast y ▁de genera tive _ ▁MR ▁LV ▁disease
D-375	-0.5414445996284485	case_report MS valve_plasty degenerative_ MR LV disease
P-375	-0.8427 -0.4154 -0.1822 -1.6287 -0.7683 -0.0295 -0.2688 -0.0870 -0.5833 -0.6397 -0.0267 -0.0709 -0.6563 -2.6313 -0.1882 -0.2551 -0.2842 -0.1878
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty prognostic heart_failure hf biological_phenotype
H-1001	-1.1546036005020142	▁fra il ty ▁heart _ fail ure ▁h f
D-1001	-1.1546036005020142	frailty heart_failure hf
P-1001	-3.2108 -0.4411 -0.2532 -1.2506 -0.2582 -1.4297 -1.4597 -0.8273 -1.7863 -1.4920 -0.2918
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients physicians readmission hospital
H-1728	-0.5675257444381714	▁read mission _ rate s
D-1728	-0.5675257444381714	readmission_rates
P-1728	-1.1298 -0.1660 -0.5297 -0.8128 -0.1516 -0.9410 -0.2419
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus cells functional_capacity mortality nondiabetic patients
H-131	-0.9248532056808472	EO - c FU s ▁cd 34 _ ve g FR 2 _ cell s ▁functional _ capaci ty ▁mortal ity ▁non dia be tic
D-131	-0.9248532056808472	EO-cFUs cd34_vegFR2_cells functional_capacity mortality nondiabetic
P-131	-4.2218 -0.0967 -0.5496 -1.1509 -0.2416 -1.0213 -0.1253 -4.4736 -1.3510 -0.5954 -1.7130 -0.0419 -2.7682 -0.2426 -0.2354 -0.8596 -0.4081 -0.0641 -0.0506 -1.5874 -0.1602 -0.2119 -0.0421 -0.2184 -0.2502 -2.0411 -0.2492
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology comorbidities patients outcomes
H-564	-0.2847650647163391	▁et i ology ▁como rbi di ties
D-564	-0.2847650647163391	etiology comorbidities
P-564	-0.2103 -0.5697 -0.0249 -0.3400 -0.0137 -0.3902 -0.0291 -0.7097 -0.2754
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni cardiovascular_mortality hospitalization heart_failure quality_of_life
H-1969	-0.6680970191955566	▁ar ni ▁cardiovascular _ ▁mortal ity ▁heart _ fail ure
D-1969	-0.6680970191955566	arni cardiovascular_ mortality heart_failure
P-1969	-1.9565 -0.8371 -0.0687 -0.6214 -0.2558 -0.0786 -1.0245 -0.2807 -0.9114 -1.3134 -0.3694 -0.2997
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right_ventricular rv prognosis patients heart_failure hf
H-1158	-0.9556020498275757	▁right _ vent ri cular RV ▁body _ ▁composición ▁advanced _ ▁heart _ fail ure HF
D-1158	-0.9556020498275757	right_ventricularRV body_ composición advanced_ heart_failureHF
P-1158	-0.1000 -0.3288 -0.8786 -0.8013 -0.3830 -1.0316 -1.8839 -0.6474 -2.4320 -1.8695 -0.3104 -2.6276 -0.2455 -1.1097 -1.1932 -0.7394 -0.3455 -0.2735
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial_dd muscle titin_hypophosphorylation
H-768	-0.5288845896720886	▁my o card ial ▁d t ▁muscle _ ▁strip ▁titi n _ hy phos phor y lation
D-768	-0.5288845896720886	myocardial dt muscle_ strip titin_hyphosphorylation
P-768	-1.0852 -0.2529 -0.2027 -0.1739 -1.1829 -0.8493 -1.2625 -0.3535 -0.4784 -0.5595 -0.1733 -0.6911 -0.6586 -0.2929 -0.5046 -0.7049 -0.0716 -0.3541 -0.1970
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins expression cardiac_hypertrophy proteins nucleolin
H-95	-0.7679760456085205	▁protein s ▁cardiac _ ▁hyper trop hy ▁protein s ▁nu cle olin
D-95	-0.7679760456085205	proteins cardiac_ hypertrophy proteins nucleolin
P-95	-3.9554 -0.2108 -0.5058 -0.3063 -1.4669 -0.2278 -0.1205 -1.5620 -0.2990 -0.7231 -0.0157 -0.7748 -0.2981 -0.2853
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise training outcomes hf patients exercise training therapy clinical
H-1934	-0.7538682222366333	▁exercise _ training ▁h f ▁exercise _ training ▁ therapy
D-1934	-0.7538682222366333	exercise_training hf exercise_training therapy
P-1934	-0.5575 -1.3690 -0.8936 -0.8592 -1.0616 -0.3231 -1.1710 -0.9780 -1.1324 -0.0318 -0.4084 -0.2609
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients exercise anaerobic_metabolism peak_respiratory_quotient
H-1756	-0.5488899350166321	▁exercise ▁ana ero bic _ ▁metabolism ▁respirator y
D-1756	-0.5488899350166321	exercise anaerobic_ metabolism respiratory
P-1756	-0.5478 -0.6822 -0.1608 -0.2601 -0.1914 -0.7848 -1.5407 -0.2951 -0.7801 -0.2459
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ef
H-192	-0.28979647159576416	▁border line
D-192	-0.28979647159576416	borderline
P-192	-0.1516 -0.0402 -0.7214 -0.2459
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-0.6576210260391235	▁cost - effect ive ness _ rati os
D-2014	-0.6576210260391235	cost-effectiveness_ratios
P-2014	-3.2534 -0.5177 -0.0185 -0.1845 -1.0974 -0.4760 -0.0146 -0.2872 -0.4317 -0.2953
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac_magnetic_resonance amyloidotic diagnosis multiple_myeloma osteomedullary_biopsy
H-999	-0.5933351516723633	▁cardiac _ magnet ic _ re son ance ▁a my lo ido tic _ ▁pattern ▁multiple _ ▁mye loma ▁osteo me dulla ry _ ▁bio psy
D-999	-0.5933351516723633	cardiac_magnetic_resonance amyloidotic_ pattern multiple_ myeloma osteomedullary_ biopsy
P-999	-0.0162 -0.1486 -0.5410 -1.7744 -0.1728 -0.4408 -3.3015 -0.0236 -0.1129 -0.8524 -0.3075 -0.1277 -0.4484 -0.6123 -2.4560 -0.6341 -0.3002 -0.7998 -0.7981 -0.0686 -0.2482 -0.1026 -0.5287 -0.3380 -0.6392 -0.2589 -0.3803 -0.1805
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash diastolic_function ventricular-arterial_coupling hypertensive_heart_failure_with_preserved_ejection_fraction
H-915	-0.3873874247074127	▁low - so dium _ ▁DAS h ▁dia sto lic ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve _ ▁heart _ fail ure ▁e je ction _ fraction
D-915	-0.3873874247074127	low-sodium_ DASh diastolic ventricular-arterial_ coupling hypertensive_ heart_failure ejection_fraction
P-915	-0.2139 -0.0499 -0.0475 -0.0377 -0.4042 -0.2758 -0.3446 -1.6577 -0.3366 -0.3011 -0.4161 -0.4515 -0.2953 -0.1902 -0.4114 -0.2210 -0.6152 -0.4097 -0.1599 -0.0681 -0.2370 -0.0579 -0.4732 -2.1443 -0.1525 -1.1395 -0.7743 -0.1130 -0.1637 -0.1138 -0.2392 -0.0047 -0.4356 -0.2151
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular_endothelial_growth_factor_blockade beta-blocker therapy cardiac_function angiogenesis remodeling heart_failure
H-448	-0.7113843560218811	▁Vas cular _ en dot heli al _ ▁Growth _ factor _ block ade ▁beta - block er _ therapy ▁cardiac _ function ▁ang io gene sis ▁heart _ fail ure
D-448	-0.7113843560218811	Vascular_endothelial_ Growth_factor_blockade beta-blocker_therapy cardiac_function angiogenesis heart_failure
P-448	-1.4659 -0.2969 -0.2920 -0.6342 -2.4286 -0.3161 -0.0376 -0.2476 -2.4913 -0.3213 -0.0219 -0.7370 -1.9688 -0.9022 -0.2141 -0.0412 -0.3160 -0.7036 -0.6832 -0.2393 -0.0573 -0.4585 -0.3672 -0.0293 -2.7381 -0.3334 -1.2519 -0.8712 -0.2624 -1.3630 -0.8439 -0.3374 -0.2032
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable_cardioverter-defibrillators icds mortality cardiac_resynchronization_therapy crt symptoms mortality
H-1068	-0.5219195485115051	▁implant able _ ▁cardio ver ter - de fi br illa tors ▁i cc d s ▁cardiac _ re syn chron ization _ therapy ▁c t ▁mortal ity
D-1068	-0.5219195485115051	implantable_ cardioverter-defibrillators iccds cardiac_resynchronization_therapy ct mortality
P-1068	-0.0037 -0.0493 -0.9287 -0.2793 -0.1031 -0.1765 -0.5185 -0.1242 -0.9490 -1.2703 -0.1463 -0.2709 -0.8102 -0.8388 -1.3042 -0.1515 -0.0843 -0.3008 -0.0569 -0.0438 -0.0159 -0.5126 -0.3231 -0.3819 -1.4941 -2.2193 -1.6373 -0.1134 -0.3252 -0.2245
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis hfpef clinical echo-doppler_cardiography invasive_haemodynamic_assessment
H-1303	-0.6980854868888855	HF p EF ▁e cho - d opp ler _ card i ography ▁invasi ve _ ha emo dynamic _ asse s s ment
D-1303	-0.6980854868888855	HFpEF echo-doppler_cardiography invasive_haemodynamic_assessment
P-1303	-2.9351 -0.1321 -0.6631 -0.2347 -0.3896 -0.1095 -2.0146 -0.0148 -1.7889 -0.3027 -1.8872 -0.4514 -0.6030 -0.4612 -0.1701 -0.7108 -1.3477 -0.3948 -0.0312 -1.4669 -0.1235 -0.0293 -0.1944 -0.9258 -0.5326 -0.2351
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker uptitrations patients hfref hfpef hospital admission
H-177	-0.8696381449699402	▁ RAS - ▁β - block er _ up ti tra tions ▁h f f ▁h f p EF
D-177	-0.8696381449699402	RAS- β-blocker_uptitrations hff hfpEF
P-177	-3.0652 -0.3368 -0.0853 -0.1338 -0.0903 -0.7327 -0.6545 -1.5289 -0.5015 -0.1779 -0.5695 -0.2901 -0.3646 -3.0297 -0.4364 -0.9665 -2.1796 -0.2222 -0.7138 -1.8900 -0.2930
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular_assist_device vad extracorporeal_membrane_oxygenation ecmo renal_function
H-1385	-0.5949047207832336	▁vent ri cular _ assist _ ▁device VAD ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁ec mo ▁renal _ function
D-1385	-0.5949047207832336	ventricular_assist_ deviceVAD extracorporeal_ membrane_ oxygenation ecmo renal_function
P-1385	-0.0244 -0.5065 -0.2077 -0.3010 -0.0186 -1.3231 -4.4564 -0.0909 -0.1193 -0.3203 -0.7635 -0.5777 -0.2442 -1.7610 -0.1552 -0.2248 -0.8383 -0.0854 -0.1039 -0.9972 -0.0355 -0.3675 -0.2611 -0.8794 -0.2098
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american_college_of_cardiology american_heart_association patients ras patients ras
H-1604	-0.8381161689758301	▁american _ co un cil _ of _ ▁Card i ology American _ ▁Heart _ association RAS RAS
D-1604	-0.8381161689758301	american_council_of_ CardiologyAmerican_ Heart_associationRASRAS
P-1604	-1.6152 -0.2826 -2.4930 -0.9583 -0.0415 -0.1836 -0.0757 -0.3035 -1.0469 -0.5064 -0.0250 -1.7069 -0.1970 -0.8053 -0.4408 -0.3672 -1.7046 -1.4325 -2.3287 -0.2474
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv_remodeling diastolic xo_inhibition symptoms hospitalizations patients severe_heart_failure
H-478	-0.6822326183319092	▁LV ▁dia sto lic ▁ XO _ ▁inhibi tion ▁heart _ fail ure
D-478	-0.6822326183319092	LV diastolic XO_ inhibition heart_failure
P-478	-0.0345 -0.2652 -0.2572 -0.1167 -1.4801 -0.0754 -1.5735 -1.5073 -0.1064 -1.0733 -0.4431 -1.4485 -1.2529 -0.3555 -0.2437
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile_function lv_dilatation lv_end-diastolic_pressure wall_stress lung
H-476	-0.666146993637085	▁contract ile _ function ▁LV _ di la tation ▁LV ▁end - dia sto lic _ press ure wall _ ▁Stress ▁lung _ weight
D-476	-0.666146993637085	contractile_function LV_dilatation LV end-diastolic_pressurewall_ Stress lung_weight
P-476	-0.0708 -0.3766 -0.3605 -0.1168 -0.2123 -0.7452 -1.7547 -0.1293 -0.0967 -0.4267 -1.9432 -0.1052 -0.0776 -1.8459 -0.5861 -0.3007 -1.2820 -1.0236 -1.3134 -0.4191 -2.4212 -0.1346 -0.4794 -0.4707 -0.4008 -0.2267
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating_progenitor_cells cpcs endothelial prognostic cardiovascular_diseases
H-120	-0.5967784523963928	▁Circula ting _ pro gen itor _ cell s ▁c p s ▁en dot heli al _ re cover y ▁cardiovascular _ ▁disease s
D-120	-0.5967784523963928	Circulating_progenitor_cells cps endothelial_recovery cardiovascular_ diseases
P-120	-1.0076 -0.1969 -0.5442 -0.2465 -0.2640 -0.3719 -0.2386 -0.2242 -0.4409 -0.1798 -2.8995 -0.3853 -0.1728 -1.3201 -0.3218 -0.0458 -0.6120 -0.1087 -1.9086 -0.2165 -0.1479 -0.6910 -2.2610 -0.0904 -0.4002 -0.2202
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable_cardioverter-defibrillator physicians heart_failure patients
H-1857	-0.6705318093299866	▁implant able _ ▁cardio ver ter - de fi br illa tor _ de activa tion ▁heart _ ▁failure
D-1857	-0.6705318093299866	implantable_ cardioverter-defibrillator_deactivation heart_ failure
P-1857	-0.0164 -0.1021 -2.1487 -0.2068 -0.2423 -0.3000 -0.4854 -0.1538 -1.9578 -1.8373 -0.1227 -0.5280 -0.2782 -0.1421 -0.2689 -0.4289 -1.1382 -0.3441 -2.1704 -0.9053 -0.3039
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp plasma patients dyspnea left_ventricular_dysfunction admission
H-265	-0.5097799301147461	▁NT - pro b NP ▁plasma ▁dys pne a ▁left _ vent ri cular _ ▁dys function ▁ad mission ▁ED
D-265	-0.5097799301147461	NT-probNP plasma dyspnea left_ventricular_ dysfunction admission ED
P-265	-0.1293 -0.0917 -0.0259 -0.9951 -0.5164 -2.0910 -0.0378 -0.0429 -0.7801 -0.2180 -0.3623 -0.6530 -1.1505 -0.6676 -0.4000 -0.9588 -0.2133 -0.2146 -0.0067 -1.1138 -0.3277 -0.2186
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped snp rs10927887 ka_renal_chloride_channel_gene clcnka
H-1802	-0.687139093875885	▁Cau ca sian ▁s n p ▁rs 109 27 887 ▁ka _ ▁renal _ ▁chlor ide _ ▁channel ▁c cn ka
D-1802	-0.687139093875885	Caucasian snp rs10927887 ka_ renal_ chloride_ channel ccnka
P-1802	-0.8816 -0.0070 -0.0804 -0.9308 -2.0080 -0.2239 -0.5225 -0.0950 -0.0473 -0.1041 -1.0688 -0.3809 -0.1052 -0.1031 -2.2975 -0.1460 -0.1932 -1.7340 -2.3446 -0.9197 -1.1455 -0.2944 -0.1707
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician outcomes patients outcomes medically diseases hf
H-1722	-0.9894758462905884	▁physical ▁h f
D-1722	-0.9894758462905884	physical hf
P-1722	-0.9637 -1.4882 -1.8591 -0.4108 -0.2256
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients frail frail biological_phenotype
H-1007	-0.712249219417572	▁fra il ▁intermedi ate _ fra il ▁bi ological _ ▁ph eno type
D-1007	-0.712249219417572	frail intermediate_frail biological_ phenotype
P-1007	-0.5787 -0.1919 -0.0297 -2.0189 -0.2596 -1.7831 -0.2200 -0.9077 -0.4262 -1.4589 -1.9401 -0.1416 -0.0091 -0.4686 -0.2497
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients lbbb implantable primary_outcome primary_outcome
H-887	-0.6291802525520325	▁l b ▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT ▁outcome
D-887	-0.6291802525520325	lb implantable_ cardioverter_defibrillator-cRT outcome
P-887	-1.3556 -0.9935 -0.0331 -0.0777 -0.8423 -0.2023 -0.1151 -0.2025 -0.3467 -0.1144 -0.2596 -0.9449 -0.1080 -0.2026 -0.2285 -0.7291 -2.7258 -2.2755 -0.5453 -0.2810
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm outcomes discharged admission heart_failure
H-149	-0.9123624563217163	▁RM ▁dis charge d ▁ad mission ▁heart _ ▁failure
D-149	-0.9123624563217163	RM discharged admission heart_ failure
P-149	-1.0049 -2.5471 -0.0119 -0.0641 -0.7455 -0.0239 -0.9988 -0.3362 -3.5781 -0.4613 -0.2643
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients exercise-induced_pasp pasp patients pasp
H-827	-0.8953749537467957	▁exercise - indu ced _ pass p ▁h g ▁pas p
D-827	-0.8953749537467957	exercise-induced_passp hg pasp
P-827	-0.2540 -0.1326 -0.0003 -0.0094 -1.4796 -1.7377 -0.4594 -0.1380 -0.0502 -3.8848 -0.9526 -2.2885 -0.2530
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone patients hf-ref hyperkalemia patients
H-1224	-0.6619671583175659	▁e pler en one HF - re f ▁hyper kal emia ▁w RF
D-1224	-0.6619671583175659	eplerenoneHF-ref hyperkalemia wRF
P-1224	-0.2609 -0.0880 -0.3111 -0.2218 -1.4132 -0.0661 -0.1353 -1.8338 -1.5355 -0.6596 -0.2586 -0.1669 -2.2978 -0.4370 -0.2441
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping myocardial heart_failure
H-1063	-0.6743189692497253	▁t 1- ma pping _ techniek ▁diffuse _ My o card ial _ change s ▁heart _ fail ure ▁contrast _ agent ▁breath - hold ing
D-1063	-0.6743189692497253	t1-mapping_techniek diffuse_Myocardial_changes heart_failure contrast_agent breath-holding
P-1063	-1.8899 -0.0962 -0.4830 -0.3472 -0.6781 -1.4172 -0.7501 -0.4232 -3.1807 -0.7584 -0.6472 -0.5492 -0.8719 -0.8489 -0.1230 -0.4826 -0.2676 -0.8643 -2.0087 -0.4887 -0.2288 -0.2013 -0.0704 -0.2574 -0.0725 -0.1186 -0.4809 -0.2748
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt dt btt patients
H-314	-0.6983617544174194	▁b t ▁d t ▁cost - effect ive ness ▁b t
D-314	-0.6983617544174194	bt dt cost-effectiveness bt
P-314	-0.5707 -0.7006 -1.4083 -0.0554 -1.5361 -0.1570 -0.0238 -0.3460 -1.7527 -0.7427 -0.5713 -0.9292 -0.2849
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients hfpef longitudinal cardiac_event
H-738	-0.7974919080734253	▁h f f ▁longitud in al _ ▁outcome - monitor ing _ phase ▁cardiac _ event
D-738	-0.7974919080734253	hff longitudinal_ outcome-monitoring_phase cardiac_event
P-738	-0.1804 -0.6498 -0.4354 -3.1295 -0.2794 -0.1364 -0.3148 -2.8395 -0.2215 -0.0215 -0.0231 -0.8969 -1.3218 -0.1415 -0.3631 -2.6697 -0.4701 -0.2606
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure health income hf
H-1800	-0.8869773745536804	▁ex pendi ture ▁health _ per _ ca pit al ▁gross _ national _ ▁income _ per _ ca pit al ▁h f
D-1800	-0.8869773745536804	expenditure health_per_capital gross_national_ income_per_capital hf
P-1800	-0.1721 -0.0323 -0.1431 -0.3670 -1.4953 -0.1500 -0.6547 -0.5419 -0.4711 -3.9640 -1.4644 -0.7365 -1.8616 -0.8775 -0.1501 -0.9800 -0.1678 -0.2864 -0.0489 -0.1783 -2.4132 -0.9267 -1.3350 -2.5584 -0.1981
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals patients hfpef
H-952	-0.3724427819252014	▁af ▁ pharma ce u tical s ▁h f f
D-952	-0.3724427819252014	af pharmaceuticals hff
P-952	-0.4112 -0.8632 -0.0435 -0.1219 -0.1313 -0.3304 -0.2171 -0.2472 -0.9411 -0.4257 -0.4684 -0.2681
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies crt-d heart_failure death
H-108	-1.0028281211853027	▁c RT - d ▁heart _ fail ure ▁death
D-108	-1.0028281211853027	cRT-d heart_failure death
P-108	-2.7080 -2.2621 -0.0848 -0.2644 -1.5511 -0.3845 -1.0235 -1.0601 -1.1078 -0.3668 -0.2178
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt atrial_pacing
H-1442	-0.8544358611106873	▁SD QT ▁h w t ▁h nor m ▁fixed - rate _ at rial _ pa cing
D-1442	-0.8544358611106873	SDQT hwt hnorm fixed-rate_atrial_pacing
P-1442	-0.1701 -2.3340 -0.5732 -3.3441 -0.7789 -0.2049 -5.3071 -0.1898 -0.0678 -0.2556 -0.1360 -0.1192 -0.1929 -0.5968 -0.2787 -0.6226 -0.4147 -0.4431 -0.2049
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical bnp inhospital mortality
H-196	-0.4364991784095764	▁b NP ▁in hospital _ ▁mortal ity
D-196	-0.4364991784095764	bNP inhospital_ mortality
P-196	-0.1640 -1.9693 -0.2066 -0.0669 -0.2691 -0.4028 -0.1631 -0.4305 -0.2561
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood_pressure therapy patients ras
H-1600	-0.513770341873169	▁blood _ tension ▁goal - direct ed _ ▁lipid - lo wering _ therapy ▁smoking RAS
D-1600	-0.513770341873169	blood_tension goal-directed_ lipid-lowering_therapy smokingRAS
P-1600	-0.8197 -0.3676 -2.1007 -1.0666 -0.0376 -0.0058 -0.1291 -0.7378 -0.1985 -0.0924 -0.0328 -0.0869 -1.0909 -0.0861 -0.0527 -1.7573 -0.3338 -0.2515
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs_morphology cardiac_resynchronization_therapy crt
H-880	-0.5759835243225098	▁QR s _ morph ology ▁cardiac _ re syn chron ization _ therapy ▁c t
D-880	-0.5759835243225098	QRs_morphology cardiac_resynchronization_therapy ct
P-880	-0.2581 -0.6997 -1.4077 -0.0882 -0.1483 -0.0465 -0.1844 -0.0933 -0.1300 -0.0206 -0.7030 -0.3249 -0.9148 -1.6476 -2.4461 -0.4350 -0.2435
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial_complex_v_activity phosphocreatine atp
H-1786	-0.649851381778717	▁mito cho ndri al _ com mun ity ▁activity ▁post - a ac ▁ratio _ of _ phos pho creati ne ▁ATP
D-1786	-0.649851381778717	mitochondrial_community activity post-aac ratio_of_phosphocreatine ATP
P-1786	-0.7011 -1.4444 -0.7404 -0.2814 -0.1656 -1.8344 -1.4836 -0.0849 -0.0211 -0.6977 -0.0306 -0.1334 -0.3966 -0.2109 -0.9813 -0.1639 -0.4606 -0.4720 -0.5339 -1.1486 -2.7620 -0.2629 -0.3989 -0.1862
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire implanted pacemakers ventricularly beats heart_failure
H-1056	-0.48222067952156067	▁York shire _ s win e ▁implant ed ▁pace makers ▁vent ri cular ly ▁beat s ▁induc e _ ▁heart _ fail ure
D-1056	-0.48222067952156067	Yorkshire_swine implanted pacemakers ventricularly beats induce_ heart_failure
P-1056	-0.1558 -0.0497 -0.3956 -0.6294 -0.0305 -0.6015 -0.0604 -0.1219 -0.3971 -0.0451 -0.2487 -0.3337 -0.1180 -0.1863 -2.4525 -0.3869 -0.1027 -0.4211 -0.7891 -1.4827 -0.2182 -0.8727 -1.3373 -0.3774 -0.2413
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality heart_failure hf implantable_cardioverter_defibrillators icds
H-60	-0.5094723105430603	▁mortal ity ▁heart _ fail ure HF ▁implant able _ ▁cardio ver ter _ de fi br illa tors ic d s
D-60	-0.5094723105430603	mortality heart_failureHF implantable_ cardioverter_defibrillatorsicds
P-60	-0.9617 -0.2999 -0.7258 -0.1745 -1.2038 -1.1224 -1.5142 -0.0239 -0.1009 -0.9235 -0.2635 -0.1406 -0.3253 -0.2201 -0.1406 -0.3126 -0.7262 -0.0907 -0.2528 -1.6049 -0.2564 -0.2119 -0.3870 -0.2441
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular_outcomes_in_renal_atherosclerotic_lesions coral stenting ras
H-1602	-0.679370641708374	▁Card io vas cular ▁Ren al _ ▁Ath eros cle ro tic _ les ions ▁co RAL ▁sten ting RAS
D-1602	-0.679370641708374	Cardiovascular Renal_ Atherosclerotic_lesions coRAL stentingRAS
P-1602	-0.6332 -3.5498 -0.2883 -0.6388 -0.7803 -0.0625 -0.3584 -0.3753 -0.2247 -0.1157 -0.0897 -0.0779 -0.3741 -4.3833 -0.5815 -0.9316 -0.0887 -0.2282 -0.2905 -0.3418 -0.3417 -0.1903
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi metoprolol elevated plasma_norepinephrine dopamine elevated epinephrine
H-1550	-0.6250101923942566	▁MI ▁met o pro lol ▁plasma _ no re pine ph rine ▁dop amine ▁e pine ph rine
D-1550	-0.6250101923942566	MI metoprolol plasma_norepinephrine dopamine epinephrine
P-1550	-0.8192 -1.0744 -0.1973 -0.0743 -0.8924 -0.4448 -0.4969 -0.3098 -0.1775 -0.1891 -2.8167 -1.2351 -0.0237 -0.1280 -0.0989 -0.0523 -1.8147 -1.1121 -0.3268 -0.2161
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 cardioprotective_signaling myocardium biomarker heart_failure hf
H-696	-0.44241663813591003	▁ST 2 ▁cardio protec tive _ signal ing ▁my o car dium ▁bio mark er ▁heart _ fail ure HF
D-696	-0.44241663813591003	ST2 cardioprotective_signaling myocardium biomarker heart_failureHF
P-696	-1.3208 -0.0239 -0.2963 -0.0609 -0.2711 -0.3818 -0.2751 -0.4039 -0.7539 -0.1386 -0.0674 -0.1335 -0.0104 -0.0846 -0.8817 -0.6377 -0.2428 -1.2847 -0.6946 -1.1882 -0.3491 -0.2323
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal_muscle sarcomere patients heart_failure type_2_diabetes
H-1243	-0.6400532722473145	▁skelet al _ ▁muscle ▁heart _ ▁failure ▁diabetes ▁e pica tech in - rich _ ▁coco a
D-1243	-0.6400532722473145	skeletal_ muscle heart_ failure diabetes epicatechin-rich_ cocoa
P-1243	-1.0051 -0.2473 -0.4821 -3.9817 -1.1860 -0.4180 -1.9549 -0.0581 -0.2116 -0.0548 -0.0510 -0.2780 -0.1891 -0.0007 -0.3578 -1.0836 -0.0780 -0.3095 -0.2133
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene pathological heart_disease transcription_factors driving gene
H-639	-0.8727651834487915	▁em bry o nic ▁heart _ ▁disease ▁tran scription _ factor s
D-639	-0.8727651834487915	embryonic heart_ disease transcription_factors
P-639	-0.7196 -0.4568 -0.2899 -0.2476 -4.2525 -0.2843 -2.6193 -0.2997 -0.0443 -0.7588 -0.3512 -0.2899 -1.2739 -0.3310
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart_rate ivabradine afterload patients systolic_heart_failure
H-516	-0.7146687507629395	▁isola ted _ heart _ rate HR ▁i va bra dine ▁after load ▁sy sto lic _ heart _ fail ure
D-516	-0.7146687507629395	isolated_heart_rateHR ivabradine afterload systolic_heart_failure
P-516	-0.0613 -0.0751 -0.3009 -2.6295 -0.2800 -0.8355 -1.4877 -0.5556 -0.0196 -0.0583 -0.2498 -2.2524 -0.0108 -1.5870 -0.2266 -0.6062 -0.2306 -1.9766 -0.1905 -1.5385 -0.6562 -0.3582 -0.2504
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard_error_of_measurement mdc clinical change
H-807	-0.3249187171459198	▁m d c ▁change
D-807	-0.3249187171459198	mdc change
P-807	-0.4115 -0.1404 -0.5310 -0.1766 -0.4168 -0.2732
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient emergency_department acute_heart_failure ahf clinical
H-57	-0.9742506742477417	▁a cute _ heart _ fail ure ▁a HF
D-57	-0.9742506742477417	acute_heart_failure aHF
P-57	-0.9982 -0.0824 -0.1244 -2.3984 -0.1401 -1.0344 -1.4150 -2.2885 -1.4233 -0.5980 -0.2141
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic patients reverse_remodeling crt clinical outcomes
H-436	-0.7804539799690247	▁multi para metric _ e cho car dio graphic ▁rever se _ ▁remodel ing ▁c t
D-436	-0.7804539799690247	multiparametric_echocardiographic reverse_ remodeling ct
P-436	-0.0897 -0.3115 -0.1417 -0.3094 -0.2071 -0.5315 -0.1531 -1.0698 -1.6380 -2.2318 -0.0954 -0.2130 -2.1930 -0.0635 -1.1902 -2.5412 -0.8291 -0.2390
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis biomedical biomedical patients dcm heart_failure
H-1264	-0.9971988797187805	▁bio medic al ▁CH m ▁bio medic al _ ▁Treatment ▁d c ▁heart _ fail ure
D-1264	-0.9971988797187805	biomedical CHm biomedical_ Treatment dc heart_failure
P-1264	-0.0897 -0.4466 -0.1327 -5.1567 -0.1024 -0.0568 -0.3446 -0.1098 -1.1516 -3.7010 -0.3306 -2.1794 -0.5464 -0.3680 -1.7665 -0.8393 -0.3746 -0.2530
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal_flow_pump hemocompatibility blood-flow pulse
H-1994	-0.40204060077667236	▁centri fu gal _ flow _ pump ▁hem o com pati bility ▁magnet ically ▁le vita ted _ ro tor ▁blood - flow _ path s ▁artificial _ ▁puls e
D-1994	-0.40204060077667236	centrifugal_flow_pump hemocompatibility magnetically levitated_rotor blood-flow_paths artificial_ pulse
P-1994	-0.0155 -0.1810 -0.1236 -0.2010 -0.3221 -0.2133 -0.7839 -1.0375 -0.2262 -0.1486 -0.2050 -0.1226 -0.0439 -0.2012 -2.0924 -0.0038 -0.0768 -0.5382 -0.0676 -0.0636 -1.7587 -0.2990 -0.0142 -0.3730 -0.1349 -0.2141 -0.3161 -0.3016 -1.8381 -0.3241 -0.3741 -0.2494
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients sst2 sst2 odds_ratios cardiovascular_events
H-409	-0.8019176721572876	▁s st 2/ low - dos e _ bb ▁s st 2/ high - dos e _ bb ▁intermedi ate _ ▁odds _ rati os ▁cardiovascular _ event s
D-409	-0.8019176721572876	sst2/low-dose_bb sst2/high-dose_bb intermediate_ odds_ratios cardiovascular_events
P-409	-0.1231 -1.3531 -1.4418 -0.5103 -0.1209 -1.4376 -0.4104 -1.3697 -1.3206 -0.1447 -1.4570 -1.3922 -2.4937 -0.2141 -1.4645 -0.4921 -0.9278 -0.7688 -0.5289 -0.7956 -0.2553 -0.6837 -0.2845 -0.1091 -0.2640 -0.1813 -0.3806 -3.1746 -0.0713 -0.4363 -0.2518
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary_approaches_to_stop_hypertension dash mortality postmenopausal hf
H-686	-0.6083465814590454	▁Mediterrane an _ and _ diet ary _ app ro ach es _ to _ ▁Stop _ ▁Hyper tension DAS h ▁die t _ ▁score s ▁mortal ity ▁post meno paus al _ ▁women ▁h f
D-686	-0.6083465814590454	Mediterranean_and_dietary_approaches_to_ Stop_ HypertensionDASh diet_ scores mortality postmenopausal_ women hf
P-686	-1.0345 -0.0749 -0.9107 -0.6150 -0.1884 -1.0372 -0.1480 -0.1153 -0.4986 -0.5089 -0.5739 -0.7837 -0.1776 -1.4046 -0.3751 -0.8828 -0.1585 -1.0047 -0.0127 -0.2098 -0.2400 -1.7262 -0.2425 -0.2443 -2.4088 -0.0272 -0.6090 -0.1091 -0.0464 -0.1127 -0.0414 -0.1354 -0.4881 -2.6821 -0.6357 -2.0978 -0.3088 -0.2465
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc diagnostic
H-1025	-1.327288269996643	▁PO c NP
D-1025	-1.327288269996643	POcNP
P-1025	-2.0297 -1.2997 -1.0938 -1.9582 -0.2551
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality_of_life functional_capacity
H-618	-0.23992058634757996	▁functional _ capaci ty
D-618	-0.23992058634757996	functional_capacity
P-618	-0.2168 -0.4420 -0.0983 -0.0678 -0.3530 -0.2617
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography cardiac cardiac_function
H-453	-0.3861158490180969	▁e cho card i ography ▁cardiac _ dia meter s ▁cardiac _ function
D-453	-0.3861158490180969	echocardiography cardiac_diameters cardiac_function
P-453	-0.1663 -0.2298 -0.4057 -0.4966 -0.5245 -0.1443 -0.3778 -0.0398 -0.0194 -0.2441 -0.2460 -0.2606 -0.6887 -1.7369 -0.2113
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients lbbb qrs implantable
H-890	-0.6326090693473816	▁l bf ▁QR s ▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT
D-890	-0.6326090693473816	lbf QRs implantable_ cardioverter_defibrillator-cRT
P-890	-1.0966 -2.3188 -1.0235 -0.6899 -0.0286 -0.0749 -1.4125 -0.1686 -0.0734 -0.1334 -0.2641 -0.0712 -0.2489 -0.7143 -0.0970 -0.1284 -0.2338 -0.6824 -3.1744 -0.4261 -0.2239
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality readmissions costs patient physician hospital
H-1725	-0.5102472901344299	▁read missions ▁costs
D-1725	-0.5102472901344299	readmissions costs
P-1725	-1.1142 -0.0750 -0.0676 -1.0149 -0.2795
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline embase psycinfo
H-151	-0.3355295956134796	▁electronic ▁med line EMBA se ▁Psy c INFO
D-151	-0.3355295956134796	electronic medlineEMBAse PsycINFO
P-151	-0.4876 -1.0832 -0.2455 -0.1619 -0.3634 -0.3365 -0.0897 -0.0088 -0.4007 -0.1780
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized medical
H-1977	-1.2177764177322388	▁medical _ center
D-1977	-1.2177764177322388	medical_center
P-1977	-2.3394 -1.2472 -1.7262 -0.5193 -0.2567
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic interatrial_shunting patients heart_failure_with_reduced_ejection_fraction
H-1950	-0.6318262219429016	▁left - to - right _ inter at rial _ ▁sh unting ▁heart _ fail ure ▁e je ction _ fraction
D-1950	-0.6318262219429016	left-to-right_interatrial_ shunting heart_failure ejection_fraction
P-1950	-1.8515 -0.2166 -0.1837 -0.3655 -0.2266 -0.3828 -0.3137 -0.2742 -0.5253 -0.9035 -3.1974 -0.5645 -0.7374 -0.2721 -1.1717 -1.7069 -0.2766 -0.1992 -0.1525 -0.2771 -0.0158 -0.4599 -0.2573
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients systolic_hf cxl-1020 right_heart_filling_pressures systemic_vascular_resistance cardiac stroke_volume_index
H-423	-0.8819404244422913	▁sy sto lic ▁h z ▁c XL -10 20 ▁left ▁right _ ▁heart ▁system ic _ ▁vas cular _ re serv ance ▁cardiac ▁stroke _ ▁volume _ index
D-423	-0.8819404244422913	systolic hz cXL-1020 left right_ heart systemic_ vascular_reservance cardiac stroke_ volume_index
P-423	-1.1259 -0.1658 -0.0723 -1.8771 -1.1573 -0.9198 -0.6080 -0.1131 -0.0670 -1.5505 -1.7430 -0.4147 -2.2015 -2.3132 -0.3350 -0.4005 -1.9664 -0.6048 -0.4316 -0.5494 -3.5458 -0.1000 -0.0668 -0.3193 -1.1969 -1.0533 -0.3690 -0.3983 -0.5231 -0.2689
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart_failure hypertension mitral_regurgitation mitral_stenosis medical_treatment heart_failure
H-336	-0.6169894337654114	▁heart _ fail ure ▁hyper tension ▁mit ral _ re gur gi tation ▁mit ral _ ▁sten osis ▁medical ▁heart _ fail ure
D-336	-0.6169894337654114	heart_failure hypertension mitral_regurgitation mitral_ stenosis medical heart_failure
P-336	-0.5868 -0.3279 -1.4997 -3.0113 -0.1530 -0.0027 -0.1264 -0.0210 -0.3136 -0.0935 -0.0221 -0.1635 -0.0376 -0.1118 -0.0246 -0.2545 -1.8796 -0.0439 -0.9620 -1.0527 -0.3220 -1.2083 -2.5964 -0.3809 -0.2288
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk scn5a kv4.3 mrnas transient_receptor_potential_cation_channel_m7 trpm7 mrna
H-1086	-0.5717027187347412	▁per k _ activa tion ▁s cn 5 a ▁kv 4.3 ▁m RNA s ▁trans ient _ ▁receptor _ pot ential _ cation ▁m 7 ▁pm 7 ▁m RNA
D-1086	-0.5717027187347412	perk_activation scn5a kv4.3 mRNAs transient_ receptor_potential_cation m7 pm7 mRNA
P-1086	-1.4366 -1.7860 -0.3100 -0.3179 -0.1177 -0.3388 -0.3780 -0.3811 -0.1059 -0.0558 -0.0834 -0.7602 -0.1135 -0.2298 -0.0245 -0.1760 -0.2778 -0.4991 -0.3449 -2.2586 -0.0019 -0.3631 -0.0358 -1.3210 -0.0294 -4.2297 -0.5993 -0.3222 -0.3815 -0.2542 -0.1892
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients implantable_cardioverter-defibrillator heart_function_clinic university_health_network toronto canada
H-1861	-0.6446725726127625	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁Heart _ function _ ▁Clinic ▁university _ health _ net work ▁tor onto ▁Canada
D-1861	-0.6446725726127625	implantable_ cardioverter-defibrillator Heart_function_ Clinic university_health_network toronto Canada
P-1861	-0.0095 -0.0929 -1.2097 -0.3439 -0.2292 -0.3502 -0.4628 -0.1989 -1.3528 -1.4029 -0.1248 -0.2375 -0.9088 -0.2566 -1.1021 -0.5331 -0.4534 -1.8268 -0.2423 -1.9365 -0.2012 -0.2293 -0.0418 -0.0831 -0.0154 -3.5417 -0.4113 -0.2523
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients followed_up composite_primary_outcome cardiovascular_death stroke heart_failure myocardial_infarction
H-1650	-0.6957855820655823	▁cardiovascular _ ▁death ▁stroke ▁heart _ fail ure ▁my o card ial _ in far ction
D-1650	-0.6957855820655823	cardiovascular_ death stroke heart_failure myocardial_infarction
P-1650	-0.9527 -1.9774 -1.1719 -0.3031 -0.3119 -0.4770 -0.8780 -1.9727 -1.1607 -0.3783 -0.4249 -0.5665 -0.3529 -0.4706 -0.0274 -0.4526 -0.3538 -0.2917
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced_pasp clinical prognostic pulmonary_hypertension patients right_ventricular_contractile_reserve
H-831	-0.6076163053512573	▁exercise - indu ced _ pas p ▁pulmonar y _ hy tension ▁vent ri cular _ contract ile _ ▁reserve
D-831	-0.6076163053512573	exercise-induced_pasp pulmonary_hytension ventricular_contractile_ reserve
P-831	-0.7409 -0.2840 -0.0008 -0.0143 -1.8097 -1.4897 -0.9481 -0.0427 -0.9504 -0.4095 -1.0564 -0.0321 -0.1416 -0.4378 -0.4686 -0.5318 -0.1422 -0.9295 -0.6110 -1.6429 -0.4673 -0.2162
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists renin-angiotensin-aldosterone sympathetic_nervous_systems clinical outcomes chf
H-636	-0.5656765699386597	▁re nin - angi oten sin - al do ster one ▁sympa the tic _ ▁ner vous _ system s ▁CHF
D-636	-0.5656765699386597	renin-angiotensin-aldosterone sympathetic_ nervous_systems CHF
P-636	-0.9593 -0.7894 -0.2403 -0.0521 -0.0168 -0.8663 -0.5310 -0.0597 -0.6986 -0.2202 -0.3477 -0.0385 -0.4471 -0.1777 -0.1946 -4.3714 -1.3405 -0.2295 -0.4560 -0.0370 -0.5008 -0.2532 -0.1828
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization_therapy crt morbidity mortality chronic_systolic_heart_failure wide_qrs_complex
H-845	-0.7745299339294434	▁Card iac - re syn chron ization _ therapy ▁c t ▁chronic _ sy sto lic _ heart _ fail ure ▁QR s
D-845	-0.7745299339294434	Cardiac-resynchronization_therapy ct chronic_systolic_heart_failure QRs
P-845	-1.4847 -0.3622 -0.0992 -0.1121 -0.1030 -0.0174 -0.7768 -0.3984 -0.9732 -1.6807 -2.5506 -1.2607 -0.6748 -1.6907 -0.5800 -0.8479 -0.1631 -2.0361 -0.1532 -1.0123 -1.2393 -0.0706 -0.4993 -0.3264 -0.2506
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate unfolded_protein_response upr scn5a remodeling hf
H-1081	-0.6960060596466064	▁tru nca ted _ na _ ▁channel s ▁un fold ed _ ▁protein _ re cover y ▁u PR ▁s cn 5 a ▁electric _ ▁remodel ing ▁h z
D-1081	-0.6960060596466064	truncated_na_ channels unfolded_ protein_recovery uPR scn5a electric_ remodeling hz
P-1081	-0.0201 -0.2207 -0.0184 -0.5692 -0.2508 -3.6510 -1.5782 -0.2055 -0.1087 -0.0070 -0.0675 -0.1625 -1.0864 -0.2618 -1.8860 -2.2773 -0.4388 -0.6378 -2.1513 -0.4579 -0.4382 -0.1610 -0.1384 -0.1615 -0.9239 -1.0571 -0.0397 -0.4026 -1.6224 -0.3735 -0.2010
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international_right_heart_foundation_working_group step syndrome right_heart_failure
H-1458	-0.6986750364303589	▁international _ right _ ▁Heart _ found ation _ working _ group ▁right _ ▁Heart _ fail ure
D-1458	-0.6986750364303589	international_right_ Heart_foundation_working_group right_ Heart_failure
P-1458	-1.0381 -0.3275 -0.3830 -0.5450 -0.5312 -0.1880 -1.4844 -0.0344 -2.1220 -0.9957 -0.3055 -0.0685 -0.6679 -0.3720 -1.7578 -0.3706 -0.5811 -1.6539 -0.3327 -0.2140
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber_dynamics myofiber_shortening emd dyssynchronous_hf
H-1156	-0.615375816822052	▁my o fi ber _ dynamic s ▁my o fi ber ▁em d ▁dys syn chron ous _ HF
D-1156	-0.615375816822052	myofiber_dynamics myofiber emd dyssynchronous_HF
P-1156	-2.2130 -0.6387 -0.4591 -0.1142 -0.7501 -0.3893 -0.1581 -0.9899 -0.3781 -0.6878 -0.1420 -1.8381 -0.0990 -0.0112 -0.0486 -0.0198 -0.3162 -1.0929 -1.8953 -0.4507 -0.2309
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial_index pulse-wave coronary_artery_calcium_scores
H-1562	-0.3899979293346405	▁cru de ▁an kle - bra chi al _ index ▁puls e - wa ve _ velo city ▁corona ry _ ▁arter y _ ▁calci um
D-1562	-0.3899979293346405	crude ankle-brachial_index pulse-wave_velocity coronary_ artery_ calcium
P-1562	-1.4233 -0.1275 -0.4469 -0.9304 -0.2787 -0.0411 -0.3064 -0.1702 -0.2575 -0.1869 -0.8497 -0.3986 -0.1900 -0.0753 -0.1469 -0.2255 -0.0273 -0.2701 -0.1108 -0.2990 -0.3914 -0.2503 -0.7536 -0.6847 -0.2316 -0.0606 -1.5645 -0.2215
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol lv_contractile_function xo-mediated_ros myofilament sensitivity
H-477	-0.5385532379150391	▁allo puri nol ▁LV ▁contract ile _ function ▁ XO - media ted _ ros _ effect s ▁my o fila ment
D-477	-0.5385532379150391	allopurinol LV contractile_function XO-mediated_ros_effects myofilament
P-477	-0.0424 -0.0148 -0.6923 -0.1337 -0.2322 -0.3490 -1.0988 -0.1157 -1.5491 -1.8509 -0.0128 -0.2323 -0.0809 -0.2614 -0.8520 -1.1324 -0.1754 -0.1217 -1.3404 -0.1531 -0.0498 -0.6750 -1.5020 -0.2574
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk_stratification antiplatelet_agents combination anticoagulants vascular_diseases
H-1355	-0.6046397686004639	▁anti plate let _ agent s ▁antico a gul ants ▁vas cular _ ▁Disease s
D-1355	-0.6046397686004639	antiplatelet_agents anticoagulants vascular_ Diseases
P-1355	-0.2630 -0.4368 -1.2238 -0.2653 -0.4218 -0.5459 -0.9032 -0.4538 -0.2138 -0.1121 -1.4388 -0.2086 -0.3565 -2.6418 -0.0933 -0.4700 -0.2304
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac_hypertrophy pressure-overload abdominal_aortic_constriction aac
H-1780	-0.5440129637718201	▁cardiac _ ▁hyper trop hy ▁pressure - over load ▁abdominal _ a or tic _ con stri ction ▁a ac
D-1780	-0.5440129637718201	cardiac_ hypertrophy pressure-overload abdominal_aortic_constriction aac
P-1780	-2.8504 -0.2698 -1.7501 -0.2290 -0.1817 -0.1400 -0.2242 -0.0702 -0.0208 -0.2039 -0.4392 -0.1501 -0.2208 -0.0902 -0.2561 -0.3786 -1.6558 -0.3918 -1.0356 -0.7462 -0.4250 -0.2388
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf hf epidemiology rheumatic_fever
H-1799	-0.8343493342399597	▁h f ▁h f ▁epidemi ology ▁h f ▁rhe u matic _ fe ver
D-1799	-0.8343493342399597	hf hf epidemiology hf rheumatic_fever
P-1799	-3.2379 -0.6637 -1.3884 -0.7834 -1.2851 -0.1752 -1.1681 -1.6625 -0.7987 -0.1266 -0.2086 -0.3229 -0.5108 -0.4262 -0.3333 -0.2582
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications patients heart_failure_and_reduced_ejection_fraction outpatient
H-667	-0.6257615685462952	▁medication s ▁heart _ fail ure ▁e je ction _ fraction ▁out patient _ setting
D-667	-0.6257615685462952	medications heart_failure ejection_fraction outpatient_setting
P-667	-2.7775 -0.1599 -0.5849 -0.3726 -0.9709 -1.4565 -0.6089 -0.2328 -0.1091 -0.3106 -0.0281 -0.8762 -0.1979 -1.0183 -0.0744 -0.5793 -0.2800
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise training exercise exercise_capacity qol obese patients hfpef
H-1976	-0.6944703459739685	▁calor ic _ re duction diet ▁aero bic _ ▁exercise _ training ▁exercise _ capaci ty ▁Q OL ▁obes e ▁h f f
D-1976	-0.6944703459739685	caloric_reductiondiet aerobic_ exercise_training exercise_capacity QOL obese hff
P-1976	-0.4628 -0.2142 -1.0540 -0.9598 -0.8944 -0.2593 -0.0863 -0.2735 -1.3241 -0.5642 -1.0626 -0.3890 -0.1004 -0.4490 -0.1247 -0.0544 -2.8610 -1.1627 -1.8766 -0.3557 -0.4878 -1.1740 -0.4341 -0.4581 -0.2790
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic_heart_failure hf hemodynamic syndrome dysfunction molecular_pathways
H-1472	-0.5937975645065308	▁chronic _ heart _ fail ure HF ▁hem o dynamic _ ▁disorder ▁inter connect ed _ ▁molecular _ path ways
D-1472	-0.5937975645065308	chronic_heart_failureHF hemodynamic_ disorder interconnected_ molecular_pathways
P-1472	-0.3801 -0.2417 -2.4170 -0.1814 -1.0214 -1.6415 -0.9044 -0.3434 -0.2474 -0.0278 -0.7087 -1.5920 -1.0448 -0.0241 -0.0994 -0.3619 -0.5094 -0.3597 -0.1201 -0.1707 -0.4227 -0.2439
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms hfpef diastolic_filling_time heart_rate symptoms
H-1172	-0.8445618152618408	▁h p EF ▁dia sto lic _ fill ing _ ▁time ▁heart _ rate
D-1172	-0.8445618152618408	hpEF diastolic_filling_ time heart_rate
P-1172	-1.3882 -1.0139 -1.1469 -0.1722 -0.4603 -0.3371 -1.1613 -1.7108 -0.0829 -0.8329 -2.6958 -0.7357 -0.4008 -0.6148 -0.4962 -0.2634
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline hgb correlated baseline kccq hgb exercise training hrqol
H-839	-0.5824453234672546	▁base line ▁h gb ▁base line ▁k cc q ▁h gb ▁exercise ▁HR Qo l
D-839	-0.5824453234672546	baseline hgb baseline kccq hgb exercise HRQol
P-839	-0.0322 -0.1691 -0.5177 -0.4367 -0.1142 -0.1483 -1.3644 -0.0551 -0.8731 -0.3029 -0.7670 -0.1319 -2.8036 -0.0430 -1.5379 -0.3914 -0.2131
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient patients heart_failure hospital discharge readmissions patient follow-up
H-722	-0.7798966765403748	▁heart _ fail ure ▁hospital _ dis charge ▁read missions ▁follow - up
D-722	-0.7798966765403748	heart_failure hospital_discharge readmissions follow-up
P-722	-3.8351 -0.2603 -0.9425 -2.3168 -0.6885 -1.0563 -0.2338 -0.0153 -0.3740 -0.0484 -0.0507 -0.2929 -0.0206 -1.2912 -0.2721
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac myocyte-specific_mena_overexpression cardiac pathology
H-1813	-0.5729173421859741	▁mi ce ▁cardiac _ My o cy te - specific _ ▁Men a _ over expression ▁t g t et Men a ▁cardiac _ path ology
D-1813	-0.5729173421859741	mice cardiac_Myocyte-specific_ Mena_overexpression tgtetMena cardiac_pathology
P-1813	-1.3131 -0.0631 -0.0780 -0.6323 -2.5371 -0.3898 -0.0424 -0.2182 -0.3605 -0.1038 -1.7176 -2.8797 -0.1256 -0.2444 -0.4019 -0.1119 -0.6563 -0.6606 -0.0900 -0.1716 -1.8580 -0.0704 -0.0832 -0.4301 -0.0707 -0.1011 -0.4091 -0.2212
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan_failure hemodynamically heart_failure systemic_vascular_resistance svr cardiac_index
H-225	-0.7729357481002808	▁Font an _ fail ure ▁hem o dynamic ally ▁heart _ ▁failure ▁system ic _ ▁vas cular _ ▁resist ance ▁s VR ▁cardiac _ index
D-225	-0.7729357481002808	Fontan_failure hemodynamically heart_ failure systemic_ vascular_ resistance sVR cardiac_index
P-225	-0.1656 -0.7492 -0.3340 -1.4662 -2.0889 -0.3809 -0.2136 -0.0274 -0.1269 -0.5184 -0.3339 -2.0820 -0.2429 -0.5542 -0.4404 -2.0245 -0.6559 -0.3593 -3.8681 -0.0576 -1.0402 -1.4181 -0.1500 -0.6037 -0.3171 -0.4173 -0.2332
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients heart_transplant prospectively ecct
H-710	-0.7436813712120056	▁isola ted _ heart _ ▁transplant ▁ec t
D-710	-0.7436813712120056	isolated_heart_ transplant ect
P-710	-0.4172 -0.1498 -0.3970 -2.1701 -0.1989 -1.2502 -0.3810 -1.6732 -0.5261 -0.2734
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential_analysis cluster_analysis
H-1610	-0.7069057822227478	▁r . _ ▁Clu ster _ analyse
D-1610	-0.7069057822227478	r._ Cluster_analyse
P-1610	-1.5517 -0.2183 -0.3676 -1.4088 -1.0960 -0.4418 -0.5400 -0.4870 -0.2510
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis metabolic_exercise cardiac kidney
H-1762	-0.5049044489860535	▁metabol ic _ ▁exercise ▁cardiac ▁ki dne y _ index _ ▁score
D-1762	-0.5049044489860535	metabolic_ exercise cardiac kidney_index_ score
P-1762	-0.3521 -0.1419 -0.5343 -0.8055 -0.0127 -0.0435 -0.2531 -0.2131 -0.3374 -0.1398 -0.7514 -2.7364 -0.4667 -0.2806
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart_failure compliance etidronate alendronate
H-1543	-0.47147336602211	▁heart _ fail ure ▁compliance ▁et id rona te ▁ale ndr onate
D-1543	-0.47147336602211	heart_failure compliance etidronate alendronate
P-1543	-0.2715 -0.3187 -1.2387 -1.6376 -0.7593 -0.0729 -0.2404 -0.0465 -0.1110 -1.0812 -0.0308 -0.0462 -0.5570 -0.1887
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians patients heart_failure equitable therapeutic
H-1823	-1.0847012996673584	▁physician s ▁advanced _ heart _ fail ure
D-1823	-1.0847012996673584	physicians advanced_heart_failure
P-1823	-0.8625 -0.1342 -1.4806 -0.2743 -2.2269 -0.2112 -1.3222 -2.9269 -1.1351 -0.2732
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic patients severe_heart_failure financial
H-1242	-0.6883733868598938	▁af ▁heart _ fail ure ▁financial _ ▁burde n
D-1242	-0.6883733868598938	af heart_failure financial_ burden
P-1242	-0.8319 -0.5836 -0.3047 -0.9625 -2.0588 -0.1134 -1.3202 -0.5655 -0.0926 -0.5242 -0.2145
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate_ratio therapy patient comorbidities
H-663	-0.4818517863750458	▁media n _ rate _ rati o ▁ therapy ▁como rbi di ties
D-663	-0.4818517863750458	median_rate_ratio therapy comorbidities
P-663	-0.2621 -0.2706 -0.1959 -1.3222 -0.2342 -0.0426 -0.0916 -1.8533 -0.0921 -1.6326 -0.0143 -0.2882 -0.0677 -0.5942 -0.2662
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular_pathways patients chronic_heart_failure chf
H-249	-1.0487533807754517	▁et ▁molecular _ path ways ▁chronic _ heart _ fail ure ▁gh f
D-249	-1.0487533807754517	et molecular_pathways chronic_heart_failure ghf
P-249	-1.5284 -3.3287 -0.6727 -0.1544 -0.3189 -0.5191 -0.2244 -1.8549 -0.1957 -1.2984 -0.5889 -4.1890 -0.2363 -0.3738 -0.2476
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization medicare hospital medicare policy
H-1715	-0.3329099118709564	▁re hospital ization ▁Medica re ▁claims ▁Medica re ▁post - a cute _ care _ transfer _ policy
D-1715	-0.3329099118709564	rehospitalization Medicare claims Medicare post-acute_care_transfer_policy
P-1715	-1.6159 -0.0446 -0.1682 -0.0657 -0.0226 -0.7912 -0.0764 -0.0206 -0.0721 -0.0768 -0.0513 -0.0732 -0.1622 -0.6524 -0.1612 -0.8296 -0.8790 -0.0764 -0.5250 -0.2937
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical activity crf hf mortality
H-1776	-0.7083169221878052	▁physical _ activ ity ▁c RF ▁h f ▁mortal ity
D-1776	-0.7083169221878052	physical_activity cRF hf mortality
P-1776	-0.1696 -2.0175 -0.1721 -0.0914 -0.2810 -1.6748 -1.0935 -1.3535 -0.8579 -0.1149 -0.4274 -0.2461
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow_up ffm patients
H-16	-0.8856719732284546	▁follow _ up _ ▁Body _ weight ▁FM ▁f f f cc
D-16	-0.8856719732284546	follow_up_ Body_weight FM fffcc
P-16	-0.1454 -1.7065 -0.8427 -0.6161 -1.7556 -0.2426 -0.4080 -2.0334 -0.6746 -1.5684 -0.8529 -0.5533 -0.7672 -0.2327
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary_endpoint intermacs interagency_registry_for_mechanically_assisted_circulatory_support
H-1996	-0.8678337335586548	▁inter mac s ▁inter age ncy _ ▁Registr y ▁mechanic ally _ assist ed _ ▁Circula tory _ support
D-1996	-0.8678337335586548	intermacs interagency_ Registry mechanically_assisted_ Circulatory_support
P-1996	-0.1959 -4.0354 -0.2505 -1.3435 -2.0518 -0.0619 -0.1353 -2.2704 -0.4125 -0.3367 -0.2978 -0.5895 -0.0163 -0.3777 -0.2678 -2.3712 -0.0743 -0.7768 -1.5043 -0.5810 -0.2739
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence clinical outcomes concentric_left_ventricular_hypertrophy heart_failure_with_preserved_ejection_fraction
H-1523	-0.7428421378135681	▁ecce n tric ▁concentr ic _ ▁left _ vent ri cular _ ▁hyper trop hy ▁heart _ fail ure ▁e je ction _ fraction
D-1523	-0.7428421378135681	eccentric concentric_ left_ventricular_ hypertrophy heart_failure ejection_fraction
P-1523	-0.2645 -0.0146 -0.9462 -0.2008 -0.0635 -0.5612 -5.4793 -0.4238 -0.9996 -1.2790 -0.4416 -0.3639 -2.5642 -0.1752 -0.3423 -0.3388 -0.2237 -1.5815 -1.5143 -0.1934 -0.1674 -0.1341 -0.2917 -0.0094 -0.4765 -0.2636
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients left_ventricular_ejection_fraction heart_failure_with_preserved_ejection_fraction hfpef
H-1887	-0.5442714691162109	▁left _ vent ri cular _ e je ction _ fraction ▁heart _ fail ure ▁pres er ved _ e je ction _ fraction HF p EF
D-1887	-0.5442714691162109	left_ventricular_ejection_fraction heart_failure preserved_ejection_fractionHFpEF
P-1887	-0.3468 -0.4956 -0.6134 -0.7924 -0.2482 -0.5100 -0.3046 -0.6061 -0.3501 -0.2581 -0.0484 -0.8366 -0.3183 -1.5394 -1.9857 -0.6370 -0.5177 -0.2250 -0.2678 -0.5180 -0.7448 -0.3263 -0.2518 -0.0547 -1.7388 -0.1157 -0.4594 -0.4170 -0.2562
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1260	-0.851980984210968	▁rate ▁left _ vent ri cular _ e je ction _ fraction ▁left _ vent ri cular _ dia sto lic _ end _ dia meter
D-1260	-0.851980984210968	rate left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter
P-1260	-3.3941 -1.1520 -0.3958 -1.9002 -1.5218 -0.4196 -0.3333 -0.5141 -0.7418 -0.2354 -0.1854 -0.0272 -0.7731 -0.4260 -1.4491 -1.4796 -0.3823 -0.3702 -0.2764 -1.0349 -0.8928 -0.2153 -4.4869 -0.1812 -0.0495 -0.1683 -0.6035 -0.2458
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic_receptor_blocker_therapy myocardial_perfusion neoangiogenesis heart
H-451	-0.4027178883552551	▁β - ad r energi c _ ▁receptor _ block er _ therapy ▁my o card ial _ per fusion ▁neo angi ogen es is ▁fail ing _ heart
D-451	-0.4027178883552551	β-adrenergic_ receptor_blocker_therapy myocardial_perfusion neoangiogenesis failing_heart
P-451	-0.0207 -0.0650 -0.0825 -0.5660 -0.1895 -0.1123 -0.1745 -0.3163 -0.2374 -1.4670 -0.4421 -0.7750 -0.1331 -0.9449 -0.2969 -0.8114 -0.5306 -0.2366 -0.1270 -0.0578 -0.1505 -0.1944 -0.0871 -0.5492 -0.1963 -0.9514 -0.0803 -0.2783 -1.8371 -0.3544 -0.2186
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular_matrix left_ventricular biopsies tissuefaxs correlated t1_time
H-741	-0.4853556156158447	▁extra cel lular _ ▁matri x ▁left _ vent ri cular _ ▁bio psi es ▁t issue FAX s ▁technology
D-741	-0.4853556156158447	extracellular_ matrix left_ventricular_ biopsies tissueFAXs technology
P-741	-0.9032 -0.1547 -0.1383 -0.1862 -1.3071 -0.2331 -0.1569 -0.4113 -0.9156 -0.9374 -0.2372 -0.4088 -1.0286 -0.6685 -0.7383 -0.7658 -0.0097 -0.2487 -0.5164 -0.0935 -0.3872 -0.2314
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart patients hfpef hf_with_reduced_ejection_fraction hfref
H-240	-0.8964709043502808	▁h ART HF p EF ▁h f ▁e je ction _ fraction ▁h r EF
D-240	-0.8964709043502808	hARTHFpEF hf ejection_fraction hrEF
P-240	-1.7480 -0.5188 -2.1692 -0.5693 -0.5596 -1.3455 -2.2855 -2.3748 -0.2534 -0.1240 -0.2045 -0.0175 -0.9246 -0.8130 -0.7264 -0.3999 -0.2058
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced_hf cxl-1020 contractility end-systolic_elastance venoarterial_dilation
H-421	-0.6153097748756409	▁dog s ▁ta chy pac ing - indu ced ▁h z ▁c XL -10 20 ▁contract ility ▁end - sy sto lic _ ▁elastan ce ▁ve no arte rial _ di lation
D-421	-0.6153097748756409	dogs tachypacing-induced hz cXL-1020 contractility end-systolic_ elastance venoarterial_dilation
P-421	-3.6701 -0.1230 -2.8196 -0.8716 -0.0112 -0.0791 -0.0892 -0.0002 -0.0090 -0.9533 -1.7072 -1.0899 -0.6773 -0.1245 -0.0407 -0.1240 -0.3581 -0.8471 -0.1752 -0.6819 -0.5642 -0.2314 -1.2901 -0.0191 -0.6303 -0.3869 -0.1559 -0.3047 -0.1603 -0.5518 -1.3248 -0.1255 -0.4694 -0.2541
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin_cytoskeleton mitochondrial_function metabolism glycolysis gluconeogenesis citrate_cycle
H-873	-0.4907500445842743	▁act in _ ▁cy tos kelet on ▁mito cho ndri al _ function ▁intermedi ate _ ▁metabolism ▁gly col ysis glu cone ogen es is ▁cit rate _ cycle
D-873	-0.4907500445842743	actin_ cytoskeleton mitochondrial_function intermediate_ metabolism glycolysisgluconeogenesis citrate_cycle
P-873	-0.0148 -0.3022 -0.2354 -2.0397 -0.9278 -0.1223 -0.2983 -0.1204 -1.5914 -0.3336 -0.1395 -0.8200 -0.2225 -0.0235 -0.8521 -0.1368 -1.3578 -0.1443 -0.1281 -0.5283 -1.0316 -0.1942 -0.3240 -0.2531 -0.2075 -0.0402 -0.0859 -0.2705 -1.9463 -0.3087 -0.2123
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated resistin biomarker anthracycline-induced_cardiotoxicity heart_failure macrophages
H-939	-0.5566180348396301	▁resist in ▁an thra cycli ne - indu ced _ ▁cardio toxic ity ▁heart _ fail ure
D-939	-0.5566180348396301	resistin anthracycline-induced_ cardiotoxicity heart_failure
P-939	-0.8447 -0.4797 -0.5661 -0.0582 -0.1617 -2.0267 -0.3569 -0.0001 -0.0071 -0.5123 -0.1275 -0.8567 -0.2465 -0.5792 -0.2551 -1.4474 -1.1339 -0.6283 -0.2875
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone_morphogenetic_protein_4 expression rrna_transcription shift heterochromatic_chromatin
H-98	-0.5969961881637573	▁bone _ ▁mor pho gene tic _ ▁protein ▁expression ▁r RNA _ trans scription ▁shift ▁hetero ch ro matic _ ▁chr omat in
D-98	-0.5969961881637573	bone_ morphogenetic_ protein expression rRNA_transscription shift heterochromatic_ chromatin
P-98	-0.7490 -0.3839 -1.0705 -0.8903 -1.9964 -0.8952 -0.1684 -1.5056 -0.0144 -0.1348 -0.1436 -0.3706 -1.2041 -0.1422 -0.1708 -0.1860 -0.3788 -0.0841 -0.6936 -0.1703 -1.7304 -0.1277 -1.0306 -0.4192 -0.2640
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left_ventricular_assist_devices lvads patients heart_failure incidence pump_dysfunction pump
H-773	-0.7705915570259094	▁left _ vent ri cular _ assist ances ▁l VAD s ▁heart _ fail ure ▁pump _ ▁dys function ▁pump _ ▁replace ment
D-773	-0.7705915570259094	left_ventricular_assistances lVADs heart_failure pump_ dysfunction pump_ replacement
P-773	-0.1698 -0.3743 -0.6652 -1.2948 -0.1296 -0.1753 -0.0152 -3.8915 -1.0927 -0.0452 -0.2024 -0.9401 -0.3133 -1.4586 -1.6447 -1.1807 -1.0938 -0.3838 -0.0129 -0.8222 -0.7716 -1.7743 -0.2045 -0.4073 -0.2009
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a angii hypoxia expression upr downregulation
H-1085	-0.7850605249404907	▁s cn 5 a ▁ang II ▁hypo xia ▁expression ▁induc ed ▁u PR ▁down regul ation
D-1085	-0.7850605249404907	scn5a angII hypoxia expression induced uPR downregulation
P-1085	-1.7242 -0.2627 -0.4865 -0.1433 -0.3323 -1.4784 -0.0726 -0.1726 -0.7860 -1.0127 -0.1907 -0.2800 -1.6362 -0.1876 -0.4079 -0.0655 -4.6199 -0.2720
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf multivariate-adjusted_odds_ratio mortality hazard_ratio mortality
H-1312	-0.4681730270385742	▁ HF ▁multi varia te - ad just ed _ ▁odds _ rati o ▁mortal ity ▁hazard _ rati o ▁mortal ity
D-1312	-0.4681730270385742	HF multivariate-adjusted_ odds_ratio mortality hazard_ratio mortality
P-1312	-3.4882 -0.5841 -1.7944 -0.7988 -0.3076 -0.2082 -0.0380 -0.0177 -0.0882 -0.2137 -0.3049 -0.2331 -0.0683 -0.0918 -0.2413 -0.3213 -0.1594 -0.3722 -0.0606 -0.0821 -0.1814 -0.7736 -0.5141 -0.2934
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas hf hyperkalemia hypokalemia spironolactone clinical
H-1708	-0.6538807153701782	▁AA s HF ▁hyper kal emia ▁hypo kal emia ▁spi rono lac tone
D-1708	-0.6538807153701782	AAsHF hyperkalemia hypokalemia spironolactone
P-1708	-3.3480 -0.2068 -1.3153 -0.2924 -0.7652 -0.2403 -0.0344 -0.8488 -0.3334 -0.0686 -0.0208 -0.1880 -0.1008 -1.8769 -0.1685
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate_logistic_regression_analysis bnp patients diastolic_dysfunction
H-1571	-0.6271476745605469	▁b n ▁dia sto lic _ ▁dys function
D-1571	-0.6271476745605469	bn diastolic_ dysfunction
P-1571	-1.0027 -1.7842 -0.3725 -0.1618 -0.5057 -0.5339 -1.1577 -0.0852 -0.4210 -0.2467
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo dopamine nesiritide secondary_end_points renal_function clinical outcomes
H-82	-0.2657257616519928	▁dop amine ▁nesi riti de ▁renal _ function
D-82	-0.2657257616519928	dopamine nesiritide renal_function
P-82	-0.4205 -0.2329 -0.0075 -0.1544 -0.1830 -0.0623 -0.6136 -0.3786 -0.3993 -0.2052
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp nonterminal_epitopes central_glycosylated_region
H-1522	-0.7119912505149841	▁NT - pro b NP _ as say ▁non termin al _ e pito pes ▁gly cos yla ted
D-1522	-0.7119912505149841	NT-probNP_assay nonterminal_epitopes glycosylated
P-1522	-0.0588 -0.1487 -0.0688 -0.9879 -0.6552 -0.4975 -0.2239 -0.5773 -2.3590 -3.1595 -0.0326 -0.2318 -0.2993 -0.2180 -1.6174 -1.0081 -0.3048 -0.7373 -0.1457 -1.3264 -0.2938
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors g-protein-coupled_receptor kinase-2 downregulation
H-1407	-0.22724997997283936	▁receptor s ▁g - prote in - co up led _ ▁receptor _ ▁kina se -2
D-1407	-0.22724997997283936	receptors g-protein-coupled_ receptor_ kinase-2
P-1407	-0.0671 -0.2735 -0.6636 -0.1705 -0.1132 -0.2785 -0.1868 -0.0174 -0.0925 -0.0850 -0.2540 -0.2932 -0.3617 -0.0889 -0.0785 -0.1241 -0.6744 -0.2675
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic_function hfpef patients long_axis_function exercise
H-1888	-0.4840157628059387	▁techniques ▁sy sto lic _ function HF p EF ▁long _ a xis _ function ▁exercise
D-1888	-0.4840157628059387	techniques systolic_functionHFpEF long_axis_function exercise
P-1888	-1.4970 -1.5067 -0.2704 -0.3938 -0.3605 -0.2346 -1.3813 -0.2526 -0.3444 -0.5079 -0.3327 -0.2248 -0.0298 -0.1537 -0.4618 -0.1153 -0.4131 -0.2318
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable_models st2 outcomes clinical amino-terminal_pro-b-type_natriuretic_peptide
H-704	-0.3974861800670624	▁ST 2 ▁amino - termin al ▁na tri ure tic _ pe pti de
D-704	-0.3974861800670624	ST2 amino-terminal natriuretic_peptide
P-704	-1.0801 -0.0298 -0.4066 -0.0750 -0.5762 -0.0693 -1.1183 -0.0741 -0.0332 -0.3896 -0.3724 -0.6720 -0.2016 -0.6979 -0.3466 -0.2172
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia medline cochrane_library
H-31	-0.2601977288722992	▁guide line ▁an emia ▁ir on _ de fici en cy ▁MED line ▁co ch rane _ ▁Library
D-31	-0.2601977288722992	guideline anemia iron_deficiency MEDline cochrane_ Library
P-31	-0.4917 -0.0376 -0.3633 -0.0955 -0.0101 -0.1928 -0.1288 -0.1641 -0.0531 -0.7705 -0.0575 -0.7493 -0.4045 -0.1364 -0.3718 -0.1147 -0.2027 -0.2170 -0.4095 -0.2329
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change correlation hospitals longitudinal
H-138	-0.9572388529777527	
D-138	-0.9572388529777527	
P-138	-1.6761 -0.2384
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine bnp furosemide dobutamine norepinephrine outcome
H-587	-0.5076541900634766	▁creati nine ▁b NP ▁fur os em ide _ ▁dose ▁oxygen _ flow ▁dobu tamine ▁no re pine ph rine
D-587	-0.5076541900634766	creatinine bNP furosemide_ dose oxygen_flow dobutamine norepinephrine
P-587	-1.5992 -1.2151 -0.2328 -1.6234 -0.1711 -0.0916 -0.1650 -0.0897 -0.8535 -1.7797 -0.2416 -0.2056 -0.1409 -0.0533 -0.0885 -0.0409 -0.0831 -0.0262 -1.5328 -0.1957 -0.5552 -0.1835
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical biomedical patients dcm heart_failure pubmed
H-1259	-0.8665938973426819	▁bio medic al ▁CH m ▁bio medic al ▁d c ▁heart _ fail ure ▁Pub Med
D-1259	-0.8665938973426819	biomedical CHm biomedical dc heart_failure PubMed
P-1259	-0.0794 -0.3139 -0.0957 -5.0963 -0.1458 -0.0582 -0.2336 -0.1135 -2.9385 -1.9163 -0.6634 -0.2564 -1.5818 -0.8474 -0.2737 -0.3966 -0.3507 -0.2374
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 myocardial_collagen myocardial
H-1064	-0.7086664438247681	▁my o card ial _ ▁collage n ▁my o card ial _ de lay ed _ ▁enhance ment _ ▁imagin g
D-1064	-0.7086664438247681	myocardial_ collagen myocardial_delayed_ enhancement_ imaging
P-1064	-1.3678 -0.5383 -1.2311 -0.6954 -0.1844 -0.2818 -0.1754 -1.9852 -0.5603 -1.1258 -0.8407 -0.3834 -0.1469 -0.1035 -0.1304 -0.3320 -2.2361 -0.0889 -0.3613 -2.8173 -0.0843 -0.4161 -0.2128
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 sst2 odds_ratio cardiovascular_event
H-408	-0.6942678689956665	▁s st 2 ▁high - dos e _ bb ▁s st 2 ▁low - dos e _ bb ▁odds _ rati o ▁cardiovascular _ evento
D-408	-0.6942678689956665	sst2 high-dose_bb sst2 low-dose_bb odds_ratio cardiovascular_evento
P-408	-0.0644 -1.3653 -0.7796 -1.4971 -0.1012 -1.3124 -0.5579 -0.7932 -0.9833 -0.2256 -1.4772 -0.0647 -1.6543 -0.0972 -1.1343 -0.4753 -0.6475 -0.8546 -0.2918 -0.4292 -0.1087 -0.0604 -0.1250 -0.6305 -2.0927 -0.6768 -0.2451
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley randomized acf allopurinol
H-473	-0.7164910435676575	▁Spr a gue - Da w ley ▁sham ▁a CF ▁allo puri nol
D-473	-0.7164910435676575	Sprague-Dawley sham aCF allopurinol
P-473	-0.5177 -1.1671 -0.0369 -0.1272 -2.2577 -0.0475 -1.4376 -1.1303 -1.2521 -1.0092 -0.1207 -0.0427 -0.9108 -0.4560 -0.2337
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular_pacing bivp cardiac_output cardiac surgery patients
H-319	-0.6424065828323364	▁bi ven tri cular _ pa cing ▁bi VP ▁cardiac _ out put ▁co ▁cardiac _ ▁surgery ▁mechanism
D-319	-0.6424065828323364	biventricular_pacing biVP cardiac_output co cardiac_ surgery mechanism
P-319	-2.4805 -0.6048 -1.4048 -0.5225 -0.3187 -0.5306 -0.5510 -1.2247 -0.7003 -0.1014 -0.2336 -0.1987 -0.0112 -1.1362 -0.0992 -0.2559 -0.9476 -0.8904 -0.3700 -0.2662
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin sitagliptin follow-up
H-1833	-0.5987279415130615	▁sax ag lip tin ▁si tag lip tin ▁follow - up ▁pair wise
D-1833	-0.5987279415130615	saxagliptin sitagliptin follow-up pairwise
P-1833	-0.3061 -0.0296 -0.5195 -2.3382 -0.7775 -0.0034 -0.3692 -2.8705 -0.0877 -0.3387 -0.0394 -0.2151 -0.2428 -0.6008 -0.2426
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq patients hfpef
H-790	-0.9311213493347168	▁k cc q ▁internal ▁h f p EF ▁ ron bach
D-790	-0.9311213493347168	kccq internal hfpEF ronbach
P-790	-1.9975 -0.0905 -0.8550 -0.2487 -1.4005 -2.3543 -0.0084 -0.7298 -1.1952 -2.4275 -0.0434 -0.5078 -0.2460
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable patients qrs_duration
H-891	-0.6965402364730835	▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT LB b ▁QR s _ du ration
D-891	-0.6965402364730835	implantable_ cardioverter_defibrillator-cRTLBb QRs_duration
P-891	-0.0099 -0.0965 -0.8724 -0.1964 -0.1112 -0.1079 -0.2936 -0.0544 -0.2061 -0.8666 -0.0616 -0.1775 -0.2360 -0.9295 -3.4903 -2.5508 -1.6505 -0.5909 -1.0720 -1.3404 -0.1401 -0.1960 -1.2264 -0.2400
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up patients
H-1538	-0.7216724157333374	▁follow - up _ times ▁et id rona te - ▁ra lo xi fen e - tre ated
D-1538	-0.7216724157333374	follow-up_times etidronate- raloxifene-treated
P-1538	-0.1705 -0.3004 -0.0441 -1.1365 -2.0785 -5.8786 -0.3984 -0.1153 -0.0704 -1.3233 -0.3142 -0.0736 -0.0398 -0.1125 -0.4948 -0.1021 -0.0252 -0.1560 -1.3482 -0.2511
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal diagnostic clinical
H-1304	-0.5896874666213989	▁principal _ me chan ism s ▁diagnose
D-1304	-0.5896874666213989	principal_mechanisms diagnose
P-1304	-0.0337 -0.2238 -0.2208 -0.0388 -0.0273 -0.1086 -3.4930 -0.9517 -0.2096
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients systolic_hf the_danish_heart_failure_database esrd danish_registry_on_dialysis
H-389	-0.8662090301513672	▁sy sto lic _ HF ▁Danish _ ▁Heart _ fail ure ▁ES RD ▁Danish _ ▁Registr y _ on _ dia lys is
D-389	-0.8662090301513672	systolic_HF Danish_ Heart_failure ESRD Danish_ Registry_on_dialysis
P-389	-1.2540 -0.1074 -0.1255 -1.0506 -1.1568 -0.7728 -0.6753 -0.5877 -0.2721 -0.5739 -0.1379 -3.1543 -2.5411 -1.7133 -1.1641 -2.4750 -0.4714 -0.2590 -0.3286 -0.3129 -1.0309 -0.4982 -0.3401 -0.4344 -0.2179
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy trastuzumab comorbidities chf international_classification_of_diseases healthcare_common_procedure_coding_system_codes
H-674	-0.26247456669807434	▁che mo therapy ▁tras tuz um ab ▁CHF ▁international _ ▁Classifica tion _ of _ ▁Disease s ▁health care ▁common _ procedure _ co ding _ system _ code s
D-674	-0.26247456669807434	chemotherapy trastuzumab CHF international_ Classification_of_ Diseases healthcare common_procedure_coding_system_codes
P-674	-1.9857 -0.1655 -0.0455 -0.1463 -0.0252 -0.0735 -0.0406 -0.1538 -0.3736 -0.2111 -0.5382 -0.0292 -0.2385 -0.0337 -0.4157 -0.2003 -0.0942 -0.1037 -0.1078 -0.6826 -0.1992 -0.0645 -0.6044 -0.1933 -0.2418 -0.1295 -0.0939 -0.3417 -0.1486 -0.1061 -0.3770 -0.2346
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart_failure hf therapies outcomes patients hf preserved_left_ventricular_ejection_fraction lvef
H-111	-0.7453126311302185	▁heart _ ▁failure HF HF ▁left _ vent ri cular _ e je ction _ fraction LV EF
D-111	-0.7453126311302185	heart_ failureHFHF left_ventricular_ejection_fractionLVEF
P-111	-2.1363 -0.3281 -2.7946 -0.7498 -0.8345 -1.6721 -0.3644 -0.6050 -0.9712 -0.2851 -0.3120 -0.3303 -0.5659 -0.2622 -0.2037 -0.0306 -1.0415 -0.8630 -0.3486 -0.2074
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths crt hazard_ratio
H-853	-0.6143689155578613	▁c t ▁hazard _ rati o
D-853	-0.6143689155578613	ct hazard_ratio
P-853	-0.5742 -2.6479 -0.5210 -0.2939 -0.0546 -0.0486 -0.5003 -0.2746
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation consultation consultation operation
H-1283	-0.7610230445861816	▁transplant ation ▁m t ▁operation
D-1283	-0.7610230445861816	transplantation mt operation
P-1283	-1.6222 -0.1221 -2.1334 -0.6534 -0.2524 -0.3469 -0.1969
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized heart_failure saxagliptin sitagliptin antihyperglycemic_drugs retrospective_cohort_study
H-1826	-0.6207742094993591	▁Hospital ized _ ▁Heart _ fail ure ▁Sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic _ drug s
D-1826	-0.6207742094993591	Hospitalized_ Heart_failure Saxagliptin sitagliptin antihyperglycemic_drugs
P-1826	-2.0191 -0.0711 -0.3499 -0.4850 -0.2576 -0.7819 -0.0950 -0.1724 -0.0281 -0.8305 -2.8019 -1.0668 -0.0022 -0.2076 -2.4403 -0.0947 -0.1007 -0.1060 -0.8757 -0.2663 -1.5973 -0.3836 -0.4252 -0.0765 -0.3512 -0.2535
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise training outcomes chronic_heart_failure heart_failure_-_a_controlled_trial_investigating_outcomes_in_exercise_training hf-action
H-1629	-0.8742941617965698	▁race ▁exercise _ training ▁chronic _ heart _ fail ure ▁Heart _ fail ure ▁exercise _ tra i N ing HF - ac tion
D-1629	-0.8742941617965698	race exercise_training chronic_heart_failure Heart_failure exercise_traiNingHF-action
P-1629	-2.0363 -1.0943 -2.2081 -0.2516 -0.4333 -0.3745 -1.5555 -0.2173 -0.7307 -0.4485 -1.0502 -0.2527 -0.4139 -0.1964 -0.7153 -0.3495 -0.8325 -1.2458 -3.7432 -0.1826 -1.0738 -0.0360 -1.0181 -1.6619 -0.3732 -0.2359
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass_correlation_coefficient icc kappa_coefficient standard_error_of_measurement minimal_detectable_change mdc
H-801	-0.2845922112464905	▁intra class _ corre lation _ co e ffi cient ▁i cc ▁ka ppa _ co e ffi cient ▁change ▁m d c
D-801	-0.2845922112464905	intraclass_correlation_coefficient icc kappa_coefficient change mdc
P-801	-0.9851 -0.1566 -0.3121 -0.4130 -0.3274 -0.2527 -0.1738 -0.5140 -0.0758 -0.1420 -0.4948 -0.1374 -0.8632 -0.0384 -0.2129 -0.1660 -0.2736 -0.0779 -0.1475 -0.0626 -0.1560 -0.0792 -0.3109 -0.5241 -0.2179
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil phosphocreatine adenine_nucleotides mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity
H-964	-0.4814590513706207	▁Nico rand il ▁ phos pho creati ne ▁a den ine _ ▁nucleo ti des ▁mito cho ndri al _ oxid ation _ capaci ty ▁creati ne _ ▁kina se _ activ ity
D-964	-0.4814590513706207	Nicorandil phosphocreatine adenine_ nucleotides mitochondrial_oxidation_capacity creatine_ kinase_activity
P-964	-0.0045 -0.0233 -0.0391 -0.1558 -0.1616 -0.3776 -0.5856 -1.6274 -0.0793 -0.0153 -0.6606 -0.1729 -0.1263 -0.0744 -0.2177 -0.0463 -1.4035 -0.2163 -0.1403 -0.4885 -0.4290 -4.0265 -0.6999 -0.6738 -0.0638 -0.9675 -0.7346 -0.3254 -0.0155 -0.0701 -1.3446 -0.0986 -0.1057 -0.4675 -0.2122
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox_proportional_hazards_models death transplantation lv_assist_device_implantation heart_failure hospitalization follow-up
H-431	-0.7982322573661804	▁death ▁transplant ation ▁LV _ assist _ ▁Device _ ▁implant ation ▁heart _ fail ure ▁follow - up
D-431	-0.7982322573661804	death transplantation LV_assist_ Device_ implantation heart_failure follow-up
P-431	-3.7167 -0.7597 -0.0708 -0.1096 -0.7278 -0.0129 -1.6519 -3.4970 -0.4667 -0.2656 -0.0724 -0.5105 -0.3954 -1.5689 -1.0583 -0.2091 -0.2727 -0.0317 -0.3301 -0.2367
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones adipokines fat_free_mass ffm fat_mass
H-11	-0.7538033723831177	▁neuro hormon es ▁adi pok ines ▁body _ ▁composición cc ▁progressive _ los s ▁fat _ free _ ▁mass ▁f m ▁fat _ ▁mass FM
D-11	-0.7538033723831177	neurohormones adipokines body_ composicióncc progressive_loss fat_free_ mass fm fat_ massFM
P-11	-0.0986 -0.1892 -0.5825 -0.1570 -0.0724 -0.3623 -1.2406 -0.3242 -3.2039 -0.8136 -1.9954 -0.6372 -1.7541 -0.3569 -2.1632 -0.1879 -0.3351 -0.2861 -1.2376 -0.9653 -0.2413 -0.8420 -0.2342 -0.8711 -0.6152 -0.3707 -0.2153
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient primary_end_point rehospitalization stroke myocardial_infarction heart_failure cabg
H-972	-0.462370365858078	▁Swedish _ national _ in patient _ ▁Registr y ▁re hospital ization ▁stroke ▁my o card ial _ in far ction ▁heart _ fail ure ▁ca BG
D-972	-0.462370365858078	Swedish_national_inpatient_ Registry rehospitalization stroke myocardial_infarction heart_failure caBG
P-972	-0.2779 -0.3245 -0.3407 -0.2340 -0.0955 -0.1547 -0.2269 -3.1784 -0.1656 -0.1741 -0.0081 -0.0991 -0.4268 -0.6542 -0.3971 -0.4485 -0.4197 -0.3313 -0.4702 -0.0641 -0.5076 -0.4016 -0.2962 -0.6750 -0.8401 -0.2908 -1.3674 -0.3517 -0.1872
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule expression regulation rad q66p rgk_protein in_vivo
H-1678	-0.6025482416152954	▁expression ▁mis tar ge ting ▁regula tion ▁rad _ q 66 p ▁r GK _ ▁protein
D-1678	-0.6025482416152954	expression mistargeting regulation rad_q66p rGK_ protein
P-1678	-0.0279 -0.0624 -0.0579 -0.1121 -0.1262 -0.5853 -0.0986 -0.5725 -0.6805 -1.9067 -0.4682 -0.7620 -1.6544 -1.0122 -0.3308 -0.8569 -1.2681 -0.2632
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter_ablation patients compensated_hfpef left_ventricular ejection_fraction
H-944	-0.5677264332771301	▁cat heter _ ab lation ▁AF ▁compensa ted ▁h f f ▁vent ri cular ▁e je ction _ fraction
D-944	-0.5677264332771301	catheter_ablation AF compensated hff ventricular ejection_fraction
P-944	-0.6790 -0.0672 -0.2692 -0.7106 -0.0980 -1.1887 -1.0668 -0.0236 -0.7299 -1.2559 -0.3650 -3.0254 -0.6071 -0.3767 -0.2830 -0.1603 -0.0863 -0.2587 -0.0074 -0.4673 -0.1964
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte_hypertrophy heart_failure global_gene_expression dna genomic
H-89	-0.7180023789405823	▁my o cy te _ ▁hyper trop hy ▁heart _ fail ure ▁gene _ expression ▁DNA
D-89	-0.7180023789405823	myocyte_ hypertrophy heart_failure gene_expression DNA
P-89	-2.1328 -0.1060 -0.0429 -0.0674 -0.2652 -1.9857 -0.1215 -0.1262 -0.5030 -0.2013 -1.2068 -1.5679 -1.1643 -0.2958 -0.2488 -1.6090 -1.0361 -0.2435
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully_magnetically_levitated_lvas mortality seattle heart_failure
H-2002	-0.5404525995254517	▁fully _ magnet ically _ le vita ted _ ▁l VAS ▁mortal ity ▁Seattle _ ▁Heart _ fail ure
D-2002	-0.5404525995254517	fully_magnetically_levitated_ lVAS mortality Seattle_ Heart_failure
P-2002	-1.8301 -0.2244 -0.1679 -0.1944 -0.2380 -1.3697 -0.0076 -0.0392 -0.8945 -3.0693 -0.7937 -0.2875 -0.0668 -0.3752 -0.3929 -0.2519 -0.2823 -0.2847 -0.0851 -0.2776 -0.2165
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa immunoassays antibodies c_termini nt-probnp
H-1518	-0.5041724443435669	▁Alpha lis a ▁immun o assa ys ▁anti bo dies ▁circula ting ▁NT - pro b NP
D-1518	-0.5041724443435669	Alphalisa immunoassays antibodies circulating NT-probNP
P-1518	-0.0805 -1.0231 -0.3822 -0.5006 -0.4903 -0.4224 -1.7877 -0.0827 -0.0333 -0.2934 -1.8448 -0.1308 -0.3814 -0.1108 -0.0613 -0.8156 -0.5765 -0.3803 -0.1815
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac_plasma_membrane s1pr1 β1ar heart_failure
H-1411	-0.5284726619720459	▁cardiac _ ▁plasma _ ▁membran e ▁s 1 PR 1 ▁β 1 ar ▁over stimul ation ▁heart _ fail ure
D-1411	-0.5284726619720459	cardiac_ plasma_ membrane s1PR1 β1ar overstimulation heart_failure
P-1411	-0.6097 -0.2261 -0.6756 -0.2647 -0.8099 -0.1192 -0.3652 -0.0838 -1.7402 -0.3495 -0.3595 -0.2986 -0.7764 -1.1479 -0.3522 -0.0752 -0.1833 -0.2399 -1.3375 -1.0377 -0.3566 -0.2177
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients new_york_heart_association nyha chronic_heart_failure reduced_ejection_fraction
H-1952	-0.7216315269470215	▁New _ York _ ▁Heart _ association NY ha ▁chronic _ ▁heart _ fail ure ▁e je ction _ fraction
D-1952	-0.7216315269470215	New_York_ Heart_associationNYha chronic_ heart_failure ejection_fraction
P-1952	-0.8340 -1.0068 -2.2517 -0.2202 -0.5370 -0.1904 -0.4419 -1.4489 -0.8025 -0.2956 -0.2872 -1.9731 -0.2081 -1.1942 -1.6696 -1.1419 -0.1520 -0.1361 -0.2513 -0.0197 -0.5841 -0.2295
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological_phenotype clinically deficit_index medical frailty
H-1013	-0.8590362071990967	▁bi ological _ ▁ph eno type ▁medical _ re cord s
D-1013	-0.8590362071990967	biological_ phenotype medical_records
P-1013	-0.8923 -0.2716 -0.6904 -2.3925 -0.1242 -0.0101 -0.3974 -0.9011 -1.2731 -0.4184 -1.5404 -1.9789 -0.2771
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel apoptotic_cells tunel-positive_cells
H-172	-0.541051983833313	▁tu nel _ as say ▁apo pto tic _ cell s ▁tu nel - posi tive _ cell s
D-172	-0.541051983833313	tunel_assay apoptotic_cells tunel-positive_cells
P-172	-1.8937 -2.2671 -0.3676 -0.5043 -0.5931 -0.5659 -0.1670 -0.1858 -0.2883 -0.2003 -0.2755 -1.0895 -1.3499 -0.1372 -0.0083 -0.1591 -0.2570 -0.1190 -0.2808 -0.3811 -0.2716
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt elevated acute β-adrenoceptor_blockade esmolol
H-1444	-0.8195024132728577	▁SD QT ▁h w t ▁h nor m ▁β - ad re no cept or _ block ade ▁es mol ol
D-1444	-0.8195024132728577	SDQT hwt hnorm β-adrenoceptor_blockade esmolol
P-1444	-0.1669 -2.1459 -0.4464 -3.6002 -0.7492 -0.2389 -3.8875 -0.2343 -0.2743 -0.0697 -0.1287 -0.1299 -0.1026 -0.7356 -0.2333 -0.1873 -1.0272 -1.7886 -1.8114 -0.0247 -0.1282 -0.5391 -0.1987
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically myocardial_infarction heart_failure randomized bisoprolol
H-452	-0.7366312742233276	▁induc ed _ My o card ial _ in far ction ▁heart _ fail ure ▁bis o pro lol ▁vehicle
D-452	-0.7366312742233276	induced_Myocardial_infarction heart_failure bisoprolol vehicle
P-452	-0.9069 -0.1187 -0.8974 -4.2187 -0.5783 -0.8219 -0.6688 -0.2950 -0.2666 -0.0355 -0.3402 -0.4171 -0.3000 -0.7408 -1.9811 -0.7021 -0.2403 -0.0546 -0.5488 -1.3481 -0.4924 -0.2325
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts hh medical all-cause_mortality discharged patients heart_failure
H-162	-0.8282240629196167	▁s ts _ HH ▁t m ▁medical ▁all - ca use _ ▁mortal ity ▁dis charge d ▁patients ▁heart _ fail ure
D-162	-0.8282240629196167	sts_HH tm medical all-cause_ mortality discharged patients heart_failure
P-162	-0.9235 -0.5205 -1.1434 -1.3157 -2.4904 -0.3262 -0.4528 -4.1767 -0.0704 -0.0119 -0.3805 -0.1704 -0.4485 -0.1071 -0.7392 -0.0088 -0.1130 -1.2730 -1.1633 -0.2582 -1.2418 -1.7892 -0.4993 -0.2537
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions readmission patients congestive_heart_failure south_dakota
H-1583	-0.6307899355888367	▁transition s _ of _ care ▁read mission _ rate ▁con ges tive _ heart _ fail ure ▁mid we stern _ state ▁South _ da kota
D-1583	-0.6307899355888367	transitions_of_care readmission_rate congestive_heart_failure midwestern_state South_dakota
P-1583	-0.2186 -0.1654 -0.6339 -0.0615 -0.2412 -0.3548 -2.2298 -0.0732 -0.4925 -0.6678 -0.6143 -0.1125 -0.7091 -0.2607 -2.0297 -0.1430 -1.0536 -1.1310 -0.6640 -0.2672 -0.0713 -0.9144 -0.0096 -2.3701 -0.8542 -1.1199 -0.0664 -0.4920 -0.2712
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia intravenous atropine cardiac vagal_tone
H-1380	-0.5376327633857727	▁ta chy car dia ▁intra ven ous _ a tropi ne ▁cardiac _ va gal _ ▁tone ▁CHF - DN x ▁CHF - in v
D-1380	-0.5376327633857727	tachycardia intravenous_atropine cardiac_vagal_ tone CHF-DNx CHF-inv
P-1380	-1.6809 -0.3596 -0.0451 -0.0524 -0.7413 -0.0426 -1.1808 -0.5596 -0.0796 -0.0757 -1.6473 -0.0640 -0.3313 -1.0254 -0.1092 -0.2484 -0.9313 -0.2441 -0.0550 -2.3475 -0.1172 -0.5043 -0.1057 -0.1146 -0.2260 -1.4157 -0.2115
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes myocardium conditions
H-990	-0.565423846244812	▁cardio my o cy tes ▁mechanic al ▁humor al ▁my o car dium ▁conditions
D-990	-0.565423846244812	cardiomyocytes mechanical humoral myocardium conditions
P-990	-0.2705 -1.3071 -0.3015 -0.0720 -0.7334 -0.0372 -0.1549 -1.1145 -0.0803 -2.4100 -0.1408 -0.0791 -0.2917 -0.0187 -1.8032 -0.2318
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse pasp step rv_function lv_dysfunction
H-501	-0.8230711817741394	▁passage ▁length - force ▁ RV _ function ▁LV _ ▁dys function
D-501	-0.8230711817741394	passage length-force RV_function LV_ dysfunction
P-501	-3.7213 -0.0296 -0.1352 -0.0179 -2.0477 -0.8468 -1.0618 -0.2159 -0.2332 -1.9425 -0.6939 -0.0199 -0.3299 -0.2274
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular_support rvads explanted
H-301	-0.5662115812301636	▁bi ven tri cular _ support ▁r VAD s ▁ex plant ed
D-301	-0.5662115812301636	biventricular_support rVADs explanted
P-301	-0.7786 -0.2196 -0.3889 -0.2426 -0.7144 -1.4774 -2.5142 -0.3837 -0.1803 -0.2818 -0.0386 -0.1369 -0.3669 -0.2029
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno_donor myocardial_function evidence hf
H-425	-0.7648565173149109	▁functional _ ef fica cy ▁h no _ ▁donor ▁my o card ial _ function ▁first - in - man _ e viden ce ▁h w
D-425	-0.7648565173149109	functional_efficacy hno_ donor myocardial_function first-in-man_evidence hw
P-425	-2.5821 -0.8523 -0.8979 -0.0673 -0.0807 -0.5108 -0.2017 -1.3862 -1.6803 -1.0339 -0.3028 -0.5645 -0.8323 -0.3308 -0.3938 -1.2067 -0.1160 -0.0846 -0.7033 -0.1064 -0.2739 -1.1237 -1.0017 -0.1802 -0.4577 -3.7586 -0.4207 -0.2650
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions training patients out-patient follow-up patient health_care
H-1579	-0.5865083932876587	▁transition s _ of _ care
D-1579	-0.5865083932876587	transitions_of_care
P-1579	-0.0263 -0.3610 -0.6396 -0.0479 -0.2551 -0.2664 -2.8749 -0.2208
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd outpatients systolic_hf patients egfr
H-396	-1.1085505485534668	▁ec r ▁out patient s ▁sy sto lic ▁h f ▁e g f
D-396	-1.1085505485534668	ecr outpatients systolic hf egf
P-396	-3.2055 -2.0412 -1.7532 -0.0427 -0.0736 -1.0580 -0.0868 -0.1247 -1.4581 -1.0987 -0.5197 -0.3576 -2.1917 -2.2666 -0.3501
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf phenotype cardiac explant progenitors regulation
H-1337	-0.38391226530075073	▁CHF ▁cardiac _ ex plant
D-1337	-0.38391226530075073	CHF cardiac_explant
P-1337	-0.4089 -0.1842 -0.2134 -0.2836 -0.0136 -1.3941 -0.1896
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy sst2 patients chronic_heart_failure
H-411	-0.9593437910079956	▁BB _ therapy ▁s st 2 _ me chan ism ▁chronic _ heart _ fail ure ▁BB
D-411	-0.9593437910079956	BB_therapy sst2_mechanism chronic_heart_failure BB
P-411	-1.3610 -1.2251 -0.1109 -0.0711 -0.8647 -0.0232 -2.5617 -0.5857 -1.8841 -0.0168 -0.6574 -0.3048 -2.2916 -0.2659 -1.7194 -0.9716 -2.2552 -0.7819 -0.2752
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission disease heart_failure hf acute_myocardial_infarction ami pneumonia
H-137	-0.9040827751159668	▁read mission _ rate s ▁heart _ fail ure HF ▁a cute _ My o card ial _ in far ction AMI ▁pneu monia
D-137	-0.9040827751159668	readmission_rates heart_failureHF acute_Myocardial_infarctionAMI pneumonia
P-137	-3.8806 -0.1258 -0.7408 -0.9819 -0.0723 -1.0292 -0.2779 -1.6420 -2.2588 -1.2257 -0.3439 -0.0476 -0.2511 -4.5140 -0.7263 -0.4054 -0.6364 -0.2581 -0.3430 -0.1015 -0.4225 -0.6635 -0.0074 -1.8612 -0.4695 -0.2197
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed heart_failure left_ventricular_ejection_fraction spironolactone kaiser_permanente northern_california
H-440	-0.4997967481613159	▁heart _ fail ure ▁left _ vent ri cular _ e je ction _ fraction ▁spi rono lac tone ▁Kaiser _ per man ent _ ▁Northern _ ▁California
D-440	-0.4997967481613159	heart_failure left_ventricular_ejection_fraction spironolactone Kaiser_permanent_ Northern_ California
P-440	-0.6761 -0.3475 -1.0464 -1.7924 -0.1288 -0.3755 -0.5235 -0.8269 -0.2524 -0.4126 -0.1695 -0.3524 -0.2238 -1.7738 -0.0093 -0.0558 -0.0076 -0.2374 -0.0454 -0.0619 -0.2709 -0.3101 -1.1591 -0.4882 -0.9531 -0.5398 -0.2086 -1.2294 -0.2864 -0.2293
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression_analysis echocardiographic lv_reverse_remodeling lv_end-systolic_volume
H-430	-0.7176752686500549	▁e cho car dio graphic ▁LV ▁rever se _ ▁remodel ing ▁LV ▁end - sy sto lic _ ▁volume
D-430	-0.7176752686500549	echocardiographic LV reverse_ remodeling LV end-systolic_ volume
P-430	-1.2145 -0.5140 -0.1783 -0.8128 -1.0098 -2.2576 -0.0459 -0.0889 -0.1038 -2.4610 -0.0940 -0.6877 -0.9003 -0.1887 -0.5414 -0.4424 -0.4284 -0.7224 -1.7253 -0.4557 -0.1984
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative renal_dysfunction cardiovascular_events stroke myocardial_infarction heart_failure death isolated_coronary_artery_bypass_grafting
H-968	-0.5261771082878113	▁renal _ ▁dys function ▁cardiovascular _ ▁events stro ke ▁my o card ial _ in far ction ▁heart _ ▁failure ▁corona ry _ ▁arter y _ ▁by pass _ ▁graf ting
D-968	-0.5261771082878113	renal_ dysfunction cardiovascular_ eventsstroke myocardial_infarction heart_ failure coronary_ artery_ bypass_ grafting
P-968	-0.4373 -0.4838 -0.4688 -0.0223 -0.0428 -0.9623 -1.8585 -0.1357 -0.0410 -0.7495 -0.2942 -0.5682 -0.4070 -0.4097 -0.5875 -0.0330 -0.2006 -0.2304 -0.4209 -1.6062 -0.1978 -0.5169 -0.3924 -0.2371 -0.7518 -0.6791 -2.2733 -0.0095 -0.7708 -0.1062 -0.6951 -0.4847 -0.2895
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone_antagonist therapy chronic_advanced_heart_failure patients post-myocardial_infarction heart_failure patients
H-1738	-0.8097035884857178	▁al do ster one _ ▁anta gon ist _ therapy ▁chronic _ ▁advanced _ heart _ ▁failure ▁post - my o card ial _ in far ction _ ▁heart _ ▁failure ▁e je ction
D-1738	-0.8097035884857178	aldosterone_ antagonist_therapy chronic_ advanced_heart_ failure post-myocardial_infarction_ heart_ failure ejection
P-1738	-0.6773 -0.1883 -0.3581 -0.3880 -0.3408 -0.3736 -0.0268 -1.5025 -0.5246 -0.1042 -2.4503 -0.4298 -3.4157 -0.2094 -2.0829 -0.1800 -2.7945 -0.0272 -0.1086 -2.8352 -0.7053 -0.9294 -0.5198 -0.3342 -0.3280 -0.0600 -0.2637 -1.0001 -1.8751 -0.1737 -2.4334 -0.5313 -0.0619 -0.1839 -0.4665 -0.2653
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial_shunting patients heart_failure_with_reduced_ejection_fraction proof-of-principle_cohort_study
H-1948	-0.8410742878913879	▁left - to - right _ inter at rial _ ▁sh unting ▁heart _ ▁failure ▁e je ction _ fraction
D-1948	-0.8410742878913879	left-to-right_interatrial_ shunting heart_ failure ejection_fraction
P-1948	-4.2934 -0.1439 -0.1108 -0.2943 -0.1977 -0.5563 -0.1569 -0.1138 -0.4031 -1.7431 -3.0475 -0.3209 -1.2200 -0.2743 -2.4157 -0.3282 -0.1944 -0.1735 -0.3126 -0.0242 -1.8648 -0.3143
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial_extracellular_matrix cardiac_magnetic_resonance t1_mapping pathobiology pathophysiology prognosis
H-735	-0.6786608099937439	▁my o card ial _ extra cel lular _ ▁matri x ▁cardiac _ ▁magnetic _ re on ance ▁path obi ology pat ho phy si ology
D-735	-0.6786608099937439	myocardial_extracellular_ matrix cardiac_ magnetic_reonance pathobiologypathophysiology
P-735	-0.9109 -0.3913 -0.6948 -0.5396 -0.2405 -2.4919 -0.4194 -0.2612 -0.3423 -1.2915 -0.4557 -0.0527 -0.2507 -1.9106 -0.2103 -0.9630 -3.1376 -0.1497 -0.8486 -0.1868 -0.0553 -0.7330 -0.4345 -0.0243 -1.1317 -0.0289 -0.5796 -0.2660
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical_examination patient bmi heart_rate rhythm blood_pressure auscultation rule valvular_disease pulmonary_congestion
H-1894	-0.7883447408676147	▁physical ▁b mi ▁weight ▁heart _ rate ▁ rhythm ▁ly ing ▁standing _ ▁Blood _ tension ▁aus cul tation ▁val vu lar _ ▁disease ▁pulmonar y _ con gestion
D-1894	-0.7883447408676147	physical bmi weight heart_rate rhythm lying standing_ Blood_tension auscultation valvular_ disease pulmonary_congestion
P-1894	-0.6988 -0.5088 -1.4462 -2.7698 -0.6916 -0.4442 -0.8581 -0.8140 -0.2594 -0.0835 -0.1768 -0.4173 -0.8612 -1.8148 -0.2375 -2.3942 -2.4747 -0.0735 -0.0520 -1.3857 -0.1839 -0.3195 -0.3498 -2.7184 -0.0047 -0.2398 -1.1863 -0.1837 -0.0049 -0.5105 -0.2752
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal_dialysis pd diuretic volume_overload heart_failure hf
H-894	-0.685375988483429	▁Peri tone al _ di al ysis ▁p d ▁di ure tic _ re press ant _ ▁volume _ over load ▁heart _ fail ure ▁h z
D-894	-0.685375988483429	Peritoneal_dialysis pd diuretic_repressant_ volume_overload heart_failure hz
P-894	-0.2008 -0.4542 -0.1902 -0.2215 -2.0371 -0.1038 -0.2379 -0.9265 -0.3768 -0.5939 -0.0586 -0.2114 -0.9762 -0.5036 -2.7296 -0.3547 -0.3333 -1.9322 -0.2188 -0.3524 -0.0174 -0.6901 -0.2357 -1.2081 -0.9215 -0.5140 -2.4315 -0.6185 -0.2256
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology national_cardiovascular_disease_registry_practice_innovation_and_clinical_excellence_registry
H-660	-1.0196493864059448	▁Card i ology ▁national _ ▁Card io vas cular _ ▁Disease _ ▁Registr y ▁clinic al _ excellence
D-660	-1.0196493864059448	Cardiology national_ Cardiovascular_ Disease_ Registry clinical_excellence
P-660	-1.9969 -1.1899 -0.0866 -1.9505 -0.4476 -1.7128 -3.1273 -0.3464 -0.7611 -0.1814 -0.4352 -0.9093 -3.1285 -0.1032 -1.4349 -0.1768 -0.5202 -1.2266 -0.3854 -0.2724
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report stable hno_donor cxl-1020 myoctyes hearts patients heart_failure hf
H-415	-0.7214681506156921	▁report ▁h no _ ▁donor ▁c XL -10 20) ▁isola ted _ My oc ty es ▁intact _ heart s ▁heart _ fail ure HF
D-415	-0.7214681506156921	report hno_ donor cXL-1020) isolated_Myoctyes intact_hearts heart_failureHF
P-415	-0.0047 -0.5122 -0.3068 -0.6935 -2.4458 -0.8409 -0.7605 -0.1782 -0.6104 -0.3583 -0.0188 -0.4302 -3.8436 -0.0853 -0.1295 -0.5051 -0.3249 -0.2347 -2.1532 -0.2165 -0.4036 -0.3958 -1.4637 -0.8703 -1.1086 -0.3649 -0.2196
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral_muscle_pump cardiac_filling exercise subpulmonary_ventricle fontan_circulation
H-1492	-0.7051448822021484	▁per i pher al _ ▁muscle _ pump ▁cardiac _ ▁fill ing ▁exercise ▁sub pul mon ary _ vent ric le ▁Font an _ circ ulation
D-1492	-0.7051448822021484	peripheral_ muscle_pump cardiac_ filling exercise subpulmonary_ventricle Fontan_circulation
P-1492	-0.2668 -0.1752 -0.0454 -0.4937 -0.2741 -4.5904 -0.2327 -0.5713 -0.1346 -0.5794 -0.8158 -0.0563 -1.0366 -0.0280 -0.7639 -2.9575 -0.0497 -0.3134 -0.1253 -1.9395 -1.1329 -0.1230 -0.4281 -0.1546 -1.7193 -0.0647 -0.4278 -0.2439
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil heart_rate aortic blood_flow mitochondrial oxidative_stress doxorubicin cardiotoxicity
H-963	-0.4938752055168152	▁Nico rand il ▁heart _ rate ▁a or tic _ ▁blood _ flow ▁mito cho ndri al _ oxid ative _ stress ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.4938752055168152	Nicorandil heart_rate aortic_ blood_flow mitochondrial_oxidative_stress doxorubicin cardiotoxicity
P-963	-0.0097 -0.0216 -0.0344 -1.1871 -0.3303 -0.9604 -0.0781 -0.0682 -0.0563 -0.2420 -2.1314 -0.2535 -0.4046 -0.0495 -1.6671 -0.7320 -0.1657 -0.2394 -0.4589 -1.7867 -0.2925 -2.0687 -0.0076 -0.0981 -0.0292 -0.1951 -0.0915 -0.8288 -0.1702 -0.4678 -0.1839
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal_dysfunction prognostic heart_failure hf dysfunction end-stage_renal_disease esrd
H-387	-1.1320502758026123	▁Ren al _ ▁dys function ▁heart _ fail ure HF ▁renal _ ▁disease ▁ec d
D-387	-1.1320502758026123	Renal_ dysfunction heart_failureHF renal_ disease ecd
P-387	-3.6257 -0.2280 -0.3144 -1.0051 -0.0629 -1.6075 -0.2759 -1.4679 -2.3698 -1.3107 -0.2572 -0.2461 -1.8228 -2.9021 -1.1029 -0.4167 -0.2291
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients heart_failure_with_preserved_ejection_fraction hfpef heart_failure obese
H-1974	-0.6599729061126709	▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁h f f ▁heart _ fail ure ▁over weight ▁obes e
D-1974	-0.6599729061126709	heart_ failure preserved_ejection_fraction hff heart_failure overweight obese
P-1974	-1.1497 -0.3109 -3.3406 -0.3750 -0.2726 -0.3293 -0.2038 -0.3368 -0.4547 -0.0625 -0.1713 -0.0121 -0.1502 -0.9856 -0.4448 -0.9329 -0.3164 -2.1536 -2.8547 -0.1622 -0.1875 -0.3492 -0.3261 -0.3500 -0.2665
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral_artery_disease pad heart_failure hf prevalence hf patients pad
H-1567	-0.8783788681030273	▁Peri pher al _ ▁arter y _ ▁Disease PAD ▁heart _ fail ure HF HF HF ▁h z PAD
D-1567	-0.8783788681030273	Peripheral_ artery_ DiseasePAD heart_failureHFHFHF hzPAD
P-1567	-0.0583 -0.0285 -0.4114 -0.3250 -0.4437 -0.5713 -0.3654 -2.2532 -0.1412 -0.3846 -0.3524 -1.2723 -2.0968 -1.2939 -0.8988 -0.8424 -1.9221 -3.0329 -0.8829 -0.6245 -0.2446
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical outcomes heart_failure charm candesartan_in_heart_failure_assessment_of_reduction_in_mortality_and_morbidity
H-554	-0.7384966015815735	▁heart _ fail ure ▁CHA r ▁can des ar tan _ in _ ▁Heart _ fail ure ▁Mor t ality ▁Morbi d ity
D-554	-0.7384966015815735	heart_failure CHAr candesartan_in_ Heart_failure Mortality Morbidity
P-554	-1.6130 -0.2723 -0.8061 -1.6016 -2.5980 -2.0348 -1.4561 -0.0871 -0.0331 -0.0607 -1.5138 -0.6465 -0.3780 -1.0340 -0.2720 -0.5699 -0.2863 -1.8173 -0.3349 -0.0568 -0.1308 -0.1218 -0.0711 -0.4373 -0.2292
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic pediatric_fontan patients catheterization
H-227	-0.5375000834465027	▁Font an PF ▁cat heter ization
D-227	-0.5375000834465027	FontanPF catheterization
P-227	-0.7349 -0.3454 -1.3104 -0.1187 -0.0618 -0.6224 -0.7981 -0.3083
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet patient subvalvular annular_ms
H-374	-0.6126722693443298	▁ms ▁sub val vu lar ▁dynamic ▁ms ▁fixed _ rings
D-374	-0.6126722693443298	ms subvalvular dynamic ms fixed_rings
P-374	-1.6167 -1.2558 -0.4365 -0.0232 -0.1887 -0.0087 -0.7505 -0.0896 -0.3483 -1.6808 -0.7124 -0.2410
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the_lancet anoop_shah air heart_failure morbidity mortality
H-1807	-0.5015879273414612	▁Lance t ▁ano op _ ▁Shah ▁air _ ▁pollution ▁heart _ fail ure ▁morbi d ity ▁mortal ity
D-1807	-0.5015879273414612	Lancet anoop_ Shah air_ pollution heart_failure morbidity mortality
P-1807	-0.3379 -0.0667 -0.3219 -0.0571 -0.2527 -0.8477 -0.0470 -0.6400 -2.5655 -0.1594 -0.2354 -0.7937 -1.3082 -0.2342 -0.0664 -0.1467 -0.0152 -0.0570 -1.5905 -0.2884
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell_therapy chronic_heart_failure chf disease progenitor_cells
H-1336	-0.5338597297668457	▁cell _ therapy ▁chronic _ heart _ fail ure ▁ch f ▁disease ▁ex plant - der i ved _ pro gen itor _ cell s
D-1336	-0.5338597297668457	cell_therapy chronic_heart_failure chf disease explant-derived_progenitor_cells
P-1336	-0.5150 -0.4780 -0.0777 -0.1244 -0.2831 -1.6319 -0.1798 -0.7845 -1.9202 -2.8130 -0.8832 -0.4397 -0.4038 -0.0213 -0.2317 -0.2426 -0.3683 -0.2163 -0.4168 -0.2569 -0.1409 -0.4775 -0.2542 -0.1757 -0.3350 -0.4645 -0.2779
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese patients clinically stable hfpef exercise training peak_vo2
H-1990	-0.6023421287536621	▁h f f ▁calor ic ▁aero bic _ ▁exercise _ training ▁pe ak _ vo 2
D-1990	-0.6023421287536621	hff caloric aerobic_ exercise_training peak_vo2
P-1990	-2.2648 -0.7697 -0.7448 -0.4041 -0.3388 -0.5952 -0.7341 -0.4809 -1.0139 -1.8520 -0.2987 -0.0328 -0.0827 -0.1461 -0.1266 -0.2312 -0.4384 -0.2877
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia hf health-related_quality_of_life hrqol hf
H-835	-0.7916752696037292	▁an emia ▁h f ▁health - related _ quality _ of _ life ▁h Qo L ▁h f
D-835	-0.7916752696037292	anemia hf health-related_quality_of_life hQoL hf
P-835	-1.3767 -0.0620 -1.2534 -1.5221 -0.4589 -0.1572 -0.0128 -1.0733 -0.3816 -0.3082 -0.0198 -0.2530 -0.9451 -0.3947 -0.3891 -2.2424 -0.6741 -1.7384 -2.3375 -0.2333
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous_nonfailing hf combinations remodeling
H-1152	-0.4601204991340637	▁dys syn chron ous _ non fail ing HF ▁can ine _ électro me chan ics
D-1152	-0.4601204991340637	dyssynchronous_nonfailingHF canine_électromechanics
P-1152	-1.6763 -0.1533 -0.0251 -0.2544 -0.1079 -0.4481 -0.0778 -0.1072 -2.2770 -0.1213 -0.2178 -0.1149 -1.1945 -0.1999 -0.0681 -0.4309 -0.5629 -0.2447
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients hr_variability mortality ami diagnosis chf lv_dysfunction
H-1586	-0.8734493851661682	▁HR ▁mortal ity AMI ▁CHF LV _ ▁dys function
D-1586	-0.8734493851661682	HR mortalityAMI CHFLV_ dysfunction
P-1586	-0.7143 -1.0200 -0.0554 -1.7918 -0.9405 -2.1763 -1.3352 -0.8035 -0.0550 -0.4405 -0.2754
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes chronic_heart_failure hf exercise training
H-1630	-0.9068708419799805	▁race ▁chronic _ heart _ fail ure HF ▁exercise _ training
D-1630	-0.9068708419799805	race chronic_heart_failureHF exercise_training
P-1630	-1.5729 -0.0912 -0.2796 -1.9450 -0.1918 -1.2399 -1.8316 -1.0307 -0.1115 -1.3926 -0.5042 -1.3507 -0.2475
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.34668970108032227	▁follow - up ▁drug - free
D-947	-0.34668970108032227	follow-up drug-free
P-947	-0.6045 -0.1664 -0.0359 -0.9189 -0.2167 -0.0251 -0.5565 -0.2496
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence exercise cell_senescence active osteoporosis
H-1901	-0.34850266575813293	▁exercise ▁cell _ se nesc ence ▁malign a ncies ▁cancer ▁prostat e ▁colon ▁osteo por osis ▁depression ▁dem entia
D-1901	-0.34850266575813293	exercise cell_senescence malignancies cancer prostate colon osteoporosis depression dementia
P-1901	-1.1683 -0.6661 -0.2602 -0.6835 -0.1832 -0.0335 -0.4217 -0.5162 -0.0167 -0.3440 -0.1313 -0.1891 -0.8653 -0.0591 -0.7459 -0.1627 -0.0688 -0.1876 -0.1062 -0.2782 -0.2311
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological capillary coronary_perfusion
H-457	-0.6603173017501831	▁his t ological ▁cap illa ry ▁corona ry _ per fusion ▁ad - f lk _ ▁rat s
D-457	-0.6603173017501831	histological capillary coronary_perfusion ad-flk_ rats
P-457	-1.8021 -0.9257 -0.2406 -1.4298 -0.0270 -0.9004 -0.0947 -0.3836 -0.2683 -0.1782 -0.0451 -0.2848 -0.0924 -1.3084 -0.6029 -0.9383 -1.1163 -0.0515 -2.2538 -0.2624
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle_walk_test hand baseline
H-1322	-0.5196180939674377	▁shu ttle _ ▁walk _ test ▁body _ ▁mass ▁hand _ ▁grip ▁base line
D-1322	-0.5196180939674377	shuttle_ walk_test body_ mass hand_ grip baseline
P-1322	-0.3495 -0.0086 -0.1529 -2.1363 -0.1952 -0.3579 -0.3793 -0.3914 -1.0796 -0.8224 -0.2753 -1.0299 -0.3019 -0.0846 -0.4684 -0.2808
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician mortality internists cardiologists
H-1730	-0.48421651124954224	▁physician ▁mortal ity ▁intern ists ▁cardio logist s
D-1730	-0.48421651124954224	physician mortality internists cardiologists
P-1730	-0.2804 -0.3976 -0.3831 -0.0761 -2.1263 -0.3669 -0.3058 -0.3250 -0.3729 -0.2080
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc frame patient consultation patients
H-1027	-1.1402472257614136	▁PO c NP ▁consultation ▁ED ▁through put
D-1027	-1.1402472257614136	POcNP consultation ED throughput
P-1027	-2.2762 -1.6428 -1.2725 -1.6889 -1.5159 -0.8422 -0.0281 -0.6735 -0.3221
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin_t n-terminal_pro-b-type_natriuretic_peptide biomarker heart_failure atherosclerosis_risk_in_communities
H-284	-0.519839882850647	▁Tro ponin _ t ▁na tri ure tic _ pe pti de ▁bio mark er ▁heart _ fail ure ▁at hero sc ler osis
D-284	-0.519839882850647	Troponin_t natriuretic_peptide biomarker heart_failure atherosclerosis
P-284	-0.5938 -0.0362 -1.1504 -0.4211 -1.3390 -0.2193 -0.0704 -0.2206 -0.3055 -0.7579 -0.3608 -0.7526 -0.1629 -0.0460 -0.5079 -0.7427 -0.1984 -1.4415 -0.4546 -0.4103 -0.1026 -0.0853 -2.1703 -0.1018 -0.6082 -0.2558
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients acute_rv_failure chronic_pulmonary_arterial_hypertension pah acute pulmonary_embolism
H-1095	-0.8155605792999268	▁a cute _ RV _ fail ure ▁chronic _ ▁pulmonar y _ ▁arterial _ hy tension pa h ▁pulmonar y _ e mbol ism
D-1095	-0.8155605792999268	acute_RV_failure chronic_ pulmonary_ arterial_hytensionpah pulmonary_embolism
P-1095	-3.8231 -0.0869 -0.2991 -1.2016 -1.3743 -0.3737 -0.6737 -0.8241 -0.5448 -0.4279 -0.2925 -0.1797 -1.5973 -0.1708 -2.0469 -0.0776 -3.5591 -1.3627 -0.2003 -0.5571 -0.4167 -0.2763 -0.0409 -0.0912 -0.4568 -0.2497
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic methylatropine vagal_tone bradycardic propranolol sympathetic_tone
H-1139	-0.7444560527801514	▁ta chy car dic ▁met hy la tropi ne ▁va gal _ tone ▁bra dy car dic ▁propra no lol ▁sympa the tic _ ▁tone
D-1139	-0.7444560527801514	tachycardic methylatropine vagal_tone bradycardic propranolol sympathetic_ tone
P-1139	-1.5147 -0.9705 -0.2172 -0.2068 -3.5470 -0.0372 -0.3127 -0.0306 -1.9168 -0.1345 -0.0503 -0.4033 -1.2032 -1.3076 -0.4195 -0.2463 -0.2843 -3.7097 -0.0093 -0.5364 -0.3280 -0.2479 -0.2594 -0.5295 -1.1659 -0.3331 -0.1786
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin_inhibitors natriuretic_peptide atrial_natriuretic_peptide b-type_natriuretic_peptide
H-1462	-0.5863600373268127	▁ne pri ly sin _ ▁inhibi tors ▁na tri ure tic _ pe pti de _ system ▁break down ▁at rial _ na tri ure tic _ pe pti de ▁na tri ure tic _ pe pti de
D-1462	-0.5863600373268127	neprilysin_ inhibitors natriuretic_peptide_system breakdown atrial_natriuretic_peptide natriuretic_peptide
P-1462	-1.5881 -0.0988 -0.3485 -0.1590 -0.4148 -0.5990 -0.0583 -0.0748 -0.3164 -0.1529 -0.7253 -0.1673 -1.6157 -1.0933 -0.8392 -0.6751 -0.0717 -0.9153 -0.1103 -0.5395 -0.2952 -0.5476 -2.3004 -0.4560 -0.2567 -0.8102 -0.2353 -1.0817 -0.9867 -0.7512 -0.2875 -0.2724 -0.1601 -0.9379 -0.3159 -1.2103 -0.7308 -0.6942 -0.3405 -0.2205
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2007	-0.781963586807251	▁economic ▁Heart _ fail ure ▁cost - effect ive ness ▁disease _ management ▁heart _ fail ure
D-2007	-0.781963586807251	economic Heart_failure cost-effectiveness disease_management heart_failure
P-2007	-0.6793 -2.3408 -0.3289 -0.6275 -0.1252 -0.5147 -0.1317 -1.3645 -0.3139 -1.6671 -1.6025 -0.5582 -0.1826 -1.6377 -0.3229 -1.2365 -0.5168 -0.4308 -0.2756
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional_flow_reserve positron_emission_tomography ischemia bottleneck_stenting left_ventricle lad
H-509	-0.7024156451225281	▁Fra ction al _ flow _ ▁reserve ▁posi tron _ e mission _ tom ography ▁ ische mia ▁bottle ne ck _ ▁sten ting ▁left _ vent ric le ▁la d
D-509	-0.7024156451225281	Fractional_flow_ reserve positron_emission_tomography ischemia bottleneck_ stenting left_ventricle lad
P-509	-2.9326 -0.0215 -0.2136 -0.3897 -0.4425 -0.2696 -2.2242 -0.2258 -0.5217 -0.3879 -0.6014 -0.1054 -0.2407 -0.2610 -0.9146 -0.6394 -0.0161 -0.4314 -0.0358 -0.1439 -0.0328 -0.7465 -2.4338 -0.4450 -0.0828 -0.2746 -0.4016 -3.4235 -1.4436 -1.1485 -0.6663 -0.8042 -0.2576
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac_resynchronization_therapy crt mild_heart_failure hf patients qrs_prolongation ejection_fraction ef
H-751	-0.6897541284561157	▁cardiac _ re syn chron ization _ therapy ▁c t ▁mild _ heart _ fail ure ▁h z ▁QR s ▁e je ction _ fraction EF
D-751	-0.6897541284561157	cardiac_resynchronization_therapy ct mild_heart_failure hz QRs ejection_fractionEF
P-751	-0.1422 -0.2311 -0.0910 -0.0635 -0.0140 -0.5713 -0.4230 -1.0058 -1.1597 -2.9005 -0.8331 -0.1564 -1.1519 -0.2087 -1.2525 -1.8431 -0.5334 -2.4194 -0.9308 -0.5635 -0.3491 -0.1410 -0.1372 -0.3407 -0.0079 -1.1008 -0.4707 -0.2709
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity oxidative_stress dna_fragmentation
H-962	-0.5951332449913025	▁mito cho ndri al _ oxid ative _ phos phor y lation _ capaci ty ▁creati ne _ ▁kina se _ activ ity ▁oxid ative _ stress _ ▁marker s ▁DNA _ ▁fragment ation
D-962	-0.5951332449913025	mitochondrial_oxidative_phosphorylation_capacity creatine_ kinase_activity oxidative_stress_ markers DNA_ fragmentation
P-962	-0.1546 -1.3440 -0.3508 -0.1663 -0.3624 -1.0804 -3.5208 -0.2352 -0.6076 -1.6112 -1.1517 -0.1367 -0.4206 -0.0531 -0.0639 -0.0451 -0.6289 -0.3662 -0.0186 -0.0780 -0.4757 -0.1194 -0.1026 -0.1258 -1.3976 -0.2128 -2.1015 -0.2427 -0.5539 -0.0884 -0.3632 -0.3504 -1.6445 -0.0956 -0.9207 -0.2335
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ventricular_assist_devices cardiac nurses gastrointestinal_bleeding
H-1660	-0.6684086918830872	▁vent ri cular _ assist _ ▁Device s ▁cardiac _ ▁nurse s ▁gastro inte stin al _ ble ed ing
D-1660	-0.6684086918830872	ventricular_assist_ Devices cardiac_ nurses gastrointestinal_bleeding
P-1660	-0.0316 -1.1010 -0.2757 -0.2965 -0.0171 -1.3263 -4.5598 -0.1462 -0.0943 -0.4858 -0.2396 -0.1453 -0.1749 -0.0355 -0.8083 -0.2142 -0.3606 -3.1300 -0.2677 -0.1374 -0.5612 -0.2961
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox_regression covariates spironolactone death hospitalization hyperkalemia acute_kidney_injury
H-442	-0.49582430720329285	▁spi rono lac tone ▁hyper kal emia ▁ki dne y _ ▁injury
D-442	-0.49582430720329285	spironolactone hyperkalemia kidney_ injury
P-442	-0.5244 -0.0221 -0.2862 -0.0708 -1.3271 -0.7714 -0.1566 -0.1135 -0.4733 -0.2567 -0.9117 -1.2892 -0.4809 -0.2577
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended_criteria_cardiac_transplant ecct transplant donors transplant comorbidity
H-708	-0.9416829943656921	▁cardiac _ ▁transplant ▁ec t ▁transplant _ pool
D-708	-0.9416829943656921	cardiac_ transplant ect transplant_pool
P-708	-0.0553 -0.2030 -2.6025 -0.0774 -1.1689 -0.6742 -0.4830 -1.3909 -2.4937 -0.2680
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum systolic lv_posterior_wall lv_internal_diameter metoprolol
H-1549	-0.5891262888908386	▁sept um sy sto lic _ thi ck ness ▁LV ▁posterior _ wall _ thi ck ness ▁LV ▁internal _ dia meter ▁met o pro lol
D-1549	-0.5891262888908386	septumsystolic_thickness LV posterior_wall_thickness LV internal_diameter metoprolol
P-1549	-0.6884 -0.0652 -1.1527 -0.3129 -0.2074 -2.0259 -1.4979 -0.1464 -0.9252 -0.9910 -0.3548 -0.1986 -2.7253 -0.4445 -1.2951 -0.1994 -0.5316 -0.4961 -0.4841 -0.2155 -0.0308 -0.0046 -0.1287 -0.1689 -0.0383 -0.5798 -0.3673 -0.2188
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat n-terminal_pro-brain_natriuretic_peptide hospitalized hf
H-1877	-0.6921352744102478	▁BAT ▁na tri ure tic _ pe pti de ▁h f
D-1877	-0.6921352744102478	BAT natriuretic_peptide hf
P-1877	-0.1610 -2.1317 -0.4047 -0.0391 -0.2857 -0.4797 -0.7952 -0.3788 -0.5925 -0.7790 -2.3231 -0.4023 -0.2250
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american_college_of_physicians acp evidence clinical anemia patients heart_disease
H-30	-0.6737436652183533	▁American _ co un cil _ of _ phy s iques ▁ec p ▁evidence ▁an emia ▁ir on _ de fici en cy ▁heart _ ▁disease
D-30	-0.6737436652183533	American_council_of_physiques ecp evidence anemia iron_deficiency heart_ disease
P-30	-1.2899 -0.2837 -2.6504 -0.3220 -0.0104 -0.1752 -0.0886 -0.3684 -0.4271 -0.4834 -0.8482 -2.9063 -0.3360 -1.7552 -1.0092 -0.1210 -0.0141 -0.2068 -0.2350 -0.1702 -0.1226 -1.0882 -0.0676 -0.5530 -0.3518 -2.4171 -0.3480 -0.2154
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes mortality hospitalization mortality cardiovascular_mortality hf hospitalization cox_models exercise training
H-1633	-0.7307643294334412	▁mortal ity ▁cardiovascular _ ▁mortal ity HF ▁race ▁adjust ed _ co x ▁exercise
D-1633	-0.7307643294334412	mortality cardiovascular_ mortalityHF race adjusted_cox exercise
P-1633	-1.1217 -0.2154 -0.4997 -0.4722 -0.2786 -0.1856 -1.3208 -3.0294 -1.8684 -0.0374 -0.6462 -0.0500 -0.0669 -0.4730 -1.1613 -0.2656
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective hf patients hf_with_reduced_ef ef hfpef ef
H-782	-1.1833609342575073	▁h f ▁h f ▁h f p EF
D-782	-1.1833609342575073	hf hf hfpEF
P-782	-2.0207 -0.6412 -2.5380 -0.4703 -1.8253 -1.2312 -0.8552 -0.9852 -0.9182 -0.3482
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional_electrical_stimulation peripheral_muscles endothelial_function clinical heart_failure patients preserved_left_ventricular_ejection_fraction
H-1326	-0.6658883690834045	▁electric al _ stimul ation ▁per i pher al _ ▁muscle s ▁en dot heli al _ function ▁emotional ▁heart _ ▁failure ▁left _ vent ri cular _ e je ction _ fraction
D-1326	-0.6658883690834045	electrical_stimulation peripheral_ muscles endothelial_function emotional heart_ failure left_ventricular_ejection_fraction
P-1326	-1.5680 -0.1430 -0.8514 -0.0780 -0.0440 -0.3543 -0.3411 -0.0503 -0.3157 -0.3592 -4.1371 -0.1242 -0.2807 -1.9516 -0.2198 -0.0276 -1.7048 -0.1179 -1.9726 -0.3428 -0.4246 -2.3835 -0.4888 -0.4447 -0.6503 -0.8981 -0.3560 -0.6767 -0.2167 -0.4147 -0.2678 -0.3096 -0.0043 -0.5115 -0.2747
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.9493075013160706	▁base line ▁SD QT - to - SD r _ rati o ▁h w t ▁h n m
D-1441	-0.9493075013160706	baseline SDQT-to-SDr_ratio hwt hnm
P-1441	-0.0140 -0.0369 -0.1644 -1.9927 -0.0669 -0.0377 -0.2247 -1.4581 -2.0455 -0.5587 -0.0448 -0.0329 -0.8417 -2.9728 -1.0579 -0.3740 -5.5031 -0.6097 -0.7430 -0.2067
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular wall_stiffness
H-1148	-0.854560375213623	▁vent ri cular ▁fiber she et _ orientation
D-1148	-0.854560375213623	ventricular fibersheet_orientation
P-1148	-0.1439 -0.5145 -0.2839 -3.9786 -0.3243 -0.0770 -0.4059 -0.0189 -2.4986 -0.3001
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad q66p cardiomyopathy
H-1677	-0.5072739124298096	▁rad _ q 66 p ▁cardio my o pathy ▁mechanism
D-1677	-0.5072739124298096	rad_q66p cardiomyopathy mechanism
P-1677	-0.7969 -0.4851 -0.7215 -0.3269 -0.5105 -0.1583 -1.0411 -0.1719 -0.0155 -0.1534 -1.4737 -0.2326
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin chemotherapy elevated cardiotoxicity
H-937	-0.7937608957290649	▁se rum _ re duction s ▁women ▁an thra cycli ne - conta ining _ che mo therapy ▁cardio toxic ity
D-937	-0.7937608957290649	serum_reductions women anthracycline-containing_chemotherapy cardiotoxicity
P-937	-0.2979 -0.4995 -0.2369 -0.2831 -5.7240 -0.6727 -2.5412 -0.1785 -0.1802 -0.5212 -1.9891 -0.4102 -0.0039 -0.6394 -0.2783 -1.3208 -0.2268 -0.1505 -0.2963 -0.5957 -0.3709 -0.5779 -0.2617
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients sst2 titrated cardiovascular_event
H-405	-0.8899000287055969	▁s st 2 ▁high - dos e _ bb ▁cardiovascular _ event _ rate
D-405	-0.8899000287055969	sst2 high-dose_bb cardiovascular_event_rate
P-405	-0.0093 -1.1562 -0.0487 -3.6401 -0.0533 -0.7035 -0.4737 -2.1761 -0.6127 -0.1282 -0.5473 -1.9766 -0.2837 -0.9033 -1.2886 -0.2371
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative patients preoperative hypoalbuminemia albumin
H-533	-0.8165705800056458	▁hypo album in emia ▁album in
D-533	-0.8165705800056458	hypoalbuminemia albumin
P-533	-0.9157 -0.6595 -0.3477 -0.3328 -1.3655 -0.3634 -2.3424 -0.2056
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration renin-angiotensin_system_blocker beta-blocker therapy patients hospitalized heart_failure preserved_left_ventricular_ejection_fractions
H-174	-0.6042336225509644	▁re nin - angi oten sin _ system _ block er ▁beta - block er _ therapy ▁heart _ ▁failure ▁left _ vent ri cular _ e je ction _ fraction s
D-174	-0.6042336225509644	renin-angiotensin_system_blocker beta-blocker_therapy heart_ failure left_ventricular_ejection_fractions
P-174	-0.1788 -1.1253 -0.2659 -0.1859 -0.1418 -0.8030 -0.3220 -0.1075 -0.3109 -2.4565 -0.7511 -0.2366 -0.0533 -0.4551 -0.9389 -2.3784 -0.1257 -0.3769 -0.3338 -2.9288 -0.5157 -0.4190 -0.6554 -1.1670 -0.4902 -0.5281 -0.2732 -0.3888 -0.2722 -0.3479 -0.0075 -0.1421 -0.5483 -0.3123
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use_of_exercise_and_medical_therapies_to_improve_cardiac_function_among_patients_with_exertional_shortness_of_breath_due_to_lung_congestion
H-1180	-0.7804392576217651	▁medical ▁Card iac _ function ▁Breath ▁Lung _ con gestion ACT RN
D-1180	-0.7804392576217651	medical Cardiac_function Breath Lung_congestionACTRN
P-1180	-0.9663 -2.7205 -0.2304 -0.1807 -0.8050 -1.0521 -0.4218 -0.5822 -0.1407 -0.0397 -1.3909 -0.8121 -1.3446 -0.2392
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective nicorandil hemodynamic mitochondrial_dysfunction administration doxorubicin
H-956	-0.3304646909236908	▁cardio protec tive _ effect ▁nic oran dil ▁hem o dynamic ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin ▁rat s
D-956	-0.3304646909236908	cardioprotective_effect nicorandil hemodynamic mitochondrial_ dysfunction doxorubicin rats
P-956	-0.1069 -0.0582 -0.1257 -0.4754 -0.1669 -0.1414 -0.0848 -0.4554 -0.3125 -0.2031 -0.0288 -0.3287 -1.4898 -0.5516 -0.1653 -0.2850 -0.5089 -0.0546 -1.0754 -0.1947 -0.0539 -0.2335 -0.9072 -0.0840 -0.3255 -0.1746
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex_sensitivity heart_rate_variability hrv renal_dnx
H-1376	-0.5996453166007996	▁Baro re flex _ sensitiv ity ▁time _ ▁domain ▁heart _ rate _ vari able ▁h v ▁CHF - in v ▁sham - in v ▁sham ▁renal _ ▁DN x
D-1376	-0.5996453166007996	Baroreflex_sensitivity time_ domain heart_rate_variable hv CHF-inv sham-inv sham renal_ DNx
P-1376	-0.0708 -0.0715 -0.3381 -0.3616 -0.0052 -0.1257 -0.3577 -0.2777 -0.4244 -2.1188 -0.4471 -1.3524 -0.4622 -0.7096 -1.5170 -0.8994 -1.9430 -1.3363 -0.1579 -0.1321 -0.3573 -0.3259 -0.2167 -0.1676 -0.3607 -0.2848 -1.3833 -1.3040 -1.0559 -0.0673 -0.3596 -0.1972
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic_cell_transplantation hct congestive_heart_failure chf anthracyclines
H-1449	-0.7315211296081543	▁ha e mato po ie tic _ cell _ ▁transplant ation ▁h t ▁con ges tive _ heart _ fail ure ▁ch f ▁h t ▁an thra cycli nes
D-1449	-0.7315211296081543	haematopoietic_cell_ transplantation ht congestive_heart_failure chf ht anthracyclines
P-1449	-0.1296 -0.3819 -0.0505 -0.0727 -0.8784 -0.1172 -0.2047 -0.7861 -0.1891 -0.7871 -0.0505 -0.4534 -2.3980 -0.5017 -0.1875 -0.6620 -0.3437 -2.1857 -0.2539 -1.2459 -1.7265 -2.6755 -0.8127 -1.6001 -1.8884 -0.3044 -0.1019 -0.1153 -0.8269 -0.4779 -0.2682
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic proteins histone_acetyltransferases epigenetic histone_deacetylases cardiac disease
H-1041	-0.8023465275764465	▁epi gene tic _ writer ▁protein s hi stone _ a ce tyl transfer as es ▁epi gene tic _ eras ers hi stone _ de ace ty las es ▁cardiac
D-1041	-0.8023465275764465	epigenetic_writer proteinshistone_acetyltransferases epigenetic_erasershistone_deacetylases cardiac
P-1041	-2.3558 -0.6653 -0.2098 -3.4605 -0.3358 -1.5665 -0.2446 -2.5222 -0.1912 -0.4021 -0.2859 -0.1663 -0.9069 -0.1534 -0.1845 -0.2412 -1.1776 -0.3670 -0.5647 -3.1981 -0.5096 -0.3153 -1.2807 -0.6016 -0.4378 -0.0904 -1.7387 -0.5335 -0.1068 -0.3459 -0.0330 -1.0273 -0.2573
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated nt-probnp admission all-cause_mortality patients acute_hf admission
H-270	-0.5261830687522888	▁NT - pro b NP ▁mortal ity ▁h f
D-270	-0.5261830687522888	NT-probNP mortality hf
P-270	-0.0910 -0.0789 -0.0356 -0.7958 -0.4582 -0.1756 -0.1532 -1.5923 -1.6947 -0.4065 -0.3062
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in_vivo mir-25 antagomir cardiac_dysfunction murine myocardium heart_failure
H-643	-0.6904501914978027	▁in _ ▁vivo _ ▁inhibi tion ▁mi r -25 ▁anta go mir ▁cardiac _ ▁dys function ▁mur ine _ my o car dium ▁heart _ fail ure ▁hand 2- dependent
D-643	-0.6904501914978027	in_ vivo_ inhibition mir-25 antagomir cardiac_ dysfunction murine_myocardium heart_failure hand2-dependent
P-643	-1.1026 -1.3930 -0.0578 -2.4619 -0.8078 -0.1522 -0.6452 -0.6469 -0.0757 -0.1841 -0.0581 -0.6392 -0.1085 -0.4062 -0.2799 -0.0290 -0.7247 -1.0118 -0.5449 -4.0022 -0.2438 -0.0580 -0.3141 -0.6147 -0.2657 -1.1054 -0.9908 -1.7407 -0.2937 -0.0565 -0.7753 -0.3040
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left_bundle_branch_block remodeling dyssynchronous_heart_failure hf heart
H-1147	-0.6477044820785522	▁electric al _ activa tion ▁dys syn chron ous _ heart _ fail ure HF ▁electro me chan ical _ be havi our ▁heart
D-1147	-0.6477044820785522	electrical_activation dyssynchronous_heart_failureHF electromechanical_behaviour heart
P-1147	-2.2642 -0.2636 -0.4777 -0.2376 -0.1342 -0.0439 -0.0604 -0.0282 -0.3170 -0.3487 -3.6669 -0.1518 -1.2985 -1.7230 -1.3719 -0.0787 -0.1727 -0.0315 -0.0823 -1.8228 -0.7040 -0.0054 -0.0156 -0.9972 -0.3011 -0.2414
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse hospitalization physician discharge patients hospitalized heart_failure
H-206	-0.7295036911964417	▁nurse ▁cognitive _ ▁im pair ment ▁physician ▁dis charge ▁heart _ fail ure
D-206	-0.7295036911964417	nurse cognitive_ impairment physician discharge heart_failure
P-206	-1.0658 -0.2287 -0.3878 -1.3929 -0.0668 -0.1870 -0.4925 -1.1174 -0.0108 -2.4164 -0.3649 -0.9698 -1.5632 -0.3910 -0.2874
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension diabetes_mellitus grade systolic diastolic_murmurs apex
H-347	-0.33958566188812256	▁hyper tension ▁diabetes _ ▁mell itus ▁sy sto lic ▁dia sto lic _ mur mur s
D-347	-0.33958566188812256	hypertension diabetes_ mellitus systolic diastolic_murmurs
P-347	-0.0922 -0.0015 -0.3037 -0.1297 -0.4486 -0.1648 -0.8042 -0.3011 -0.2996 -0.0531 -0.2528 -0.3253 -1.1147 -0.5113 -0.2986 -0.3656 -0.4017 -0.2441
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients heart_failure heart cardiologists cardiovascular surgeons medical patient
H-1822	-0.9315952062606812	▁heart _ fail ure heart _ team ▁cardio logist s ▁cardiovascular _ ▁surge ons ▁medical _ ▁staff
D-1822	-0.9315952062606812	heart_failureheart_team cardiologists cardiovascular_ surgeons medical_ staff
P-1822	-3.1257 -0.3969 -1.6723 -2.5465 -2.1354 -0.2735 -0.1001 -0.2765 -0.2297 -0.2732 -0.1082 -0.6789 -2.2351 -0.3080 -0.1234 -2.0327 -0.2058 -0.7229 -0.2555
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine patients dilated_cardiomyopathy dcm heart_failure
H-1258	-0.6524677872657776	▁Chinese _ ▁herbal _ ▁medicine ch m ▁ad ju nc tive _ ▁Treatment ▁dil ated _ ▁cardio my o pathy ▁d m ▁heart _ fail ure
D-1258	-0.6524677872657776	Chinese_ herbal_ medicinechm adjunctive_ Treatment dilated_ cardiomyopathy dm heart_failure
P-1258	-0.7683 -0.2805 -0.1170 -0.1854 -0.5242 -3.4650 -0.1337 -0.8945 -0.0200 -0.0361 -0.0498 -0.5029 -3.4697 -0.4379 -0.0400 -0.2186 -0.2729 -1.7104 -0.4411 -0.0176 -0.4959 -0.9194 -0.1965 -0.3125 -1.2459 -0.9603 -0.3116 -0.2416
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse pasp downward hfref hfpef prognostic resolution
H-500	-0.8324440717697144	▁t AP se ▁PAS p ▁non sur viv ors ▁h f f ▁h f p EF ▁h f p EF ▁resolution
D-500	-0.8324440717697144	tAPse PASp nonsurvivors hff hfpEF hfpEF resolution
P-500	-1.8621 -2.3391 -0.6471 -1.0419 -0.7891 -0.4370 -0.0113 -0.0168 -0.0518 -0.2981 -2.4421 -0.2824 -0.6365 -1.6519 -0.3841 -0.7171 -1.5895 -1.8806 -0.0554 -0.8332 -0.6100 -0.3761 -0.1930
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute_rv_failure pulmonary_embolism mortality diagnostic
H-1097	-0.423390656709671	▁ rv ▁pulmonar y _ e mbol ism ▁mortal ity
D-1097	-0.423390656709671	rv pulmonary_embolism mortality
P-1097	-2.0923 -0.6522 -0.0722 -0.3303 -0.3453 -0.3907 -0.0501 -0.1293 -0.1512 -0.2074 -0.3925 -0.2673
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates alendronate etidronate heart_failure compliance
H-1542	-0.3801758587360382	▁bis phos phon ates ▁ale ndr onate ▁et id rona te ▁heart _ fail ure ▁compliance
D-1542	-0.3801758587360382	bisphosphonates alendronate etidronate heart_failure compliance
P-1542	-0.1225 -0.0888 -0.0964 -0.6506 -1.4565 -0.0325 -0.0543 -0.0117 -0.3326 -0.0961 -0.0767 -0.3150 -0.2793 -0.9711 -0.8105 -0.4044 -0.7925 -0.2517
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action randomized patients hf ejection_fraction exercise training
H-1632	-0.6860010027885437	HF - ac tion ▁h f ▁e je ction _ fraction ▁exercise _ training
D-1632	-0.6860010027885437	HF-action hf ejection_fraction exercise_training
P-1632	-1.5402 -0.1542 -0.7922 -1.3710 -1.0940 -1.6220 -0.8887 -0.3666 -0.1116 -0.3254 -0.0293 -0.0700 -1.4272 -0.4260 -0.4958 -0.2617
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol nonselective_β-blocker selective_β-blocker metoprolol thromboembolic_events heart_failure
H-1111	-0.6553842425346375	▁car vedi lol ▁β - block er ▁β - block er _ met o pro lol ▁ thro mbo e mbol ic _ event s ▁heart _ fail ure
D-1111	-0.6553842425346375	carvedilol β-blocker β-blocker_metoprolol thromboembolic_events heart_failure
P-1111	-0.7457 -0.0126 -0.3817 -0.3415 -0.1263 -0.9293 -0.8352 -0.8930 -0.0948 -0.9535 -1.0307 -1.8604 -0.0327 -0.8644 -0.1180 -1.0111 -0.4525 -0.0903 -0.3319 -0.8892 -0.0593 -0.2541 -0.8891 -2.8995 -0.1379 -0.2613 -0.2740 -1.4738 -1.5053 -0.3793 -0.1886
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ami pna mortality
H-1700	-1.1495949029922485	▁h f AMI ▁p na ▁mortal ity
D-1700	-1.1495949029922485	hfAMI pna mortality
P-1700	-0.7191 -2.9738 -3.0980 -1.7167 -0.7353 -0.0565 -0.3020 -0.4719 -0.2731
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline cardiac_transplant ecct
H-716	-0.44164547324180603	▁base line ▁cardiac _ ▁transplant ▁ec t
D-716	-0.44164547324180603	baseline cardiac_ transplant ect
P-716	-0.1274 -0.1002 -0.0447 -0.1545 -1.2654 -0.3151 -1.2598 -0.4715 -0.2362
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients heart_failure hf evidence outcomes hf
H-685	-1.3717246055603027	▁heart _ fail ure HF HF HF HF
D-685	-1.3717246055603027	heart_failureHFHFHFHF
P-685	-2.4513 -0.2267 -1.5999 -1.5885 -1.0185 -0.9293 -1.2493 -2.2652 -2.0903 -0.2983
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling arrhythmia ami hr_variability arrhythmia
H-1590	-1.0665740966796875	▁ar rhythm ia _ ▁substrat e AMI ▁HR ▁ar rhythm ia _ event s
D-1590	-1.0665740966796875	arrhythmia_ substrateAMI HR arrhythmia_events
P-1590	-0.6270 -0.5582 -2.5389 -0.3196 -0.4107 -0.3927 -1.5578 -1.2703 -0.9802 -1.0104 -2.2914 -0.6117 -3.5502 -0.1794 -0.5004 -0.2665
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients hypertension compensated_hfpef dash sodium
H-919	-0.6333280205726624	▁hyper tension ▁h f f ▁DAS h ▁s rd tar get _ so dium ▁kcal
D-919	-0.6333280205726624	hypertension hff DASh srdtarget_sodium kcal
P-919	-0.3262 -0.0059 -0.1770 -1.1237 -0.6138 -1.2804 -0.2680 -3.0942 -0.7314 -0.7736 -0.0712 -0.1758 -0.4209 -0.1147 -0.4721 -0.8700 -0.2476
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd dyssynchronous_hf remodeling insignificantly
H-1154	-0.517303466796875	▁em d ▁dys syn chron ous _ HF
D-1154	-0.517303466796875	emd dyssynchronous_HF
P-1154	-0.9190 -0.1787 -0.0299 -0.0984 -0.0238 -0.3855 -0.6041 -2.1987 -0.4360 -0.2987
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ejection_fraction cardiac_index inotropes medical transplant
H-1997	-0.31386563181877136	▁e je ction _ fraction ▁cardiac _ index ▁in o trop es ▁in ot rope - dependent ▁medical ▁transplant
D-1997	-0.31386563181877136	ejection_fraction cardiac_index inotropes inotrope-dependent medical transplant
P-1997	-0.2464 -0.2408 -0.1081 -0.3082 -0.0159 -0.1184 -0.3618 -0.1613 -0.1546 -0.5974 -0.4148 -0.8833 -0.2384 -0.9103 -0.3441 -0.4428 -0.0212 -0.0720 -0.2968 -0.3770 -0.2776
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced_cardiotoxicity resistin retn
H-933	-0.40219053626060486	▁do xor ubi cin - indu ced _ ▁cardio toxic ity ▁Hum - re t n _ mi ce ▁litt er mate ▁resist in ▁re t n
D-933	-0.40219053626060486	doxorubicin-induced_ cardiotoxicity Hum-retn_mice littermate resistin retn
P-933	-0.0170 -0.0490 -0.0047 -0.1555 -0.1422 -0.0003 -0.0174 -0.6202 -0.1238 -0.6445 -0.3176 -0.4001 -0.0655 -0.9954 -1.0396 -0.0854 -0.2653 -0.4652 -0.4492 -0.4953 -0.0458 -0.1230 -0.9554 -0.2616 -1.7166 -1.6466 -0.0479 -0.3293 -0.1841
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic_dysfunction pathophysiology hfpef cardiovascular_function
H-1302	-0.48257526755332947	▁dia sto lic _ ▁dys function ▁pat ho phy si ology ▁h p EF ▁non - dia sto lic _ ab normal ities ▁cardiovascular _ function
D-1302	-0.48257526755332947	diastolic_ dysfunction pathophysiology hpEF non-diastolic_abnormalities cardiovascular_function
P-1302	-0.0774 -0.5902 -0.9441 -0.1583 -1.0979 -0.0538 -0.2897 -0.1346 -0.0140 -1.3571 -0.0466 -0.9940 -0.5188 -0.7680 -0.0978 -0.0999 -0.5371 -1.3738 -0.7265 -0.3943 -0.6302 -0.7195 -0.1239 -0.2869 -0.4302 -0.4466 -0.3607 -0.2403
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp phosphomimic ser77 ser83 riα proteins riα
H-1432	-0.6508401036262512	▁8- flu o - c AMP ▁ binding ▁ phos pho mi mic ▁ser 77 ▁ser 83 ▁mu tant _ ri α _ ▁protein s ▁double _ mu tant ▁w t _ ri α
D-1432	-0.6508401036262512	8-fluo-cAMP binding phosphomimic ser77 ser83 mutant_riα_ proteins double_mutant wt_riα
P-1432	-0.1755 -0.3311 -0.3757 -0.0612 -0.0608 -0.3140 -1.2268 -0.2092 -0.2645 -0.0843 -0.0826 -0.2222 -2.7279 -0.3236 -0.2160 -0.1650 -1.3025 -2.8600 -0.1756 -1.7959 -0.5170 -1.1458 -2.1248 -1.1013 -0.1517 -0.4974 -0.1486 -0.9952 -0.2023 -0.2898 -0.1321 -0.5072 -0.4158 -1.7701 -0.2724 -0.1843
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density_lipoprotein hdl endothelial_cell nitric_oxide
H-246	-0.5499265193939209	▁high - dens ity _ ▁lipo prote in HD l ▁en dot heli al - protec tive _ effect s ▁en dot heli al _ cell ▁ni tric _ oxid e
D-246	-0.5499265193939209	high-density_ lipoproteinHDl endothelial-protective_effects endothelial_cell nitric_oxide
P-246	-0.8814 -0.1366 -0.0373 -0.2070 -0.2472 -0.2543 -0.2526 -0.7291 -1.2657 -1.2679 -0.2773 -1.8799 -0.7343 -0.1468 -0.9524 -0.0164 -0.3303 -1.9060 -0.2780 -0.1715 -0.2436 -1.8803 -0.5723 -0.0743 -0.4280 -0.5427 -0.3175 -0.3681 -0.1883 -0.1876 -0.7220 -0.4310 -0.2197
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis patients hf hospitalization all-cause_hospitalization mortality hf hospitalization death
H-910	-0.7302695512771606	▁dia lys is HF HF ▁mortal ity HF
D-910	-0.7302695512771606	dialysisHFHF mortalityHF
P-910	-0.3999 -0.1443 -0.1833 -0.9851 -1.7820 -1.0977 -0.2876 -1.5638 -0.5811 -0.2780
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome admission discharge hospitalized heart_failure hf nursing_outcomes_classification noc
H-1398	-0.8172816634178162	▁outcome _ rati os ▁ad mission _ to _ dis charge ▁older _ ▁adults ▁heart _ fail ure HF ▁Nur sing _ out com es _ ▁Classifica tion no c
D-1398	-0.8172816634178162	outcome_ratios admission_to_discharge older_ adults heart_failureHF Nursing_outcomes_ Classificationnoc
P-1398	-1.4072 -0.4813 -0.8374 -0.4264 -0.0822 -0.0180 -0.9685 -0.9036 -0.3203 -0.1037 -0.0202 -2.1272 -0.6367 -3.2428 -0.6164 -0.2435 -1.1775 -1.6173 -1.9913 -0.6611 -0.2391 -0.3230 -0.3162 -2.2305 -1.3155 -1.0672 -0.2700 -0.0388 -0.9440 -0.8666 -0.3979 -0.2622
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort_study saxagliptin sitagliptin antihyperglycemic_agents
H-1840	-0.6533946990966797	▁h HF ▁sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic _ agent s
D-1840	-0.6533946990966797	hHF saxagliptin sitagliptin antihyperglycemic_agents
P-1840	-0.0034 -1.9778 -0.2240 -0.0179 -0.7757 -3.0189 -0.7494 -0.0030 -0.2184 -2.4827 -0.0284 -0.0632 -0.1564 -0.2420 -0.1347 -1.8197 -0.4304 -0.1416 -0.4912 -0.5089 -0.2335
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate_analysis preoperative albumin mortality lvad implantation hazard_ratio confidence_interval
H-535	-0.3921186029911041	▁album in ▁mortal ity ▁l VAD ▁implant ation haz ard _ rati o
D-535	-0.3921186029911041	albumin mortality lVAD implantationhazard_ratio
P-535	-1.1227 -0.6189 -0.0746 -0.0776 -0.4917 -0.0555 -1.0820 -0.0591 -0.0742 -0.1156 -0.2664 -0.0678 -0.0227 -1.4609 -0.2920
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients systolic_heart_failure qrs_duration crt death hospitalization heart_failure mortality
H-854	-0.829674482345581	▁sy sto lic _ heart _ fail ure ▁QR s ▁c t ▁rate _ of _ ▁death ▁hospital ization ▁heart _ fail ure ▁mortal ity
D-854	-0.829674482345581	systolic_heart_failure QRs ct rate_of_ death hospitalization heart_failure mortality
P-854	-0.6577 -0.2502 -0.4819 -0.2012 -2.1455 -0.1873 -1.3085 -1.8429 -0.2754 -0.9341 -1.6605 -3.0511 -1.5994 -0.3852 -0.0875 -0.3403 -1.0631 -1.0688 -0.2354 -0.7199 -0.2170 -1.1989 -1.7124 -0.0552 -0.1038 -0.3719 -0.2460
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially_expressed_genes degs ischemic_heart_failure healthy diagnosis heart_failure
H-1608	-1.0701733827590942	▁de g s ▁non - ische mic ▁ ische mic _ heart _ fail ure ▁heart _ fail ure
D-1608	-1.0701733827590942	degs non-ischemic ischemic_heart_failure heart_failure
P-1608	-1.8581 -0.8930 -0.1483 -2.0266 -0.0489 -0.1415 -0.5045 -2.3798 -0.0322 -0.5545 -1.8427 -2.2796 -0.2717 -1.6806 -1.8876 -1.4273 -0.3527 -1.4441 -2.0094 -0.4061 -0.2847
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse_events reoperation bleeding driveline infection gastrointestinal_bleeding stroke rankin_score
H-2003	-0.5575555562973022	▁ble ed ing ▁drive line _ ▁infection ▁gastro inte stin al _ blad ed ing ▁stroke ▁Rank in _ ▁Score
D-2003	-0.5575555562973022	bleeding driveline_ infection gastrointestinal_bladeding stroke Rankin_ Score
P-2003	-0.6481 -0.1169 -0.2619 -0.0600 -0.1944 -0.7945 -1.7075 -0.0398 -0.0231 -0.5539 -0.1510 -0.8074 -4.0236 -0.2285 -0.2241 -0.3068 -0.2958 -0.6083 -0.3487 -0.1807 -0.4316 -0.2598
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox_regression_models propensity_score oral glucocorticoid hf hospitalisations loop_diuretics
H-605	-0.7583364844322205	▁co x _ re gression _ model s ▁pro pens ity _ ▁score ▁oral _ ▁gluco cor tico id ▁ HF ▁loop _ di ure tics
D-605	-0.7583364844322205	cox_regression_models propensity_ score oral_ glucocorticoid HF loop_diuretics
P-605	-0.1075 -0.2381 -0.1862 -0.0876 -0.2018 -1.0691 -1.1363 -0.4616 -0.0542 -0.2201 -0.4709 -0.1568 -4.1906 -0.2906 -1.3523 -0.1110 -0.3552 -1.0676 -1.3653 -2.8017 -0.7320 -0.0298 -0.2267 -2.0858 -0.0694 -1.3738 -0.5561 -0.2354
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin_resistance type_2_diabetes insulin_receptor_substrates_1 irs1 irs2 cellular_metabolism
H-653	-0.5321003794670105	▁insulin _ re ▁resist ance ▁diabetes ▁insulin _ ▁receptor _ ▁substrat es ▁ir s 1 ▁ir s 2 ▁insulin - signal ing ▁cel lular _ ▁metabolism
D-653	-0.5321003794670105	insulin_re resistance diabetes insulin_ receptor_ substrates irs1 irs2 insulin-signaling cellular_ metabolism
P-653	-1.7012 -0.2495 -0.4358 -4.4312 -0.0321 -0.1072 -0.0447 -0.2548 -0.1022 -0.6154 -0.1790 -0.1749 -1.1104 -0.1958 -0.0464 -0.4695 -0.6804 -0.1819 -0.3826 -0.1275 -0.0247 -0.1867 -1.9436 -0.1018 -0.2232 -0.3105 -0.3540 -0.2318
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous_hf electromechanical_delay emd myocyte_depolarization myofiber_shortening
H-1149	-0.472277969121933	▁dys syn chron ous _ HF ▁electro me chan ical _ de lay ▁em d ▁my o cy te _ de po lar ization ▁my o fi ber
D-1149	-0.472277969121933	dyssynchronous_HF electromechanical_delay emd myocyte_depolarization myofiber
P-1149	-0.0438 -0.0535 -0.0096 -0.1881 -1.6109 -1.4103 -0.0315 -0.3163 -0.0580 -0.1069 -0.2679 -0.0987 -0.2058 -2.8103 -0.0708 -2.1648 -0.3462 -0.3663 -0.4165 -0.3008 -0.1137 -0.2900 -0.2015 -0.1759 -0.8360 -0.2162 -0.5437 -0.0721 -0.5700 -0.2724
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta_blockers all-cause_mortality readmissions heart_failure_with_reduced_ejection_fraction hfref heart_rate
H-1936	-0.6719244122505188	▁Beta _ block ers ▁read missions ▁heart _ fail ure ▁e je ction _ fraction HF r EF ▁heart _ rate HR
D-1936	-0.6719244122505188	Beta_blockers readmissions heart_failure ejection_fractionHFrEF heart_rateHR
P-1936	-0.3870 -0.3841 -1.3417 -0.3884 -0.6857 -0.0348 -0.5157 -0.2333 -1.2101 -2.2737 -0.2061 -0.1919 -0.0592 -0.2516 -0.0122 -2.5532 -0.1712 -0.8489 -0.7992 -0.4331 -0.7320 -1.7699 -0.3941 -0.2493
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional_electrical_stimulation fes exercise_capacity quality_of_life endothelial_function chronic_heart_failure systolic_function
H-1327	-0.6576413512229919	▁function al _ electric al _ stimul ation ▁f es ▁exercise _ capaci ty ▁emotional ▁en dot heli al _ function ▁chronic _ heart _ fail ure ▁sy sto lic _ function
D-1327	-0.6576413512229919	functional_electrical_stimulation fes exercise_capacity emotional endothelial_function chronic_heart_failure systolic_function
P-1327	-1.7210 -0.9125 -0.3720 -0.8378 -0.0925 -0.4155 -0.2317 -0.0649 -2.3325 -0.5256 -0.1064 -2.2638 -0.0617 -0.0522 -0.0515 -1.0013 -1.1594 -0.2556 -0.0343 -1.1033 -0.3168 -1.0855 -0.4820 -1.7778 -0.2462 -1.0254 -0.7972 -0.6343 -0.3966 -0.6023 -0.5695 -0.2275 -0.3785 -0.2247
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report patient right_atrial_myxoma massive_embolism pulmonary_arteries surgically right_atrial pulmonary_embolectomy
H-595	-0.6796445846557617	▁report ▁right _ at rial _ My xo ma ▁e mbol ism ▁pulmonar y _ ▁arteri es ▁right _ at rial _ ▁mass _ ▁remo val ▁pulmonar y _ e mbol ecto my
D-595	-0.6796445846557617	report right_atrial_Myxoma embolism pulmonary_ arteries right_atrial_ mass_ removal pulmonary_embolectomy
P-595	-0.3515 -0.0358 -0.4336 -1.9450 -0.4088 -0.2600 -3.8931 -0.3167 -1.1372 -2.3987 -0.0607 -0.1385 -0.0576 -0.4151 -0.3432 -0.3219 -0.3196 -0.2068 -0.4457 -1.3703 -1.0138 -0.2465 -0.5636 -0.2253 -1.5737 -0.2919 -0.0108 -0.3151 -0.6373 -0.3232 -0.0852 -0.2159 -2.7089 -0.5043 -0.2123
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant patients pd hf clinical
H-896	-0.8145903944969177	▁transplant ▁p d ▁h f ▁volume _ management ▁post - PD
D-896	-0.8145903944969177	transplant pd hf volume_management post-PD
P-896	-0.8325 -1.1479 -1.1332 -0.8223 -1.1810 -1.6907 -0.2961 -0.1829 -0.2575 -0.0959 -1.8699 -0.7913 -0.2884
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker clinical therapeutic
H-1478	-0.8016340732574463	▁bio mark er _ studie s ▁bio mark er - guide d _ ▁clinic al _ ▁trial _ design
D-1478	-0.8016340732574463	biomarker_studies biomarker-guided_ clinical_ trial_design
P-1478	-0.2091 -0.2037 -0.8978 -0.8145 -2.4565 -0.2427 -0.4946 -0.2070 -0.9458 -0.3217 -0.0446 -0.1355 -0.8307 -1.5547 -0.2658 -0.3626 -2.5718 -0.9050 -0.1375 -2.9155 -0.3173
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf incidence liver nodularity
H-231	-0.5375772714614868	SAF ▁ab normal _ liver _ ▁texture ▁no du lar ity
D-231	-0.5375772714614868	SAF abnormal_liver_ texture nodularity
P-231	-0.2310 -1.6512 -0.1073 -0.3641 -1.1908 -0.4815 -0.6696 -1.0500 -0.0273 -0.2093 -0.2877 -0.4573 -0.2615
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty biological_phenotype physical activity
H-1004	-0.527276337146759	▁fra il ty ▁bi ological _ ▁ph eno type ▁we ak _ grip ▁physical ▁activity ▁weight _ los s
D-1004	-0.527276337146759	frailty biological_ phenotype weak_grip physical activity weight_loss
P-1004	-3.0062 -0.2092 -0.1943 -0.6051 -0.1324 -0.7709 -0.9498 -0.0667 -0.0072 -0.0399 -0.0439 -0.1157 -0.8776 -0.8178 -0.1867 -1.1713 -0.4117 -0.7400 -0.1294 -0.3733 -0.2237
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d patients ic crt-d ies
H-109	-1.2304270267486572	▁c t - d ▁i cc ▁c t - d ▁IE s
D-109	-1.2304270267486572	ct-d icc ct-d IEs
P-109	-0.7728 -3.0892 -0.1487 -0.4799 -0.7836 -2.4223 -0.8786 -2.7411 -0.1900 -0.4168 -3.0317 -1.7252 -0.3250 -0.2211
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds discharge patients heart_failure outcomes driven readmissions
H-467	-0.8627763390541077	▁low - volu me _ ▁ED s ▁dis charge ▁heart _ fail ure ▁ED _ case s ▁read missions ▁repeat _ ed _ visit s
D-467	-0.8627763390541077	low-volume_ EDs discharge heart_failure ED_cases readmissions repeat_ed_visits
P-467	-4.3403 -0.0904 -0.1839 -0.1550 -0.6446 -1.8139 -0.0950 -0.6202 -0.0053 -1.1078 -0.2384 -1.3014 -1.0734 -1.7190 -2.1990 -0.0975 -0.0538 -1.1774 -0.0214 -0.5674 -0.8907 -1.9703 -0.8779 -1.2100 -0.2444 -0.3579 -0.2386
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs_morphology outcomes cardiac_resynchronization_therapy resynchronization-defibrillation_for_ambulatory_heart_failure_trial raft
H-879	-0.4460378885269165	▁QR s _ morph ology ▁cardiac _ re syn chron ization _ therapy ▁re syn chron ization - Def i bril lation ▁amb ulator y _ ▁Heart _ fail ure _ tri al RAF t
D-879	-0.4460378885269165	QRs_morphology cardiac_resynchronization_therapy resynchronization-Defibrillation ambulatory_ Heart_failure_trialRAFt
P-879	-0.1994 -0.4608 -1.5902 -0.0321 -0.0688 -0.0463 -0.7212 -0.1305 -0.0721 -0.0295 -0.3341 -0.6273 -0.6345 -0.1683 -0.0960 -0.0908 -0.4433 -0.6245 -2.1968 -0.4580 -0.2266 -0.1057 -0.7953 -0.3580 -0.3893 -0.2466 -0.7695 -0.2295 -1.1031 -0.0853 -0.2862 -1.1092 -0.6291 -0.3363 -0.3242 -0.2527 -0.2322
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute_right_heart_failure therapy refractory_cardiogenic_shock heart extra_corporeal_membrane_oxygenation ecmo cpr icu
H-1295	-0.6928337216377258	▁right _ ▁heart _ fail ure ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁heart _ team ▁corpore al _ ▁membran e _ ▁oxygen ation ▁ec mo ▁c PR ICU
D-1295	-0.6928337216377258	right_ heart_failure refractory_ cardiogenic_ shock heart_team corporeal_ membrane_ oxygenation ecmo cPRICU
P-1295	-0.8318 -0.2979 -2.3398 -0.9921 -1.2502 -1.7686 -1.0259 -0.0437 -0.0371 -0.4485 -0.0957 -0.0803 -0.0545 -0.1676 -1.9350 -1.0515 -0.9479 -0.0650 -0.7201 -0.1975 -0.4396 -2.0806 -0.4506 -0.2288 -0.8288 -0.0781 -0.1556 -0.9653 -0.2502 -2.5097 -0.0418 -0.3147 -0.1690
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency_room undiagnosed heart_disease symptoms hf surgical_palliation
H-201	-0.9567158222198486	▁heart _ ▁disease ▁h f ▁sur g ical _ ▁palli ation
D-201	-0.9567158222198486	heart_ disease hf surgical_ palliation
P-201	-3.0344 -0.1778 -2.4416 -0.5929 -2.0511 -1.8851 -0.0493 -0.0805 -0.2618 -1.1153 -0.0710 -0.4292 -0.2473
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene_expression bax pacing bcl-2 mrna expression heart_failure bcl-2 bax
H-168	-0.7660139203071594	▁Gene _ expression ▁Bax ▁b cl -2 ▁m RNA _ expression ▁heart _ fail ure ▁ratio ▁b cl - 2/ Ba x
D-168	-0.7660139203071594	Gene_expression Bax bcl-2 mRNA_expression heart_failure ratio bcl-2/Bax
P-168	-1.7972 -0.2174 -0.2194 -0.0821 -0.2170 -0.4130 -0.0836 -0.4693 -0.0996 -1.0365 -0.2883 -0.8528 -0.2728 -0.7889 -1.7660 -1.1392 -0.2456 -0.7797 -0.0826 -0.2362 -6.5339 -0.1328 -0.4420 -0.1882
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart_magnetic_resonance_imaging chelation patient compliance heart_failure arrhythmias
H-745	-0.7285477519035339	▁heart _ magnet ic _ re on ance _ ▁imagin g ▁che lation ▁compliance ▁heart _ fail ure ▁ar rhythm ias
D-745	-0.7285477519035339	heart_magnetic_reonance_ imaging chelation compliance heart_failure arrhythmias
P-745	-1.5819 -0.3842 -0.7905 -1.7744 -0.1898 -0.6739 -2.1671 -0.2353 -0.1966 -1.7131 -0.1372 -0.1712 -0.0871 -0.1253 -1.1847 -0.4100 -1.3449 -0.8899 -0.0378 -0.4079 -1.5366 -0.4665 -0.2507
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl hno inotropic lusitropic vasodilator in_vivo camp
H-413	-0.2290000319480896	▁ni tro x yl ▁h no ▁Angeli ▁in o tropi c ▁ lusi tropi c ▁vaso dila tor _ effect s ▁c AMP
D-413	-0.2290000319480896	nitroxyl hno Angeli inotropic lusitropic vasodilator_effects cAMP
P-413	-0.0799 -0.1035 -0.0983 -0.6388 -0.2407 -0.1365 -0.2052 -0.4311 -0.4045 -0.0245 -0.3116 -0.5760 -0.0066 -0.0413 -0.4452 -0.0146 -0.0215 -0.0920 -0.4385 -0.1377 -0.0996 -0.2854 -0.3209 -0.3647 -0.2062
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection_fraction ef patients nyha_class_iiib symptoms right_ventricular_dysfunction
H-897	-0.8014786243438721	▁mean _ e je ction _ fraction ▁pre - PD ▁NY ha ▁right _ vent ri cular _ ▁dys function
D-897	-0.8014786243438721	mean_ejection_fraction pre-PD NYha right_ventricular_ dysfunction
P-897	-1.0137 -0.2653 -0.2353 -0.5752 -0.1188 -0.1908 -0.0263 -4.9865 -0.0326 -1.1118 -1.7000 -0.5747 -1.4557 -0.3307 -0.9398 -1.2016 -0.6721 -0.3990 -1.1039 -0.1427 -0.3501 -0.2061
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs early-outgrowth_colony-forming_units eo-cfus cells
H-124	-0.8547881841659546	▁c PC s ▁early - out g row th _ ▁colon y - form ing _ ▁unit s ▁e - c FU s ▁circula ting ▁cd 34 ▁v g f 2 ▁cd 133
D-124	-0.8547881841659546	cPCs early-outgrowth_ colony-forming_ units e-cFUs circulating cd34 vgf2 cd133
P-124	-0.1477 -2.6983 -0.1304 -2.4497 -0.1228 -0.2497 -1.4564 -0.0965 -0.0913 -2.6865 -1.0110 -0.1274 -0.1747 -0.0100 -0.0838 -0.3066 -0.9204 -0.3884 -1.1698 -2.8805 -0.6190 -1.4324 -0.2917 -0.2626 -0.1794 -2.1303 -0.1322 -1.3851 -1.5642 -1.6358 -0.0176 -1.6782 -0.2148 -0.9128 -0.2593
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence clinical continuous-flow_lvads heartmate_ii hm_ii heartware btt dt patients
H-309	-0.6802071332931519	▁evidence ▁continuo us - flow _ ▁L VAD s ▁he art Mate _ ▁II HM ▁Heart War e ▁b t ▁d t
D-309	-0.6802071332931519	evidence continuous-flow_ LVADs heartMate_ IIHM HeartWare bt dt
P-309	-1.2776 -0.6147 -0.1676 -0.4564 -0.0265 -0.4825 -4.4279 -0.0681 -0.1833 -0.2174 -0.1755 -0.1254 -1.8047 -0.5311 -0.8098 -1.3937 -0.8802 -0.1834 -0.4953 -0.2491 -0.9328 -0.0923 -0.5091 -0.2206
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy anticoagulation rate_control cardiovascular complications stroke cardiovascular_death acute_heart_failure patients atrial_fibrillation
H-1643	-0.5885977745056152	▁antico ag ulation ▁rate _ control ▁cardiovascular _ ▁complica tions stro ke ▁cardiovascular _ ▁death ▁a cute _ heart _ fail ure ▁at rial _ fi bril lation AF
D-1643	-0.5885977745056152	anticoagulation rate_control cardiovascular_ complicationsstroke cardiovascular_ death acute_heart_failure atrial_fibrillationAF
P-1643	-2.6679 -0.3555 -0.0366 -0.3442 -0.4210 -0.0124 -0.1408 -2.3962 -0.1747 -0.1837 -1.3097 -0.1540 -0.0833 -0.7305 -0.8142 -0.0426 -0.0434 -0.1988 -2.1939 -0.1976 -1.0769 -1.0714 -0.2842 -0.4732 -0.2853 -0.7440 -0.1120 -0.1514 -0.9574 -0.3297 -0.2601
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients baseline ef ef core
H-753	-1.1987026929855347	▁base line ▁EF
D-753	-1.1987026929855347	baseline EF
P-753	-0.0852 -0.0724 -1.9046 -3.6563 -0.2750
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef bnp bnp inhospital mortality
H-197	-0.6317606568336487	▁b NP ▁b NP ▁in hospital _ ▁mortal ity
D-197	-0.6317606568336487	bNP bNP inhospital_ mortality
P-197	-1.2603 -2.0575 -0.4262 -1.3932 -0.4511 -0.0757 -0.2235 -0.3151 -0.1189 -0.3835 -0.2444
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash mortality hf nonsignificant
H-693	-0.7177030444145203	▁DAS h ▁mortal ity ▁h f ▁Mediterrane an _ diet _ ▁score s
D-693	-0.7177030444145203	DASh mortality hf Mediterranean_diet_ scores
P-693	-0.0784 -0.2354 -0.8763 -0.1002 -0.2047 -1.9538 -1.1334 -0.2407 -0.2927 -1.8773 -0.3203 -2.7058 -0.0635 -0.4596 -0.2236
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal_muscle lean_mass z-score
H-1499	-0.8778766393661499	kelet al _ ▁muscle _ ▁mass ▁relative _ ▁appen di cular _ ▁lean _ ▁mass _ index ▁z - s core
D-1499	-0.8778766393661499	keletal_ muscle_ mass relative_ appendicular_ lean_ mass_index z-score
P-1499	-3.0332 -0.2812 -0.4513 -4.7700 -0.2809 -2.0303 -0.2908 -0.2424 -1.2931 -0.0835 -0.2087 -0.6322 -1.5562 -0.2651 -1.5840 -0.1751 -0.4130 -1.2456 -0.1144 -0.0508 -0.5995 -0.3319 -0.2581
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 functional_capacity outcomes ambulatory patients hf
H-706	-0.4965653419494629	▁ST 2 ▁functional _ capaci ty ▁ambula tory HF
D-706	-0.4965653419494629	ST2 functional_capacity ambulatoryHF
P-706	-1.2526 -0.0244 -0.1925 -0.2607 -0.0843 -0.0378 -0.3073 -0.0865 -2.4393 -0.4798 -0.2969
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality_of_life all-cause_mortality mortality
H-561	-0.529421865940094	▁all - ca use _ ▁mortal ity ▁mortal ity
D-561	-0.529421865940094	all-cause_ mortality mortality
P-561	-3.2799 -0.0699 -0.0157 -0.1911 -0.1551 -0.5018 -0.1851 -0.0999 -0.2385 -0.8306 -0.2561
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene_expression cardiomyocytes jq1 drug genes
H-1046	-0.5898787379264832	▁Gene _ expression _ profil ing ▁culture d _ ▁cardio my o cy tes ▁j q 1 ▁drug ▁ phen yle ph rine - indu ced _ ▁gene s
D-1046	-0.5898787379264832	Gene_expression_profiling cultured_ cardiomyocytes jq1 drug phenylephrine-induced_ genes
P-1046	-0.9376 -0.3017 -0.2708 -1.5337 -0.0628 -0.3319 -0.1800 -0.1774 -0.2820 -0.1929 -2.1198 -0.6287 -0.1712 -1.0687 -0.3586 -1.3937 -0.0886 -0.2841 -0.6871 -0.4037 -0.7967 -1.5631 -0.4119 -0.3586 -0.0001 -0.0125 -0.6026 -2.3774 -0.1132 -0.3687 -0.2063
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka polymorphism rs10927887 p.arg83gly heart_failure estimated_glomerular_filtration_rate renastur
H-1801	-0.6611555814743042	▁c cn ka _ poly morph ism ▁ar g 83 g ly ▁heart _ fail ure ▁glo mer ular _ filter ation _ rate ▁re NAS tur
D-1801	-0.6611555814743042	ccnka_polymorphism arg83gly heart_failure glomerular_filteration_rate reNAStur
P-1801	-2.0730 -0.4278 -0.5694 -1.6020 -0.7260 -0.0891 -0.3402 -3.3371 -0.0635 -0.1982 -0.7632 -0.1182 -0.2328 -0.2700 -1.1915 -1.5572 -0.1232 -0.1762 -0.0545 -0.2855 -0.8194 -0.6233 -0.2858 -0.4877 -0.6733 -0.7413 -0.5447 -0.5835 -0.2160
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular_diseases heart_failure hf incidence hf
H-285	-0.9918994307518005	▁cardiovascular _ ▁disease s ▁heart _ fail ure HF HF HF
D-285	-0.9918994307518005	cardiovascular_ diseases heart_failureHFHFHF
P-285	-0.2122 -0.3917 -3.2720 -0.0866 -0.3602 -0.1496 -0.9392 -1.7735 -1.3861 -1.7383 -1.6521 -0.6912 -0.2419
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac_vegf_expression endothelial_no_synthase_activation hearts
H-455	-0.7410247325897217	▁cardiac _ ve GF _ expression ▁Akt ▁en dot heli al _ no _ ▁synth ase _ activa tion ▁heart s
D-455	-0.7410247325897217	cardiac_veGF_expression Akt endothelial_no_ synthase_activation hearts
P-455	-0.3589 -2.0518 -0.2489 -0.8623 -0.4582 -0.1508 -0.0496 -0.1733 -2.0301 -0.3921 -0.0342 -0.4754 -0.1501 -0.5215 -3.4381 -1.7394 -0.1282 -0.2182 -0.1871 -2.3864 -0.2513 -0.4400 -0.2978
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial exercise outcomes heart_failure patients heart_failure outcomes exercise training hf-action
H-1924	-0.6575331091880798	▁Psycho social _ factor s ▁exercise ▁Heart _ fail ure ▁Heart _ fail ure ▁exercise _ training HF - ac tion
D-1924	-0.6575331091880798	Psychosocial_factors exercise Heart_failure Heart_failure exercise_trainingHF-action
P-1924	-0.4631 -0.0399 -0.6642 -0.0380 -0.1255 -1.6141 -2.0430 -0.4440 -0.7957 -0.1749 -0.8096 -0.3879 -0.7623 -0.2180 -0.4232 -0.7186 -0.2886 -1.6785 -0.0567 -0.7407 -1.9178 -0.4490 -0.2700
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart_failure left_ventricular_systolic_dysfunction post_hoc_analysis
H-402	-0.782832145690918	▁heart _ fail ure ▁left _ vent ri cular _ sy sto lic _ ▁dys function ▁BB
D-402	-0.782832145690918	heart_failure left_ventricular_systolic_ dysfunction BB
P-402	-1.0249 -0.4584 -1.2404 -1.7801 -0.2111 -0.3257 -0.8691 -1.2648 -0.2457 -0.4030 -1.6789 -0.9800 -1.2520 -0.2207 -0.7914 -0.0925 -1.1730 -0.6292 -0.2328
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients coronary_angiography diagnosis systolic_hf etiology ejection_fraction
H-1186	-0.5715504288673401	▁deriva tion _ co hor t ▁corona ry _ ang i ography ▁sy sto lic _ HF ▁et i ology ej ection _ fraction
D-1186	-0.5715504288673401	derivation_cohort coronary_angiography systolic_HF etiologyejection_fraction
P-1186	-2.8659 -0.1806 -0.7471 -0.1599 -0.0959 -0.5632 -0.0456 -0.8859 -0.3137 -0.4324 -1.3519 -0.3782 -0.6419 -0.2038 -0.2352 -0.8939 -1.3109 -0.7780 -0.3713 -0.0174 -1.0643 -0.0095 -0.4269 -0.0041 -0.6194 -0.2634
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac insulin-resistance glycolysis glucose_oxidation plasma_membrane_translocation glucose
H-1784	-0.3825411796569824	▁cardiac ▁insulin - re si stance ▁insulin - stimul ated _ rate s ▁gly col ysis ▁gluco se _ oxid ation ▁plasma _ ▁membran e ▁trans location ▁gluco se _ transport
D-1784	-0.3825411796569824	cardiac insulin-resistance insulin-stimulated_rates glycolysis glucose_oxidation plasma_ membrane translocation glucose_transport
P-1784	-0.7571 -1.3415 -0.0871 -0.0529 -0.0814 -0.0056 -0.7079 -0.0917 -0.1620 -0.1085 -0.8207 -0.9323 -0.0648 -0.3587 -0.1213 -0.2953 -0.0647 -0.1844 -0.1364 -0.7998 -0.1429 -0.1342 -0.1886 -1.9040 -0.0926 -0.7511 -0.0781 -0.2526 -0.1017 -0.1514 -1.0294 -0.3633 -0.2597
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells angiotensin_ii angii hypoxia scn5a mrna_splicing scn5a
H-1083	-0.5634135007858276	▁ang io ten sin _ ▁II ▁ang II ▁hypo xia ▁activa tors ▁s cn 5 a ▁m RNA _ s plic ing ▁induc ed ▁s cn 5 a
D-1083	-0.5634135007858276	angiotensin_ II angII hypoxia activators scn5a mRNA_splicing induced scn5a
P-1083	-0.6533 -4.4259 -0.1419 -0.5757 -0.5467 -0.6748 -0.3396 -0.9916 -0.0269 -0.0620 -0.1104 -0.0943 -0.4129 -0.3097 -0.7488 -0.3025 -0.6103 -0.1568 -1.5669 -0.5291 -0.3479 -0.1488 -0.0144 -0.1436 -0.3312 -0.5058 -0.8571 -0.4092 -0.6052 -0.2592
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced_pasp right_ventricular_contractile_reserve patients exercise-induced_pasp
H-824	-0.6242933869361877	▁exercise - indu ced _ pas p ▁right _ vent ri cular _ contract ile _ re serve ▁exercise - indu ced _ pass p
D-824	-0.6242933869361877	exercise-induced_pasp right_ventricular_contractile_reserve exercise-induced_passp
P-824	-0.2321 -0.1665 -0.0011 -0.0184 -0.7658 -2.0286 -1.6994 -0.4096 -0.4611 -0.8537 -1.2007 -0.3422 -0.3305 -0.1272 -0.9760 -0.3107 -0.7234 -1.7309 -0.4725 -0.1646 -0.0014 -0.0354 -0.6994 -1.5850 -0.9984 -0.2600 -0.2613
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial_elastance ea end-systolic_elastance ees ventricular-arterial_coupling ees ea
H-922	-0.42631828784942627	▁arterial _ ▁elastan ce ▁end - sy sto lic _ ▁elastan ce ▁e es ▁vent ri cular - arte rial _ ▁coup ling ▁ratio ▁e es ▁techniques
D-922	-0.42631828784942627	arterial_ elastance end-systolic_ elastance ees ventricular-arterial_ coupling ratio ees techniques
P-922	-0.2147 -0.8076 -0.2970 -0.9297 -1.3297 -0.1872 -0.2315 -0.2600 -0.3467 -0.4313 -0.0566 -0.4844 -0.5550 -0.0455 -0.2246 -0.3270 -0.2480 -0.2572 -0.3084 -0.1211 -0.4195 -1.7474 -0.3432 -0.8800 -0.5521 -0.1020 -0.0582 -0.3724 -0.2251
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline central_blood_pressure radial_arterial_tonometry cardiovascular_function echocardiographic invasively
H-920	-0.759789764881134	▁base line ▁post - DAS h ▁s rd _ bra chi al ▁central _ ▁Blood _ tension ▁radi al _ ▁arterial _ to ometr y ▁cardiovascular ▁e cho car dio graphic
D-920	-0.759789764881134	baseline post-DASh srd_brachial central_ Blood_tension radial_ arterial_toometry cardiovascular echocardiographic
P-920	-0.0194 -0.1006 -0.0244 -0.0865 -0.2833 -0.2881 -1.4954 -0.5538 -0.7850 -0.0801 -0.0937 -0.0623 -0.0920 -0.4917 -3.0303 -0.4852 -3.1967 -0.0350 -0.1926 -0.5313 -1.7272 -0.3702 -5.6508 -0.3012 -0.3713 -0.1428 -1.1612 -0.2326 -0.0669 -0.8954 -1.2766 -0.6943 -0.2552
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene_expression_profile gse9128 gene_expression_omnibus non-ischemic_heart_failure ischemic
H-1609	-0.5109337568283081	▁Gene _ expression _ profil e ▁g se 91 28 ▁Gene _ ▁Express ion _ ▁Omni bus ▁non - ische mic _ heart _ fail ure ▁ ische mic
D-1609	-0.5109337568283081	Gene_expression_profile gse9128 Gene_ Expression_ Omnibus non-ischemic_heart_failure ischemic
P-1609	-0.6872 -0.2951 -0.2563 -0.4678 -0.0684 -0.2229 -0.7401 -0.1562 -0.0916 -0.0521 -0.4994 -0.3327 -0.8915 -0.0701 -0.3298 -0.4106 -0.1463 -0.8043 -0.0384 -0.1591 -0.8852 -0.6311 -1.5630 -0.1911 -0.9361 -1.0951 -1.4652 -0.0502 -1.2481 -0.7974 -0.2564
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm_control_therapy rhythm_control_therapy antiarrhythmic_drugs catheter_ablation electrocardiographic rhythm
H-1653	-0.4334884583950043	▁ rhythm _ control _ therapy ▁ rhythm _ control _ therapy ▁anti ar rhythm ic _ drug s ▁cat heter _ ab lation ▁electro car dio graphic ▁ rhythm
D-1653	-0.4334884583950043	rhythm_control_therapy rhythm_control_therapy antiarrhythmic_drugs catheter_ablation electrocardiographic rhythm
P-1653	-0.2310 -1.0584 -0.4640 -0.0235 -0.5476 -0.2105 -0.3797 -0.7420 -0.3476 -0.0241 -0.3944 -0.2037 -0.0394 -0.3131 -0.5314 -0.0990 -0.6031 -1.0178 -0.0718 -0.0343 -0.0293 -0.3127 -0.4292 -0.0322 -0.0259 -0.1065 -0.5389 -1.0669 -2.7733 -0.6689 -0.2663 -0.2854
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures hospitalizations noncardiovascular diagnoses implantable_cardiac_arrhythmia_devices noncardiovascular drugs rate-control
H-1240	-0.6852794885635376	▁ex pendi tures ▁non car dio vas cular ▁implant able _ ▁cardiac _ ar rhythm ia _ geräte s ▁non car dio vas cular _ drug s ▁rate - control _ group
D-1240	-0.6852794885635376	expenditures noncardiovascular implantable_ cardiac_arrhythmia_gerätes noncardiovascular_drugs rate-control_group
P-1240	-0.1806 -0.0143 -0.0905 -0.1087 -0.3256 -1.2920 -1.3258 -0.8214 -0.0808 -0.1001 -1.1976 -0.2134 -0.2946 -0.2716 -0.3512 -1.7182 -0.2848 -4.9973 -0.2179 -0.0907 -0.3510 -1.2789 -1.6248 -1.0518 -0.5678 -1.0322 -0.0679 -0.8198 -0.1965 -0.0075 -0.7231 -0.7617 -0.5636 -0.2756
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence hf_with_reduced_ejection_fraction hfref hf_with_preserved_ejection_fraction hfpef
H-1488	-0.9290353059768677	▁evidence HF ▁e je ction _ fraction HF r EF ▁treatment HF ▁pres er ved _ e je ction _ fraction HF p EF
D-1488	-0.9290353059768677	evidenceHF ejection_fractionHFrEF treatmentHF preserved_ejection_fractionHFpEF
P-1488	-4.0295 -0.5602 -2.5112 -0.6063 -0.2703 -0.2097 -0.0591 -1.7424 -0.2294 -0.5042 -2.5799 -1.6921 -3.6830 -0.2307 -0.2021 -0.2096 -0.6356 -0.8353 -0.2834 -0.2853 -0.0742 -1.2877 -0.2450 -0.6447 -0.3532 -0.1910
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal_life_support therapy patients acute_ischemic_right_heart_failure refractory_cardiogenic_shock reperfusion therapy
H-1298	-0.544405996799469	▁extra corp o real _ life _ support ▁ brid ging _ therapy ▁a cute _ ische mic _ right _ ▁heart _ ▁failure ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁reper fusion _ therapy
D-1298	-0.544405996799469	extracorporeal_life_support bridging_therapy acute_ischemic_right_ heart_ failure refractory_ cardiogenic_ shock reperfusion_therapy
P-1298	-1.1302 -0.0675 -0.4859 -0.1402 -0.3117 -0.1892 -1.5348 -0.6477 -0.5849 -0.0642 -0.0463 -0.3911 -0.1257 -3.5476 -0.0287 -0.4800 -0.2611 -0.7324 -0.2989 -1.0123 -0.4833 -2.3503 -0.6034 -1.3041 -0.0051 -0.0557 -0.1246 -0.5407 -0.1063 -0.0774 -0.0645 -0.1754 -1.6029 -0.0120 -0.0273 -0.6544 -0.2193 -0.4950 -0.2500
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart_failure reduced_left_ventricular_ejection_fraction fes exercise_capacity quality_of_life endothelial_function hfpef
H-1332	-0.6232686638832092	▁heart _ ▁failure ▁left _ vent ri cular _ e je ction _ fraction ▁f es ▁exercise _ capaci ty ▁emotional ▁en dot heli al _ function ▁h p EF
D-1332	-0.6232686638832092	heart_ failure left_ventricular_ejection_fraction fes exercise_capacity emotional endothelial_function hpEF
P-1332	-0.5899 -0.5615 -2.9333 -0.2464 -0.4508 -0.5337 -1.0140 -0.2905 -0.3759 -0.2647 -0.4464 -0.1890 -0.1970 -0.0101 -3.6084 -0.7909 -0.0674 -0.7506 -0.0916 -0.0399 -0.8613 -0.4907 -0.9525 -0.1820 -0.0513 -0.7188 -0.1216 -0.4043 -1.0333 -1.0872 -0.3440 -0.2454
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.30425792932510376	▁in tub ation _ rate s
D-220	-0.30425792932510376	intubation_rates
P-220	-0.1192 -0.0467 -0.0558 -0.5342 -0.9502 -0.0352 -0.4830 -0.2099
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts heart_mass transgenic
H-1814	-0.6338114142417908	▁heart s ▁t t t et Men a _ mi ce ▁litt er mates ▁heart _ ▁mass ▁trans ge nic _ mi ce
D-1814	-0.6338114142417908	hearts tttetMena_mice littermates heart_ mass transgenic_mice
P-1814	-0.9532 -0.2011 -0.8617 -0.3224 -0.6456 -0.7719 -0.9475 -0.0479 -0.3683 -0.7031 -0.3567 -3.7866 -0.0987 -0.1936 -1.2422 -0.3815 -1.7676 -0.1294 -0.0665 -0.0642 -0.2914 -0.7488 -0.3293 -0.3940 -0.1725
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene heart_failure
H-1541	-0.490274041891098	▁ra lo xi fen e ▁mechanism _ of _ action ▁heart _ fail ure
D-1541	-0.490274041891098	raloxifene mechanism_of_action heart_failure
P-1541	-0.3121 -0.0443 -0.0229 -0.0640 -0.6922 -0.0392 -0.4869 -0.0991 -0.3460 -0.0862 -0.8893 -0.3026 -1.4525 -1.3605 -1.4248 -0.2218
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients hfref exercise respiratory_gas_analysis baseline
H-1938	-0.6427996158599854	▁h f f ▁exercise ▁respirator y _ gas ▁base line
D-1938	-0.6427996158599854	hff exercise respiratory_gas baseline
P-1938	-0.8736 -3.1698 -1.1453 -0.1072 -0.7239 -0.2243 -0.2744 -0.0357 -0.1738 -0.1007 -0.5645 -0.3204
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients drugs heart_failure biomedical nonprescribing patients
H-1126	-0.8114766478538513	▁guide line - re com mend ed _ ▁drugs ▁heart _ ▁failure ▁bio medic al
D-1126	-0.8114766478538513	guideline-recommended_ drugs heart_ failure biomedical
P-1126	-3.7151 -0.0468 -0.6201 -0.0079 -0.2394 -0.1875 -0.0801 -0.8296 -1.6477 -0.6609 -0.2064 -3.1058 -0.1711 -0.3801 -0.1131 -1.5002 -0.2835
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients chronic_hf prevalence exercise hf hospitalization mortality exercise training
H-1641	-0.5939419269561768	▁black _ race ▁ HF ▁exercise _ per form ance ▁ HF ▁mortal ity ▁exercise _ training
D-1641	-0.5939419269561768	black_race HF exercise_performance HF mortality exercise_training
P-1641	-0.2686 -0.2507 -1.0883 -3.0999 -0.2697 -0.3512 -0.8529 -0.0947 -0.0230 -0.0264 -1.7370 -0.6699 -0.3639 -0.1082 -0.0961 -0.9178 -0.3461 -0.4045 -0.3160
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean_mass adverse_outcome adipose_tissue cardioprotective hf
H-1169	-0.6471571326255798	▁was ting _ of _ ▁fat ▁lean _ ▁mass ▁fat _ los s ▁cata bol ism ▁adi pose _ ▁tissu e ▁cardio protec tive HF
D-1169	-0.6471571326255798	wasting_of_ fat lean_ mass fat_loss catabolism adipose_ tissue cardioprotectiveHF
P-1169	-3.1231 -0.0357 -0.8459 -0.0836 -0.3420 -3.0005 -0.2771 -0.1427 -1.1140 -0.8405 -0.2065 -1.3401 -0.2254 -1.1671 -0.0927 -0.0484 -0.0622 -0.0126 -0.1075 -1.6399 -0.4714 -0.1616 -0.0471 -0.1527 -1.4713 -0.2632 -0.1986
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads heartmate_ii thoratec_corp pleasanton calif hvad heartware framingham
H-546	-0.7614870667457581	▁l VAD s ▁CF ▁Heart Mate _ ▁II _ ▁devices ▁tho r a tec _ ▁Corp ▁Ple asan ton _ ▁Cali f ▁h VAD ▁Heart War e _ in t l ▁Fram ing ham ▁mass
D-546	-0.7614870667457581	lVADs CF HeartMate_ II_ devices thoratec_ Corp Pleasanton_ Calif hVAD HeartWare_intl Framingham mass
P-546	-0.9488 -0.0977 -0.1597 -3.5663 -1.8237 -0.0832 -0.1571 -0.7890 -0.9913 -3.0889 -0.3278 -0.2306 -2.2146 -0.0068 -0.1401 -0.8335 -1.0707 -0.0737 -0.1388 -1.2603 -1.3390 -0.0674 -0.5921 -0.5848 -3.0409 -0.9132 -0.2268 -0.1417 -0.2751 -0.4090 -0.0807 -0.6507 -0.0266 -0.0992 -1.1725 -0.3514 -0.2012
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts nucleolin chamber_patterning cardiac_looping myocyte_differentiation
H-97	-0.6089553833007812	▁heart s ▁nu cle olin ▁cha mber _ ▁pattern ing ▁cardiac _ ▁loop ing ▁my o cy te _ ▁differenti ation
D-97	-0.6089553833007812	hearts nucleolin chamber_ patterning cardiac_ looping myocyte_ differentiation
P-97	-1.3390 -0.1948 -2.7887 -0.0204 -0.9521 -0.0533 -0.0078 -0.3445 -1.4475 -0.6913 -0.5275 -0.2603 -1.8175 -0.0997 -0.6252 -0.2066 -0.0901 -0.2464 -0.5751 -0.8987 -0.0269 -0.5175 -0.2751
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma collected hf patients immunoreactive nt-probnp c-terminally nt-probnp
H-1520	-0.8756389021873474	▁plasma HF ▁immun ore active ▁NT - pro b NP ▁tru nca ted ▁NT - pro b NP _ ▁mole cule
D-1520	-0.8756389021873474	plasmaHF immunoreactive NT-probNP truncated NT-probNP_ molecule
P-1520	-1.1275 -2.4126 -0.0212 -0.8666 -0.0361 -0.2312 -0.1254 -0.5008 -1.8773 -0.8245 -1.3593 -0.3234 -0.0459 -2.2849 -0.1165 -0.3583 -1.9797 -1.2200 -1.3112 -1.9940 -0.4984 -0.4065 -0.2182
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma_nps adiponectin baseline ffm correlate nps adiponectin follow_up
H-19	-0.9278259873390198	▁FM ▁plasma _ NP s ▁total _ ▁adi pon ect in ▁base line ▁FM ▁f f f NP s ▁adi pon ect in ▁follow _ up
D-19	-0.9278259873390198	FM plasma_NPs total_ adiponectin baseline FM fffNPs adiponectin follow_up
P-19	-2.9878 -0.8088 -1.7178 -0.1597 -0.0750 -3.0606 -0.3267 -0.9597 -0.1594 -0.1908 -1.1785 -0.0328 -0.0542 -2.8255 -0.8363 -1.9337 -2.5853 -1.5527 -0.1119 -0.5253 -0.1800 -0.2779 -0.7469 -0.0680 -1.7289 -0.3503 -0.3507 -0.1939
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages cardiomyocytes doxorubicin in_vitro resistin mrna protein_expression
H-935	-0.46460166573524475	▁Mac rop hage s ▁cardio my o cy tes ▁Hum - re t n _ mi ce ▁do xor ubi cin ▁h re t n ▁m RNA ▁protein _ expression
D-935	-0.46460166573524475	Macrophages cardiomyocytes Hum-retn_mice doxorubicin hretn mRNA protein_expression
P-935	-2.5754 -0.1517 -0.0046 -0.0662 -0.0521 -0.5549 -0.1898 -0.0418 -0.3065 -0.3421 -0.1444 -0.7895 -0.9154 -0.0837 -0.4461 -0.5652 -0.3830 -0.1425 -0.2799 -0.0379 -0.1584 -0.1028 -1.1478 -0.6895 -0.0557 -2.9797 -0.2131 -0.1589 -0.4915 -0.0844 -0.4892 -0.2235
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt_interval ecgs baseline atrial_pacing esmolol isoprenaline atropine infusion
H-1438	-0.5115516185760498	▁beat - to - beat _ QT _ ▁interval ▁surface _ e CG s ▁base line ▁at rial _ pa cing ▁es mol ol ▁iso pren a line ▁a tropi ne _ in fusion
D-1438	-0.5115516185760498	beat-to-beat_QT_ interval surface_eCGs baseline atrial_pacing esmolol isoprenaline atropine_infusion
P-1438	-0.0384 -0.2001 -0.1367 -0.2500 -0.2559 -0.6628 -0.6162 -0.1634 -0.4982 -0.8811 -1.1959 -1.4634 -0.7227 -0.1304 -0.0304 -0.1399 -3.1878 -0.2694 -0.5179 -0.4955 -0.2702 -1.4826 -0.0273 -0.1228 -0.0147 -0.3195 -0.4779 -0.1186 -0.0891 -0.0421 -2.1377 -0.4380 -0.2063 -0.0774 -0.4828 -0.2530
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic_tone parasympathetic_tone heart_rate intravenous_bolus metoprolol atropine
H-1378	-0.5202693343162537	▁sympa the tic _ tone ▁para sy mpa the tic _ tone ▁heart _ ▁rate ▁met o pro lol ▁a tropi ne
D-1378	-0.5202693343162537	sympathetic_tone parasympathetic_tone heart_ rate metoprolol atropine
P-1378	-0.2040 -0.3269 -0.1253 -0.3209 -1.0417 -0.1476 -0.2316 -0.7505 -0.4801 -0.2342 -0.2933 -1.2146 -1.3786 -0.5746 -1.8429 -0.4442 -0.4235 -0.0945 -0.6520 -0.0964 -0.0191 -1.0395 -0.3558 -0.1946
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef pathophysiologically hf_with_reduced_ef hfref hfref therapy
H-1533	-0.9286250472068787	▁EH ▁h f p EF ▁h f f ▁h f f ▁ therapy
D-1533	-0.9286250472068787	EH hfpEF hff hff therapy
P-1533	-1.3326 -0.7824 -2.0861 -0.0315 -1.0161 -0.6507 -0.5119 -1.7708 -0.7225 -1.3441 -0.8361 -2.0613 -0.0625 -0.4830 -0.2376
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse_event acute_myocardial_infarction congestive_heart_failure adverse_events
H-4	-0.7311397790908813	▁advers e _ event _ rate s ▁a cute _ My o card ial _ in far ction ▁con ges tive _ heart _ fail ure
D-4	-0.7311397790908813	adverse_event_rates acute_Myocardial_infarction congestive_heart_failure
P-4	-1.6478 -0.2511 -0.1823 -2.7972 -0.2685 -1.3840 -0.0556 -0.3148 -0.0911 -0.2523 -3.8211 -0.5408 -0.5172 -0.3750 -0.1998 -0.2941 -0.0457 -0.4141 -0.0890 -0.0658 -0.3047 -0.2708 -1.7439 -0.1467 -0.9124 -1.3744 -1.8756 -0.2362
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence_interval
H-803	-0.752334713935852	▁confidence _ ▁interval
D-803	-0.752334713935852	confidence_ interval
P-803	-0.7863 -0.9476 -1.2377 -0.4918 -0.2982
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change follow-up readmissions hospital follow-up
H-721	-0.6510450839996338	▁follow - up _ visit s ▁read missions ▁hospital ▁follow - up _ visit s
D-721	-0.6510450839996338	follow-up_visits readmissions hospital follow-up_visits
P-721	-0.2227 -0.2290 -0.0411 -0.7024 -2.6438 -0.3869 -1.4744 -0.0423 -0.3327 -0.5749 -0.2576 -0.0556 -0.5876 -2.5336 -0.3746 -0.3363 -0.2722
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac jq1 bet pathological cardiac gene_expression
H-1049	-0.8703712224960327	▁cardiac _ ▁tissu e ▁mi ce ▁j q 1 ▁vehicle ▁bet _ ▁inhibi tion ▁path ological _ ▁cardiac _ ▁gene _ expression _ programm e
D-1049	-0.8703712224960327	cardiac_ tissue mice jq1 vehicle bet_ inhibition pathological_ cardiac_ gene_expression_programme
P-1049	-1.4890 -0.1549 -3.4315 -0.5015 -1.6507 -0.0596 -1.1731 -1.7445 -0.0772 -0.4171 -1.9396 -0.9728 -2.3553 -0.1540 -0.4006 -0.7554 -0.5888 -0.4562 -0.2166 -2.0657 -0.2930 -0.1497 -1.2644 -0.1225 -0.3767 -0.4102 -0.2795
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power_spectral_analysis hf dnx
H-1377	-0.5403578877449036	▁power _ spec tral _ analyse ▁low - fre que ncy ▁high - fre que ncy LF HF _ rati o ▁CHF - in v ▁sham - in v ▁sham _ niveau s ▁DN x
D-1377	-0.5403578877449036	power_spectral_analyse low-frequency high-frequencyLFHF_ratio CHF-inv sham-inv sham_niveaus DNx
P-1377	-0.1765 -0.3330 -1.7863 -0.1423 -1.1558 -0.3268 -0.0817 -0.1265 -0.8439 -0.7113 -0.1070 -0.6683 -0.2812 -0.8195 -0.7228 -0.0970 -1.1110 -0.6096 -2.2825 -0.2375 -0.0281 -0.8564 -0.2006 -0.1929 -0.3908 -0.3902 -0.2606 -0.1638 -0.5265 -0.1414 -0.9211 -1.2720 -0.0349 -1.3156 -0.1127 -0.3339 -0.2311
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal_pro-b-type_natriuretic_peptide nt-probnp misdiagnosis heart_failure hf
H-1511	-0.5521491169929504	▁na tri ure tic _ pe pti de NT - pro b NP ▁mis diagnos is ▁heart _ fail ure HF
D-1511	-0.5521491169929504	natriuretic_peptideNT-probNP misdiagnosis heart_failureHF
P-1511	-0.3169 -0.2198 -0.0752 -0.2553 -0.3113 -0.8393 -0.2219 -0.7161 -2.0651 -0.0514 -0.0738 -1.4119 -0.4071 -0.0742 -0.1455 -0.5939 -0.7978 -0.2349 -1.2518 -0.9079 -1.0982 -0.3514 -0.2787
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action randomized patients left_ventricular_ejection_fraction new_york_heart_association_class_ii hf exercise training
H-698	-0.8725181221961975	▁left _ vent ri cular _ e je ction _ fraction ▁New _ ▁York _ ▁Heart _ association ▁h f ▁exercise
D-698	-0.8725181221961975	left_ventricular_ejection_fraction New_ York_ Heart_association hf exercise
P-698	-4.9696 -0.3269 -0.9801 -1.1331 -0.3466 -0.3755 -0.2693 -0.6004 -0.3545 -0.2334 -0.0222 -0.7840 -0.9898 -2.3252 -0.3401 -0.4569 -0.2351 -0.4050 -1.8076 -1.7175 -0.1124 -0.9848 -0.2980
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial_dd collagen_deposition titin obese diabetic zsf1 heart_failure_with_preserved_ejection_fraction
H-762	-0.37059664726257324	▁my o card ial ▁collage n _ de position ▁titi n ▁diabet ic ▁z SF 1 ▁rat s ▁heart _ fail ure ▁e je ction _ fraction
D-762	-0.37059664726257324	myocardial collagen_deposition titin diabetic zSF1 rats heart_failure ejection_fraction
P-762	-0.6428 -0.3054 -0.3849 -0.4187 -1.4571 -0.2189 -0.3517 -0.0794 -0.1724 -0.0386 -0.1267 -0.3048 -0.0554 -0.3472 -0.8504 -0.1073 -0.8627 -0.0426 -0.2551 -0.2290 -1.0912 -1.1791 -0.1116 -0.0818 -0.1131 -0.2309 -0.0095 -0.4846 -0.1942
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac_magnetic_resonance_postcontrast_t1_time prognosis hfpef postcontrast_t1 biomarker hfpef
H-743	-0.8005579710006714	▁cardiac _ magnet ic _ re on ance ▁h f f ▁bio mark er ▁h f f
D-743	-0.8005579710006714	cardiac_magnetic_reonance hff biomarker hff
P-743	-0.1098 -0.1624 -0.5396 -2.5534 -0.1585 -0.5515 -2.2613 -0.1274 -0.1683 -1.7012 -0.7431 -2.0205 -0.1562 -0.4807 -0.2580 -1.4917 -0.9870 -0.5056 -0.2343
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ventricular-arterial_coupling patients
H-524	-0.4495517313480377	▁contract ility ▁vent ri cular - arte rial _ ▁coup ling ▁SV ▁i va bra dine - tre ated
D-524	-0.4495517313480377	contractility ventricular-arterial_ coupling SV ivabradine-treated
P-524	-0.2805 -1.3509 -0.1247 -0.4979 -0.2551 -0.2967 -0.1539 -0.1830 -0.4727 -1.1477 -0.4240 -1.3799 -0.3823 -0.0334 -0.0526 -0.1582 -0.1325 -0.0294 -0.1349 -1.7025 -0.2478
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 hypertrophy fibrosis ventricular_dysfunction gene
H-642	-0.4687210023403168	▁condition al _ ge - tar get ed _ hand 2 _ mi ce ▁pressure - over load - indu ced _ ▁hyper trop hy ▁fibro sis ▁vent ri cular _ ▁dys function ▁fet al _ ge _ program
D-642	-0.4687210023403168	conditional_ge-targeted_hand2_mice pressure-overload-induced_ hypertrophy fibrosis ventricular_ dysfunction fetal_ge_program
P-642	-0.1400 -0.1843 -1.1652 -1.8451 -0.6938 -0.0428 -0.0746 -0.0548 -0.3405 -0.0389 -0.2256 -0.3386 -0.5003 -0.3559 -0.0765 -0.2669 -0.1590 -0.0368 -0.5777 -0.0005 -0.0112 -0.8509 -2.5284 -0.1298 -0.2593 -0.0222 -1.1740 -0.0890 -0.4675 -0.4596 -0.4052 -0.7479 -0.0247 -0.3172 -0.0545 -0.2834 -1.6603 -0.7754 -1.1874 -0.3604 -0.2915
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission nt-probnp patients acute_hf diagnosis
H-264	-0.6261122822761536	▁cut off _ valu e ▁ad mission ▁NT - pro b NP ▁ed ▁h z
D-264	-0.6261122822761536	cutoff_value admission NT-probNP ed hz
P-264	-0.0706 -0.0351 -0.7875 -0.2189 -0.3395 -0.0378 -0.0247 -0.0831 -0.0762 -0.0362 -0.9607 -0.4908 -1.6891 -2.6314 -1.9448 -0.9187 -0.2986
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical rule patients cad angiography patients systolic_hf cost
H-1193	-0.5805463194847107	▁rule ▁CAD ▁ang i ography ▁sy sto lic _ HF ▁cost
D-1193	-0.5805463194847107	rule CAD angiography systolic_HF cost
P-1193	-1.4848 -0.7506 -0.1809 -0.2641 -0.3467 -0.9073 -0.1485 -0.2405 -0.8062 -1.3230 -0.0790 -0.6700 -0.3455
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic cardiac cardiac gene signal_transduction pathological gene_expression hf
H-1053	-0.5826057195663452	▁epi gene tic _ ▁readers ▁cardiac _ bi ology ▁cardiac _ gene _ control ▁chr omat in - dependent _ signal _ trans duction ▁a bro gate ▁path ological _ ▁gene _ expression ▁h f
D-1053	-0.5826057195663452	epigenetic_ readers cardiac_biology cardiac_gene_control chromatin-dependent_signal_transduction abrogate pathological_ gene_expression hf
P-1053	-0.2545 -0.5383 -0.1300 -1.8130 -0.4458 -0.0348 -0.2145 -0.6745 -0.0498 -0.1258 -0.2034 -3.7620 -0.4643 -0.0167 -0.2926 -0.1221 -2.1070 -0.4653 -0.0590 -0.1896 -0.8567 -0.1854 -0.0889 -0.2170 -0.2400 -0.0103 -0.0342 -0.0253 -0.6262 -0.3890 -3.7606 -0.1930 -0.0990 -0.4216 -1.3311 -0.8403 -0.2750
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic_blood_pressure elevated left_ventricular hypertrophy
H-277	-0.928922712802887	▁Sy sto lic _ ▁blood _ tension ▁left _ vent ri cular LV ▁hyper trop hy ▁an ▁as ANS _ mi ce
D-277	-0.928922712802887	Systolic_ blood_tension left_ventricularLV hypertrophy an asANS_mice
P-277	-2.8579 -0.3692 -0.1981 -0.1562 -2.3548 -0.2995 -1.9021 -0.2935 -0.2994 -0.4993 -0.6858 -0.3901 -0.4940 -0.5868 -0.1730 -0.2683 -2.5617 -2.7034 -2.9780 -0.5702 -0.3698 -0.5380 -0.4840 -0.2611
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up patients combined_end_point death heart_failure death cardiac_transplant
H-1747	-0.6470601558685303	▁follow - up ▁death heart _ fail ure ▁sud den _ ▁death ▁non card iac ▁cardiac _ ▁transplant
D-1747	-0.6470601558685303	follow-up deathheart_failure sudden_ death noncardiac cardiac_ transplant
P-1747	-0.5638 -0.2962 -0.0215 -2.8435 -0.7646 -0.3025 -1.3005 -1.6306 -0.5204 -0.0187 -0.2769 -1.6335 -0.0403 -0.3960 -0.3375 -0.0738 -0.2307 -1.0978 -0.3336 -0.2588
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous revascularization angioplasty stenting clinical patients randomized clinical
H-1601	-0.661747932434082	▁cat heter - based _ per cuta ne ous _ re vas cular ization ▁ang io plast y ▁sten ting
D-1601	-0.661747932434082	catheter-based_percutaneous_revascularization angioplasty stenting
P-1601	-5.4099 -0.0340 -0.1112 -0.0170 -0.3574 -0.0487 -0.0143 -0.7638 -1.0745 -0.1906 -0.0653 -0.1608 -0.2958 -0.3472 -0.1188 -3.1372 -0.0352 -0.6625 -0.0319 -0.6768 -0.7528 -0.2528
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic_response heart_rate exercise baseline follow-up tests heart_rate exercise
H-1176	-0.6629863381385803	▁load - corre cted _ ch ono tropi c _ re lation ship ▁heart _ rate ▁exercise ▁base line ▁follow - up _ test s ▁heart _ rate ▁exercise
D-1176	-0.6629863381385803	load-corrected_chonotropic_relationship heart_rate exercise baseline follow-up_tests heart_rate exercise
P-1176	-0.2562 -0.2860 -0.0122 -0.2718 -0.6565 -1.1964 -0.5853 -0.2351 -0.2372 -0.6306 -2.0499 -3.0877 -0.5350 -2.1462 -0.4332 -1.2198 -0.8248 -0.0697 -0.0646 -0.0179 -0.2909 -0.0295 -0.4391 -0.6427 -0.0805 -1.6056 -0.5252 -1.1820 -0.4109 -0.2544 -0.2753
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak_oxygen_consumption vo2max resting_hr bpm p_value
H-1943	-0.9159597158432007	▁Peak _ ▁oxygen _ ▁consum p tion VO 2 max ▁HR ▁bp m ▁m L
D-1943	-0.9159597158432007	Peak_ oxygen_ consumptionVO2max HR bpm mL
P-1943	-0.0231 -0.1868 -1.5057 -1.1260 -2.0538 -0.1919 -0.1543 -1.0445 -0.0337 -0.0287 -2.8075 -1.8131 -0.1530 -0.0333 -3.3045 -0.9079 -0.2035
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional_hazard_models negative_binomial_regression_models health
H-1624	-0.5732359290122986	▁co x - propor tional _ ▁hazard _ model s ▁negative _ bi nom ial _ re gression _ ▁models ▁health
D-1624	-0.5732359290122986	cox-proportional_ hazard_models negative_binomial_regression_ models health
P-1624	-1.4370 -0.3449 -0.0497 -0.4484 -0.0403 -0.1959 -3.0981 -0.3439 -1.2413 -0.3148 -0.1737 -0.2678 -0.2274 -0.4579 -0.0597 -0.1565 -0.0933 -0.0501 -0.4486 -2.8835 -0.2068 -0.3893 -0.2555
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients hf t2d erc vo2max maximum_oxygen_consumption skm biopsies
H-1251	-0.5562505125999451	▁h f ▁t 2 d ▁ ERC ▁tre ad m ill _ test ing VO 2 max ▁oxygen ▁Sk m ▁bio psi es
D-1251	-0.5562505125999451	hf t2d ERC treadmill_testingVO2max oxygen Skm biopsies
P-1251	-0.9387 -1.3778 -0.1565 -0.0294 -0.1257 -0.9851 -0.1287 -1.4322 -0.0112 -0.1203 -0.0736 -1.5335 -0.5004 -1.3668 -1.4806 -0.0387 -0.0254 -0.4981 -0.9225 -0.1926 -0.4262 -0.3312 -0.5101 -0.4902 -0.2107
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient hospital gastrointestinal_bleeding patient ventricular_tachycardia terminal_heart_failure
H-1961	-0.5345531702041626	▁gastro inte stin al _ blad ed ing ▁vent ri cular _ ta chy car dia _ ▁storm ▁terminal _ heart _ fail ure
D-1961	-0.5345531702041626	gastrointestinal_bladeding ventricular_tachycardia_ storm terminal_heart_failure
P-1961	-0.7588 -0.0151 -1.0124 -0.0929 -0.4647 -2.4823 -0.1017 -0.1524 -0.1853 -0.4363 -0.1813 -1.0272 -0.8272 -0.2921 -0.0559 -0.0431 -0.4066 -0.1067 -0.5491 -0.4213 -1.7653 -0.3264 -0.4926 -1.1707 -0.3010 -0.2300
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic β-ar catecholamine infusions pde2 expression camp activity correlated cardiac β-ar_responsiveness
H-1214	-0.42928704619407654	▁β - ar ▁cate chol amine _ in fusion s ▁p de 2 _ expression ▁c AMP _ hydro ly tic _ activ ity ▁blu n ted _ ▁cardiac ▁β - ar _ ▁responsive ness
D-1214	-0.42928704619407654	β-ar catecholamine_infusions pde2_expression cAMP_hydrolytic_activity blunted_ cardiac β-ar_ responsiveness
P-1214	-3.3691 -0.0511 -1.0213 -0.3929 -0.0908 -0.1449 -0.2851 -0.2303 -0.0246 -0.2412 -1.3035 -0.0410 -0.0591 -0.8063 -0.1301 -0.0683 -0.3315 -1.0489 -0.1407 -0.2802 -0.3205 -0.2872 -0.1088 -0.0469 -0.1166 -0.2799 -0.1150 -0.2864 -0.1267 -0.4623 -0.0246 -0.9815 -0.4926 -1.0248 -0.4164 -0.4611 -0.2714
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild_hf qrs_prolongation lvef crt reverse_remodeling clinical systolic_dysfunction
H-758	-1.0273224115371704	▁h f ▁QR s _ ▁prolong ation ▁LV EF ▁c t ▁rever se _ ▁remodel ing ▁LV _ sy sto lic _ ▁dys function
D-758	-1.0273224115371704	hf QRs_ prolongation LVEF ct reverse_ remodeling LV_systolic_ dysfunction
P-758	-1.4826 -1.5190 -0.7169 -0.9862 -2.8058 -1.1225 -0.0267 -1.5804 -1.5389 -1.6640 -2.5256 -0.0267 -0.0588 -0.1124 -2.2136 -0.0771 -1.0914 -1.2808 -3.2312 -0.4899 -0.3352 -0.2554 -0.9533 -0.0586 -0.3587 -0.1985
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic_pah clinical hospitalized patients acute rv_decompensation pharmacologic therapies rv_failure pah
H-1096	-0.6951680779457092	▁chronic _ p AH ▁ rv ▁ pharma c ologic ▁ therapie s ▁ RV _ fail ure _ management ▁p AH
D-1096	-0.6951680779457092	chronic_pAH rv pharmacologic therapies RV_failure_management pAH
P-1096	-0.1470 -0.7172 -1.9654 -0.3875 -0.9140 -1.5280 -0.7156 -0.2298 -0.1167 -0.1837 -0.9271 -0.8743 -0.1529 -0.7782 -0.7914 -1.3969 -0.4580 -0.3214 -0.6468 -0.0671 -2.2837 -0.4157 -0.3838 -0.2818
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up patients
H-268	-1.0624258518218994	▁follow - up _ ▁period
D-268	-1.0624258518218994	follow-up_ period
P-268	-0.3330 -0.3015 -0.0406 -0.4881 -3.7182 -2.3204 -0.2353
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians patients patient clinician medication patient
H-1129	-0.8412734270095825	▁medication
D-1129	-0.8412734270095825	medication
P-1129	-1.8014 -0.4299 -0.2925
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty gill_index hf
H-628	-0.6914033889770508	▁non - fra il ▁Gill _ index ▁h f
D-628	-0.6914033889770508	non-frail Gill_index hf
P-628	-0.8534 -0.0532 -0.1572 -0.0913 -3.3612 -0.1745 -0.1778 -0.6116 -1.5609 -0.2934 -0.2709
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty health_abc_short_physical_performance_battery habc_battery gill_index hf
H-625	-0.6058266162872314	▁fra il ty ▁health _ ▁ABC _ short _ phy s ical _ per form ance _ ▁Bat tery ▁h bc _ ▁Bat tery ▁Gill _ index ▁h z
D-625	-0.6058266162872314	frailty health_ ABC_short_physical_performance_ Battery hbc_ Battery Gill_index hz
P-625	-1.2952 -0.1014 -0.3502 -0.0754 -1.4785 -1.1877 -0.2137 -0.2083 -0.1728 -0.4775 -0.7063 -0.4354 -0.1560 -0.4485 -0.0230 -0.0383 -0.2914 -1.2947 -0.3801 -0.2737 -2.2414 -0.4736 -1.2509 -0.2385 -0.6285 -0.1726 -0.1804 -0.2457 -3.1095 -0.3675 -0.2637
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients rv_support lvad patients cardiogenic_shock myocardial_infarction chronic_decompensated_heart_failure
H-295	-0.8097950220108032	▁ rv ▁l VAD ▁cardio ge nic _ ▁shock ▁my o card ial _ in far ction ▁chronic _ de com pensa ted _ heart _ ▁failure
D-295	-0.8097950220108032	rv lVAD cardiogenic_ shock myocardial_infarction chronic_decompensated_heart_ failure
P-295	-2.8479 -0.7704 -1.9281 -0.0545 -0.5638 -0.0924 -0.1276 -0.2791 -2.5531 -0.9851 -0.4014 -0.5104 -0.6143 -0.4745 -0.4181 -0.0617 -0.3623 -2.3639 -1.9975 -0.1052 -0.0794 -0.0412 -0.3201 -0.4286 -1.8071 -0.3176 -2.0939 -0.5284 -0.3565
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic_heart_failure chf multisystem_disease comorbidities anemia insulin_resistance autonomic_dysbalance cardiac_cachexia
H-1357	-0.8047615885734558	▁Chro nic _ heart _ fail ure ▁ch f ▁multi system _ ▁disease ▁an emia ▁insulin _ re serv ance ▁autonomi c _ ▁dys balance ▁cardiac _ ▁cache xia
D-1357	-0.8047615885734558	Chronic_heart_failure chf multisystem_ disease anemia insulin_reservance autonomic_ dysbalance cardiac_ cachexia
P-1357	-0.5140 -0.8190 -0.1529 -2.6696 -0.1149 -1.0732 -1.2848 -2.8026 -0.7571 -0.5069 -0.0546 -0.2437 -2.8950 -0.7996 -0.0913 -0.0548 -0.4458 -0.4722 -4.4611 -0.1048 -0.0116 -1.1458 -0.4486 -0.8531 -0.1743 -0.0488 -0.2367 -0.9639 -0.0981 -0.3979 -0.2512
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine_oxidase xo left_ventricular myocytes volume_overload vo mitral_regurgitation aortocaval_fistula acf
H-470	-0.414223313331604	▁Xan thi ne _ oxid ase XO ▁rat ▁left _ vent ri cular LV ▁my o cy tes ▁volume _ over load VO ▁mit ral _ re gur gi tation ▁a orto ca val _ fi stu la ▁ac f
D-470	-0.414223313331604	Xanthine_oxidaseXO rat left_ventricularLV myocytes volume_overloadVO mitral_regurgitation aortocaval_fistula acf
P-470	-0.0089 -0.0217 -0.4421 -0.1307 -0.5978 -1.3285 -0.7919 -0.8112 -0.8046 -0.2740 -0.4987 -0.5083 -0.2120 -1.1610 -0.3489 -0.1303 -0.0376 -0.6979 -0.8950 -0.2288 -0.2088 -0.0138 -1.7085 -0.4907 -0.0810 -0.3347 -0.1024 -0.0164 -0.2676 -0.0519 -0.1179 -0.1925 -0.0767 -0.2087 -0.3127 -0.5684 -0.0566 -0.6498 -1.1103 -0.4515 -0.2829 -0.1635
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese zsf1 heart_failure_with_preserved_ejection_fraction lung preserved_left_ventricular_ejection_fraction left_ventricular_dd
H-767	-0.7017959356307983	▁z SF 1 ▁heart _ fail ure ▁e je ction _ fraction ▁lung _ weight ▁left _ vent ri cular _ e je ction _ fraction ▁left _ vent ri cular
D-767	-0.7017959356307983	zSF1 heart_failure ejection_fraction lung_weight left_ventricular_ejection_fraction left_ventricular
P-767	-0.8597 -1.3030 -0.1894 -1.3931 -0.2329 -0.8119 -1.9688 -0.3060 -0.3928 -0.3394 -0.2142 -0.0365 -0.7388 -0.6867 -0.5781 -1.2971 -0.4140 -1.2365 -1.0081 -0.3929 -0.9707 -0.3235 -0.9371 -0.5520 -0.2278 -0.0582 -0.9810 -0.3535 -1.1616 -1.1816 -0.4496 -1.3320 -0.2305
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients physicians mortality physicians hospitals
H-1727	-0.46265360713005066	▁physician s ▁mortal ity ▁physician s ▁low - volu me _ hospital s
D-1727	-0.46265360713005066	physicians mortality physicians low-volume_hospitals
P-1727	-1.7030 -0.1759 -0.0463 -0.1604 -1.3198 -0.2210 -0.4118 -0.1328 -0.3976 -0.0931 -0.6238 -0.8641 -0.2349 -0.2915 -0.2638
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western administrative health patients hf hospitalized ami
H-1307	-0.9702184200286865	▁western _ au stria ▁administrative ▁health ▁h f ▁hospital ized ▁index AMI
D-1307	-0.9702184200286865	western_austria administrative health hf hospitalized indexAMI
P-1307	-0.4224 -0.1851 -2.5283 -0.4935 -0.0573 -1.2536 -0.3158 -1.3597 -2.7359 -0.1125 -2.0356 -1.2444 -0.5681 -0.2709
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report connection patients disease healthcare conditions turkey
H-1825	-0.23998811841011047	▁report ▁conditions ▁tur key
D-1825	-0.23998811841011047	report conditions turkey
P-1825	-0.0362 -0.2742 -0.2186 -0.2672 -0.3874 -0.2565
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome prospective hospitalized hf nursing outcomes
H-1403	-1.340322732925415	▁science ▁treatment ▁h f
D-1403	-1.340322732925415	science treatment hf
P-1403	-0.9060 -1.6185 -2.3903 -2.2252 -0.6089 -0.2930
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence hf ami adjusted_odds_ratio
H-1310	-0.6262187361717224	▁h f AMI ▁adjust ed _ ▁odds _ rati o
D-1310	-0.6262187361717224	hfAMI adjusted_ odds_ratio
P-1310	-1.0380 -1.1173 -2.2057 -0.9553 -0.1242 -0.1959 -0.5204 -0.2640 -0.0761 -0.0729 -0.7084 -0.2363
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas rnas expression genes messenger_rna repression
H-1482	-0.6769750118255615	▁mi RNA s ▁non co ding _ RNA s ▁expression ▁ binding ▁messenger _ RNA
D-1482	-0.6769750118255615	miRNAs noncoding_RNAs expression binding messenger_RNA
P-1482	-2.1388 -0.2271 -0.2282 -0.1485 -0.0169 -0.1599 -0.5611 -0.1944 -0.1918 -0.3215 -3.0036 -0.7091 -0.0499 -0.8032 -0.9424 -1.5787 -0.2336
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse myocardial_t1 heart_failure
H-1055	-0.592024028301239	▁free - bre a thing _ puls e _ se que nce ▁my o card ial _ t 1 ▁changes ▁s win e ▁ta chy car dia - indu ced _ heart _ fail ure
D-1055	-0.592024028301239	free-breathing_pulse_sequence myocardial_t1 changes swine tachycardia-induced_heart_failure
P-1055	-0.0086 -0.1629 -0.1690 -0.0609 -0.4594 -0.1733 -1.9671 -0.4652 -0.1638 -0.3962 -0.4823 -0.0698 -0.6999 -0.3563 -0.6741 -0.3872 -0.4709 -0.5424 -0.1718 -3.2890 -0.2306 -0.0707 -0.2099 -3.1566 -0.8238 -0.1100 -0.0533 -0.1308 -0.0004 -0.0381 -0.4651 -2.3034 -0.1858 -1.1456 -1.1498 -0.3755 -0.2854
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients hfpef ivabradine placebo double-blind
H-1173	-0.5131322741508484	HF p EF ▁i va bra dine
D-1173	-0.5131322741508484	HFpEF ivabradine
P-1173	-2.3893 -0.1078 -0.5010 -0.0740 -0.0177 -0.0569 -0.1934 -1.0642 -0.2138
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic new_york_heart_association_classes saf
H-229	-0.9845536947250366	▁p f ▁New _ York _ ▁Heart _ association SAF ▁p f
D-229	-0.9845536947250366	pf New_York_ Heart_associationSAF pf
P-229	-2.6816 -0.3083 -2.4410 -0.9424 -1.8843 -0.2478 -0.5187 -0.1918 -0.4107 -0.6635 -1.1905 -1.6861 -0.3645 -0.2525
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective_cohort eds diagnosis heart_failure
H-463	-1.2348501682281494	▁ed s ▁heart _ fail ure ▁ed
D-463	-1.2348501682281494	eds heart_failure ed
P-463	-1.3468 -0.2275 -2.5367 -0.2643 -1.4161 -1.9322 -2.0937 -0.9705 -0.3259
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac cells cardiac cells cardiac_functions myocardial_infarction
H-1335	-0.628412663936615	▁cardiac _ c - K it _ cell s ▁cardiac _ ex plant - der i ved _ cell s ▁cardiac _ function s ▁my o card ial _ in far ction
D-1335	-0.628412663936615	cardiac_c-Kit_cells cardiac_explant-derived_cells cardiac_functions myocardial_infarction
P-1335	-1.5161 -1.7267 -0.2998 -0.1524 -3.3893 -0.1372 -1.2373 -0.6736 -0.2642 -0.5193 -1.4262 -0.5977 -0.0112 -0.2063 -0.1552 -0.3151 -0.0768 -0.6387 -0.1335 -0.3023 -0.3238 -0.9754 -0.2147 -0.2311 -1.8984 -0.3288 -0.7854 -0.7698 -0.3716 -0.3103 -0.0437 -0.5272 -0.5315 -0.2754
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses pathophysiology hf nursing medical symptoms pathophysiologic
H-2022	-0.7794233560562134	▁pat ho phy si ology HF ▁medical _ management ▁pat ho phy si ologic _ state
D-2022	-0.7794233560562134	pathophysiologyHF medical_management pathophysiologic_state
P-2022	-2.7967 -0.7654 -0.0461 -1.5585 -0.0744 -1.7014 -0.0909 -1.3304 -0.0587 -1.0484 -0.5488 -0.1115 -1.6888 -0.5939 -0.9292 -0.0236 -0.4260 -0.2370
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 bets chromatin downstream_signalling rna polymerase_ii pol_ii
H-1043	-0.5214127898216248	▁inhibi tor ▁j q 1 BET s ▁chr omat in ▁down stream ▁ RNA _ poly mera se _ ▁II pol _ ▁II
D-1043	-0.5214127898216248	inhibitor jq1BETs chromatin downstream RNA_polymerase_ IIpol_ II
P-1043	-0.2593 -0.0456 -0.8101 -0.9954 -0.0864 -1.1137 -0.4153 -1.0342 -0.0888 -1.4456 -0.0230 -0.0032 -1.5691 -0.1581 -0.1520 -0.6760 -0.1588 -0.2661 -0.3478 -0.3230 -1.3255 -0.6942 -0.4884 -0.3228 -0.2328
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps adverse_outcomes patients heart_failure pulmonary_embolism diabetes chemotherapy
H-1022	-0.4965418875217438	NP s ▁heart _ fail ure ▁pulmonar y _ e mbol ism ▁diabetes ▁che mo therapy
D-1022	-0.4965418875217438	NPs heart_failure pulmonary_embolism diabetes chemotherapy
P-1022	-0.3535 -0.0551 -2.5174 -0.3865 -1.3291 -1.8452 -0.0114 -0.3879 -0.4652 -0.2751 -0.0340 -0.1261 -0.0796 -0.2541 -0.1589 -0.0526 -0.3603 -0.2458
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome heart_failure hf acute_myocardial_infarction ami pneumonia pna
H-1691	-0.7915093898773193	▁em pir ically ▁heart _ fail ure HF ▁a cute _ My o card ial _ in far ction AMI ▁pneu monia ▁p na
D-1691	-0.7915093898773193	empirically heart_failureHF acute_Myocardial_infarctionAMI pneumonia pna
P-1691	-3.0651 -0.0216 -0.0736 -1.3997 -0.2438 -0.8820 -1.8225 -1.7517 -0.4262 -0.0332 -0.2396 -3.8656 -0.5096 -0.3152 -0.4853 -0.2749 -0.3510 -0.0702 -0.3244 -0.4580 -0.0024 -1.6581 -0.6547 -0.9592 -0.4072 -0.2845
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal_dysfunction intestinal lead chronic inflammatory catabolic anabolic cardiac_cachexia terminal chf prognosis
H-1360	-0.5714406967163086	▁intestinal _ ▁dys function ▁disturb ed _ ▁intestinal _ ▁barrier ▁chronic _ ▁infla mma tory _ state ▁cata bo lic ana bo lic _ im balance ▁cardiac _ ▁cache xia ▁CHF
D-1360	-0.5714406967163086	intestinal_ dysfunction disturbed_ intestinal_ barrier chronic_ inflammatory_state catabolicanabolic_imbalance cardiac_ cachexia CHF
P-1360	-0.2042 -0.5667 -1.0036 -0.0400 -0.5161 -0.0462 -0.4501 -0.6898 -0.1815 -2.6695 -0.0826 -0.3022 -1.0697 -0.3261 -0.0219 -0.2252 -0.0817 -0.1974 -0.0437 -0.2576 -3.2478 -0.1118 -0.2750 -1.0910 -1.7341 -0.1076 -0.0412 -0.1703 -2.3409 -0.0313 -0.1818 -0.3249 -0.2237
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic heart_failure_with_preserved_ejection_fraction hfpef patients health symptoms quality_of_life
H-780	-0.6312519311904907	▁heart _ fail ure ▁e je ction _ fraction ▁h p EF ▁health
D-780	-0.6312519311904907	heart_failure ejection_fraction hpEF health
P-780	-1.0332 -0.2622 -0.8665 -2.6505 -0.3786 -0.2251 -0.0866 -0.1999 -0.0167 -0.9260 -0.2703 -0.8774 -0.2362 -1.1850 -0.2545
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic_adenosine_monophosphate camp cyclic_guanosine_monophosphate cgmp hearts
H-1209	-0.6682915687561035	▁ cycli c ▁ad enos ine _ ▁mono phos pha te ▁c AMP ▁gua no sine _ ▁mono phos pha te ▁c g m ▁heart s
D-1209	-0.6682915687561035	cyclic adenosine_ monophosphate cAMP guanosine_ monophosphate cgm hearts
P-1209	-1.2883 -0.6683 -0.3506 -1.1111 -0.2556 -0.9147 -0.1784 -0.3197 -0.2971 -0.8651 -0.2838 -0.6624 -0.6347 -4.2444 -0.0502 -0.6664 -0.2134 -0.2130 -0.4473 -0.7057 -0.2027 -0.3433 -0.4329 -1.5703 -0.7427 -0.2956 -0.4650 -0.2894
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality healthcare telehealth congestive_heart_failure chronic_obstructive_pulmonary_disease diabetes_mellitus
H-1618	-0.6257784962654114	▁mortal ity ▁health care ▁tele health ▁con ges tive _ heart _ fail ure ▁chronic _ ob struct ive _ ▁pulmonar y _ ▁disease ▁diabetes _ ▁mell itus
D-1618	-0.6257784962654114	mortality healthcare telehealth congestive_heart_failure chronic_obstructive_ pulmonary_ disease diabetes_ mellitus
P-1618	-0.2737 -0.1512 -0.0282 -0.0396 -5.0554 -0.3137 -0.1618 -0.0685 -0.6457 -0.4129 -2.5050 -0.2336 -1.0711 -0.9252 -0.0271 -0.6093 -0.7356 -0.1543 -0.0852 -0.3758 -0.2610 -0.3023 -0.4774 -2.1494 -0.1000 -0.2967 -0.6455 -0.0473 -0.3300 -0.2906
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction hfpef
H-942	-0.4999975860118866	▁cat heter _ ab lation ▁at rial _ fi bril lation ▁af ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁h f f
D-942	-0.4999975860118866	catheter_ablation atrial_fibrillation af heart_ failure preserved_ejection_fraction hff
P-942	-0.0245 -0.2580 -0.3282 -0.5636 -0.1563 -0.3018 -0.5247 -0.3870 -0.6587 -0.1648 -0.1063 -2.3900 -0.3517 -0.3035 -2.7222 -0.9939 -0.1886 -0.2567 -0.3071 -0.2265 -0.5183 -0.1706 -0.2382 -0.0118 -0.1639 -0.9313 -0.3723 -0.5998 -0.2796
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report patient diagnosis ischemic-hypertensive_cardiomyiopathy angina myocardial_ischemia coronary_arteries
H-998	-0.6600562334060669	▁report ▁ ische mic - hy per tensi ve _ ▁cardio my io pathy ▁ang ina ▁induc ible _ My o card ial _ ische mia ▁corona ry _ ▁arteri es
D-998	-0.6600562334060669	report ischemic-hypertensive_ cardiomyiopathy angina inducible_Myocardial_ischemia coronary_ arteries
P-998	-0.0065 -0.8868 -0.2213 -0.3539 -0.1189 -0.0276 -0.0323 -0.2768 -0.0757 -0.2652 -0.3659 -1.6415 -5.0020 -0.0779 -0.2117 -0.4838 -0.0140 -0.5871 -0.4555 -4.9088 -0.8337 -0.8778 -0.5106 -0.3072 -0.2721 -1.0317 -0.0778 -0.3059 -0.2933 -0.3223 -0.2824 -0.4450 -0.2088
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra methotrexate tnf_antagonist non-biological_disease_modifying_antirheumatic_drug nbdmard
H-604	-0.6660857796669006	▁RA ▁met ho tre xa te ▁t NF _ ▁anta gon ist ▁non - bi ological _ ▁disease ▁anti r heu matic _ drug ▁n b DM ARD
D-604	-0.6660857796669006	RA methotrexate tNF_ antagonist non-biological_ disease antirheumatic_drug nbDMARD
P-604	-0.4292 -0.2735 -0.1181 -0.0269 -0.3219 -0.1285 -0.5283 -1.5656 -2.5843 -0.3671 -0.0273 -0.7401 -0.2825 -0.1129 -0.2886 -0.4462 -1.0333 -2.0468 -0.0922 -0.9560 -0.3205 -0.4971 -0.4736 -0.5758 -2.9226 -0.0543 -1.6214 -0.5081 -0.3740 -0.2659
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate_cox_proportional_hazards_regression_modeling hospitalization acute_coronary_syndromes coronary_interventions patients
H-104	-0.5422394275665283	▁multi varia te _ co x _ ▁proportion al _ ▁hazard s _ re gression _ model ing ▁i e ▁a cute _ ▁corona ry _ ▁syndrome s ▁corona ry
D-104	-0.5422394275665283	multivariate_cox_ proportional_ hazards_regression_modeling ie acute_ coronary_ syndromes coronary
P-104	-1.0868 -0.6645 -0.2098 -0.3362 -0.0372 -0.2931 -0.2277 -1.5872 -0.1794 -0.1417 -2.0902 -0.3819 -0.2633 -0.0732 -0.0333 -0.8785 -0.5885 -0.2580 -0.7654 -0.2740 -0.3815 -0.0516 -0.1930 -1.6128 -0.5406 -0.2730 -0.7238 -0.0856 -0.0761 -0.4789 -2.2154 -0.3494
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate_receptor_1 s1pr1 β1-adrenergic_receptor β1ar g-protein-coupled_receptors heart
H-1405	-0.5317144393920898	▁sp hing os ine -1 - phos pha te _ ▁receptor ▁s 1 PR 1 ▁β 1- ad r energi c _ ▁receptor β 1 ar ▁g - prote in - co up led _ ▁receptor s ▁heart
D-1405	-0.5317144393920898	sphingosine-1-phosphate_ receptor s1PR1 β1-adrenergic_ receptorβ1ar g-protein-coupled_ receptors heart
P-1405	-0.0439 -0.3892 -0.3074 -1.1849 -2.2950 -0.3292 -0.2018 -0.3927 -0.1859 -0.2241 -0.7476 -1.5089 -0.0699 -1.4893 -1.6254 -0.2024 -0.1953 -0.4784 -0.9160 -0.2567 -0.2965 -0.2210 -1.1054 -1.4622 -0.0973 -0.9754 -1.2022 -0.1053 -0.0759 -0.2728 -0.2363 -0.0206 -0.0534 -0.0601 -0.3245 -0.6881 -0.1510 -0.1762 -0.4793 -0.2215
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal correlated pcwp p_values
H-484	-0.4723632335662842	sept al ▁pc w p
D-484	-0.4723632335662842	septal pcwp
P-484	-0.0210 -0.0965 -0.1782 -1.9024 -0.2999 -0.4912 -0.3173
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy atrial_fibrillation patients carvedilol metoprolol
H-864	-0.3210306465625763	▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-864	-0.3210306465625763	atrial_fibrillation carvedilol metoprolol
P-864	-0.6826 -0.2954 -0.3170 -0.6450 -0.1714 -0.1397 -0.3806 -0.0362 -0.2839 -0.0652 -0.3034 -0.0388 -0.5141 -0.7228 -0.2194
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls lvef prognostic clinical echocardiographic systolic
H-820	-0.9199362397193909	▁gr s ▁LV EF ▁cv ▁e cho car dio graphic _ sy sto lic ▁af
D-820	-0.9199362397193909	grs LVEF cv echocardiographic_systolic af
P-820	-0.6881 -0.9394 -0.7011 -1.3561 -2.6682 -1.5853 -0.5011 -0.1527 -0.9092 -0.8132 -0.3485 -1.3213 -0.3881 -0.5460 -2.0585 -0.4277 -0.2345
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia intravenous metoprolol cardiac sympathetic_tone
H-1379	-0.46747252345085144	▁Brad y car dia ▁intra ven ous _ met o pro lol ▁cardiac _ ▁sympa the tic _ ▁tone ▁CHF - in v ▁rabbi ts ▁sham - in v ▁CHF - d x
D-1379	-0.46747252345085144	Bradycardia intravenous_metoprolol cardiac_ sympathetic_ tone CHF-inv rabbits sham-inv CHF-dx
P-1379	-0.1641 -0.1912 -0.0627 -0.0726 -2.9508 -0.0372 -1.3774 -0.5320 -0.0332 -0.5155 -0.0738 -0.7654 -0.0151 -0.4210 -1.2534 -0.1608 -0.2404 -0.1884 -1.0232 -0.8411 -0.0438 -0.1192 -0.3424 -0.1917 -0.0732 -0.0495 -0.1266 -0.1670 -0.2482 -0.8286 -0.0656 -1.7935 -0.6001 -0.5669 -0.2259
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes patients prescribed pharmacological discharge left_ventricular_function
H-1849	-0.6953040957450867	▁ pharma c ological ▁device ▁dis charge ▁left _ vent ri cular _ function _ asse s s ment
D-1849	-0.6953040957450867	pharmacological device discharge left_ventricular_function_assessment
P-1849	-3.0903 -0.0538 -0.0859 -0.3156 -4.7070 -0.6187 -0.0115 -0.3125 -0.4046 -1.0501 -1.0179 -0.4554 -0.3084 -0.1983 -0.4071 -0.1788 -0.0461 -0.2780 -0.3423 -0.4369 -0.2823
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized walking cardiac_rehabilitation functional_capacity outcomes patients severe_heart_failure
H-569	-0.7226563692092896	▁Nordic _ ▁walking ▁standard _ ▁cardiac _ rehabilit ation ▁functional _ capaci ty ▁heart _ fail ure
D-569	-0.7226563692092896	Nordic_ walking standard_ cardiac_rehabilitation functional_capacity heart_failure
P-569	-1.3881 -0.2940 -2.0320 -0.2285 -0.2852 -0.6053 -0.2609 -0.9705 -0.8192 -0.6400 -0.5239 -0.0952 -0.0509 -1.4342 -0.2730 -1.6532 -1.5456 -0.3658 -0.2651
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad q66p rad cav1.2 cav1.3 l-type_channel isoforms heart
H-1674	-0.7599937319755554	▁rad _ q 66 p ▁inhibi tory _ action s ▁rad _ on _ ca v 1.2 ▁ca v 1.3 ▁l - type _ ▁channel _ iso form s ▁heart
D-1674	-0.7599937319755554	rad_q66p inhibitory_actions rad_on_cav1.2 cav1.3 l-type_ channel_isoforms heart
P-1674	-1.2504 -0.9088 -0.8054 -0.5477 -0.4528 -1.7306 -0.0907 -0.5443 -0.1738 -0.4203 -0.9642 -2.1016 -1.1987 -0.4804 -0.0330 -2.3016 -0.7990 -0.6412 -2.2590 -0.2433 -1.5861 -0.0924 -0.0210 -0.1309 -2.2211 -0.2489 -0.3691 -0.3136 -0.2901 -0.4483 -0.3699 -0.2815
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef lcx lad stenting infarcted left_ventricle lcx lad
H-512	-0.7868998050689697	▁EF LC x ▁ LAD ▁sten ting ▁in far cted ▁left _ vent ric le ▁ LC x ▁ LAD
D-512	-0.7868998050689697	EFLCx LAD stenting infarcted left_ventricle LCx LAD
P-512	-0.1935 -0.9239 -0.7196 -1.1829 -1.7827 -0.5890 -0.3480 -0.4804 -0.0219 -0.2521 -1.1312 -0.2526 -0.1621 -2.3131 -0.6542 -2.1246 -0.9343 -1.0894 -0.5893 -0.8278 -0.5269 -0.2123
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas expression bhlh transcription_factor hand2 myocardium gene heart_failure
H-644	-0.6516501903533936	▁signal ling _ ▁casca des ▁micro RNA s ▁expression ▁b HL h _ trans scription _ factor ▁hand 2 ▁post na tal _ ▁mamma lian _ My o car dium ▁em bry o nic _ ▁gene ▁heart _ fail ure
D-644	-0.6516501903533936	signalling_ cascades microRNAs expression bHLh_transscription_factor hand2 postnatal_ mammalian_Myocardium embryonic_ gene heart_failure
P-644	-1.7689 -0.4070 -0.2196 -0.9063 -0.1457 -0.0622 -0.2179 -0.1470 -0.9504 -0.0362 -0.8047 -0.2743 -0.6162 -2.0992 -0.1971 -0.3381 -0.0571 -1.0467 -0.2104 -0.0193 -0.3596 -0.0970 -0.3131 -0.3290 -1.7902 -0.2845 -3.3227 -0.3966 -0.1239 -0.5034 -0.1358 -0.1504 -0.2204 -0.3050 -0.2581 -2.9370 -2.1357 -0.3872 -1.2186 -0.9960 -0.3299 -0.2511
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc dapc_protein sarcomeric_microstructure skm myofibre_regeneration
H-1254	-0.6299406886100769	ERC ▁induc ed _ re cover y ▁DAP c _ ▁protein ▁sar come ric ▁Sk m ▁my o fi bre
D-1254	-0.6299406886100769	ERC induced_recovery DAPc_ protein sarcomeric Skm myofibre
P-1254	-0.2729 -3.5529 -0.0807 -0.4092 -0.1923 -0.2296 -0.2476 -0.0324 -0.5486 -0.4343 -0.8473 -0.2302 -0.3284 -1.1185 -0.2045 -0.1883 -1.1819 -0.2269 -0.1968 -0.1139 -2.9786 -0.2430
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva surgical implantation leaflet leaflet edge-to-edge_anastomosis
H-360	-0.4640655219554901	▁m va ▁sur g ical _ ring _ ▁implant ation ▁le a flet _ motion ▁le a flet _ re ection ▁edge - to - ed ge _ an asto mos is
D-360	-0.4640655219554901	mva surgical_ring_ implantation leaflet_motion leaflet_reection edge-to-edge_anastomosis
P-360	-0.1650 -0.1064 -1.3034 -0.0612 -0.0752 -0.4021 -1.0825 -0.8379 -0.0493 -0.0739 -0.7625 -0.0887 -0.0630 -0.5348 -1.4470 -1.0921 -0.0622 -0.2040 -0.5300 -0.8345 -0.8804 -0.1295 -0.0878 -0.1407 -0.4994 -0.0856 -0.0296 -0.2967 -1.5209 -0.0192 -0.6449 -0.9027 -0.5011 -0.2640
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart patients new_york_heart_association nyha hospitalized hf primary_outcome death hf hospitalization
H-239	-0.9026376605033875	▁h ART ▁New _ York _ ▁Heart _ association NY ha ▁ HF ▁self - management _ co un cil ing ▁death ▁ HF
D-239	-0.9026376605033875	hART New_York_ Heart_associationNYha HF self-management_counciling death HF
P-239	-2.6437 -0.8419 -0.9796 -0.8492 -1.8785 -0.2072 -0.5876 -0.1826 -0.2907 -1.5906 -0.9327 -2.7355 -1.0586 -0.0816 -0.1267 -0.0136 -0.4180 -1.8205 -0.1721 -0.0917 -1.0811 -1.5699 -1.8250 -0.6664 -0.5643 -0.2593
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet bromodomain_proteins bets acetyl-lysine_reader_proteins hf pathogenesis hf
H-1038	-0.6886756420135498	BET _ family _ bro modo main _ ▁protein s BET s ▁a ce tyl - ly sine _ ▁reader _ ▁protein s ▁h f
D-1038	-0.6886756420135498	BET_family_bromodomain_ proteinsBETs acetyl-lysine_ reader_ proteins hf
P-1038	-0.5959 -2.4256 -1.2302 -0.1837 -0.2223 -0.0739 -0.2660 -0.2050 -1.4409 -0.3842 -0.6436 -0.5262 -0.2155 -0.1461 -0.3947 -0.1214 -1.2859 -0.4792 -0.1039 -1.2688 -0.3839 -1.0658 -0.2761 -1.1350 -1.7104 -1.5281 -0.2820
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in_vivo cardiac_function echocardiography diastolic_dysfunction systolic_dysfunction ejection_fraction
H-1783	-0.34537726640701294	▁cardiac _ function ▁e cho card i ography ▁dia sto lic _ ▁dys function ▁sy sto lic _ ▁dys function ▁e je ction _ fraction
D-1783	-0.34537726640701294	cardiac_function echocardiography diastolic_ dysfunction systolic_ dysfunction ejection_fraction
P-1783	-0.6668 -0.2524 -0.3047 -0.1152 -0.2878 -0.2485 -0.3053 -0.4351 -0.0553 -0.4147 -0.7065 -0.5291 -0.7689 -0.0420 -0.8938 -0.4681 -0.6680 -0.2661 -0.6207 -0.0363 -0.1295 -0.2172 -0.1200 -0.2184 -0.0112 -0.3433 -0.2005
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone_antagonism heart_failure aldosterone neurohormone electrolytes heart_failure patients systolic_dysfunction
H-1733	-0.5938884615898132	▁al do ster one _ ▁anta gon ism ▁heart _ fail ure ▁al do ster one ▁neuro hormon e ▁electro ly tes ▁heart _ fail ure ▁sy sto lic _ ▁dys function
D-1733	-0.5938884615898132	aldosterone_ antagonism heart_failure aldosterone neurohormone electrolytes heart_failure systolic_ dysfunction
P-1733	-0.7873 -0.2438 -0.6486 -0.4401 -0.5972 -0.5530 -0.0483 -0.2960 -1.4788 -0.2997 -1.9578 -1.6362 -1.0461 -0.2045 -0.6105 -0.2998 -0.0750 -0.1983 -0.4592 -0.0111 -0.1431 -0.3204 -1.4272 -0.3691 -1.3260 -1.5312 -0.7515 -0.2644 -0.5184 -0.5694 -0.4367 -0.0401 -0.3755 -0.2280
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv_compliance lv_end-diastolic_volume lv_end-diastolic_pressure β_coefficient
H-1531	-0.898747980594635	▁eh ▁LV ▁compliance LV ▁end - dia sto lic _ ▁volume ▁LV ▁end - dia sto lic _ press ure ▁h g _ ▁β _ co e ffi cient
D-1531	-0.898747980594635	eh LV complianceLV end-diastolic_ volume LV end-diastolic_pressure hg_ β_coefficient
P-1531	-1.8432 -1.7563 -0.0717 -1.6856 -3.2547 -0.1970 -0.1332 -1.7185 -0.8155 -0.2740 -1.9621 -1.4469 -2.5643 -0.2384 -0.1192 -1.7180 -0.7250 -0.1607 -2.5752 -0.3757 -0.2403 -0.0287 -0.8622 -1.4664 -0.1967 -0.2948 -0.2401 -0.0381 -0.0832 -0.5611 -0.2143
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade clinical
H-202	-1.1970566511154175	▁grade
D-202	-1.1970566511154175	grade
P-202	-2.5411 -0.8246 -0.2255
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf hospitalization
H-563	-0.9487385749816895	▁h f
D-563	-0.9487385749816895	hf
P-563	-1.8132 -1.3755 -0.3191 -0.2872
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right_heart_circulatory_failure disease right_heart
H-1460	-1.017081618309021	▁right _ ▁Heart ▁circula tory _ fail ure ▁mechanism s _ of _ dis tribution ▁right _ ▁Heart
D-1460	-1.017081618309021	right_ Heart circulatory_failure mechanisms_of_distribution right_ Heart
P-1460	-0.4948 -0.4078 -3.5058 -1.6607 -0.0784 -0.5592 -0.1916 -1.8438 -0.2163 -0.1870 -0.4493 -0.1053 -0.2834 -2.9346 -2.6373 -0.2593 -0.3613 -3.5587 -0.3352 -0.2719
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular_action_potentials excitation-contraction myocardium
H-1671	-0.36806002259254456	▁volta ge - ga ted ▁vent ri cular _ action _ pot ential s ▁trigger ▁excita tion - con traction ▁coup ling ▁my o car dium
D-1671	-0.36806002259254456	voltage-gated ventricular_action_potentials trigger excitation-contraction coupling myocardium
P-1671	-0.5145 -0.1164 -0.1495 -0.1019 -0.0847 -0.4491 -0.7924 -0.3453 -0.3304 -0.0858 -1.6704 -0.6268 -0.0176 -0.2053 -1.2558 -0.2307 -0.2280 -0.1774 -0.1797 -0.4530 -0.0097 -0.1981 -0.9196 -0.2194 -0.0406 -0.2476 -0.3890 -0.2668
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1_receptors neprilysin renin-angiotensin-aldosteron ras vasodilatory diuretic natriuretic_peptides
H-1967	-0.3520250916481018	▁AT 1 _ ▁receptor s ▁nepri ly sin _ block s ▁re nin - angi oten sin - al do ster on RAS ▁a xis ▁natural _ ▁vaso dila tory ▁di ure tic ▁na tri ure tic _ pe pti des
D-1967	-0.3520250916481018	AT1_ receptors neprilysin_blocks renin-angiotensin-aldosteronRAS axis natural_ vasodilatory diuretic natriuretic_peptides
P-1967	-0.6206 -0.0583 -0.8115 -0.1120 -0.3313 -0.0346 -0.0418 -0.1690 -0.2625 -1.0267 -0.1159 -0.0295 -0.2853 -0.2364 -0.0294 -0.0809 -1.4773 -0.3332 -0.0463 -0.8667 -0.3313 -0.5281 -0.2014 -0.6898 -0.0073 -0.1814 -1.3715 -0.0613 -0.0380 -0.1213 -0.1216 -0.0151 -0.2891 -1.1068 -0.0537 -0.0434 -0.2750 -0.5352 -0.5041 -0.2613 -0.7439 -0.4159 -0.2717
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine exercise_capacity left_ventricular_filling patients heart_failure_with_preserved_ejection_fraction hfpef
H-1171	-0.4346977472305298	▁i va bra dine ▁exercise _ capaci ty ▁left _ vent ri cular _ ▁fill ing ▁heart _ fail ure ▁e je ction _ fraction ▁h p EF
D-1171	-0.4346977472305298	ivabradine exercise_capacity left_ventricular_ filling heart_failure ejection_fraction hpEF
P-1171	-0.0826 -0.0195 -0.0297 -0.3715 -0.0634 -0.3943 -0.0529 -0.0660 -0.1432 -0.3526 -0.6740 -0.8462 -0.2289 -0.8625 -2.3496 -0.0431 -0.4508 -0.2345 -1.2196 -0.8105 -0.1935 -0.1514 -0.0805 -0.1883 -0.0080 -0.9325 -0.3044 -1.3268 -0.3111 -0.2490
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood_transfusions erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_disease transfusion
H-42	-0.5289287567138672	▁blood _ trans fusion s ▁ir on ▁er y thro po ies is - stimul ating _ agent s ▁an emia ▁con ges tive _ heart _ fail ure ▁corona ry _ heart _ ▁disease ▁trans fusion
D-42	-0.5289287567138672	blood_transfusions iron erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_ disease transfusion
P-42	-1.4654 -0.2659 -0.1763 -0.0854 -0.1637 -0.0390 -0.1816 -0.0430 -0.3285 -0.2867 -0.1089 -2.0808 -0.2210 -0.5236 -0.3936 -0.1720 -0.3653 -0.3261 -0.3717 -0.6635 -0.1150 -0.0947 -0.1406 -0.9756 -0.3794 -2.2199 -0.2228 -1.5696 -0.6017 -0.0225 -0.3045 -0.3637 -2.4518 -0.1431 -2.0249 -0.1195 -0.0971 -0.2661 -0.2536
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate_analysis bnp estimated_glomerular_filtration_rate hypertension transmitral e-wave diastolic_mitral_annular_velocity
H-1570	-0.5450306534767151	▁b NP ▁glo mer ular _ filter ation _ rate ▁hyper tension ▁transmit ral _ e - wa ve ▁dia sto lic _ met ral _ ▁ann ular _ velo city
D-1570	-0.5450306534767151	bNP glomerular_filteration_rate hypertension transmitral_e-wave diastolic_metral_ annular_velocity
P-1570	-0.1810 -2.0794 -0.1432 -0.1360 -0.0380 -0.3514 -0.8247 -0.5774 -0.2977 -0.9401 -0.0419 -0.0015 -0.2506 -0.1886 -1.5022 -0.8005 -0.1997 -0.1056 -0.1334 -0.5703 -0.5189 -0.1632 -0.3952 -1.0703 -0.0645 -0.2730 -3.6773 -0.0272 -0.3180 -0.0720 -0.1413 -1.6295 -0.2722
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade halt disease protein_kinase pka β-adrenergic_receptor
H-1425	-0.4365427792072296	▁β - block ade ▁disease ▁c AMP - dependent _ ▁protein _ ▁kina se ▁p ka ▁down stream ▁β - ad r energi c _ ▁receptor _ activa tion ▁post - trans la tional _ state s
D-1425	-0.4365427792072296	β-blockade disease cAMP-dependent_ protein_ kinase pka downstream β-adrenergic_ receptor_activation post-translational_states
P-1425	-0.2550 -0.1327 -1.0044 -0.9111 -0.3213 -1.6374 -0.2232 -0.0833 -0.0282 -0.2842 -0.9326 -0.2810 -0.1037 -0.2206 -0.9343 -0.8413 -1.6952 -0.0014 -0.5840 -0.1248 -0.1912 -0.8696 -0.2869 -0.2648 -0.1406 -0.7564 -0.5140 -0.2820 -0.2250 -0.8598 -0.0700 -0.0425 -0.1852 -0.0477 -0.7822 -0.0356 -0.0544 -0.5730 -0.2446
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence erythropoiesis-stimulating_agent therapy venous_thromboembolism
H-47	-0.49432453513145447	▁er y thro po ies is - stimul ating _ agent _ therapy ▁benefits ▁ve nous _ thro mbo e mbol ism
D-47	-0.49432453513145447	erythropoiesis-stimulating_agent_therapy benefits venous_thromboembolism
P-47	-1.0265 -0.2619 -0.7961 -0.1358 -2.1521 -0.2274 -0.2891 -0.3504 -0.2102 -0.2519 -0.1520 -0.2018 -0.3408 -0.3490 -0.9518 -0.9513 -0.2909 -0.3864 -1.2994 -0.4657 -0.0546 -0.0961 -0.4191 -0.2034
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical genetic chf area_under_the_curve auc genetic auc clinical auc
H-1456	-0.830786943435669	▁genetic ▁CHF ▁cur ve ▁genetic
D-1456	-0.830786943435669	genetic CHF curve genetic
P-1456	-1.3635 -0.1954 -1.7540 -0.0592 -0.2414 -1.9906 -0.2114
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable_adjustment mortality hospitalization hazard_ratio cardiovascular_mortality hf hospitalization
H-1638	-0.3185908794403076	▁black _ race ▁mortal ity haz ard _ rati o ▁cardiovascular _ ▁mortal ity HF
D-1638	-0.3185908794403076	black_race mortalityhazard_ratio cardiovascular_ mortalityHF
P-1638	-0.0547 -0.2602 -0.7538 -1.2199 -0.1521 -0.0386 -0.1015 -0.2543 -0.0339 -0.0399 -0.0804 -0.5423 -0.3609 -0.1790 -0.3481 -0.6266 -0.3700
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous chronic_myocardial_ischemia stent polytetrafluoroethylene
H-504	-0.4863024055957794	▁chronic _ My o card ial _ ische mia ▁sten t ▁poly te tra flu oro e thy lene _ tube ▁bottle ne ck
D-504	-0.4863024055957794	chronic_Myocardial_ischemia stent polytetrafluoroethylene_tube bottleneck
P-504	-0.3890 -0.3256 -3.8406 -0.9186 -0.9058 -0.4971 -0.2200 -0.1916 -0.8736 -0.0991 -0.1087 -0.0745 -0.0931 -0.1135 -0.1477 -0.0569 -0.9053 -0.1112 -0.6366 -0.4498 -0.0765 -0.3274 -0.0725 -0.0324 -0.9208 -0.2559
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers_for_medicare_and_medicaid_services cms hospital outcomes reported mortality readmission penalties
H-1031	-0.49444401264190674	▁Center s _ for _ ▁Medica re _ and _ ▁Medica id _ service s ▁c ms ▁public ly ▁mortal ity ▁read mission ▁penal ties
D-1031	-0.49444401264190674	Centers_for_ Medicare_and_ Medicaid_services cms publicly mortality readmission penalties
P-1031	-0.6166 -0.1412 -0.2633 -0.8149 -0.4143 -0.2340 -0.0426 -1.6218 -0.0887 -0.4672 -0.1534 -0.2637 -0.2469 -0.1230 -0.0608 -1.5107 -0.5342 -1.9549 -0.5507 -0.2248 -0.1621 -1.2392 -0.0552 -0.7064 -0.0665 -0.5032 -0.2896
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart_failure hf tumor_necrosis_factor tnf tnf_antagonists disease severe_hf
H-601	-0.7682551741600037	▁heart _ fail ure HF ▁tumor _ ▁nec rosi s _ factor ▁t n f ▁t n f ▁ HF
D-601	-0.7682551741600037	heart_failureHF tumor_ necrosis_factor tnf tnf HF
P-601	-0.4542 -0.3208 -1.5203 -2.2359 -0.7636 -0.0291 -0.3067 -0.8719 -0.0284 -0.2024 -0.3812 -0.0276 -0.7241 -1.6528 -0.1461 -0.1633 -0.7203 -0.1838 -3.7655 -1.8492 -0.3538 -0.2006
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate signal_transduction transcription_factors pathological cardiomyocytes transcription_factors epigenetic chromatin_structure
H-1040	-0.6417890787124634	▁signal _ trans duction _ ▁casca de ▁tran scription _ factor s ▁cardio my o cy tes ▁tran scription _ factor s ▁epi gene tic ▁chr omat in
D-1040	-0.6417890787124634	signal_transduction_ cascade transcription_factors cardiomyocytes transcription_factors epigenetic chromatin
P-1040	-0.8537 -0.2740 -0.1165 -0.3021 -0.2273 -1.4384 -0.1024 -0.8793 -0.0720 -0.5087 -0.2064 -0.3095 -0.6703 -2.2570 -0.4573 -0.0722 -0.5200 -1.2548 -0.2280 -0.5977 -0.1803 -0.2866 -0.5868 -0.7249 -0.3097 -1.9347 -0.1046 -1.2195 -2.2692 -0.2897
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox_proportional_hazard_models covariates follow-up physician discharge primary_outcome death all-cause_readmission
H-1416	-0.34930261969566345	▁follow - up ▁physician ▁dis charge ▁death ▁read mission
D-1416	-0.34930261969566345	follow-up physician discharge death readmission
P-1416	-0.3031 -0.2110 -0.0190 -0.3250 -0.1381 -0.0217 -1.3931 -0.7552 -0.0395 -0.3680 -0.2687
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable_logistic_analysis peak_oxygen_uptake metabolic_exercise cardiac kidney prognostic hf_index
H-1760	-0.6038748621940613	▁multi vari able _ ▁logistic _ analyse ▁pe ak _ ▁oxygen _ up take ▁metabol ic _ ▁exercise ▁cardiac ▁ki dne y _ index ▁h z _ index
D-1760	-0.6038748621940613	multivariable_ logistic_analyse peak_ oxygen_uptake metabolic_ exercise cardiac kidney_index hz_index
P-1760	-2.3413 -0.0031 -0.0704 -0.7295 -0.3345 -2.2164 -0.4508 -0.1895 -0.0483 -0.1760 -1.4695 -0.2861 -0.7154 -0.1830 -0.1242 -0.0792 -0.7290 -0.4947 -0.0228 -0.1655 -0.4421 -0.2468 -0.2919 -0.2957 -2.0226 -2.0982 -0.8325 -0.3714 -0.4192 -0.2665
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular_dilatation
H-334	-0.6359956860542297	▁mechanism ▁surgery ▁dia sto lic _ mit ral _ val ve _ te ther ing ▁anterior _ le a flet _ ▁opening ▁papil lar y _ ▁muscle s ▁left _ vent ri cular _ di la tation
D-334	-0.6359956860542297	mechanism surgery diastolic_mitral_valve_tethering anterior_leaflet_ opening papillary_ muscles left_ventricular_dilatation
P-334	-0.0838 -1.0043 -0.0130 -0.2647 -0.2539 -0.3039 -1.4856 -0.0635 -0.2900 -1.4997 -0.8029 -0.3658 -0.6423 -0.1882 -0.0649 -0.1875 -0.5391 -2.5396 -0.1287 -0.0201 -0.2921 -1.7029 -0.9140 -0.4976 -0.8935 -0.3564 -3.4028 -0.0778 -0.2362 -0.3730 -0.5392 -1.5148 -0.2759 -0.4040 -1.6859 -0.1513 -0.0440 -0.4264 -0.2746
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients hypertensive_hfpef dash ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling
H-926	-0.4392244517803192	▁h f f ▁so dium - re strict ed _ ▁DAS h ▁vent ri cular _ dia sto lic _ function ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial _ ▁coup ling
D-926	-0.4392244517803192	hff sodium-restricted_ DASh ventricular_diastolic_function arterial_ elastance ventricular-arterial_ coupling
P-926	-1.3272 -0.7867 -0.5333 -0.2752 -0.0560 -0.0365 -0.0156 -0.0456 -0.0590 -0.5944 -0.5569 -0.3348 -1.0212 -0.6524 -0.2308 -0.3175 -0.2219 -0.5738 -0.4865 -0.4942 -0.2286 -0.2061 -1.2541 -0.1312 -0.2122 -0.1803 -0.8813 -0.4834 -0.4822 -0.5796 -0.1841 -0.5152 -0.7560 -0.3461 -0.5194 -0.2331
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf hct polymorphisms genes anthracycline metabolism iron_homeostasis anti-oxidant_defence myocardial_remodelling
H-1450	-0.5222693681716919	▁CHF ▁h t ▁an thra cycli ne _ ▁metabolism ▁ir on _ home osta sis ▁anti - oxid ant _ de fen ce ▁my o card ial _ ▁remodel ling
D-1450	-0.5222693681716919	CHF ht anthracycline_ metabolism iron_homeostasis anti-oxidant_defence myocardial_ remodelling
P-1450	-0.3181 -0.2284 -1.6820 -1.1366 -0.1728 -0.4145 -1.6676 -0.3368 -0.5412 -0.0067 -0.0773 -0.1871 -1.2059 -0.5885 -2.4930 -0.0146 -0.0941 -0.0205 -0.2574 -0.3439 -0.1283 -0.1920 -0.0969 -0.6275 -0.2919 -0.7228 -0.4770 -0.5766 -0.9374 -0.1646 -0.4810 -0.2296
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate_logistic_regression_analysis rule cad stenosis 3-vessel_cad 2-vessel_cad left_anterior_descending_artery
H-1187	-1.3581314086914062	▁logistic _ re gression ▁rule ▁CAD ▁diameter _ ▁sten osis ▁left _ main ▁CAD ▁proxima l _ de part ing _ ▁arter y
D-1187	-1.3581314086914062	logistic_regression rule CAD diameter_ stenosis left_main CAD proximal_departing_ artery
P-1187	-0.5055 -0.6948 -0.0770 -0.0330 -0.2252 -3.1419 -0.4595 -0.5045 -1.8911 -0.1292 -3.9957 -0.5687 -0.7459 -2.7926 -5.8246 -0.2173 -0.6025 -5.3189 -1.1339 -3.5422 -0.2374 -0.1956 -0.4080 -0.4724 -0.2358
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence mortality outcomes heart_failure acute_myocardial_infarction patients acute_myocardial_infarction western_australia
H-1305	-1.0373384952545166	▁heart _ fail ure ▁a cute _ My o card ial _ in far ction ▁a cute _ My o card ial _ in far ction ▁western _ au stria
D-1305	-1.0373384952545166	heart_failure acute_Myocardial_infarction acute_Myocardial_infarction western_austria
P-1305	-1.3655 -0.3325 -1.4465 -1.1349 -0.8852 -0.0730 -0.2746 -5.2536 -1.2212 -1.8484 -0.9992 -0.2204 -0.6857 -0.0810 -0.7878 -1.1854 -0.1863 -0.2441 -4.7700 -1.2327 -2.0461 -1.6636 -0.2340 -0.5830 -0.1064 -0.8539 -0.4384 -0.2288 -1.8502 -0.3878 -0.3097 -0.2648
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized_aldactone_evaluation_study symptomatic_chronic_advanced_heart_failure patients aldosterone_antagonist spironolactone mortality placebo
H-1735	-0.6181800365447998	▁Rand om ized _ al da cto ne _ evalua tion _ ▁Study ▁advanced _ heart _ ▁failure ▁al do ster one _ ▁anta gon ist ▁spi rono lac tone ▁mortal ity
D-1735	-0.6181800365447998	Randomized_aldactone_evaluation_ Study advanced_heart_ failure aldosterone_ antagonist spironolactone mortality
P-1735	-0.4717 -0.1178 -0.0877 -0.2276 -1.1462 -0.8605 -0.2721 -0.7376 -0.3240 -0.3456 -0.1260 -0.6119 -2.0367 -3.6209 -0.2181 -2.2030 -0.1933 -2.4516 -0.4122 -0.1765 -0.4829 -0.3621 -0.5601 -0.2862 -0.0177 -1.3276 -0.1380 -0.0116 -0.2989 -0.1265 -0.0351 -0.1464 -0.3532 -0.2307
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-0.6955594420433044	▁medication ▁no nadh er ence ▁salt
D-559	-0.6955594420433044	medication nonadherence salt
P-559	-0.1591 -0.7978 -1.3250 -0.0338 -0.0954 -0.3262 -2.5546 -0.2727
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological diagnostic prognostic
H-1278	-0.5525696873664856	▁pat ho phy si ological
D-1278	-0.5525696873664856	pathophysiological
P-1278	-0.8843 -0.4795 -0.0157 -0.9480 -0.4250 -0.8625 -0.2529
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad surgery patients albumin hypoalbuminemia surgery
H-534	-0.42829957604408264	▁l VAD ▁album in ▁hypo album in emia ▁surgery
D-534	-0.42829957604408264	lVAD albumin hypoalbuminemia surgery
P-534	-0.6275 -0.0883 -1.3715 -0.3661 -0.1090 -0.3953 -0.2534 -0.2896 -0.6367 -0.3528 -0.2212
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical hm_ii heartware patients economic hm_ii
H-310	-0.7149656414985657	▁scientific ▁h m _ ▁II ▁Heart War e ▁economic ▁h m _ ▁II
D-310	-0.7149656414985657	scientific hm_ II HeartWare economic hm_ II
P-310	-2.0188 -0.8660 -0.2621 -0.8098 -0.9417 -1.0385 -0.1913 -0.1370 -0.3229 -0.4501 -1.2318 -0.8655 -0.8468 -0.4667 -0.2754
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate_model creatinine hazard_ratio confidence_interval mortality
H-717	-0.4716900885105133	▁creati nine haz ard _ rati o ▁d L ▁confidence _ ▁interval ▁post - trans plant _ ▁mortal ity
D-717	-0.4716900885105133	creatininehazard_ratio dL confidence_ interval post-transplant_ mortality
P-717	-0.0489 -0.8963 -0.0260 -0.0390 -0.1645 -0.0297 -0.0311 -0.2463 -3.3461 -1.7386 -0.6283 -0.7463 -0.0131 -0.1430 -0.1112 -0.0647 -0.4176 -0.3443 -0.1860 -0.3674 -0.3171
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications implantation lvad_therapy transplantation btt dt medical_therapy
H-313	-0.5267986059188843	▁implant ation ▁l VAD _ therapy ▁transplant ation ▁b t ▁d t ▁medical _ therapy
D-313	-0.5267986059188843	implantation lVAD_therapy transplantation bt dt medical_therapy
P-313	-0.1656 -0.0907 -0.4641 -0.0421 -2.0557 -0.0987 -0.6194 -0.0640 -1.2159 -0.2245 -2.1168 -0.0480 -0.0874 -1.0104 -0.1125 -0.2965 -0.2433
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical artery_tonometry prospectively admission patients icu clinical
H-580	-0.8010046482086182	▁radi al _ ▁arter y _ ton ometr y ▁ad mission ▁PH ICU
D-580	-0.8010046482086182	radial_ artery_tonometry admission PHICU
P-580	-0.0745 -0.1883 -0.3950 -0.2838 -1.3508 -0.2863 -4.0916 -0.0492 -0.2687 -1.5220 -0.0188 -2.3558 -0.2776 -0.6034 -0.2494
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized hr_variability hr_variability clinical risk_stratification cardiac patients
H-1591	-1.3376802206039429	▁HR _ ▁variabil ity _ tur bul ence ▁HR _ ▁variabil ity _ tur bul ence ▁cardiac _ ▁pacientes
D-1591	-1.3376802206039429	HR_ variability_turbulence HR_ variability_turbulence cardiac_ pacientes
P-1591	-1.8423 -0.5940 -1.9557 -0.5737 -1.0497 -6.3953 -0.6024 -0.3233 -1.2645 -0.6699 -1.3429 -0.7438 -1.0642 -4.4542 -0.3996 -0.3739 -0.2236 -0.7833 -2.7172 -0.3959 -0.3216
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine nesiritide renal_function patients acute_heart_failure renal_dysfunction
H-72	-0.4792862832546234	▁low - dos e _ ▁dop amine ▁low - dos e _ ▁nesi riti de ▁renal _ function ▁a cute _ heart _ fail ure ▁renal _ ▁dys function
D-72	-0.4792862832546234	low-dose_ dopamine low-dose_ nesiritide renal_function acute_heart_failure renal_ dysfunction
P-72	-0.5591 -0.0721 -1.5844 -0.5113 -0.3841 -0.1971 -0.1729 -0.1527 -0.0672 -0.7286 -0.3656 -0.2059 -0.2073 -0.1908 -0.2092 -0.0551 -0.4689 -0.2756 -0.3618 -0.0443 -0.2273 -2.5661 -0.2789 -1.8217 -0.7536 -0.0389 -0.4440 -1.0448 -0.0682 -0.5180 -0.2824
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death patients estimated_glomerular_filtration_rate odds_ratio confidence_interval
H-977	-0.41262373328208923	▁glo mer ular _ filter ation _ rate odd s _ rati o ▁confidence _ ▁interval
D-977	-0.41262373328208923	glomerular_filteration_rateodds_ratio confidence_ interval
P-977	-0.8033 -0.1228 -0.0375 -0.2347 -0.7975 -0.5731 -0.2733 -0.8715 -0.1920 -0.0465 -0.2498 -0.0870 -0.0365 -0.9127 -0.6152 -0.8067 -0.4528 -0.3144
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast_cancer patients medicare diagnosed breast_cancer chemotherapy seer-medicare texas medicare
H-672	-0.8585972189903259	▁Breast _ cancer ▁Medica re _ ▁coverage ▁breast _ cancer ▁che mo therapy ▁s EER - Medic are ▁Texas _ cancer _ ▁Registr y - Medic are
D-672	-0.8585972189903259	Breast_cancer Medicare_ coverage breast_cancer chemotherapy sEER-Medicare Texas_cancer_ Registry-Medicare
P-672	-1.3435 -0.2397 -1.2922 -0.0750 -0.0154 -2.1487 -0.4874 -0.2291 -0.1380 -1.3698 -0.1841 -0.2069 -0.0826 -1.9615 -0.1852 -0.0414 -0.1953 -2.4648 -0.2727 -0.4893 -1.2871 -0.3940 -2.1144 -0.1135 -2.5864 -0.6631 -3.7668 -0.3289 -0.2225
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome_complex scaffold_protein drives kinases phosphorylation effector_molecules
H-995	-0.5733678936958313	▁e RK 1/2 ▁signal ling ▁signal o some ▁sc af fold _ ▁protein _ drive s ▁kina ses ▁sequenti al _ phos phor y lation
D-995	-0.5733678936958313	eRK1/2 signalling signalosome scaffold_ protein_drives kinases sequential_phosphorylation
P-995	-1.8522 -0.1492 -0.3048 -0.5891 -0.4449 -0.4624 -0.6550 -0.2518 -1.8872 -0.3527 -0.0445 -0.2368 -1.1623 -0.6960 -0.0371 -0.1580 -0.0549 -0.6143 -0.1156 -0.1081 -0.4108 -1.2592 -1.3286 -1.1706 -0.0978 -0.7577 -0.2790
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully_magnetically_levitated_centrifugal-flow_chronic_lvas adverse_event quality_of_life functional_status
H-2006	-0.8075101375579834	▁magnet ically _ le vita ted ▁centri fu gal - flow _ ▁chronic _ VAS
D-2006	-0.8075101375579834	magnetically_levitated centrifugal-flow_ chronic_VAS
P-2006	-0.4239 -0.1837 -2.2151 -1.1175 -0.0067 -0.0626 -0.4611 -0.1943 -0.1336 -0.4453 -0.0231 -0.5867 -2.4535 -0.4444 -3.8851 -0.8570 -0.2341
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased cardiomyocytes pde2 activity cgmp_synthesis nitric_oxide donors pde2_inhibition β-ar_responsiveness
H-1215	-0.5878129005432129	▁cardio my o cy tes ▁p de 2 ▁activity ▁c g MP ▁ni tric _ oxid e ▁p de 2 _ ▁inhibi tion ▁β - ar _ ▁responsive ness
D-1215	-0.5878129005432129	cardiomyocytes pde2 activity cgMP nitric_oxide pde2_ inhibition β-ar_ responsiveness
P-1215	-0.3070 -1.3378 -0.3884 -0.0656 -0.5485 -1.2625 -0.0570 -0.1165 -0.4676 -0.0611 -0.3499 -2.4772 -0.4375 -0.3581 -0.3238 -0.4762 -0.8785 -0.9362 -0.0460 -0.1805 -0.6314 -2.2181 -0.1528 -0.1205 -0.0470 -0.8289 -0.5415 -1.2607 -0.6922 -0.4160 -0.2371
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection_fraction b-type_natriuretic_peptide patients hospitalized heart_failure inhospital outcomes get_with_the_guideline-heart_failure_registry
H-186	-0.6032065749168396	▁e je ction _ fraction ▁na tri ure tic _ pe pti de ▁heart _ fail ure ▁in hospital ▁guide line - he art _ fail ure _ ▁Registr y
D-186	-0.6032065749168396	ejection_fraction natriuretic_peptide heart_failure inhospital guideline-heart_failure_ Registry
P-186	-0.2672 -0.3321 -0.0700 -0.3233 -0.0179 -0.3005 -0.2794 -0.1082 -0.3405 -0.4063 -0.7504 -0.1480 -0.5596 -1.1487 -0.2686 -1.3539 -0.6379 -1.0663 -0.1375 -1.7812 -0.0719 -0.2665 -3.0725 -0.4163 -0.2708 -0.3687 -0.1615 -1.1221 -2.3464 -0.1458 -0.4748 -0.2878
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic_receptor sphingosine-1-phosphate_receptor_1 s1pr1 downregulation cardiac hypertrophic heart_failure s1pr1 cardiac gene therapy
H-1404	-0.4967714548110962	▁beta 1- ad r energi c _ ▁receptor ▁sp hing os ine -1 - phos pha te _ ▁receptor ▁s 1 PR ▁reciproc al _ down regul ation ▁cardiac _ ▁hyper trop hic ▁heart _ fail ure ▁s 1 PR 1 ▁cardiac _ ▁gene _ therapy
D-1404	-0.4967714548110962	beta1-adrenergic_ receptor sphingosine-1-phosphate_ receptor s1PR reciprocal_downregulation cardiac_ hypertrophic heart_failure s1PR1 cardiac_ gene_therapy
P-1404	-0.4612 -0.2392 -0.4637 -0.4370 -0.1271 -0.1501 -0.2426 -0.3682 -0.0444 -0.1902 -0.0786 -0.6570 -1.8752 -0.2366 -0.0879 -0.2424 -0.2173 -0.1519 -0.3166 -1.5103 -0.1349 -2.2813 -0.5410 -0.0465 -0.4056 -1.9503 -0.1611 -0.0438 -0.0530 -0.3931 -1.0969 -0.0565 -0.2049 -0.8283 -0.2366 -1.0838 -0.5992 -0.3463 -0.0978 -2.1979 -0.2837 -0.0773 -0.4359 -1.1251 -0.5619 -0.0750 -0.2720 -0.1576
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs hdl phosphorylation
H-251	-0.49545907974243164	▁HD l ▁ phos phor y lation ▁e NOS - Ser ▁e NOS - th r ▁p 70 s 6 k - Ser
D-251	-0.49545907974243164	HDl phosphorylation eNOS-Ser eNOS-thr p70s6k-Ser
P-251	-0.9814 -1.6404 -0.1285 -0.2528 -0.2598 -0.7379 -0.0712 -0.0917 -0.1586 -0.1004 -1.0080 -0.1734 -0.1343 -0.0636 -1.2121 -0.0174 -1.5674 -0.5988 -0.2221 -0.2414 -1.5449 -0.0722 -0.5253 -0.3794 -0.2034
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts patients sts hh sts
H-155	-1.111474633216858	▁s ts ▁h m ▁h m ▁s ts ▁t m
D-155	-1.111474633216858	sts hm hm sts tm
P-155	-1.4779 -0.6229 -0.1589 -1.9697 -1.4729 -0.2815 -2.9765 -1.2823 -1.6317 -0.6670 -0.5111 -0.2854
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular_myocytes sarcomere shortening
H-417	-0.7185042500495911	▁mouse ▁vent ri cular _ My o cy tes ▁sar com ere ▁trans ient
D-417	-0.7185042500495911	mouse ventricular_Myocytes sarcomere transient
P-417	-0.2793 -1.3115 -0.2261 -0.1130 -0.3005 -2.9929 -0.2686 -0.0558 -0.8920 -1.1952 -0.1095 -0.9073 -2.0779 -0.2834 -0.2681 -0.2148
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative alberta discharged hospital diagnosis heart_failure
H-1415	-0.620876669883728	▁administrative ▁Albert a ▁dis charge d ▁hospital ▁heart _ fail ure
D-1415	-0.620876669883728	administrative Alberta discharged hospital heart_failure
P-1415	-0.0162 -0.4007 -0.1330 -1.6867 -0.0142 -0.0432 -2.7330 -0.6363 -0.2449 -0.7071 -0.8901 -0.3620 -0.2039
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp 6-minute_walking_distance peak_o2
H-829	-0.5183079838752747	▁pas p ▁pe ak _ o 2
D-829	-0.5183079838752747	pasp peak_o2
P-829	-1.8596 -0.5703 -0.3125 -0.0999 -0.2473 -0.3463 -0.1343 -0.8396 -0.2550
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates crt death hf hospitalization hazard_ratio lvef
H-757	-0.6524261236190796	▁c t ▁time _ to _ ▁death ▁h f haz ard _ rati o ▁LV f
D-757	-0.6524261236190796	ct time_to_ death hfhazard_ratio LVf
P-757	-0.4448 -2.1282 -1.9847 -0.5976 -0.4882 -0.4474 -0.8228 -0.5684 -0.9169 -0.7235 -0.1409 -0.2096 -0.0264 -0.0311 -0.2484 -1.2945 -0.4139 -0.2563
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart_failure histologically myocardial_collagen healthy heart_failure
H-1062	-0.9079672694206238	▁heart _ fail ure ▁his t ological ly ▁my o card ial _ ▁collage n ▁heart _ fail ure
D-1062	-0.9079672694206238	heart_failure histologically myocardial_ collagen heart_failure
P-1062	-1.4494 -0.3592 -1.4382 -2.7173 -3.0244 -0.2326 -0.1320 -0.1308 -0.8482 -0.3318 -0.3708 -0.2067 -0.1887 -0.2121 -0.1596 -3.4724 -0.3371 -0.8624 -2.0392 -0.3501 -0.2043
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko cardiac irs1 irs2 proteins heart_failure cardiac_energy_metabolism_gene_expression p38α mitogen-activated_protein_kinase p38
H-656	-0.5423873066902161	▁l - d ko _ mi ce ▁cardiac ▁i RS 1 ▁i RS 2 ▁heart _ fail ure ▁im pair ed _ ▁cardiac _ ener gy _ ▁metabolism ▁mit ogen - activa ted _ ▁protein _ ▁kina se
D-656	-0.5423873066902161	l-dko_mice cardiac iRS1 iRS2 heart_failure impaired_ cardiac_energy_ metabolism mitogen-activated_ protein_ kinase
P-656	-0.4375 -0.2595 -0.2654 -1.0787 -0.6196 -0.1517 -0.2661 -0.0948 -1.1914 -0.6467 -0.1189 -1.2903 -0.8224 -0.0214 -2.2761 -0.3200 -1.1032 -1.9975 -0.6479 -0.0060 -0.0517 -1.2527 -0.1848 -0.3846 -0.1567 -0.0999 -0.1389 -0.3400 -1.3572 -0.5028 -0.2963 -0.0279 -0.4923 -0.3012 -1.1224 -0.2536 -0.0676 -0.2197 -0.5695 -0.2604
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil heart_failure hemodynamic mitochondrial_dysfunction antitumor activity
H-967	-0.42000505328178406	▁nic oran dil ▁do xor ubi cin - indu ced _ heart _ fail ure ▁rat s ▁hem o dynamic ▁mito cho ndri al _ ▁dys function ▁anti tum or _ activ ity
D-967	-0.42000505328178406	nicorandil doxorubicin-induced_heart_failure rats hemodynamic mitochondrial_ dysfunction antitumor_activity
P-967	-0.0358 -0.0953 -0.3791 -0.0223 -0.0487 -0.0042 -0.2310 -0.1213 -0.0004 -0.0220 -0.3938 -1.8934 -0.2463 -1.1741 -1.6296 -0.6776 -0.0820 -0.3550 -0.2569 -0.0413 -1.7437 -1.0944 -0.3516 -0.2146 -0.4446 -0.8143 -0.0255 -0.1018 -0.6565 -0.1486 -0.5486 -0.0900 -0.1486 -0.3983 -0.2089
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm_control_therapy diagnosis atrial sinus_rhythm rhythm_control symptoms rate_control
H-1646	-0.7638275027275085	▁ Rhythm _ control _ therapy ▁af ▁at rial ▁sinus _ rhythm ▁ rhythm ▁ rhythm _ control ▁rate _ control
D-1646	-0.7638275027275085	Rhythm_control_therapy af atrial sinus_rhythm rhythm rhythm_control rate_control
P-1646	-1.2545 -2.0743 -0.2307 -0.0615 -0.2970 -0.1530 -0.8197 -0.2443 -0.2478 -2.7384 -0.6586 -0.8875 -1.1628 -0.5379 -2.6342 -0.6267 -0.9426 -0.0566 -0.6748 -0.6047 -0.0500 -0.3979 -0.2125
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative_risk rr heart_failure bisphophonates rr confidence_interval hazard_ratio
H-1540	-0.7448446154594421	▁relative _ risk RR ▁heart _ fail ure ▁bis pho phon ates ▁cru de _ r r ▁confidence _ ▁interval ▁hazard _ rati o HR
D-1540	-0.7448446154594421	relative_riskRR heart_failure bisphophonates crude_rr confidence_ interval hazard_ratioHR
P-1540	-0.1133 -0.2810 -0.4536 -1.7773 -0.5786 -0.1962 -1.2936 -1.5802 -0.1806 -0.2081 -0.1624 -1.9346 -0.1985 -0.0547 -2.2505 -1.6006 -1.1157 -0.9144 -0.3524 -0.5593 -1.3893 -0.4383 -0.0986 -0.0304 -1.7152 -0.3882 -0.2452
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician heart_failure clinical_practice_guideline cpg outcomes heart_failure hf
H-1841	-0.9317976832389832	▁guide line ▁heart _ fail ure ▁Clinic al _ prac tice ▁guide line ▁c g ▁heart _ fail ure HF
D-1841	-0.9317976832389832	guideline heart_failure Clinical_practice guideline cg heart_failureHF
P-1841	-1.2403 -0.0899 -1.8113 -0.2983 -2.0054 -1.9024 -0.6870 -0.2257 -0.4271 -0.2094 -0.0488 -2.1314 -0.0913 -0.9217 -0.7824 -1.7040 -0.3457 -1.5783 -1.5553 -1.7632 -0.4266 -0.2540
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute_heart_failure renal_dysfunction dopamine nesiritide renal_function diuretic therapy
H-83	-0.4533073604106903	▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁low - dos e _ ▁dop amine ▁low - dos e _ ▁nesi riti de ▁renal _ function ▁di ure tic _ therapy
D-83	-0.4533073604106903	acute_heart_ failure renal_ dysfunction low-dose_ dopamine low-dose_ nesiritide renal_function diuretic_therapy
P-83	-0.7984 -0.0331 -0.2285 -1.9133 -0.2230 -1.8807 -0.0307 -0.2921 -0.5473 -0.0370 -0.1510 -0.1202 -1.6017 -0.4198 -0.4897 -0.1354 -0.3491 -0.1013 -0.1713 -0.8300 -0.5417 -0.2373 -1.2440 -0.4746 -0.2114 -0.0563 -0.4436 -0.2084 -0.1379 -0.0412 -0.3850 -0.7407 -0.1294 -0.4430 -0.2178
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf prospective dual-energy_x-ray_absorptiometry echocardiography blood
H-1161	-0.627619206905365	▁h f ▁skin fold _ thi ck ness ▁dual - ener gy _ ▁x - ray _ ab sor pti ometr y ▁e cho card i ography ▁blood _ test
D-1161	-0.627619206905365	hf skinfold_thickness dual-energy_ x-ray_absorptiometry echocardiography blood_test
P-1161	-1.1379 -0.3886 -5.1613 -0.0976 -0.3807 -1.2069 -0.0479 -0.1607 -0.0816 -0.1387 -0.0547 -0.0065 -0.4475 -2.2180 -0.2986 -0.5646 -0.1190 -0.8023 -0.9247 -0.2400 -0.2118 -0.1537 -0.1025 -0.2619 -0.5114 -0.4582 -0.3634 -0.2227 -1.0395 -0.4358 -1.5387 -0.3063
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare centers_for_medicare_and_medicaid_services clinics propensity-score
H-1621	-0.4531581997871399	▁high - co st _ ▁Medica re ▁Center s _ for _ ▁Medica re ▁Medica id _ service s ▁pro pens ity - s core
D-1621	-0.4531581997871399	high-cost_ Medicare Centers_for_ Medicare Medicaid_services propensity-score
P-1621	-0.8927 -0.0730 -0.0585 -0.5082 -0.3885 -0.3747 -0.0836 -2.2570 -0.1676 -0.3034 -1.4194 -0.4281 -0.4741 -0.0686 -0.1117 -0.5279 -0.3398 -0.1227 -0.0401 -0.6244 -0.1258 -0.3193 -0.2109 -0.1117 -0.5615 -1.3718 -0.2703
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals patients hospitalized heart_failure hf conditions acute_myocardial_infarction pneumonia conditions
H-1032	-0.7799203395843506	▁heart _ fail ure HF ▁conditions ▁a cute _ My o card ial _ in far ction ▁pneu monia ▁conditions
D-1032	-0.7799203395843506	heart_failureHF conditions acute_Myocardial_infarction pneumonia conditions
P-1032	-2.4599 -0.2970 -0.7412 -2.6017 -0.7969 -0.0878 -1.2682 -0.0296 -0.2402 -4.5510 -0.5255 -0.2717 -0.6258 -0.2448 -0.3098 -0.0503 -0.3499 -0.0033 -1.0014 -0.0401 -0.3538 -0.3082
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients heart_failure
H-1744	-1.0598419904708862	▁heart _ fail ure
D-1744	-1.0598419904708862	heart_failure
P-1744	-1.9551 -0.3750 -0.9774 -1.0277 -1.7453 -0.2786
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq new_york_heart_association_class patients hfpef hf_with_reduced_ef
H-788	-0.8348268866539001	▁k cc q ▁New _ York _ ▁Heart _ association ▁h f p EF ▁h f
D-788	-0.8348268866539001	kccq New_York_ Heart_association hfpEF hf
P-788	-2.2003 -0.1160 -1.1540 -1.0131 -0.9112 -1.7588 -0.2242 -0.7910 -0.1765 -0.4065 -0.6287 -1.8505 -0.0948 -0.5412 -0.6265 -0.7557 -1.5147 -0.2633
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp red_blood_cell_transfusion hemoglobin hemoglobin hospitalized patients coronary_heart_disease
H-36	-1.0815162658691406	▁ab p ▁red _ ▁blood _ cell _ trans fusion _ strate gy ▁hem o glob in _ ▁thre s hold ▁hem o glob in ▁corona ry _ ▁Heart _ ▁Disease
D-36	-1.0815162658691406	abp red_ blood_cell_transfusion_strategy hemoglobin_ threshold hemoglobin coronary_ Heart_ Disease
P-36	-2.3618 -1.1170 -0.6376 -0.5589 -2.3094 -0.3532 -1.7106 -0.2313 -0.2345 -0.0860 -2.6562 -0.4278 -0.6849 -2.8108 -0.8161 -0.8727 -2.4857 -1.6053 -0.9902 -0.0692 -1.0871 -1.6538 -0.8326 -0.5881 -1.6109 -0.5851 -0.4524 -0.3279 -2.7123 -0.4592 -1.7199 -0.3617 -0.2796
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted interatrial_shunt clinical haemodynamic outcomes patients heart_failure_with_reduced_ejection_fraction
H-1962	-0.651999294757843	▁implant ed ▁left - to - right _ inter at rial _ ▁shu nt ▁ha emo dynamic ▁heart _ ▁failure ▁e je ction _ fraction
D-1962	-0.651999294757843	implanted left-to-right_interatrial_ shunt haemodynamic heart_ failure ejection_fraction
P-1962	-0.0217 -0.1020 -3.7209 -0.1361 -0.2232 -0.3410 -0.2557 -0.6172 -0.2957 -0.4163 -0.7303 -0.3604 -3.6908 -1.0686 -0.0282 -0.1669 -0.0246 -0.9959 -0.3816 -2.2297 -0.2525 -0.2567 -0.1913 -0.3219 -0.0102 -0.4816 -0.2831
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise training peak_oxygen_consumption quality_of_life obese patients heart_failure_with_preserved_ejection_fraction randomized clinical
H-1973	-0.6300323009490967	▁Cal o ric _ re stri ction ▁aero bic ▁Peak _ o xy gen _ ▁Consum p tion ▁Heart _ fail ure ▁e je ction _ fra ction
D-1973	-0.6300323009490967	Caloric_restriction aerobic Peak_oxygen_ Consumption Heart_failure ejection_fraction
P-1973	-0.5266 -0.3729 -1.0344 -0.2804 -0.0331 -0.3313 -0.1796 -0.0812 -0.3014 -0.8606 -0.4523 -1.4209 -0.5540 -0.3257 -0.7811 -0.6503 -1.5894 -0.1334 -2.4283 -0.5342 -0.7496 -0.1230 -2.3563 -0.1103 -0.1299 -0.1809 -0.8770 -0.1631 -1.0766 -0.2633
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left_ventricular_assist_devices lvads chronic_end-stage_heart_failure bridge_to_transplantation btt patients destination_therapy dt
H-308	-0.7383419871330261	▁vent ri cular _ assist ances ▁l VAD s ▁chronic _ end - s tage _ heart _ fail ure bridge _ to _ ▁transplant ation ▁b t ▁transplant - ine ligi ble ▁d t
D-308	-0.7383419871330261	ventricular_assistances lVADs chronic_end-stage_heart_failurebridge_to_ transplantation bt transplant-ineligible dt
P-308	-0.5051 -1.0043 -0.2202 -0.2213 -0.0099 -3.5131 -0.7441 -0.0466 -0.1945 -0.4241 -0.6397 -2.6191 -0.1700 -0.0544 -0.0205 -0.1633 -1.6499 -0.2196 -1.1184 -1.6038 -0.5507 -0.5958 -0.9851 -0.3244 -2.4349 -0.0764 -0.5162 -0.2001 -2.1354 -0.3603 -0.6817 -0.3222 -0.0348 -2.3063 -0.1027 -0.3397 -0.2102
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1_time correlated right_ventricular-pulmonary_arterial_coupling pulmonary_vascular_resistance right_ventricular_ejection_fraction
H-742	-0.8256514668464661	▁right _ vent ri cular - pul mon ary _ ▁arterial _ ▁coup ling ▁pulmonar ary _ vas cular _ re serv ance ▁right _ vent ri cular _ e je ction _ fraction
D-742	-0.8256514668464661	right_ventricular-pulmonary_ arterial_ coupling pulmonarary_vascular_reservance right_ventricular_ejection_fraction
P-742	-0.3175 -0.6607 -1.0879 -1.2696 -0.3243 -0.4118 -2.3283 -2.2259 -0.0667 -0.2638 -1.0723 -0.3853 -0.6870 -0.2084 -3.9759 -0.7643 -0.4812 -1.0658 -1.3320 -0.3831 -0.6787 -4.1494 -0.1648 -0.1271 -0.4105 -0.7689 -0.8309 -0.4250 -0.4186 -0.4735 -0.7086 -0.2781 -0.2328 -0.0242 -0.4294 -0.2913
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol metoprolol implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-855	-0.6412891149520874	▁car vedi lol ▁met o pro lol ▁implant able _ ▁cardio ver ter - de fi br illa tor _ therapy ▁MAD t - c RT ▁multi center _ automat ic _ de ib rilla tor _ ▁implant ation ▁Card iac _ re syn chron ization _ ▁Therapy
D-855	-0.6412891149520874	carvedilol metoprolol implantable_ cardioverter-defibrillator_therapy MADt-cRT multicenter_automatic_deibrillator_ implantation Cardiac_resynchronization_ Therapy
P-855	-0.7118 -0.0197 -0.1946 -0.0344 -0.0708 -0.0243 -0.6623 -0.0074 -0.0382 -2.2451 -0.4373 -0.1503 -0.2961 -0.3603 -0.2075 -1.9978 -1.8760 -0.2536 -0.4946 -0.2933 -0.3067 -0.5104 -2.9699 -0.0442 -0.4248 -2.9381 -0.9129 -0.1070 -0.2431 -0.6290 -0.3289 -0.3275 -0.6083 -4.5313 -1.1738 -0.3410 -0.7005 -0.3942 -0.1195 -0.8006 -0.7757 -0.2414 -0.0656 -0.0580 -0.0104 -0.5922 -0.4225 -0.5197 -0.3793 -0.2123
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral glucocorticoids hf
H-610	-0.8733904957771301	▁Oral _ ▁gluco cor tico ids ▁h f
D-610	-0.8733904957771301	Oral_ glucocorticoids hf
P-610	-0.8071 -0.2659 -0.2660 -0.2473 -1.4040 -1.6734 -0.5438 -2.1629 -1.1505 -0.2130
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ea tac placebo
H-523	-0.5952851176261902	▁HR ▁i va bra dine ▁ea TAC
D-523	-0.5952851176261902	HR ivabradine eaTAC
P-523	-2.1449 -0.1004 -0.0095 -0.0226 -0.0512 -1.1932 -1.3742 -0.2635 -0.1980
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi death medical hospitalization hf clinic outpatients hf health
H-385	-0.8200936913490295	HF PSI ▁medical ▁h f ▁clinic _ out patient s ▁h f ▁health _ system s
D-385	-0.8200936913490295	HFPSI medical hf clinic_outpatients hf health_systems
P-385	-3.1735 -0.4838 -0.1808 -1.2873 -1.8618 -1.6529 -0.5940 -0.1615 -0.1735 -0.1617 -1.7677 -1.2251 -0.1379 -0.6307 -0.3767 -0.1052 -0.4628 -0.3249
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up systemic adverse_events patients dcm heart_failure
H-1265	-0.8046998381614685	▁follow - up ▁et h nic _ group s ▁CH m ▁ad ju nc tive _ behandlung ▁d c ▁heart _ fail ure
D-1265	-0.8046998381614685	follow-up ethnic_groups CHm adjunctive_behandlung dc heart_failure
P-1265	-2.4040 -0.1795 -0.0278 -0.7227 -0.0449 -0.4970 -0.3234 -0.4515 -0.1604 -3.3835 -0.1562 -0.5351 -0.0581 -0.0351 -0.0649 -0.8885 -3.7063 -0.3566 -1.8463 -0.3508 -0.3438 -1.3940 -1.5655 -0.3970 -0.2245
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol therapy metoprolol hazard_ratio confidence_interval
H-862	-0.33623209595680237	▁car vedi lol ▁met o pro lol haz ard _ rati o ▁confidence _ ▁interval
D-862	-0.33623209595680237	carvedilol metoprololhazard_ratio confidence_ interval
P-862	-1.1981 -0.0425 -0.3511 -0.2306 -0.1618 -0.0408 -0.3733 -0.0664 -0.0427 -0.2272 -0.0411 -0.0276 -0.6530 -0.4958 -0.6940 -0.8227 -0.2474
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone_supplementation exercise_rehabilitation health outcomes patients chf testosterone
H-1325	-0.6560693383216858	▁testosteron e ▁exercise ▁health ▁CHF ▁testosteron e _ status
D-1325	-0.6560693383216858	testosterone exercise health CHF testosterone_status
P-1325	-0.6825 -0.2784 -0.6071 -1.0749 -0.9393 -0.9400 -0.2621 -1.6730 -0.0402 -0.4742 -0.2451
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change peak_vo2 correlated change lean_body_mass change thigh muscle
H-1987	-0.5992366075515747	▁change ▁pe ak _ vo 2 ▁lean _ ▁Body _ ▁mass ▁change ▁th igh _ ▁muscle ▁inter mus cular _ ▁fat _ rati o
D-1987	-0.5992366075515747	change peak_vo2 lean_ Body_ mass change thigh_ muscle intermuscular_ fat_ratio
P-1987	-0.1796 -0.9348 -0.0703 -0.2076 -0.1063 -0.1651 -1.3535 -0.2082 -1.9499 -0.2687 -1.4610 -0.0466 -0.6386 -0.4803 -0.8101 -2.4108 -0.6721 -0.2658 -0.5866 -0.3736 -1.3224 -0.2934 -0.0452 -0.0348 -0.4004 -0.2944
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals get_with_the_guidelines-heart_failure hf patients ef ef ef ef
H-189	-0.6332189440727234	▁guide lines - he art _ fail ure ▁h f ▁border line
D-189	-0.6332189440727234	guidelines-heart_failure hf borderline
P-189	-1.7556 -0.0258 -0.2068 -2.6638 -0.1085 -0.3674 -0.1557 -0.1313 -0.5002 -0.5175 -0.4369 -0.0314 -1.7047 -0.2596
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate_cox_model pasp exercise peak_o2 prognostic hazard_ratio peak_o2 pasp
H-830	-0.7264017462730408	▁multi varia te _ co x _ model ▁exercise ▁pe ak _ o 2 _ per _ ▁kilogram haz ard _ rati o ▁pe ak _ o 2 _ per _ ▁kilogram
D-830	-0.7264017462730408	multivariate_cox_model exercise peak_o2_per_ kilogramhazard_ratio peak_o2_per_ kilogram
P-830	-0.0850 -0.4999 -0.1566 -0.4604 -0.0486 -0.3707 -0.2085 -0.3668 -4.7291 -0.7933 -0.3063 -0.3639 -0.8033 -0.1635 -2.0814 -0.2257 -0.5298 -1.0565 -2.6321 -0.3950 -0.2411 -0.0395 -0.0462 -0.2328 -0.2552 -0.2989 -0.6990 -0.1954 -0.9766 -0.1914 -0.3877 -0.9248 -3.6842 -0.2485
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac insulin-resistance mitochondrial_oxidative_metabolism metabolic cardiac_hypertrophy hypertrophy heart_failure
H-1787	-0.5171449184417725	▁cardiac _ ▁insulin - re si stance ▁mito cho ndri al _ oxid ative _ ▁metabolism ▁cardiac _ ▁hyper trop hy ▁energy _ ▁deficit ▁hyper trop hy ▁heart _ fail ure
D-1787	-0.5171449184417725	cardiac_ insulin-resistance mitochondrial_oxidative_ metabolism cardiac_ hypertrophy energy_ deficit hypertrophy heart_failure
P-1787	-0.1715 -1.1757 -0.1343 -0.1036 -0.0332 -0.3582 -0.0067 -0.0274 -1.0115 -0.2075 -0.1407 -0.2335 -0.4459 -1.8763 -0.2662 -0.5056 -1.0832 -0.2451 -2.5905 -0.5022 -0.2758 -0.0589 -1.0293 -0.2756 -0.0972 -0.9739 -0.4565 -0.1673 -0.2356 -1.0980 -0.7718 -0.2695 -0.2376
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad rgk rem rem2 rad monomeric_g_proteins ventricular_action_potential gain cardiac l-type_channel activity
H-1672	-0.5629939436912537	▁rad ▁r GK ▁rem ▁rem 2 ▁rad ▁gem Kir ▁mono me ric _ g _ ▁protein s ▁vent ri cular _ action _ pot ential _ du ration ▁coup ling _ ▁gain ▁cardiac _ l - type _ ▁channel _ activ ity
D-1672	-0.5629939436912537	rad rGK rem rem2 rad gemKir monomeric_g_ proteins ventricular_action_potential_duration coupling_ gain cardiac_l-type_ channel_activity
P-1672	-0.9054 -1.0461 -1.1462 -0.1120 -0.1144 -0.1013 -0.1672 -0.8009 -3.6921 -0.1185 -0.0804 -0.4244 -0.9545 -0.0752 -0.2203 -1.0601 -0.2253 -0.1296 -0.4006 -0.4057 -0.4858 -0.1290 -0.6090 -1.0576 -0.0045 -1.3355 -0.0208 -0.0506 -0.4799 -0.4978 -0.6020 -0.7789 -0.2405 -1.5185 -1.6633 -0.0723 -0.0151 -0.1158 -1.5832 -0.3766 -0.1871 -0.0757 -0.4549 -0.2373
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular dilatation
H-338	-0.6377622485160828	▁mechanism ▁dia sto lic _ mit ral _ val ve _ te ther ing ▁anterior _ le a flet _ ▁opening ▁papil lar y _ ▁muscle s ▁left _ vent ri cular LV ▁di la tation
D-338	-0.6377622485160828	mechanism diastolic_mitral_valve_tethering anterior_leaflet_ opening papillary_ muscles left_ventricularLV dilatation
P-338	-0.0806 -1.3517 -0.3515 -0.2006 -0.2457 -1.5384 -0.0808 -0.2497 -1.5231 -0.7464 -0.3053 -0.6076 -0.1683 -0.0682 -0.1587 -0.5585 -2.4969 -0.1216 -0.0200 -0.2968 -1.6818 -0.8568 -0.4764 -0.8937 -0.3064 -3.7301 -0.0779 -0.1024 -0.2789 -0.5211 -1.3132 -0.1947 -0.3463 -1.5292 -0.0783 -0.0356 -0.3829 -0.2591
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology heart_failure_with_preserved_ejection_fraction hfpef myocardial_extracellular_matrix
H-734	-0.5597367882728577	▁pat ho phy si ology ▁heart _ fail ure ▁pres er ved _ e je ction _ fraction ▁h f f ▁my o card ial _ extra cel lular _ ▁matri x _ accumul ation
D-734	-0.5597367882728577	pathophysiology heart_failure preserved_ejection_fraction hff myocardial_extracellular_ matrix_accumulation
P-734	-0.8634 -0.3979 -0.0183 -1.2782 -0.0393 -0.6040 -0.2314 -0.9096 -2.0253 -1.0200 -0.1683 -0.2799 -0.2897 -0.1867 -0.3392 -0.0718 -0.2898 -0.0114 -0.1675 -0.7356 -0.2882 -1.2918 -0.3058 -0.6030 -0.4076 -0.3944 -1.3723 -0.7603 -0.2432 -0.1362 -1.6780 -0.3762 -0.4926 -0.3446 -1.2502 -0.5898 -0.2487
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing cardiac_arrest advantage pulseless_ventricular_fibrillation pvf implanted cardioverter-defibrillator_device
H-1346	-0.577488899230957	▁breath ing _ control ▁cardiac _ ▁arrest ▁puls e less _ vent ri cular _ fi bril lation PV f ▁implant ed ▁cardio ver ter - de fi br illa tor _ ▁device
D-1346	-0.577488899230957	breathing_control cardiac_ arrest pulseless_ventricular_fibrillationPVf implanted cardioverter-defibrillator_ device
P-1346	-0.6142 -0.1862 -0.6078 -0.0068 -0.0287 -0.1673 -1.6313 -0.3633 -0.2476 -0.1391 -0.4595 -0.7206 -0.5198 -0.1794 -0.2898 -1.0478 -0.2715 -0.2121 -2.0845 -0.4789 -0.0095 -0.0874 -1.5391 -0.0908 -0.1551 -0.3276 -0.0725 -1.0063 -1.2309 -0.1894 -0.1692 -0.3383 -4.0393 -0.4820 -0.2186
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal_probnp nt-probnp midregional_proanp mr-proanp adiponectin elevated chf correlated bmi
H-14	-0.8014361262321472	▁pro b NP ▁t - pro b NP ▁mid region al _ pro an p ▁m - pro an p ▁adi pon ect in ▁CHF ▁b mi ▁FM
D-14	-0.8014361262321472	probNP t-probNP midregional_proanp m-proanp adiponectin CHF bmi FM
P-14	-1.2977 -1.6970 -0.8965 -2.5840 -0.1892 -0.1839 -1.4021 -0.9155 -0.3321 -0.3084 -0.0556 -0.4375 -0.1779 -2.6600 -0.6852 -1.5404 -0.6904 -0.0294 -1.5866 -0.6507 -0.2097 -0.0309 -0.0393 -0.4455 -0.4619 -0.8453 -1.1305 -1.8905 -0.4389 -0.2304
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase_inhibitor pyridostigmine sympathovagal_balance cardiac_remodeling cardiac_function hf myocardial_infarction
H-1136	-0.45971500873565674	▁a ce tyl cho line ster ase _ ▁inhibi tor _ ▁py rido stig mine ▁sympa t hova gal _ ▁balance ▁cardiac _ ▁remodel ing ▁cardiac _ function ▁h f ▁my o card ial _ in far ction
D-1136	-0.45971500873565674	acetylcholinesterase_ inhibitor_ pyridostigmine sympathovagal_ balance cardiac_ remodeling cardiac_function hf myocardial_infarction
P-1136	-0.2136 -0.1330 -0.2564 -0.8369 -0.1145 -0.6044 -0.5310 -0.3426 -0.4800 -0.0661 -0.3643 -0.5549 -0.0239 -0.0020 -0.1689 -0.1252 -0.3539 -0.1335 -0.1473 -0.4071 -0.8827 -0.0524 -0.7221 -1.2349 -0.0691 -0.0491 -0.5943 -0.2037 -0.5441 -2.2152 -1.5591 -0.7818 -1.1867 -0.8261 -0.3560 -0.2747 -0.0239 -0.3303 -0.3759 -0.2471
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac_sympathetic_activity β-blocker
H-1112	-0.35064008831977844	▁cardiac _ ▁sympa the tic _ activ ity ▁i - meta - i odob enz yl guan i dine ▁i - mi BG ▁β - block er
D-1112	-0.35064008831977844	cardiac_ sympathetic_activity i-meta-iodobenzylguanidine i-miBG β-blocker
P-1112	-0.2610 -0.3970 -1.2618 -0.1690 -0.1557 -0.7385 -0.1201 -0.0752 -0.2263 -0.1113 -0.1528 -0.0971 -0.2058 -0.1768 -0.1487 -0.9908 -0.0307 -0.1692 -0.0628 -0.0744 -0.0989 -0.9522 -1.1910 -0.4100 -0.0701 -0.7596 -0.4601 -0.3603 -0.2416
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based heart_disease therapies patients cabg sweden
H-971	-0.6183879375457764	▁Swedish _ web - system _ for _ en han ce ment _ and _ develop ment _ of _ e viden ce - based _ care ▁Heart _ ▁disease ▁Therapie s ▁primary _ isola ted _ ca b ▁stockholm
D-971	-0.6183879375457764	Swedish_web-system_for_enhancement_and_development_of_evidence-based_care Heart_ disease Therapies primary_isolated_cab stockholm
P-971	-0.7160 -2.2121 -0.2006 -0.0654 -0.0800 -0.3790 -0.3976 -0.5652 -0.7377 -0.8604 -0.6901 -0.0132 -0.3152 -0.4945 -0.3618 -0.8122 -0.1736 -0.3141 -0.4130 -0.4690 -0.7815 -0.0293 -0.1496 -0.0386 -0.0090 -0.1636 -0.3815 -0.5907 -0.1379 -1.5624 -3.5443 -0.1685 -2.7889 -0.4498 -0.1810 -0.0395 -0.4498 -0.0265 -1.6596 -1.9022 -0.4412 -0.2058
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef clinical reverse_remodeling death hf hospitalization hazard_ratio
H-756	-0.5637786984443665	▁LV EF ▁rever se _ re duction ing ▁time _ to _ ▁death ▁h z haz ard _ rati o
D-756	-0.5637786984443665	LVEF reverse_reductioning time_to_ death hzhazard_ratio
P-756	-0.1823 -0.9312 -0.0737 -0.0768 -0.1659 -0.4715 -2.1124 -0.9025 -1.0926 -0.6243 -0.6038 -0.3035 -0.6242 -0.5796 -2.0618 -0.3862 -0.1676 -0.1960 -0.0340 -0.0423 -0.4874 -0.2835
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients brain_natriuretic_peptide bnp bnp patients bnp bnp
H-1569	-0.7276570200920105	▁brain _ ▁na tri ure tic _ pe pti de ▁b NP ▁b NP ▁b NP
D-1569	-0.7276570200920105	brain_ natriuretic_peptide bNP bNP bNP
P-1569	-0.5943 -0.3040 -1.0104 -0.0798 -0.0227 -0.2807 -0.2183 -0.5592 -0.3236 -0.4118 -0.3815 -1.5160 -0.7597 -1.7356 -0.7817 -1.6804 -2.2193 -0.2189
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde pde2 cgmp leading camp_hydrolysis cross_talk cgmp camp_signaling
H-1210	-0.7823709845542908	▁p de ▁p de ▁p de 2 ▁c g MP ▁c AMP _ hydro lys is ▁cross _ talk ▁c g MP ▁c AMP _ signal ing
D-1210	-0.7823709845542908	pde pde pde2 cgMP cAMP_hydrolysis cross_talk cgMP cAMP_signaling
P-1210	-0.2864 -0.0405 -0.7040 -0.0318 -3.5623 -0.0283 -0.0215 -0.1073 -0.7939 -2.4771 -0.2230 -3.1365 -0.4316 -0.2667 -0.4579 -0.5477 -0.6134 -0.2547 -1.1259 -0.0590 -0.7558 -2.4934 -0.1156 -2.0650 -1.0253 -0.2193 -0.2537 -0.3323 -0.2590
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse longitudinal_rv_fiber_shortening pasp rv in_vivo rv prognosis
H-493	-0.8310614228248596	▁t pac se long itud in al _ RV _ fi ber _ short en ing ▁PAS p force ▁ RV ▁in _ ▁vivo ▁ RV ▁length - force _ re lation ship ▁ratio
D-493	-0.8310614228248596	tpacselongitudinal_RV_fiber_shortening PASpforce RV in_ vivo RV length-force_relationship ratio
P-493	-1.4819 -1.8573 -0.6713 -0.0936 -0.2167 -0.9283 -0.2021 -0.6263 -1.7298 -0.3591 -2.1940 -0.8360 -0.4156 -0.8271 -0.3477 -0.1405 -1.3760 -0.8871 -0.2189 -1.8026 -0.9248 -1.5100 -0.7210 -0.1939 -1.7568 -0.8652 -0.1751 -0.2067 -0.0319 -0.8898 -2.6137 -0.3299 -0.0819 -1.8026 -0.3423 -0.2606
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides szeto-schiller ss ss20 cardiac_function proteomic_remodeling signaling_pathways
H-870	-0.484998881816864	▁mito cho ndri al - tar get ed _ ▁antioxidant ▁Sze to - sch iller ▁SS 20 ▁cardiac _ function ▁prote om ic _ ▁remodel ing
D-870	-0.484998881816864	mitochondrial-targeted_ antioxidant Szeto-schiller SS20 cardiac_function proteomic_ remodeling
P-870	-0.5963 -1.2141 -0.4982 -0.2897 -0.2473 -0.0395 -0.1049 -0.0267 -0.2280 -1.0357 -0.0484 -0.1469 -0.2127 -2.0576 -0.4518 -1.7996 -0.1478 -0.0418 -0.6912 -0.1715 -0.0968 -0.8268 -0.4727 -0.4588 -0.6729 -0.0445 -0.7353 -0.2227
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2017	-1.026090145111084	▁economic ▁Heart _ fail ure ▁cost - effect ive ness _ model ▁disease _ management ▁heart _ fail ure
D-2017	-1.026090145111084	economic Heart_failure cost-effectiveness_model disease_management heart_failure
P-2017	-0.6803 -2.0524 -0.3193 -0.5586 -0.1547 -1.0535 -0.1359 -3.6192 -0.6333 -1.5179 -1.4106 -0.6839 -2.6923 -0.5596 -0.1955 -2.2247 -0.3253 -1.3996 -0.7392 -0.3190 -0.2730
2021-01-18 18:33:46 | INFO | fairseq.logging.progress_bar | :    101 / 145 wps=199
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization admissions patient
H-900	-0.18113023042678833	▁re - hospital ization ▁ad missions
D-900	-0.18113023042678833	re-hospitalization admissions
P-900	-0.4328 -0.1403 -0.0414 -0.1882 -0.0320 -0.0325 -0.3995 -0.1824
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes coprimary_end_points end_point change serum_cystatin_c renal_function end_point
H-79	-0.7090217471122742	▁co prima ry _ end _ point s ▁cum ul ative _ ▁urin e _ ▁volume ▁de con gestion ▁change ▁se rum _ ▁cyst atin _ c ren al _ function _ end _ point
D-79	-0.7090217471122742	coprimary_end_points cumulative_ urine_ volume decongestion change serum_ cystatin_crenal_function_end_point
P-79	-0.6297 -0.0159 -0.2077 -0.3459 -3.0509 -0.6478 -0.9293 -0.0738 -0.2970 -0.1022 -0.1729 -0.3246 -1.5908 -0.4287 -1.4654 -1.3657 -1.3785 -0.0487 -0.0163 -1.3472 -0.3932 -0.1307 -0.2817 -0.3977 -0.7898 -1.8350 -0.1829 -2.1664 -0.1395 -0.3238 -0.2787 -1.3186 -1.9538 -0.3462 -0.5732 -0.4614 -0.2223
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical cardiac_arrest cardiopulmonary_resuscitation cpr diagnosis posterior_wall_infarction hospitalized cardiac
H-1291	-0.8570303916931152	▁cardiac _ ▁arrest ▁cardio pul mon ary _ re uscita tion ▁c PR ▁posterior _ wall _ in far ction ▁cardiac _ centre
D-1291	-0.8570303916931152	cardiac_ arrest cardiopulmonary_reuscitation cPR posterior_wall_infarction cardiac_centre
P-1291	-3.1916 -0.1480 -2.4410 -0.2068 -1.0035 -3.3959 -0.1493 -0.3074 -0.5260 -0.3668 -0.3211 -0.7333 -2.2381 -0.0585 -0.2992 -1.6713 -0.3249 -0.1393 -0.0211 -0.3253 -0.0925 -0.9093 -1.7812 -0.5088 -0.2655
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients patients type_2_diabetes therapy saxagliptin sitagliptin pioglitazone second-generation_sulfonylureas insulin
H-1831	-0.5061274170875549	▁diabetes ▁sax ag lip tin ▁si tag lip tin ▁pi og lita zone ▁second - genera tion _ ▁sul fon yl ure as ▁insulin
D-1831	-0.5061274170875549	diabetes saxagliptin sitagliptin pioglitazone second-generation_ sulfonylureas insulin
P-1831	-0.6906 -0.2347 -0.0221 -0.4796 -2.0996 -0.4617 -0.0009 -0.1148 -2.3210 -0.0229 -0.1345 -0.0782 -0.0912 -0.0956 -0.1140 -0.0401 -0.0591 -0.3533 -3.0307 -0.0353 -0.8373 -0.1395 -0.0603 -0.5312 -0.8495 -0.2615
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence hyperkalemia mineralocorticoid_receptor_antagonists mineralocorticoid_receptor_antagonists heart_failure hf
H-1702	-1.1275426149368286	▁hyper kal emia ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁race ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁heart _ fail ure ▁h z
D-1702	-1.1275426149368286	hyperkalemia mineralocorticoid_ receptor_ antagonists race mineralocorticoid_ receptor_ antagonists heart_failure hz
P-1702	-0.3455 -0.7511 -0.4404 -0.2282 -0.7767 -2.3909 -3.4757 -2.4061 -0.1460 -1.2547 -0.5179 -0.5083 -0.1061 -2.2346 -0.2899 -0.8290 -0.8847 -2.3545 -4.2508 -2.3746 -0.2504 -1.1200 -0.9181 -0.2711 -0.1198 -2.3348 -0.3116 -0.2508 -1.0881 -2.1587 -0.7622 -1.5671 -0.3758 -0.2423
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade evidence acp erythropoiesis-stimulating_agents patients anemia congestive_heart_failure coronary_heart_disease
H-37	-0.7767005562782288	▁evidence ▁ab p ▁er y thro po ies is - stimul ating _ agent s ▁an emia ▁con ges tive _ heart _ fail ure ▁corona ry _ heart _ ▁Disease
D-37	-0.7767005562782288	evidence abp erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_ Disease
P-37	-0.6883 -2.4837 -0.8858 -0.1766 -0.2988 -0.6785 -0.1621 -2.4931 -0.2358 -1.6483 -0.6125 -0.3110 -0.3825 -0.4693 -0.2295 -0.7752 -0.1039 -0.0985 -0.1716 -0.8872 -0.4018 -1.7944 -0.2869 -1.8687 -0.9027 -0.0215 -0.4487 -0.3744 -2.5153 -0.4317 -2.0988 -0.4159 -0.2780
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory patients heart_failure hf reduced_ejection_fraction renin-angiotensin_system ras β-blockers all-cause_mortality readmissions
H-175	-0.6628862023353577	▁heart _ ▁failure HF ▁e je ction _ fraction r EF ▁re nin - angi oten sin _ system RAS ▁β - block ers
D-175	-0.6628862023353577	heart_ failureHF ejection_fractionrEF renin-angiotensin_systemRAS β-blockers
P-175	-2.6179 -0.2928 -3.0380 -0.6444 -0.3551 -0.1722 -0.0867 -0.3387 -0.0096 -0.9566 -0.7648 -0.0127 -1.1441 -0.3283 -0.1294 -0.0436 -1.3449 -0.3084 -0.1027 -0.7606 -0.7313 -0.0375 -0.5253 -0.1101 -2.1058 -0.2737
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr scn5a ventricular_systolic_hf human_induced_pluripotent_stem_cell-derived_cardiomyocytes hipsc-cms
H-1082	-0.6111032366752625	▁u PR ▁s cn 5 a ▁vent ri cular _ sy sto lic ▁h z ▁induc ed _ ▁pluri potent _ ▁stem _ cell - der i ved _ ▁cardio my o cy tes hi PS c - CM s
D-1082	-0.6111032366752625	uPR scn5a ventricular_systolic hz induced_ pluripotent_ stem_cell-derived_ cardiomyocyteshiPSc-CMs
P-1082	-0.1412 -3.3387 -0.2077 -0.3446 -0.1163 -0.0993 -0.1045 -0.6844 -0.2892 -0.7050 -1.2068 -0.3465 -0.2694 -1.5396 -1.5586 -0.0257 -0.1040 -0.4346 -0.9284 -0.0235 -1.0505 -0.3075 -0.4296 -0.2622 -0.5697 -0.2299 -0.4551 -0.0839 -0.4455 -0.2435 -1.9535 -0.2632 -0.0597 -0.6806 -2.1880 -1.2219 -0.2225 -0.0556 -1.7680 -0.0604 -0.4137 -0.2339
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd chf crf icc kappa_coefficients
H-802	-0.6731249094009399	▁co PD ▁CHF ▁c RF ▁i cc ▁ka ppa _ co ef fici ents
D-802	-0.6731249094009399	coPD CHF cRF icc kappa_coefficients
P-802	-0.8331 -3.3121 -0.1861 -1.2665 -2.5836 -0.2532 -0.0170 -0.9489 -0.0333 -0.1710 -0.1677 -0.0792 -0.0134 -0.1471 -0.4812 -0.2767
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient implantable_cardioverter-defibrillator implant change clinical
H-1865	-0.5578809976577759	▁implant able ▁cardio ver ter - de fi br illa tor _ de activa tion ▁implant
D-1865	-0.5578809976577759	implantable cardioverter-defibrillator_deactivation implant
P-1865	-0.0284 -0.1442 -1.2289 -0.1854 -0.2489 -0.4201 -0.1490 -1.2471 -1.5142 -0.0799 -0.4109 -0.6582 -0.1187 -0.2439 -0.3163 -0.0324 -2.7730 -0.2423
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients stable_heart_failure left_ventricular_ejection_fraction training training
H-1913	-0.765133261680603	▁heart _ fail ure ▁left _ vent ri cular _ e je ction _ fraction ▁aero bic ▁dynamic _ ▁resist ance _ training ▁lower _ ▁lim bs
D-1913	-0.765133261680603	heart_failure left_ventricular_ejection_fraction aerobic dynamic_ resistance_training lower_ limbs
P-1913	-2.8935 -0.5670 -0.7956 -1.6206 -0.3686 -0.4683 -0.6941 -0.9940 -0.1904 -0.3856 -0.2597 -0.5125 -0.1787 -0.2518 -0.0413 -0.0844 -0.5358 -0.0596 -0.4511 -3.9925 -0.0572 -1.1785 -0.4476 -0.2896 -0.4397 -1.5322 -2.1970 -0.4254 -0.2767
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients heart_failure myocardial_function dilated contracting ventricles aetiologies
H-987	-0.9898287653923035	▁heart _ fail ure ▁my o card ial _ function ▁vent ric les
D-987	-0.9898287653923035	heart_failure myocardial_function ventricles
P-987	-1.5630 -0.2994 -1.1756 -2.3924 -1.7816 -0.3623 -0.8464 -0.8012 -0.2961 -0.2807 -0.3414 -2.7351 -1.1233 -0.5816 -0.2672
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial cochrane_effective_practice_and_organisation_of_care_taxonomy
H-1847	-0.6121435761451721	▁decision - support ▁financial ▁co ch rane ▁organisation _ of _ care _ tax ono my
D-1847	-0.6121435761451721	decision-support financial cochrane organisation_of_care_taxonomy
P-1847	-1.6253 -0.1084 -0.1169 -0.0303 -1.8314 -0.5732 -0.2363 -0.7163 -0.3268 -0.0637 -0.3924 -0.2213 -0.2584 -0.1848 -0.3785 -3.2868 -0.4078 -0.2599
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad q65p murine rad q66p l-type_currents cav1.2 cav1.3 wild-type_rad
H-1675	-0.8803911209106445	▁mouse _ rad _ q 65 p ▁mur ine ▁human _ rad _ q 66 p ▁current s ▁ca v 1.2 ▁ca v 1.3 ▁rad
D-1675	-0.8803911209106445	mouse_rad_q65p murine human_rad_q66p currents cav1.2 cav1.3 rad
P-1675	-0.0673 -0.3588 -0.6657 -1.9250 -1.3218 -0.2635 -1.0509 -0.5148 -0.4944 -3.3315 -0.4740 -0.8842 -1.7986 -1.2256 -0.4445 -0.6509 -1.5285 -0.3511 -0.1682 -1.1300 -0.4121 -0.5073 -1.1993 -0.1320 -2.2691 -0.3789 -0.2226
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients implantable_cardioverter-defibrillator patients implantable_cardioverter-defibrillator
H-1866	-0.7687293291091919	▁implant able _ ▁cardio ver ter - de fi br illa tor _ de activa tion ▁implant able _ ▁cardio ver ter - de fi br illa tor _ ▁shock s
D-1866	-0.7687293291091919	implantable_ cardioverter-defibrillator_deactivation implantable_ cardioverter-defibrillator_ shocks
P-1866	-0.0194 -0.1717 -1.2685 -0.4610 -0.4209 -0.5448 -0.6034 -0.3050 -2.8720 -2.8741 -0.3085 -0.7645 -0.1873 -0.1146 -0.3203 -0.3909 -0.0473 -0.2389 -1.0035 -0.6240 -0.3667 -0.5408 -0.5908 -0.1372 -2.5335 -2.3610 -0.4015 -0.4732 -0.1930 -3.0635 -0.2881 -0.5829 -0.2953
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart_failure hf hypertensive_heart_disease hhd pathophysiology therapeutic hhd stable phenotypes
H-274	-0.7461687326431274	▁mouse _ ▁heart _ fail ure HF ▁hyper tensi ve _ heart _ ▁disease ▁h d h ▁pat ho phy si ology ▁h d h
D-274	-0.7461687326431274	mouse_ heart_failureHF hypertensive_heart_ disease hdh pathophysiology hdh
P-274	-0.0490 -0.3611 -1.4347 -0.1867 -1.1065 -1.8135 -1.2332 -0.0600 -0.1645 -0.0714 -0.2628 -2.4389 -0.1520 -2.3433 -0.2065 -0.9241 -1.2778 -0.8511 -0.1846 -0.0235 -0.8716 -0.0416 -0.3928 -0.5317 -2.6132 -0.3493 -0.2013
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient mi hazard_ratios hf
H-1108	-0.7292221784591675	▁MI ▁hazard _ rati os ▁h f
D-1108	-0.7292221784591675	MI hazard_ratios hf
P-1108	-1.3337 -0.4830 -0.3104 -0.0456 -0.2238 -1.3156 -2.2245 -0.3022 -0.3242
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare patients acute hospital hf ami pna
H-1693	-0.8777758479118347	▁Medica re ▁a cute _ care _ hospital ▁h f AMI ▁p na
D-1693	-0.8777758479118347	Medicare acute_care_hospital hfAMI pna
P-1693	-2.7590 -0.0217 -0.8546 -0.0894 -0.1979 -0.3680 -0.2811 -0.3389 -0.4809 -2.3218 -3.2765 -0.5475 -0.8577 -0.4841 -0.2875
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt nt-probnp aric hf aucs nris
H-289	-0.7639681696891785	▁c t n t ▁NT - pro b NP ▁a RIC _ HF _ model ▁ab c s ▁NR Is
D-289	-0.7639681696891785	ctnt NT-probNP aRIC_HF_model abcs NRIs
P-289	-0.0239 -0.1642 -0.0460 -0.1603 -0.1903 -0.0492 -0.0340 -0.6761 -0.6310 -0.2137 -2.2964 -0.2831 -1.5814 -2.0802 -0.1375 -3.6347 -0.5157 -0.3020 -0.2187 -2.8227 -0.5407 -0.2054
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular_events baseline sst2 metoprolol_succinate
H-404	-0.7783282995223999	▁cardio vas cular _ event s ▁base line ▁s st 2 ▁BB _ ▁dose ▁met o pro lol _ ▁suc cina te
D-404	-0.7783282995223999	cardiovascular_events baseline sst2 BB_ dose metoprolol_ succinate
P-404	-1.5516 -0.9635 -0.4641 -0.8714 -3.8145 -0.0664 -0.0231 -0.0561 -0.4844 -1.1187 -0.0519 -2.9955 -1.9060 -1.0776 -0.2876 -0.3162 -0.0880 -0.6877 -0.2901 -0.9030 -0.0225 -0.1174 -0.3559 -0.1669
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl nyha-iiib phosphorylation phosphorylation hdl healthy
H-255	-0.8488526940345764	▁ phos phor y lation ▁e NOS - Ser ▁ phos phor y lation ▁e NOS - th r ▁HD l
D-255	-0.8488526940345764	phosphorylation eNOS-Ser phosphorylation eNOS-thr HDl
P-255	-2.9029 -2.3150 -1.1884 -1.0855 -0.1359 -0.5183 -0.1243 -0.1215 -0.9148 -0.2144 -0.6884 -1.4117 -1.2094 -0.1443 -0.3556 -0.1112 -0.0936 -0.7089 -0.0276 -1.6136 -2.9571 -0.4527 -0.2285
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients hospitalized hf preserved_lvef mortality patients lvef lvef mortality
H-117	-0.8275551199913025	▁h f ▁LV EF ▁LV EF ▁LV EF ▁long - term _ ▁mortal ity
D-117	-0.8275551199913025	hf LVEF LVEF LVEF long-term_ mortality
P-117	-1.3796 -0.3105 -1.0328 -1.0531 -1.2643 -0.8466 -1.1044 -1.0017 -1.8598 -0.2443 -1.1041 -0.2302 -0.7048 -0.3415 -0.4845 -0.2787
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic_reticular protein phospholamban infarcted hearts metoprolol
H-1551	-0.6944479942321777	▁sar co plas mic _ ▁reti cular SR ▁protein ▁SR ▁ phos pho lam ban ▁in far cted _ heart s ▁met o pro lol
D-1551	-0.6944479942321777	sarcoplasmic_ reticularSR protein SR phospholamban infarcted_hearts metoprolol
P-1551	-0.1461 -0.1107 -0.7189 -2.6188 -0.2169 -1.1343 -0.6809 -0.8461 -0.3190 -1.4190 -2.7783 -0.2379 -0.3039 -1.7429 -0.2934 -0.2050 -0.0592 -0.7507 -0.2708 -1.9537 -0.2524 -0.2054 -0.2262 -0.0859 -0.6006 -0.3632 -0.2099
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global_left_ventricular_longitudinal_systolic_strain gls left_ventricular cardiovascular atrial_fibrillation
H-809	-0.6618748307228088	▁left _ vent ri cular _ ▁longitud in al _ sy sto lic _ ▁strain ▁gr s ▁left _ vent ri cular _ ▁mechanic s ▁cardiovascular CV ▁at rial _ fi bril lation AF
D-809	-0.6618748307228088	left_ventricular_ longitudinal_systolic_ strain grs left_ventricular_ mechanics cardiovascularCV atrial_fibrillationAF
P-809	-1.3662 -0.4356 -1.3593 -1.2190 -0.4545 -0.4395 -0.6425 -0.3698 -0.1525 -0.3542 -1.9732 -0.7136 -0.3864 -0.2694 -1.0611 -1.2035 -0.7566 -1.5437 -0.4539 -1.2276 -0.9521 -0.3668 -0.4050 -0.8774 -0.2518 -0.0419 -0.5350 -0.5433 -0.2187 -0.4002 -1.2241 -0.0775 -0.1549 -0.7590 -0.3811 -0.2568
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf hf_with_reduced_ef hf_with_preserved_ef change hf mi
H-1109	-1.4722291231155396	▁early - ons et ▁late - ons et _ HF ▁h f ▁EF ▁ HF ▁f f ▁change ▁ HF ▁MI
D-1109	-1.4722291231155396	early-onset late-onset_HF hf EF HF ff change HF MI
P-1109	-2.1719 -0.1475 -0.1313 -0.3486 -2.7068 -0.0633 -0.0899 -0.3069 -1.6252 -1.5733 -2.7758 -1.3779 -2.4680 -2.3784 -1.4526 -3.9795 -1.3551 -1.5861 -2.5004 -1.4714 -2.6965 -0.3927 -0.2621
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol von_willebrand_factor metoprolol β2-adrenergic_receptor_haplotype
H-1118	-0.45860475301742554	▁car vedi lol ▁von _ Will e brand _ factor ▁met o pro lol ▁β 2- ad r energi c _ ▁receptor _ ha plo type
D-1118	-0.45860475301742554	carvedilol von_Willebrand_factor metoprolol β2-adrenergic_ receptor_haplotype
P-1118	-1.4585 -0.0340 -0.5761 -0.6983 -0.4194 -3.0353 -0.2931 -0.0162 -0.4097 -0.0215 -0.1290 -0.2031 -0.0456 -0.7775 -0.1322 -0.2725 -0.3856 -0.6490 -0.2165 -0.1973 -0.1670 -0.4453 -0.4521 -0.8760 -0.3092 -0.0142 -0.4096 -0.1972
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise intramuscular_testosterone_supplementation patients chronic_heart_failure chf testosterone collected health outcomes
H-1317	-0.9842172265052795	▁exercise ▁intra mus cular _ ▁testosteron e ▁chronic _ heart _ fail ure ▁ch f ▁low _ ▁testosteron e ▁health _ ▁outcome s
D-1317	-0.9842172265052795	exercise intramuscular_ testosterone chronic_heart_failure chf low_ testosterone health_ outcomes
P-1317	-1.0676 -2.9570 -0.0592 -0.5107 -0.4787 -0.5452 -0.2069 -2.0158 -0.3067 -2.3079 -0.2908 -1.1513 -1.1003 -2.4550 -1.0211 -0.6583 -0.3465 -1.2355 -0.4778 -0.8391 -1.4032 -2.3047 -0.1390 -0.4678 -0.2595
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart_failure hf plasma_b-type_natriuretic_peptide bnp preserved_ejection_fraction ef hf
H-187	-0.7386539578437805	▁heart _ fail ure HF ▁plasma ▁na tri ure tic _ pe pti de ▁b NP ▁e je ction _ fraction ▁ef HF ▁sex
D-187	-0.7386539578437805	heart_failureHF plasma natriuretic_peptide bNP ejection_fraction efHF sex
P-187	-0.5427 -0.2991 -1.6184 -1.5555 -1.5481 -0.4794 -1.2851 -0.1962 -0.0792 -0.4064 -0.2034 -0.6453 -0.1966 -0.6392 -0.4870 -1.4817 -0.4680 -0.2697 -0.0913 -0.2326 -0.0136 -2.4157 -2.8101 -0.5309 -0.5074 -0.2024
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls left_ventricular_ejection_fraction lvef systolic_mitral_annulus_velocity multivariate_models
H-818	-0.8387137055397034	▁gr s ▁left _ vent ri cular _ e je ction _ fraction LV EF ▁sy sto lic _ met ral _ ann ulus _ velo city ▁CV _ event s
D-818	-0.8387137055397034	grs left_ventricular_ejection_fractionLVEF systolic_metral_annulus_velocity CV_events
P-818	-0.7760 -0.9902 -0.8399 -0.4167 -0.9747 -0.7574 -0.3423 -0.4257 -0.4951 -0.6824 -0.4582 -0.2591 -0.0377 -0.9911 -0.9188 -0.6921 -0.5529 -0.5044 -0.4187 -2.1944 -0.1481 -0.3558 -5.3270 -1.2794 -0.2210 -0.0190 -0.1060 -1.6021 -1.5054 -2.4624 -0.0590 -0.5880 -0.2765
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm telemonitoring implanted medical structured_telephone_support sts human-to-human_contact hh human-to-machine_interface
H-153	-0.7421632409095764	▁RM ▁home _ monitor ing ▁implant ed _ monitor ing ▁medical ▁s s ▁contact ▁h h ▁human - to - machine _ ▁interface ▁h m
D-153	-0.7421632409095764	RM home_monitoring implanted_monitoring medical ss contact hh human-to-machine_ interface hm
P-153	-0.6689 -0.6038 -0.3050 -3.4489 -0.0248 -0.9858 -0.1277 -0.3659 -0.0634 -0.0302 -1.5494 -2.6225 -0.8154 -1.5167 -0.1175 -0.8793 -1.4334 -0.0920 -0.2204 -0.2250 -0.3179 -0.3863 -1.2958 -0.2591 -1.1854 -0.2867 -0.2112
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug patients chronic_obstructive_pulmonary_disease copd chronic_heart_failure chf chronic_renal_failure crf
H-794	-1.1127606630325317	▁time d _ up _ and _ go ▁tu g ▁chronic _ ob struct ive _ ▁pulmonar y _ ▁disease ▁co PD ▁chronic _ heart _ fail ure ▁ch f ▁chronic _ ▁renal _ fail ure ▁cr f
D-794	-1.1127606630325317	timed_up_and_go tug chronic_obstructive_ pulmonary_ disease coPD chronic_heart_failure chf chronic_ renal_failure crf
P-794	-1.6149 -1.7085 -0.3891 -0.6250 -0.6902 -1.9018 -0.4097 -0.8890 -0.4872 -1.3551 -2.0073 -0.4132 -1.1589 -0.1434 -0.2193 -0.3150 -0.6719 -0.2256 -0.4141 -2.0066 -2.0202 -3.7952 -0.4287 -0.3285 -2.4017 -0.3490 -1.5904 -1.5373 -3.0897 -1.4368 -1.0136 -0.2749 -1.5099 -0.4504 -0.7521 -1.8344 -2.7639 -0.7296 -0.2513 -0.3074
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox_regression_analysis patients beta-blockers beta-blockers primary_endpoint therapy antitachycardia_pacing atp shock_therapy
H-859	-0.5223761200904846	▁co x _ re gression ▁beta - block ers ▁beta - block ers ▁anti ta chy car dia _ pa cing ▁a TP ▁shock _ therapy
D-859	-0.5223761200904846	cox_regression beta-blockers beta-blockers antitachycardia_pacing aTP shock_therapy
P-859	-0.5363 -0.2426 -0.2891 -0.1025 -0.0665 -1.7405 -0.1173 -1.1956 -0.3065 -0.4878 -0.2052 -0.9364 -0.3715 -0.3294 -0.4768 -0.4159 -0.0651 -0.0992 -0.3215 -0.9140 -0.4195 -2.0542 -1.5700 -0.1292 -0.3839 -0.2056 -0.3858 -0.2585
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically legal decisions
H-1680	-0.7377221584320068	▁et h ically ▁religious _ be havi our s ▁legal ▁decisions
D-1680	-0.7377221584320068	ethically religious_behaviours legal decisions
P-1680	-0.2356 -0.4350 -0.1726 -1.6552 -0.4920 -0.1539 -2.1644 -0.1216 -0.0850 -0.4065 -3.0417 -0.3846 -0.2423
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient prescribing medications medical
H-1122	-0.8095765709877014	▁medical _ re cord s ▁performance _ me chan ism s
D-1122	-0.8095765709877014	medical_records performance_mechanisms
P-1122	-2.2067 -1.1800 -0.8319 -0.7153 -1.2459 -0.4033 -0.4114 -1.0280 -1.4449 -0.0260 -0.3343 -0.4687 -0.2280
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost patient rhythm-control rate-control
H-1241	-0.34869956970214844	▁cost ▁ rhythm - control ▁rate - control
D-1241	-0.34869956970214844	cost rhythm-control rate-control
P-1241	-0.0493 -0.3504 -0.7811 -0.3716 -0.0110 -0.6483 -0.3493 -0.0222 -0.5865 -0.3172
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left_ventricular_ejection_fraction egfr
H-393	-0.8339859247207642	▁left _ vent ri cular _ e je ction _ fraction ▁e g FR ▁m l
D-393	-0.8339859247207642	left_ventricular_ejection_fraction egFR ml
P-393	-2.9421 -0.3801 -0.5903 -0.6155 -0.1722 -0.5667 -0.3118 -0.4460 -0.2407 -0.2475 -0.0467 -0.4695 -0.7780 -2.0321 -0.0362 -3.5154 -1.2998 -0.3210
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells functional_capacity cells peak_vo2
H-127	-1.033463716506958	▁cd 34 _ ve g f 2 _ cell s ▁functional _ capaci ty ▁cd 34 _ ve g f 2 _ cell s ▁pe ak _ vo 2
D-127	-1.033463716506958	cd34_vegf2_cells functional_capacity cd34_vegf2_cells peak_vo2
P-127	-1.3535 -0.2666 -3.5312 -0.7399 -0.9889 -2.7802 -0.0982 -2.2129 -0.7519 -0.1895 -0.2573 -0.3173 -0.0977 -0.0354 -3.0922 -0.3579 -3.5482 -1.9250 -1.2029 -2.8996 -0.0743 -1.9885 -0.9298 -0.2128 -0.8578 -0.0847 -0.1564 -0.0997 -0.3449 -0.4050 -0.2372
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf hazard_ratios body_mass_index obese
H-1773	-0.6566627621650696	▁fit ▁un fit ▁c RF _ dis tribution ▁hazard _ rati os ▁fit ▁un fit ▁over weight _ ▁Body _ ▁mass _ index ▁obes e
D-1773	-0.6566627621650696	fit unfit cRF_distribution hazard_ratios fit unfit overweight_ Body_ mass_index obese
P-1773	-0.0984 -0.6336 -0.0332 -0.3493 -1.0157 -2.3893 -0.0835 -0.0016 -0.3618 -0.6704 -0.0407 -0.2882 -1.2315 -1.0040 -0.0642 -0.4611 -0.2085 -1.1859 -1.2518 -0.4101 -1.4768 -0.1953 -0.6428 -0.5667 -1.0147 -1.8006 -0.2502
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare_patient_safety_monitoring_system mpsms adverse_event patients hospitalized acute_myocardial_infarction congestive_heart_failure pneumonia conditions surgery
H-2	-0.6468047499656677	▁Medica re ▁Patient _ ▁Safety _ monitor ing _ system ▁mp s ▁advers e _ event _ rate s ▁a cute _ My o card ial _ in far ction ▁con ges tive _ heart _ ▁failure ▁pneu monia ▁conditions ▁surgery
D-2	-0.6468047499656677	Medicare Patient_ Safety_monitoring_system mps adverse_event_rates acute_Myocardial_infarction congestive_heart_ failure pneumonia conditions surgery
P-2	-0.1350 -0.0181 -1.2539 -0.2873 -0.7726 -0.2456 -0.0245 -0.0384 -0.2498 -0.1654 -1.1233 -1.0494 -1.7350 -0.2086 -0.1359 -2.5709 -0.7757 -1.4718 -0.0441 -0.8736 -0.0215 -0.2166 -4.5713 -0.6618 -0.3326 -0.6830 -0.2461 -0.4744 -0.0647 -0.3425 -0.0676 -0.0640 -0.5360 -0.3557 -1.9266 -0.2559 -1.6786 -0.0019 -1.1855 -0.3097 -0.0567 -0.3587 -0.2219
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi blood_urea_nitrogen b-type_natriuretic_peptide new_york_heart_association_class diabetes atrial_fibrillation all-cause_hospitalization
H-382	-0.4988483190536499	▁h f PSI ▁blood _ u rea _ ▁nit rogen ▁na tri ure tic _ pe pti de ▁New _ ▁York _ ▁Heart _ association ▁diabetes ▁at rial _ fi bril lation flu tter
D-382	-0.4988483190536499	hfPSI blood_urea_ nitrogen natriuretic_peptide New_ York_ Heart_association diabetes atrial_fibrillationflutter
P-382	-1.1491 -2.0685 -1.1166 -0.8559 -0.3986 -0.2748 -1.0403 -0.2399 -0.1407 -0.0729 -0.0308 -0.1482 -0.0497 -0.1497 -0.2248 -0.3578 -0.2113 -0.3940 -0.3831 -0.9925 -1.9552 -0.2916 -0.6636 -0.1577 -0.4601 -0.1772 -0.3176 -0.3623 -0.2365 -0.5845 -0.1359 -0.1226 -1.4692 -0.0883 -0.4007 -0.2363
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary_outcome patients crt hazard_ratio confidence_interval
H-852	-0.6809865236282349	▁c t ▁hazard _ rati o ▁confidence _ ▁interval
D-852	-0.6809865236282349	ct hazard_ratio confidence_ interval
P-852	-0.7606 -2.8905 -1.0283 -0.4309 -0.0719 -0.0278 -0.3727 -0.4170 -0.6703 -0.5348 -0.2859
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality_rate patients hf hf case-fatality_rate
H-1311	-0.6521907448768616	▁case - fat ality _ rate ▁concurrent _ HF ▁concurrent _ HF ▁case - fat ality _ rate
D-1311	-0.6521907448768616	case-fatality_rate concurrent_HF concurrent_HF case-fatality_rate
P-1311	-0.9131 -0.3463 -0.2607 -0.4158 -0.2650 -0.9204 -0.4776 -0.5160 -2.2886 -0.1923 -0.3536 -2.6801 -0.2874 -0.2950 -0.4038 -0.5246 -0.2766 -0.8497 -0.5334 -0.2437
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients heart_failure_and_reduced_ejection_fraction patient
H-659	-0.9585129618644714	▁out patient s ▁heart _ fail ure ▁e je ction _ fraction
D-659	-0.9585129618644714	outpatients heart_failure ejection_fraction
P-659	-6.2104 -0.1387 -0.1489 -0.8491 -0.2747 -1.0054 -1.6844 -0.7541 -0.1612 -0.1082 -0.2798 -0.0157 -1.5116 -0.2768
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame chf anthracycline stem_cell allogeneic autologous follow-up
H-1453	-0.6255604028701782	▁CHF ▁an thra cycli ne ▁stem _ cell allo gene ic ▁follow - up
D-1453	-0.6255604028701782	CHF anthracycline stem_cellallogeneic follow-up
P-1453	-0.4562 -3.5992 -0.1723 -0.2401 -1.5042 -0.8786 -0.6080 -0.6153 -0.2522 -0.3637 -0.2603 -0.2130 -0.2484 -0.0152 -0.3574 -0.2250
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting_tension fpassive muscle kcl-ki titin titin extracellular_matrix fpassive
H-765	-0.6226661801338196	▁Rest ing _ tension ▁f pass ive - sar com ere _ leng th ▁muscle _ ▁strip s ▁k c l - KI ▁treatment ▁titi n ▁titi n ▁extra cel lular _ ▁matri x ▁f pass ive
D-765	-0.6226661801338196	Resting_tension fpassive-sarcomere_length muscle_ strips kcl-KI treatment titin titin extracellular_ matrix fpassive
P-765	-1.8428 -0.1016 -0.4113 -0.1030 -4.4064 -0.0373 -0.0538 -1.4580 -0.5840 -0.1215 -1.8040 -0.2409 -0.0538 -0.0056 -3.5141 -0.7335 -0.2981 -0.2247 -0.9093 -0.4181 -0.4896 -0.0397 -0.0876 -1.8297 -0.2403 -0.1167 -0.6808 -0.0924 -0.0987 -0.1949 -0.1607 -0.2092 -0.5156 -0.1107 -1.4465 -0.0154 -0.0937 -0.3391 -0.2009
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training exercise_capacity muscle quality_of_life cardiac nt-probnp inflammatory il6 hscrp biomarkers
H-1922	-0.47868067026138306	▁aero bic ▁resist ance _ training ▁exercise _ capaci ty ▁muscle ▁cardiac NT - pro b NP ▁infla mma tory ▁i 6 ▁h s cr p ▁bio mark ers
D-1922	-0.47868067026138306	aerobic resistance_training exercise_capacity muscle cardiacNT-probNP inflammatory i6 hscrp biomarkers
P-1922	-0.1804 -0.6551 -0.1653 -0.0369 -0.8506 -0.3161 -0.0785 -0.5289 -0.1287 -0.0973 -0.7258 -1.1695 -1.4989 -0.0363 -0.6447 -1.3286 -0.5469 -0.4011 -0.3174 -0.0625 -1.5286 -0.4371 -0.0045 -0.0300 -0.1945 -0.4361 -1.4988 -0.1248 -0.1164 -0.4276 -0.2713
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital readmission all-cause_readmission acr potential_preventable_readmission ppr medicare medicaid readmission cms
H-135	-1.076784610748291	▁read mission ▁all - ca use _ read mission ▁a cr ▁potential _ preven table _ re mission ▁p d p ▁center s _ for _ ▁Medica re ▁Medica id ▁c ms
D-135	-1.076784610748291	readmission all-cause_readmission acr potential_preventable_remission pdp centers_for_ Medicare Medicaid cms
P-135	-1.7313 -0.2302 -2.0460 -0.0748 -0.0082 -0.3309 -0.1342 -5.2243 -0.0949 -0.9000 -0.3316 -1.0738 -0.1892 -1.8566 -1.6915 -0.2295 -4.4237 -1.5396 -0.1503 -3.0777 -0.7396 -0.9321 -0.2948 -0.3070 -1.8776 -0.5482 -0.3390 -0.0961 -0.1225 -1.0500 -3.3312 -0.9537 -0.4218 -0.2587
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart_failure myocardial_infarction mi β-adrenoceptor_blockade infarcted metoprolol
H-1547	-0.583375871181488	▁rever si bility ▁heart _ fail ure ▁my o card ial _ in far ction ▁m ▁β - ad re no cept or _ block ade ▁in far cted ▁met o pro lol
D-1547	-0.583375871181488	reversibility heart_failure myocardial_infarction m β-adrenoceptor_blockade infarcted metoprolol
P-1547	-0.1068 -0.1925 -0.0159 -1.2736 -0.2698 -1.3618 -2.2875 -0.5282 -0.3965 -0.7024 -0.6142 -0.3252 -0.3998 -0.0459 -0.4005 -1.6036 -2.8481 -0.0472 -0.0805 -0.1071 -0.1674 -0.6856 -0.1689 -0.2139 -0.9684 -1.0104 -0.0837 -0.0642 -0.8415 -0.9675 -0.2638 -0.0946 -0.6804 -0.4086 -0.1920
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise rehabilitation walking minnesota_quality_of_life exercise
H-1882	-1.2439123392105103	▁Minnesota ▁quality _ of _ life ▁exercise
D-1882	-1.2439123392105103	Minnesota quality_of_life exercise
P-1882	-3.9656 -3.2162 -0.2279 -0.0293 -0.2167 -1.3740 -0.9858 -0.9748 -0.2050
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive_heart_failure correlation_coefficient
H-218	-0.7430473566055298	▁con ges tive _ heart _ fail ure ▁ed ▁corre lation _ co e ffi cient
D-218	-0.7430473566055298	congestive_heart_failure ed correlation_coefficient
P-218	-4.7709 -0.0865 -0.1871 -0.2281 -2.3466 -0.1743 -0.7177 -1.9535 -0.8674 -0.6621 -0.0627 -0.2198 -0.1135 -0.2365 -0.0240 -0.0588 -0.4541 -0.2113
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine_vasopressin avp physiologic chf avp vasopressin_receptor_antagonist therapy therapeutic chf
H-637	-0.7170636653900146	▁argi nine _ ▁vaso press in ▁a VP ▁physio logic ▁CHF ▁a VP ▁vaso press in _ ▁receptor _ ▁anta gon ist _ therapy ▁CHF
D-637	-0.7170636653900146	arginine_ vasopressin aVP physiologic CHF aVP vasopressin_ receptor_ antagonist_therapy CHF
P-637	-1.0974 -0.8100 -0.1716 -0.3786 -0.1418 -1.5099 -1.4211 -0.8461 -0.8693 -0.7394 -1.4632 -1.7005 -1.6868 -0.2152 -0.1330 -1.4736 -0.2781 -0.4965 -0.6904 -0.4685 -0.0245 -0.7507 -0.4480 -0.1637 -0.7807 -0.3436 -0.2587
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies medication physical_therapy implantable_defibrillators circulatory_support transplantation risk_stratification patient heart_failure therapies disease
H-1205	-0.5250797867774963	▁physical ▁implant able _ de fi br illa tors ▁circula tory _ support ▁transplant ation ▁heart _ fail ure ▁disease
D-1205	-0.5250797867774963	physical implantable_defibrillators circulatory_support transplantation heart_failure disease
P-1205	-0.1235 -0.0349 -0.0702 -0.5753 -0.1538 -0.3574 -1.1794 -0.0921 -0.3704 -0.1429 -0.0397 -1.1455 -1.0358 -0.6989 -0.0397 -0.8253 -0.3232 -1.0067 -1.6323 -0.8307 -0.5352 -0.3389
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts caspase-3 activity phosphocreatine adenine_nucleotides cytochrome_c bcl2 bax caspase_3 expression
H-961	-0.27212655544281006	▁rat s ▁heart s ▁cas pas e -3 ▁activity ▁ phos pho creati ne ▁a den ine _ ▁nucleo ti des ▁cy to ch rom e ▁b cl 2 ▁Bax ▁cas pas e ▁expression
D-961	-0.27212655544281006	rats hearts caspase-3 activity phosphocreatine adenine_ nucleotides cytochrome bcl2 Bax caspase expression
P-961	-1.1691 -0.1313 -0.6716 -0.1570 -0.0790 -0.1141 -0.3528 -1.1161 -0.0682 -0.3989 -0.0790 -0.2818 -0.2966 -1.3647 -0.0998 -0.0105 -0.2271 -0.1511 -0.2974 -0.1175 -0.2875 -0.1147 -0.1048 -0.0648 -0.0078 -0.2175 -0.0778 -0.1178 -0.0098 -0.0421 -0.0142 -0.2501 -0.3604 -0.3606 -0.3685 -0.2145
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right_ventricular_pacing gene_expressions bax bcl-2 caspase-3 rtq-pcr interventricular_septum biopsies heart_failure
H-166	-0.5699116587638855	▁right _ vent ri cular _ pa cing ▁gene _ expression s ▁Bax ▁b cl -2 ▁Cas pas e -3 ▁RT q - PC r ▁interven tri cular _ ▁sept um _ ▁bio psi es ▁beag le _ ▁dog s ▁heart _ fail ure
D-166	-0.5699116587638855	right_ventricular_pacing gene_expressions Bax bcl-2 Caspase-3 RTq-PCr interventricular_ septum_ biopsies beagle_ dogs heart_failure
P-166	-0.2248 -0.3731 -0.7899 -0.9563 -0.3629 -0.1663 -0.6557 -0.6135 -1.7271 -0.3045 -0.1870 -0.1862 -0.1202 -0.1288 -0.2218 -0.1625 -1.0405 -0.1605 -0.0864 -0.0946 -0.9767 -2.2240 -0.0601 -1.4351 -0.1322 -0.0564 -0.7398 -0.2883 -0.3205 -3.1018 -0.1056 -0.3452 -0.9293 -0.2021 -0.3098 -0.0269 -0.3224 -1.0260 -1.1677 -0.0846 -0.1226 -0.3011 -1.2473 -1.5824 -0.3332 -0.2124
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers β-blockers patients heart_failure_and_reduced_ejection_fraction
H-661	-0.5838170647621155	▁ang io ten sin - con ver ting _ ▁enzym e _ ▁inhibi tors angi oten sin _ ▁receptor _ block ers ▁β - block ers ▁heart _ fail ure ▁e je ction _ fraction
D-661	-0.5838170647621155	angiotensin-converting_ enzyme_ inhibitorsangiotensin_ receptor_blockers β-blockers heart_failure ejection_fraction
P-661	-1.2400 -4.4633 -0.3414 -1.2469 -1.6374 -0.0552 -0.1483 -0.2057 -0.2504 -0.9124 -0.3609 -0.4075 -0.4503 -0.0733 -0.2111 -0.0231 -0.6912 -0.2908 -0.2413 -0.3861 -1.0526 -0.1289 -0.1790 -0.0740 -0.4445 -0.1579 -1.5426 -0.3622 -1.3753 -1.1894 -0.2540 -0.1254 -0.1450 -0.3191 -0.0140 -0.3597 -0.2409
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary_approaches_to_stop_hypertension dash left_ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling hypertensive_hfpef
H-918	-0.5815970301628113	▁hyper tension ▁die t DAS h ▁s rd ▁left _ vent ri cular _ dia sto lic _ function ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve ▁h f f
D-918	-0.5815970301628113	hypertension dietDASh srd left_ventricular_diastolic_function arterial_ elastance ventricular-arterial_ coupling hypertensive hff
P-918	-1.9463 -0.0038 -2.0522 -0.1720 -0.5531 -0.5136 -1.8312 -0.9169 -0.9238 -0.5164 -1.1369 -1.0754 -0.1792 -0.3052 -0.2676 -0.5236 -0.6111 -0.5053 -0.2244 -0.0495 -1.2317 -0.1508 -0.1339 -0.1599 -0.9835 -0.4846 -0.4205 -0.5349 -0.1179 -0.5667 -0.7943 -0.2309 -0.2988 -0.2583 -0.0510 -0.6168 -0.7163 -0.4004 -0.5589 -0.2461
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute_hf relax-ahf astronaut pronto patient patients end_points
H-1017	-0.9014076590538025	▁a cute _ HF ▁RELA x - a HF ▁ AST RON AUT ▁pr ONTO ▁patient _ en roll ment
D-1017	-0.9014076590538025	acute_HF RELAx-aHF ASTRONAUT prONTO patient_enrollment
P-1017	-1.6170 -0.0496 -0.3463 -1.4467 -1.1196 -1.2152 -0.0685 -0.0701 -1.3273 -1.7307 -3.1848 -0.4625 -0.1746 -2.1277 -0.2188 -1.6792 -0.5583 -0.3590 -0.5077 -0.1648 -1.1650 -0.2377
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol carvedilol sympathetic_activity von_willebrand_factor
H-1119	-0.4692223370075226	▁met o pro lol ▁car vedi lol ▁sympa the tic _ activ ity ▁von _ Will e brand _ factor
D-1119	-0.4692223370075226	metoprolol carvedilol sympathetic_activity von_Willebrand_factor
P-1119	-0.0914 -0.2277 -0.0271 -0.6585 -0.1528 -0.0714 -0.6463 -0.2598 -0.1547 -0.1978 -0.3674 -0.0891 -0.1022 -0.3030 -0.3005 -2.5888 -0.3624 -0.0460 -0.3342 -0.0599 -3.0759 -0.2060
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized hf international_classification_of_diseases clinical principal discharge diagnosis
H-1832	-0.40807196497917175	▁h f ▁international _ ▁Classifica tion _ of _ ▁Disease s ▁Nin th _ re vision ▁Clinic al ▁principal _ dis charge _ diagnos is
D-1832	-0.40807196497917175	hf international_ Classification_of_ Diseases Ninth_revision Clinical principal_discharge_diagnosis
P-1832	-1.0400 -0.7477 -0.1998 -0.2005 -0.5332 -0.0352 -0.1649 -0.0348 -0.3445 -0.5155 -0.1309 -0.2633 -0.0305 -0.1739 -0.1884 -0.1392 -0.8646 -0.0908 -3.0625 -0.2273 -0.1877 -0.0230 -0.8255 -0.0970 -0.3460 -0.3463 -0.2051
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad q65p movement wild-type_rad q65p l-type_channel rgk_proteins
H-1676	-1.0039840936660767	▁rad _ q 65 p ▁ga ting _ ▁movement ▁wild - type _ rad ▁q 65 p ▁l - type _ ▁channel _ ▁inhibi tion ▁r GK _ ▁protein s
D-1676	-1.0039840936660767	rad_q65p gating_ movement wild-type_rad q65p l-type_ channel_ inhibition rGK_ proteins
P-1676	-0.9374 -1.8004 -1.1247 -0.6118 -1.1333 -2.0478 -0.0420 -0.1805 -0.8000 -0.7423 -0.0569 -0.0594 -0.1849 -1.5943 -2.9437 -0.6201 -1.3593 -4.1925 -0.3012 -0.1964 -0.0909 -3.1643 -0.5398 -1.7505 -0.2534 -1.2821 -1.6103 -0.3490 -1.1312 -0.3529 -0.4348 -0.2394
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 heart_failure proteomics actin_cytoskeleton ss20 mitochondrial metabolic_pathways
H-876	-0.7153681516647339	▁SS 20 ▁heart _ fail ure ▁prote o mics ▁cy tos kelet on _ path ways ▁SS 20 ▁mito cho ndri al ▁metabol ic _ path ways
D-876	-0.7153681516647339	SS20 heart_failure proteomics cytoskeleton_pathways SS20 mitochondrial metabolic_pathways
P-876	-2.1650 -0.3125 -0.9492 -0.2646 -1.2724 -1.4704 -0.9299 -0.6849 -0.0613 -2.3178 -0.9994 -0.1618 -0.3138 -2.2480 -0.1057 -0.4462 -1.0331 -0.2531 -0.2134 -1.5478 -0.4074 -0.1957 -0.1064 -0.1034 -0.7385 -0.2133 -0.4474 -0.5449 -0.2383
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms left_ventricular_base midpapillary apex baseline ivc_occlusion bivp ste rs
H-324	-0.6025203466415405	▁e cho card i ogram s ▁left _ vent ri cular _ base ▁mid pap illa ry ▁base line ▁IV c ▁oc clusi on ▁Bi VP ▁twist ▁twist ▁bas al _ rota tions ▁RS ▁synchron y
D-324	-0.6025203466415405	echocardiograms left_ventricular_base midpapillary baseline IVc occlusion BiVP twist twist basal_rotations RS synchrony
P-324	-0.7563 -0.2571 -0.2010 -0.2958 -0.0321 -0.3020 -0.3981 -0.4039 -0.6292 -0.6800 -0.2088 -0.3805 -0.8416 -0.0307 -0.7349 -0.0429 -0.3331 -0.1249 -0.0951 -1.1696 -0.5408 -1.8148 -0.0311 -0.1875 -1.2479 -1.1128 -3.4108 -1.6865 -0.3458 -0.0919 -0.2464 -0.4495 -0.1305 -1.8989 -0.5974 -0.5514 -0.4139 -0.2203
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration pyridostigmine coronary_artery_ligation cardiac sympathetic_tone cardiac_remodeling left_ventricular_dysfunction hf
H-1145	-0.4927617907524109	▁py rido stig mine ▁corona ry _ ▁arter y _ ▁liga tion ▁cardiac _ va gal ▁sympa the tic _ tone ▁cardiac _ ▁remodel ing ▁left _ vent ri cular _ ▁dys function ▁h f
D-1145	-0.4927617907524109	pyridostigmine coronary_ artery_ ligation cardiac_vagal sympathetic_tone cardiac_ remodeling left_ventricular_ dysfunction hf
P-1145	-0.4590 -0.0304 -0.0018 -0.0735 -0.0789 -0.3866 -0.4410 -0.2639 -0.8903 -0.3516 -1.3259 -0.5576 -0.2548 -0.3467 -0.5363 -0.0333 -0.1909 -0.2254 -0.2087 -0.5364 -1.0813 -0.0648 -0.5533 -0.5661 -0.0702 -0.1784 -0.3473 -1.0174 -1.3470 -0.5675 -0.6823 -0.4511 -0.0421 -0.3255 -2.3077 -1.2099 -0.2271
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes patients new_york_heart_association nyha heart_failure eplerenone placebo heart_failure medicines emphasis-hf
H-1229	-0.853976309299469	▁New _ York _ ▁Heart _ association NY ha ▁class _ ▁II _ ▁Heart _ fail ure ▁e pler en one ▁standard _ ▁Heart _ ▁Fail ure ▁Medicine s EMP ha SIS - HF
D-1229	-0.853976309299469	New_York_ Heart_associationNYha class_ II_ Heart_failure eplerenone standard_ Heart_ Failure MedicinesEMPhaSIS-HF
P-1229	-1.5859 -1.0299 -2.5344 -0.2459 -0.9285 -0.2012 -0.5479 -1.6890 -0.8794 -2.2287 -0.3049 -0.4236 -0.3811 -0.8866 -0.2623 -0.9724 -0.2014 -0.7015 -0.0781 -0.3313 -0.1833 -2.4263 -0.3066 -1.4136 -0.4398 -1.2398 -0.1861 -0.4061 -0.0622 -2.1456 -2.1471 -1.4276 -0.0453 -0.7729 -0.8518 -0.2753
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge patients follow-up physician physician
H-1418	-0.6042788624763489	▁dis charge ▁follow - up
D-1418	-0.6042788624763489	discharge follow-up
P-1418	-1.3253 -0.0382 -0.0322 -0.3069 -0.0323 -2.2440 -0.2510
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life_expectancy heart_failure patients disease terminal_heart_failure
H-1665	-1.2415399551391602	▁heart _ fail ure ▁re frac tory ▁terminal _ heart _ fail ure
D-1665	-1.2415399551391602	heart_failure refractory terminal_heart_failure
P-1665	-2.4442 -0.3282 -1.8578 -2.9319 -2.2614 -0.1865 -0.1644 -0.8577 -0.3396 -2.5986 -0.2549 -1.0215 -2.7183 -0.3774 -0.2808
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart_failure discharges university_of_connecticut_health_center patients follow-up
H-723	-0.7862774729728699	▁heart _ fail ure _ dis charge s ▁university _ of _ connect i cut ▁health _ center ▁follow - up
D-723	-0.7862774729728699	heart_failure_discharges university_of_connecticut health_center follow-up
P-723	-2.0513 -0.2375 -1.1113 -1.1518 -2.3834 -0.0888 -0.0097 -0.1932 -1.1453 -0.4071 -0.1008 -0.3674 -2.7059 -0.4405 -0.5544 -0.9024 -0.3545 -1.7242 -0.0644 -0.2471 -0.0361 -1.5696 -0.2375
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary_capillary_wedge_pressure baseline right_atrial_pressure pulmonary_arterial_pressure pulmonary_resistance
H-1959	-0.6266494989395142	▁pulmonar y _ cap illa ry _ we dge _ press ure ▁h g ▁base line ▁h g ▁right _ at rial _ press ure ▁pulmonar y _ ▁arterial _ press ure ▁pulmonar y _ ▁resist ance
D-1959	-0.6266494989395142	pulmonary_capillary_wedge_pressure hg baseline hg right_atrial_pressure pulmonary_ arterial_pressure pulmonary_ resistance
P-1959	-2.0483 -1.7769 -0.3740 -1.5625 -0.1473 -0.3520 -0.2608 -1.1089 -0.0444 -0.1259 -1.8312 -0.7691 -0.3623 -0.0561 -0.0159 -0.0340 -0.2839 -0.0519 -0.1357 -0.3262 -1.3619 -0.5175 -0.3102 -0.8546 -0.7614 -0.0239 -0.2186 -0.3113 -0.9133 -0.4759 -1.3291 -1.0222 -0.0155 -0.3330 -0.5005 -3.2028 -0.0370 -0.3581 -0.2253
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute_heart_failure hf pharmacologic therapeutics calcium-sensitizing_agents antagonists endothelin vasopressin adenosine
H-1015	-0.5258986353874207	▁a cute _ heart _ fail ure HF ▁ pharma c ologic ▁calci um - sensi t izing _ agent s ▁en do the lin ▁vaso press in ▁ad enos ine
D-1015	-0.5258986353874207	acute_heart_failureHF pharmacologic calcium-sensitizing_agents endothelin vasopressin adenosine
P-1015	-0.2049 -0.1304 -0.1376 -2.3657 -0.1468 -1.3321 -1.2852 -0.7991 -1.1146 -0.0477 -0.1596 -0.2348 -0.6928 -0.0188 -0.1267 -0.1351 -2.5453 -0.1019 -0.8183 -0.2648 -0.4528 -0.2268 -0.1286 -0.1295 -2.6439 -0.0336 -0.0145 -0.3816 -0.0142 -0.0213 -0.0696 -0.3513 -0.2246
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic_insufficiency mechanical_circulatory_support continuous_flow left_ventricular_assist_devices lvads pulsatile_devices
H-542	-0.797494113445282	▁New - ons et _ a or tic _ insu ffi cie ncy AI ▁mechanic al _ circ ulation ▁flow ▁continuo us _ flow ▁left _ vent ri cular _ assist _ ▁devices ▁l VAD s ▁pulsa tile _ ▁devices
D-542	-0.797494113445282	New-onset_aortic_insufficiencyAI mechanical_circulation flow continuous_flow left_ventricular_assist_ devices lVADs pulsatile_ devices
P-542	-2.2333 -0.1511 -0.5356 -0.2073 -0.3493 -0.1260 -0.2898 -0.1635 -0.1623 -0.9700 -0.0875 -1.6336 -0.1943 -3.7442 -0.0151 -0.1723 -0.4638 -1.8314 -0.6112 -1.1243 -2.0069 -0.6885 -0.4347 -0.1534 -0.2724 -0.4905 -0.6106 -1.1281 -0.1993 -0.2728 -0.0169 -1.1364 -3.3405 -1.3515 -0.0443 -0.2390 -0.0611 -0.3121 -0.3340 -4.5969 -0.4864 -0.2524
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in_vivo hf phenylephrine haemodynamic surgical transverse_aortic_constriction tac jq1 pathological cardiac_hypertrophy
H-1047	-0.5267094373703003	▁h f ▁induc ed ▁mi ce ▁ phen yle ph rine ▁ha emo dynamic _ ▁stress ▁trans verse _ a or tic _ con stri ction TAC ▁j q 1 ▁cardiac _ ▁hyper trop hy
D-1047	-0.5267094373703003	hf induced mice phenylephrine haemodynamic_ stress transverse_aortic_constrictionTAC jq1 cardiac_ hypertrophy
P-1047	-0.5014 -0.5896 -0.2864 -0.0970 -1.4152 -0.0473 -0.6780 -0.1417 -0.2169 -0.3289 -0.3914 -0.0097 -0.0639 -0.0248 -0.3351 -2.3020 -0.3872 -0.8035 -0.3775 -0.2139 -0.2444 -0.0994 -0.2615 -0.8426 -1.4980 -0.6677 -1.5022 -0.3315 -1.4796 -0.0637 -0.2819 -0.3815 -1.8736 -0.0865 -0.1003 -0.3415 -0.2208
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence drugs drugs raas renin_inhibitors endopeptidase_inhibitors vasopeptidase_inhibitors angiotensin_receptor_blockers
H-1490	-0.4686568081378937	▁evidence ▁drugs ▁RA as ▁direct _ re nin _ ▁inhibi tors ▁neutral _ en dop ep tida se _ ▁inhibi tors ▁vaso pe pti das e _ ▁inhibi tors ▁ang io ten sin _ ▁receptor _ block ers
D-1490	-0.4686568081378937	evidence drugs RAas direct_renin_ inhibitors neutral_endopeptidase_ inhibitors vasopeptidase_ inhibitors angiotensin_ receptor_blockers
P-1490	-0.1299 -0.1258 -1.3476 -0.3812 -0.0035 -0.2576 -0.1662 -1.8206 -0.2966 -0.7765 -0.0457 -0.1510 -0.6237 -0.4578 -0.4183 -0.6953 -0.0429 -0.4409 -0.2910 -0.7900 -0.0653 -0.0526 -0.3304 -0.2220 -0.8782 -0.1868 -0.3748 -0.8625 -0.0728 -0.0455 -2.8638 -0.1419 -0.7424 -0.1612 -0.2425 -0.5261 -0.9094 -0.0454 -0.4909 -0.2700
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 healthy cardiomyocytes camp inotropic_effect acute β-ar contractility
H-1216	-0.42197057604789734	▁p de 2 _ over expression ▁cardio my o cy tes ▁c AMP ▁ca 2 ▁current _ ▁amplitud e ▁in o tropi c _ effect ▁β - ar _ stimul ation ▁bas al _ contract ility
D-1216	-0.42197057604789734	pde2_overexpression cardiomyocytes cAMP ca2 current_ amplitude inotropic_effect β-ar_stimulation basal_contractility
P-1216	-0.4194 -0.0295 -0.0693 -0.7542 -0.0886 -0.0975 -0.3344 -1.3348 -0.3872 -0.1232 -1.0422 -0.0681 -0.6833 -0.6828 -0.2210 -0.6723 -0.3900 -0.2514 -0.2817 -0.1368 -0.6163 -0.0854 -0.3438 -0.8916 -0.1876 -0.2615 -0.0238 -0.5794 -1.1737 -0.2131 -0.0667 -0.0973 -0.4059 -0.2812 -0.3373 -1.6567 -0.4706 -0.2752
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck_stent implanted lad circumflex_artery lcx lcx lad
H-505	-0.7528402805328369	▁bottle ne ck _ ▁sten t ▁implant ed ▁left _ ▁anterior _ ▁descend ing ▁la d ▁proxima l _ ▁circum flex _ ▁arter y LC x ▁proxima l _ LC x ▁la d ▁pig s
D-505	-0.7528402805328369	bottleneck_ stent implanted left_ anterior_ descending lad proximal_ circumflex_ arteryLCx proximal_LCx lad pigs
P-505	-0.2853 -0.1372 -0.0400 -0.4582 -2.8652 -0.2134 -0.0290 -0.0761 -1.7046 -0.4195 -2.1572 -0.2942 -1.0894 -0.0815 -0.6321 -1.0869 -0.3362 -0.2383 -0.8384 -1.0169 -0.5452 -0.3973 -0.1466 -0.4212 -1.8338 -1.2289 -0.9483 -0.1137 -0.7545 -1.5599 -0.7587 -2.3632 -0.3862 -1.5426 -0.1783 -0.4340 -0.2430
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute_myocardial_infarction ami incidence deaths heart_failure hf ami
H-1306	-1.140323519706726	▁a cute _ My o card ial _ in far ction AMI ▁heart _ fail ure HF AMI
D-1306	-1.140323519706726	acute_Myocardial_infarctionAMI heart_failureHFAMI
P-1306	-2.5983 -0.1060 -0.1987 -4.5337 -0.8463 -0.6829 -0.8657 -0.1843 -0.4619 -0.0699 -0.6073 -1.8381 -1.7351 -0.3500 -1.2682 -2.0639 -1.7000 -1.8886 -0.5268 -0.2809
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac_washout carvedilol metoprolol β2-adrenergic_receptor_haplotype
H-1117	-0.47686028480529785	▁i - mi BG ▁cardiac _ was hout ▁car vedi lol ▁met o pro lol ▁β 2- ad r energi c _ ▁receptor _ ha plo type
D-1117	-0.47686028480529785	i-miBG cardiac_washout carvedilol metoprolol β2-adrenergic_ receptor_haplotype
P-1117	-0.0179 -0.2568 -0.6275 -1.4281 -0.2337 -0.4787 -3.4925 -0.0894 -0.2372 -0.0451 -0.3058 -0.0658 -0.2222 -0.0801 -0.6817 -0.7174 -0.2763 -0.3798 -0.7161 -0.2311 -0.2270 -0.1789 -0.5332 -0.4300 -0.8883 -0.3802 -0.0108 -0.3830 -0.2140
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle_aerobic_capacity postexercise_phosphocreatine_resynthesis fontan
H-1502	-0.5238092541694641	▁Mus cle _ ▁aero bic _ capaci ty ▁rate ▁poste xer ci se _ phos pho creati ne _ re syn the sis ▁Font an
D-1502	-0.5238092541694641	Muscle_ aerobic_capacity rate postexercise_phosphocreatine_resynthesis Fontan
P-1502	-1.3009 -0.1932 -0.1790 -0.4568 -0.7232 -0.3778 -0.0974 -0.0516 -0.6857 -0.0315 -0.1864 -0.0117 -0.3801 -0.6954 -0.1833 -0.4908 -0.4947 -2.5572 -0.1690 -0.0319 -0.1096 -0.4141 -2.5425 -0.1756 -0.1002 -1.2811 -0.2218
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac_resynchronization_therapy crt patients heart_failure hf outcomes crt dialysis reported
H-904	-0.9264588356018066	▁Card iac _ re syn chron ization _ therapy ▁c t ▁di al ysis - dependent ▁heart _ fail ure ▁h f ▁c t ▁di al ysis
D-904	-0.9264588356018066	Cardiac_resynchronization_therapy ct dialysis-dependent heart_failure hf ct dialysis
P-904	-1.0017 -0.6085 -0.1267 -0.0485 -0.0593 -0.0085 -0.5354 -0.3104 -0.6432 -1.3566 -2.6269 -1.8661 -0.3698 -0.4356 -0.2102 -0.0574 -1.9344 -0.3209 -1.2544 -1.9704 -0.9320 -2.6011 -1.6221 -3.3210 -1.1478 -0.3617 -0.4771 -0.4019 -0.2577
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone patients hyperkalemia renal_function emphasis-hf eplerenone patients hospitalization heart_failure
H-1221	-0.6302785277366638	▁e pler en one ▁hyper kal emia ▁renal _ function ▁em PHA s - HF ▁e pler en one ▁Heart _ fail ure
D-1221	-0.6302785277366638	eplerenone hyperkalemia renal_function emPHAs-HF eplerenone Heart_failure
P-1221	-0.2089 -0.6255 -0.5484 -0.6250 -0.1841 -0.8424 -0.1406 -0.0393 -0.3741 -0.2614 -1.4032 -0.8232 -1.7096 -0.0580 -0.9281 -0.4668 -0.7777 -0.6657 -0.5710 -2.8999 -0.4095 -0.5536 -0.0762 -0.3321 -0.2329
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ventricular_mass cardiac_apoptosis fibrosis cardiac_metabolic_gene_expression atp
H-655	-0.5415632724761963	▁h - d ko _ mi ce ▁vent ri cular _ mas s ▁cardiac _ ▁apo pto sis ▁fibro sis ▁Akt ▁for k head _ box ▁im pair ed _ ▁cardiac _ ▁metabol ic _ ▁gene _ expression ▁ATP
D-655	-0.5415632724761963	h-dko_mice ventricular_mass cardiac_ apoptosis fibrosis Akt forkhead_box impaired_ cardiac_ metabolic_ gene_expression ATP
P-655	-0.2682 -0.2945 -0.1711 -1.0890 -1.4632 -0.1340 -0.3951 -0.1092 -0.3688 -0.4611 -0.5195 -1.3432 -0.5149 -0.1888 -0.4838 -1.9681 -0.3690 -1.3895 -0.0065 -0.3768 -0.2529 -1.9540 -0.5385 -0.2932 -0.2403 -0.1516 -0.7108 -0.0078 -0.0243 -1.0444 -0.2866 -0.4221 -0.1126 -0.0664 -0.2437 -2.3901 -0.4799 -0.1167 -0.2300 -0.5234 -0.2004
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp shock_therapy
H-863	-0.36622247099876404	▁ATP ▁shock _ therapy
D-863	-0.36622247099876404	ATP shock_therapy
P-863	-0.6913 -0.3250 -0.3166 -0.1605 -0.4261 -0.2777
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint cardiorespiratory_fitness crf body_mass_index heart_failure hf mortality cardiovascular hf mortality
H-1766	-0.7570549845695496	▁joint _ association s ▁cardio re spira tory _ ▁fitness ▁cr f ▁body _ ▁mass _ index ▁heart _ fail ure HF ▁mortal ity ▁cardiovascular _ risk _ factor s ▁h f ▁mortal ity ▁fit ▁un fit _ men
D-1766	-0.7570549845695496	joint_associations cardiorespiratory_ fitness crf body_ mass_index heart_failureHF mortality cardiovascular_risk_factors hf mortality fit unfit_men
P-1766	-0.1299 -1.7330 -0.1887 -0.3817 -0.3931 -0.1424 -0.0664 -0.0373 -0.2650 -1.3490 -2.7659 -0.2808 -0.1403 -0.5071 -1.4667 -0.1610 -0.4759 -0.8015 -0.3474 -1.4153 -1.6492 -1.3268 -1.6367 -0.1214 -0.0553 -0.6298 -0.2125 -0.4714 -0.0798 -0.2959 -2.0019 -1.2808 -1.1292 -0.1446 -0.8196 -1.3836 -0.0328 -0.3154 -3.6907 -0.4619 -0.2519
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized heart_failure dipeptidyl_peptidase-4 dpp-4 antihyperglycemic_agents
H-1827	-0.6589213609695435	▁post marketing ▁heart _ fail ure ▁h HF ▁di pe pti dy l _ ▁pep tida se -4 ▁d p -4 ▁anti hy per gly ce mic _ agent s
D-1827	-0.6589213609695435	postmarketing heart_failure hHF dipeptidyl_ peptidase-4 dp-4 antihyperglycemic_agents
P-1827	-1.5168 -0.1104 -1.9058 -0.3417 -1.2281 -1.2968 -0.0359 -2.7236 -0.0564 -0.0538 -0.1155 -1.8305 -2.6492 -0.2362 -0.2597 -0.0525 -0.9323 -0.2642 -0.0905 -0.9168 -0.1125 -0.1301 -0.0966 -0.1174 -0.5054 -0.1064 -1.6568 -0.4047 -0.2127 -0.3797 -0.4966 -0.2499
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox_modeling heart_failure_patient_severity_index hfpsi university_of_michigan hf clinic primary_outcome
H-380	-0.7429737448692322	▁multi vari able _ co x _ model ing ▁Heart _ fail ure _ ▁Patient _ ▁Sever ity _ index ▁h PSI ▁university _ of _ ▁Michigan ▁h f
D-380	-0.7429737448692322	multivariable_cox_modeling Heart_failure_ Patient_ Severity_index hPSI university_of_ Michigan hf
P-380	-0.3405 -0.0129 -0.0646 -0.3681 -0.0661 -0.2585 -0.4787 -0.4460 -0.3288 -1.2054 -0.3615 -0.8293 -0.1493 -0.5795 -1.4043 -0.3180 -1.0890 -0.4004 -0.1921 -0.4536 -0.9197 -2.0067 -1.5076 -0.3322 -0.0814 -0.3877 -0.9235 -0.5408 -2.6307 -4.1132 -0.2420
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart_rate cardiac patients patients acute_myocardial_infarction ami patients congestive_heart_failure chf left_ventricular dysfunction
H-1585	-0.8781473636627197	▁Heart _ rate HR ▁cardiac _ ▁pacientes ▁a cute _ My o card ial _ in far ction AMI ▁con ges tive _ heart _ ▁failure CH f ▁left _ vent ri cular LV
D-1585	-0.8781473636627197	Heart_rateHR cardiac_ pacientes acute_Myocardial_infarctionAMI congestive_heart_ failureCHf left_ventricularLV
P-1585	-0.9758 -0.5232 -0.9695 -2.7120 -0.1807 -0.9661 -2.0115 -0.2929 -0.0412 -0.3341 -4.0041 -0.5846 -0.5186 -0.9717 -0.2961 -0.5271 -0.0547 -0.4845 -0.9351 -0.4313 -0.0673 -0.8704 -0.3649 -2.0557 -0.2161 -2.2329 -3.3501 -0.8865 -0.1889 -0.3192 -0.6589 -1.1170 -0.5519 -0.1276 -0.5507 -0.2401
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular_cardiomyocytes chronic insulin irs1 irs2 proteins insulin p38 cardiac_dysfunction insulin_resistance type_2_diabetes
H-657	-0.6391050815582275	▁ne ona tal _ rati o ▁vent ri cular _ ▁cardio my o cy tes ▁chronic _ ▁insulin _ ▁exposure ▁i RS 1 ▁i RS 2 _ ▁protein s ▁insulin _ action ▁mechanism _ of _ ▁cardiac _ ▁dys function ▁insulin _ ▁resist ance ▁diabetes
D-657	-0.6391050815582275	neonatal_ratio ventricular_ cardiomyocytes chronic_ insulin_ exposure iRS1 iRS2_ proteins insulin_action mechanism_of_ cardiac_ dysfunction insulin_ resistance diabetes
P-657	-0.1188 -0.2643 -0.2106 -0.2073 -3.3971 -0.0509 -0.9659 -0.2433 -0.2213 -0.5882 -0.0876 -1.5101 -0.1888 -0.0638 -0.7206 -0.4363 -0.3967 -1.1010 -0.9482 -1.6808 -0.8338 -0.5470 -0.1028 -1.9233 -1.0144 -0.0220 -1.2129 -0.9108 -0.1929 -1.2778 -0.7808 -0.0646 -0.1232 -0.9148 -0.1264 -0.4251 -0.3248 -0.5604 -0.3536 -0.0164 -0.1436 -0.3725 -3.6420 -0.0227 -0.1475 -0.3678 -0.2124
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms left_ventricular midpapillary atrioventricular_delay avd interventricular_delay vvd ste circumferential_strain radial_strain rs
H-323	-0.5244702696800232	▁e cho card i ogram s ▁left _ vent ri cular _ mid pap illa ry ▁at rio ven tri cular _ de lay ▁av d ▁interven tri cular _ de lay ▁v d ▁ste ▁circum fer ential _ ▁strain ▁radi al _ ▁strain RS
D-323	-0.5244702696800232	echocardiograms left_ventricular_midpapillary atrioventricular_delay avd interventricular_delay vd ste circumferential_ strain radial_ strainRS
P-323	-1.3163 -0.3989 -0.2145 -0.3780 -0.0309 -0.2638 -0.3277 -0.3941 -0.4704 -0.6648 -0.2707 -0.4610 -0.6129 -2.4170 -0.0604 -0.3222 -0.4338 -1.0899 -0.3180 -0.7006 -0.8957 -0.3445 -0.1956 -0.3320 -0.9599 -0.0730 -0.0959 -0.5096 -0.3468 -0.4692 -0.1328 -0.4817 -0.1831 -0.0642 -2.1511 -0.2473 -0.6615 -0.0476 -0.4554 -0.9379 -0.0501 -0.2087 -0.5761 -1.5079 -0.9965 -0.4042 -0.1758
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients new_york_heart_association nyha functional_class hf ejection_fractions chronic stable guideline-directed_medical_therapy gdmt united_states canada europe
H-1870	-0.6470932364463806	▁New _ York _ ▁Heart _ association NY ha ▁functional ▁h f ▁e je ction _ fraction s ▁chronic _ ▁stable ▁guide line - direct ed _ ▁medical _ therapy ▁gh t ▁unit ed _ state s ▁Canada ▁ europe
D-1870	-0.6470932364463806	New_York_ Heart_associationNYha functional hf ejection_fractions chronic_ stable guideline-directed_ medical_therapy ght united_states Canada europe
P-1870	-0.7615 -1.0259 -2.3510 -0.2030 -0.6513 -0.2088 -0.3771 -1.6588 -0.7928 -1.2996 -1.4178 -2.3489 -0.2210 -0.2106 -0.1140 -0.2680 -0.0211 -0.1677 -0.3848 -1.6648 -1.1087 -0.3343 -0.1158 -0.1769 -0.0071 -0.3554 -0.3153 -1.7528 -0.3435 -0.0753 -0.9262 -0.6019 -0.1851 -0.0039 -0.6536 -0.3186 -0.0396 -2.7574 -0.4129 -0.0266 -0.3264 -0.1923
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients qrs hazard_ratio primary_outcome patients qrs hazard_ratio
H-889	-0.7183811664581299	▁non - LB b ▁QR s ▁hazard _ rati o ▁primary _ ▁outcome ▁QR s ▁hazard _ rati o
D-889	-0.7183811664581299	non-LBb QRs hazard_ratio primary_ outcome QRs hazard_ratio
P-889	-0.3478 -0.0607 -2.4901 -1.6673 -0.2876 -1.0234 -1.0381 -0.3425 -0.1549 -0.0634 -0.4611 -0.4202 -1.7550 -1.3685 -1.0619 -1.2703 -0.4323 -0.2055 -0.0760 -0.3155 -0.2439
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka change riiα cα expression riiα ser96 cα thr197 phosphorylation hf
H-1428	-0.7703328132629395	▁p ka ▁regulator y ▁ri i α ▁cata ly tic ▁c α ▁expression ▁r II α ▁ser 96) ▁c α ▁ phos phor y lation ▁h z
D-1428	-0.7703328132629395	pka regulatory riiα catalytic cα expression rIIα ser96) cα phosphorylation hz
P-1428	-0.4875 -0.9401 -0.9324 -0.2107 -3.2892 -0.8411 -0.8587 -0.1953 -0.1252 -0.0629 -1.0989 -1.9397 -0.0525 -1.1538 -1.6048 -0.9995 -0.3055 -0.1142 -0.9337 -1.6734 -0.3155 -0.2694 -0.6177 -0.8437 -0.0826 -0.3566 -1.4431 -0.4024 -0.1897
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous_hf myofiber_shortening septum myofiber_shortening stretch wall
H-1155	-0.7460030317306519	▁dys syn chron ous _ HF ▁my o fi ber _ short en ing _ velo city ▁sept um ▁my o fi ber _ short en ing ▁stretch _ rate ▁late - activa ted _ ▁lateral _ wall
D-1155	-0.7460030317306519	dyssynchronous_HF myofiber_shortening_velocity septum myofiber_shortening stretch_rate late-activated_ lateral_wall
P-1155	-0.3827 -0.0517 -0.0132 -0.2421 -0.8500 -1.2800 -2.2032 -0.6153 -0.8050 -0.2560 -1.0153 -1.4142 -0.5698 -0.4384 -0.2184 -0.0513 -0.1236 -2.6202 -0.1127 -2.0308 -0.4779 -0.7935 -0.1979 -1.6442 -0.8605 -0.6312 -0.4360 -0.5374 -0.4382 -1.3427 -1.3590 -0.0949 -0.0472 -0.1809 -0.2306 -1.8007 -0.2290 -2.4081 -0.5371 -0.2993
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells transforming_growth_factor-β tgf-β epithelial mesenchymal transition expression pluripotency_markers
H-1342	-0.5331904292106628	▁transform ing ▁growth _ factor - β ▁t g f - β ▁epi the li al ▁mes en chy mal _ trans mission _ ▁marker s ▁expression ▁pluri pote ncy _ ▁marker s ▁sham s
D-1342	-0.5331904292106628	transforming growth_factor-β tgf-β epithelial mesenchymal_transmission_ markers expression pluripotency_ markers shams
P-1342	-0.3913 -0.1427 -3.6124 -0.2783 -0.0470 -1.5298 -1.3990 -0.2761 -0.2661 -0.5806 -0.0941 -0.3947 -0.1738 -0.0655 -0.6809 -0.1146 -0.1073 -1.6717 -0.1587 -0.0713 -0.2517 -0.1400 -2.2453 -0.6929 -0.3176 -0.1009 -0.4096 -0.5853 -0.1584 -0.2142 -0.7609 -0.5193 -0.1329 -0.0873 -0.2997 -0.4423 -0.3140
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics proteomics transverse_aortic_constriction tac heart_failure signaling_pathway ingenuity_pathway_analysis
H-871	-0.6444342732429504	▁label - free _ shot gun _ prote o mics ▁global _ prote o mics ▁trans verse _ a or tic _ con stri ction TAC ▁heart _ fail ure ▁signal ing _ path way
D-871	-0.6444342732429504	label-free_shotgun_proteomics global_proteomics transverse_aortic_constrictionTAC heart_failure signaling_pathway
P-871	-0.8188 -0.1889 -0.0361 -0.4386 -0.3958 -0.2349 -0.3656 -1.7865 -0.9018 -0.1456 -0.8272 -0.3689 -1.7851 -1.0219 -0.1530 -0.0696 -0.5257 -0.4121 -0.2058 -0.3188 -0.1184 -0.2689 -0.8518 -2.6306 -0.4926 -1.0401 -0.3113 -0.2951 -1.1936 -0.7690 -0.7199 -0.5054 -0.3937 -0.1628 -0.3897 -2.4822 -0.2183
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients hfref left_ventricular_ejection_fraction hfpef left_ventricular_ejection_fraction β-blocker hf hospitalization
H-178	-0.7533407807350159	▁h f ▁left _ vent ri cular _ e je ction _ fraction ▁h f p EF ▁left _ vent ri cular _ e je ction _ fraction ▁ RAS - ▁β - block er _ ▁dose _ change s ▁index ▁h f
D-178	-0.7533407807350159	hf left_ventricular_ejection_fraction hfpEF left_ventricular_ejection_fraction RAS- β-blocker_ dose_changes index hf
P-178	-0.1380 -1.4101 -2.7680 -0.3062 -1.1260 -1.3059 -0.7404 -0.2782 -0.5811 -1.2338 -1.1088 -0.1993 -0.1228 -0.3605 -1.9913 -0.0735 -0.5646 -0.4968 -0.3192 -1.3687 -1.3466 -0.8852 -0.2863 -0.6894 -1.4921 -1.1068 -0.2545 -0.1297 -2.0705 -0.2408 -0.0450 -0.0493 -0.0719 -0.3935 -0.3767 -0.3171 -1.3592 -0.8699 -0.6909 -0.0724 -0.3035 -3.0358 -0.8183 -0.2469 -0.2545
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated p70s6k pkc-βii hdl nyha-iiib malondialdehyde bound hdl nyha-iiib hdl healthy
H-257	-0.6890145540237427	▁p 70 s 6 k ▁PK c - β II ▁malo ndi alde hy de _ bound
D-257	-0.6890145540237427	p70s6k PKc-βII malondialdehyde_bound
P-257	-0.1441 -0.0956 -0.2145 -0.0864 -1.8520 -0.9595 -0.5732 -0.0463 -1.0136 -1.3641 -0.2547 -0.1073 -0.0755 -0.1601 -0.0485 -2.0456 -0.0061 -3.8384 -0.2057
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross_talk g-protein-coupled_receptors physiological significance regulation hearts chronic β-adrenergic_receptor postischemic_heart_failure
H-1410	-0.45548999309539795	▁g - prote in - co up led _ ▁receptor s ▁reciproc al _ regula tion ▁mouse _ ▁heart s ▁chronic ▁β - ad r energi c _ ▁receptor ▁post ische mic _ heart _ fail ure
D-1410	-0.45548999309539795	g-protein-coupled_ receptors reciprocal_regulation mouse_ hearts chronic β-adrenergic_ receptor postischemic_heart_failure
P-1410	-0.8171 -0.2164 -0.1711 -0.2431 -0.2563 -0.0162 -0.0623 -0.0526 -0.1951 -0.6561 -0.2732 -0.4558 -0.0624 -0.7732 -0.5724 -0.2136 -0.1361 -0.6658 -1.3750 -0.1586 -1.0467 -0.9849 -0.0685 -0.3516 -0.8957 -0.2182 -0.1179 -0.1857 -0.7041 -0.6570 -0.1288 -0.5361 -0.2579 -1.4178 -0.2386 -1.0848 -0.9975 -0.3099 -0.1903
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise exercise
H-1989	-1.1725214719772339	▁body _ weight ▁exercise
D-1989	-1.1725214719772339	body_weight exercise
P-1989	-2.3524 -0.6249 -1.0185 -0.1915 -2.6365 -0.2113
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp inflammatory biomarkers hscrp il6 patients hscrp
H-1920	-0.5178075432777405	▁NT - pro b NP ▁infla mma tory _ ▁bio mark ers ▁h s cr p ▁il 6 ▁il 6 ▁h s cr p
D-1920	-0.5178075432777405	NT-probNP inflammatory_ biomarkers hscrp il6 il6 hscrp
P-1920	-0.1098 -0.1155 -0.5254 -1.0186 -0.3295 -0.1253 -0.2184 -0.0662 -0.2529 -1.1820 -0.1186 -0.1922 -0.0648 -0.0475 -0.3434 -0.6972 -0.8965 -1.2335 -1.5860 -2.1669 -0.0350 -0.0513 -0.7005 -0.7713 -0.4056 -0.2092
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection_fraction patients frail biological_phenotype death frailty deficit_index death
H-1010	-0.4121912121772766	▁e je ction _ fraction ▁fra il ▁bi ological _ ▁ph eno type ▁death ▁fra il ty ▁deficit _ index ▁death
D-1010	-0.4121912121772766	ejection_fraction frail biological_ phenotype death frailty deficit_index death
P-1010	-0.2336 -0.2208 -0.0521 -0.2021 -0.0070 -0.4941 -0.0740 -0.5976 -0.1470 -0.5394 -1.8240 -0.0767 -0.0300 -1.6307 -0.5552 -0.1150 -0.4768 -0.1169 -0.0973 -0.3859 -1.0032 -0.3449 -0.2561
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients resting_hr follow-up baseline vo2max patients resting_hr p_value
H-1945	-1.2197030782699585	▁rest ing _ HR ▁follow - up ▁base line ▁VO 2 max ▁rest ing _ HR
D-1945	-1.2197030782699585	resting_HR follow-up baseline VO2max resting_HR
P-1945	-4.2108 -0.1038 -0.5309 -1.6400 -0.0750 -0.3730 -0.0333 -0.0403 -0.0696 -5.4584 -0.0843 -0.0683 -5.5431 -0.1563 -0.4106 -2.1597 -0.7261 -0.2710
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β cell phenotype in_vitro cardiac_progenitor_function cell clinical
H-1344	-0.6770304441452026	▁t g f - β _ ▁inhibi tion ▁c - K it _ + _ cell _ ▁ph eno type ▁cardiac _ pro gen itor _ function ▁cell _ exp an sion
D-1344	-0.6770304441452026	tgf-β_ inhibition c-Kit_+_cell_ phenotype cardiac_progenitor_function cell_expansion
P-1344	-0.5140 -0.3695 -0.8996 -0.0634 -0.9294 -0.3832 -2.0130 -0.2249 -0.0234 -0.1589 -3.2395 -0.1049 -0.4064 -3.6730 -1.0473 -0.6133 -0.2667 -1.1316 -0.1242 -0.0322 -0.8834 -0.3610 -0.3274 -0.2380 -1.1260 -0.3652 -0.3313 -0.1548 -0.3101 -0.2743 -1.0210 -0.4723 -0.7017 -0.2342
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets in_vitro neurohormonally heart_disease nanomolar jq1 phenylephrine-mediated_hypertrophy cardiomyocytes pathological gene_induction
H-1044	-0.7106277346611023	BET s ▁neuro hormon ally _ indu ced _ heart _ ▁disease ▁j q 1 ▁block ed _ phen yle ph rine - media ted _ hy per trop hy ▁cardio my o cy tes ▁path ological _ ▁gene _ in duction
D-1044	-0.7106277346611023	BETs neurohormonally_induced_heart_ disease jq1 blocked_phenylephrine-mediated_hypertrophy cardiomyocytes pathological_ gene_induction
P-1044	-0.2701 -0.2982 -0.4060 -0.1730 -0.1902 -0.8559 -0.9862 -0.1592 -0.5611 -2.3101 -0.2169 -1.7181 -1.2330 -2.2242 -0.1166 -1.6013 -0.0692 -1.4003 -1.3270 -0.7842 -1.5143 -0.5680 -0.2162 -0.4918 -0.1500 -0.1463 -0.9321 -2.9017 -0.4596 -0.2283 -0.1832 -1.2930 -0.4492 -0.0485 -1.0066 -0.0591 -0.3641 -0.4854 -1.4816 -0.4761 -0.2086 -0.0189 -0.4580 -0.2263
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric_remodeling concentric_hypertrophy left_ventricular remodeling heart_failure_with_preserved_ejection_fraction hfpef eccentric_hypertrophy patients
H-1524	-0.8339874744415283	▁concentr ic _ re cover ing cr ▁concentr ic _ ▁hyper trop hy ▁left _ vent ri cular LV ▁remodel ing ▁heart _ fail ure ▁e je ction _ fraction ▁h p EF ▁ecce n tric _ ▁hyper trop hy EH
D-1524	-0.8339874744415283	concentric_recoveringcr concentric_ hypertrophy left_ventricularLV remodeling heart_failure ejection_fraction hpEF eccentric_ hypertrophyEH
P-1524	-0.0716 -0.1245 -0.3438 -2.3477 -2.5153 -0.4045 -1.8642 -0.1490 -0.1640 -0.3130 -3.4919 -0.8710 -0.1676 -0.8262 -0.3889 -0.6799 -0.9705 -0.4764 -0.4285 -4.9688 -0.0606 -0.4242 -0.2689 -1.1688 -1.9417 -0.9554 -0.1514 -0.0858 -0.3059 -0.0098 -0.7801 -1.2065 -0.6639 -0.0134 -0.1092 -1.0753 -0.2698 -2.5915 -0.8374 -0.2723 -0.4353 -0.3744 -0.2926
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat functional_status quality_of_life exercise_capacity n-terminal_pro-brain_natriuretic_peptide heart_failure hospitalizations patients nyha_functional_class_iii hf
H-1878	-0.570584774017334	▁BAT ▁exercise _ capaci ty ▁n - termin al _ pro - bra in _ na tri ure tic _ pe pti de ▁burde n ▁heart _ fail ure ▁gh t - tre ated _ ▁NY ha
D-1878	-0.570584774017334	BAT exercise_capacity n-terminal_pro-brain_natriuretic_peptide burden heart_failure ght-treated_ NYha
P-1878	-0.0699 -0.1004 -0.8483 -0.0449 -0.0396 -3.5545 -0.0578 -1.2703 -0.0606 -0.6759 -0.6630 -0.2359 -0.0747 -0.2066 -0.2909 -1.7168 -0.0720 -0.0700 -0.3097 -0.4329 -0.5392 -0.2115 -0.3236 -0.3379 -0.0424 -0.5555 -0.2799 -1.1953 -0.9491 -2.0599 -0.3477 -0.0476 -0.0154 -0.2924 -0.4259 -1.1324 -0.6092 -1.8760 -0.2171
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change exercise exercise
H-1986	-0.7649122476577759	▁ml f ▁exercise ▁die t ▁exercise ▁die t
D-1986	-0.7649122476577759	mlf exercise diet exercise diet
P-1986	-2.2172 -1.7746 -0.4492 -0.7186 -0.2517 -0.2870 -0.7257 -0.6507 -0.3309 -0.2435
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx dnx
H-1374	-0.9679321050643921	▁non pa ce ▁non - DN x ▁ham - i nner vat ed ▁ham - in v ▁non pa ce _ ▁DN x ▁s ham - DN x ▁pace _ non - DN x ▁cm f - in v ▁pace _ ▁DN x ▁cm f - d x
D-1374	-0.9679321050643921	nonpace non-DNx ham-innervated ham-inv nonpace_ DNx sham-DNx pace_non-DNx cmf-inv pace_ DNx cmf-dx
P-1374	-0.6134 -0.5186 -0.0947 -0.7476 -0.2158 -2.6794 -0.3024 -0.6372 -0.0649 -1.9868 -0.0085 -0.0651 -0.0523 -0.6335 -0.1141 -0.1173 -0.1834 -0.6151 -0.3056 -0.0568 -2.4187 -1.2845 -0.1496 -3.0433 -0.5977 -0.0785 -3.3406 -0.1970 -0.5163 -1.6632 -0.4598 -0.1378 -3.3572 -0.2668 -3.7649 -1.8700 -0.0326 -0.0783 -0.1903 -1.6123 -1.6012 -1.7605 -0.1463 -3.8639 -1.8603 -0.0674 -2.7974 -0.5792 -0.4729 -0.1757
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise correlated psss btes exercise psss btes
H-1929	-1.1028882265090942	▁exercise _ time ▁ps s s ▁b tes ▁exercise _ time ▁ps s s ▁b tes
D-1929	-1.1028882265090942	exercise_time psss btes exercise_time psss btes
P-1929	-0.6128 -0.9377 -3.2989 -2.3533 -0.1731 -0.8084 -0.8192 -0.6027 -0.1123 -0.7847 -2.4110 -2.7546 -0.1570 -1.8096 -0.7572 -0.8058 -0.3953 -0.2584
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin hgb hrqol hrqol patients heart_failure outcomes exercise training hf-action
H-836	-0.8930110335350037	▁hem o glob in ▁h gb ▁HR Qo l ▁HR Qo l ▁Heart _ fail ure ▁exercise _ training HF - ac tion
D-836	-0.8930110335350037	hemoglobin hgb HRQol HRQol Heart_failure exercise_trainingHF-action
P-836	-0.3005 -0.2540 -0.1337 -1.0657 -0.4682 -0.5123 -1.7655 -0.1545 -2.8870 -2.2746 -0.1751 -3.1053 -1.8222 -0.2575 -0.5345 -0.0921 -0.5093 -0.3454 -0.7039 -1.4954 -0.0553 -0.9683 -1.8207 -0.3565 -0.2676
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv_dysfunction hazard_ratio confidence_interval cachexia hazard_ratio multivariate_analyses
H-1166	-0.3643992841243744	RV _ ▁dys function haz ard _ rati o ▁confidence _ ▁interval ▁cache xia haz ard _ rati o
D-1166	-0.3643992841243744	RV_ dysfunctionhazard_ratio confidence_ interval cachexiahazard_ratio
P-1166	-0.9640 -2.3743 -0.2996 -0.0187 -0.2076 -0.0724 -0.1717 -0.0746 -0.0537 -0.6827 -0.3423 -0.7747 -0.1230 -0.0935 -0.0409 -0.2101 -0.2003 -0.0731 -0.0454 -0.5339 -0.2959
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial_fibrillation congestive_heart_failure health_care expenditures patients québec randomized rhythm rate-control
H-1234	-0.6026685833930969	▁at rial _ fi bril lation ▁con ges tive _ ▁Heart _ fail ure ▁health _ care ▁ex pendi tures ▁Québec ▁ rhythm ▁rate - control ▁single - pay er ▁cost - mini m ization
D-1234	-0.6026685833930969	atrial_fibrillation congestive_ Heart_failure health_care expenditures Québec rhythm rate-control single-payer cost-minimization
P-1234	-0.7175 -0.1153 -0.4549 -0.4834 -0.2188 -0.1931 -0.3747 -0.1633 -0.6769 -0.2562 -0.7700 -0.3835 -0.4325 -0.1059 -2.6817 -0.8108 -0.3512 -0.2718 -0.0214 -0.3227 -1.1067 -0.3582 -0.7660 -0.3243 -0.2186 -0.0155 -3.7820 -0.0806 -0.0639 -0.3235 -1.8995 -0.2032 -0.6698 -0.7664 -0.3136 -1.2662 -0.3351
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report calcineurin nfat mir-25 expression basic_helix-loop-helix bhlh transcription_factor dhand hand2 diseased myocardium
H-640	-0.6066791415214539	▁report ▁calci ne uri n ▁na fat _ signal ling ▁mi r -25 ▁expression ▁heli x - loop - heli x ▁b HL h ▁tran scription _ factor ▁d hand ▁hand ▁mouse _ My o car dium
D-640	-0.6066791415214539	report calcineurin nafat_signalling mir-25 expression helix-loop-helix bHLh transcription_factor dhand hand mouse_Myocardium
P-640	-0.0158 -0.1192 -0.5093 -0.0193 -0.2592 -2.8726 -2.2932 -0.3098 -0.2450 -0.2459 -1.5243 -0.9819 -0.0596 -0.2301 -1.0117 -0.5823 -0.1864 -0.4410 -0.4085 -0.1248 -0.4662 -0.4319 -1.3748 -0.3926 -0.0869 -0.0310 -0.4947 -0.0312 -0.0682 -0.6266 -1.2349 -0.7384 -0.3834 -3.8431 -0.2150 -0.0157 -0.2106 -0.3610 -0.2147
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart_failure patient compliance myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal_dysfunction
H-1668	-0.5199576020240784	▁rever sible ▁heart _ ▁failure ▁compliance ▁my o card ial _ is cha emia ▁bra dy ar rhythm ias ▁val vu lar _ re gur gi tation ▁pulmonar y _ e mbol ism ▁infection ▁renal _ ▁dys function
D-1668	-0.5199576020240784	reversible heart_ failure compliance myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal_ dysfunction
P-1668	-1.0880 -0.0257 -1.9588 -0.2927 -2.2901 -0.0567 -0.7151 -0.2775 -0.6971 -0.4783 -0.4977 -3.1899 -0.0200 -0.3795 -1.5148 -0.2788 -0.0687 -0.2810 -1.4772 -0.8165 -0.2963 -0.1605 -0.3572 -0.1096 -0.0349 -0.2715 -0.0589 -0.0052 -0.3455 -0.6571 -0.2661 -0.0287 -0.0627 -0.2150 -0.0191 -0.5566 -0.3408 -0.0126 -0.3707 -0.2252
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc_battery hf health_abc_hf_model death
H-629	-1.1340913772583008	▁h bc _ ▁Bat tery _ sco te e ▁h f ▁health ▁ABC _ h f _ model ▁death
D-629	-1.1340913772583008	hbc_ Battery_scotee hf health ABC_hf_model death
P-629	-0.6737 -1.7442 -1.2595 -0.6075 -0.1638 -0.3374 -1.3111 -4.6925 -0.6980 -0.6052 -2.4227 -0.1000 -1.6451 -0.6549 -2.2644 -0.9902 -0.6533 -0.1354 -1.6996 -0.9147 -0.2427
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp admission sensitivity specificity confidence_interval area_under_the_curve
H-269	-0.44557681679725647	▁NT - pro b NP ▁cut off _ point ▁confidence _ ▁interval ▁cur ve
D-269	-0.44557681679725647	NT-probNP cutoff_point confidence_ interval curve
P-269	-0.1509 -0.0986 -0.0493 -0.6589 -0.4836 -0.7891 -0.0514 -0.4455 -0.2522 -1.3799 -0.3522 -0.8155 -0.8001 -0.2051 -0.3756 -0.2216
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic r-r_interval hr_variability short-term_fractal_scaling_exponent prognostic
H-1588	-0.5228533744812012	▁prognos tic _ power ▁r - r _ ▁interval _ os cilla tions ▁non - line ar _ ▁HR _ ▁variabil ity ▁short - term _ fra c tal _ ▁scal ing _ ex ponent
D-1588	-0.5228533744812012	prognostic_power r-r_ interval_oscillations non-linear_ HR_ variability short-term_fractal_ scaling_exponent
P-1588	-0.4677 -0.2772 -0.2933 -0.0614 -0.9433 -0.2549 -0.6896 -0.1701 -0.5107 -1.1138 -0.1092 -0.0258 -0.2227 -0.2699 -0.0423 -0.0937 -0.0258 -0.4656 -1.1340 -0.9247 -1.0228 -0.1235 -1.4963 -0.1369 -0.5773 -0.3265 -0.8099 -0.3422 -0.2866 -0.2283 -2.7903 -0.1104 -0.7569 -0.3030 -1.1040 -0.5987 -0.2365
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart_failure hf patients spontaneous_ventricular_tachycardia hf patients spontaneous_vt hearts
H-1437	-1.0120192766189575	▁heart _ fail ure HF ▁vent ri cular _ ta chy car dia ▁h n m
D-1437	-1.0120192766189575	heart_failureHF ventricular_tachycardia hnm
P-1437	-1.2398 -0.3659 -1.4464 -2.8250 -1.5555 -0.1348 -0.4763 -0.2159 -0.5165 -0.7534 -0.1760 -0.0507 -0.0712 -1.3173 -4.5161 -1.7175 -0.6392 -0.1989
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls cox_model chronic_heart_failure hypertension diabetes stroke estimated_glomerular_filtration_rate lvef
H-819	-0.8039451241493225	▁gr s ▁co x _ model ▁chronic _ heart _ fail ure ▁hyper tension ▁diabetes ▁prior _ stro ke _ ▁score ▁glo mer ular _ filter ation _ rate ▁LV EF ▁cv _ event s
D-819	-0.8039451241493225	grs cox_model chronic_heart_failure hypertension diabetes prior_stroke_ score glomerular_filteration_rate LVEF cv_events
P-819	-0.9345 -1.0681 -0.3818 -0.1756 -0.3285 -0.2144 -0.7546 -0.3563 -2.0347 -0.2061 -1.3790 -2.3875 -0.0165 -0.0018 -0.0567 -1.3496 -0.2815 -0.2616 -1.9525 -0.3459 -3.2536 -0.1519 -0.1506 -0.1121 -0.2815 -1.3849 -0.7421 -0.2797 -0.7871 -0.2971 -1.1229 -2.0639 -1.1217 -2.7330 -0.0492 -0.4992 -0.2284
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic_function diastolic_filling_formalism relaxation doppler_mitral_inflow_velocity e-wave
H-921	-0.48706144094467163	▁dia sto lic _ function ▁dia sto lic _ ▁fill ing ▁relax ation vis co ela stic ▁passiv e ▁sti ff ness ▁do pp ler _ mit ral _ in flow _ velo city ▁e - wa ve
D-921	-0.48706144094467163	diastolic_function diastolic_ filling relaxationviscoelastic passive stiffness doppler_mitral_inflow_velocity e-wave
P-921	-0.1268 -0.3768 -0.1109 -0.5187 -0.2388 -0.1686 -0.6188 -0.2085 -0.5048 -1.9859 -0.0542 -3.0811 -0.0132 -0.6343 -0.0531 -0.0015 -0.0035 -0.0695 -0.1238 -3.1998 -0.3504 -0.1060 -0.2607 -0.3473 -1.8700 -0.4009 -1.6240 -0.2248 -0.3355 -0.1873 -0.1793 -0.2574 -0.0235 -0.1191 -0.2939 -0.0867 -0.0226 -0.1089 -0.3490 -0.2425
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient vad patients ventricular_assist_device ecmo patients extracorporeal_membrane_oxygenation ecmo vad patients ecmo vad
H-1387	-1.1558594703674316	▁ VAD ▁vent ri cular _ assist _ ▁device ▁ec mo ▁extra corp o real _ ▁membran e _ ▁oxygen ation _ ▁membran e ▁ec mo ▁ VAD
D-1387	-1.1558594703674316	VAD ventricular_assist_ device ecmo extracorporeal_ membrane_ oxygenation_ membrane ecmo VAD
P-1387	-2.9452 -0.6622 -0.0476 -0.5955 -0.2218 -0.3763 -0.0108 -1.3956 -3.3533 -1.3861 -2.8266 -1.4741 -0.3687 -0.7333 -0.5966 -0.3206 -3.1419 -0.1353 -0.8789 -0.9096 -0.1726 -0.2147 -1.4458 -0.1339 -1.1573 -2.7142 -4.1187 -1.6852 -0.4071 -0.2464
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional_status 6-mwt nyha_class patients hfpef hfref prescribed therapy patients hfpef death hf hospitalization
H-244	-0.8001251220703125	▁mw t ▁NY ha ▁h f f ▁h f f ▁ therapy ▁h f p EF ▁death ▁h f
D-244	-0.8001251220703125	mwt NYha hff hff therapy hfpEF death hf
P-244	-0.9036 -0.1210 -0.6205 -0.3884 -1.3304 -1.7474 -0.6409 -0.9646 -1.3634 -0.4038 -0.9789 -0.0560 -0.8179 -1.6252 -0.0552 -0.4639 -1.6124 -0.7171 -0.9397 -0.7793 -0.2732
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart_failure disease evidence-based health_care
H-2016	-0.7754303812980652	▁cost - effect ive ness ▁heart _ fail ure _ ▁disease _ management ▁evidence - based _ ▁Treatment s ▁health _ care _ system
D-2016	-0.7754303812980652	cost-effectiveness heart_failure_ disease_management evidence-based_ Treatments health_care_system
P-2016	-1.0245 -0.2605 -0.0425 -0.2471 -1.9548 -1.2056 -0.2398 -1.7691 -1.6594 -0.7091 -1.3537 -0.7052 -0.0835 -1.0184 -0.0532 -0.0059 -0.8257 -4.1492 -0.1679 -0.0728 -0.5598 -0.4353 -0.6191 -0.0994 -0.6262 -0.2737
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin heart_failure murine resistin transgenic retn gene resistin
H-930	-0.833143949508667	▁resist in ▁heart _ fail ure ▁mouse ▁mur ine ▁trans ge nic ▁Ret n _ gene ▁h um - re t n _ mi ce ▁ inflammation - stimul ated _ re sist in ▁humans
D-930	-0.833143949508667	resistin heart_failure mouse murine transgenic Retn_gene hum-retn_mice inflammation-stimulated_resistin humans
P-930	-2.0014 -0.6860 -1.3730 -0.2426 -0.7481 -1.5616 -0.6358 -1.1188 -0.5377 -2.5257 -0.0591 -0.0205 -0.2449 -0.0183 -0.0969 -3.4680 -1.2531 -0.8491 -0.0570 -0.5387 -0.7038 -0.0233 -0.1052 -0.6003 -0.5442 -1.5187 -0.1692 -0.1163 -0.2998 -0.1528 -0.7214 -0.3576 -4.3978 -1.0178 -1.4476 -0.3743 -0.2400
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients angiotensin-converting_enzyme_inhibitors angiotensin_receptors_blockers β-blockers
H-1745	-0.5619171857833862	▁ang io ten sin - con ver ting _ ▁enzym e _ ▁inhibi tors angi oten sin _ ▁receptor s ▁β - block ers
D-1745	-0.5619171857833862	angiotensin-converting_ enzyme_ inhibitorsangiotensin_ receptors β-blockers
P-1745	-0.2263 -3.8342 -0.2892 -1.0381 -1.5068 -0.0328 -0.1223 -0.2463 -0.2490 -1.0755 -0.3495 -0.3445 -0.4678 -0.0670 -0.1221 -0.0083 -0.4338 -0.2100 -0.2047 -0.3856 -1.0341 -0.0740 -0.4781 -0.1598 -1.3379 -0.3123
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac_injury ejection_fraction fractional_shortening heart_dilatation hypertrophy transverse_aortic_constriction tac
H-1815	-0.5029898881912231	▁t t t et Men a _ mi ce ▁cardiac _ ▁injury ▁e je ction _ fraction ▁ fraction al ▁heart _ di la tation ▁hyper trop hy ▁trans verse _ a or tic _ con stri ction TAC
D-1815	-0.5029898881912231	tttetMena_mice cardiac_ injury ejection_fraction fractional heart_dilatation hypertrophy transverse_aortic_constrictionTAC
P-1815	-0.7521 -0.2382 -0.7603 -1.0524 -1.4006 -0.1620 -0.3424 -0.3579 -0.2775 -0.0929 -0.2875 -1.1110 -0.2847 -0.1088 -0.1410 -0.4185 -0.0223 -2.1589 -0.0035 -1.0837 -1.9756 -0.4951 -1.3266 -0.1690 -0.0967 -0.0163 -0.2817 -0.2130 -0.0079 -0.5474 -0.4527 -0.1798 -0.4034 -0.0755 -0.2921 -0.5210 -1.0273 -0.5692 -0.2904 -0.4025 -0.2234
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart_failure patients italy confirmatory_factor_analysis cfa schfi_v.6.2 self-care_maintenance self-care_management self-care_confidence
H-1505	-0.7283620834350586	▁heart _ ▁failure ▁ital y ▁confirma tory _ factor _ analyse ▁c fa ▁sch fi ▁self - Car e _ ▁Main ten ance ▁self - Car e _ management ▁self - Car e _ ▁Confi den ce
D-1505	-0.7283620834350586	heart_ failure italy confirmatory_factor_analyse cfa schfi self-Care_ Maintenance self-Care_management self-Care_ Confidence
P-1505	-1.1287 -0.3563 -2.6813 -0.7808 -0.7149 -0.0139 -0.0107 -0.3064 -0.0185 -0.3976 -0.4720 -0.8160 -0.6667 -0.9493 -2.2338 -0.2490 -0.1311 -2.2726 -0.4043 -0.1483 -2.8794 -1.0673 -0.0913 -0.5972 -0.1557 -1.8511 -0.4088 -0.1801 -0.1153 -0.6149 -0.1592 -1.9192 -0.4358 -0.1813 -2.1492 -0.0959 -0.1680 -0.3646 -0.2200
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation_for_ambulatory_heart_failure_trial implantable primary_end_point all-cause_mortality heart_failure hospitalization
H-882	-0.560831606388092	▁re syn chron ization - Def i bril lation ▁amb ulator y _ ▁Heart _ fail ure ▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT ▁mortal ity ▁heart _ fail ure
D-882	-0.560831606388092	resynchronization-Defibrillation ambulatory_ Heart_failure implantable_ cardioverter_defibrillator-cRT mortality heart_failure
P-882	-0.2150 -0.0649 -0.0257 -0.4202 -0.3599 -1.9840 -0.3794 -0.3122 -0.0899 -0.6921 -0.3988 -0.5984 -0.3328 -1.3490 -0.3140 -1.0445 -0.2200 -0.3766 -0.1042 -1.2676 -0.4066 -0.1654 -0.2961 -0.3224 -0.1045 -0.2322 -0.9863 -0.0629 -0.1553 -0.1890 -0.6535 -3.3882 -0.9675 -0.0984 -0.6102 -0.3248 -1.4970 -0.6632 -0.5189 -0.2416
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic_events ies patients ischemic_cardiomyopathy ic cardiac_resynchronization_therapy defibrillator crt-d
H-102	-0.581092894077301	▁ ische mic _ event s ▁i e s ▁ ische mic _ ▁cardio my o pathy ▁i cc ▁cardiac _ re syn chron ization _ therapy ▁de fi br illa tor ▁c t - d
D-102	-0.581092894077301	ischemic_events ies ischemic_ cardiomyopathy icc cardiac_resynchronization_therapy defibrillator ct-d
P-102	-1.6253 -0.1138 -0.7430 -0.2450 -3.4468 -0.1061 -0.2936 -1.4421 -1.3213 -1.2734 -0.0787 -0.6524 -0.2263 -0.1865 -1.4061 -0.4115 -0.0252 -0.2945 -0.7590 -0.0613 -0.2120 -0.0692 -0.0422 -0.0147 -0.4490 -0.4534 -0.5394 -0.2042 -0.1726 -0.4183 -0.0562 -0.2005 -1.0158 -2.0935 -0.0884 -0.1696 -0.8804 -0.2902
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal_dysfunction chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks follow-up mortality ischemic_cardiomyopathy
H-69	-0.46604520082473755	▁renal _ ▁dys function ▁chronic _ ob struct ive _ ▁pulmonar y ▁diabetes ▁per i pher al _ ▁vas cular _ ▁disease ▁left _ vent ri cular _ e je ction _ fraction ▁i CD _ ▁shock s ▁follow - up ▁mortal ity ▁ ische mic _ ▁cardio my o pathy
D-69	-0.46604520082473755	renal_ dysfunction chronic_obstructive_ pulmonary diabetes peripheral_ vascular_ disease left_ventricular_ejection_fraction iCD_ shocks follow-up mortality ischemic_ cardiomyopathy
P-69	-0.1087 -0.3660 -0.3178 -0.0267 -0.0229 -0.3156 -0.8048 -0.0740 -0.1433 -0.2606 -0.2356 -0.1942 -1.6890 -0.0579 -0.2697 -0.0912 -0.4166 -0.2766 -2.9640 -0.3185 -0.4601 -1.4813 -0.3411 -0.3105 -0.6104 -1.2006 -0.1977 -0.4224 -0.2530 -0.4244 -0.2083 -0.2456 -0.0261 -0.5141 -0.9198 -0.8708 -0.9557 -0.0833 -0.0780 -0.2135 -0.0151 -0.9940 -0.0640 -1.6850 -0.0155 -0.3895 -0.2240 -0.0998 -0.8601 -0.2986 -0.0109 -1.0422 -0.2308
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients chf testosterone exercise testosterone placebo
H-1318	-0.43785372376441956	▁CHF ▁SD _ ▁testosteron e ▁exercise ▁testosteron e
D-1318	-0.43785372376441956	CHF SD_ testosterone exercise testosterone
P-1318	-0.1852 -0.6357 -0.7365 -0.2445 -0.1725 -0.8002 -0.2393 -0.4127 -0.7742 -0.1777
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold_proteins cardiac_remodelling field therapeutic
H-996	-0.5481584668159485	▁Raf - MEK 1/2 - er k 1/2 _ sc af fold _ ▁Protein s ▁cardiac _ ▁remodel ling
D-996	-0.5481584668159485	Raf-MEK1/2-erk1/2_scaffold_ Proteins cardiac_ remodelling
P-996	-0.2168 -0.1795 -0.0552 -0.1954 -0.1046 -0.5003 -0.4891 -0.5283 -0.3750 -2.2339 -1.5130 -0.1065 -0.1782 -1.4212 -0.2908 -0.6692 -0.2604 -1.0716 -0.1170 -0.7904 -0.2149
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional_ms lv_dilatation heart_failure hf functional_ms hf prolapse degenerative_mitral_valve
H-341	-1.1519625186920166	▁ms ▁dynamic ▁LV _ di la tation ▁treatment _ for _ heart _ fail ure ▁h f ▁LV ▁functional _ ▁ms ▁h f ▁MR ▁pro lapse ▁de genera tive _ mit ral _ val ve
D-341	-1.1519625186920166	ms dynamic LV_dilatation treatment_for_heart_failure hf LV functional_ ms hf MR prolapse degenerative_mitral_valve
P-341	-3.3768 -0.7925 -2.1360 -2.8228 -1.1063 -0.0706 -0.0318 -1.9340 -1.8070 -0.1322 -0.7016 -2.4627 -0.3268 -1.0075 -2.7207 -1.0332 -2.0775 -2.0256 -1.4960 -1.2709 -2.5528 -1.9777 -2.1833 -0.7923 -0.1275 -0.1921 -1.0957 -0.0242 -0.1797 -0.2545 -1.6793 -0.0495 -0.2403 -0.9163 -0.1684 -0.6222 -0.2339
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blockers β-blockers patients heart_failure medications medical
H-1130	-0.9438523650169373	▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin - recept or _ block ers ▁β - block ers ▁heart _ fail ure ▁medication s ▁medical
D-1130	-0.9438523650169373	angiotensin_ converting_ enzyme_ inhibitor angiotensin-receptor_blockers β-blockers heart_failure medications medical
P-1130	-0.8184 -5.2959 -0.4037 -0.8010 -1.5610 -0.0676 -0.1381 -0.2434 -0.5399 -0.2964 -0.2067 -0.9093 -0.2154 -0.1285 -5.1068 -0.7667 -2.0888 -1.3325 -0.4060 -0.4929 -0.4325 -1.9741 -0.3252 -0.3821 -0.0993 -0.5993 -0.1927 -0.6296 -0.3992 -1.5001 -1.7911 -1.1419 -0.1720 -0.1541 -2.0687 -0.2979
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new_york_heart_association_class kccq symptom spearman_correlations 2-way_anova patients hf_with_reduced_ef hfpef
H-783	-0.8387974500656128	▁New _ York _ ▁Heart _ association ▁k cc q ▁Spe ar man _ corre lation s ▁2- way _ a NOVA ▁h f ▁ef ▁h p EF
D-783	-0.8387974500656128	New_York_ Heart_association kccq Spearman_correlations 2-way_aNOVA hf ef hpEF
P-783	-0.7707 -1.1301 -2.6272 -0.2006 -0.4825 -0.1837 -0.2947 -1.5904 -0.0941 -0.9654 -0.9320 -0.0214 -0.1201 -3.0486 -0.7454 -0.0714 -0.0773 -1.2405 -0.0611 -0.1915 -0.0568 -0.0798 -1.4885 -1.6943 -3.4473 -0.7641 -1.2688 -0.5453 -0.7204 -0.2501
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic lv_ejection_fraction lv_strain strain systole diastolic lv_strain_rate diastole transmitral_flow patients sinus_rhythm follow-up
H-951	-0.8931031227111816	▁LV _ sy sto lic _ ▁indice s LV _ e je ction _ fraction ▁strain ▁strain _ rate _ at _ sy stol e ▁dia sto lic _ ▁indice s ▁ratio ▁strain _ rate ▁dia stol e ▁transmit ral _ flow ▁sinus _ rhythm ▁follow - up
D-951	-0.8931031227111816	LV_systolic_ indicesLV_ejection_fraction strain strain_rate_at_systole diastolic_ indices ratio strain_rate diastole transmitral_flow sinus_rhythm follow-up
P-951	-1.6153 -1.5439 -4.0059 -1.6785 -0.1919 -0.1423 -1.2864 -0.0438 -0.8671 -1.3091 -0.2470 -0.5571 -0.1047 -0.2138 -0.0213 -1.4573 -3.5533 -1.0305 -1.6761 -1.7214 -0.9564 -0.3205 -4.2127 -1.3609 -0.4770 -0.1887 -1.4198 -0.3885 -0.2044 -1.2361 -0.1006 -1.2163 -1.4295 -0.1912 -1.0388 -0.6430 -0.7482 -0.6069 -1.6713 -0.2828 -0.5628 -0.3732 -0.3799 -0.3008 -0.2806 -0.0284 -0.2484 -0.0132 -0.3080 -0.1999
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang_ii_infusion ang_ii_infusion uninephrectomy ang_ii_infusion salt_loading ang_ii_infusion uninephrectomy salt_loading
H-276	-0.7981211543083191	▁c 57 b ▁ang _ ▁II _ in fusion ▁ang _ ▁II _ in fusion ▁un ine ph r ecto my ▁ang _ ▁II _ in fusion ▁salt _ load ing ▁ANG _ ▁II _ in fusion ▁un ine ph r ecto my ▁salt _ load ing
D-276	-0.7981211543083191	c57b ang_ II_infusion ang_ II_infusion uninephrectomy ang_ II_infusion salt_loading ANG_ II_infusion uninephrectomy salt_loading
P-276	-0.1899 -0.1425 -2.3577 -3.1702 -0.4479 -1.0054 -0.4819 -0.3835 -0.2872 -3.0278 -0.4571 -1.1752 -0.3925 -0.5561 -0.3280 -0.1995 -0.4364 -2.0238 -0.3385 -0.1346 -2.0730 -2.4937 -0.4655 -1.3184 -0.3942 -0.5465 -0.3474 -0.2018 -0.2516 -0.1645 -0.1880 -2.4264 -0.6100 -1.1027 -0.4319 -0.4333 -0.2656 -0.3978 -0.2887 -2.3221 -0.2701 -0.3544 -2.4905 -0.0990 -0.3252 -0.1696 -0.1426 -0.8084 -0.1897
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral_blood_flow_velocity tissue_doppler diastolic_mitral_annulus_velocity pulmonary_capillary_wedge_pressure pcwp patients decompensated_systolic_heart_failure hf
H-480	-0.761160135269165	▁transmission ral _ ▁blood _ flow _ velo city ▁do pp ler ▁early _ dia sto lic _ mit ral _ ▁ann ulus _ velo city ▁pulmonar y _ cap illa ry _ we dge _ press ure ▁pc p ▁sy sto lic _ ▁heart _ fail ure HF
D-480	-0.761160135269165	transmissionral_ blood_flow_velocity doppler early_diastolic_mitral_ annulus_velocity pulmonary_capillary_wedge_pressure pcp systolic_ heart_failureHF
P-480	-5.6958 -0.3096 -0.6132 -2.6823 -0.2135 -0.5918 -0.2579 -0.0274 -0.2053 -0.4707 -0.0900 -0.6678 -0.5736 -0.3554 -0.4734 -1.2572 -0.3956 -0.2184 -1.9264 -0.0866 -0.2384 -3.4961 -0.3329 -0.2671 -0.0211 -0.1747 -0.0161 -0.1670 -0.7385 -0.9431 -0.0860 -0.4827 -0.4694 -2.0223 -0.0749 -0.1790 -1.2090 -0.4911 -0.2943 -1.1293 -0.6513 -0.7777 -0.8425 -0.2101 -2.2022 -0.2648 -1.2637 -1.3099 -0.7944 -0.3748 -0.1825
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak_vo2 exercise
H-1984	-0.8815538287162781	▁pe ak _ vo 2 ▁exercise ▁body _ ▁mass ▁die t ▁body _ ▁mass
D-1984	-0.8815538287162781	peak_vo2 exercise body_ mass diet body_ mass
P-1984	-0.7813 -0.0681 -0.2067 -0.1434 -0.2402 -0.2838 -2.4649 -0.3625 -1.3396 -1.2635 -0.3975 -3.6657 -0.3538 -1.7186 -0.4626 -0.3526
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami patient hospital hospital_compare p-value
H-1698	-1.0133638381958008	AMI ▁hospital ▁odds _ of _ ▁dy ing
D-1698	-1.0133638381958008	AMI hospital odds_of_ dying
P-1698	-0.8357 -0.7482 -4.7598 -1.3112 -0.1451 -0.2960 -1.2668 -0.1120 -0.3936 -0.2652
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq patients hfpef log_rank ef
H-789	-0.9705386161804199	▁k cc q HF p EF log _ rati o ▁ef
D-789	-0.9705386161804199	kccqHFpEFlog_ratio ef
P-789	-2.5097 -0.2155 -0.8373 -1.9616 -0.0494 -0.5426 -1.7302 -1.0111 -1.5312 -0.0348 -1.5093 -0.4119 -0.2724
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt nt-probnp report ctnt nt-probnp clinical hf
H-292	-0.5028000473976135	▁c t n t ▁NT - pro b NP ▁report ▁c t n t ▁NT - pro b NP ▁ HF _ pred i ction _ model
D-292	-0.5028000473976135	ctnt NT-probNP report ctnt NT-probNP HF_prediction_model
P-292	-0.0479 -0.2669 -0.1409 -0.2916 -0.4231 -0.1103 -0.1169 -1.3232 -0.5049 -0.1609 -0.0589 -0.3639 -0.0589 -0.4755 -0.3591 -0.1475 -0.1522 -1.8206 -0.5578 -2.8452 -0.7695 -1.1563 -0.0764 -0.2287 -0.5482 -0.6077 -0.3377 -0.3833 -0.2470
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass_spectrometry c-terminally nt-probnp physiological proteolysis
H-1517	-0.5579477548599243	▁Mass _ spec tro met ry ▁circula ting ▁NT - pro b NP ▁physio logic al _ prote ol ysis ▁pro 2- le u 3 ▁le u 3- g ly 4 ▁pro 6 - g ly 7 ▁pro 75 - ar g 76
D-1517	-0.5579477548599243	Mass_spectrometry circulating NT-probNP physiological_proteolysis pro2-leu3 leu3-gly4 pro6-gly7 pro75-arg76
P-1517	-1.1134 -0.4248 -1.1198 -0.2483 -0.1150 -1.1882 -0.4416 -0.0905 -0.6763 -0.0780 -0.2999 -1.5300 -0.3109 -0.0318 -0.7355 -0.1878 -0.5899 -1.6565 -0.4876 -1.2747 -1.7025 -0.3383 -1.6545 -0.0907 -0.0182 -0.5369 -0.0379 -0.1506 -1.1418 -0.3051 -0.0174 -0.9476 -0.6543 -0.0526 -1.1836 -0.4595 -0.0371 -0.9361 -0.4056 -0.0499 -0.8043 -0.1135 -0.1580 -0.4952 -0.2159
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef patients new_york_heart_association_class_ii ejection_fraction fes placebo
H-1329	-0.7053290605545044	▁h p EF ▁New _ York _ ▁Heart _ association ▁mean _ e je ction _ fraction ▁fe s
D-1329	-0.7053290605545044	hpEF New_York_ Heart_association mean_ejection_fraction fes
P-1329	-1.5926 -1.0546 -0.6525 -1.7080 -1.3378 -2.2548 -0.2655 -0.5242 -0.1785 -0.3788 -0.0755 -0.2347 -0.2829 -0.3513 -0.0995 -0.1883 -0.0252 -2.4356 -0.5302 -0.4226 -0.2187
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left_ventricular systolic_pressure ejection_fraction fractional_shortening cardiac_output lv_end-diastolic_pressure mi metoprolol
H-1548	-0.6104233264923096	▁de press ed _ ▁left _ vent ri cular LV ▁sy sto lic _ press ure ▁pressure ▁e je ction _ fraction ▁cardiac _ out put ▁LV ▁end - dia sto lic _ press ure ▁MI ▁met o pro lol
D-1548	-0.6104233264923096	depressed_ left_ventricularLV systolic_pressure pressure ejection_fraction cardiac_output LV end-diastolic_pressure MI metoprolol
P-1548	-1.1295 -0.0056 -0.0250 -0.4690 -2.1250 -0.1927 -0.6028 -0.9404 -0.3397 -0.6976 -1.3627 -0.8621 -0.5297 -0.1461 -2.3188 -0.9883 -0.4791 -0.2279 -0.1411 -0.1210 -0.3500 -0.0148 -0.9382 -0.2171 -0.3833 -0.0159 -0.7680 -0.2563 -0.1244 -0.1033 -2.6527 -0.6107 -0.1536 -1.9474 -0.7185 -0.9643 -0.4005 -0.2220 -0.0405 -0.4331 -0.4058 -0.2136
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex_activation_therapy_for_the_treatment_of_heart_failure_with_a_reduced_ejection_fraction clinical carotid baroreflex_activation_therapy bat heart_failure hf
H-1867	-0.8143113851547241	▁bar ore flex _ activ ation _ ▁Therapy ▁Heart _ fail ure ▁e je ction _ fra ction ▁caro tid _ ▁baro re flex _ activa tion _ therapy BAT ▁heart _ fail ure HF
D-1867	-0.8143113851547241	baroreflex_activation_ Therapy Heart_failure ejection_fraction carotid_ baroreflex_activation_therapyBAT heart_failureHF
P-1867	-1.4680 -1.5513 -2.0231 -0.2522 -0.5001 -0.5379 -0.1822 -0.6350 -0.8827 -0.2900 -0.5658 -0.1365 -2.5900 -0.0801 -0.0863 -0.1631 -1.3164 -0.2731 -0.4635 -1.1383 -0.6334 -1.9300 -1.3849 -1.7807 -0.1865 -1.0596 -0.2166 -0.2537 -0.8730 -1.0778 -1.6522 -0.2887 -1.1511 -0.9620 -0.9914 -0.3564 -0.1962
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome hazard_ratio
H-1748	-0.8019917011260986	haz ard _ rati o
D-1748	-0.8019917011260986	hazard_ratio
P-1748	-3.7063 -0.0714 -0.2800 -0.0419 -0.0512 -1.1801 -0.2829
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf blood_glucose obesity systemic_hypertension rheumatic_fever disease
H-1793	-0.557256281375885	▁h f ▁raised _ ▁blood _ ▁gluco se ▁obes ity ▁to ba cco ▁system ic _ hy tension SH ▁rhe u matic _ fe ver ▁cha gas ▁disease ▁la
D-1793	-0.557256281375885	hf raised_ blood_ glucose obesity tobacco systemic_hytensionSH rheumatic_fever chagas disease la
P-1793	-1.3812 -0.2020 -0.7216 -0.4197 -1.2321 -0.2398 -0.2233 -0.0996 -0.6579 -0.3551 -0.0373 -0.4022 -0.1994 -0.6120 -0.3578 -0.2517 -0.9551 -0.6977 -0.7421 -0.0202 -0.1028 -0.1877 -0.2999 -0.7870 -0.2766 -0.7257 -0.0183 -1.1316 -0.8379 -2.8813 -0.2181
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard_ratios confidence_interval hf hf
H-1107	-0.6751829385757446	▁hazard _ rati os ▁confidence _ ▁interval ▁early - ons et _ HF ▁late - ons et _ HF
D-1107	-0.6751829385757446	hazard_ratios confidence_ interval early-onset_HF late-onset_HF
P-1107	-3.0334 -0.2789 -0.0637 -0.2753 -1.1115 -0.3997 -0.8099 -0.3801 -0.1687 -0.3502 -0.2824 -0.7488 -1.9656 -0.5830 -0.1206 -0.4111 -0.3957 -0.5201 -1.8427 -0.2127 -0.2246
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard_ratios crf obese body_mass_index
H-1772	-0.7078315019607544	▁c RF ▁over weight ▁obes e _ ▁Body _ ▁mass _ index
D-1772	-0.7078315019607544	cRF overweight obese_ Body_ mass_index
P-1772	-0.8186 -2.2818 -0.0991 -0.1843 -0.2753 -0.4484 -0.7058 -1.5942 -0.3886 -1.7513 -0.1808 -0.4386 -0.4659 -0.2769
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline egfr egfr egfr hypertension diuretics esrd
H-395	-0.880285382270813	▁base line ▁e g FR ▁e g FR ▁e g FR ▁hyper tension ▁di ure tics ▁ec d
D-395	-0.880285382270813	baseline egFR egFR egFR hypertension diuretics ecd
P-395	-0.0678 -0.0637 -0.4611 -0.6044 -1.7462 -0.4560 -0.7507 -2.4398 -1.0895 -0.6856 -1.8345 -0.4272 -0.0037 -0.0965 -0.0716 -0.7416 -3.6840 -1.6277 -0.5398 -0.2142
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial phosphodiesterase-2 pde2 heart_failure hf beta-adrenergic_receptor β-ar healthy diseased cardiomyocytes
H-1208	-0.6158438920974731	▁my o card ial _ phos pho dies tera se -2 ▁p de 2 ▁heart _ fail ure ▁h z ▁p de 2- media ted _ effect s ▁beta - ad r energi c _ ▁receptor β - ar ▁cardio my o cy tes
D-1208	-0.6158438920974731	myocardial_phosphodiesterase-2 pde2 heart_failure hz pde2-mediated_effects beta-adrenergic_ receptorβ-ar cardiomyocytes
P-1208	-1.2572 -0.3634 -0.8561 -0.8172 -0.3258 -0.1681 -1.1355 -0.9219 -0.3012 -1.0252 -0.8084 -0.3577 -0.0329 -0.2751 -0.7327 -0.3167 -1.3393 -1.1568 -0.6926 -1.8078 -0.3904 -0.0238 -0.3006 -2.8671 -0.0441 -1.6858 -0.2195 -0.1600 -0.6271 -0.0731 -0.1511 -0.9500 -0.6212 -0.3264 -0.1419 -0.3668 -0.7847 -0.0268 -0.4002 -0.2729 -1.4162 -0.4238 -0.0425 -0.7240 -0.3915 -0.2056
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart_failure patients cardiac_resynchronization_therapy defibrillator implantable_cardioverter-defibrillator carvedilol atp shock_therapy metoprolol
H-866	-0.6115812659263611	▁heart _ fail ure ▁cardiac _ re syn chron ization _ therapy ▁de fi br illa tor ▁implant able _ ▁cardio ver ter - de fi br illa tor _ ▁device ▁car vedi lol ▁ATP ▁shock _ therapy ▁met o pro lol
D-866	-0.6115812659263611	heart_failure cardiac_resynchronization_therapy defibrillator implantable_ cardioverter-defibrillator_ device carvedilol ATP shock_therapy metoprolol
P-866	-0.8455 -0.4028 -1.6924 -1.6749 -0.0663 -0.2212 -0.0785 -0.0690 -0.0210 -0.5933 -0.9717 -0.4989 -0.1034 -0.3378 -1.6246 -0.2743 -0.6326 -0.0137 -0.0522 -1.4895 -0.3989 -0.1124 -0.1806 -0.4888 -0.0997 -1.4140 -2.7626 -0.5254 -0.6249 -0.2369 -4.5088 -0.1354 -0.0330 -0.1926 -1.3771 -0.1591 -0.3111 -0.1149 -0.0654 -0.2232 -0.0423 -0.4953 -0.5044 -0.2393
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich_cocoa skm mitochondrial_structure taub ramirez-sanchez ciaraldi perkins murphy naviaux hogan ceballos maisel henry
H-1245	-0.45514580607414246	ERC ▁e pica tech in - rich _ ▁coco a ▁Sk m ▁mito cho ndri al _ structure ▁rob ▁ram i rez - s anche z ▁ci ar aldi ▁per kin s ▁Murphy ▁na vi aux ▁Hoga n ▁ce ball os ▁mais el ▁Henry
D-1245	-0.45514580607414246	ERC epicatechin-rich_ cocoa Skm mitochondrial_structure rob ramirez-sanchez ciaraldi perkins Murphy naviaux Hogan ceballos maisel Henry
P-1245	-0.2811 -0.3290 -0.0322 -0.0406 -0.4729 -0.1118 -0.0021 -0.2623 -2.5582 -0.0901 -0.3063 -0.1973 -0.4254 -0.9612 -0.4458 -0.0627 -0.9120 -3.5931 -2.4744 -2.3823 -0.1977 -0.0253 -0.0660 -0.4722 -0.0192 -0.0886 -0.0191 -0.0133 -0.0087 -0.2381 -0.8781 -0.2017 -0.6688 -0.0433 -0.0117 -0.0183 -0.0090 -0.0539 -0.0232 -0.3387 -0.0757 -0.8402 -0.0132 -0.0957 -0.3929 -0.1829
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up death readmission patients physician physicians
H-1420	-0.8420002460479736	▁follow - up ▁urgent _ ▁read mission ▁physician s
D-1420	-0.8420002460479736	follow-up urgent_ readmission physicians
P-1420	-0.2070 -0.2276 -0.0310 -2.1441 -0.1425 -4.2874 -0.0482 -0.4509 -0.3662 -1.1367 -0.2206
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena_overexpression tac surgery mena cardiac_hypertrophy cardiac
H-1816	-1.1276313066482544	▁men a _ over expression ▁ TTA ▁ TAC _ ▁surgery ▁cardiac _ ▁hyper trop hy ▁t ta ▁post - TAC ▁cardiac _ function
D-1816	-1.1276313066482544	mena_overexpression TTA TAC_ surgery cardiac_ hypertrophy tta post-TAC cardiac_function
P-1816	-4.7748 -0.9925 -0.3552 -0.3743 -0.0796 -2.9586 -0.3403 -3.2268 -0.8268 -2.0452 -1.1630 -0.7473 -0.2281 -1.9389 -0.1791 -0.1954 -1.4211 -1.7309 -1.0920 -0.0513 -0.8683 -1.5423 -0.5062 -0.2137 -1.2531 -0.2137
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd diuretic hf outcomes clinical hospitalizations pdrelated complications
H-901	-0.6439477801322937	▁p ▁di ure tic _ re frac tory ▁h f
D-901	-0.6439477801322937	p diuretic_refractory hf
P-901	-0.6855 -0.4536 -0.0257 -0.1310 -0.2372 -0.0367 -0.2561 -0.1032 -1.2419 -0.8906 -3.4361 -0.2298
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp mitochondrial_oxidation glucose lactate fatty_acids myocardial glycolysis
H-1785	-0.37308448553085327	▁ATP _ product ion _ rate s ▁post - a ac ▁mito cho ndri al _ oxid ation ▁gluco se ▁lac tate ▁fa tty _ ▁acid s ▁my o card ial _ ▁gly col ysis
D-1785	-0.37308448553085327	ATP_production_rates post-aac mitochondrial_oxidation glucose lactate fatty_ acids myocardial_ glycolysis
P-1785	-0.3237 -1.0994 -0.1821 -0.0401 -0.4539 -0.6278 -0.0482 -0.5618 -0.0696 -0.1203 -0.5028 -0.1547 -1.2122 -0.3288 -0.0995 -0.1839 -0.3023 -0.1219 -0.2087 -0.1541 -0.0404 -0.2059 -0.0490 -0.1226 -0.1596 -1.1615 -0.1011 -0.9176 -0.2563 -0.7231 -0.4984 -0.1709 -0.5750 -0.1401 -0.1702 -1.4545 -0.2622
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic vegf_pathway intravenously injected adenoviral vegf_receptor adenovirus
H-456	-0.5187675952911377	▁pro angi ogen ic _ effect s ▁ve g f _ path way ▁a den ovi ral _ ve ctor ▁de co y _ ve g f _ ▁receptor ▁ade no virus ▁ad - c
D-456	-0.5187675952911377	proangiogenic_effects vegf_pathway adenoviral_vector decoy_vegf_ receptor adenovirus ad-c
P-456	-0.0745 -0.4178 -0.2816 -0.2802 -0.6894 -0.6048 -0.1052 -1.8150 -2.1024 -0.5048 -0.6477 -0.1462 -0.1808 -0.5589 -0.0358 -0.0969 -0.2210 -0.3346 -1.1526 -0.0724 -0.6722 -0.0077 -0.2514 -1.7111 -0.7845 -1.4839 -0.9415 -0.3593 -0.4347 -0.5680 -0.0249 -0.0375 -0.1731 -0.1333 -0.1853 -0.8725 -0.2312
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients eplerenone potassium potassium hospitalization hyperkalemia medication adverse_events
H-1226	-0.5738130211830139	▁e pler en one ▁po tas s ium ▁po tas s ium ▁hyper kal emia ▁medication
D-1226	-0.5738130211830139	eplerenone potassium potassium hyperkalemia medication
P-1226	-0.1075 -0.1445 -0.3127 -0.2418 -0.1028 -1.0806 -0.3266 -1.3030 -0.1478 -1.2503 -0.4359 -1.8221 -0.2425 -1.1912 -0.2189 -0.2160 -0.9787 -0.2057
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation bottleneck_stent lad lcx myocardial_ischemia stent ischemic_heart_failure stent therapeutic
H-514	-0.6943016648292542	▁implant ation ▁bottle ne ck _ ▁sten t ▁proxima l _ lad ▁ LC x ▁rever sible _ My o card ial _ ische mia open _ ▁sten t ▁ ische mic _ heart _ fail ure ▁sten t
D-514	-0.6943016648292542	implantation bottleneck_ stent proximal_lad LCx reversible_Myocardial_ischemiaopen_ stent ischemic_heart_failure stent
P-514	-0.0051 -0.0651 -0.0933 -0.2206 -0.0285 -0.4816 -3.4783 -0.1241 -0.1954 -0.0599 -0.7521 -1.4527 -1.5341 -0.8064 -0.7506 -0.1116 -0.0277 -0.6165 -3.7391 -0.5740 -0.3721 -0.2637 -0.3762 -0.1288 -0.7796 -0.7515 -0.5527 -3.2331 -0.3022 -0.5860 -0.0493 -0.4336 -0.4624 -1.4592 -0.2954 -0.7455 -1.1791 -0.3018 -0.3598 -0.4756 -0.2422
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient new_york_heart_association_class_iii heart_failure hf left_ventricular_ejection_fraction periodic_breathing pb report
H-1347	-0.7520570755004883	▁New _ York _ ▁Heart _ association ▁heart _ fail ure HF ▁vent ri cular _ e je ction _ fraction ▁permanent _ per man ent _ ▁breath ing ▁p b ▁report
D-1347	-0.7520570755004883	New_York_ Heart_association heart_failureHF ventricular_ejection_fraction permanent_permanent_ breathing pb report
P-1347	-1.1406 -1.3337 -3.0971 -0.2283 -0.5410 -0.1831 -0.4240 -0.7650 -0.2734 -1.1813 -2.7878 -1.6452 -2.2870 -0.6119 -0.3930 -0.4931 -0.1940 -0.3368 -0.1470 -0.2392 -0.0089 -0.1496 -0.2015 -1.7098 -0.6639 -0.1765 -0.0999 -3.3385 -0.2207 -0.0237 -0.0508 -0.0293 -0.3979 -0.1964
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium spironolactone aas
H-1705	-0.807957649230957	▁po tas s ium ▁spi rono lac tone ▁AA s ▁race _ by _ re lation ship
D-1705	-0.807957649230957	potassium spironolactone AAs race_by_relationship
P-1705	-0.7667 -0.4448 -0.1858 -0.8967 -0.1398 -0.0158 -0.2257 -0.1302 -1.3489 -0.2409 -0.3114 -0.6026 -2.4756 -0.3527 -3.8149 -2.4756 -0.0548 -0.6203 -0.2480
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom cpet patients chf patients exercise exercise patients exercise rehabilitation
H-1880	-0.48516646027565	▁c PET ▁CHF ▁exercise ▁exercise ▁exercise ▁rehabilita tion
D-1880	-0.48516646027565	cPET CHF exercise exercise exercise rehabilitation
P-1880	-0.4239 -1.2999 -0.1697 -0.1208 -0.1098 -0.2924 -1.4935 -0.1778 -0.4947 -0.2693
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography lv_end-diastolic_volume mitral_valve_opening mva
H-357	-0.6929950714111328	▁e cho card i ography ▁LV ▁end - dia sto lic ▁m l ▁ml ▁mit ral _ val ve ▁m va ▁pressure _ grad ient ▁h g
D-357	-0.6929950714111328	echocardiography LV end-diastolic ml ml mitral_valve mva pressure_gradient hg
P-357	-0.0676 -0.2108 -0.2911 -0.3479 -0.4230 -0.4040 -1.6457 -0.1201 -0.0521 -0.9245 -0.1874 -0.4032 -4.6362 -2.1154 -0.7786 -0.0528 -0.4076 -0.8357 -0.3856 -0.2673 -0.2480 -0.4543 -0.2676 -0.7774 -1.5620 -1.2233 -0.0305 -0.7570 -0.2203
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical post-lvad_ai aortic_valve leaflet bioprosthetic_aortic_valve_replacement functional_capacity lvad patients symptomatic
H-552	-0.9296115040779114	▁surgery ▁post - L VAD _ ai ▁a or tic _ val ve _ over se wing ▁le a flet ▁bio pro sthetic _ a or tic _ val ve _ ▁replace ment ▁functional _ capaci ty ▁CF _ l VAD ▁AI
D-552	-0.9296115040779114	surgery post-LVAD_ai aortic_valve_oversewing leaflet bioprosthetic_aortic_valve_ replacement functional_capacity CF_lVAD AI
P-552	-3.3854 -0.0586 -0.0321 -5.3585 -0.2186 -1.2163 -1.2486 -0.7018 -0.1287 -0.2581 -0.2124 -2.3747 -0.7042 -1.0956 -0.1695 -0.1751 -0.1054 -0.2227 -0.0233 -0.0408 -0.4104 -0.0342 -0.0568 -1.5077 -0.1049 -0.1731 -0.4292 -0.2181 -2.4728 -0.8753 -0.2467 -2.9122 -0.1425 -2.1782 -0.6271 -0.0655 -0.0192 -0.9773 -0.5445 -5.3836 -0.3430 -2.8875 -0.3054 -0.2575
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods_study health_care systolic_heart_failure prescribed β-blocker angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blocker
H-1123	-0.8211091160774231	▁va ▁health _ care _ system s ▁sy sto lic _ heart _ fail ure ▁β - block er ▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin - recept or _ block er
D-1123	-0.8211091160774231	va health_care_systems systolic_heart_failure β-blocker angiotensin_ converting_ enzyme_ inhibitor angiotensin-receptor_blocker
P-1123	-2.8952 -0.2761 -0.6182 -0.1266 -0.7738 -0.2009 -0.0372 -1.5656 -0.2397 -0.6153 -0.2008 -1.8043 -0.1456 -0.7742 -0.7794 -0.5148 -0.0489 -1.1674 -0.4998 -0.2809 -4.7722 -0.8692 -0.9983 -0.4437 -0.1726 -0.1979 -0.1853 -0.3402 -0.3657 -0.2280 -1.1465 -0.0997 -0.1205 -4.6753 -1.0305 -1.6555 -1.1076 -0.4720 -0.3367 -0.4285 -1.7375 -0.5441 -0.4246 -0.2123
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced_pulmonary_artery_systolic_pressure pasp stress_doppler_echocardiography right_ventricular_contractile_reserve patients pulmonary_hypertension right_heart_failure
H-822	-0.6540229320526123	▁exercise - indu ced ▁pulmonar y _ ▁arter y _ sy sto lic _ press ure ▁pas p ▁stress ▁do pp ler _ e cho card i ography ▁right _ vent ri cular _ contract ile _ ▁reserve ▁pulmonar y _ ▁hyper tension ▁right _ ▁heart _ fail ure
D-822	-0.6540229320526123	exercise-induced pulmonary_ artery_systolic_pressure pasp stress doppler_echocardiography right_ventricular_contractile_ reserve pulmonary_ hypertension right_ heart_failure
P-822	-0.8813 -0.2122 -0.0002 -0.0101 -0.7556 -0.4174 -0.4426 -0.2057 -0.5972 -0.7990 -2.3366 -0.7286 -0.5761 -0.2121 -1.2842 -0.6110 -1.6926 -0.1970 -1.5459 -0.1785 -0.1187 -1.1461 -0.2841 -0.1647 -0.9526 -0.6116 -0.3050 -0.3318 -0.0720 -0.4310 -0.8157 -1.9524 -0.2934 -0.2636 -0.2450 -0.8473 -0.7875 -0.8924 -0.0896 -0.4315 -0.6093 -1.9514 -0.0031 -0.0462 -0.3017 -2.3252 -0.3711 -1.1773 -1.1598 -0.4467 -0.2433
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline embase healthstar cinahl cochrane_library campbell_collaboration joanna_briggs_institute_evidence_based_practice centre_for_reviews_and_dissemination evidence_based_practice_centres
H-1844	-0.7614660859107971	▁MED line EMBA se ▁he al th STAR ▁c INA HL ▁co ch rane _ ▁Library ▁Campbell ▁Joan na _ ▁Brig gs _ institut e ▁evidence _ based _ prac tice
D-1844	-0.7614660859107971	MEDlineEMBAse healthSTAR cINAHL cochrane_ Library Campbell Joanna_ Briggs_institute evidence_based_practice
P-1844	-1.1676 -0.2790 -0.1251 -0.7541 -1.9713 -0.5407 -1.4656 -1.9908 -3.9301 -3.7270 -0.8436 -0.2778 -0.2883 -0.1669 -0.1915 -0.4401 -0.1012 -1.1044 -0.1138 -0.2715 -0.7563 -0.4234 -0.0905 -0.0854 -0.0522 -1.4661 -0.1888 -0.7070 -0.1587 -0.2163 -0.0095 -0.9706 -0.2530
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart_failure neuro-hormonal_system angiotensin_converting_enzyme_inhibitors angiotensin_receptor_blockers angiotensin_converting_enzyme_inhibitors beta_receptor_blockers mineralocorticoid_receptor_antagonists
H-647	-0.7440621852874756	▁heart _ fail ure ▁neuro - hormon al _ system ▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tors angi oten sin _ ▁receptor _ block ers ▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi tors ▁beta _ ▁receptor _ block ers ▁mineral o cor tico id _ ▁receptor
D-647	-0.7440621852874756	heart_failure neuro-hormonal_system angiotensin_ converting_ enzyme_ inhibitorsangiotensin_ receptor_blockers angiotensin_ converting_ enzyme_ inhibitors beta_ receptor_blockers mineralocorticoid_ receptor
P-647	-1.6340 -0.2805 -1.2421 -1.0776 -0.4825 -0.1219 -0.1083 -0.0680 -1.0425 -0.0873 -0.1554 -3.8909 -0.6151 -1.7201 -0.4628 -0.2967 -0.2032 -0.2432 -1.1911 -0.4395 -0.2056 -1.3003 -0.0610 -0.1905 -0.0419 -1.1312 -0.1724 -1.1633 -1.1948 -1.5510 -0.0437 -0.0486 -4.0278 -0.5648 -1.5949 -0.3586 -0.3303 -0.3317 -0.2246 -0.6657 -0.5367 -0.1853 -1.0251 -0.1923 -0.6423 -0.2763 -0.6875 -0.8749 -1.9990 -0.0416 -0.0277 -0.3773 -0.7688 -2.1302 -1.2465 -0.2060 -0.1272 -1.6895 -0.3000
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest rs rs_synchrony ste noninvasive rvpo rs_synchrony strain bivp
H-330	-1.074862003326416	▁open _ che st _ model ▁twist ▁twist ▁RS ▁RS _ syn chron y ▁ rte ▁ rv po ▁RS _ syn chron y ▁c p ▁bi VP
D-330	-1.074862003326416	open_chest_model twist twist RS RS_synchrony rte rvpo RS_synchrony cp biVP
P-330	-0.3828 -0.3130 -4.0142 -0.5576 -1.0882 -0.2007 -0.0058 -2.3922 -0.4603 -0.5662 -0.8422 -0.2572 -0.0298 -0.8300 -1.1076 -3.1071 -1.1571 -0.9991 -1.0895 -1.8748 -0.4257 -0.1695 -0.0641 -1.0845 -2.7584 -2.1057 -1.5394 -1.7276 -0.8227 -0.2728
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse pasp tapse pasp cox_regression kaplan-meier_analyses tapse pasp
H-498	-1.3552583456039429	▁t AP se ▁pas p ▁t AP se - to - pass p _ rati o ▁pi p ▁co x _ re gression ▁ka plan - me ier _ analyse s ▁t AP se ▁pas p
D-498	-1.3552583456039429	tAPse pasp tAPse-to-passp_ratio pip cox_regression kaplan-meier_analyses tAPse pasp
P-498	-2.9856 -3.4575 -1.6728 -2.4515 -1.5746 -2.8281 -3.4030 -1.8686 -0.1951 -0.2235 -0.3996 -1.9228 -1.9122 -0.2689 -0.1059 -0.0388 -6.0331 -0.6389 -0.3559 -0.2456 -0.3041 -0.1080 -0.2184 -0.8813 -0.1100 -0.1162 -0.4409 -0.2480 -2.4170 -0.0696 -0.1782 -3.6717 -2.3672 -1.2265 -2.8568 -1.9785 -1.4787 -0.2468
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese body_mass_index chronic stable hfpef
H-1978	-0.7215371131896973	▁obes e ▁body _ ▁mass _ index ▁chronic ▁h f f
D-1978	-0.7215371131896973	obese body_ mass_index chronic hff
P-1978	-0.7230 -0.3747 -0.3956 -0.4348 -1.2589 -0.1873 -0.3967 -1.0458 -1.0289 -1.1559 -0.5204 -1.6056 -0.2524
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart_failure hf mrna_splicing cardiac scn5a endoplasmic_reticulum
H-1080	-0.6841824054718018	▁heart _ fail ure HF ▁m RNA ▁volta ge - ga ted _ ▁cardiac ▁na + _ kanal ▁s cn 5 a ▁en co ding ▁tru nca ted ▁en do plas mic _ ▁reti culum
D-1080	-0.6841824054718018	heart_failureHF mRNA voltage-gated_ cardiac na+_kanal scn5a encoding truncated endoplasmic_ reticulum
P-1080	-3.2345 -0.2792 -0.9406 -1.4128 -1.5753 -0.0307 -0.0339 -0.0440 -0.0765 -0.1975 -0.1328 -0.1703 -0.4119 -0.1477 -0.2139 -3.9277 -0.3282 -2.4863 -1.6557 -0.7004 -0.2878 -0.1125 -1.1393 -0.0569 -0.2373 -0.0744 -0.0695 -0.0188 -1.1278 -0.6024 -0.1548 -1.9198 -0.3034 -0.5049 -0.0048 -0.4745 -0.2259
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart_failure diagnosis myocarditis dilated_cardiomyopathy heart_failure heart_failure anthracycline disease
H-988	-0.8391685485839844	▁pa e dia tric _ heart _ fail ure ▁my o card itis ▁dil ated _ ▁cardio my o pathy ▁heart _ fail ure ▁heart _ fail ure ▁an thra cycli ne ▁malign ant _ ▁disease
D-988	-0.8391685485839844	paediatric_heart_failure myocarditis dilated_ cardiomyopathy heart_failure heart_failure anthracycline malignant_ disease
P-988	-1.5150 -0.3482 -0.1195 -2.4669 -0.4731 -2.8503 -0.2299 -2.0967 -2.0105 -0.6246 -0.2823 -0.6304 -0.3232 -0.1385 -0.0150 -0.3894 -0.1234 -1.1409 -0.3831 -0.0265 -1.5460 -0.5357 -2.0331 -1.4117 -0.8738 -0.3416 -1.7857 -1.1292 -0.1680 -0.1861 -0.4506 -1.0663 -0.0451 -0.4839 -0.3720 -2.2098 -0.7942 -0.2682
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model clinical evidence-based medications costs outcomes
H-2010	-0.7664632797241211	▁economic ▁Heart _ fail ure ▁costs
D-2010	-0.7664632797241211	economic Heart_failure costs
P-2010	-0.9483 -1.5342 -0.3416 -0.4173 -0.0585 -2.1791 -0.4201 -0.2326
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic_peptides nps b-type_np n-terminal_pro-b-type_np diagnosis acute_heart_failure patients emergency_department acute_dyspnea
H-1020	-0.558828592300415	▁na tri ure tic _ pe pti des NP s ▁a cute _ heart _ fail ure ▁Emer gen cy _ de part ment ▁ed ▁a cute _ ▁dys pne a
D-1020	-0.558828592300415	natriuretic_peptidesNPs acute_heart_failure Emergency_department ed acute_ dyspnea
P-1020	-0.0094 -0.1333 -0.0662 -0.1872 -0.2415 -0.7907 -0.2791 -1.1450 -0.5043 -0.0548 -2.1937 -0.2356 -0.1836 -2.1500 -0.1975 -0.8092 -1.7933 -0.2659 -0.3033 -0.4434 -0.2921 -1.0210 -0.0736 -0.0835 -1.2814 -0.4962 -0.0626 -0.1370 -1.7705 -0.0400 -0.4790 -0.4541 -0.2635
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak_oxygen_consumption peak_vo2 exercise exercise_oscillatory_ventilation eov partial_pressure_of_end-tidal_co2 petco2 gain cardiopulmonary_exercise_testing
H-1275	-0.6370119452476501	▁pe ak _ ▁oxygen _ ▁consum p tion ▁pe ak _ vo 2 ▁v co 2 _ s lope ▁exercise _ os cilla tory _ ventil ation ▁e OV ▁pressure ▁end - ti dal _ co 2 PET co 2 ▁cardio pul mon ary _ ▁exercise
D-1275	-0.6370119452476501	peak_ oxygen_ consumption peak_vo2 vco2_slope exercise_oscillatory_ventilation eOV pressure end-tidal_co2PETco2 cardiopulmonary_ exercise
P-1275	-0.0446 -0.0606 -0.1594 -2.8358 -0.3142 -2.7708 -0.4147 -0.2771 -0.7905 -0.0280 -0.1596 -0.2066 -0.7825 -1.1365 -0.9661 -0.1099 -1.6310 -0.2082 -0.3881 -0.0372 -2.1894 -0.2113 -0.0728 -0.1039 -0.2671 -1.6340 -0.0978 -0.4739 -0.6832 -0.3866 -0.3367 -0.1006 -0.0244 -1.4983 -0.3344 -0.1267 -0.1821 -0.4014 -0.4386 -0.5065 -0.2913 -0.8301 -2.4025 -0.1500 -0.7668 -1.1498 -1.3234 -0.2718
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective_cohort_study denmark bisphosphonates raloxifene
H-1536	-0.6298203468322754	▁den mark ▁bis phos phon ates ▁ra lo xi fen e
D-1536	-0.6298203468322754	denmark bisphosphonates raloxifene
P-1536	-1.6837 -0.0073 -0.3000 -0.1166 -0.1822 -1.3222 -0.2059 -0.1192 -0.0541 -0.1782 -0.7672 -3.0169 -0.2342
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal strain left_ventricle echocardiographic patients baseline echocardiography crt follow-up echocardiograms
H-429	-0.6934613585472107	▁longitud in al _ ▁strain ▁left _ vent ric le ▁e cho car dio graphic ▁base line _ e cho card i ography ▁c t ▁follow - up _ e cho card i ogram s
D-429	-0.6934613585472107	longitudinal_ strain left_ventricle echocardiographic baseline_echocardiography ct follow-up_echocardiograms
P-429	-0.3503 -0.3711 -0.0922 -0.2785 -1.9383 -0.4369 -0.3153 -0.2983 -3.1581 -1.1985 -0.2288 -0.6210 -0.2592 -1.2818 -0.8353 -0.0524 -0.0954 -0.5092 -0.2445 -0.8455 -1.8518 -1.0638 -0.7536 -0.5255 -2.6125 -0.0068 -0.2177 -0.0222 -0.3661 -0.4676 -0.9030 -1.3222 -1.0594 -0.0496 -0.3233 -0.5091 -0.1931
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension lv_dilatation lv_dysfunction mitral_valve organic lesion systolic diastolic_tethering etiology
H-365	-0.5140632390975952	▁hyper tension ▁LV _ di la tation ▁LV ▁ms ▁mit ral _ val ve ▁organic _ les ion ▁sy sto lic ▁dia sto lic _ te ther ing ▁functional _ eth i ology ▁ms
D-365	-0.5140632390975952	hypertension LV_dilatation LV ms mitral_valve organic_lesion systolic diastolic_tethering functional_ethiology ms
P-365	-0.0614 -0.0021 -0.0409 -1.1186 -1.1799 -0.0633 -0.0330 -0.0298 -1.4323 -0.3581 -0.0291 -0.3998 -0.7391 -0.2630 -0.8036 -0.7378 -1.7157 -0.2909 -1.0088 -0.4495 -0.2190 -0.0266 -0.4665 -0.3387 -1.8058 -0.6183 -0.2432 -0.0617 -0.7266 -0.5931 -0.4995 -0.3226 -0.0073 -1.1857 -0.4590 -0.1760
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl healthy hdl healthy patients chf-nyha-iii hdl nyha-iiib patients chf-nyha-ii hdl nyha-ii
H-250	-1.7775901556015015	▁HD l HD l ▁CHF - NY ha - III HD l ▁mw - NY ha - II HD l
D-250	-1.7775901556015015	HDlHDl CHF-NYha-IIIHDl mw-NYha-IIHDl
P-250	-3.1949 -3.6725 -3.3983 -2.2521 -1.2350 -0.1208 -0.7304 -1.1679 -0.2025 -0.1330 -2.9892 -2.3879 -5.7556 -1.4117 -1.3321 -0.8430 -0.1118 -0.7878 -2.7314 -2.2263 -2.2498 -0.1729
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating_factor paf metabolic enzymes follow-up patients diagnosed heart_failure hf healthy
H-1267	-0.8661746978759766	▁plate let - activa ting _ factor pa f ▁metabol ic _ ▁enzym es ▁heart _ fail ure ▁h z ▁b mi - match ed
D-1267	-0.8661746978759766	platelet-activating_factorpaf metabolic_ enzymes heart_failure hz bmi-matched
P-1267	-0.4574 -2.4506 -0.3139 -0.0871 -0.7804 -0.4662 -0.0637 -3.0956 -1.1210 -0.1178 -0.0606 -0.2197 -0.8808 -0.4232 -1.8542 -0.2801 -1.7102 -1.2393 -0.7486 -2.2171 -1.7793 -1.3192 -0.0889 -0.0179 -0.1004 -1.2429 -0.2503
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute_care_surgery acs consultations oht transplantation medical_therapy intravenous inotropes ventricular_assist_devices vads
H-1281	-0.659961998462677	▁a cute _ care _ ▁surgery ▁ac s ▁o t ▁transplant ation ▁medical _ therapy ▁m ▁intra ven ous _ in o trop es ▁vent ri cular _ assist _ ▁devices VAD s
D-1281	-0.659961998462677	acute_care_ surgery acs ot transplantation medical_therapy m intravenous_inotropes ventricular_assist_ devicesVADs
P-1281	-0.0782 -0.0187 -0.2703 -0.5785 -0.2244 -2.1850 -0.7734 -0.2080 -0.8375 -4.5909 -0.2138 -0.0601 -0.0195 -0.6940 -0.0301 -0.7543 -1.8357 -0.0502 -1.1072 -0.4444 -0.3609 -1.3563 -0.2534 -0.6244 -0.0173 -0.4982 -0.1693 -0.3429 -0.0061 -1.0089 -2.5116 -0.0524 -0.2124 -0.4906 -0.2198
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone_system raas hfref angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers aldosterone_blockade evidence hfpef
H-1489	-0.8092414140701294	▁re nin - angi oten sin - al do ster one _ system ▁ra as ▁h f f ▁ang io ten sin - con ver ting _ ▁enzym e _ ▁inhibi tors ▁ang io ten sin _ ▁receptor _ block ers ▁al do ster one _ block ade ▁h bf p EF
D-1489	-0.8092414140701294	renin-angiotensin-aldosterone_system raas hff angiotensin-converting_ enzyme_ inhibitors angiotensin_ receptor_blockers aldosterone_blockade hbfpEF
P-1489	-0.0435 -1.2540 -0.2183 -0.4467 -0.0382 -1.4095 -0.4321 -0.1282 -1.0630 -0.9675 -0.7172 -0.2230 -0.0785 -2.3887 -0.0607 -0.6600 -2.7207 -1.0239 -0.0494 -4.8381 -0.6984 -1.8652 -1.4914 -0.0769 -0.2079 -0.1826 -0.1754 -0.4240 -0.2309 -0.4721 -0.1958 -0.0380 -0.0462 -4.3004 -0.6409 -1.3819 -0.4125 -0.2214 -0.5187 -1.1423 -0.0428 -0.1018 -0.5174 -1.3987 -0.8897 -0.1911 -1.5265 -1.0965 -0.5855 -2.6040 -0.0240 -0.7359 -0.3186 -0.1824
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients hfpef ivabradine exercise_capacity left_ventricular_filling_pressure exercise peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1178	-0.629923403263092	▁h p EF ▁i va bra dine ▁exercise _ capaci ty ▁left _ vent ri cular ▁fill ing _ press ure ▁exercise ▁dia sto lic _ met ral _ flow _ velo city ▁dia sto lic _ met ral _ annu ular _ velo city
D-1178	-0.629923403263092	hpEF ivabradine exercise_capacity left_ventricular filling_pressure exercise diastolic_metral_flow_velocity diastolic_metral_annuular_velocity
P-1178	-1.8194 -0.8839 -1.4544 -0.2299 -0.0250 -0.0577 -0.2525 -0.1310 -1.0546 -0.0645 -0.0513 -0.5392 -0.5104 -0.9165 -0.9027 -0.1314 -1.2011 -0.0496 -0.2706 -1.0351 -0.4822 -0.1977 -1.4530 -0.8897 -0.3320 -0.2304 -2.5391 -0.0627 -0.2117 -1.0027 -0.1892 -0.0432 -0.2108 -0.3398 -0.7296 -0.5063 -0.2907 -3.0063 -0.1932 -0.2409 -2.4077 -1.1746 -0.3397 -0.0424 -0.2689 -0.4190 -0.2220
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission lvet patients outcome tonometric
H-583	-0.5550116896629333	▁l VET ▁to no metric _ ▁indice s
D-583	-0.5550116896629333	lVET tonometric_ indices
P-583	-1.0097 -0.9252 -0.2142 -0.1095 -0.1214 -0.8281 -1.4158 -0.1144 -0.5396 -0.2722
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart_rate blood_pressure renal_function spironolactone ras_blockers β-blockers
H-182	-0.5442194938659668	▁heart _ rate ▁blood _ tension ▁renal _ function ▁spi rono lac tone ▁ RAS _ block ers ▁β - block ers
D-182	-0.5442194938659668	heart_rate blood_tension renal_function spironolactone RAS_blockers β-blockers
P-182	-1.1945 -0.4776 -1.0761 -0.9184 -0.5651 -1.8693 -0.0156 -0.7700 -0.2051 -0.0492 -0.0113 -0.2358 -0.0569 -0.9650 -0.2749 -0.9853 -1.2020 -0.1198 -0.3285 -0.0544 -0.6344 -0.2685 -0.5281 -0.2554
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac β-adrenoceptor_blockade heart_failure reverse cardiac_remodeling elevated plasma_catecholamines
H-1553	-0.5202575922012329	▁cardiac ▁β - ad re no cept or _ block ade ▁heart _ fail ure ▁SR _ ca (2 +) - pump _ function ▁rever se _ ▁cardiac _ ▁remodel ing ▁plasma _ ▁cate chol amine s
D-1553	-0.5202575922012329	cardiac β-adrenoceptor_blockade heart_failure SR_ca(2+)-pump_function reverse_ cardiac_ remodeling plasma_ catecholamines
P-1553	-0.4871 -0.2842 -0.0465 -0.2031 -0.1803 -0.1725 -0.7731 -0.2271 -0.1623 -1.0341 -1.2783 -0.4845 -0.1728 -1.1360 -1.9218 -1.0184 -1.4566 -0.0439 -2.0500 -0.0268 -0.1216 -0.4465 -0.4422 -0.1873 -0.0132 -0.0330 -0.3364 -0.7231 -0.2991 -1.1644 -0.0877 -0.1292 -0.2312 -1.8974 -0.0511 -0.1489 -0.1592 -0.4219 -0.2374
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 congestive_heart_failure phenotypes mitochondrial tac mitochondrial_proteome mitochondrial nonmitochondrial_protein
H-874	-1.2934014797210693	▁SS 31 ▁con ges tive _ heart _ fail ure ▁mito cho ndri al _ dama ge TAC ▁mito cho ndri al _ ▁prote ome ▁mito cho ndri al ▁non mi to cho ndri al _ ▁Protein
D-874	-1.2934014797210693	SS31 congestive_heart_failure mitochondrial_damageTAC mitochondrial_ proteome mitochondrial nonmitochondrial_ Protein
P-874	-0.2980 -0.4297 -0.6359 -0.0885 -0.4730 -0.3649 -2.3996 -0.2528 -1.3471 -1.7971 -0.9989 -3.1391 -2.9151 -0.4536 -0.4892 -2.8279 -0.2909 -1.0158 -0.7865 -2.3696 -3.1822 -0.3574 -0.3684 -3.1117 -1.1120 -1.7248 -2.6915 -3.0034 -0.1537 -0.2811 -0.7687 -0.7876 -3.4164 -2.1889 -0.1992 -0.2273 -1.9950 -1.3048 -0.1953
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action randomized exercise training patients hf left_ventricular_ejection_fractions hrqol kansas_city_cardiomyopathy_questionnaire kccq baseline
H-837	-0.5997059941291809	▁h f - ac tion ▁exercise ▁h f ▁left _ vent ri cular _ e je ction _ fraction s ▁h Qo l ▁Kansas _ city _ ▁Card i om yo pathy _ ▁Question naire ▁k cc q ▁base line
D-837	-0.5997059941291809	hf-action exercise hf left_ventricular_ejection_fractions hQol Kansas_city_ Cardiomyopathy_ Questionnaire kccq baseline
P-837	-1.0411 -0.9711 -0.0685 -0.5002 -1.5479 -0.1679 -1.0967 -0.6631 -1.9153 -0.3195 -0.5412 -1.0702 -0.3544 -0.3412 -0.3175 -0.5744 -0.3592 -0.3903 -0.0357 -0.1285 -0.9676 -0.2731 -2.0663 -0.0256 -0.7482 -0.3415 -1.3621 -0.9402 -0.0327 -0.0614 -0.8557 -0.1126 -0.4744 -0.2245 -0.0988 -1.8409 -0.1647 -1.4481 -0.0374 -0.0568 -0.3904 -0.2610
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan hyponatremia united_states japan congestive_heart_failure patients diuretic therapy serum_sodium systolic_function
H-1196	-0.44195619225502014	▁to lv ap tan ▁hypo na trem ia ▁unit ed _ state s ▁japon ▁con ges tive _ heart _ fail ure ▁di ure tic _ therapy ▁se rum _ so dium ▁sy sto lic _ function
D-1196	-0.44195619225502014	tolvaptan hyponatremia united_states japon congestive_heart_failure diuretic_therapy serum_sodium systolic_function
P-1196	-0.0334 -0.2504 -0.1380 -0.1276 -0.0948 -0.0873 -0.0457 -1.0295 -0.5687 -0.0057 -0.4579 -0.2579 -0.0872 -1.3958 -0.7284 -0.0864 -0.7612 -0.3281 -2.0033 -0.2579 -0.9707 -1.2254 -0.1241 -0.1320 -0.3953 -0.7815 -0.3138 -0.1904 -0.1221 -0.2489 -0.6748 -0.0358 -0.9695 -0.4220 -0.4217 -0.4745 -0.4252 -0.3814 -0.1822
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar atpase activity mrna phospholamban α-myosin_heavy_chain mrna β-myosin_heavy_chain metoprolol
H-1552	-0.7909643650054932	▁my o fi bril lar ▁ATP ase ▁m RNA ▁SR _ ca (2 +) - pump ▁ phos pho lam ban ▁α - my os in _ ▁heavy _ chain ▁m RNA ▁β - my os in _ ▁heavy _ chain ▁met o pro lol
D-1552	-0.7909643650054932	myofibrillar ATPase mRNA SR_ca(2+)-pump phospholamban α-myosin_ heavy_chain mRNA β-myosin_ heavy_chain metoprolol
P-1552	-3.5390 -0.5236 -0.2775 -0.3119 -0.4921 -0.5353 -1.0371 -0.1658 -0.3250 -1.9363 -2.4410 -0.1741 -1.8638 -0.0159 -0.1045 -0.3755 -0.4588 -0.1573 -0.1834 -1.1475 -0.3349 -0.0916 -0.0601 -3.8554 -0.2096 -1.0361 -0.1667 -2.8008 -0.1686 -1.3097 -0.0309 -0.3309 -0.8430 -0.0844 -2.7157 -0.2718 -0.7547 -0.1331 -2.8013 -0.1709 -1.2041 -0.1473 -0.2095 -0.1030 -0.6221 -0.4453 -0.2085
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized coronary_microembolization-induced_hf cxl-1020 left_ventricular_end-diastolic_pressure myocardial_oxygen_consumption ejection_fraction maximal_ventricular_power_index
H-420	-0.5686835646629333	▁an est het ized ▁dog s ▁corona ry _ ▁micro e mbol ization - indu ced ▁h z ▁c XL -10 20 ▁left _ vent ri cular _ end - dia sto lic _ press ure ▁my o card ial _ ▁oxygen ▁e je ction _ fraction ▁vent ri cular _ power _ index
D-420	-0.5686835646629333	anesthetized dogs coronary_ microembolization-induced hz cXL-1020 left_ventricular_end-diastolic_pressure myocardial_ oxygen ejection_fraction ventricular_power_index
P-420	-1.5738 -0.2740 -0.6191 -0.2012 -1.7380 -0.0883 -0.1243 -0.1634 -0.3618 -1.7714 -0.5130 -0.0101 -0.1951 -0.1581 -0.0001 -0.0049 -1.0448 -1.7090 -1.3407 -0.8727 -0.1848 -0.0688 -0.3774 -0.4644 -1.3089 -0.8752 -0.2620 -0.9955 -3.3483 -0.3267 -0.0612 -1.2333 -0.5327 -0.2215 -1.1084 -0.4726 -0.4213 -0.1866 -0.5637 -0.5613 -0.1957 -0.7208 -0.1486 -0.1569 -0.1387 -0.4215 -0.0100 -0.1563 -0.9070 -0.9107 -0.2991 -0.0986 -0.2507 -0.3845 -0.4684 -0.2401
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline heart_failure t1-mapping administration administration
H-1061	-0.7502945065498352	▁base line ▁heart _ fail ure ▁administration ▁contrast _ agent ▁ms ▁contrast _ agent _ administration ▁ms
D-1061	-0.7502945065498352	baseline heart_failure administration contrast_agent ms contrast_agent_administration ms
P-1061	-0.0845 -0.1165 -0.3485 -0.3198 -1.1062 -1.1959 -0.1500 -3.0347 -0.2644 -0.5450 -0.1448 -3.7936 -0.2605 -0.7994 -1.1681 -0.1055 -0.1382 -0.4203 -0.2598
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard_error_of_measurement mdc mdc
H-805	-0.7339943647384644	▁m d c ▁confidence _ level ▁m d c ▁m d c ▁confidence _ level ▁m d c
D-805	-0.7339943647384644	mdc confidence_level mdc mdc confidence_level mdc
P-805	-0.5032 -0.2082 -1.1451 -2.5164 -0.9421 -0.3393 -0.1539 -0.1571 -0.6884 -1.3024 -0.1196 -0.9030 -2.7364 -0.6305 -0.3384 -0.1891 -0.1317 -0.6914 -0.7385 -0.2453
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies hf idiopathic_dilated_cardiomyopathy ischemic valvular
H-1794	-0.5988715291023254	▁et i ologie s ▁h f ▁la ▁ idio pathi c ▁dil ated _ ▁cardio my o pathy ▁c ' d ▁ ische mic ▁SH ▁val vu lar ▁alcohol
D-1794	-0.5988715291023254	etiologies hf la idiopathic dilated_ cardiomyopathy c'd ischemic SH valvular alcohol
P-1794	-1.9571 -0.5046 -0.0994 -0.1433 -1.3618 -0.9535 -0.3679 -5.4379 -0.0104 -0.0242 -0.1658 -0.3203 -0.0055 -0.3809 -0.0583 -0.7531 -0.2378 -0.0071 -0.0879 -2.7241 -0.0773 -0.3991 -0.0341 -0.2829 -0.7650 -0.2057 -0.0273 -0.1294 -0.0975 -0.6658 -0.2802
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 functional_capacity clinical outcomes ambulatory patients hf heart_failure outcomes exercise training hf-action randomized exercise training hf
H-697	-0.7435298562049866	▁ST 2 ▁functional _ capaci ty ▁ambula tory _ ▁pacientes ▁ HF ▁Heart _ fail ure ▁exercise _ training ▁h f
D-697	-0.7435298562049866	ST2 functional_capacity ambulatory_ pacientes HF Heart_failure exercise_training hf
P-697	-0.6448 -0.0470 -0.8514 -0.3319 -0.0724 -0.0386 -0.2328 -0.0916 -1.7072 -2.0926 -1.9992 -0.8897 -1.7821 -0.2573 -0.4353 -0.0953 -0.6305 -0.2757 -0.8323 -1.0624 -1.9058 -0.5576 -0.2676
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol metoprolol endpoint implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-856	-0.6566023230552673	▁car vedi lol ▁met o pro lol ▁implant able _ ▁cardio ver ter - de fi br illa tor _ therapy ▁MAD - c t ▁multi center _ automat ic _ ▁Def ib rilla tor _ ▁implant ation ▁Card iac _ re syn chron ization _ ▁Therapy
D-856	-0.6566023230552673	carvedilol metoprolol implantable_ cardioverter-defibrillator_therapy MAD-ct multicenter_automatic_ Defibrillator_ implantation Cardiac_resynchronization_ Therapy
P-856	-2.0131 -0.0730 -0.3602 -0.0381 -0.0958 -0.0315 -0.7779 -0.0198 -0.0535 -1.8068 -0.4315 -0.1855 -0.3488 -0.4249 -0.2755 -1.2628 -1.5822 -0.2386 -0.5054 -0.2833 -0.3988 -0.4306 -1.3491 -0.6430 -3.7711 -0.5168 -0.3638 -0.2783 -0.6011 -0.3651 -0.3261 -3.4799 -1.3371 -1.0106 -0.2675 -0.7716 -0.3815 -0.1524 -0.9268 -1.3204 -0.2218 -0.1224 -0.1170 -0.0144 -0.6225 -0.3393 -0.5953 -0.4167 -0.2240
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate_ratio confidence_interval angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers therapy confidence_interval β-blockers therapy
H-666	-0.5968288779258728	▁adjust ed _ media n _ rati o ▁ang io ten sin - con ver ting _ ▁enzym e _ ▁inhibi tors angi oten sin _ ▁receptor _ block ers _ therapy ▁β - block ers _ therapy
D-666	-0.5968288779258728	adjusted_median_ratio angiotensin-converting_ enzyme_ inhibitorsangiotensin_ receptor_blockers_therapy β-blockers_therapy
P-666	-1.5465 -0.1000 -0.3778 -1.6029 -0.3050 -0.5035 -1.0749 -0.0315 -0.2309 -4.1359 -0.3433 -1.0473 -0.8960 -0.0358 -0.1163 -0.1091 -0.1839 -0.3779 -0.2166 -0.2511 -0.6773 -0.0511 -0.1065 -0.0117 -0.3127 -0.2948 -0.4627 -0.4113 -1.3344 -0.0774 -2.7602 -0.2308 -0.6675 -0.0572 -0.5293 -0.1541 -1.1717 -0.4883 -0.3606 -0.2274
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ischemic_hf pathogenesis nyha_functional_class_iv estimated_glomerular_filtration_rate heart_rate hypertension diabetes_mellitus myocardial_infarction
H-1704	-0.6075054407119751	▁ ische mic _ HF ▁NY ha ▁glo mer ular _ filter ation _ rate ▁heart _ rate ▁hyper tension ▁diabetes _ ▁mell itus ▁my o card ial _ in far ction
D-1704	-0.6075054407119751	ischemic_HF NYha glomerular_filteration_rate heart_rate hypertension diabetes_ mellitus myocardial_infarction
P-1704	-3.2659 -0.0731 -0.2999 -0.8778 -0.9239 -1.1494 -0.7815 -0.3224 -0.1267 -0.0667 -0.2625 -1.1670 -0.6747 -0.4336 -0.5551 -0.9378 -0.4865 -1.1247 -0.0399 -0.0052 -0.0312 -0.1900 -0.4785 -0.0561 -1.1039 -0.4857 -0.3742 -0.5481 -0.2857 -0.4250 -0.0362 -0.2959 -2.5082 -0.2622
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt systolic_dysfunction outcomes resynchronization_reverses_remodeling_in_systolic_left_ventricular_dysfunction reverse patients left_ventricular ejection_fraction lvef
H-752	-0.7719166874885559	▁c t ▁sy sto lic _ ▁dys function ▁re syn chron ization _ re ve rse s _ re model ing ▁Sy sto lic _ ▁left _ v _ en tri cular _ ▁dys function ▁left _ vent ri cular LV ▁e je ction _ fraction LV EF
D-752	-0.7719166874885559	ct systolic_ dysfunction resynchronization_reverses_remodeling Systolic_ left_v_entricular_ dysfunction left_ventricularLV ejection_fractionLVEF
P-752	-0.4152 -2.2965 -0.7316 -0.2988 -0.6342 -0.2051 -1.4834 -0.0579 -0.1588 -0.0481 -0.0135 -0.4012 -0.5086 -0.0659 -0.9348 -0.3314 -0.3793 -0.7277 -0.0508 -0.5725 -0.0687 -1.8262 -0.2582 -0.6139 -0.3630 -4.0100 -0.3565 -3.1039 -5.4764 -2.2540 -0.6635 -0.5415 -0.4191 -0.7192 -0.0909 -0.9575 -0.2807 -1.2404 -1.0237 -0.3557 -0.5980 -0.1113 -0.1654 -0.1000 -0.2324 -0.0099 -0.6715 -1.1356 -0.4100 -0.2235
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars s1pr1s myocyte camp report receptors g-protein-coupled_receptor kinase-2
H-1408	-0.32607731223106384	▁β 1 ar s ▁s 1 PR 1 s ▁my o cy te ▁c AMP ▁report ▁receptor s ▁regulator y ▁g - prote in - co up led _ ▁receptor _ ▁kina se -2
D-1408	-0.32607731223106384	β1ars s1PR1s myocyte cAMP report receptors regulatory g-protein-coupled_ receptor_ kinase-2
P-1408	-0.6647 -0.4951 -0.6877 -0.6218 -0.6560 -0.0780 -1.1711 -0.1322 -0.1219 -0.6004 -0.0807 -0.0697 -0.0879 -0.5195 -1.1626 -0.1771 -0.3843 -0.2822 -0.1829 -0.1814 -0.7780 -0.1321 -0.1403 -0.2212 -0.1567 -0.0163 -0.0799 -0.0700 -0.1643 -0.2394 -0.3330 -0.0977 -0.0853 -0.1690 -0.4954 -0.2027
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up paf-cpt paf lyso-paf-at downregulated paf-ah lp-pla2 elevated
H-1270	-0.8390625715255737	▁follow - up ▁PA f - c pt ▁PA f ▁lys o - pa f - at ▁PA f - AH ▁l p - PLA 2
D-1270	-0.8390625715255737	follow-up PAf-cpt PAf lyso-paf-at PAf-AH lp-PLA2
P-1270	-2.6225 -0.2078 -0.0190 -2.8577 -0.8594 -0.1672 -0.2912 -1.0074 -2.2708 -1.4054 -0.9376 -0.1027 -0.0823 -0.8481 -1.2310 -0.3864 -0.3316 -3.6302 -1.1547 -0.1299 -1.4978 -0.3744 -0.0404 -0.1002 -0.0846 -0.0753 -0.5229 -0.2554
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic patients auc auc
H-488	-1.338200569152832	▁diagnostic
D-488	-1.338200569152832	diagnostic
P-488	-1.2118 -2.4573 -0.3454
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control patients cardiac driven cardioversions costs antiarrhythmic_drugs cad patient confidence_interval patient
H-1239	-0.45683780312538147	▁cardiac _ procedure s ▁cardio version s ▁costs ▁anti ar rhythm ic _ drug s ▁confidence _ ▁interval
D-1239	-0.45683780312538147	cardiac_procedures cardioversions costs antiarrhythmic_drugs confidence_ interval
P-1239	-1.2346 -1.5076 -0.0836 -0.1243 -0.4722 -0.0166 -0.1539 -0.2538 -0.1201 -0.1411 -0.1919 -0.0425 -0.4701 -1.1947 -0.0699 -0.6003 -0.4324 -0.6964 -0.9991 -0.3315
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients follow-up patients spironolactone hospitalization hazard_ratio confidence_interval death hazard_ratio confidence_interval
H-443	-0.6317479014396667	▁follow - up ▁spi rono lac tone ▁hospital ization ▁ad just ed _ ▁hazard _ rati o
D-443	-0.6317479014396667	follow-up spironolactone hospitalization adjusted_ hazard_ratio
P-443	-1.4029 -0.3073 -0.0211 -0.0751 -0.0175 -0.1644 -0.0778 -0.9552 -0.2091 -0.7362 -0.0118 -0.0358 -0.2584 -2.4767 -0.2936 -0.3308 -0.0273 -4.3440 -0.2580
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients bundle_branch_morphology diabetes_mellitus cardiomyopathy β-blocker angiotensin-converting_enzyme_inhibitor angiotensin_ii_receptor_blocker
H-906	-0.6699366569519043	▁diabetes _ ▁mell itus ▁cardio my o pathy ▁β - block er ▁ang io ten sin - con ver ting _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin _ ▁II _ ▁receptor _ block er
D-906	-0.6699366569519043	diabetes_ mellitus cardiomyopathy β-blocker angiotensin-converting_ enzyme_ inhibitor angiotensin_ II_ receptor_blocker
P-906	-0.9374 -0.3983 -0.6461 -0.0610 -0.0535 -1.1577 -0.2142 -0.0114 -0.1993 -0.0508 -1.3224 -0.4205 -0.1958 -3.9064 -0.9369 -1.6579 -1.0542 -0.0337 -0.1240 -0.1802 -0.1852 -0.6780 -0.3684 -0.2255 -1.0325 -0.1154 -0.0596 -3.4184 -0.5596 -0.8761 -0.3219 -0.4002 -0.2151 -0.4488 -0.4672 -1.9862 -0.5106 -0.4645 -0.2326
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone_post_myocardial_infarction_heart_failure_efficacy_and_survival_study ephesus post-myocardial_infarction patients heart_failure mortality hospitalizations patients randomized aldosterone_antagonist eplerenone
H-1737	-0.9108195304870605	▁e pler en one ▁post _ my o card ial _ in far ction ▁heart _ fail ure ▁su rvi val ▁e he SUS ▁post - my o card ial _ in far ction ▁heart _ fail ure ▁mortal ity ▁al do ster one _ ▁anta gon ist _ e pler en one
D-1737	-0.9108195304870605	eplerenone post_myocardial_infarction heart_failure survival eheSUS post-myocardial_infarction heart_failure mortality aldosterone_ antagonist_eplerenone
P-1737	-0.2785 -0.1534 -0.6277 -0.4178 -0.2182 -0.4933 -6.2565 -1.1999 -2.3953 -1.3660 -0.3534 -0.8674 -0.1322 -0.8479 -1.8705 -0.1890 -1.7487 -1.8319 -0.1743 -0.0494 -0.1309 -1.2708 -2.8496 -0.3493 -0.0148 -0.2216 -4.7234 -1.3181 -2.6324 -1.2320 -0.4514 -0.7869 -0.1684 -0.9124 -0.9571 -0.2821 -1.0127 -1.9231 -0.1899 -0.1407 -0.3462 -0.1889 -0.4179 -0.4521 -0.6213 -0.0890 -0.0267 -1.4659 -0.5843 -0.2578 -0.6533 -0.3557 -1.0767 -0.2657 -0.2544
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report cardiopulmonary_exercise_testing exercise_rehabilitation patients chronic_heart_failure exercise_rehabilitation patient chronic_heart_failure chf clinical cardiopulmonary_exercise_testing cpet exercise_rehabilitation china
H-1879	-1.4399927854537964	▁report ▁cardio pul mon ary _ ▁exercise _ test ing ▁exercise _ ▁rehabilita tion ▁chronic _ heart _ fail ure ▁exercise _ re ▁Rehabilita tion ▁chronic _ heart _ fail ure ▁gh f ▁Card io P ul mon ary _ ▁Exerci se _ test ing ▁c PET ▁exercise _ re cover y ▁ china
D-1879	-1.4399927854537964	report cardiopulmonary_ exercise_testing exercise_ rehabilitation chronic_heart_failure exercise_re Rehabilitation chronic_heart_failure ghf CardioPulmonary_ Exercise_testing cPET exercise_recovery china
P-1879	-0.0825 -0.7700 -1.7565 -3.5291 -0.4125 -0.6230 -1.5717 -0.9789 -2.2246 -0.8141 -0.4799 -1.0091 -2.8767 -0.1188 -2.4190 -0.3813 -2.2873 -0.3349 -1.9834 -1.5467 -0.9417 -1.2693 -1.4137 -3.8483 -0.2290 -1.1450 -0.2882 -2.9077 -0.2826 -0.8654 -1.7696 -3.8546 -0.2310 -1.1733 -3.6558 -6.1297 -0.6498 -4.5970 -0.2130 -0.3881 -3.2862 -1.2263 -0.3073 -0.4485 -0.1219 -0.8643 -1.4616 -0.1103 -0.8240 -0.7024 -3.1120 -2.6620 -2.3797 -0.3037 -0.5298 -0.2467
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence_interval heart mortality death
H-1749	-0.7662513256072998	▁heart _ fail ure - related _ ▁mortal ity ▁sud den _ ▁death
D-1749	-0.7662513256072998	heart_failure-related_ mortality sudden_ death
P-1749	-2.5577 -0.4717 -1.2179 -1.9409 -0.1877 -0.0287 -0.3201 -0.5106 -0.1204 -0.0098 -0.0198 -0.1660 -1.8267 -1.8495 -0.2664
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash clinic brachial_systolic_pressure central_end-systolic_pressure
H-924	-0.8375826478004456	▁DAS h ▁s rd ▁bra chi al _ sy sto lic _ press ure ▁central _ end - sy sto lic _ press ure ▁h g
D-924	-0.8375826478004456	DASh srd brachial_systolic_pressure central_end-systolic_pressure hg
P-924	-0.0254 -0.2060 -1.4854 -0.8372 -1.2082 -0.1683 -0.3352 -0.2980 -2.3129 -0.7963 -0.5714 -0.2251 -1.9122 -0.7170 -1.5225 -0.4691 -4.3634 -0.3269 -0.9931 -0.8420 -0.6188 -0.1878 -1.2477 -0.5035 -0.4145 -0.0612 -0.5864 -0.2171
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause_mortality hospitalization hf lvef patients heart_failure_survey israel
H-113	-0.8634745478630066	▁mortal ity HF ▁LV EF ▁Heart _ fail ure _ ▁Survey ▁ir ra el
D-113	-0.8634745478630066	mortalityHF LVEF Heart_failure_ Survey irrael
P-113	-2.1381 -0.1780 -1.7318 -0.3354 -0.6141 -2.0683 -0.5022 -0.6265 -0.0836 -0.3310 -0.3670 -3.6897 -0.4179 -0.0283 -0.4557 -0.2481
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients hf obese body_mass_index idiopathic-dilated_cardiomyopathy
H-558	-0.5620039105415344	▁h f ▁obes e ▁body _ ▁mass _ index ▁black _ ▁et hni city ▁ idio pathi c - dila ted _ ▁cardio my o pathy
D-558	-0.5620039105415344	hf obese body_ mass_index black_ ethnicity idiopathic-dilated_ cardiomyopathy
P-558	-1.3057 -0.4738 -2.8346 -0.3699 -0.2690 -0.4546 -1.9177 -0.1861 -0.2860 -0.3185 -0.5232 -2.1557 -0.1215 -0.0608 -0.8348 -0.0312 -0.0566 -0.4330 -0.2563 -0.0353 -0.0894 -0.2511 -0.1770 -1.1314 -0.2244 -0.0131 -0.6255 -0.3001
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients left_ventricular_ejection_fraction world_health_organization idiopathic_dilated_cardiomyopathy coronary_angiography followed_up
H-1743	-0.6121986508369446	▁left _ vent ri cular _ e je ction _ fraction ▁world _ ▁health _ organisation ▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁negative _ ▁corona ry _ ang i ography
D-1743	-0.6121986508369446	left_ventricular_ejection_fraction world_ health_organisation idiopathic_ dilated_ cardiomyopathy negative_ coronary_angiography
P-1743	-0.4736 -0.3986 -0.7460 -1.2561 -0.2840 -0.3875 -0.2752 -0.3880 -0.2768 -0.2234 -0.0312 -0.1724 -0.7716 -2.3208 -0.2765 -2.1244 -1.1376 -0.0085 -0.0570 -0.3562 -0.4336 -1.1590 -0.0203 -0.2315 -0.3303 -2.4335 -0.3838 -0.0189 -0.5650 -0.4985 -1.4041 -0.4597 -0.2870 -0.6929 -1.2357 -0.2660 -0.6573 -0.2213
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european_society_of_cardiology hfpef symptoms heart_failure preserved_lv_ejection_fraction non-dilated_left_ventricle evidence diastolic_dysfunction lv_relaxation lv_diastolic_stiffness elevated lv_filling_pressures
H-27	-0.5940697193145752	▁european _ soci ety _ of _ ▁Card i ology ▁h f f ▁heart _ fail ure ▁LV ▁e je ction _ fraction ▁left _ vent ric le ▁dia sto lic _ ▁dys function impa i red ▁LV ▁dia sto lic _ ▁sti ff ness ▁LV ▁fill ing _ tension s
D-27	-0.5940697193145752	european_society_of_ Cardiology hff heart_failure LV ejection_fraction left_ventricle diastolic_ dysfunctionimpaired LV diastolic_ stiffness LV filling_tensions
P-27	-0.1170 -0.2947 -0.5964 -0.0662 -0.2176 -0.0339 -0.3062 -0.9712 -0.6000 -0.0434 -0.1973 -0.7075 -0.3766 -0.8571 -0.2179 -0.5878 -2.0337 -1.0870 -0.9089 -0.0988 -0.0753 -0.3253 -0.0073 -2.0973 -0.2662 -0.2610 -3.5155 -0.8309 -0.1373 -0.8796 -0.6998 -0.3941 -1.1277 -0.0211 -0.5709 -0.1681 -0.0245 -0.7155 -1.0970 -0.9345 -0.6835 -0.3318 -1.5535 -0.9176 -0.2741 -0.5305 -0.1249 -0.0365 -0.2495 -1.5301 -0.1548 -0.4127 -0.2180
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated_glomerular_filtration_rate egfr type_2_diabetes cholesterol ldl-cholesterol clcnka genotype
H-1803	-0.7185487747192383	▁glo mer ular _ filter ation _ rate ▁e g f ▁diabetes ▁total _ ▁cholesterol ▁l DL - ch olesterol ▁c cn ka _ GG
D-1803	-0.7185487747192383	glomerular_filteration_rate egf diabetes total_ cholesterol lDL-cholesterol ccnka_GG
P-1803	-0.0928 -0.2555 -0.0522 -0.2301 -1.2471 -0.7487 -0.2717 -0.6398 -0.4393 -0.6213 -2.0660 -0.1114 -0.3826 -0.2983 -1.5055 -0.6531 -2.3958 -0.1777 -0.1528 -0.0052 -2.1197 -1.0784 -1.1358 -0.8634 -0.9970 -0.6148 -0.2448
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography lv_end-diastolic_dimension lv_end-diastolic_pressure wall_stress lung acf
H-474	-0.9095511436462402	▁e cho card i ography ▁LV ▁end - dia sto lic _ dimension ▁LV ▁end - dia sto lic _ press ure wall _ ▁Stress ▁lung _ weight ▁a CF ▁sham _ group
D-474	-0.9095511436462402	echocardiography LV end-diastolic_dimension LV end-diastolic_pressurewall_ Stress lung_weight aCF sham_group
P-474	-0.5605 -0.3728 -0.3430 -0.2715 -0.4163 -0.5702 -2.3564 -0.2008 -0.1778 -1.7162 -0.8990 -0.9588 -0.1586 -0.6479 -1.8000 -0.2277 -0.1778 -2.2218 -1.3024 -0.3295 -1.7601 -0.3796 -2.6762 -0.3798 -2.6576 -0.7601 -0.3660 -0.6957 -2.5731 -1.5279 -0.0745 -0.5703 -0.6761 -0.7816 -0.2467
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients heart_failure ejection_fraction cardiac_rehabilitation walking exercise
H-570	-0.7662644982337952	▁heart _ fail ure ▁e je ction _ fraction ▁standard _ ▁cardiac _ rehabilit ation _ care ▁Nordic _ ▁walking ▁exercise
D-570	-0.7662644982337952	heart_failure ejection_fraction standard_ cardiac_rehabilitation_care Nordic_ walking exercise
P-570	-1.0426 -0.3540 -1.0996 -2.6747 -0.8886 -0.1060 -0.0505 -0.3400 -0.0125 -1.6407 -0.4988 -0.3296 -0.3273 -1.2398 -0.7166 -0.8554 -0.0967 -2.0333 -0.2333 -1.9740 -0.4326 -0.4284 -0.2489
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard_ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
H-1836	-0.7453794479370117	▁d RS - stra t ified _ ▁hazard _ rati os ▁si tag lip tin ▁pi og lita zone ▁si tag lip tin ▁sul fon yl ure as ▁si tag lip tin ▁insulin
D-1836	-0.7453794479370117	dRS-stratified_ hazard_ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
P-1836	-0.2823 -1.3081 -0.0253 -0.2491 -0.3507 -0.0531 -0.3782 -2.2270 -0.3157 -0.0661 -0.2579 -1.5450 -0.0271 -1.1839 -3.2097 -0.0727 -0.5511 -0.1542 -0.1162 -1.1167 -0.0546 -1.1085 -3.2521 -0.0862 -0.0238 -0.5615 -0.1757 -0.1078 -1.5520 -0.0605 -1.3596 -3.6744 -0.0198 -0.3562 -0.2055
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal_muscle t-score fontan sarcopenic_range_muscle_wasting t-score clinically t-score
H-1501	-0.9152407646179199	▁skelet al _ ▁muscle _ ▁mass ▁t - s core ▁sar co pen ic _ range _ ▁muscle _ was ting ▁t - s core ▁was ting ▁t - s core
D-1501	-0.9152407646179199	skeletal_ muscle_ mass t-score sarcopenic_range_ muscle_wasting t-score wasting t-score
P-1501	-0.2666 -0.1928 -0.4385 -4.8159 -0.2355 -1.8996 -0.4086 -0.2324 -0.1204 -1.0902 -2.3563 -0.0473 -0.1265 -0.3834 -0.2174 -0.1573 -0.6295 -3.8938 -0.4499 -3.3161 -0.0875 -0.8299 -0.1658 -0.1464 -2.0324 -2.4315 -0.1281 -0.6822 -0.1629 -0.1062 -1.6878 -0.3029 -0.1613
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker uptitrations composite_end-point all-cause_mortality hf readmissions hfref hazard_ratio confidence_interval
H-181	-0.7110738754272461	▁ RAS - ▁β - block er _ up ti tra tions ▁mortal ity ▁h f _ read missions ▁h f haz ard _ rati o ▁confidence _ ▁interval ▁h f
D-181	-0.7110738754272461	RAS- β-blocker_uptitrations mortality hf_readmissions hfhazard_ratio confidence_ interval hf
P-181	-3.7280 -0.9713 -0.0673 -0.0612 -0.0235 -0.5781 -0.3146 -0.2853 -0.5642 -0.1500 -0.2977 -0.1800 -0.2370 -0.1675 -0.9396 -0.8830 -1.0066 -3.6820 -0.1513 -0.0903 -1.3123 -1.4047 -0.2892 -0.1597 -0.0779 -0.0351 -1.2868 -0.2642 -0.7437 -0.7156 -2.0658 -0.4741 -0.2578
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise testosterone baseline peak_oxygen_uptake beck_depression_inventory leg medical_outcomes_study_short-form quality_of_life exercise placebo
H-1323	-0.4797172546386719	▁exercise ▁testosteron e ▁base line ▁pe ak _ ▁oxygen _ up take ▁Beck _ de pression _ in ven tory ▁leg _ streng th ▁medical ▁short - form _ quality _ of _ life ▁exercise
D-1323	-0.4797172546386719	exercise testosterone baseline peak_ oxygen_uptake Beck_depression_inventory leg_strength medical short-form_quality_of_life exercise
P-1323	-0.8406 -0.6282 -0.1638 -0.0147 -0.0501 -0.1915 -0.0349 -0.1439 -1.4054 -0.3292 -0.5920 -0.2390 -0.0552 -0.5686 -0.0848 -0.0168 -0.1997 -0.4416 -0.8372 -0.0315 -0.7133 -0.4079 -1.7771 -0.9375 -0.4171 -0.8177 -0.0542 -0.2663 -0.3125 -1.5015 -0.2901 -0.0298 -0.2735 -0.9882 -0.1956 -1.6458 -0.2525
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients heart_failure outcomes exercise training hf-action exercise perceived_social_support_score psss barriers_to_exercise_score btes
H-1927	-1.0607271194458008	▁Heart _ fail ure ▁exercise _ training ▁h - ac tion ▁social _ support ▁exercise ▁social _ support _ ▁score ▁p s s ▁barrier s _ to _ ▁exercise ▁b tes
D-1927	-1.0607271194458008	Heart_failure exercise_training h-action social_support exercise social_support_ score pss barriers_to_ exercise btes
P-1927	-1.9496 -0.3307 -0.4539 -0.0903 -0.3405 -0.7026 -0.5941 -0.6890 -2.4452 -0.5704 -1.5669 -0.8562 -0.8640 -3.1758 -0.8479 -0.5348 -0.6212 -3.1995 -1.0168 -2.3341 -2.2781 -0.2743 -0.0630 -1.5196 -0.1825 -1.2434 -1.2125 -0.5552 -1.6287 -1.8312 -0.4121 -0.3768 -0.2431
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable_analysis st2 death hospitalization hazard_ratio cardiovascular_death hf hospitalization hazard_ratio all-cause_mortality hazard_ratio hazard_ratios
H-703	-0.7132782340049744	▁ST 2 ▁cardiovascular _ ▁death ▁h h ▁hospital ization haz ard _ rati o ▁mortal ity haz ard _ rati o ▁hazard _ rati os ▁log 2
D-703	-0.7132782340049744	ST2 cardiovascular_ death hh hospitalizationhazard_ratio mortalityhazard_ratio hazard_ratios log2
P-703	-0.8494 -0.0538 -1.9682 -1.6033 -1.1539 -0.4154 -2.7827 -1.8388 -0.3484 -0.8046 -0.5535 -0.2613 -0.1554 -0.1183 -0.3686 -0.1644 -2.0934 -1.1218 -0.2287 -0.1676 -0.5178 -0.5007 -0.3238 -0.1232 -0.7570 -0.3148 -0.2001 -0.5912 -0.3049
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients new_york_heart_association_class_i fontan cardiopulmonary_exercise_testing lean_mass_quantification dual_x-ray_absorptiometry dxa calf muscle magnetic_resonance_spectroscopy healthy
H-1495	-0.7464805245399475	▁New _ York _ ▁Heart _ association ▁cardio pul mon ary _ ▁exercise ▁lean _ mas s _ ▁quant ification ▁dual _ ▁x - ray _ ab sor pti ometr y ▁d XA ▁cal f _ ▁muscle ▁magnetic _ re on ance _ spec tros copy
D-1495	-0.7464805245399475	New_York_ Heart_association cardiopulmonary_ exercise lean_mass_ quantification dual_ x-ray_absorptiometry dXA calf_ muscle magnetic_reonance_spectroscopy
P-1495	-1.2266 -1.0036 -2.8694 -0.1927 -0.9907 -0.1690 -0.4701 -0.0649 -1.1157 -3.1347 -0.1983 -0.8554 -0.9847 -0.1361 -0.2090 -2.2938 -0.2014 -1.6115 -0.3656 -0.1125 -0.2103 -0.3590 -0.4559 -0.3344 -0.6097 -0.1214 -0.7289 -0.7963 -0.5359 -0.3667 -0.1252 -0.2999 -0.9549 -0.1867 -0.0713 -0.2779 -3.6555 -0.1408 -0.3098 -1.5978 -1.9345 -0.1313 -0.1641 -0.8506 -0.5927 -1.2419 -0.3348 -0.2370
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo dopamine nesiritide bolus diuretic therapy renal_function patients acute_heart_failure renal_dysfunction
H-73	-0.4942897856235504	▁dop amine ▁low - dos e _ ▁dop amine ▁nesi riti de ▁di ure tic _ therapy ▁renal _ function ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function
D-73	-0.4942897856235504	dopamine low-dose_ dopamine nesiritide diuretic_therapy renal_function acute_heart_ failure renal_ dysfunction
P-73	-1.2277 -0.1560 -0.9716 -0.0824 -1.0500 -0.3792 -0.2490 -0.1851 -0.1905 -0.7646 -0.1545 -0.1080 -0.1367 -0.0583 -0.1893 -1.2380 -0.1458 -0.0213 -0.4375 -0.2915 -0.4728 -0.0669 -0.2137 -2.0427 -0.2909 -1.7377 -0.0233 -0.4783 -1.5909 -0.1306 -0.4818 -0.2507
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized crt patients new_york_heart_association_class_iii heart_failure left_ventricular_ejection_fraction qrs_duration echocardiographic evidence left_ventricular_dyssynchrony
H-847	-0.8436570167541504	▁c t ▁New _ York _ ▁Heart _ association ▁heart _ fail ure ▁left _ vent ri cular _ e je ction _ fraction ▁QR s ▁e cho car dio graphic ▁left _ vent ri cular _ ▁dys syn chron y
D-847	-0.8436570167541504	ct New_York_ Heart_association heart_failure left_ventricular_ejection_fraction QRs echocardiographic left_ventricular_ dyssynchrony
P-847	-0.7852 -3.0884 -1.4836 -1.4525 -2.7476 -0.3477 -0.8137 -0.2656 -0.5367 -0.6591 -0.3680 -1.6016 -1.4198 -0.8560 -0.4247 -2.0435 -1.8951 -0.5727 -0.4916 -0.1927 -0.5821 -0.3177 -0.3025 -0.0178 -0.1047 -0.8947 -0.2433 -0.2631 -0.1011 -0.6137 -0.8421 -1.4074 -0.3713 -1.4997 -1.9886 -0.9336 -0.2406 -2.0007 -0.1113 -0.0071 -0.6943 -0.4293 -0.2649
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients left_ventricular ejection_fraction stable_hf right-sided_cardiac_catheterization transthoracic_echocardiography transmitral_flow mitral_annulus_velocities systole diastole
H-482	-0.4220164120197296	▁left _ vent ri cular LV ▁e je ction _ fraction ▁h f ▁right - side d _ ▁cardiac _ ▁cat heter ization ▁trans t hora cic _ e cho card i ography ▁transmit ral _ flow _ velo ci ties ▁mit ral _ ann ulus _ velo ci ties ▁sy stol e ▁dia stol e
D-482	-0.4220164120197296	left_ventricularLV ejection_fraction hf right-sided_ cardiac_ catheterization transthoracic_echocardiography transmitral_flow_velocities mitral_annulus_velocities systole diastole
P-482	-0.1094 -0.4358 -0.4954 -0.7469 -0.2338 -1.9251 -0.3472 -0.1427 -0.1174 -0.2840 -0.0043 -0.9435 -2.0019 -0.1456 -0.2064 -0.1197 -0.6226 -0.3853 -0.0966 -0.3918 -1.6382 -0.0184 -0.3807 -0.0103 -0.2625 -0.0350 -0.1354 -0.4893 -0.1642 -0.5572 -0.4752 -0.2378 -0.3312 -0.2167 -0.3422 -0.4263 -0.4836 -0.2852 -0.0267 -0.4350 -0.0528 -0.0590 -0.1142 -0.3334 -3.4261 -0.1965 -0.2251 -0.0335 -0.3560 -0.0492 -0.7067 -0.3367 -0.4977 -0.0204 -0.1508 -0.5158 -0.4782 -0.2182
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients acute_coronary_syndromes patients stable cad bnp nt-probnp cad prognostic clinical outcome
H-1367	-0.7707895040512085	▁a cute _ ▁corona ry _ ▁syndrome s ▁CAD ▁b NP ▁NT - pro b NP ▁CAD
D-1367	-0.7707895040512085	acute_ coronary_ syndromes CAD bNP NT-probNP CAD
P-1367	-0.1101 -0.0580 -0.1518 -1.2807 -0.6057 -0.2562 -1.3700 -0.0944 -1.7358 -0.4079 -2.2224 -0.1638 -0.1851 -0.0273 -1.1730 -1.2223 -2.8707 -0.4148 -0.2948
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline patients hf lyso-paf-at paf-cpt paf paf-ah lp-pla2
H-1269	-0.7551220655441284	▁base line ▁h f ▁lys o - pa f - at ▁PA f - c pt ▁PA f _ level s ▁PA f - AH ▁l p - PLA 2
D-1269	-0.7551220655441284	baseline hf lyso-paf-at PAf-cpt PAf_levels PAf-AH lp-PLA2
P-1269	-0.9524 -0.0546 -0.3878 -1.2450 -0.7682 -0.0462 -0.0786 -0.7444 -1.0906 -0.1781 -0.2908 -2.9657 -0.8138 -0.1384 -0.4325 -0.7347 -3.1477 -0.9268 -2.2163 -1.0883 -0.1053 -2.7285 -0.7729 -0.1167 -0.7651 -0.3725 -0.0291 -0.0824 -0.0407 -0.0656 -0.5249 -0.2592
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical_therapy patients redo_sternotomy aortic_valve bioprosthetic_valve_replacement dacron_patch_closure aortic_valve patients transcatheter_aortic_valve_procedure surgery aortic_valve
H-549	-0.7717766165733337	▁medical _ therapy ▁ster no to my ▁a or tic _ val ve ▁bio pro sthetic _ val ve _ ▁replace ment ▁da cro n _ ▁patch _ closure ▁a or tic _ val ve ▁trans cat heter _ a or tic _ val ve _ procedure ▁open _ ▁surgery ▁a or tic _ val ve _ ▁replace ment
D-549	-0.7717766165733337	medical_therapy sternotomy aortic_valve bioprosthetic_valve_ replacement dacron_ patch_closure aortic_valve transcatheter_aortic_valve_procedure open_ surgery aortic_valve_ replacement
P-549	-0.0592 -1.5077 -0.0326 -1.6769 -0.0381 -0.1082 -1.3742 -0.2908 -0.1565 -0.5087 -0.3334 -2.9001 -1.1586 -0.1338 -0.0610 -0.1004 -0.7220 -1.5002 -0.5067 -0.4373 -4.1629 -0.1492 -0.2105 -0.1297 -0.1140 -0.1594 -0.6982 -0.2969 -0.0084 -0.1228 -0.2112 -0.7975 -0.3857 -2.9444 -1.2123 -0.7820 -0.5026 -0.1265 -1.3973 -0.2347 -0.2092 -0.5885 -0.2446 -2.5264 -1.0006 -2.3426 -0.3011 -0.3752 -0.3912 -1.0054 -0.3145 -0.1588 -0.6899 -0.2864 -3.3510 -0.8784 -0.3795 -2.9788 -0.2049 -0.4018 -0.1968
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma_n-terminal_pro-b-type_natriuretic_peptide nt-probnp patients acute_heart_failure hf admission emergency_department
H-263	-0.6133174300193787	▁cut off _ valu e ▁plasma ▁na tri ure tic _ pe pti de ▁na tri ure tic _ pe pti de NT - pro b NP ▁a cute _ heart _ fail ure HF ▁emergency _ de part ment ▁ed
D-263	-0.6133174300193787	cutoff_value plasma natriuretic_peptide natriuretic_peptideNT-probNP acute_heart_failureHF emergency_department ed
P-263	-0.0393 -0.0617 -0.4674 -0.2185 -0.3087 -1.0389 -1.4799 -0.1849 -0.0823 -0.2487 -0.2392 -0.7926 -0.2613 -0.5781 -2.5435 -0.1876 -0.1543 -0.2611 -0.2517 -0.8074 -0.4148 -0.5782 -1.3273 -0.0384 -0.0513 -1.4289 -0.6202 -0.1601 -0.2551 -0.1443 -2.4904 -0.1750 -0.8633 -1.4144 -0.9028 -0.0893 -0.2262 -2.3488 -0.3576 -0.0504 -0.9336 -1.0352 -0.2597
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac_troponin_t ctnt n-terminal_pro-b-type_natriuretic_peptide nt-probnp biomarkers hf hf atherosclerosis_risk_in_communities aric
H-286	-0.509617805480957	▁cardiac _ ▁trop onin ▁c t n t ▁high - sensitiv ity _ as say ▁na tri ure tic _ pe pti de NT - pro b NP ▁bio mark ers ▁h f ▁h f ▁Ath eros cle rosi s _ risk _ in _ com muni ties ARI
D-286	-0.509617805480957	cardiac_ troponin ctnt high-sensitivity_assay natriuretic_peptideNT-probNP biomarkers hf hf Atherosclerosis_risk_in_communitiesARI
P-286	-0.0276 -0.2125 -0.3273 -0.3796 -1.3207 -0.0676 -0.0184 -0.2450 -0.6315 -0.0500 -0.0086 -0.0680 -0.2055 -0.1415 -0.4241 -0.0945 -0.0949 -0.0730 -0.1569 -0.2358 -0.8150 -0.3294 -0.6410 -2.0288 -0.0369 -0.0605 -1.4884 -0.6088 -0.1367 -0.0659 -0.2136 -0.5982 -2.0217 -1.0530 -1.7991 -1.9233 -0.2161 -0.1817 -0.2577 -0.0940 -0.2017 -0.7569 -0.3446 -0.6577 -0.3123 -0.0707 -0.2561 -0.0629 -1.4934 -2.2475 -0.2341
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body_mass_index fat_mass fat-free_mass
H-1167	-0.8557270169258118	▁body _ ▁mass _ index ▁event _ rate HR ▁fat _ ▁mass ▁fat - free _ ▁mass _ index
D-1167	-0.8557270169258118	body_ mass_index event_rateHR fat_ mass fat-free_ mass_index
P-1167	-1.0058 -0.3547 -2.5744 -0.1788 -0.5328 -0.6594 -0.4579 -0.8884 -3.0244 -1.8391 -0.6181 -2.0470 -0.6441 -0.2583 -0.0402 -0.3205 -1.2039 -0.2017 -0.4973 -0.3774 -0.2460
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile_range body_mass_index interquartile_range copd chf crf
H-797	-0.6705131530761719	▁inter quart ile _ range ▁body _ ▁mass _ index ▁inter quart ile _ range ▁COP d ▁CHF ▁c RF
D-797	-0.6705131530761719	interquartile_range body_ mass_index interquartile_range COPd CHF cRF
P-797	-0.8321 -0.0950 -0.2038 -0.4122 -0.2188 -0.7862 -0.5574 -1.7498 -0.3410 -0.3987 -1.2516 -0.0886 -0.3990 -0.4694 -0.3094 -1.5269 -0.2710 -0.1669 -0.5665 -3.2704 -0.5455 -0.2908
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse_remodeling ejection_fraction mortality all-cause_hospitalizations hf hospitalizations dialysis patients
H-911	-0.4513649344444275	▁rever se _ ▁remodel ing ▁e je ction _ fraction ▁mortal ity HF ▁di al ysis
D-911	-0.4513649344444275	reverse_ remodeling ejection_fraction mortalityHF dialysis
P-911	-0.0199 -0.1290 -0.2002 -2.2312 -0.0943 -0.0652 -0.2050 -0.0755 -0.3102 -0.0101 -0.0244 -0.1887 -1.8798 -0.3664 -0.0715 -0.0547 -1.9278 -0.2707
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates lv_contractility lvef β_coefficient confidence_interval systolic_blood_pressure end-systolic_volume β_coefficient
H-1530	-0.8819314241409302	▁eh ▁LV _ contract ility ▁LV EF β _ co e ffi cient ▁confidence _ ▁interval ▁ratio _ of _ sy sto lic _ ▁blood _ press ure ▁end - sy sto lic _ ▁volume β _ co e ffi cient ▁h g
D-1530	-0.8819314241409302	eh LV_contractility LVEFβ_coefficient confidence_ interval ratio_of_systolic_ blood_pressure end-systolic_ volumeβ_coefficient hg
P-1530	-1.6070 -0.7852 -1.6400 -0.6030 -0.5409 -0.8835 -0.8791 -4.7314 -0.3975 -0.6809 -0.4675 -0.0784 -0.1211 -0.6702 -0.5143 -0.5833 -0.1633 -0.8756 -0.1137 -0.8063 -3.7924 -1.1863 -0.3574 -0.2225 -2.9507 -0.2961 -2.7851 -0.7207 -0.2589 -0.1641 -0.6045 -1.1747 -0.5414 -0.2982 -1.8593 -2.0006 -0.3060 -0.6157 -0.3693 -0.1154 -0.1459 -0.3670 -0.0277 -1.1556 -0.2293
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography dilated_lv end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mva
H-348	-0.7981104254722595	▁e cho card i ography ▁dil ated ▁LV ▁end - dia sto lic _ ▁volume _ index ▁m l ▁e je ction _ fraction ▁MR ▁mit ral _ val ve _ ▁opening ▁ms ▁m va ▁mean _ press ure _ grad ient ▁h g
D-348	-0.7981104254722595	echocardiography dilated LV end-diastolic_ volume_index ml ejection_fraction MR mitral_valve_ opening ms mva mean_pressure_gradient hg
P-348	-0.8081 -0.4717 -0.4263 -0.3039 -0.3420 -3.9763 -0.0149 -0.8558 -0.4562 -0.1379 -0.0425 -0.9624 -0.2168 -0.3521 -1.8743 -0.1709 -0.3704 -0.3787 -4.7910 -3.6297 -0.1772 -0.1296 -0.3579 -0.0107 -2.4877 -0.1409 -0.0537 -0.3631 -0.8772 -0.4924 -0.4044 -2.5163 -0.5033 -0.3870 -0.3090 -0.8669 -0.2694 -0.7384 -0.3770 -0.2540 -0.9494 -1.3936 -1.0055 -0.0704 -0.7725 -0.2240
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind clinical renal_optimization_strategies_evaluation rose hospitalized patients acute_heart_failure renal_dysfunction estimated_glomerular_filtration_rate randomized admission
H-74	-0.7781915664672852	▁re nal _ optim ization _ strategi es _ evalua tion ROS e ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁glo mer ular _ filter ation _ rate ▁m l
D-74	-0.7781915664672852	renal_optimization_strategies_evaluationROSe acute_heart_ failure renal_ dysfunction glomerular_filteration_rate ml
P-74	-3.4239 -0.6420 -0.2463 -0.5776 -0.2744 -0.1208 -0.4081 -2.1086 -0.1811 -0.6939 -0.1870 -2.0441 -0.1120 -0.3954 -0.0329 -0.2696 -2.2311 -0.3127 -2.0763 -0.0214 -0.4402 -0.5503 -0.0439 -0.2347 -0.1584 -0.0677 -0.2007 -1.2106 -0.6499 -0.2516 -0.7275 -0.1713 -4.3143 -1.5152 -0.3412
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets signal_transduction pol_ii transcription_factor hf pathogenesis nuclear_factor_of_activated_t_cells nfat nuclear_factor-κb nf-κb transcription_factor gata4
H-1051	-0.720465362071991	▁molecular BET s ▁chr omat in - media ted _ signal _ trans duction ▁pol _ ▁II ▁co - activa ting _ trans scription _ factor _ net work s ▁h z ▁nuclear _ factor _ of _ activa ted _ t _ cell s ▁na FAT ▁nuclear _ factor - κ b NF - κ b ▁tran scription _ factor
D-1051	-0.720465362071991	molecularBETs chromatin-mediated_signal_transduction pol_ II co-activating_transscription_factor_networks hz nuclear_factor_of_activated_t_cells naFAT nuclear_factor-κbNF-κb transcription_factor
P-1051	-3.0422 -1.2165 -0.2703 -0.4998 -0.0714 -1.6269 -0.2373 -0.1977 -0.3185 -0.1983 -0.6093 -0.1515 -0.0830 -0.2529 -1.1263 -0.5242 -0.6090 -1.0900 -0.0726 -0.0257 -0.6829 -0.9070 -2.6376 -0.4219 -0.6981 -0.1229 -0.2514 -0.1419 -0.1293 -0.1290 -1.0711 -2.1326 -1.1497 -0.2298 -0.0833 -0.5452 -0.1139 -0.2497 -0.0943 -0.2612 -0.2863 -1.2494 -0.5482 -0.7179 -0.4013 -2.2235 -2.7643 -0.3570 -0.2222 -0.0962 -0.9222 -1.9560 -0.5461 -1.1274 -0.0949 -1.8591 -0.4788 -0.6203 -0.2970 -0.4818 -0.0881 -3.5239 -0.2515
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes mortality hospitalization exercise_tolerance quality_of_life cardiovascular_events myocardial_infarction congestive_heart_failure arrhythmia cardiac_death hypertension venous_thromboembolic_events ischemic_cerebrovascular_events
H-33	-0.7479258179664612	▁guide line ▁cardiovascular _ event s ▁my o card ial _ in far ction ▁con ges tive _ heart _ fail ure ▁ar rhythm ia ▁cardiac _ ▁death ▁hyper tension ▁ve nous _ thro mbo e mbol ic ▁ ische mic _ ▁cerebro vas cular _ evento s
D-33	-0.7479258179664612	guideline cardiovascular_events myocardial_infarction congestive_heart_failure arrhythmia cardiac_ death hypertension venous_thromboembolic ischemic_ cerebrovascular_eventos
P-33	-1.5259 -0.0346 -1.4015 -0.8188 -3.7155 -0.0931 -1.3625 -0.3396 -0.4359 -0.5342 -0.3956 -0.8145 -0.0635 -0.2440 -0.1143 -0.1040 -0.6093 -0.4704 -2.1009 -0.2818 -1.4683 -0.8235 -0.0570 -0.9642 -1.9392 -0.0318 -0.1963 -1.0162 -0.0715 -0.0040 -0.0864 -0.3671 -0.4764 -0.0780 -0.8684 -0.8166 -0.0503 -0.2480 -3.8061 -0.0233 -0.3742 -0.2842 -0.8773 -0.4593 -1.0535 -1.0027 -3.4482 -0.2610 -0.5487 -0.2344
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus diabetes patients diabetes peak_vo2 patients diabetes eo-cfus peak_vo2
H-128	-1.1061407327651978	▁ EO - c FU s ▁diabetes EO - c FU ▁pe ak _ vo 2 ▁diabetes ▁ EO - c FU s ▁pe ak _ vo 2
D-128	-1.1061407327651978	EO-cFUs diabetesEO-cFU peak_vo2 diabetes EO-cFUs peak_vo2
P-128	-4.3197 -1.7373 -0.1182 -0.7420 -2.9363 -0.2846 -0.2821 -4.0882 -0.1950 -0.9272 -2.4899 -1.7189 -0.0930 -0.1956 -0.1152 -0.3689 -0.4110 -4.1407 -2.0628 -0.2240 -0.8727 -2.5605 -0.3727 -0.1410 -0.1613 -0.1663 -0.1064 -0.5410 -0.5436 -0.2683
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular_mortality multivariable_adjustment hazard_ratio confidence_interval hazard_ratio confidence_interval
H-562	-0.523151695728302	▁cardiovascular _ ▁mortal ity ▁multi vari able ▁hazard _ rati o ▁confidence _ ▁interval ▁hazard _ rati o
D-562	-0.523151695728302	cardiovascular_ mortality multivariable hazard_ratio confidence_ interval hazard_ratio
P-562	-0.2142 -0.3387 -0.3112 -0.1609 -0.6103 -0.0035 -0.1126 -2.5698 -0.3392 -0.1551 -0.0303 -2.4400 -0.3736 -0.9436 -0.1945 -0.3758 -0.2410 -0.0383 -0.6964 -0.3140
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting video_edge_detection epifluorescence_microscopy myocardial_tissues cardiomyocytes hf
H-1212	-0.5745262503623962	▁immun o blo tting ▁radio en zy matic - ▁fluor esc ence _ re on ance _ ener gy _ transfer - based _ as say s ▁video _ ed ge ▁epi flu o resc ence _ micro s copy ▁ca 2 ▁my o card ial _ ▁tissu es ▁cardio my o cy tes ▁h z
D-1212	-0.5745262503623962	immunoblotting radioenzymatic- fluorescence_reonance_energy_transfer-based_assays video_edge epifluorescence_microscopy ca2 myocardial_ tissues cardiomyocytes hz
P-1212	-0.1701 -0.1907 -0.0225 -0.3584 -1.0573 -0.3449 -0.0329 -0.3705 -0.9634 -1.1296 -0.0651 -0.0397 -0.2614 -0.6292 -3.0444 -0.1766 -0.2874 -0.1937 -0.0298 -0.1874 -0.2313 -0.6387 -0.0101 -0.7084 -0.1616 -0.6476 -0.3036 -1.4012 -0.3065 -2.7574 -0.7085 -1.0384 -0.0581 -0.4223 -0.1129 -0.1254 -0.1623 -1.7483 -0.3561 -0.8337 -0.6432 -0.0627 -0.9503 -0.2701 -0.2653 -0.4635 -0.1753 -1.4024 -1.1911 -0.2662 -1.5837 -0.3770 -0.0718 -0.4126 -0.3531 -1.8233 -0.5073 -0.2160
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes exercise_capacity peak_oxygen_consumption vo2 co-primary_outcome qol minnesota heart_failure heart qol co-primary_outcome
H-1980	-1.145798921585083	▁exercise _ capaci ty ▁pe ak _ ▁oxygen _ ▁consum p tion VO 2 ▁m d p ▁q ol ▁Minnesota _ ▁Living _ with _ ▁Heart _ fail ure ▁ml f ▁heart _ fail ure
D-1980	-1.145798921585083	exercise_capacity peak_ oxygen_ consumptionVO2 mdp qol Minnesota_ Living_with_ Heart_failure mlf heart_failure
P-1980	-0.6590 -0.4270 -0.1705 -0.1108 -0.1363 -0.0402 -0.1346 -1.6898 -0.5024 -1.8221 -0.3671 -0.2051 -1.2352 -0.0650 -4.7707 -4.0688 -1.9734 -6.0058 -1.3766 -0.1642 -0.7920 -0.6697 -0.2271 -1.5308 -0.3264 -0.4020 -0.3433 -0.6144 -0.2832 -0.8298 -2.2629 -1.8858 -0.2846 -0.9608 -1.0480 -3.7732 -0.2358
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial randomize patients stroke rhythm_control_therapy prospective randomized outcome
H-1649	-0.7114070653915405	▁e ast ▁at rial _ fi bril lation ▁Stro ke _ pre vention _ tri al ▁ons et ▁AF ▁stroke ▁ha 2 s 2 VAS c ▁guide line - manda ted _ ▁usual _ care ▁ rhythm _ control _ therapy ▁blind ed _ ▁outcome _ asse s s ment
D-1649	-0.7114070653915405	east atrial_fibrillation Stroke_prevention_trial onset AF stroke ha2s2VASc guideline-mandated_ usual_care rhythm_control_therapy blinded_ outcome_assessment
P-1649	-0.9431 -0.2004 -0.8769 -0.1276 -0.3470 -0.7632 -0.1835 -0.1188 -2.2515 -0.5831 -0.7004 -1.1329 -0.0481 -0.6718 -1.2791 -0.8136 -1.6549 -0.0903 -1.1058 -0.1780 -3.6589 -0.1707 -2.5689 -0.0253 -0.9816 -0.0799 -3.1314 -0.0336 -0.2358 -0.0237 -0.1793 -1.8284 -0.1887 -0.5406 -0.0957 -0.9657 -0.4091 -0.5043 -0.0273 -0.8498 -0.0724 -0.5595 -0.5664 -0.4528 -0.9538 -0.3986 -0.5967 -0.0453 -0.2041 -0.3589 -1.9507 -0.2652
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients left_ventricular_ejection_fraction patients hf preserved_left_ventricular_ejection_fraction hospital physicians acute outpatient epidemic medical financial_costs
H-55	-0.8315431475639343	▁left _ vent ri cular _ e je ction _ fraction ▁h f ▁left _ vent ri cular _ e je ction _ fraction ▁hospital ▁physician s ▁out patient _ setting s ▁medical ▁financial ▁costs
D-55	-0.8315431475639343	left_ventricular_ejection_fraction hf left_ventricular_ejection_fraction hospital physicians outpatient_settings medical financial costs
P-55	-1.7730 -0.3760 -1.0429 -1.3764 -0.8408 -0.3193 -0.6889 -1.3210 -0.7101 -0.2641 -0.0868 -0.7926 -2.1660 -1.7107 -0.4202 -1.2214 -1.4975 -0.8193 -0.3501 -0.6813 -1.6193 -0.8113 -0.3019 -0.0722 -1.9710 -1.0376 -0.1439 -0.7120 -0.3025 -1.6389 -0.0408 -0.2281 -1.2799 -0.1769 -1.2358 -0.4994 -0.2370
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic mitochondrial-targeted_peptide ss31 mitochondrial_function tac clinical mitochondrial-targeted_peptide drugs heart_failure
H-878	-1.1300052404403687	▁ TAC - indu ced _ prote om ic ▁mito cho ndri al - tar get ed _ pe pti de ▁SS 31 ▁per tur bed _ ▁mito cho ndri al _ function ▁up stream _ signal ▁path way _ ▁altera tions ▁ TAC ▁mito cho ndri al - tar get ed _ pe pti de _ drug s ▁heart _ fail ure
D-878	-1.1300052404403687	TAC-induced_proteomic mitochondrial-targeted_peptide SS31 perturbed_ mitochondrial_function upstream_signal pathway_ alterations TAC mitochondrial-targeted_peptide_drugs heart_failure
P-878	-3.0990 -0.5194 -0.1385 -0.0010 -0.0535 -0.2899 -2.1545 -1.1730 -0.3621 -2.8627 -4.0382 -3.7296 -0.8404 -0.7496 -0.6188 -0.8182 -0.1306 -0.2059 -2.4547 -1.0699 -0.8767 -0.5956 -0.4757 -1.2582 -0.0377 -0.1975 -0.4878 -3.1839 -2.9415 -2.3759 -0.3494 -0.3422 -0.2170 -0.0650 -0.0030 -0.4566 -0.7861 -1.5847 -0.0579 -3.6377 -1.8877 -0.0772 -2.1771 -0.5584 -1.4023 -2.7703 -3.8193 -0.7362 -0.6681 -0.4195 -0.8654 -0.1219 -0.2141 -2.3674 -2.1467 -0.9535 -0.8475 -1.7302 -0.0610 -0.3226 -0.2950 -1.7586 -1.4542 -0.3435 -0.2131
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf patients hfref left_ventricular ejection_fraction hfpef echo-doppler n-terminal_pro-brain-type_natriuretic_peptide adverse_events
H-494	-0.626936674118042	▁h f ▁left _ vent ri cular LV ▁e je ction _ fraction ▁h p EF ▁e cho - d opp ler ▁na tri ure tic _ pe pti de
D-494	-0.626936674118042	hf left_ventricularLV ejection_fraction hpEF echo-doppler natriuretic_peptide
P-494	-0.8036 -0.1830 -0.8929 -0.4214 -0.7879 -0.7555 -0.3849 -0.5544 -0.2750 -0.2818 -0.1639 -0.3859 -0.0320 -0.9000 -1.9034 -1.4383 -0.1516 -0.8234 -0.0726 -2.1809 -0.0127 -1.2532 -1.3800 -0.1700 -0.0942 -0.4602 -0.3214 -0.5225 -0.2776 -0.7356 -1.1864 -0.2560
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds comorbidities hospitalized adjusted_odds_ratio aor confidence_interval eds aor
H-464	-0.949715793132782	▁low - volu me _ ed s
D-464	-0.949715793132782	low-volume_eds
P-464	-0.6835 -0.1073 -0.1923 -0.1211 -0.9257 -1.9008 -0.3549 -4.0343 -0.2276
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc_battery health_abc_hf_risk_model change c-index net-reclassification-improvement hf
H-631	-0.7196251749992371	▁h bc _ ▁Bat tery ▁health ▁ABC _ HF _ risk _ model ▁discrimina tion ▁c - index net - re class ification - improv ement ▁h b
D-631	-0.7196251749992371	hbc_ Battery health ABC_HF_risk_model discrimination c-indexnet-reclassification-improvement hb
P-631	-0.8526 -1.6038 -0.9864 -0.9021 -0.1115 -0.3563 -1.3729 -0.6333 -2.0546 -0.7260 -0.2093 -0.1417 -0.3173 -1.0144 -0.4010 -1.2640 -0.1167 -0.0191 -2.6725 -0.0707 -0.0517 -0.2635 -0.1373 -0.1264 -0.1082 -0.8868 -0.6757 -2.5813 -0.6752 -0.2564
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients cardiac_transplant ecct patients diabetes_mellitus chronic_kidney_disease estimated_glomerular_filtration_rate
H-715	-0.7317429780960083	▁cardiac _ ▁transplant ▁ec t ▁diabetes _ ▁mell itus ▁chronic _ ▁ki dne y _ ▁disease ▁glo mer ular _ filter ation _ rate ▁m L
D-715	-0.7317429780960083	cardiac_ transplant ect diabetes_ mellitus chronic_ kidney_ disease glomerular_filteration_rate mL
P-715	-0.0379 -0.2792 -1.3632 -0.1975 -1.3398 -0.1623 -0.8303 -0.3128 -0.0599 -0.0918 -0.3139 -3.3708 -0.5359 -0.2799 -0.3060 -1.7835 -0.1062 -0.1640 -0.0383 -0.2386 -1.7449 -0.8018 -0.3491 -0.6455 -0.0657 -3.6863 -1.0493 -0.3346
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi rmsea self-care_maintenance cfi rmsea self-care_management cfi rmsea self-care_confidence
H-1507	-1.2284609079360962	▁c fi ▁RM se a ▁self - Car e _ ▁Main ten ance _ ▁Scal e ▁c fi ▁RM se a ▁self - Car e _ management _ ▁Scal e ▁c fi ▁RM se a ▁self - Car e _ ▁Confi den ce _ ▁Scal e
D-1507	-1.2284609079360962	cfi RMsea self-Care_ Maintenance_ Scale cfi RMsea self-Care_management_ Scale cfi RMsea self-Care_ Confidence_ Scale
P-1507	-1.1720 -3.6817 -4.2422 -0.4526 -0.3618 -0.5959 -0.2665 -2.6651 -0.7152 -0.1649 -2.8928 -1.8072 -0.0977 -0.3535 -1.3256 -0.1901 -0.6142 -3.5540 -4.2258 -0.5339 -0.4167 -0.6923 -0.2786 -2.4804 -0.7784 -0.2234 -0.2265 -0.4201 -1.1459 -0.1926 -0.4981 -3.4936 -4.1843 -0.5400 -0.6158 -0.5995 -0.2272 -2.3964 -0.7624 -0.3618 -3.1271 -0.2389 -0.4157 -0.6405 -3.3760 -0.1613 -0.3297 -0.2303
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients bat patients quality-of-life nyha_functional_class change
H-1876	-0.5822920799255371	▁BAT ▁quality - of - life ▁NY ha ▁change _ in _ dis tribution
D-1876	-0.5822920799255371	BAT quality-of-life NYha change_in_distribution
P-1876	-0.1535 -0.4637 -0.1634 -0.0114 -0.4855 -0.0554 -4.1542 -0.7777 -0.3902 -0.5614 -0.8186 -0.4527 -0.0312 -0.0009 -0.5150 -0.2819
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients preoperative hypoalbuminemia postoperative albumin hypoalbuminemia albumin lvad
H-537	-0.7343651652336121	▁hypo album in emia ▁post operativ e _ normal ization _ of _ album in _ level s ▁hypo album in emia ▁album in _ level s ▁l VAD
D-537	-0.7343651652336121	hypoalbuminemia postoperative_normalization_of_albumin_levels hypoalbuminemia albumin_levels lVAD
P-537	-0.1580 -1.5293 -0.8402 -0.5241 -0.5255 -0.5407 -0.3258 -1.3260 -1.4661 -0.3976 -2.1423 -0.0969 -0.3894 -0.3435 -0.8305 -0.4025 -1.5961 -0.0594 -0.0930 -0.9390 -1.1134 -0.6782 -1.6571 -0.7967 -1.3694 -1.2831 -0.0696 -0.5942 -0.1085 -0.3596 -0.2096
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization confidence_interval acute_myocardial_infarction ami complications kidney_infection urinary_tract_infection uti complications
H-1717	-0.7659949064254761	▁re hospital ization ▁a cute _ My o card ial _ in far ction AMI ▁ki dne y _ ▁infection ▁urin ary _ ▁tract _ infect ion UTI
D-1717	-0.7659949064254761	rehospitalization acute_Myocardial_infarctionAMI kidney_ infection urinary_ tract_infectionUTI
P-1717	-1.1191 -0.0134 -0.2078 -0.9815 -0.1213 -0.1783 -4.3252 -0.7264 -0.3091 -0.3371 -0.2341 -0.3703 -0.0389 -0.5873 -0.2708 -0.6894 -0.7322 -0.1931 -0.4772 -2.3280 -0.0615 -0.1059 -0.4330 -4.4078 -0.2120 -2.4144 -0.3635 -0.1523 -0.3400 -0.2489
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients heart_failure hf ischemic nonischemic_cardiomyopathies pharmacological implantable_cardioverter_defibrillators cardiac_resynchronization_therapy cardiac_transplantation right_ventricular_assist_devices
H-54	-0.6077374219894409	▁heart _ fail ure HF ▁ ische mic ▁non ische mic _ ▁cardio my o pathi es ▁implant able _ ▁cardio ver ter _ de fi br illa tors ▁cardiac _ re syn chron ization _ therapy ▁cardiac _ ▁transplant ation ▁right _ vent ri cular _ assist _ ▁devices
D-54	-0.6077374219894409	heart_failureHF ischemic nonischemic_ cardiomyopathies implantable_ cardioverter_defibrillators cardiac_resynchronization_therapy cardiac_ transplantation right_ventricular_assist_ devices
P-54	-2.4379 -0.2917 -1.2426 -2.4181 -0.6188 -3.2593 -0.0620 -0.2883 -0.6304 -0.1227 -0.3909 -0.6498 -0.5017 -0.9645 -0.5906 -0.0515 -0.8533 -0.1838 -0.0582 -1.0596 -0.9624 -0.2570 -0.3568 -0.2899 -0.1579 -0.5524 -1.0715 -0.0817 -0.3840 -0.1022 -0.3773 -0.1477 -0.0543 -0.0077 -0.3310 -0.4876 -0.1344 -0.2070 -0.2478 -0.2198 -0.0401 -1.2691 -0.5139 -0.4515 -1.0139 -0.1899 -0.2409 -0.0055 -0.6669 -3.3467 -0.5140 -0.2439
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf catheterization central_venous_pressure svr cardiac_index
H-230	-0.788489043712616	SAF PF ▁cat heter ization ▁central _ ve nous _ press ure ▁h g ▁s VR _ index ▁dyn ▁cardiac _ index
D-230	-0.788489043712616	SAFPF catheterization central_venous_pressure hg sVR_index dyn cardiac_index
P-230	-0.3192 -2.0299 -2.8677 -0.0525 -0.4723 -0.0382 -0.3559 -1.7981 -0.5686 -0.1606 -1.3083 -0.5982 -0.1220 -0.0594 -1.9878 -2.0271 -1.2267 -0.3428 -0.4689 -0.4363 -0.7066 -0.2923 -0.4143 -0.2699
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission bnp reduced_ef preserved_ef bnp ef
H-193	-1.1198084354400635	▁ad mission ▁media n _ b NP ▁EF ▁media n _ b NP ▁women ▁EF ▁border line ▁p g
D-193	-1.1198084354400635	admission median_bNP EF median_bNP women EF borderline pg
P-193	-0.1484 -0.0931 -1.1558 -0.1412 -0.5071 -0.6577 -1.7516 -0.6528 -2.4539 -0.2105 -0.2609 -0.7755 -1.7893 -4.6933 -3.5082 -0.2029 -0.0210 -0.7632 -0.1577 -3.2471 -0.3247
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart_failure admission heart_transplantation lv_assist_device death hazard_ratio confidence_interval death hazard_ratio confidence_interval ischemic functional_class
H-435	-0.6982418298721313	▁heart _ fail ure _ ad mission ▁heart _ ▁transplant ation LV _ assist ance _ ▁Device ▁death haz ard _ rati o ▁death haz ard _ rati o
D-435	-0.6982418298721313	heart_failure_admission heart_ transplantationLV_assistance_ Device deathhazard_ratio deathhazard_ratio
P-435	-1.3512 -0.4340 -1.4018 -2.6789 -1.9339 -0.4152 -0.0145 -0.6701 -0.3000 -0.9394 -0.0748 -0.4744 -0.7370 -0.0164 -1.2593 -0.1918 -3.5008 -0.1029 -0.3379 -0.2708 -0.2167 -0.1247 -0.0414 -1.0529 -0.4329 -0.6013 -0.1926 -0.1363 -0.0497 -1.4654 -0.2266
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv_ejection_fraction shortening systolic_elastance contractile_efficiency acf acf allopurinol cardiomyocytes extracellular_flux_analyzer
H-475	-0.6595702171325684	▁LV ▁e je ction _ fraction ▁veloci ty _ of _ ▁circum fer ential _ short en ing ▁sy sto lic _ ▁elastan ce ▁contract ile _ ef fici ence ▁a cf ▁a CF ▁allo puri nol _ ▁rat s ▁o 2 _ ▁consum p tion _ rate ▁cardio my o cy tes ▁extra cel lular _ ▁flux _ ▁anal y zer
D-475	-0.6595702171325684	LV ejection_fraction velocity_of_ circumferential_shortening systolic_ elastance contractile_efficience acf aCF allopurinol_ rats o2_ consumption_rate cardiomyocytes extracellular_ flux_ analyzer
P-475	-0.3897 -0.4699 -0.2376 -0.1082 -0.2054 -0.0133 -0.0280 -0.1033 -3.1137 -0.3048 -0.3583 -0.6499 -1.2014 -0.0214 -0.3717 -1.4852 -0.2796 -0.0583 -1.5978 -0.4139 -0.1434 -0.5070 -0.0369 -0.5904 -0.0509 -1.0233 -0.3516 -2.7481 -0.3864 -1.0152 -1.5478 -1.3487 -1.9656 -2.3958 -0.4038 -0.1039 -0.4939 -0.3939 -1.3675 -0.0651 -0.3264 -0.0633 -0.8059 -1.6974 -0.5437 -0.1903 -0.2101 -1.2162 -0.1475 -1.8635 -0.2408 -0.0666 -0.8930 -0.0579 -0.5450 -0.2789 -0.1682 -1.1793 -0.3763 -1.9018 -0.1615 -0.2609 -0.4563 -0.2108
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively patients hfpef lv_hypertrophy lvh relative_wall_thickness rwt lvh rwt lvh rwt lvh rwt
H-1526	-1.127049207687378	▁h f p EF ▁LV _ ge ometr y ▁LV _ ▁hyper trop hy LV h ▁relative _ wall _ thi ck ness ▁r w t ▁cr ▁LV h ▁r w t ▁v h ▁ rv w
D-1526	-1.127049207687378	hfpEF LV_geometry LV_ hypertrophyLVh relative_wall_thickness rwt cr LVh rwt vh rvw
P-1526	-0.9773 -1.7521 -0.0744 -0.5742 -1.2436 -1.7530 -1.4291 -0.0301 -0.1329 -1.6631 -1.1046 -2.1163 -0.2442 -0.1618 -2.0578 -0.9022 -0.0117 -0.2642 -1.6480 -0.3454 -1.1447 -0.2951 -0.8566 -2.6929 -0.7064 -0.0343 -2.0027 -1.9322 -1.3677 -1.8930 -0.1119 -0.5680 -1.9922 -1.9407 -3.0755 -1.9180 -0.8213 -1.8653 -0.2504
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 angiotensin_receptor_neprilysin_inhibitor neprilysin_inhibitor prodrug angiotensin_receptor_antagonist valsartan hypertension heart_failure_with_preserved_ejection_fraction outcomes heart_failure_with_reduced_ejection_fraction
H-1463	-0.7324061393737793	▁l CZ 696 ▁ang io ten sin _ ▁receptor ▁nepri ly sin _ ▁inhibi tor ▁nepri ly sin _ ▁inhibi tor ▁pro drug ▁ang io ten sin _ ▁receptor _ ▁anta gon ist _ val sar tan ▁hyper tension ▁heart _ fail ure ▁e je ction _ fraction ▁heart _ fail ure ▁e je ction _ fraction
D-1463	-0.7324061393737793	lCZ696 angiotensin_ receptor neprilysin_ inhibitor neprilysin_ inhibitor prodrug angiotensin_ receptor_ antagonist_valsartan hypertension heart_failure ejection_fraction heart_failure ejection_fraction
P-1463	-1.0929 -0.8667 -0.0389 -0.0646 -4.9663 -0.8080 -1.4957 -0.4543 -0.7014 -0.1594 -0.1674 -0.3891 -0.1896 -1.0813 -0.1132 -0.0131 -0.2557 -0.8577 -0.2309 -1.3504 -0.2317 -1.4450 -0.0086 -0.0503 -4.5025 -0.7380 -1.8744 -0.3328 -0.7566 -0.8805 -0.1519 -0.0164 -1.1913 -0.3210 -1.4709 -0.3223 -0.0892 -0.0263 -0.0016 -1.3330 -0.3271 -1.5709 -1.6586 -0.5485 -0.2508 -0.2850 -0.3544 -0.0069 -1.4263 -0.3034 -1.2318 -2.1165 -0.4475 -0.2610 -0.3415 -0.3935 -0.0112 -0.4108 -0.2256
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood_pressure mitral_valve_plasty degenerative_mr p3_prolapse chordal_ruptures triangular_resection edge-to-edge_anastomosis ring_annuloplasty physio_ring_30 edwards_lifesciences irvine
H-343	-0.5152692198753357	▁blood _ tension ▁mit ral _ val ve _ plast y ▁de genera tive _ m m ▁pro lapse ▁chor dal _ ▁rup tures ▁tri ang ular _ re ection ▁edge - to - ed ge _ an asto mos is ▁ring _ ▁ann ulo plast y ▁Ph y sio _ ring ▁ed ward s _ life science s ▁ir vine
D-343	-0.5152692198753357	blood_tension mitral_valve_plasty degenerative_mm prolapse chordal_ ruptures triangular_reection edge-to-edge_anastomosis ring_ annuloplasty Physio_ring edwards_lifesciences irvine
P-343	-0.4654 -0.4108 -1.8944 -0.1141 -0.0532 -0.4130 -1.3942 -0.1434 -0.2052 -0.0613 -0.7820 -0.3379 -0.0357 -0.1022 -0.9503 -0.7981 -1.3844 -2.6898 -0.1966 -0.0828 -0.5741 -0.2565 -1.1163 -0.0594 -0.0347 -0.0380 -0.0138 -0.4291 -0.6391 -0.3419 -0.0488 -0.1121 -0.1577 -0.3972 -0.0887 -0.0346 -0.3950 -1.1771 -0.0465 -0.9091 -0.8033 -0.0990 -0.3058 -2.8870 -0.3262 -0.0174 -0.1494 -2.4424 -0.0511 -0.0703 -0.2352 -1.6880 -0.3793 -0.0020 -0.0400 -0.1221 -0.2118 -0.1555 -0.0440 -0.0390 -0.0981 -2.6775 -0.2332
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes incremental_shuttle_walk_test peak_oxygen_uptake muscular echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory beck_depression_inventory health-related_quality_of_life minnesota_living_with_heart_failure_questionnaire medical_outcomes_study_short-form
H-1320	-0.5547888875007629	▁shu ttle _ walk _ test ▁pe ak _ ▁oxygen _ up take ▁muscular _ streng th ▁e cho car dio graphic ▁pro - bra in _ na tri ure tic _ pe pti de ▁infla mma tory _ ▁marker s ▁depression ▁be ck _ de pression _ in ven tory ▁min nes ota ▁Heart _ fail ure ▁medical
D-1320	-0.5547888875007629	shuttle_walk_test peak_ oxygen_uptake muscular_strength echocardiographic pro-brain_natriuretic_peptide inflammatory_ markers depression beck_depression_inventory minnesota Heart_failure medical
P-1320	-0.1342 -0.0058 -0.1738 -2.0650 -0.3091 -0.4053 -0.0898 -0.0227 -0.2190 -1.8675 -0.3329 -0.7743 -0.1148 -0.0241 -1.6040 -0.4319 -0.7913 -0.1922 -0.3040 -0.1058 -0.9364 -0.7440 -1.5135 -0.0786 -0.1824 -0.0702 -0.5276 -1.2457 -0.1191 -0.0744 -0.2516 -0.3683 -0.7184 -0.4759 -0.5094 -0.0512 -0.8495 -0.0724 -0.4781 -0.3489 -0.1077 -0.1170 -1.6143 -0.1485 -0.4223 -0.1603 -0.1402 -0.3097 -0.5212 -1.1355 -0.0394 -3.8492 -1.3206 -0.5320 -1.5160 -0.3513 -0.3909 -0.0848 -0.7394 -0.4620 -0.2968
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction_term_analysis lvef patients patients mortality lvef p_value
H-116	-0.7911218404769897	▁action _ ter me ▁LV EF ▁long - term _ ▁mortal ity ▁LV EF ▁age - by - LV EF
D-116	-0.7911218404769897	action_terme LVEF long-term_ mortality LVEF age-by-LVEF
P-116	-1.9831 -0.3747 -1.6841 -0.1445 -1.8158 -0.6929 -2.4477 -0.1531 -0.9412 -0.2659 -0.6068 -0.1607 -1.3175 -0.6036 -1.0103 -0.0755 -0.1424 -0.1762 -0.3298 -0.7197 -1.5249 -0.2344
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto zsf1 obese zsf1 obese zsf1 followed_up metabolic renal echocardiographic hemodynamically euthanization
H-763	-0.7472190260887146	▁we star - k yo to ▁lean _ z SF 1 ▁obes e _ z s 1 ▁obes e _ z s 1 ▁high - fat _ diet ▁metabol ic ▁renal ▁e cho car dio graphic ▁hem o dynamic ally ▁eu than ization
D-763	-0.7472190260887146	westar-kyoto lean_zSF1 obese_zs1 obese_zs1 high-fat_diet metabolic renal echocardiographic hemodynamically euthanization
P-763	-3.0506 -0.3837 -0.0886 -4.5997 -0.9701 -0.1791 -0.2614 -0.9658 -1.5530 -2.3717 -0.5301 -0.2797 -0.3206 -1.7622 -0.8149 -2.2531 -1.5244 -0.3562 -0.4529 -1.4833 -0.6209 -1.6175 -1.1868 -0.1190 -0.1885 -0.7688 -0.1545 -1.2817 -0.4338 -0.0445 -0.0158 -0.1351 -0.1751 -0.0495 -0.2938 -0.6657 -0.3094 -0.1717 -0.0210 -0.2746 -0.0084 -0.0697 -0.1906 -0.4032 -0.2241
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier_curves log-rank_testing risk_stratification patients patients
H-384	-1.1007343530654907	▁ka plan - me ier _ cur ves ▁log - rank _ test ing ▁UM / va - RT _ co hor ts
D-384	-1.1007343530654907	kaplan-meier_curves log-rank_testing UM/va-RT_cohorts
P-384	-1.0970 -0.0414 -0.1716 -0.6663 -0.3026 -0.3985 -0.7430 -1.1998 -1.3463 -0.1523 -0.2092 -0.5376 -1.3309 -1.4442 -1.9385 -2.3831 -0.9024 -2.9985 -4.1758 -2.0456 -0.3499 -0.5168 -1.0734 -1.1317 -0.3618
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate_cox_regression_analyses hypertension sinus_rhythm hazard_ratio confidence_interval
H-950	-0.5111953616142273	▁multi varia te _ co x _ re gression ▁AF ▁hyper tension ▁sinus _ rhythm haz ard _ rati o ▁confidence _ ▁interval
D-950	-0.5111953616142273	multivariate_cox_regression AF hypertension sinus_rhythmhazard_ratio confidence_ interval
P-950	-1.4667 -0.7604 -0.2012 -0.3086 -0.0516 -0.2925 -0.1800 -0.0813 -0.0738 -1.1987 -1.2134 -0.0036 -0.7379 -0.4652 -0.3687 -0.0913 -0.0452 -0.2186 -0.0458 -0.0305 -1.4600 -0.3402 -0.7216 -2.1385 -0.2845
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients chronic hf-ref nyha_functional_class_ii egfr potassium eplerenone hyperkalemia
H-1228	-0.7312308549880981	▁chronic _ HF - re f ▁NY ha _ function al _ class _ ▁II ▁e g f ▁po tas s ium ▁e pler en one ▁hyper kal emia ▁w r
D-1228	-0.7312308549880981	chronic_HF-ref NYha_functional_class_ II egf potassium eplerenone hyperkalemia wr
P-1228	-0.9675 -1.1899 -1.8205 -0.0810 -0.0978 -1.4699 -0.9786 -0.8249 -2.8686 -0.0640 -1.3905 -0.6613 -0.1692 -0.8571 -0.5957 -0.4375 -0.7254 -2.1807 -0.1717 -1.0415 -0.2708 -0.2506 -0.3690 -0.2797 -0.1496 -0.0949 -0.0359 -0.4515 -0.0961 -0.1595 -2.6886 -0.4475 -0.2439
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm dual_energy_x-ray_absorptiometry dxa patients chronic_heart_failure chf non-cachectic_chf myocardial
H-12	-0.8047339916229248	▁f f f f ▁body _ dis tribution ▁body _ ▁fat _ dis tribution ▁dual _ ener gy _ ▁x - ray _ ab sor pti ometr y ▁d XA ▁non - dia be tic _ ▁pacientes ▁chronic _ heart _ fail ure ▁ch f cc ▁non - ca che ctic _ ▁CHF ▁my o card ial _ in far ction - bo th
D-12	-0.8047339916229248	ffff body_distribution body_ fat_distribution dual_energy_ x-ray_absorptiometry dXA non-diabetic_ pacientes chronic_heart_failure chfcc non-cachectic_ CHF myocardial_infarction-both
P-12	-1.6666 -0.9078 -0.6738 -1.8306 -1.2948 -0.3920 -4.6952 -0.0111 -1.6906 -0.3287 -1.6917 -1.2186 -0.0767 -0.0108 -0.1263 -0.4333 -0.2425 -0.1340 -1.4067 -1.6280 -0.2268 -0.3055 -0.1696 -0.4633 -0.8619 -0.5741 -0.6693 -0.2116 -0.3358 -0.5720 -0.2711 -0.0553 -0.0359 -0.3703 -0.1901 -2.6263 -1.5699 -1.4565 -0.2846 -2.1397 -0.3105 -0.9387 -2.1051 -3.5068 -0.7747 -0.2760 -1.3448 -0.0627 -0.0044 -1.0378 -1.0713 -1.3435 -1.0820 -1.5401 -0.4589 -0.3146 -0.3054 -0.3654 -0.1788 -0.0233 -0.1731 -0.3393 -0.0380 -0.8202 -0.6443 -0.2033
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline drug spironolactone combined_end_point death hospitalization hf hazard_ratio confidence_interval aas hazard_ratio confidence_interval p_value
H-1707	-0.6907435655593872	▁base line ▁drug _ ▁dose ▁spi rono lac tone ▁end _ point _ of _ ▁death ▁hospital ization ▁h f haz ard _ rati o ▁AA s haz ard _ rati o
D-1707	-0.6907435655593872	baseline drug_ dose spironolactone end_point_of_ death hospitalization hfhazard_ratio AAshazard_ratio
P-1707	-0.0197 -0.0695 -0.6289 -2.4136 -0.9418 -0.0495 -0.0083 -0.1918 -0.0978 -2.2762 -0.5415 -0.3237 -0.2286 -0.0920 -0.2492 -0.4125 -2.6721 -0.2582 -1.0000 -2.2330 -1.5901 -0.2930 -0.1435 -0.1288 -0.0382 -4.3930 -0.1620 -0.3702 -0.4898 -0.1363 -0.1789 -0.0333 -0.5953 -0.2250
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective_study patients invasively diagnosed pulmonary_arterial_hypertension inoperable chronic_thromboembolic_pulmonary_hypertension right_ventricular pump stable pulmonary_arterial_hypertension medication noninvasive stress_echocardiography cardiopulmonary_exercise_testing
H-823	-0.656575083732605	▁pulmonar y _ ▁arterial _ hy tension ▁chronic _ thro mbo e mbol ic _ ▁pulmonar y _ ▁Hyper tension ▁right _ vent ri cular _ pump ▁pulmonar y _ ▁arterial _ hy tension ▁medication ▁stress _ e cho card i ography ▁cardio pul mon ary _ ▁exercise
D-823	-0.656575083732605	pulmonary_ arterial_hytension chronic_thromboembolic_ pulmonary_ Hypertension right_ventricular_pump pulmonary_ arterial_hytension medication stress_echocardiography cardiopulmonary_ exercise
P-823	-0.4324 -0.6825 -0.3244 -1.5251 -0.3688 -2.4186 -0.1934 -0.3435 -0.8518 -0.0745 -0.5818 -0.5917 -0.0596 -0.1654 -0.4497 -1.0309 -0.5852 -0.2878 -3.4266 -0.0241 -0.4466 -0.4771 -0.7976 -1.3056 -0.2202 -0.3418 -1.0788 -0.3218 -0.6563 -0.2897 -1.0603 -0.2514 -2.1598 -0.1333 -0.5031 -0.1226 -0.4421 -0.3066 -0.2609 -0.3057 -0.3094 -0.3077 -0.0456 -1.2307 -2.3609 -0.1426 -0.6068 -0.6786 -1.0066 -0.2408
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular_death hf hospitalization randomization btes btes cardiovascular_death hf hospitalization exercise hazard_ratio confidence_interval hazard_ratio confidence_interval
H-1930	-0.9329120516777039	▁cardiovascular _ ▁death ▁h f ▁b tes ▁b tes ▁cardiovascular _ ▁death ▁h f ▁exercise _ group haz ard _ rati o
D-1930	-0.9329120516777039	cardiovascular_ death hf btes btes cardiovascular_ death hf exercise_grouphazard_ratio
P-1930	-1.1860 -0.3919 -1.6624 -0.9008 -2.9100 -1.3435 -0.7357 -1.0627 -0.6022 -0.2314 -0.3406 -1.8105 -0.2908 -1.8873 -0.4525 -1.7366 -0.2990 -0.2024 -0.3945 -0.2060 -0.2139 -0.0246 -3.2535 -0.2511
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients hospitalized death all-cause_readmission aor eds aor
H-466	-0.6700167655944824	▁index _ ed _ visit ▁low - volu me _ ed _ case s ▁death ▁read mission ▁a OR ▁high - volu me _ ed s ▁a OR
D-466	-0.6700167655944824	index_ed_visit low-volume_ed_cases death readmission aOR high-volume_eds aOR
P-466	-0.1556 -0.3992 -1.7708 -0.4548 -2.6192 -0.1097 -0.0679 -0.2110 -0.0775 -0.5464 -2.0550 -0.2152 -0.1243 -0.0656 -2.1745 -2.2060 -0.0526 -0.4550 -0.7952 -0.4753 -0.1491 -0.3240 -0.1348 -0.3248 -1.4067 -0.1753 -0.4901 -1.3946 -0.3947 -0.2757
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients implantable_cardioverter-defibrillator implantation engage patients decisions implantable_cardioverter-defibrillator
H-1863	-0.7628647089004517	▁implant able _ ▁cardio ver ter - de fi br illa tor _ de activa tion ▁implant ation ▁decisions ▁implant able _ ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1863	-0.7628647089004517	implantable_ cardioverter-defibrillator_deactivation implantation decisions implantable_ cardioverter-defibrillator_deactivation
P-1863	-0.0177 -0.2020 -0.9568 -0.3902 -0.4350 -0.5656 -0.6261 -0.2459 -2.5658 -2.7658 -0.3064 -0.6594 -0.3151 -0.1083 -0.6912 -0.4156 -0.0510 -0.2780 -3.9772 -0.0815 -0.2412 -0.7972 -0.9446 -0.4345 -0.6283 -0.6188 -0.1398 -2.9537 -2.6754 -0.3684 -0.5427 -0.3464 -0.1007 -0.5411 -0.4706 -0.5419 -0.2260
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac_magnetic_resonance t1_time hazard_ratio confidence_interval left_atrial_area hazard_ratio confidence_interval pulmonary_vascular_resistance hazard_ratio confidence_interval cardiac_events
H-739	-0.7746782898902893	▁Card iac _ magnet ic _ re on ance ▁left _ at rial _ area haz ard _ rati o ▁pulmonar y _ vas cular _ re serv ance haz ard _ rati o ▁cardiac _ event s
D-739	-0.7746782898902893	Cardiac_magnetic_reonance left_atrial_areahazard_ratio pulmonary_vascular_reservancehazard_ratio cardiac_events
P-739	-1.2623 -0.4233 -0.2149 -1.0703 -1.9268 -0.2111 -0.7002 -3.1493 -0.1485 -2.9447 -0.3249 -0.8934 -0.4212 -0.5110 -0.1268 -1.1908 -0.2322 -0.3445 -0.1938 -0.0523 -0.2459 -0.2368 -0.3733 -1.1854 -0.5233 -0.3706 -0.2842 -5.2507 -0.1098 -0.2335 -0.3630 -0.3745 -0.2516 -0.0715 -0.2639 -0.3943 -3.3810 -0.1103 -0.3774 -0.2439
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively followed_up hf patients systolic left_ventricular_ejection_fraction hf stable clinical conditions new_york_heart_association_class_i clinical echocardiographic cardiopulmonary_exercise_test
H-1755	-0.7776381969451904	▁h f ▁sy sto lic ▁le ft _ vent ri cular _ e je ction _ fraction ▁h f ▁New _ ▁York _ ▁Heart _ association ▁e cho car dio graphic ▁cardio pul mon ary _ ▁exercise
D-1755	-0.7776381969451904	hf systolic left_ventricular_ejection_fraction hf New_ York_ Heart_association echocardiographic cardiopulmonary_ exercise
P-1755	-1.3617 -1.1641 -2.1756 -0.1846 -0.1394 -2.6701 -0.4554 -0.3604 -0.4490 -0.7564 -0.3120 -0.3700 -0.2043 -0.5000 -0.3502 -0.3049 -0.0160 -1.6394 -1.9504 -2.1047 -1.2333 -2.3658 -0.4019 -0.4961 -0.1724 -0.3881 -0.1326 -0.2611 -0.0438 -0.5231 -0.7301 -0.0898 -0.9470 -2.6589 -0.0974 -0.7570 -0.5649 -0.7430 -0.2529
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients end_stage_heart_failure abcd_classification american_college_of_cardiology acc american_heart_association aha new_york_heart_association nyha heart_disease symptoms heart_failure physical medical_treatment
H-1666	-1.2884697914123535	▁heart _ fail ure ▁ABC d ▁American _ ▁College _ of _ ▁Card i ology ▁a cc American _ ▁Heart _ association ▁ha a ▁New _ York _ ▁Heart _ association ▁ny ha ▁structura l _ heart _ ▁disease ▁heart _ fail ure ▁physical ▁medical
D-1666	-1.2884697914123535	heart_failure ABCd American_ College_of_ Cardiology accAmerican_ Heart_association haa New_York_ Heart_association nyha structural_heart_ disease heart_failure physical medical
P-1666	-4.0276 -0.3041 -2.2698 -3.2343 -1.3965 -0.0842 -1.5076 -0.4153 -2.1952 -0.2922 -0.0984 -0.4452 -0.8690 -0.3888 -0.0437 -1.8379 -0.0637 -2.4388 -0.3477 -1.8762 -0.2366 -0.5411 -2.3017 -3.7018 -3.0907 -1.0967 -2.1006 -0.4116 -0.9856 -0.2523 -0.5102 -3.4332 -0.6293 -3.5338 -0.3788 -0.4766 -2.9075 -0.2332 -2.5473 -1.3270 -0.2232 -1.5174 -2.8176 -0.1665 -0.0633 -0.6737 -0.2643
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva continuity_equation lv_end-diastolic_volume lv_end-systolic_volume mitral_filling_flow mva mitral_filling_flow continuous_wave_doppler_echocardiography mitral_valve_plasty
H-345	-0.7217345833778381	▁m va ▁continu ity LV ▁end - dia sto lic _ ▁volume ▁LV ▁end - sy sto lic _ ▁volume ▁mit ral _ ▁fill ing _ flow ▁m va ▁veloci ty _ time ▁mit ral _ ▁fill ing _ flow ▁continuo us _ wa ve ▁do pp ler _ e cho card i ography ▁MR ▁mit ral _ val ve _ plast y
D-345	-0.7217345833778381	mva continuityLV end-diastolic_ volume LV end-systolic_ volume mitral_ filling_flow mva velocity_time mitral_ filling_flow continuous_wave doppler_echocardiography MR mitral_valve_plasty
P-345	-0.4743 -0.1434 -1.6543 -0.0960 -2.7478 -2.5602 -0.1182 -0.0948 -1.0347 -0.3150 -1.0488 -1.8963 -1.8621 -2.3830 -0.1546 -0.8285 -0.6174 -0.3270 -0.8559 -1.9689 -0.9224 -0.1863 -0.4601 -3.2994 -0.1157 -0.2998 -0.3664 -0.8465 -0.3536 -0.0558 -0.0713 -0.3148 -3.0542 -0.6432 -0.1260 -0.5133 -2.5184 -0.1304 -0.3316 -0.3828 -0.2819 -0.2969 -0.4410 -0.2015 -0.1567 -1.0790 -0.3075 -0.9066 -0.1998 -0.2037 -0.2650 -0.2057 -0.4659 -0.2507 -0.6428 -0.5311 -0.1185 -0.3162 -1.7828 -0.2166 -0.2644 -0.1198 -0.8836 -0.3792 -0.2225
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance rm all-cause_mortality sts hh cri cri cri
H-157	-1.3212943077087402	▁stati tis tical _ ▁significa nce ▁RM ▁mortal ity ▁s ts _ h h ▁cred ible _ ▁interval ▁c r i ▁t m ▁office _ ▁hours ▁Cr i
D-157	-1.3212943077087402	statitistical_ significance RM mortality sts_hh credible_ interval cri tm office_ hours Cri
P-157	-1.0907 -1.4571 -0.7127 -3.5635 -0.3431 -0.0982 -2.1599 -0.2737 -0.0768 -0.2615 -0.5852 -0.8676 -1.2289 -2.0355 -3.7480 -0.3192 -0.4198 -0.3958 -2.9397 -0.1077 -3.3488 -1.8569 -1.7151 -0.3871 -0.4609 -1.3783 -1.5646 -3.3288 -2.6712 -0.2425
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi hf clinic outcomes hfpsi outcomes tracking patients hfpsi
H-381	-1.1425138711929321	▁h f PSI ▁Ann _ ar bor ▁Veteran s _ af fair s ▁h f _ ▁clinic ▁va _ co hor t ▁h f PSI ▁va - RT _ co hor t ▁va _ ▁pacientes ▁h f PSI
D-381	-1.1425138711929321	hfPSI Ann_arbor Veterans_affairs hf_ clinic va_cohort hfPSI va-RT_cohort va_ pacientes hfPSI
P-381	-1.5320 -2.6560 -1.2172 -0.6660 -0.9910 -0.2619 -0.7034 -0.4071 -0.4866 -0.6087 -2.2854 -0.0123 -0.0922 -1.0203 -1.1643 -1.4735 -1.9318 -1.1746 -1.0416 -0.8279 -0.5988 -0.6328 -1.0541 -4.1435 -1.4601 -0.4978 -0.1965 -1.9918 -2.4688 -0.1074 -0.9944 -0.6031 -0.8109 -0.4918 -2.1129 -0.5636 -3.6546 -2.0308 -0.4841 -0.2490
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas spironolactone hyperkalemia potassium hypokalemia potassium
H-1706	-0.7655991911888123	▁AA s ▁non - AA s ▁spi rono lac tone _ ▁dose ▁hyper kal emia ▁hypo kal emia ▁po tas s ium
D-1706	-0.7655991911888123	AAs non-AAs spironolactone_ dose hyperkalemia hypokalemia potassium
P-1706	-0.5255 -0.2065 -2.8725 -0.0452 -1.4422 -0.0966 -0.1104 -0.0211 -0.4216 -0.1729 -1.0069 -1.0802 -0.3609 -0.8177 -0.1999 -1.9378 -1.3771 -0.1866 -1.0604 -1.2508 -0.1643 -1.9927 -0.7922 -0.2326
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate_analysis patients preserved_lvef mortality patients lvef hazard_ratio lvef preserved_lvef
H-115	-0.6512529850006104	▁LV EF ▁long - term _ ▁mortal ity ▁LV EF haz ard _ rati o ▁LV EF ▁LV EF
D-115	-0.6512529850006104	LVEF long-term_ mortality LVEFhazard_ratio LVEF LVEF
P-115	-1.5507 -0.9137 -1.6733 -0.1272 -0.4172 -0.2032 -0.3315 -0.1363 -0.9725 -0.3865 -0.1551 -0.1312 -0.1850 -0.0360 -0.0442 -0.7053 -0.6940 -2.6071 -0.8080 -1.3202 -0.2780
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients hfpef primary_outcome odds_ratio nyha_class_iii 6-minute_walk_test 6-mwt feet prescribed medications
H-242	-0.5922325849533081	HF p EF odd s _ rati o ▁NY ha ▁walk _ test ▁mw t
D-242	-0.5922325849533081	HFpEFodds_ratio NYha walk_test mwt
P-242	-1.9525 -0.0533 -0.4256 -0.2867 -0.0795 -0.2955 -0.0450 -0.0755 -2.1078 -0.4717 -0.5541 -0.2213 -0.2097 -0.4146 -0.1478 -2.4883 -0.2390
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived_pulmonary_arterial_systolic_pressure pasp right_ventricular rv tricuspid_annular_plane_systolic_excursion tapse diastole end-systole clinical follow-up heart_failure hf patients cardiac
H-492	-0.7657679915428162	▁e cho - der i ved _ ▁pulmonar y _ ▁arterial _ sy sto lic _ tension PAS p ▁right _ vent ri cular RV ▁tri cus pid _ annu ular _ plan e _ sy sto lic _ excursion TA PS e ▁dia stol e ▁end - sy stol e ▁follow - up ▁heart _ ▁failure HF ▁cardiac _ risk
D-492	-0.7657679915428162	echo-derived_ pulmonary_ arterial_systolic_tensionPASp right_ventricularRV tricuspid_annuular_plane_systolic_excursionTAPSe diastole end-systole follow-up heart_ failureHF cardiac_risk
P-492	-2.4410 -0.1573 -0.0282 -0.3461 -0.1357 -0.1255 -0.7610 -0.6139 -0.4424 -0.4195 -1.2920 -0.2142 -0.9794 -0.8347 -0.4711 -0.1795 -1.7669 -1.0613 -0.9855 -0.0615 -0.4486 -0.6355 -0.9861 -0.3515 -2.0054 -0.0366 -0.9158 -0.5379 -0.4319 -2.0404 -0.6379 -0.2607 -0.4917 -0.0938 -0.4401 -2.9414 -2.3475 -0.7092 -0.5959 -0.0306 -3.9000 -1.6246 -0.1352 -0.0740 -0.6272 -0.8507 -0.4719 -0.2065 -0.8195 -1.4019 -0.6916 -0.3651 -0.1123 -0.0207 -1.1551 -0.2441 -2.3961 -0.9044 -0.1484 -0.5611 -0.5395 -0.4927 -0.2454
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad diabetes odds_ratio electrocardiographic_q_waves left_bundle_branch_block odds_ratio nondiabetes dyslipidemia hypertension odds_ratio
H-1190	-0.42183297872543335	▁CAD ▁diabetes odd s _ rati o ▁electro car dio graphic ▁wa ves ▁left _ ▁bund le _ ▁bran ch _ block odd s _ rati o ▁non dia bete s ▁dys li pide mia ▁hyper tension ▁to ba cco odd s _ rati o
D-1190	-0.42183297872543335	CAD diabetesodds_ratio electrocardiographic waves left_ bundle_ branch_blockodds_ratio nondiabetes dyslipidemia hypertension tobaccoodds_ratio
P-1190	-1.3816 -0.1020 -0.7844 -0.1141 -0.3029 -0.1185 -0.0468 -0.0102 -0.0401 -0.1803 -0.4317 -0.1316 -0.4283 -0.1602 -0.5723 -1.4401 -0.8600 -0.1690 -2.6789 -0.0550 -0.3167 -2.8304 -0.5763 -0.0841 -0.3250 -0.1322 -0.0631 -0.1295 -0.2102 -0.5903 -0.0831 -0.2110 -0.1112 -0.0441 -0.4068 -0.0095 -0.0010 -0.0167 -0.5377 -0.3482 -1.4481 -0.0829 -0.3000 -0.1453 -0.1491 -0.4343 -0.2314
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area_under_the_receiver_operating_characteristic_curve auc pcwp confidence_interval septal p_values
H-485	-0.7703344225883484	▁receive r ▁operating _ ▁character istic _ cur ve ▁ab c ▁ratio s ▁pc w p ▁confidence _ ▁interval sept al
D-485	-0.7703344225883484	receiver operating_ characteristic_curve abc ratios pcwp confidence_ intervalseptal
P-485	-1.3247 -0.0835 -1.1819 -0.5311 -0.7242 -0.1742 -0.2860 -0.0874 -0.1242 -5.1620 -0.4460 -0.4410 -0.1569 -0.0868 -1.9097 -0.2914 -0.5515 -0.5084 -0.6335 -0.0181 -0.0710 -2.6582 -0.2660
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients coronary_artery_disease hypertension trastuzumab administration chf
H-680	-0.6396878361701965	▁tras tuz um ab - tre ated ▁corona ry _ ▁arter y _ ▁disease ▁hyper tension ▁tras tuz um ab _ administration ▁CHF
D-680	-0.6396878361701965	trastuzumab-treated coronary_ artery_ disease hypertension trastuzumab_administration CHF
P-680	-2.3644 -0.2487 -0.5221 -0.9013 -0.4742 -0.1813 -0.2400 -0.9094 -0.3134 -0.4055 -0.1202 -0.4791 -0.5227 -2.2539 -0.2654 -0.0032 -2.4719 -0.0611 -0.3157 -0.2193 -1.3617 -0.0329 -0.6137 -0.4030 -0.3078
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef clinical crt crt systolic_volume_index lv_mass
H-754	-1.3018499612808228	▁LV EF ▁com posit e _ re lation ship ▁c t _ on ▁c t _ off ▁LV _ end _ sy sto lic _ ▁volume _ index ▁m d p ▁LV _ ▁mass
D-754	-1.3018499612808228	LVEF composite_relationship ct_on ct_off LV_end_systolic_ volume_index mdp LV_ mass
P-754	-1.0693 -1.3263 -3.8711 -0.0941 -0.0438 -0.6484 -0.5956 -2.2461 -0.2188 -1.0816 -2.7979 -2.3631 -0.1405 -1.2383 -2.9125 -0.5274 -0.2449 -1.7988 -0.7600 -4.0124 -0.2224 -3.2441 -0.5467 -0.2409 -0.1483 -2.0182 -0.2101 -0.2514 -0.1521 -4.5978 -2.1861 -2.9908 -0.4932 -0.9157 -0.4209 -0.2370
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β_signaling tgf-β_receptor_type_i cell yield epithelial mesenchymal transition pluripotency_marker nanog cell cells in_vitro
H-1343	-0.6618620157241821	▁t g f - β _ signal ing ▁t g f - β _ ▁receptor ▁s mad ▁small - mo le cule _ ▁inhibi tors ▁c - K it _ cell _ ▁yi eld ▁epi the li al ▁mes en chy mal _ trans mission _ ▁marker s ▁pluri pote ncy _ ▁marker ▁na nog ▁c - K it _ cell _ ▁differenti ation ▁cardio my o cy te - like _ cell s
D-1343	-0.6618620157241821	tgf-β_signaling tgf-β_ receptor smad small-molecule_ inhibitors c-Kit_cell_ yield epithelial mesenchymal_transmission_ markers pluripotency_ marker nanog c-Kit_cell_ differentiation cardiomyocyte-like_cells
P-1343	-0.4399 -0.6698 -0.9290 -0.1316 -1.7441 -0.5473 -0.4030 -0.3541 -0.3186 -0.8341 -0.6589 -0.1321 -1.7344 -0.2290 -0.3584 -1.2574 -0.1370 -0.8029 -0.0768 -0.1708 -1.1087 -0.7062 -0.2699 -1.7102 -0.0546 -0.0456 -0.1537 -4.1477 -1.1948 -0.6326 -6.9530 -0.1583 -0.6803 -0.0026 -0.0641 -0.1001 -0.5342 -0.0422 -0.0881 -1.7557 -0.2457 -0.0690 -0.1748 -0.2136 -2.2053 -0.4029 -0.4583 -0.0780 -0.0443 -0.1400 -0.1252 -0.3014 -0.6284 -0.0421 -0.0142 -0.0240 -0.0638 -2.3249 -0.6593 -0.4368 -2.6954 -0.6721 -0.3145 -0.0662 -0.0447 -1.2780 -0.4222 -0.0680 -0.3175 -0.8896 -0.4596 -0.3922 -0.1588 -0.0963 -1.2264 -0.2167
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients hfref diuretics co-morbidities 6-mwt feet nyha_class_iii
H-243	-0.6924448609352112	▁h f ▁di ure tics ▁co - mor bid ities ▁mw t ▁NY ha
D-243	-0.6924448609352112	hf diuretics co-morbidities mwt NYha
P-243	-0.4299 -2.0420 -0.9757 -0.1088 -0.9334 -0.0554 -0.1856 -0.8790 -0.0833 -0.2147 -0.9333 -0.2437 -2.4549 -0.6297 -0.6182 -0.2915
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery hf postoperative echocardiography end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mitral_valve_area mva
H-344	-0.48857390880584717	▁surgery ▁h f ▁post operativ e _ e cho card i ography ▁LV ▁end - dia sto lic _ ▁volume _ index ▁LV ▁e je ction _ fraction ▁MR ▁mit ral _ val ve _ open ▁mit ral _ val ve _ area ▁m va ▁mean _ press ure _ grad ient ▁h g
D-344	-0.48857390880584717	surgery hf postoperative_echocardiography LV end-diastolic_ volume_index LV ejection_fraction MR mitral_valve_open mitral_valve_area mva mean_pressure_gradient hg
P-344	-1.2628 -0.7864 -0.8591 -0.1107 -0.3533 -0.0816 -0.9086 -0.2844 -0.2830 -0.4077 -0.2997 -0.3004 -0.5537 -0.4211 -0.2141 -0.0567 -0.7289 -0.2783 -0.3816 -2.0581 -0.1548 -0.2843 -2.2276 -0.5355 -0.3220 -0.1476 -0.3131 -0.0068 -0.9862 -0.2868 -0.1110 -0.4392 -0.9119 -0.4924 -0.3538 -1.2862 -0.1185 -0.0863 -0.3757 -1.0015 -0.3776 -0.2439 -0.2281 -0.2328 -0.1141 -0.2067 -0.2210 -0.9445 -0.4034 -0.2499 -0.7902 -1.0991 -0.3687 -0.0649 -0.5449 -0.1990
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients systolic_heart_failure ejection_fraction randomized placebo ivabradine shift systolic_heart_failure_treatment_with_the_if_inhibitor_ivabradine_trial patients placebo ivabradine echocardiographic
H-519	-0.8774576187133789	▁sy sto lic _ heart _ fail ure ▁i va bra dine ▁SHI ft ▁sy sto lic _ ▁Heart _ fail ure ▁treatment ▁if _ in hib itor _ i va bra dine _ tri al ▁i va bra dine ▁e cho car dio graphic
D-519	-0.8774576187133789	systolic_heart_failure ivabradine SHIft systolic_ Heart_failure treatment if_inhibitor_ivabradine_trial ivabradine echocardiographic
P-519	-1.8519 -0.7205 -0.8095 -0.2164 -2.7614 -0.2536 -1.0019 -0.3848 -4.7528 -0.1400 -0.1846 -0.9164 -0.2755 -1.9418 -2.4104 -0.5634 -0.7607 -0.2719 -1.3241 -0.3906 -0.7674 -0.1555 -3.0951 -3.0451 -0.6655 -0.0896 -0.0536 -0.8276 -0.3466 -2.1207 -0.1927 -0.1845 -0.8642 -0.2868 -0.6783 -0.4101 -0.1664 -0.1067 -0.2488 -1.0030 -0.3915 -0.4190 -0.1324 -0.8728 -1.5603 -0.4162 -0.2081
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard_ratios multivariate_regression tapse pasp hazard_ratio tapse new_york_heart_association_functional_class
H-499	-1.133971095085144	▁Hazard _ rati os ▁multi varia te _ re gression ▁t AP se ▁h g haz ard _ rati o ▁p se ▁New _ York _ ▁Heart _ association
D-499	-1.133971095085144	Hazard_ratios multivariate_regression tAPse hghazard_ratio pse New_York_ Heart_association
P-499	-0.9368 -0.3503 -0.0720 -0.2832 -6.6320 -1.0300 -0.1336 -0.3155 -0.0471 -0.0799 -3.1353 -2.1238 -1.0803 -3.6622 -0.2983 -0.7963 -0.4586 -0.2976 -0.0737 -0.2693 -3.4378 -0.9686 -2.4588 -1.2020 -2.2550 -0.3346 -0.6185 -0.2640 -0.4520 -0.8294 -0.2569
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal_function the_chronic_kidney_disease_epidemiology_collaboration patients estimated_glomerular_filtration_rate egfr
H-390	-0.7941732406616211	▁Ren al _ function ▁Chro nic _ ▁Kid ney _ ▁Disease ▁Epidemi ology ▁glo mer ular _ filter ation _ rate ▁e g f ▁m L
D-390	-0.7941732406616211	Renal_function Chronic_ Kidney_ Disease Epidemiology glomerular_filteration_rate egf mL
P-390	-2.7782 -0.1803 -0.2892 -0.3841 -0.0206 -0.3661 -0.1877 -0.1342 -0.4403 -0.7049 -0.1024 -0.5779 -0.1439 -0.2312 -0.3565 -0.0645 -0.2802 -1.2984 -0.9025 -0.2972 -0.5142 -0.5428 -0.4367 -2.3049 -0.0758 -4.4295 -3.8897 -0.3026
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective randomized paradigm-hf chronic_heart_failure systolic_dysfunction lv_ef functional_class nyha elevated bnp nt-pro_bnp primary_endpoint cardiovascular_death hospitalization heart_failure arni lcz696 sacubiltril valsartan
H-1968	-0.9320875406265259	▁para dig m - HF ▁chronic _ heart _ fail ure ▁sy sto lic _ ▁dys function ▁v f ▁functional ▁NY ha _ ▁II - III ▁b NP ▁b n ▁primary _ end point ▁cardio vas cular _ ▁death ▁hospital ization ▁heart _ fail ure ▁ar ni ▁l z 696 ▁sa cubi lt ril ▁val sar tan
D-1968	-0.9320875406265259	paradigm-HF chronic_heart_failure systolic_ dysfunction vf functional NYha_ II-III bNP bn primary_endpoint cardiovascular_ death hospitalization heart_failure arni lz696 sacubiltril valsartan
P-1968	-2.6870 -1.6285 -0.7000 -0.0633 -0.6913 -0.7078 -0.5254 -2.4006 -0.3289 -2.6036 -2.3153 -0.3391 -0.2923 -0.5975 -0.2133 -0.6709 -0.0198 -2.8631 -4.0415 -1.5374 -1.4302 -0.6032 -2.5140 -0.4901 -0.0350 -0.0283 -0.2251 -1.3742 -0.5164 -2.1619 -1.3687 -0.4725 -1.8496 -0.4092 -1.2695 -0.6228 -0.5633 -1.5429 -1.1537 -0.7796 -0.1991 -1.4577 -0.2593 -1.3981 -2.7827 -0.3927 -0.4388 -0.9701 -1.1722 -0.0107 -0.0151 -0.0331 -0.0461 -0.1795 -0.1488 -0.0827 -0.1009 -0.4585 -0.2104
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia outcomes african_americans aas new_york_heart_association nyha hf left_ventricular_dysfunction randomized spironolactone titrated placebo randomized_aldactone_evaluation_study rales
H-1703	-0.6987869143486023	▁hyper kal emia ▁African _ American s ▁non - AA s ▁white ▁New _ York _ ▁Heart _ association NY ha ▁h f ▁left _ vent ri cular _ ▁dys function ▁spi rono lac tone ▁Rand om ized _ al da cto ne _ evalua tion _ ▁Study RAL es
D-1703	-0.6987869143486023	hyperkalemia African_Americans non-AAs white New_York_ Heart_associationNYha hf left_ventricular_ dysfunction spironolactone Randomized_aldactone_evaluation_ StudyRALes
P-1703	-0.4451 -0.6525 -0.3164 -0.9888 -0.4191 -1.4657 -0.2974 -3.0197 -0.0903 -2.6637 -0.0425 -0.3334 -1.3256 -1.1647 -1.9532 -0.2959 -0.4428 -0.2874 -0.3881 -2.1439 -0.9131 -1.4989 -2.0801 -0.2206 -0.3204 -0.6598 -1.4441 -0.4421 -0.3013 -0.5873 -0.0710 -0.0990 -0.0024 -0.1224 -0.0571 -1.7028 -0.1037 -0.1208 -0.1764 -0.3722 -0.1899 -0.2336 -0.7094 -0.1728 -0.3379 -0.2116 -0.3343 -3.0432 -0.1308 -0.4483 -0.2895 -0.2038
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv_reverse_remodeling lv_end-diastolic_dimension longitudinal strain left_ventricle left_atrial_area right_ventricular_end-diastolic_area_index right_atrial right_ventricular_fractional_area change
H-432	-0.9797659516334534	▁LV ▁rever se _ ▁remodel ing ▁pre - c t ▁LV ▁end - dia sto lic _ dimension _ index ▁longitud in al _ ▁strain ▁left _ vent ric le ▁left _ at rial _ area ▁right _ vent ri cular ▁end - dia sto lic _ area _ index ▁right _ at rial _ area ▁right _ vent ri cular _ fraction al _ area _ change
D-432	-0.9797659516334534	LV reverse_ remodeling pre-ct LV end-diastolic_dimension_index longitudinal_ strain left_ventricle left_atrial_area right_ventricular end-diastolic_area_index right_atrial_area right_ventricular_fractional_area_change
P-432	-0.6170 -0.2258 -0.0404 -0.1958 -2.7254 -0.0810 -2.8896 -0.0127 -0.7492 -2.8245 -0.8559 -3.5824 -0.1803 -0.0989 -2.1102 -0.5544 -0.9714 -0.4508 -0.5964 -0.3413 -0.3244 -0.2617 -0.0654 -0.3550 -2.2378 -1.0113 -0.3580 -1.0922 -2.8102 -0.8526 -0.7959 -0.3862 -3.4602 -0.8090 -0.5475 -0.2132 -0.3415 -0.3831 -1.9258 -1.4802 -0.3772 -5.2671 -0.3385 -0.1084 -2.6060 -1.4782 -0.4061 -0.4363 -2.3079 -0.6221 -0.1192 -0.3519 -4.4151 -1.1873 -0.5101 -0.2042 -0.3438 -0.3404 -1.9708 -1.4643 -0.5018 -1.0071 -0.0489 -0.0876 -0.2657 -0.2194 -0.5563 -0.6544 -0.3635 -0.2096
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type_natriuretic_peptide n-terminal_pro-b-type_natriuretic_peptide diagnostic stable coronary_artery_disease b-type_natriuretic_peptide bnp nt-probnp ventricular_cardiomyocytes ventricular wall_stress myocardial_ischemia
H-1364	-0.8028642535209656	▁b - type _ na tri ure tic _ pe pti de ▁na tri ure tic _ pe pti de ▁stable _ ▁corona ry _ ▁arter y _ ▁disease ▁b - type _ na tri ure tic _ pe pti de ▁b NP ▁n - termin al _ ▁fragment NT - pro b NP ▁vent ri cular _ ▁cardio my o cy tes ▁vent ri cular _ wall _ ▁stress ▁my o card ial _ ische mia
D-1364	-0.8028642535209656	b-type_natriuretic_peptide natriuretic_peptide stable_ coronary_ artery_ disease b-type_natriuretic_peptide bNP n-terminal_ fragmentNT-probNP ventricular_ cardiomyocytes ventricular_wall_ stress myocardial_ischemia
P-1364	-2.1229 -0.3332 -0.3149 -0.2347 -2.8520 -0.6542 -0.3803 -0.5383 -0.2560 -1.5006 -1.1442 -0.6466 -1.2280 -0.3739 -0.5030 -0.7247 -0.2460 -2.1890 -0.9839 -0.4839 -1.5199 -0.7251 -1.7505 -0.3382 -0.4097 -0.2424 -0.5595 -0.7620 -1.9049 -1.0613 -0.9745 -0.1364 -0.3164 -2.5472 -0.6925 -0.2813 -0.9899 -0.2617 -1.3592 -1.2681 -0.4688 -0.2985 -1.6387 -1.5715 -0.0519 -1.7919 -0.0331 -0.6974 -1.6278 -2.7391 -0.0199 -0.0645 -1.1914 -0.8919 -0.0657 -0.4759 -0.3698 -0.3906 -0.1104 -1.3987 -0.2051 -0.0452 -0.6775 -0.0286 -0.7245 -0.6106 -0.3723 -3.5351 -0.5930 -1.0621 -0.3619 -0.4032 -0.7618 -0.3957 -0.4160 -0.0346 -0.8809 -0.4072 -0.2021
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 irs2 heart hyperinsulinemia myocardial_insulin_resistance cellular_dysfunction irs1 irs2 heart-specific_irs1_and_irs2_gene_double-knockout h-dko liver-specific_irs1_and_irs2_double-knockout l-dko
H-654	-0.8613464832305908	▁i RS 1 ▁ir s 2 ▁heart ▁hyper insu line mia ▁my o card ial _ ▁insulin _ re serv ance ▁cel lular _ ▁dys function ▁i RS 1 ▁ir s 2 ▁heart - specific ▁i RS 1 ▁ir s 2 _ ▁gene _ dou ble - k no ckou t ▁h - d ko ▁ liver - specific ▁i RS 1 ▁ir s 2 ▁double - k no ckou t ▁l - d ko
D-654	-0.8613464832305908	iRS1 irs2 heart hyperinsulinemia myocardial_ insulin_reservance cellular_ dysfunction iRS1 irs2 heart-specific iRS1 irs2_ gene_double-knockout h-dko liver-specific iRS1 irs2 double-knockout l-dko
P-654	-1.1315 -1.6898 -0.3101 -2.3112 -2.6724 -0.0530 -1.8897 -0.1189 -0.0798 -0.0809 -2.1336 -0.3522 -0.3632 -0.9489 -0.4231 -0.3819 -0.1544 -0.2759 -0.5515 -3.8033 -0.1468 -0.5015 -0.0836 -0.3796 -0.9146 -0.0344 -0.8279 -1.5032 -0.5365 -2.3954 -2.2460 -0.0565 -2.0699 -0.1824 -0.1760 -1.8552 -1.4655 -0.3642 -1.9429 -1.9104 -0.0455 -0.9225 -2.0729 -0.3318 -1.3801 -0.3268 -0.2012 -1.6964 -0.2659 -0.2379 -0.2217 -0.5016 -0.2409 -0.2205 -1.1148 -0.7772 -0.5910 -0.2992 -0.2174 -1.4268 -1.4470 -0.3403 -2.6828 -1.7196 -0.0845 -1.0571 -0.2781 -1.7820 -0.1976 -0.5568 -0.2209 -1.0268 -0.2355 -0.2462 -1.0944 -0.7044 -0.2400
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers interquartile_range β-blockers interquartile_range interquartile_range
H-665	-0.5150436758995056	▁ang io ten sin - con ver ting _ ▁enzym e _ ▁inhibi tors angi oten sin _ ▁receptor _ block ers ▁inter quart ile _ range ▁β - block ers ▁inter quart ile _ range
D-665	-0.5150436758995056	angiotensin-converting_ enzyme_ inhibitorsangiotensin_ receptor_blockers interquartile_range β-blockers interquartile_range
P-665	-1.8731 -4.7481 -0.2050 -0.7869 -0.6854 -0.0356 -0.1602 -0.1358 -0.2937 -0.5005 -0.2654 -0.3217 -0.6367 -0.0655 -0.2254 -0.0095 -0.3337 -0.3833 -0.4023 -0.5901 -1.2341 -0.0912 -0.1976 -0.1104 -0.5538 -0.4472 -0.1765 -0.3175 -0.0377 -0.4555 -0.2068 -0.1671 -0.1365 -0.8576 -0.5280 -0.2755 -0.8173 -0.3035
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ivabradine change peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity correlates exercise_capacity therapy ivabradine correlated peak_oxygen_uptake
H-1177	-0.6302171945571899	▁Therapy ▁i va bra dine ▁change ▁dia sto lic _ met ral _ flow _ velo city ▁dia sto lic _ met ral _ an ular _ velo city ▁exercise _ capaci ty ▁i va bra dine ▁pe ak _ ▁oxygen _ up take
D-1177	-0.6302171945571899	Therapy ivabradine change diastolic_metral_flow_velocity diastolic_metral_anular_velocity exercise_capacity ivabradine peak_ oxygen_uptake
P-1177	-1.6146 -0.3667 -0.0295 -0.0533 -0.5389 -3.1246 -0.7545 -0.8026 -0.3020 -0.3017 -2.0416 -0.0743 -0.2750 -0.8770 -0.2359 -0.0389 -0.1727 -0.7863 -1.1230 -0.4243 -0.3344 -2.1686 -0.1576 -0.2773 -3.5928 -0.2068 -0.2871 -0.0400 -0.1708 -0.0556 -0.5841 -0.1110 -0.0418 -1.5460 -0.0379 -0.0989 -0.6448 -1.1738 -0.0491 -0.1880 -1.7103 -0.2101 -0.7033 -0.1391 -0.2817 -0.2415
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence transfusion mortality relative_risk mortality patients acute_coronary_syndrome
H-45	-0.49542760848999023	▁liberal _ trans fusion ▁mortal ity _ rate s ▁i 2 ▁mortal ity _ rate s ▁a cute _ ▁corona ry _ ▁syndrome
D-45	-0.49542760848999023	liberal_transfusion mortality_rates i2 mortality_rates acute_ coronary_ syndrome
P-45	-0.4347 -0.3348 -0.1859 -0.2658 -2.0387 -0.2601 -0.8018 -1.1951 -0.0518 -0.7455 -0.0297 -0.0743 -0.2182 -0.6588 -1.0633 -0.0480 -0.0330 -0.0678 -0.1752 -1.1513 -0.4038 -0.2308 -1.0148 -0.6052 -0.2974
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death readmission patients physician hazard_ratio confidence_interval physician follow-up patients follow-up
H-1419	-1.0496704578399658	▁read mission ▁follow - up ▁follow - up _ ▁visit s
D-1419	-1.0496704578399658	readmission follow-up follow-up_ visits
P-1419	-1.1188 -0.0504 -6.5608 -0.2572 -0.0232 -1.1243 -0.2653 -0.0287 -0.8966 -2.5420 -0.1459 -0.4045 -0.2280
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek human_embryonic_kidney cells β1ar s1pr1 β1ar downregulation sphingosine-1-phosphate s1pr1_agonist s1pr1 downregulation isoproterenol β-adrenergic_receptor_agonist
H-1409	-0.8192225098609924	▁h ek ▁em bry o nic _ ▁ki dne y ▁β 1 ar ▁s 1 PR 1 ▁β 1 ar ▁down regul ation ▁sp hing os ine -1 - phos pha te ▁s 1 PR 1 _ ▁ago nist ▁iso prot eren ol ▁β - ad r energi c _ ▁receptor _ ▁ago nist
D-1409	-0.8192225098609924	hek embryonic_ kidney β1ar s1PR1 β1ar downregulation sphingosine-1-phosphate s1PR1_ agonist isoproterenol β-adrenergic_ receptor_ agonist
P-1409	-1.4187 -1.0946 -1.7148 -0.1746 -0.2113 -0.1888 -0.1671 -2.1058 -0.5313 -0.3383 -2.8922 -0.6414 -0.7671 -1.3484 -0.2764 -2.7001 -0.5056 -4.7265 -0.6839 -1.1107 -3.4849 -0.5488 -0.0735 -0.2197 -0.4494 -0.1358 -0.6997 -1.6022 -0.2569 -0.1287 -0.4090 -0.2006 -0.3644 -0.1613 -2.2658 -0.2172 -0.6125 -1.2629 -0.3715 -1.6934 -0.0426 -0.0692 -0.2769 -0.2091 -0.1756 -0.1707 -1.3448 -0.3151 -0.3342 -0.1997 -0.7390 -0.4518 -1.4974 -0.2659 -0.8197 -0.2090
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline training 6-minute_walked_distance quality_of_life kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire symptoms beck_depression_inventory zung_self-rated_depression_scores b-type_natriuretic_peptide endothelial_function flow-mediated_dilatation left_ventricular_diastolic_function
H-1330	-0.5183229446411133	▁base line ▁kan sas _ city ▁Card i om yo pathy ▁Minnesota ▁Heart _ fail ure _ ▁Question naire ▁ depressiv e ▁be ck _ de pression _ in ven tory ▁z ung ▁self - rat ed _ de pression ▁na tri ure tic _ pe pti de ▁en dot heli al _ function ▁flow - media ted _ di la tation ▁left _ vent ri cular _ dia sto lic _ function
D-1330	-0.5183229446411133	baseline kansas_city Cardiomyopathy Minnesota Heart_failure_ Questionnaire depressive beck_depression_inventory zung self-rated_depression natriuretic_peptide endothelial_function flow-mediated_dilatation left_ventricular_diastolic_function
P-1330	-0.1578 -0.0823 -1.7878 -0.1177 -0.4554 -0.2698 -2.0136 -0.0626 -0.0719 -0.7231 -0.0858 -0.5563 -1.7385 -0.4555 -0.1893 -0.1037 -1.2956 -0.4736 -0.0769 -0.4581 -0.0100 -0.2065 -2.8837 -0.0512 -0.4135 -0.2034 -0.0953 -0.6761 -0.2723 -0.7321 -0.0310 -1.9030 -0.2330 -0.0949 -0.0198 -0.2469 -0.0254 -0.3396 -1.9360 -0.3046 -0.7226 -0.1105 -0.0456 -0.1238 -0.3534 -0.6886 -0.3604 -0.3735 -0.1520 -2.0854 -0.3497 -0.0382 -1.1942 -0.3296 -0.9238 -0.0660 -0.1699 -0.3086 -0.2358 -2.2598 -0.0838 -0.0727 -0.2765 -0.4102 -1.1546 -0.9557 -0.3112 -0.3198 -0.2370 -0.3489 -0.3675 -0.6193 -0.3419 -0.4173 -0.2134
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds_ratios confidence_intervals cardiovascular_events atrial_fibrillation left_ventricular_ejection_fraction diabetes_mellitus peripheral_vascular_disease myocardial_infarction heart_failure stroke patients estimated_glomerular_filtration_rate nonsignificant acute_kidney_injury
H-976	-0.5418246984481812	▁odds _ rati os ▁cardiovascular _ event s ▁at rial _ fi bril lation ▁left _ vent ri cular _ e je ction _ fraction ▁diabetes _ ▁mell itus ▁per i pher al _ ▁vas cular _ ▁disease ▁my o card ial _ in far ction ▁heart _ fail ure ▁stroke ▁glo mer ular _ filter ation _ rate ▁ki dne y _ ▁injury
D-976	-0.5418246984481812	odds_ratios cardiovascular_events atrial_fibrillation left_ventricular_ejection_fraction diabetes_ mellitus peripheral_ vascular_ disease myocardial_infarction heart_failure stroke glomerular_filteration_rate kidney_ injury
P-976	-2.0372 -0.2910 -0.0879 -0.1595 -0.2961 -0.7316 -2.6822 -0.0514 -0.1760 -0.2384 -0.3314 -0.7312 -0.1188 -0.1776 -0.1644 -0.4213 -0.8793 -0.9414 -0.4132 -0.3825 -0.2593 -0.3987 -0.2690 -0.2800 -0.0288 -0.0478 -0.5201 -0.1813 -0.0759 -0.0242 -0.1690 -0.1205 -0.5676 -0.2274 -3.6428 -0.3567 -0.4838 -2.3133 -0.4529 -0.2704 -0.7222 -0.4834 -0.4047 -0.3663 -0.0610 -0.4631 -0.2319 -0.4283 -1.0923 -1.6202 -0.2891 -0.0511 -0.1241 -0.0267 -0.1873 -1.0197 -0.5904 -0.2358 -0.8570 -1.3718 -0.6359 -0.2274 -0.4221 -1.3054 -0.3095 -0.2319
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic_function ea ventricular-arterial_coupling ees ea
H-925	-0.7105940580368042	▁dia sto lic _ function ▁ea ▁vent ri cular - arte rial _ ▁coup ling ▁e es ▁e a
D-925	-0.7105940580368042	diastolic_function ea ventricular-arterial_ coupling ees ea
P-925	-0.0718 -0.4492 -0.2211 -0.4086 -0.1719 -2.0615 -0.3021 -0.8631 -0.3203 -0.2064 -0.1276 -0.1694 -0.3707 -0.9139 -0.5278 -1.2758 -1.9864 -3.4137 -0.2308 -0.5065 -0.3240
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard_ratios disease_risk_score drs saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas saxagliptin insulin
H-1835	-1.061749815940857	▁hazard _ rati os ▁disease _ risk _ rati o ▁d RS ▁sax ag lip tin ▁si tag lip tin ▁sax ag lip tin ▁pi og lita zone ▁sax ag lip tin ▁sul fon yl ure as ▁sax ag lip tin ▁insulin
D-1835	-1.061749815940857	hazard_ratios disease_risk_ratio dRS saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas saxagliptin insulin
P-1835	-1.6134 -0.5241 -0.1414 -0.2495 -0.1351 -0.2848 -0.2459 -0.4045 -4.5276 -0.9114 -0.1062 -1.7587 -1.5263 -0.2605 -1.7333 -3.6902 -1.2190 -0.0045 -0.8057 -3.4943 -1.0437 -0.5523 -1.8003 -3.7970 -0.0359 -0.2741 -0.0681 -0.0695 -0.4712 -0.7599 -2.1088 -4.0775 -0.0369 -0.0172 -0.5892 -0.2511 -0.1061 -0.3190 -0.5192 -1.8360 -3.8585 -0.0206 -0.2846 -0.1840
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients revascularization coronary_artery_bypass_surgery hazard_ratio percutaneous_coronary_intervention systolic_blood_pressure left_bundle_branch_block_pattern baseline electrocardiogram
H-106	-0.741418719291687	▁i e ▁re vas cular ization ▁co ron ary _ ▁arter y _ ▁by pass ▁surgery ▁hazard _ rati o ▁per cuta ne ous _ ▁corona ry _ intervention ▁sy sto lic _ ▁blood _ press ure ▁left _ ▁bund le _ ▁bran ch _ block _ ▁pattern ▁base line _ ▁electro card i ogram ▁i e
D-106	-0.741418719291687	ie revascularization coronary_ artery_ bypass surgery hazard_ratio percutaneous_ coronary_intervention systolic_ blood_pressure left_ bundle_ branch_block_ pattern baseline_ electrocardiogram ie
P-106	-1.1262 -0.7243 -1.2396 -0.0298 -0.0655 -0.3065 -1.5985 -1.5020 -0.2038 -0.4970 -0.2513 -0.5942 -0.3817 -2.1334 -0.0120 -1.4819 -0.5134 -0.6946 -0.0985 -0.0532 -0.0910 -0.0054 -1.0094 -0.1903 -0.6069 -1.3892 -0.3994 -0.8010 -0.2372 -1.1664 -0.2661 -0.3399 -0.3147 -1.9033 -0.4773 -1.7855 -0.3380 -0.7580 -0.7591 -1.4888 -0.9092 -0.3603 -4.0835 -0.0500 -0.3105 -2.6035 -0.9090 -0.6540 -0.0046 -0.0740 -0.4428 -1.3384 -0.2782 -0.3659 -0.0181 -2.1654 -0.5147 -0.6072 -0.2204
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical biomedical relative_risk confidence_interval left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1262	-0.8798691630363464	▁bio medic al _ ▁Treatment ▁bio medic al _ ▁Treatment ▁CH m ▁confidence _ ▁interval ▁left _ vent ri cular _ e je ction _ fraction ▁left _ vent ri cular _ dia sto lic _ end _ dia meter
D-1262	-0.8798691630363464	biomedical_ Treatment biomedical_ Treatment CHm confidence_ interval left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter
P-1262	-0.0330 -0.2365 -0.0802 -1.3117 -4.4191 -0.0822 -0.2476 -0.0546 -0.7092 -3.7993 -2.3980 -0.0888 -1.4502 -0.4818 -0.9826 -0.4255 -0.5544 -1.7059 -1.2800 -0.3474 -0.5150 -0.5944 -0.6121 -0.3997 -0.2921 -0.0217 -1.0871 -0.4832 -1.2696 -1.0296 -0.3088 -0.4225 -0.3085 -0.6430 -0.5971 -0.2403 -4.9364 -0.2455 -0.0664 -0.2124 -1.6672 -0.3138
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective randomized crossover_study outcome stable_heart_failure patients left_ventricular_ejection_fraction homozygous haplotype β2-receptor randomized carvedilol metoprolol
H-1114	-0.7971758842468262	▁heart _ fail ure ▁vent ri cular _ e je ction _ fraction ▁ar g 16 ▁gr n 27 ▁g ly 16 ▁gh 27 _ ha plo type ▁β 2- recept or ▁equipo tent _ ▁dos ages ▁car vedi lol ▁met o pro lol
D-1114	-0.7971758842468262	heart_failure ventricular_ejection_fraction arg16 grn27 gly16 gh27_haplotype β2-receptor equipotent_ dosages carvedilol metoprolol
P-1114	-6.1757 -0.4630 -1.5378 -1.0644 -1.1807 -0.4327 -0.3077 -0.6075 -0.2107 -0.3843 -0.2105 -0.3837 -0.0100 -0.8512 -0.0787 -0.1278 -1.1347 -0.9486 -0.0394 -1.2846 -1.0309 -0.1866 -4.2547 -2.0169 -1.5426 -0.7723 -0.3076 -0.1102 -0.1958 -0.1654 -0.1171 -0.1680 -0.4459 -1.6777 -0.9792 -1.5182 -0.0735 -0.8429 -0.0174 -0.4364 -0.1015 -0.2756 -0.0514 -1.2883 -0.4553 -0.2047
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients death hospitalization aor aor aor aor
H-465	-0.6753888726234436	▁low - volu me _ ed _ case s hospital ization ED ▁a OR ▁high - volu me _ ed _ case s ▁a OR ▁a OR
D-465	-0.6753888726234436	low-volume_ed_caseshospitalizationED aOR high-volume_ed_cases aOR aOR
P-465	-1.1164 -0.1049 -0.1656 -0.1269 -0.6528 -2.1508 -0.4501 -0.1386 -0.0406 -1.1333 -0.2087 -2.4399 -1.4355 -0.7924 -0.6646 -0.1274 -0.2262 -0.1809 -0.3544 -1.6213 -0.4384 -0.1308 -0.0804 -0.4570 -1.1776 -1.1286 -1.3757 -0.4224 -0.2442
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health_buddy_program all-cause_mortality hazard_ratio confidence_interval inpatient admissions baseline
H-1625	-0.4742993712425232	▁health _ ▁Budd y _ programm e haz ard _ rati o ▁confidence _ ▁interval ▁in patient _ ad missions ▁base line
D-1625	-0.4742993712425232	health_ Buddy_programmehazard_ratio confidence_ interval inpatient_admissions baseline
P-1625	-0.0722 -0.5201 -1.7513 -0.0857 -0.3939 -1.1823 -0.3756 -1.6851 -0.1655 -0.2662 -0.0678 -0.0285 -1.1394 -0.5366 -0.5947 -0.8185 -0.3378 -0.5015 -0.2078 -0.0244 -0.0131 -0.0413 -0.2941 -0.2796
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted_hazard_ratios dash
H-691	-0.7723869681358337	▁multi vari able - ad just ed _ ▁hazard _ rati os ▁quart ile s ▁Mediterrane an _ diet _ ▁Score ▁DAS h _ die t _ ▁Score
D-691	-0.7723869681358337	multivariable-adjusted_ hazard_ratios quartiles Mediterranean_diet_ Score DASh_diet_ Score
P-691	-0.3698 -0.0067 -0.0601 -0.2322 -0.0656 -0.0267 -0.1065 -0.2004 -1.8731 -0.2461 -0.0875 -0.2163 -0.8204 -0.0987 -0.1045 -1.4824 -0.2139 -0.5133 -1.9613 -0.3900 -3.4756 -1.1780 -0.2176 -0.5180 -2.8749 -1.7751 -0.2088 -3.2318 -0.3800 -0.2362
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt nt-probnp report aric hf systolic_blood_pressure antihypertensive_medication diabetes body_mass_index coronary_heart_disease heart_rate hf area_under_the_receiver_operating_characteristic_curve auc integrated_discrimination_improvement net_reclassification_improvement nri
H-287	-0.7259892225265503	▁c t n t ▁NT - pro b NP labora tory _ report ▁a RIC _ HF ▁sy sto lic _ ▁blood _ tension ▁anti hy per tensi ve ▁medication ▁smoking ▁diabetes ▁body _ ▁mass _ index ▁corona ry _ heart _ ▁disease ▁heart _ rate ▁h f ▁receive r _ opera tion _ ▁character istic _ cur ve ▁au c ▁discrimina tion ▁net _ re class ification _ ▁improvement ▁n ri
D-287	-0.7259892225265503	ctnt NT-probNPlaboratory_report aRIC_HF systolic_ blood_tension antihypertensive medication smoking diabetes body_ mass_index coronary_heart_ disease heart_rate hf receiver_operation_ characteristic_curve auc discrimination net_reclassification_ improvement nri
P-287	-0.0434 -0.0844 -0.1269 -0.1035 -0.1218 -0.0430 -0.0249 -0.7883 -0.4620 -0.4187 -0.0186 -0.2125 -0.2654 -0.6653 -1.3982 -0.4895 -2.6244 -1.3518 -0.7921 -0.5104 -0.3016 -2.5540 -0.3944 -2.5643 -0.1239 -0.1078 -0.0332 -0.0577 -0.0765 -2.0635 -0.1181 -0.0461 -0.2026 -0.5347 -1.4883 -0.1758 -0.4749 -0.0045 -0.2739 -0.3263 -2.2499 -0.2564 -2.0297 -0.2267 -0.4257 -1.7396 -1.4168 -2.6620 -0.7508 -0.0377 -0.8668 -0.9532 -1.7873 -0.7699 -0.3062 -0.0749 -0.2909 -0.1287 -0.0525 -3.7440 -1.6066 -0.1472 -0.2200 -0.0548 -0.2071 -0.2514 -0.1020 -0.0492 -1.7232 -1.5403 -2.7690 -1.0608 -0.5766 -0.1782
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone patients hyperkalemia renal_function emphasis-hf patients heart_failure_and_reduced_ejection_fraction hf-ref new_york_heart_association nyha functional_class estimated_glomerular_filtration_rate egfr serum_potassium
H-1222	-0.6545107364654541	▁e pler en one ▁hyper kal emia ▁renal _ function ▁w RF ▁em PHA s - HF ▁heart _ fail ure ▁e je ction _ fraction HF - re f ▁New _ York _ ▁Heart _ association NY ha ▁glo mer ular _ filter ation _ rate ▁e g f ▁se rum _ po tas s ium
D-1222	-0.6545107364654541	eplerenone hyperkalemia renal_function wRF emPHAs-HF heart_failure ejection_fractionHF-ref New_York_ Heart_associationNYha glomerular_filteration_rate egf serum_potassium
P-1222	-0.1443 -0.1472 -0.2005 -0.1823 -0.0670 -0.9738 -0.1403 -0.0180 -0.3228 -0.2624 -0.6864 -3.0415 -1.5656 -0.9523 -1.3403 -0.0383 -0.9688 -1.3400 -0.3757 -1.2334 -1.8589 -0.8777 -0.1789 -0.0834 -0.3041 -0.0079 -1.6711 -0.0281 -0.1202 -1.5529 -0.7956 -1.3014 -1.8208 -0.3428 -0.2649 -0.3018 -0.4286 -1.8514 -0.8974 -0.1191 -0.2577 -0.0903 -0.1994 -1.0685 -0.6509 -0.2373 -0.4541 -0.4598 -0.6196 -1.7255 -0.2006 -0.1028 -0.2207 -0.5857 -1.4040 -0.5831 -0.3221 -0.4094 -0.2172
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide nesiritide placebo change cystatin_c nesiritide placebo
H-81	-0.8270648717880249	▁low - dos e _ ▁nesi riti de ▁cum ul ative _ ▁urin e _ ▁volume nesi riti de ▁m l ▁change ▁cyst atin _ c _ level nesi riti de
D-81	-0.8270648717880249	low-dose_ nesiritide cumulative_ urine_ volumenesiritide ml change cystatin_c_levelnesiritide
P-81	-0.4983 -0.0679 -1.5456 -0.4107 -0.6997 -0.3441 -0.6594 -0.2181 -0.9890 -0.0462 -0.0535 -0.4321 -1.9736 -0.5235 -1.3368 -1.1756 -0.8794 -0.9871 -0.1440 -0.8704 -4.3440 -1.7925 -0.5905 -0.4743 -1.3387 -0.0651 -0.6348 -0.0889 -0.8362 -0.9720 -0.1116 -1.9322 -0.2573
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking functional_capacity 6mwt physical activity symptoms hospital_anxiety_and_depression_scale
H-572	-0.5893126130104065	▁Nordic _ ▁walking ▁functional _ capaci ty ▁mw t ▁physical ▁activity ▁right _ ▁grip ▁ depressiv e Hospital _ an xie ty _ and _ de pression _ ▁Scal e
D-572	-0.5893126130104065	Nordic_ walking functional_capacity mwt physical activity right_ grip depressiveHospital_anxiety_and_depression_ Scale
P-572	-1.0795 -0.3304 -1.8387 -0.5596 -0.3109 -0.0642 -0.0251 -1.0543 -0.1353 -0.0524 -0.5891 -0.1494 -0.3647 -0.9455 -1.0260 -0.0691 -0.3325 -0.9393 -0.5724 -1.2997 -0.3152 -0.1791 -1.8192 -0.2573 -0.7322 -0.4298 -0.0496 -0.2636 -1.3630 -0.0725 -1.3579 -0.2808
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients hyperkalemia patients diabetes egfr systolic_blood_pressure potassium hyperkalemia leading hospitalization hospitalization primary_outcome hospitalization hf cardiovascular_mortality
H-1225	-0.9477195143699646	▁hyper kal emia ▁w RF ▁diabetes ▁e g f ▁sy sto lic _ ▁blood _ press ure ▁h g ▁po tas s ium ▁hyper kal emia ▁study - drug _ dis continu ation ▁w RF ▁cardiovascular _ ▁mortal ity
D-1225	-0.9477195143699646	hyperkalemia wRF diabetes egf systolic_ blood_pressure hg potassium hyperkalemia study-drug_discontinuation wRF cardiovascular_ mortality
P-1225	-0.3554 -1.2370 -0.7590 -0.2724 -3.5656 -0.3030 -0.3024 -0.3740 -2.0187 -2.0292 -0.5126 -0.3377 -0.2332 -2.6412 -0.3293 -2.5996 -0.8094 -2.1662 -0.0494 -0.5272 -0.7787 -0.1231 -0.3818 -0.6348 -1.5561 -0.6464 -3.3894 -0.0771 -0.0055 -0.7357 -0.1959 -0.0042 -0.0589 -0.6038 -3.6648 -3.1303 -0.4603 -0.2447 -0.0645 -0.4486 -0.2292
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf biosynthetic_enzymes lyso-paf_acetyltransferase lyso-paf-at 1-alkyl-2-acetyl-sn-glycerol_cholinephosphotransferase paf-cpt catabolic_isoenzymes paf-acetylhydrolase paf-ah lipoprotein-associated_phospholipase_a2 lp-pla2 leukocytes
H-1268	-0.6607376337051392	▁PA f ▁bio syn the tic _ ▁enzym es lys o - pa f _ a ce tyl transfer ase lys o - pa f - at ▁di thi oth rei tol ▁d t - in sensitiv e ▁cd p ▁cho line ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁cho line _ phos pho transfer ase ▁p f - c pt ▁cata bo lic _ iso en zy mes ▁pi f - ace tyl hydro lase ▁p f - AH ▁lipo prote in - as soci ated _ phos pho lipa se _ a 2 ▁l p - PLA 2] ▁leuk o cy tes
D-1268	-0.6607376337051392	PAf biosynthetic_ enzymeslyso-paf_acetyltransferaselyso-paf-at dithiothreitol dt-insensitive cdp choline 1-alkyl-2-acetyl-sn-glycerol choline_phosphotransferase pf-cpt catabolic_isoenzymes pif-acetylhydrolase pf-AH lipoprotein-associated_phospholipase_a2 lp-PLA2] leukocytes
P-1268	-2.2344 -0.8853 -0.0365 -0.0541 -0.3387 -0.2054 -0.2252 -0.9145 -0.4401 -1.0957 -0.1007 -0.0807 -0.8429 -1.5862 -0.5771 -0.1790 -0.2583 -0.9418 -1.0800 -2.0631 -1.9843 -0.2022 -0.1740 -0.8332 -1.8102 -0.4335 -0.2911 -0.1078 -0.0190 -0.4138 -0.2481 -1.7645 -0.2827 -0.0811 -1.4340 -0.0304 -0.0127 -0.0574 -0.6280 -0.1822 -0.2720 -0.1095 -0.6461 -0.0711 -0.3984 -0.1248 -0.0901 -3.2975 -0.7977 -0.1470 -0.0796 -0.0635 -0.1435 -0.3842 -0.0497 -0.1947 -0.8730 -0.1796 -4.3984 -0.5057 -1.6085 -1.6453 -1.7222 -2.3587 -2.9729 -0.0760 -0.2358 -1.1385 -0.0591 -0.0690 -0.0388 -0.2316 -0.8196 -0.2345 -0.0451 -0.0552 -4.8849 -1.4261 -0.0412 -0.6988 -0.7297 -0.3913 -0.3027 -1.9056 -3.3432 -0.0676 -2.1550 -0.1250 -0.1814 -0.3611 -0.1478 -0.0318 -0.0035 -0.0587 -0.2958 -0.3683 -0.3654 -0.3246 -0.7624 -0.1934 -0.2417 -0.0086 -0.7643 -0.0438 -0.1299 -0.1017 -1.0575 -0.4149 -0.1649 -0.0356 -0.7050 -0.3405 -0.2227
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine baseline follow-up exercise_capacity mets mets peak_oxygen_uptake peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1175	-0.5803401470184326	▁i va bra dine ▁base line ▁follow - up _ ▁exercise _ capaci ty ▁pe ak _ ▁oxygen _ up take ▁pe ak _ ▁early _ dia sto lic _ mit ral _ flow _ velo city ▁pe ak _ ▁early _ dia sto lic _ mit ral _ annu ular _ velo city
D-1175	-0.5803401470184326	ivabradine baseline follow-up_ exercise_capacity peak_ oxygen_uptake peak_ early_diastolic_mitral_flow_velocity peak_ early_diastolic_mitral_annuular_velocity
P-1175	-0.0667 -0.0204 -0.0365 -0.1729 -0.0742 -0.0742 -0.0049 -0.0981 -0.0179 -0.5774 -1.3607 -0.3950 -0.0909 -0.0646 -0.8943 -0.0343 -0.2599 -2.2854 -0.2113 -0.5219 -0.3862 -1.8582 -0.0725 -0.2485 -1.5039 -0.3636 -0.6328 -1.2434 -0.2327 -0.1840 -3.2499 -0.1036 -0.1778 -0.9661 -0.2531 -0.0589 -0.1840 -0.5803 -0.0476 -0.2967 -1.0537 -0.4443 -0.6669 -1.5887 -0.4896 -0.2229 -3.0469 -0.2483 -0.1975 -2.6861 -0.6503 -0.3363 -0.0717 -0.2208 -0.4546 -0.2150
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate_analysis chf odds_ratio chest hypertension genes rac2 doxorubicin_efflux_transporter abcc2
H-1455	-0.6089338064193726	▁CHF Od ds _ rati o ▁h t ▁che st _ radi ation ▁hyper tension ▁gene s _ co ding ▁na d p _ h - oxid ase RAC 2 ▁h fe ▁do xor ubi cin _ eff lux _ transport ▁ab c 2
D-1455	-0.6089338064193726	CHFOdds_ratio ht chest_radiation hypertension genes_coding nadp_h-oxidaseRAC2 hfe doxorubicin_efflux_transport abc2
P-1455	-1.0976 -1.2092 -0.0989 -0.2431 -0.1423 -0.0242 -0.0611 -1.8652 -1.1243 -0.1884 -0.3400 -0.1168 -0.2314 -0.0568 -0.0032 -0.3161 -0.2099 -1.1781 -0.0304 -0.6399 -2.8169 -0.6201 -2.5371 -2.4081 -0.3890 -0.2965 -0.0127 -1.7160 -0.5073 -0.0445 -0.2084 -1.6508 -0.1496 -0.3959 -0.0186 -0.1194 -0.7623 -0.1842 -0.1859 -0.2262 -0.6685 -1.8048 -0.1131 -0.0329 -0.6742 -0.2909
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline follow-up nyha_classification patients patient change patient quality_of_life duke_activity_status_index kansas_city_cardiomyopathy_questionnaire 6_min_walk_test
H-1958	-0.4472879469394684	▁base line ▁follow - up ▁NY ha ▁change ▁Duke ▁activity _ status _ index ▁Kansas _ city _ ▁Card i om yo pathy _ ▁Question naire ▁walk _ test _ distan ce
D-1958	-0.4472879469394684	baseline follow-up NYha change Duke activity_status_index Kansas_city_ Cardiomyopathy_ Questionnaire walk_test_distance
P-1958	-0.0798 -0.1231 -1.5235 -0.1817 -0.0134 -0.7381 -0.4578 -2.3747 -0.3995 -0.5195 -0.2458 -0.3107 -0.3639 -0.6923 -0.0281 -1.0230 -0.2728 -1.6328 -0.8798 -0.0235 -0.0501 -0.2673 -0.0823 -0.5848 -0.5748 -0.1040 -0.1658 -0.2468 -0.2315 -0.2615 -0.0452 -0.0487 -0.3775 -0.2840
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo dopamine dopamine placebo change cystatin_c dopamine placebo
H-80	-0.9269105195999146	▁low - dos e _ ▁dop amine ▁cum ul ative _ ▁urin e _ ▁volume dop amine ▁m L ▁m L ▁change ▁cyst atin _ c _ level dop amine
D-80	-0.9269105195999146	low-dose_ dopamine cumulative_ urine_ volumedopamine mL mL change cystatin_c_leveldopamine
P-80	-0.5302 -0.1125 -1.4099 -0.5957 -0.9017 -0.5422 -0.4164 -0.5731 -0.0523 -0.0960 -0.4122 -1.9131 -0.4792 -0.9297 -1.1780 -1.1824 -0.5044 -0.6958 -4.7049 -0.5096 -4.7164 -0.4490 -0.5425 -0.5430 -0.9180 -0.0702 -0.6794 -0.0943 -1.1758 -0.4156 -2.0608 -0.2567
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard_ratio confidence_interval baseline glomerular_filtration_rate chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks new_york_heart_association_class atrial_fibrillation congestive_hf mortality
H-66	-0.6039372682571411	haz ard _ rati o ▁base line _ glo mer ular _ filter ation _ rate ▁chronic _ ob struct ive _ ▁pulmonar y _ ▁disease ▁diabetes ▁per i pher al _ ▁vas cular _ ▁Disease ▁left _ vent ri cular _ e je ction _ fraction ▁i CD _ ▁shock s ▁New _ ▁York _ ▁Heart _ association ▁at rial _ fi bril lation ▁con ges tive _ HF ▁mortal ity
D-66	-0.6039372682571411	hazard_ratio baseline_glomerular_filteration_rate chronic_obstructive_ pulmonary_ disease diabetes peripheral_ vascular_ Disease left_ventricular_ejection_fraction iCD_ shocks New_ York_ Heart_association atrial_fibrillation congestive_HF mortality
P-66	-4.4604 -0.1226 -0.2222 -0.0492 -0.0410 -0.1929 -0.0926 -0.8567 -2.9064 -0.2170 -0.0243 -0.2419 -0.8063 -0.5437 -0.3689 -0.6802 -0.4303 -0.3934 -1.0337 -0.1280 -0.0975 -0.2595 -0.3346 -0.1898 -0.6365 -2.0081 -0.1129 -0.2400 -0.2848 -0.2119 -0.2978 -0.2697 -2.9860 -0.4390 -0.4750 -1.9243 -0.5513 -0.3860 -1.0643 -1.0459 -0.1681 -0.4188 -0.1805 -0.3606 -0.0553 -0.2003 -0.0160 -0.7965 -1.4361 -0.3694 -1.1736 -0.1155 -0.5075 -1.2308 -2.3866 -0.3226 -0.4039 -0.2541 -0.3157 -0.1230 -0.2433 -0.2521 -0.8432 -0.0932 -0.1412 -0.2559 -0.0240 -0.2580 -0.6844 -2.2448 -0.3057 -0.0911 -0.4958 -0.2972
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable_analysis end_point peak_oxygen_uptake hazard_ratio confidence_interval ventilatory_efficiency_slope hemoglobin left_ventricular_ejection_fraction renal_function renal_disease sodium
H-1761	-0.5646606087684631	▁pe ak _ ▁oxygen _ up take ▁hazard _ rati o ▁confidence _ ▁interval ▁ventilator y _ ef fici ence _ s lope ▁hem o glob in ▁left _ vent ri cular _ e je ction _ fraction ▁renal _ function ▁renal _ ▁disease ▁so dium
D-1761	-0.5646606087684631	peak_ oxygen_uptake hazard_ratio confidence_ interval ventilatory_efficience_slope hemoglobin left_ventricular_ejection_fraction renal_function renal_ disease sodium
P-1761	-1.2341 -0.0546 -0.2452 -1.7552 -0.2977 -0.6236 -0.5527 -0.2160 -0.6211 -0.1016 -0.0852 -0.2478 -0.6505 -0.7181 -0.6280 -0.8474 -0.6169 -1.6643 -0.4938 -1.2906 -0.9648 -0.2272 -0.3815 -0.3205 -0.2752 -0.1004 -0.9957 -0.8845 -0.4675 -0.7128 -1.3454 -0.2502 -0.4791 -0.2553 -0.3920 -0.0750 -0.3089 -0.0125 -0.0536 -0.2885 -1.2937 -0.4120 -0.2311 -2.7103 -0.0452 -0.0196 -0.3512 -0.3056
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute_walked_distance kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire beck_depression_inventory flow-mediated_dilatation fes placebo b-type_natriuretic_peptide mitral
H-1331	-0.4358997046947479	▁Kansas _ city ▁Card i om yo pathy ▁Minnesota ▁Living ▁Heart _ fail ure _ ▁Question naire ▁Beck _ de pression _ in ven tory ▁z ung ▁flow - media ted _ di la tation _ dia meter ▁f es ▁place bo ▁na tri ure tic _ pe pti de ▁mit ral ▁wa ve _ rati o
D-1331	-0.4358997046947479	Kansas_city Cardiomyopathy Minnesota Living Heart_failure_ Questionnaire Beck_depression_inventory zung flow-mediated_dilatation_diameter fes placebo natriuretic_peptide mitral wave_ratio
P-1331	-0.0466 -1.0954 -0.2864 -2.0589 -0.0363 -0.0894 -0.3054 -0.0529 -1.1264 -1.1038 -1.7183 -0.4028 -0.2005 -0.0947 -2.5505 -0.5152 -0.0877 -0.0977 -0.7745 -0.0369 -0.0419 -0.2032 -0.2128 -1.1526 -0.0260 -0.9410 -0.7366 -0.0071 -0.0687 -0.3686 -0.3861 -0.1192 -1.0407 -0.1616 -0.0747 -0.1215 -0.0533 -0.0159 -1.8703 -0.7705 -1.3917 -0.0271 -0.2101 -0.0883 -0.0776 -0.1307 -0.2074 -0.4239 -0.2172 -0.4081 -0.0998 -0.0221 -0.0187 -0.0695 -0.3056 -0.0874 -0.0989 -0.5294 -0.2522
2021-01-18 18:35:09 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-18 18:35:09 | INFO | fairseq_cli.generate | Translated 2,024 sentences (36,124 tokens) in 192.9s (10.49 sentences/s, 187.30 tokens/s)
2021-01-18 18:35:09 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 38.18, 63.4/46.3/35.7/27.6 (BP=0.925, ratio=0.928, syslen=36124, reflen=38932)
